Anhang 4-G: Ergänzende Daten zu den in Abschnitt 4.3.2.3 gezeigten Ergebnissen für die Studien MAGNOLIA und BGB-3111-AU-003

Studie BGB-3111-AU-003	
Datenschnitt 31.03.2021	**Seite**
Gesamtüberleben	2.979
Progressionsfreies Überleben	2.991
Gesamtansprechen	3.003
Unerwünschte Ereignisse – Gesamtrate	3.007
Unerwünschte Ereignisse von besonderem Interesse (Gesamtrate)	3.013
Unerwünschte Ereignisse von besonderem Interesse (CTCAE-Grad ≤ 2)	3.097
Unerwünschte Ereignisse von besonderem Interesse (CTCAE-Grad ≥ 3)	3.127
Unerwünschte Ereignisse von besonderem Interesse (schwerwiegend)	3.145

Trat ein unerwünschtes Ereignisse von besonderem Interesse nicht auf, erfolgte keine Darstellung des jeweiligen Ereignis (n = 0) in der entsprechenden Ergebnistabelle.

Für Subgruppenanalysen, bei denen die resultierenden Subgruppen < 10 Patienten umfassten, wurden für die entsprechenden Analysen und Merkmale keine Leertabellen ausgegeben.

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
Age (years)	
n	68
Mean (SD)	67.9 (11.41)
Median	70.0
Q1, Q3	59.5, 77.0
Min, Max	37, 95
Age Group, n (%)	
< 65 years	27 (39.7)
≥ 65 and < 75 years	22 (32.4)
≥ 75 years	19 (27.9)
Gender, n (%)	
Male	36 (52.9)
Female	32 (47.1)

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
Race, n (%)	
White	41 (60.3)
Asian	13 (19.1)
Not Reported	10 (14.7)
Multiple	2 (2.9)
Other	1 (1.5)
Unknown	1 (1.5)
Ethnicity, n (%)	
Not Hispanic or Latino	59 (86.8)
Not Reported	8 (11.8)
Unknown	1 (1.5)

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
Geographic Region, n (%)	
Europe	28 (41.2)
Australia/New Zealand	21 (30.9)
Asia	12 (17.6)
North America	7 (10.3)
Country, n (%)	
Australia	14 (20.6)
China	11 (16.2)
Italy	11 (16.2)
United Kingdom	11 (16.2)
New Zealand	7 (10.3)
United States	7 (10.3)
France	5 (7.4)
Czech Republic	1 (1.5)
South Korea	1 (1.5)

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
Height (cm)	
n	68
Mean (SD)	168.41 (9.702)
Median	167.80
Q1, Q3	163.25, 175.30
Min, Max	146.0, 195.5
Weight (kg)	
n	68
Mean (SD)	76.29 (15.953)
Median	74.05
Q1, Q3	64.80, 86.20
Min, Max	45.5, 114.0

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
ECOG Performance Status, n (%)	
0	39 (57.4)
1	24 (35.3)
2	5 (7.4)
Temperature (℃)	
n	68
Mean (SD)	36.45 (0.458)
Median	36.50
Q1, Q3	36.15, 36.70
Min, Max	35.5, 37.8
Systolic Blood Pressure (mmHg)	
n	68
Mean (SD)	126.4 (13.78)
Median	125.5
Q1, Q3	115.0, 138.0
Min, Max	100, 157

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
Diastolic Blood Pressure (mmHg)	
n	68
Mean (SD)	71.6 (10.34)
Median	71.0
Q1, Q3	65.0, 77.0
Min, Max	48, 100
Heart Rate (bpm)	
n	68
Mean (SD)	76.6 (13.97)
Median	75.0
Q1, Q3	66.5, 83.5
Min, Max	46, 114

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.1.2.1:
Demographics and Other Baseline Characteristics
Safety Analysis Set

	Zanubrutinib (N = 68)
HBcAb, n (%)	
Positive	6 (8.8)
Negative	62 (91.2)
HBV DNA, n (%)	
Positive	0 (0.0)
Negative	12 (17.6)
Missing	56 (82.4)
HCV antibody, n (%)	
Positive	0 (0.0)
Negative	68 (100.0)

Source: ADSL,ADBASE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
All percentages are based on N.
Note: Baseline value was the last non-missing result before first dose of study drug.
In the data cutoff of 18Jan2021, one patient's race is "White", and the ethnicity is "Not Hispanic or Latino". In the data cutoff of 04May2022, this patient's race and ethnicity are corrected to "Not Reported".
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-dm.sas 26AUG2022 01:09 t-14-01-02-01-dm.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
ORR by IRC (months)	
n	68
Mean (SD)	10.46 (4.531)
Median	11.07
Q1, Q3	7.44, 11.55
Min, Max	0.0, 16.9
PFS by IRC (months)	
n	68
Mean (SD)	10.86 (4.435)
Median	11.07
Q1, Q3	8.67, 15.75
Min, Max	0.0, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
OS (months)	
n	68
Mean (SD)	13.78 (3.657)
Median	13.98
Q1, Q3	12.01, 16.56
Min, Max	1.6, 21.0
AE (months)	
n	68
Mean (SD)	12.32 (5.394)
Median	13.83
Q1, Q3	7.69, 16.34
Min, Max	1.6, 19.6

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
EQ VAS (months)	
n	68
Mean (SD)	10.25 (4.766)
Median	11.07
Q1, Q3	7.79, 11.93
Min, Max	0.0, 17.5
QLQ-C30 (months)	
n	68
Mean (SD)	10.30 (4.708)
Median	11.07
Q1, Q3	8.21, 12.14
Min, Max	0.0, 17.5

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.2.1.1.10.1:
Analysis of Overall Survival by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	4 (11.1)	3 (9.4)	7 (10.3)
Death	4 (11.1)	3 (9.4)	7 (10.3)
Censored, n (%)	32 (88.9)	29 (90.6)	61 (89.7)
Alive	32 (88.9)	29 (90.6)	61 (89.7)
Follow-up Time (months) [a]			
Median (95% CI)	14.09 (13.83, 16.56)	14.52 (13.60, 16.33)	14.06 (13.83, 16.30)
(Min, Max)	(3.6, 17.2)	(1.6, 21.0)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each gender group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-01-ef-os-grp-sex.rtf

Table 14.2.1.1.10.1:
Analysis of Overall Survival by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (15.5, NE)	NE (13.8, NE)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(3.6 ,17.2^{+})	(1.6^{+} ,21.0^{+})	(1.6^{+} ,21.0^{+})
Event Free Rate at, % (95% CI) [c]			
3 Month	100.0 (NE, NE)	96.8 (79.2, 99.5)	98.5 (89.9, 99.8)
6 Month	97.2 (81.9, 99.6)	96.8 (79.2, 99.5)	97.0 (88.6, 99.2)
9 Month	97.2 (81.9, 99.6)	93.5 (76.6, 98.3)	95.5 (86.8, 98.5)
12 Month	94.4 (79.3, 98.6)	93.5 (76.6, 98.3)	93.9 (84.6, 97.7)
15 Month	94.4 (79.3, 98.6)	88.0 (66.0, 96.2)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each gender group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-01-ef-os-grp-sex.rtf

Table 14.2.1.1.10.2:
Analysis of Overall Survival by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Overall Survival					
Events, n (%)	1 (3.7)	6 (14.6)	4 (8.2)	3 (15.8)	7 (10.3)
Death	1 (3.7)	6 (14.6)	4 (8.2)	3 (15.8)	7 (10.3)
Censored, n (%)	26 (96.3)	35 (85.4)	45 (91.8)	16 (84.2)	61 (89.7)
Alive	26 (96.3)	35 (85.4)	45 (91.8)	16 (84.2)	61 (89.7)
Follow-up Time (months) [a]					
Median (95% CI)	14.09 (12.29, 16.43)	14.06 (13.83, 16.39)	14.09 (13.80, 16.33)	14.06 (13.14, 16.56)	14.06 (13.83, 16.30)
(Min, Max)	(1.6, 21.0)	(2.8, 19.4)	(1.6, 21.0)	(6.4, 19.4)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-02-ef-os-grp-age.rtf

Table 14.2.1.1.10.2:
Analysis of Overall Survival by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
OS (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (15.5, NE)	NE (13.8, NE)	NE (15.5, NE)	NE (6.4, NE)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(1.6^+ ,21.0^+)	(2.8 ,19.4^+)	(1.6^+ ,21.0^+)	(6.4 ,19.4^+)	(1.6^+ ,21.0^+)
Event Free Rate at, % (95% CI) [c]					
3 Month	100.0 (NE, NE)	97.6 (83.9, 99.7)	97.9 (86.1, 99.7)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	100.0 (NE, NE)	95.1 (81.9, 98.8)	95.8 (84.4, 98.9)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	100.0 (NE, NE)	92.7 (79.0, 97.6)	95.8 (84.4, 98.9)	94.7 (68.1, 99.2)	95.5 (86.8, 98.5)
12 Month	100.0 (NE, NE)	90.2 (75.9, 96.2)	95.8 (84.4, 98.9)	89.5 (64.1, 97.3)	93.9 (84.6, 97.7)
15 Month	100.0 (NE, NE)	86.7 (70.6, 94.3)	95.8 (84.4, 98.9)	82.0 (53.1, 94.0)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-02-ef-os-grp-age.rtf

Table 14.2.1.1.10.3:
Analysis of Overall Survival by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	1 (2.6)	6 (20.7)	7 (10.3)
Death	1 (2.6)	6 (20.7)	7 (10.3)
Censored, n (%)	38 (97.4)	23 (79.3)	61 (89.7)
Alive	38 (97.4)	23 (79.3)	61 (89.7)
Follow-up Time (months) [a]			
Median (95% CI)	14.19 (13.83, 16.56)	14.06 (11.83, 16.33)	14.06 (13.83, 16.30)
(Min, Max)	(1.6, 19.3)	(3.6, 21.0)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each ECOG group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-03-ef-os-grp-ecog.rtf

Table 14.2.1.1.10.3:
Analysis of Overall Survival by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	15.5 (10.3, NE)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(1.6^+ ,19.3^+)	(3.6 ,21.0^+)	(1.6^+ ,21.0^+)
Event Free Rate at, % (95% CI) [c]			
3 Month	97.4 (82.8, 99.6)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	97.4 (82.8, 99.6)	96.6 (77.9, 99.5)	97.0 (88.6, 99.2)
9 Month	97.4 (82.8, 99.6)	93.1 (75.1, 98.2)	95.5 (86.8, 98.5)
12 Month	97.4 (82.8, 99.6)	89.4 (70.5, 96.5)	93.9 (84.6, 97.7)
15 Month	97.4 (82.8, 99.6)	83.4 (60.3, 93.7)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each ECOG group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-03-ef-os-grp-ecog.rtf

Table 14.2.1.1.10.4:
Analysis of Overall Survival by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	5 (10.2)	2 (10.5)	7 (10.3)
Death	5 (10.2)	2 (10.5)	7 (10.3)
Censored, n (%)	44 (89.8)	17 (89.5)	61 (89.7)
Alive	44 (89.8)	17 (89.5)	61 (89.7)
Follow-up Time (months) [a]			
Median (95% CI)	14.06 (13.77, 16.39)	14.09 (13.60, 15.21)	14.06 (13.83, 16.30)
(Min, Max)	(2.8, 21.0)	(1.6, 19.4)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each prior line of therapy group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-04-ef-os-grp-pst.rtf

Table 14.2.1.1.10.4:
Analysis of Overall Survival by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Q1 (95% CI)	NE (16.0, NE)	15.5 (13.8, NE)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Range	(2.8 ,21.0+)	(1.6+ ,19.4+)	(1.6+ ,21.0+)
Event Free Rate at, % (95% CI) [c]			
3 Month	98.0 (86.4, 99.7)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	95.9 (84.7, 99.0)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	93.9 (82.2, 98.0)	100.0 (NE, NE)	95.5 (86.8, 98.5)
12 Month	91.7 (79.3, 96.8)	100.0 (NE, NE)	93.9 (84.6, 97.7)
15 Month	91.7 (79.3, 96.8)	92.9 (59.1, 99.0)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each prior line of therapy group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-04-ef-os-grp-pst.rtf

Table 14.2.1.1.10.5:
Analysis of Overall Survival by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Overall Survival					
Events, n (%)	2 (7.7)	3 (11.5)	1 (8.3)	1 (25.0)	7 (10.3)
Death	2 (7.7)	3 (11.5)	1 (8.3)	1 (25.0)	7 (10.3)
Censored, n (%)	24 (92.3)	23 (88.5)	11 (91.7)	3 (75.0)	61 (89.7)
Alive	24 (92.3)	23 (88.5)	11 (91.7)	3 (75.0)	61 (89.7)
Follow-up Time (months) [a]					
Median (95% CI)	15.44 (13.80, 16.82)	14.36 (13.83, 16.56)	13.67 (9.23, 14.52)	11.07 (10.22, 16.62)	14.06 (13.83, 16.30)
(Min, Max)	(1.6, 21.0)	(10.1, 17.5)	(8.0, 16.6)	(3.6, 16.6)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-05-ef-os-grp-mzltype.rtf

Table 14.2.1.1.10.5:
Analysis of Overall Survival by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
OS (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (16.0, NE)	NE (13.8, NE)	NE (3.6, NE)	NE (NE, NE)
Q1 (95% CI)	NE (2.8, NE)	NE (10.3, NE)	NE (13.8, NE)	NE (3.6, NE)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (13.8, NE)	NE (3.6, NE)	NE (NE, NE)
Range	(1.6^+ ,21.0^+)	(10.1^+ ,17.5^+)	(8.0^+ ,16.6^+)	(3.6 ,16.6^+)	(1.6^+ ,21.0^+)
Event Free Rate at, % (95% CI) [c]					
3 Month	96.0 (74.8, 99.4)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	96.0 (74.8, 99.4)	100.0 (NE, NE)	100.0 (NE, NE)	75.0 (12.8, 96.1)	97.0 (88.6, 99.2)
9 Month	92.0 (71.6, 97.9)	100.0 (NE, NE)	100.0 (NE, NE)	75.0 (12.8, 96.1)	95.5 (86.8, 98.5)
12 Month	92.0 (71.6, 97.9)	95.8 (73.9, 99.4)	100.0 (NE, NE)	75.0 (12.8, 96.1)	93.9 (84.6, 97.7)
15 Month	92.0 (71.6, 97.9)	95.8 (73.9, 99.4)	80.0 (20.4, 96.9)	75.0 (12.8, 96.1)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-05-ef-os-grp-mzltype.rtf

Table 14.2.1.1.10.6:
Analysis of Overall Survival by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Overall Survival				
Events, n (%)	2 (6.1)	2 (7.1)	3 (42.9)	7 (10.3)
Death	2 (6.1)	2 (7.1)	3 (42.9)	7 (10.3)
Censored, n (%)	31 (93.9)	26 (92.9)	4 (57.1)	61 (89.7)
Alive	31 (93.9)	26 (92.9)	4 (57.1)	61 (89.7)
Follow-up Time (months) [a]				
Median (95% CI)	15.21 (13.77, 16.62)	14.03 (13.73, 15.44)	13.83 (10.05, NE)	14.06 (13.83, 16.30)
(Min, Max)	(1.6, 21.0)	(8.0, 16.9)	(6.4, 16.0)	(1.6, 21.0)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each geographic region group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-06-ef-os-grp-region.rtf

Table 14.2.1.1.10.6:
Analysis of Overall Survival by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
OS (months) [b]				
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	16.0 (6.4, 16.0)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	NE (13.8, NE)	10.3 (6.4, 16.0)	NE (15.5, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	16.0 (10.3, 16.0)	NE (NE, NE)
Range	(1.6^{+} ,21.0^{+})	(8.0^{+} ,16.9^{+})	(6.4 ,16.0)	(1.6^{+} ,21.0^{+})
Event Free Rate at, % (95% CI) [c]				
3 Month	96.9 (79.8, 99.6)	100.0 (NE, NE)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	85.7 (33.4, 97.9)	95.5 (86.8, 98.5)
12 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	68.6 (21.3, 91.2)	93.9 (84.6, 97.7)
15 Month	93.8 (77.3, 98.4)	94.7 (68.1, 99.2)	68.6 (21.3, 91.2)	91.7 (80.9, 96.5)

Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each geographic region group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-os-grp.sas 04AUG2022 00:30 t-14-02-01-01-10-06-ef-os-grp-region.rtf

Figure 14.2.1.1.3.1:
Kaplan-Meier Plot of Overall Survival
Safety Analysis Set



Source: ADSL,ADTTE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: CI, confidence interval.
Note: Confidence intervals were calculated using a generalized Brookmeyer and Crowley method.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-ef-km-os.sas 21JUL2022 06:33 f-14-02-01-01-03-01-ef-km-os.rtf

Table 14.2.1.2.10.1:
Analysis of Progression Free Survival by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	7 (19.4)	8 (25.0)	15 (22.1)
Progressive disease	5 (13.9)	8 (25.0)	13 (19.1)
Death	2 (5.6)	0 (0.0)	2 (2.9)
Censored, n (%)	29 (80.6)	24 (75.0)	53 (77.9)
No documented disease progression/death	28 (77.8)	23 (71.9)	51 (75.0)
No baseline/post-baseline assessment	0 (0.0)	1 (3.1)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	1 (2.8)	0 (0.0)	1 (1.5)
Follow-up Time (months) [a]			
Median (95% CI)	11.14 (11.07, 11.50)	11.27 (9.33, 16.20)	11.14 (11.07, 11.30)
(Min, Max)	(0.82, 16.92)	(0.03, 16.79)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each gender group or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-01-ef-pfs-grp-irc-sex.rtf

Table 14.2.1.2.10.1:
Analysis of Progression Free Survival by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
PFS (months) [b]			
Median (95% CI)	NE (16.0, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	16.0 (4.9, NE)	5.6 (2.7, NE)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(0.82 ,16.92+)	(0.03+ ,16.79+)	(0.03+ ,16.92+)
Event Free Rate at, % (95% CI) [c]			
3 Month	94.4 (79.57, 98.58)	80.6 (61.91, 90.80)	88.1 (77.54, 93.84)
6 Month	88.9 (73.05, 95.68)	73.6 (53.99, 85.87)	81.9 (70.31, 89.29)
9 Month	88.9 (73.05, 95.68)	73.6 (53.99, 85.87)	81.9 (70.31, 89.29)
12 Month	85.8 (69.19, 93.85)	73.6 (53.99, 85.87)	80.0 (68.04, 87.92)
15 Month	85.8 (69.19, 93.85)	73.6 (53.99, 85.87)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each gender group or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-01-ef-pfs-grp-irc-sex.rtf

Table 14.2.1.2.10.2:
Analysis of Progression Free Survival by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Progression-free Survival					
Events, n (%)	8 (29.6)	7 (17.1)	12 (24.5)	3 (15.8)	15 (22.1)
Progressive disease	7 (25.9)	6 (14.6)	10 (20.4)	3 (15.8)	13 (19.1)
Death	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Censored, n (%)	19 (70.4)	34 (82.9)	37 (75.5)	16 (84.2)	53 (77.9)
No documented disease progression/death	18 (66.7)	33 (80.5)	36 (73.5)	15 (78.9)	51 (75.0)
No baseline/post-baseline assessment	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Follow-up Time (months) [a]					
Median (95% CI)	11.50 (11.07, 16.23)	11.14 (11.07, 11.30)	11.20 (11.07, 16.20)	11.14 (11.07, 11.30)	11.14 (11.07, 11.30)
(Min, Max)	(0.03, 16.82)	(1.84, 16.92)	(0.03, 16.92)	(2.56, 16.53)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-02-ef-pfs-grp-irc-age.rtf

Table 14.2.1.2.10.2:
Analysis of Progression Free Survival by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
PFS (months) [b]					
Median (95% CI)	NE (15.5, NE)	NE (NE, NE)	NE (16.0, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	5.6 (2.7, NE)	NE (5.4, NE)	15.5 (2.8, NE)	NE (2.6, NE)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(0.03^{+} ,16.82^{+})	(1.84 ,16.92^{+})	(0.03^{+} ,16.92^{+})	(2.56 ,16.53^{+})	(0.03^{+} ,16.92^{+})
Event Free Rate at, % (95% CI) [c]					
3 Month	84.6 (64.04, 93.93)	90.2 (76.06, 96.22)	85.4 (71.83, 92.77)	94.7 (68.12, 99.24)	88.1 (77.54, 93.84)
6 Month	72.9 (51.35, 86.05)	87.7 (72.85, 94.68)	78.9 (64.37, 88.08)	89.2 (63.15, 97.18)	81.9 (70.31, 89.29)
9 Month	72.9 (51.35, 86.05)	87.7 (72.85, 94.68)	78.9 (64.37, 88.08)	89.2 (63.15, 97.18)	81.9 (70.31, 89.29)
12 Month	72.9 (51.35, 86.05)	84.5 (68.59, 92.79)	78.9 (64.37, 88.08)	82.8 (55.36, 94.15)	80.0 (68.04, 87.92)
15 Month	72.9 (51.35, 86.05)	84.5 (68.59, 92.79)	78.9 (64.37, 88.08)	82.8 (55.36, 94.15)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-02-ef-pfs-grp-irc-age.rtf

Table 14.2.1.2.10.3:
Analysis of Progression Free Survival by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	6 (15.4)	9 (31.0)	15 (22.1)
Progressive disease	6 (15.4)	7 (24.1)	13 (19.1)
Death	0 (0.0)	2 (6.9)	2 (2.9)
Censored, n (%)	33 (84.6)	20 (69.0)	53 (77.9)
No documented disease progression/death	32 (82.1)	19 (65.5)	51 (75.0)
No baseline/post-baseline assessment	1 (2.6)	0 (0.0)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	1 (3.4)	1 (1.5)
Follow-up Time (months) [a]			
Median (95% CI)	11.14 (11.01, 11.50)	11.20 (11.07, 16.20)	11.14 (11.07, 11.30)
(Min, Max)	(0.03, 16.92)	(2.56, 16.56)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-03-ef-pfs-grp-irc-ecog.rtf

Table 14.2.1.2.10.3:
Analysis of Progression Free Survival by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
PFS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Q1 (95% CI)	NE (3.0, NE)	10.9 (2.8, NE)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (16.0, NE)	NE (NE, NE)
Range	(0.03+ ,16.92+)	(2.56 ,16.56+)	(0.03+ ,16.92+)
Event Free Rate at, % (95% CI) [c]			
3 Month	89.5 (74.34, 95.91)	86.2 (67.31, 94.59)	88.1 (77.54, 93.84)
6 Month	83.9 (67.53, 92.42)	79.2 (59.36, 90.06)	81.9 (70.31, 89.29)
9 Month	83.9 (67.53, 92.42)	79.2 (59.36, 90.06)	81.9 (70.31, 89.29)
12 Month	83.9 (67.53, 92.42)	74.8 (53.98, 87.18)	80.0 (68.04, 87.92)
15 Month	83.9 (67.53, 92.42)	74.8 (53.98, 87.18)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-03-ef-pfs-grp-irc-ecog.rtf

Table 14.2.1.2.10.4:
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	10 (20.4)	5 (26.3)	15 (22.1)
Progressive disease	9 (18.4)	4 (21.1)	13 (19.1)
Death	1 (2.0)	1 (5.3)	2 (2.9)
Censored, n (%)	39 (79.6)	14 (73.7)	53 (77.9)
No documented disease progression/death	38 (77.6)	13 (68.4)	51 (75.0)
No baseline/post-baseline assessment	0 (0.0)	1 (5.3)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	1 (2.0)	0 (0.0)	1 (1.5)
Follow-up Time (months) [a]			
Median (95% CI)	11.17 (11.07, 16.20)	11.10 (8.18, 11.50)	11.14 (11.07, 11.30)
(Min, Max)	(0.82, 16.92)	(0.03, 16.56)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-04-ef-pfs-grp-irc-pst.rtf

Table 14.2.1.2.10.4:
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
PFS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Q1 (95% CI)	NE (2.8, NE)	15.5 (2.8, NE)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (15.5, NE)	NE (NE, NE)
Range	(0.82 ,16.92^{+})	(0.03^{+} ,16.56^{+})	(0.03^{+} ,16.92^{+})
Event Free Rate at, % (95% CI) [c]			
3 Month	87.8 (74.76, 94.30)	88.9 (62.42, 97.10)	88.1 (77.54, 93.84)
6 Month	83.5 (69.71, 91.40)	77.4 (50.33, 90.87)	81.9 (70.31, 89.29)
9 Month	83.5 (69.71, 91.40)	77.4 (50.33, 90.87)	81.9 (70.31, 89.29)
12 Month	81.1 (66.67, 89.69)	77.4 (50.33, 90.87)	80.0 (68.04, 87.92)
15 Month	81.1 (66.67, 89.69)	77.4 (50.33, 90.87)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-04-ef-pfs-grp-irc-pst.rtf

Table 14.2.1.2.10.5:
Analysis of Progression Free Survival by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Progression-free Survival					
Events, n (%)	6 (23.1)	4 (15.4)	3 (25.0)	2 (50.0)	15 (22.1)
Progressive disease	6 (23.1)	2 (7.7)	3 (25.0)	2 (50.0)	13 (19.1)
Death	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Censored, n (%)	20 (76.9)	22 (84.6)	9 (75.0)	2 (50.0)	53 (77.9)
No documented disease progression/death	19 (73.1)	21 (80.8)	9 (75.0)	2 (50.0)	51 (75.0)
No baseline/post-baseline assessment	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Follow-up Time (months) [a]					
Median (95% CI)	11.27 (10.97, 16.23)	11.25 (11.01, 16.36)	11.07 (5.45, 11.30)	13.82 (11.07, 16.56)	11.14 (11.07, 11.30)
(Min, Max)	(0.03, 16.92)	(2.73, 16.79)	(2.96, 11.60)	(2.76, 16.56)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile. MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-05-ef-pfs-grp-irc-mzltype.rtf

Table 14.2.1.2.10.5:
Analysis of Progression Free Survival by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
PFS (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (16.0, NE)	NE (5.4, NE)	NE (2.8, NE)	NE (NE, NE)
Q1 (95% CI)	NE (0.8, NE)	16.0 (2.8, NE)	5.6 (3.0, NE)	3.2 (2.8, NE)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (2.8, NE)	NE (NE, NE)
Range	(0.03^{+} ,16.92^{+})	(2.73 ,16.79^{+})	(2.96 ,11.60^{+})	(2.76 ,16.56^{+})	(0.03^{+} ,16.92^{+})
Event Free Rate at, % (95% CI) [c]					
3 Month	84.0 (62.81, 93.67)	92.3 (72.60, 98.02)	91.7 (53.90, 98.78)	75.0 (12.79, 96.05)	88.1 (77.54, 93.84)
6 Month	80.0 (58.44, 91.15)	92.3 (72.60, 98.02)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	81.9 (70.31, 89.29)
9 Month	80.0 (58.44, 91.15)	92.3 (72.60, 98.02)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	81.9 (70.31, 89.29)
12 Month	75.0 (52.35, 88.00)	92.3 (72.60, 98.02)	NE (NE, NE)	50.0 (5.78, 84.49)	80.0 (68.04, 87.92)
15 Month	75.0 (52.35, 88.00)	92.3 (72.60, 98.02)	NE (NE, NE)	50.0 (5.78, 84.49)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile. MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-05-ef-pfs-grp-irc-mzltype.rtf

Table 14.2.1.2.10.6:
Analysis of Progression Free Survival by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Progression-free Survival				
Events, n (%)	9 (27.3)	2 (7.1)	4 (57.1)	15 (22.1)
Progressive disease	9 (27.3)	1 (3.6)	3 (42.9)	13 (19.1)
Death	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Censored, n (%)	24 (72.7)	26 (92.9)	3 (42.9)	53 (77.9)
No documented disease progression/death	23 (69.7)	26 (92.9)	2 (28.6)	51 (75.0)
No baseline/post-baseline assessment	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Follow-up Time (months) [a]				
Median (95% CI)	11.27 (11.01, 16.23)	11.14 (11.07, 11.30)	11.07 (5.32, NE)	11.14 (11.07, 11.30)
(Min, Max)	(0.03, 16.76)	(4.01, 16.92)	(2.56, 16.03)	(0.03, 16.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each geographic region group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-06-ef-pfs-grp-irc-region.rtf

Table 14.2.1.2.10.6:
Analysis of Progression Free Survival by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
PFS (months) [b]				
Median (95% CI)	NE (NE, NE)	NE (15.5, NE)	10.9 (2.6, 16.0)	NE (NE, NE)
Q1 (95% CI)	5.2 (2.8, NE)	NE (15.5, NE)	2.7 (2.6, 16.0)	16.0 (4.9, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	16.0 (10.9, 16.0)	NE (NE, NE)
Range	(0.03+ ,16.76+)	(4.01+ ,16.92+)	(2.56 ,16.03)	(0.03+ ,16.92+)
Event Free Rate at, % (95% CI) [c]				
3 Month	81.3 (62.95, 91.11)	100.0 (NE, NE)	71.4 (25.82, 91.98)	88.1 (77.54, 93.84)
6 Month	71.9 (52.91, 84.26)	96.3 (76.49, 99.47)	71.4 (25.82, 91.98)	81.9 (70.31, 89.29)
9 Month	71.9 (52.91, 84.26)	96.3 (76.49, 99.47)	71.4 (25.82, 91.98)	81.9 (70.31, 89.29)
12 Month	71.9 (52.91, 84.26)	96.3 (76.49, 99.47)	47.6 (7.51, 80.85)	80.0 (68.04, 87.92)
15 Month	71.9 (52.91, 84.26)	96.3 (76.49, 99.47)	47.6 (7.51, 80.85)	80.0 (68.04, 87.92)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each geographic region group or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 04AUG2022 00:29 t-14-02-01-02-10-06-ef-pfs-grp-irc-region.rtf

Figure 14.2.1.2.1.1:
Kaplan-Meier Plot of Progression Free Survival by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set



Source: ADSL,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: CI, confidence interval; IRC, independent review committee.
Note: Confidence intervals were calculated using a generalized Brookmeyer and Crowley method.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-ef-km-pfs-irc.sas 21JUL2022 06:34 f-14-02-01-02-01-01-ef-km-pfs-irc.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Cycle 09	
Patients expected to complete questionnaire at visit, n	49
Patients who completed questionnaire, n	48
Compliance Rate (%) [a]	98.0
Cycle 12	
Patients expected to complete questionnaire at visit, n	46
Patients who completed questionnaire, n	42
Compliance Rate (%) [a]	91.3
Cycle 18	
Patients expected to complete questionnaire at visit, n	16
Patients who completed questionnaire, n	13
Compliance Rate (%) [a]	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:19 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Safety Follow-up	
Patients expected to complete questionnaire at visit, n	5
Patients who completed questionnaire, n	2
Compliance Rate (%) [a]	40.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:19 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	12 (33.3)	5 (15.6)	17 (25.0)
Partial Response	18 (50.0)	10 (31.3)	28 (41.2)
Stable Disease	3 (8.3)	10 (31.3)	13 (19.1)
Non Progressive Disease	1 (2.8)	0 (0.0)	1 (1.5)
Progressive Disease	2 (5.6)	6 (18.8)	8 (11.8)
Discontinued Study Prior to First Assessment	0 (0.0)	1 (3.1)	1 (1.5)
Overall Response Rate, n (%)	30 (83.3)	15 (46.9)	45 (66.2)
(95% CI [a])	(67.19, 93.63)	(29.09, 65.26)	(53.68, 77.21)
Complete Response Rate, n (%)	12 (33.3)	5 (15.6)	17 (25.0)
(95% CI [a])	(18.56, 50.97)	(5.28, 32.79)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each gender group or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Time to Response (months)			
n	30	15	45
Mean (SD)	3.55 (1.803)	3.31 (1.150)	3.47 (1.606)
Median	2.84	2.79	2.79
Q1, Q3	2.73, 3.68	2.63, 3.78	2.69, 3.68
Min, Max	1.7, 11.1	2.6, 6.3	1.7, 11.1
Time to Complete Response (months)			
n	12	5	17
Mean (SD)	4.85 (4.162)	3.92 (1.788)	4.57 (3.592)
Median	2.92	2.79	2.86
Q1, Q3	2.81, 4.68	2.56, 5.32	2.79, 5.32
Min, Max	2.7, 16.9	2.6, 6.3	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each gender group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	36	32	68
Mean (SD)	15.28 (2.981)	15.36 (4.707)	15.32 (3.859)
Median	15.80	15.34	15.70
Q1, Q3	14.37, 16.85	13.80, 18.09	13.83, 17.43
Min, Max	3.6, 19.9	1.6, 21.9	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each gender group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	≥ 65 years (N = 41)	< 75 years (N = 49)	≥ 75 years (N = 19)	Total (N = 68)
Best Overall Response, n (%)					
Complete Response	7 (25.9)	10 (24.4)	13 (26.5)	4 (21.1)	17 (25.0)
Partial Response	8 (29.6)	20 (48.8)	15 (30.6)	13 (68.4)	28 (41.2)
Stable Disease	6 (22.2)	7 (17.1)	12 (24.5)	1 (5.3)	13 (19.1)
Non Progressive Disease	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Progressive Disease	4 (14.8)	4 (9.8)	7 (14.3)	1 (5.3)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	15 (55.6)	30 (73.2)	28 (57.1)	17 (89.5)	45 (66.2)
(95% CI [a])	(35.33, 74.52)	(57.06, 85.78)	(42.21, 71.18)	(66.86, 98.70)	(53.68, 77.21)
Complete Response Rate, n (%)	7 (25.9)	10 (24.4)	13 (26.5)	4 (21.1)	17 (25.0)
(95% CI [a])	(11.11, 46.28)	(12.36, 40.30)	(14.95, 41.08)	(6.05, 45.57)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Time to Response (months)					
n	15	30	28	17	45
Mean (SD)	3.32 (1.096)	3.54 (1.820)	3.46 (1.791)	3.48 (1.293)	3.47 (1.606)
Median	2.79	2.81	2.79	2.83	2.79
Q1, Q3	2.73, 3.65	2.66, 3.84	2.71, 3.32	2.66, 4.30	2.69, 3.68
Min, Max	2.6, 6.3	1.7, 11.1	1.8, 11.1	1.7, 5.6	1.7, 11.1
Time to Complete Response (months)					
n	7	10	13	4	17
Mean (SD)	4.47 (2.300)	4.65 (4.404)	4.86 (4.047)	3.65 (1.336)	4.57 (3.592)
Median	2.99	2.86	2.86	3.25	2.86
Q1, Q3	2.79, 6.34	2.73, 3.84	2.79, 5.32	2.69, 4.60	2.79, 5.32
Min, Max	2.6, 8.5	2.6, 16.9	2.6, 16.9	2.6, 5.5	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each age group or total.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Study Follow-up Time (months)					
n	27	41	49	19	68
Mean (SD)	15.54 (3.804)	15.17 (3.936)	15.41 (3.985)	15.09 (3.607)	15.32 (3.859)
Median	15.47	15.80	15.87	15.11	15.70
Q1, Q3	13.83, 18.07	13.83, 17.25	14.49, 17.48	13.37, 16.69	13.83, 17.43
Min, Max	1.6, 21.9	2.8, 21.8	1.6, 21.9	6.4, 21.8	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each age group or total.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	9 (23.1)	8 (27.6)	17 (25.0)
Partial Response	16 (41.0)	12 (41.4)	28 (41.2)
Stable Disease	8 (20.5)	5 (17.2)	13 (19.1)
Non Progressive Disease	1 (2.6)	0 (0.0)	1 (1.5)
Progressive Disease	4 (10.3)	4 (13.8)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (2.6)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	25 (64.1)	20 (69.0)	45 (66.2)
(95% CI [a])	(47.18, 78.80)	(49.17, 84.72)	(53.68, 77.21)
Complete Response Rate, n (%)	9 (23.1)	8 (27.6)	17 (25.0)
(95% CI [a])	(11.13, 39.33)	(12.73, 47.24)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each ECOG group or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Time to Response (months)			
n	25	20	45
Mean (SD)	3.62 (1.857)	3.28 (1.244)	3.47 (1.606)
Median	2.86	2.79	2.79
Q1, Q3	2.73, 3.65	2.66, 3.81	2.69, 3.68
Min, Max	2.6, 11.1	1.7, 6.3	1.7, 11.1
Time to Complete Response (months)			
n	9	8	17
Mean (SD)	5.36 (4.742)	3.69 (1.450)	4.57 (3.592)
Median	2.99	2.84	2.86
Q1, Q3	2.73, 5.32	2.79, 4.68	2.79, 5.32
Min, Max	2.6, 16.9	2.6, 6.3	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each ECOG group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	39	29	68
Mean (SD)	15.71 (3.821)	14.79 (3.916)	15.32 (3.859)
Median	15.87	15.15	15.70
Q1, Q3	14.49, 18.07	13.31, 17.15	13.83, 17.43
Min, Max	1.6, 21.8	3.6, 21.9	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each ECOG group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	15 (30.6)	2 (10.5)	17 (25.0)
Partial Response	21 (42.9)	7 (36.8)	28 (41.2)
Stable Disease	6 (12.2)	7 (36.8)	13 (19.1)
Non Progressive Disease	1 (2.0)	0 (0.0)	1 (1.5)
Progressive Disease	6 (12.2)	2 (10.5)	8 (11.8)
Discontinued Study Prior to First Assessment	0 (0.0)	1 (5.3)	1 (1.5)
Overall Response Rate, n (%)	36 (73.5)	9 (47.4)	45 (66.2)
(95% CI [a])	(58.92, 85.05)	(24.45, 71.14)	(53.68, 77.21)
Complete Response Rate, n (%)	15 (30.6)	2 (10.5)	17 (25.0)
(95% CI [a])	(18.25, 45.42)	(1.30, 33.14)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Time to Response (months)			
n	36	9	45
Mean (SD)	3.58 (1.749)	3.03 (0.726)	3.47 (1.606)
Median	2.79	2.83	2.79
Q1, Q3	2.68, 3.81	2.73, 3.65	2.69, 3.68
Min, Max	1.7, 11.1	1.8, 4.3	1.7, 11.1
Time to Complete Response (months)			
n	15	2	17
Mean (SD)	4.75 (3.800)	3.27 (0.581)	4.57 (3.592)
Median	2.86	3.27	2.86
Q1, Q3	2.73, 5.52	2.86, 3.68	2.79, 5.32
Min, Max	2.6, 16.9	2.9, 3.7	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	49	19	68
Mean (SD)	15.32 (3.769)	15.32 (4.189)	15.32 (3.859)
Median	15.87	15.38	15.70
Q1, Q3	13.60, 17.25	14.23, 18.14	13.83, 17.43
Min, Max	2.8, 21.9	1.6, 20.7	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Best Overall Response, n (%)					
Complete Response	10 (38.5)	5 (19.2)	1 (8.3)	1 (25.0)	17 (25.0)
Partial Response	6 (23.1)	14 (53.8)	7 (58.3)	1 (25.0)	28 (41.2)
Stable Disease	4 (15.4)	5 (19.2)	3 (25.0)	1 (25.0)	13 (19.1)
Non Progressive Disease	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive Disease	4 (15.4)	2 (7.7)	1 (8.3)	1 (25.0)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	16 (61.5)	19 (73.1)	8 (66.7)	2 (50.0)	45 (66.2)
(95% CI [a])	(40.57, 79.77)	(52.21, 88.43)	(34.89, 90.08)	(6.76, 93.24)	(53.68, 77.21)
Complete Response Rate, n (%)	10 (38.5)	5 (19.2)	1 (8.3)	1 (25.0)	17 (25.0)
(95% CI [a])	(20.23, 59.43)	(6.55, 39.35)	(0.21, 38.48)	(0.63, 80.59)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Time to Response (months)					
n	16	19	8	2	45
Mean (SD)	3.00 (0.719)	3.24 (1.104)	5.14 (2.819)	2.69 (0.139)	3.47 (1.606)
Median	2.81	2.79	4.93	2.69	2.79
Q1, Q3	2.68, 2.92	2.66, 3.78	2.79, 5.95	2.60, 2.79	2.69, 3.68
Min, Max	2.6, 5.5	1.7, 5.6	2.7, 11.1	2.6, 2.8	1.7, 11.1
Time to Complete Response (months)					
n	10	5	1	1	17
Mean (SD)	5.12 (4.547)	3.49 (1.137)	6.34 (--)	2.79 (--)	4.57 (3.592)
Median	2.86	2.99	6.34	2.79	2.86
Q1, Q3	2.79, 5.52	2.73, 3.84	6.34, 6.34	2.79, 2.79	2.79, 5.32
Min, Max	2.6, 16.9	2.6, 5.3	6.3, 6.3	2.8, 2.8	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Study Follow-up Time (months)					
n	26	26	12	4	68
Mean (SD)	15.34 (4.947)	16.21 (2.563)	14.68 (1.372)	11.30 (6.084)	15.32 (3.859)
Median	16.44	15.80	14.01	11.76	15.70
Q1, Q3	14.23, 18.53	14.69, 18.07	13.59, 15.49	6.90, 15.70	13.83, 17.43
Min, Max	1.6, 21.9	10.3, 21.8	13.4, 17.5	3.6, 18.1	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Best Overall Response, n (%)				
Complete Response	6 (18.2)	10 (35.7)	1 (14.3)	17 (25.0)
Partial Response	12 (36.4)	13 (46.4)	3 (42.9)	28 (41.2)
Stable Disease	7 (21.2)	5 (17.9)	1 (14.3)	13 (19.1)
Non Progressive Disease	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive Disease	6 (18.2)	0 (0.0)	2 (28.6)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	18 (54.5)	23 (82.1)	4 (57.1)	45 (66.2)
(95% CI [a])	(36.35, 71.89)	(63.11, 93.94)	(18.41, 90.10)	(53.68, 77.21)
Complete Response Rate, n (%)	6 (18.2)	10 (35.7)	1 (14.3)	17 (25.0)
(95% CI [a])	(6.98, 35.46)	(18.64, 55.93)	(0.36, 57.87)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each geographic region group or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Time to Response (months)				
n	18	23	4	45
Mean (SD)	3.01 (0.789)	3.88 (1.985)	3.17 (1.639)	3.47 (1.606)
Median	2.79	2.86	2.73	2.79
Q1, Q3	2.63, 2.99	2.73, 5.32	2.18, 4.16	2.69, 3.68
Min, Max	1.8, 5.6	2.6, 11.1	1.7, 5.5	1.7, 11.1
Time to Complete Response (months)				
n	6	10	1	17
Mean (SD)	3.04 (0.572)	5.40 (4.508)	5.52 (--)	4.57 (3.592)
Median	2.79	2.92	5.52	2.86
Q1, Q3	2.56, 3.68	2.83, 6.34	5.52, 5.52	2.79, 5.32
Min, Max	2.6, 3.8	2.7, 16.9	5.5, 5.5	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each geographic region group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Study Follow-up Time (months)				
n	33	28	7	68
Mean (SD)	15.60 (5.048)	15.33 (1.601)	13.91 (4.015)	15.32 (3.859)
Median	16.92	15.23	16.03	15.70
Q1, Q3	13.57, 19.06	14.01, 16.25	10.28, 16.69	13.83, 17.43
Min, Max	1.6, 21.9	12.5, 18.5	6.4, 16.8	1.6, 21.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each geographic region group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 04AUG2022 00:27 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	35	31	66
Mean (SD)	80.1 (16.42)	71.5 (21.66)	76.1 (19.39)
Median	85.0	80.0	80.0
Q1, Q3	70.0, 95.0	70.0, 85.0	70.0, 90.0
Min, Max	50, 100	0, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	80.6 (13.80)	75.4 (17.86)	78.2 (15.87)
Median	85.0	80.0	80.0
Q1, Q3	75.0, 90.0	67.5, 88.0	70.0, 90.0
Min, Max	50, 98	30, 100	30, 100
Change from Baseline			
n	32	27	59
Mean (SD)	0.7 (19.21)	1.6 (16.49)	1.1 (17.87)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 14.0	-4.0, 5.0	-5.0, 10.0
Min, Max	-45, 40	-40, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	30	21	51
Mean (SD)	79.8 (16.05)	74.8 (22.35)	77.7 (18.85)
Median	82.5	80.0	80.0
Q1, Q3	70.0, 90.0	75.0, 87.0	70.0, 90.0
Min, Max	40, 100	0, 100	0, 100
Change from Baseline			
n	29	21	50
Mean (SD)	0.1 (15.90)	5.1 (15.53)	2.2 (15.78)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 10.0	-5.0, 13.0	-5.0, 10.0
Min, Max	-35, 39	-25, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	18	48
Mean (SD)	77.5 (17.90)	72.8 (21.64)	75.7 (19.30)
Median	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 85.0	65.0, 90.0
Min, Max	20, 100	0, 95	0, 100
Change from Baseline			
n	29	18	47
Mean (SD)	-3.4 (15.53)	5.9 (16.22)	0.2 (16.28)
Median	0.0	0.0	0.0
Q1, Q3	-15.0, 5.0	-3.0, 15.0	-10.0, 10.0
Min, Max	-45, 25	-20, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	80.8 (15.39)	77.3 (22.07)	79.5 (17.99)
Median	90.0	80.0	85.0
Q1, Q3	70.0, 95.0	79.0, 87.5	70.0, 90.0
Min, Max	50, 100	0, 100	0, 100
Change from Baseline			
n	26	16	42
Mean (SD)	-1.2 (13.91)	9.2 (17.88)	2.8 (16.15)
Median	0.0	5.0	0.0
Q1, Q3	-8.0, 10.0	0.0, 12.0	-5.0, 10.0
Min, Max	-45, 20	-15, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	96.5 (4.95)	77.5 (3.54)	87.0 (11.52)
Median	96.5	77.5	86.5
Q1, Q3	93.0, 100.0	75.0, 80.0	77.5, 96.5
Min, Max	93, 100	75, 80	75, 100
Change from Baseline			
n	2	2	4
Mean (SD)	9.0 (5.66)	18.5 (37.48)	13.8 (22.56)
Median	9.0	18.5	9.0
Q1, Q3	5.0, 13.0	-8.0, 45.0	-1.5, 29.0
Min, Max	5, 13	-8, 45	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	90.8 (10.68)	82.3 (13.73)	86.2 (12.71)
Median	95.0	88.0	90.0
Q1, Q3	90.0, 95.0	70.0, 90.0	78.0, 95.0
Min, Max	70, 100	60, 100	60, 100
Change from Baseline			
n	5	7	12
Mean (SD)	4.4 (8.76)	8.3 (21.73)	6.7 (17.02)
Median	0.0	0.0	0.0
Q1, Q3	0.0, 2.0	-5.0, 10.0	0.0, 9.0
Min, Max	0, 20	-10, 55	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	4	9	13
Mean (SD)	49.3 (30.70)	73.3 (11.73)	65.9 (21.47)
Median	61.0	75.0	70.0
Q1, Q3	28.5, 70.0	70.0, 80.0	65.0, 75.0
Min, Max	5, 70	50, 90	5, 90
Change from Baseline			
n	4	8	12
Mean (SD)	-34.5 (37.43)	-3.1 (14.87)	-13.6 (27.59)
Median	-20.0	-5.0	-6.5
Q1, Q3	-55.0, -14.0	-12.5, 7.5	-20.0, 0.0
Min, Max	-90, -8	-25, 20	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
EQ-5D-5L					
EQ VAS Score					
Baseline					
n	26	40	47	19	66
Mean (SD)	77.6 (22.30)	75.1 (17.47)	77.4 (18.54)	72.8 (21.51)	76.1 (19.39)
Median	81.5	80.0	80.0	80.0	80.0
Q1, Q3	70.0, 95.0	70.0, 87.5	70.0, 90.0	50.0, 90.0	70.0, 90.0
Min, Max	0, 100	30, 100	0, 100	30, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	76.8 (18.01)	79.0 (14.62)	79.0 (15.68)	76.3 (16.63)	78.2 (15.87)
Median	80.0	80.0	80.0	80.0	80.0
Q1, Q3	60.0, 90.0	70.0, 90.0	70.0, 90.0	65.0, 90.0	70.0, 90.0
Min, Max	30, 96	45, 100	30, 100	45, 98	30, 100
Change from Baseline					
n	22	37	41	18	59
Mean (SD)	-2.1 (21.76)	3.0 (15.12)	0.8 (17.58)	1.7 (19.03)	1.1 (17.87)
Median	0.0	5.0	0.0	0.0	0.0
Q1, Q3	-10.0, 1.0	-5.0, 10.0	-5.0, 10.0	-10.0, 13.0	-5.0, 10.0
Min, Max	-45, 40	-35, 40	-45, 40	-35, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	74.1 (22.26)	80.1 (16.25)	77.6 (19.81)	78.1 (16.96)	77.7 (18.85)
Median	80.0	80.0	82.5	80.0	80.0
Q1, Q3	68.0, 87.5	75.0, 93.0	72.5, 90.0	65.0, 93.0	70.0, 90.0
Min, Max	0, 95	40, 100	0, 100	45, 100	0, 100
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	-2.4 (14.09)	5.2 (16.34)	1.0 (14.94)	5.1 (17.81)	2.2 (15.78)
Median	0.0	4.0	0.0	3.0	0.0
Q1, Q3	-12.5, 2.5	-5.0, 13.0	-10.0, 10.0	-5.0, 13.0	-5.0, 10.0
Min, Max	-25, 30	-35, 40	-25, 39	-35, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	18	30	33	15	48
Mean (SD)	74.4 (21.69)	76.5 (18.06)	76.4 (18.89)	74.3 (20.78)	75.7 (19.30)
Median	80.0	80.0	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0	65.0, 90.0	65.0, 90.0
Min, Max	0, 95	20, 100	0, 95	20, 100	0, 100
Change from Baseline					
n	18	29	32	15	47
Mean (SD)	-1.0 (14.88)	0.9 (17.30)	0.1 (14.18)	0.5 (20.63)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0	0.0
Q1, Q3	-15.0, 10.0	-5.0, 10.0	-12.5, 10.0	-5.0, 10.0	-10.0, 10.0
Min, Max	-25, 30	-45, 40	-25, 30	-45, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	78.1 (23.23)	80.3 (14.47)	80.0 (19.46)	78.5 (15.11)	79.5 (17.99)
Median	85.0	80.0	85.0	79.0	85.0
Q1, Q3	80.0, 90.0	70.0, 94.0	80.0, 90.0	70.0, 94.0	70.0, 90.0
Min, Max	0, 95	50, 100	0, 100	50, 100	0, 100
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	2.2 (9.99)	3.1 (19.17)	2.7 (10.93)	2.9 (23.98)	2.8 (16.15)
Median	0.0	0.0	0.0	-1.5	0.0
Q1, Q3	-2.5, 5.0	-8.0, 10.0	-2.5, 10.0	-10.0, 14.0	-5.0, 10.0
Min, Max	-15, 30	-45, 50	-20, 30	-45, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	89.3 (12.90)	80.0 (-)	89.3 (12.90)	80.0 (-)	87.0 (11.52)
Median	93.0	80.0	93.0	80.0	86.5
Q1, Q3	75.0, 100.0	80.0, 80.0	75.0, 100.0	80.0, 80.0	77.5, 96.5
Min, Max	75, 100	80, 80	75, 100	80, 80	75, 100
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	3.3 (10.60)	45.0 (-)	3.3 (10.60)	45.0 (-)	13.8 (22.56)
Median	5.0	45.0	5.0	45.0	9.0
Q1, Q3	-8.0, 13.0	45.0, 45.0	-8.0, 13.0	45.0, 45.0	-1.5, 29.0
Min, Max	-8, 13	45, 45	-8, 13	45, 45	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	80.8 (15.56)	88.7 (11.39)	83.1 (14.00)	93.3 (5.38)	86.2 (12.71)
Median	84.0	90.0	90.0	92.5	90.0
Q1, Q3	69.0, 92.5	88.0, 95.0	70.0, 95.0	89.0, 97.5	78.0, 95.0
Min, Max	60, 95	70, 100	60, 100	88, 100	60, 100
Change from Baseline					
n	4	8	8	4	12
Mean (SD)	-1.3 (8.54)	10.6 (19.23)	1.9 (9.23)	16.3 (26.06)	6.7 (17.02)
Median	-2.5	1.0	0.0	5.0	0.0
Q1, Q3	-7.5, 5.0	0.0, 14.0	-2.5, 5.0	1.0, 31.5	0.0, 9.0
Min, Max	-10, 10	0, 55	-10, 20	0, 55	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	6	7	11	2	13
Mean (SD)	62.5 (28.77)	68.9 (14.52)	62.9 (21.84)	82.5 (10.61)	65.9 (21.47)
Median	70.0	70.0	70.0	82.5	70.0
Q1, Q3	70.0, 75.0	52.0, 80.0	52.0, 75.0	75.0, 90.0	65.0, 75.0
Min, Max	5, 85	50, 90	5, 85	75, 90	5, 90
Change from Baseline					
n	5	7	10	2	12
Mean (SD)	-24.0 (40.84)	-6.1 (11.36)	-16.8 (29.14)	2.5 (10.61)	-13.6 (27.59)
Median	-20.0	-5.0	-14.0	2.5	-6.5
Q1, Q3	-25.0, -5.0	-20.0, 5.0	-20.0, -5.0	-5.0, 10.0	-20.0, 0.0
Min, Max	-90, 20	-20, 10	-90, 20	-5, 10	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	40, 40	-, -	40, 40
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	40, 40	-, -	40, 40
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	39	27	66
Mean (SD)	81.8 (13.98)	67.8 (23.09)	76.1 (19.39)
Median	83.0	75.0	80.0
Q1, Q3	70.0, 95.0	50.0, 85.0	70.0, 90.0
Min, Max	50, 100	0, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	81.3 (15.93)	74.0 (15.10)	78.2 (15.87)
Median	85.0	77.5	80.0
Q1, Q3	75.0, 95.0	65.0, 85.0	70.0, 90.0
Min, Max	30, 100	45, 95	30, 100
Change from Baseline			
n	35	24	59
Mean (SD)	-0.3 (17.33)	3.1 (18.81)	1.1 (17.87)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-7.5, 12.5	-5.0, 10.0
Min, Max	-45, 40	-35, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	28	23	51
Mean (SD)	84.8 (12.27)	69.0 (21.91)	77.7 (18.85)
Median	85.0	75.0	80.0
Q1, Q3	80.0, 91.5	60.0, 85.0	70.0, 90.0
Min, Max	45, 100	0, 95	0, 100
Change from Baseline			
n	28	22	50
Mean (SD)	2.9 (13.77)	1.3 (18.33)	2.2 (15.78)
Median	1.5	0.0	0.0
Q1, Q3	-5.0, 10.0	-10.0, 5.0	-5.0, 10.0
Min, Max	-25, 39	-35, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	21	48
Mean (SD)	79.6 (17.54)	70.7 (20.69)	75.7 (19.30)
Median	80.0	75.0	80.0
Q1, Q3	70.0, 90.0	60.0, 80.0	65.0, 90.0
Min, Max	20, 100	0, 95	0, 100
Change from Baseline			
n	27	20	47
Mean (SD)	-2.1 (12.41)	3.3 (20.34)	0.2 (16.28)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 5.0	-7.5, 17.5	-10.0, 10.0
Min, Max	-30, 20	-45, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	83.6 (12.69)	73.8 (22.63)	79.5 (17.99)
Median	90.0	80.0	85.0
Q1, Q3	70.0, 95.0	70.0, 90.0	70.0, 90.0
Min, Max	60, 100	0, 95	0, 100
Change from Baseline			
n	25	17	42
Mean (SD)	1.1 (9.49)	5.2 (22.87)	2.8 (16.15)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-5.0, 20.0	-5.0, 10.0
Min, Max	-20, 20	-45, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	89.3 (12.90)	80.0 (-)	87.0 (11.52)
Median	93.0	80.0	86.5
Q1, Q3	75.0, 100.0	80.0, 80.0	77.5, 96.5
Min, Max	75, 100	80, 80	75, 100
Change from Baseline			
n	3	1	4
Mean (SD)	3.3 (10.60)	45.0 (-)	13.8 (22.56)
Median	5.0	45.0	9.0
Q1, Q3	-8.0, 13.0	45.0, 45.0	-1.5, 29.0
Min, Max	-8, 13	45, 45	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	89.0 (12.82)	80.0 (11.55)	86.2 (12.71)
Median	95.0	80.0	90.0
Q1, Q3	88.0, 95.0	70.0, 90.0	78.0, 95.0
Min, Max	60, 100	70, 90	60, 100
Change from Baseline			
n	9	3	12
Mean (SD)	1.7 (8.43)	21.7 (29.30)	6.7 (17.02)
Median	0.0	10.0	0.0
Q1, Q3	0.0, 2.0	0.0, 55.0	0.0, 9.0
Min, Max	-10, 20	0, 55	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	7	6	13
Mean (SD)	64.3 (29.22)	67.8 (8.61)	65.9 (21.47)
Median	70.0	70.0	70.0
Q1, Q3	50.0, 85.0	65.0, 75.0	65.0, 75.0
Min, Max	5, 90	52, 75	5, 90
Change from Baseline			
n	7	5	12
Mean (SD)	-22.1 (32.26)	-1.6 (15.01)	-13.6 (27.59)
Median	-20.0	-5.0	-6.5
Q1, Q3	-25.0, -5.0	-8.0, 5.0	-20.0, 0.0
Min, Max	-90, 10	-20, 20	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)
Median	-	40.0	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0
Min, Max	-, -	40, 40	40, 40
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)
Median	-	-20.0	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)
Median	-	40.0	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0
Min, Max	-, -	40, 40	40, 40
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)
Median	-	-20.0	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	48	18	66
Mean (SD)	76.7 (19.28)	74.4 (20.14)	76.1 (19.39)
Median	80.0	80.0	80.0
Q1, Q3	70.0, 91.5	60.0, 90.0	70.0, 90.0
Min, Max	0, 100	30, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	78.4 (16.25)	77.7 (15.39)	78.2 (15.87)
Median	80.0	77.5	80.0
Q1, Q3	70.0, 90.0	65.0, 90.0	70.0, 90.0
Min, Max	30, 100	45, 100	30, 100
Change from Baseline			
n	42	17	59
Mean (SD)	-0.1 (17.63)	4.0 (18.66)	1.1 (17.87)
Median	0.0	5.0	0.0
Q1, Q3	-8.0, 10.0	0.0, 10.0	-5.0, 10.0
Min, Max	-45, 40	-40, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	37	14	51
Mean (SD)	79.2 (19.79)	73.8 (16.13)	77.7 (18.85)
Median	85.0	72.5	80.0
Q1, Q3	75.0, 90.0	65.0, 85.0	70.0, 90.0
Min, Max	0, 100	40, 100	0, 100
Change from Baseline			
n	37	13	50
Mean (SD)	1.5 (11.88)	4.1 (24.26)	2.2 (15.78)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-15.0, 30.0	-5.0, 10.0
Min, Max	-35, 25	-24, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	35	13	48
Mean (SD)	78.1 (21.53)	69.2 (9.09)	75.7 (19.30)
Median	80.0	70.0	80.0
Q1, Q3	75.0, 90.0	60.0, 75.0	65.0, 90.0
Min, Max	0, 100	60, 90	0, 100
Change from Baseline			
n	35	12	47
Mean (SD)	0.5 (14.69)	-0.8 (20.98)	0.2 (16.28)
Median	0.0	-7.5	0.0
Q1, Q3	-5.0, 10.0	-15.0, 12.5	-10.0, 10.0
Min, Max	-45, 30	-25, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	81.2 (18.79)	73.8 (14.41)	79.5 (17.99)
Median	85.0	74.0	85.0
Q1, Q3	80.0, 90.0	60.0, 85.0	70.0, 90.0
Min, Max	0, 100	50, 95	0, 100
Change from Baseline			
n	33	9	42
Mean (SD)	2.1 (12.93)	5.3 (25.66)	2.8 (16.15)
Median	0.0	-5.0	0.0
Q1, Q3	-3.0, 10.0	-15.0, 10.0	-5.0, 10.0
Min, Max	-45, 30	-20, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	89.3 (12.90)	80.0 (-)	87.0 (11.52)
Median	93.0	80.0	86.5
Q1, Q3	75.0, 100.0	80.0, 80.0	77.5, 96.5
Min, Max	75, 100	80, 80	75, 100
Change from Baseline			
n	3	1	4
Mean (SD)	3.3 (10.60)	45.0 (-)	13.8 (22.56)
Median	5.0	45.0	9.0
Q1, Q3	-8.0, 13.0	45.0, 45.0	-1.5, 29.0
Min, Max	-8, 13	45, 45	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	87.4 (12.83)	80.0 (14.14)	86.2 (12.71)
Median	90.0	80.0	90.0
Q1, Q3	78.0, 95.0	70.0, 90.0	78.0, 95.0
Min, Max	60, 100	70, 90	60, 100
Change from Baseline			
n	11	1	12
Mean (SD)	2.3 (7.98)	55.0 (-)	6.7 (17.02)
Median	0.0	55.0	0.0
Q1, Q3	0.0, 8.0	55.0, 55.0	0.0, 9.0
Min, Max	-10, 20	55, 55	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	5	13
Mean (SD)	66.5 (27.32)	65.0 (8.66)	65.9 (21.47)
Median	75.0	70.0	70.0
Q1, Q3	61.0, 82.5	65.0, 70.0	65.0, 75.0
Min, Max	5, 90	50, 70	5, 90
Change from Baseline			
n	7	5	12
Mean (SD)	-11.9 (35.95)	-16.0 (11.94)	-13.6 (27.59)
Median	-5.0	-20.0	-6.5
Q1, Q3	-8.0, 10.0	-20.0, -20.0	-20.0, 0.0
Min, Max	-90, 20	-25, 5	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
EQ-5D-5L					
EQ VAS Score					
Baseline					
n	26	24	12	4	66
Mean (SD)	75.4 (18.76)	82.8 (12.76)	63.8 (26.89)	77.5 (18.48)	76.1 (19.39)
Median	80.0	81.5	72.5	80.0	80.0
Q1, Q3	60.0, 90.0	77.5, 94.0	50.0, 80.0	62.5, 92.5	70.0, 90.0
Min, Max	35, 100	50, 100	0, 90	55, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	80.4 (13.79)	77.8 (16.65)	77.4 (13.91)	71.3 (28.39)	78.2 (15.87)
Median	80.0	85.0	80.0	82.5	80.0
Q1, Q3	75.0, 90.0	60.0, 90.0	70.0, 86.0	52.5, 90.0	70.0, 90.0
Min, Max	50, 100	50, 95	45, 100	30, 90	30, 100
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	4.0 (15.55)	-3.5 (20.22)	7.8 (12.02)	-6.3 (24.96)	1.1 (17.87)
Median	0.0	0.0	5.0	-2.5	0.0
Q1, Q3	-5.0, 5.0	-15.0, 10.0	0.0, 15.0	-22.5, 10.0	-5.0, 10.0
Min, Max	-15, 40	-45, 40	-10, 30	-40, 20	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	83.0 (12.16)	78.8 (16.37)	67.2 (29.49)	70.0 (25.00)	77.7 (18.85)
Median	85.0	80.0	75.0	70.0	80.0
Q1, Q3	75.0, 90.0	75.0, 90.0	60.0, 85.0	45.0, 95.0	70.0, 90.0
Min, Max	50, 100	40, 100	0, 100	45, 95	0, 100
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	5.8 (17.14)	-0.2 (15.05)	6.1 (12.19)	-15.0 (13.23)	2.2 (15.78)
Median	0.0	0.0	5.0	-20.0	0.0
Q1, Q3	-10.0, 17.0	-5.0, 7.5	0.0, 10.0	-25.0, 0.0	-5.0, 10.0
Min, Max	-20, 40	-35, 30	-5, 35	-25, 0	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	20	7	3	48
Mean (SD)	76.7 (14.04)	80.0 (14.23)	57.9 (34.86)	83.3 (10.41)	75.7 (19.30)
Median	80.0	80.0	70.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 92.5	20.0, 80.0	75.0, 95.0	65.0, 90.0
Min, Max	50, 95	60, 100	0, 95	75, 95	0, 100
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	-0.6 (18.30)	-0.6 (13.62)	5.0 (21.02)	-1.7 (12.58)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0	0.0
Q1, Q3	-10.0, 10.0	-5.0, 10.0	0.0, 15.0	-15.0, 10.0	-10.0, 10.0
Min, Max	-45, 30	-25, 25	-30, 40	-15, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	80.0 (13.73)	82.8 (14.32)	65.0 (32.71)	87.5 (10.61)	79.5 (17.99)
Median	80.0	90.0	75.0	87.5	85.0
Q1, Q3	70.0, 92.5	80.0, 90.0	70.0, 80.0	80.0, 95.0	70.0, 90.0
Min, Max	50, 100	50, 100	0, 90	80, 95	0, 100
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	0.0 (20.06)	2.0 (10.02)	11.7 (21.37)	5.0 (7.07)	2.8 (16.15)
Median	0.0	0.0	5.0	5.0	0.0
Q1, Q3	-11.5, 10.0	-5.0, 10.0	0.0, 20.0	0.0, 10.0	-5.0, 10.0
Min, Max	-45, 43	-15, 20	-10, 50	0, 10	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	90.0 (14.14)	84.0 (12.73)	- (-)	- (-)	87.0 (11.52)
Median	90.0	84.0	-	-	86.5
Q1, Q3	80.0, 100.0	75.0, 93.0	-, -	-, -	77.5, 96.5
Min, Max	80, 100	75, 93	-, -	-, -	75, 100
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	25.0 (28.28)	2.5 (14.85)	- (-)	- (-)	13.8 (22.56)
Median	25.0	2.5	-	-	9.0
Q1, Q3	5.0, 45.0	-8.0, 13.0	-, -	-, -	-1.5, 29.0
Min, Max	5, 45	-8, 13	-, -	-, -	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	89.0 (11.40)	88.0 (10.57)	- (-)	60.0 (-)	86.2 (12.71)
Median	90.0	90.0	-	60.0	90.0
Q1, Q3	90.0, 95.0	78.0, 95.0	-, -	60.0, 60.0	78.0, 95.0
Min, Max	70, 100	70, 100	-, -	60, 60	60, 100
Change from Baseline					
n	5	6	0	1	12
Mean (SD)	15.0 (23.98)	2.5 (5.58)	- (-)	-10.0 (-)	6.7 (17.02)
Median	0.0	1.0	-	-10.0	0.0
Q1, Q3	0.0, 20.0	0.0, 8.0	-, -	-10.0, -10.0	0.0, 9.0
Min, Max	0, 55	-5, 10	-, -	-10, -10	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	4	2	1	13
Mean (SD)	58.7 (27.94)	75.0 (10.80)	67.5 (24.75)	70.0 (-)	65.9 (21.47)
Median	70.0	72.5	67.5	70.0	70.0
Q1, Q3	52.0, 75.0	67.5, 82.5	50.0, 85.0	70.0, 70.0	65.0, 75.0
Min, Max	5, 80	65, 90	50, 85	70, 70	5, 90
Change from Baseline					
n	6	3	2	1	12
Mean (SD)	-18.0 (37.60)	-3.3 (18.93)	-12.5 (10.61)	-20.0 (-)	-13.6 (27.59)
Median	-6.5	5.0	-12.5	-20.0	-6.5
Q1, Q3	-20.0, -5.0	-25.0, 10.0	-20.0, -5.0	-20.0, -20.0	-20.0, 0.0
Min, Max	-90, 20	-25, 10	-20, -5	-20, -20	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	40.0 (-)	- (-)	- (-)	- (-)	40.0 (-)
Median	40.0	-	-	-	40.0
Q1, Q3	40.0, 40.0	-, -	-, -	-, -	40.0, 40.0
Min, Max	40, 40	-, -	-, -	-, -	40, 40
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-20.0 (-)	- (-)	- (-)	- (-)	-20.0 (-)
Median	-20.0	-	-	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-, -	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-, -	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	40.0 (-)	- (-)	- (-)	- (-)	40.0 (-)
Median	40.0	-	-	-	40.0
Q1, Q3	40.0, 40.0	-, -	-, -	-, -	40.0, 40.0
Min, Max	40, 40	-, -	-, -	-, -	40, 40
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-20.0 (-)	- (-)	- (-)	- (-)	-20.0 (-)
Median	-20.0	-	-	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-, -	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-, -	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
EQ-5D-5L				
EQ VAS Score				
Baseline				
n	32	28	6	66
Mean (SD)	75.1 (19.18)	75.6 (21.35)	83.3 (8.76)	76.1 (19.39)
Median	80.0	80.0	82.5	80.0
Q1, Q3	57.5, 90.0	70.0, 90.0	80.0, 90.0	70.0, 90.0
Min, Max	35, 100	0, 100	70, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	78.8 (17.13)	78.6 (14.38)	74.3 (17.42)	78.2 (15.87)
Median	80.0	80.0	80.0	80.0
Q1, Q3	75.0, 90.0	70.0, 90.0	50.0, 85.0	70.0, 90.0
Min, Max	30, 100	45, 96	50, 95	30, 100
Change from Baseline				
n	28	25	6	59
Mean (SD)	3.8 (21.01)	-0.5 (14.60)	-5.0 (14.14)	1.1 (17.87)
Median	0.0	0.0	-2.5	0.0
Q1, Q3	-5.0, 16.5	-10.0, 5.0	-10.0, 5.0	-5.0, 10.0
Min, Max	-40, 40	-45, 30	-30, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	24	23	4	51
Mean (SD)	78.5 (17.26)	77.4 (20.59)	75.0 (22.73)	77.7 (18.85)
Median	82.5	80.0	77.5	80.0
Q1, Q3	70.0, 91.5	75.0, 90.0	60.0, 90.0	70.0, 90.0
Min, Max	40, 100	0, 99	45, 100	0, 100
Change from Baseline				
n	23	23	4	50
Mean (SD)	4.3 (16.82)	2.0 (14.04)	-8.8 (18.87)	2.2 (15.78)
Median	0.0	0.0	-2.5	0.0
Q1, Q3	-5.0, 17.0	-5.0, 10.0	-22.5, 5.0	-5.0, 10.0
Min, Max	-25, 40	-24, 39	-35, 5	-35, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	22	23	3	48
Mean (SD)	76.8 (18.49)	73.5 (21.08)	85.0 (8.66)	75.7 (19.30)
Median	80.0	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	60.0, 90.0	80.0, 95.0	65.0, 90.0
Min, Max	20, 100	0, 95	80, 95	0, 100
Change from Baseline				
n	21	23	3	47
Mean (SD)	2.5 (17.26)	-1.9 (16.28)	0.0 (10.00)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0
Q1, Q3	-10.0, 15.0	-5.0, 5.0	-10.0, 10.0	-10.0, 10.0
Min, Max	-30, 30	-45, 40	-10, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.9 (13.00)	75.1 (22.24)	86.7 (10.41)	79.5 (17.99)
Median	82.5	82.5	90.0	85.0
Q1, Q3	79.0, 92.0	66.0, 90.0	75.0, 95.0	70.0, 90.0
Min, Max	50, 100	0, 95	75, 95	0, 100
Change from Baseline				
n	19	20	3	42
Mean (SD)	7.8 (14.26)	-1.9 (17.00)	1.7 (17.56)	2.8 (16.15)
Median	10.0	0.0	0.0	0.0
Q1, Q3	0.0, 14.0	-9.0, 2.5	-15.0, 20.0	-5.0, 10.0
Min, Max	-20, 43	-45, 50	-15, 20	-45, 50

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	80.0 (-)	89.3 (12.90)	- (-)	87.0 (11.52)
Median	80.0	93.0	-	86.5
Q1, Q3	80.0, 80.0	75.0, 100.0	-, -	77.5, 96.5
Min, Max	80, 80	75, 100	-, -	75, 100
Change from Baseline				
n	1	3	0	4
Mean (SD)	45.0 (-)	3.3 (10.60)	- (-)	13.8 (22.56)
Median	45.0	5.0	-	9.0
Q1, Q3	45.0, 45.0	-8.0, 13.0	-, -	-1.5, 29.0
Min, Max	45, 45	-8, 13	-, -	-8, 45

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	84.8 (14.51)	89.5 (8.02)	- (-)	86.2 (12.71)
Median	90.0	92.5	-	90.0
Q1, Q3	70.0, 95.0	84.0, 95.0	-, -	78.0, 95.0
Min, Max	60, 100	78, 95	-, -	60, 100
Change from Baseline				
n	8	4	0	12
Mean (SD)	8.1 (19.87)	3.8 (11.09)	- (-)	6.7 (17.02)
Median	1.0	0.0	-	0.0
Q1, Q3	0.0, 9.0	-2.5, 10.0	-, -	0.0, 9.0
Min, Max	-10, 55	-5, 20	-, -	-10, 55

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	9	1	3	13
Mean (SD)	63.9 (24.85)	52.0 (-)	76.7 (2.89)	65.9 (21.47)
Median	70.0	52.0	75.0	70.0
Q1, Q3	65.0, 70.0	52.0, 52.0	75.0, 80.0	65.0, 75.0
Min, Max	5, 90	52, 52	75, 80	5, 90
Change from Baseline				
n	9	1	2	12
Mean (SD)	-16.1 (31.90)	-8.0 (-)	-5.0 (0.00)	-13.6 (27.59)
Median	-20.0	-8.0	-5.0	-6.5
Q1, Q3	-20.0, 5.0	-8.0, -8.0	-5.0, -5.0	-20.0, 0.0
Min, Max	-90, 20	-8, -8	-5, -5	-90, 20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	-, -	40, 40
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	-, -	40, 40
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-vas.sas 04AUG2022 00:30 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	36	32	68
Patients who completed questionnaire, n	35	31	66
Compliance Rate (%) [a]	97.2	96.9	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	34	29	63
Patients who completed questionnaire, n	33	28	61
Compliance Rate (%) [a]	97.1	96.6	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	31	22	53
Patients who completed questionnaire, n	30	21	51
Compliance Rate (%) [a]	96.8	95.5	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	30	19	49
Patients who completed questionnaire, n	30	18	48
Compliance Rate (%) [a]	100.0	94.7	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	29	17	46
Patients who completed questionnaire, n	27	16	43
Compliance Rate (%) [a]	93.1	94.1	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	8	8	16
Patients who completed questionnaire, n	6	7	13
Compliance Rate (%) [a]	75.0	87.5	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	4	1	5
Patients who completed questionnaire, n	1	0	1
Compliance Rate (%) [a]	25.0	0.0	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Baseline					
Patients expected to complete questionnaire at visit, n	27	41	49	19	68
Patients who completed questionnaire, n	26	40	47	19	66
Compliance Rate (%) [a]	96.3	97.6	95.9	100.0	97.1
Cycle 03					
Patients expected to complete questionnaire at visit, n	25	38	45	18	63
Patients who completed questionnaire, n	23	38	43	18	61
Compliance Rate (%) [a]	92.0	100.0	95.6	100.0	96.8
Cycle 06					
Patients expected to complete questionnaire at visit, n	20	33	36	17	53
Patients who completed questionnaire, n	20	31	36	15	51
Compliance Rate (%) [a]	100.0	93.9	100.0	88.2	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 09					
Patients expected to complete questionnaire at visit, n	19	30	34	15	49
Patients who completed questionnaire, n	18	30	33	15	48
Compliance Rate (%) [a]	94.7	100.0	97.1	100.0	98.0
Cycle 12					
Patients expected to complete questionnaire at visit, n	17	29	31	15	46
Patients who completed questionnaire, n	16	27	29	14	43
Compliance Rate (%) [a]	94.1	93.1	93.5	93.3	93.5
Cycle 18					
Patients expected to complete questionnaire at visit, n	7	9	12	4	16
Patients who completed questionnaire, n	4	9	9	4	13
Compliance Rate (%) [a]	57.1	100.0	75.0	100.0	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
Patients expected to complete questionnaire at visit, n	3	2	4	1	5
Patients who completed questionnaire, n	0	1	1	0	1
Compliance Rate (%) [a]	0.0	50.0	25.0	0.0	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	39	29	68
Patients who completed questionnaire, n	39	27	66
Compliance Rate (%) [a]	100.0	93.1	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	36	27	63
Patients who completed questionnaire, n	35	26	61
Compliance Rate (%) [a]	97.2	96.3	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	29	24	53
Patients who completed questionnaire, n	28	23	51
Compliance Rate (%) [a]	96.6	95.8	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	27	22	49
Patients who completed questionnaire, n	27	21	48
Compliance Rate (%) [a]	100.0	95.5	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	27	19	46
Patients who completed questionnaire, n	25	18	43
Compliance Rate (%) [a]	92.6	94.7	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	11	5	16
Patients who completed questionnaire, n	9	4	13
Compliance Rate (%) [a]	81.8	80.0	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	1	4	5
Patients who completed questionnaire, n	0	1	1
Compliance Rate (%) [a]	0.0	25.0	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	49	19	68
Patients who completed questionnaire, n	48	18	66
Compliance Rate (%) [a]	98.0	94.7	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	45	18	63
Patients who completed questionnaire, n	43	18	61
Compliance Rate (%) [a]	95.6	100.0	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	38	15	53
Patients who completed questionnaire, n	37	14	51
Compliance Rate (%) [a]	97.4	93.3	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	36	13	49
Patients who completed questionnaire, n	35	13	48
Compliance Rate (%) [a]	97.2	100.0	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	35	11	46
Patients who completed questionnaire, n	33	10	43
Compliance Rate (%) [a]	94.3	90.9	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	14	2	16
Patients who completed questionnaire, n	11	2	13
Compliance Rate (%) [a]	78.6	100.0	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	3	2	5
Patients who completed questionnaire, n	1	0	1
Compliance Rate (%) [a]	33.3	0.0	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Baseline					
Patients expected to complete questionnaire at visit, n	26	26	12	4	68
Patients who completed questionnaire, n	26	24	12	4	66
Compliance Rate (%) [a]	100.0	92.3	100.0	100.0	97.1
Cycle 03					
Patients expected to complete questionnaire at visit, n	21	26	12	4	63
Patients who completed questionnaire, n	21	25	11	4	61
Compliance Rate (%) [a]	100.0	96.2	91.7	100.0	96.8
Cycle 06					
Patients expected to complete questionnaire at visit, n	18	22	10	3	53
Patients who completed questionnaire, n	18	21	9	3	51
Compliance Rate (%) [a]	100.0	95.5	90.0	100.0	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 09					
Patients expected to complete questionnaire at visit, n	18	21	7	3	49
Patients who completed questionnaire, n	18	20	7	3	48
Compliance Rate (%) [a]	100.0	95.2	100.0	100.0	98.0
Cycle 12					
Patients expected to complete questionnaire at visit, n	17	20	7	2	46
Patients who completed questionnaire, n	16	19	6	2	43
Compliance Rate (%) [a]	94.1	95.0	85.7	100.0	93.5
Cycle 18					
Patients expected to complete questionnaire at visit, n	7	8	0	1	16
Patients who completed questionnaire, n	5	7	0	1	13
Compliance Rate (%) [a]	71.4	87.5	-	100.0	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
Patients expected to complete questionnaire at visit, n	3	2	0	0	5
Patients who completed questionnaire, n	1	0	0	0	1
Compliance Rate (%) [a]	33.3	0.0	-	-	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Baseline				
Patients expected to complete questionnaire at visit, n	33	28	7	68
Patients who completed questionnaire, n	32	28	6	66
Compliance Rate (%) [a]	97.0	100.0	85.7	97.1
Cycle 03				
Patients expected to complete questionnaire at visit, n	29	27	7	63
Patients who completed questionnaire, n	29	25	7	61
Compliance Rate (%) [a]	100.0	92.6	100.0	96.8
Cycle 06				
Patients expected to complete questionnaire at visit, n	25	24	4	53
Patients who completed questionnaire, n	24	23	4	51
Compliance Rate (%) [a]	96.0	95.8	100.0	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-06-eq5d-comprate-region.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 09				
Patients expected to complete questionnaire at visit, n	23	23	3	49
Patients who completed questionnaire, n	22	23	3	48
Compliance Rate (%) [a]	95.7	100.0	100.0	98.0
Cycle 12				
Patients expected to complete questionnaire at visit, n	20	23	3	46
Patients who completed questionnaire, n	20	20	3	43
Compliance Rate (%) [a]	100.0	87.0	100.0	93.5
Cycle 18				
Patients expected to complete questionnaire at visit, n	10	6	0	16
Patients who completed questionnaire, n	9	4	0	13
Compliance Rate (%) [a]	90.0	66.7	-	81.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-06-eq5d-comprate-region.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
Patients expected to complete questionnaire at visit, n	2	3	0	5
Patients who completed questionnaire, n	0	1	0	1
Compliance Rate (%) [a]	0.0	33.3	-	20.0

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eq5d-comprate.sas 08AUG2022 01:34 t-14-02-01-07-06-eq5d-comprate-region.rtf

Figure 14.2.1.8.1:
EQ-5D-5L Questionnaire - EQ-5D Score Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-08-01-meanot-qol-eq5d.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Baseline	
Patients expected to complete questionnaire at visit, n	68
Patients who completed questionnaire, n	66
Compliance Rate (%) [a]	97.1
Cycle 03	
Patients expected to complete questionnaire at visit, n	63
Patients who completed questionnaire, n	60
Compliance Rate (%) [a]	95.2
Cycle 06	
Patients expected to complete questionnaire at visit, n	53
Patients who completed questionnaire, n	50
Compliance Rate (%) [a]	94.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:19 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	35	32	67
Mean (SD)	69.524 (18.6276)	62.240 (23.3779)	66.045 (21.1871)
Median	66.667	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 83.333	50.000, 83.333
Min, Max	25.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	75.253 (17.6143)	75.893 (16.5644)	75.546 (17.0014)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 83.333	62.500, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	5.990 (18.8413)	10.714 (21.2589)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-41.67, 50.00	-33.33, 66.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	77.679 (16.6749)	71.591 (24.3513)	75.000 (20.4124)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 87.500	58.333, 91.667	66.667, 91.667
Min, Max	41.67, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	6.481 (11.8604)	9.470 (19.8032)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-16.67, 66.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	76.667 (19.2533)	65.789 (23.8783)	72.449 (21.5974)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	4.598 (17.6195)	6.579 (23.8273)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 25.000	0.000, 16.667
Min, Max	-50.00, 41.67	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	79.012 (15.2210)	70.313 (26.1705)	75.775 (20.1527)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	66.667, 83.333
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	4.487 (17.0344)	11.458 (17.4470)	7.143 (17.3216)
Median	4.167	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 20.833	0.000, 16.667
Min, Max	-33.33, 41.67	-16.67, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	91.667 (11.7851)	70.833 (17.6777)	81.250 (17.1796)
Median	91.667	70.833	83.333
Q1, Q3	83.333, 100.000	58.333, 83.333	70.833, 91.667
Min, Max	83.33, 100.00	58.33, 83.33	58.33, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	8.333 (11.7851)	16.667 (58.9256)	12.500 (35.0264)
Median	8.333	16.667	8.333
Q1, Q3	0.000, 16.667	-25.000, 58.333	-12.500, 37.500
Min, Max	0.00, 16.67	-25.00, 58.33	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	81.944 (13.3507)	76.190 (17.6308)	78.846 (15.4468)
Median	83.333	75.000	83.333
Q1, Q3	83.333, 83.333	75.000, 83.333	75.000, 83.333
Min, Max	58.33, 100.00	41.67, 100.00	41.67, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	11.111 (20.1843)	9.524 (22.7855)	10.256 (20.7370)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 33.333	-8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 33.33	-8.33, 58.33	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	38.333 (20.0693)	62.500 (24.9227)	54.444 (25.5625)
Median	33.333	66.667	58.333
Q1, Q3	25.000, 50.000	50.000, 75.000	33.333, 66.667
Min, Max	16.67, 66.67	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-35.000 (29.1071)	-2.500 (24.5484)	-13.333 (29.6808)
Median	-33.333	4.167	-16.667
Q1, Q3	-50.000, -16.667	-25.000, 8.333	-33.333, 8.333
Min, Max	-75.00, 0.00	-41.67, 41.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	35	32	67
Mean (SD)	88.762 (13.6023)	77.083 (23.2757)	83.184 (19.6041)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	63.333, 93.333	80.000, 100.000
Min, Max	46.67, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	32	28	60
Mean (SD)	89.583 (12.5510)	81.667 (20.0103)	85.889 (16.7890)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	76.667, 93.333	83.333, 100.000
Min, Max	53.33, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	31	28	59
Mean (SD)	0.000 (14.4016)	2.857 (13.1379)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-6.667, 6.667
Min, Max	-33.33, 40.00	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	90.805 (11.4661)	80.606 (23.2683)	86.405 (18.0843)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	73.333, 93.333	80.000, 100.000
Min, Max	53.33, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	1.905 (14.1546)	3.636 (19.2700)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-13.333, 13.333	-6.667, 6.667
Min, Max	-33.33, 33.33	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	88.222 (18.5020)	79.298 (26.0004)	84.762 (21.9004)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-0.690 (17.4888)	4.912 (20.3479)	1.528 (18.6666)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 13.333	0.000, 6.667
Min, Max	-73.33, 40.00	-40.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	26	16	42
Mean (SD)	91.538 (10.7592)	75.417 (29.8856)	85.397 (21.4508)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000
Min, Max	66.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	16	41
Mean (SD)	1.600 (9.6762)	2.917 (21.9047)	2.114 (15.3796)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-3.333, 6.667	0.000, 6.667
Min, Max	-20.00, 26.67	-40.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	100.000 (0.0000)	93.333 (0.0000)	96.667 (3.8490)
Median	100.000	93.333	96.667
Q1, Q3	100.000, 100.000	93.333, 93.333	93.333, 100.000
Min, Max	100.00, 100.00	93.33, 93.33	93.33, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	30.000 (42.4264)	15.000 (30.0000)
Median	0.000	30.000	0.000
Q1, Q3	0.000, 0.000	0.000, 60.000	0.000, 30.000
Min, Max	0.00, 0.00	0.00, 60.00	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	92.222 (9.8131)	79.048 (25.3651)	85.128 (20.2125)
Median	96.667	86.667	93.333
Q1, Q3	80.000, 100.000	66.667, 93.333	80.000, 100.000
Min, Max	80.00, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	-3.333 (8.1650)	4.762 (27.1387)	1.026 (20.3390)
Median	0.000	0.000	0.000
Q1, Q3	-13.333, 0.000	-13.333, 6.667	-13.333, 6.667
Min, Max	-13.33, 6.67	-26.67, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	73.333 (19.4365)	78.000 (17.7917)	76.444 (17.7936)
Median	80.000	80.000	80.000
Q1, Q3	60.000, 86.667	66.667, 93.333	60.000, 93.333
Min, Max	46.67, 93.33	46.67, 100.00	46.67, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-13.333 (10.5409)	-2.000 (15.0882)	-5.778 (14.4457)
Median	-13.333	0.000	-6.667
Q1, Q3	-20.000, -6.667	-13.333, 6.667	-20.000, 0.000
Min, Max	-26.67, 0.00	-20.00, 26.67	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	58.333 (-)	- (-)	58.333 (-)
Median	58.333	-	58.333
Q1, Q3	58.333, 58.333	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	60.000 (-)	- (-)	60.000 (-)
Median	60.000	-	60.000
Q1, Q3	60.000, 60.000	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline			
n	1	0	1
Mean (SD)	-6.667 (-)	- (-)	-6.667 (-)
Median	-6.667	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Role functioning			
Baseline			
n	35	32	67
Mean (SD)	88.571 (18.8611)	77.604 (30.1161)	83.333 (25.2929)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	58.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	87.374 (22.8333)	86.310 (20.8135)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	75.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-2.604 (22.0416)	7.738 (24.2085)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	92.529 (13.7914)	86.364 (22.2042)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	1.786 (14.5857)	10.606 (24.9579)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	88.333 (22.3821)	83.333 (29.3972)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-2.874 (18.4030)	8.772 (22.4766)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	93.210 (14.8059)	75.000 (33.8843)	86.434 (25.0015)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	58.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.923 (12.7601)	1.042 (30.1040)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	-33.33, 33.33	-50.00, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	100.000 (0.0000)	100.000 (0.0000)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	8.333 (11.7851)	50.000 (70.7107)	29.167 (47.8714)
Median	8.333	50.000	8.333
Q1, Q3	0.000, 16.667	0.000, 100.000	0.000, 58.333
Min, Max	0.00, 16.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	94.444 (13.6083)	76.190 (25.1976)	84.615 (22.0075)
Median	100.000	66.667	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	66.67, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	-2.778 (16.3865)	4.762 (44.8395)	1.282 (33.6523)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	43.333 (38.3695)	73.333 (25.0924)	63.333 (32.2441)
Median	50.000	75.000	66.667
Q1, Q3	16.667, 50.000	66.667, 100.000	33.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-36.667 (27.3861)	-1.667 (22.8387)	-13.333 (29.0047)
Median	-50.000	0.000	-16.667
Q1, Q3	-50.000, -16.667	-16.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 0.00	-33.33, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	35	32	67
Mean (SD)	83.810 (18.1838)	80.469 (17.6598)	82.214 (17.8786)
Median	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	25.00, 100.00	41.67, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	84.343 (24.2740)	84.821 (16.6749)	84.563 (20.9627)
Median	100.000	91.667	91.667
Q1, Q3	75.000, 100.000	70.833, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.302 (23.8639)	3.869 (10.9906)	2.500 (18.8724)
Median	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 12.500	0.000, 16.667
Min, Max	-75.00, 33.33	-25.00, 25.00	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	83.631 (22.9602)	82.576 (21.0362)	83.167 (21.9183)
Median	91.667	91.667	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	1.543 (20.2860)	5.303 (17.5454)	3.231 (19.0042)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 33.33	-25.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	87.500 (18.9208)	75.439 (25.9798)	82.823 (22.4645)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	3.736 (17.8988)	-0.877 (22.3770)	1.910 (19.6932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 8.333	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	88.272 (18.5274)	73.958 (28.8475)	82.946 (23.6370)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	54.167, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	2.885 (16.3201)	-2.083 (20.5255)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 8.333	0.000, 8.333
Min, Max	-41.67, 25.00	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	100.000 (0.0000)	79.167 (5.8926)	89.583 (12.5000)
Median	100.000	79.167	91.667
Q1, Q3	100.000, 100.000	75.000, 83.333	79.167, 100.000
Min, Max	100.00, 100.00	75.00, 83.33	75.00, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	16.667 (11.7851)	4.167 (5.8926)	10.417 (10.4859)
Median	16.667	4.167	8.333
Q1, Q3	8.333, 25.000	0.000, 8.333	4.167, 16.667
Min, Max	8.33, 25.00	0.00, 8.33	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	80.556 (36.0041)	82.143 (11.2099)	81.410 (24.5689)
Median	95.833	83.333	83.333
Q1, Q3	83.333, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	8.33, 100.00	66.67, 100.00	8.33, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	-1.389 (21.3546)	3.571 (9.4491)	1.282 (15.5330)
Median	0.000	8.333	0.000
Q1, Q3	-8.333, 0.000	-8.333, 8.333	-8.333, 8.333
Min, Max	-33.33, 33.33	-8.33, 16.67	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	75.000 (25.6851)	77.500 (25.1692)	76.667 (24.4381)
Median	91.667	83.333	83.333
Q1, Q3	66.667, 91.667	75.000, 100.000	66.667, 91.667
Min, Max	33.33, 91.67	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-18.333 (22.3607)	-7.500 (17.7648)	-11.111 (19.3307)
Median	-8.333	-4.167	-8.333
Q1, Q3	-33.333, 0.000	-25.000, 0.000	-25.000, 0.000
Min, Max	-50.00, 0.00	-33.33, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	-13.889 (-)	- (-)	-13.889 (-)
Median	-13.889	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	35	32	67
Mean (SD)	90.952 (14.2014)	84.896 (20.8937)	88.060 (17.8391)
Median	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	86.364 (16.9018)	85.119 (17.1769)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-4.167 (21.1667)	-2.976 (11.1606)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-8.333, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-33.33, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	85.714 (21.1375)	83.333 (25.7172)	84.667 (23.0449)
Median	83.333	100.000	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	-4.938 (17.7920)	-4.545 (11.7083)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-66.67, 33.33	-33.33, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	86.111 (23.1947)	81.579 (27.1568)	84.354 (24.6288)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-4.598 (24.3554)	-5.263 (11.1840)	-4.861 (20.0349)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	85.802 (20.5188)	81.250 (25.7301)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	-3.846 (19.0366)	-7.292 (13.5657)	-5.159 (17.0636)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-33.33, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	100.000 (0.0000)	100.000 (0.0000)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	83.333 (40.8248)	88.095 (18.5450)	85.897 (29.5382)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	-8.333 (29.3447)	-7.143 (8.9087)	-7.692 (19.9715)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-66.67, 16.67	-16.67, 0.00	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	70.000 (13.9443)	80.000 (25.8199)	76.667 (22.5374)
Median	66.667	83.333	83.333
Q1, Q3	66.667, 83.333	83.333, 100.000	66.667, 100.000
Min, Max	50.00, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-26.667 (14.9071)	-3.333 (13.1468)	-11.111 (17.4423)
Median	-16.667	0.000	-16.667
Q1, Q3	-33.333, -16.667	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, -16.67	-16.67, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Social functioning			
Baseline			
n	35	32	67
Mean (SD)	87.619 (17.7781)	82.292 (26.4160)	85.075 (22.3106)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	88.889 (18.4780)	89.286 (21.3795)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (22.7726)	5.357 (26.4706)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 66.67	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	91.071 (15.3707)	93.182 (16.7925)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	4.321 (17.6581)	9.848 (30.2805)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 33.33	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	87.222 (22.1815)	85.965 (25.0081)	86.735 (23.0688)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	0.000 (24.3975)	4.386 (34.1755)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 8.333
Min, Max	-83.33, 50.00	-66.67, 83.33	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	91.358 (13.3736)	92.708 (12.1240)	91.860 (12.7927)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (16.9464)	9.375 (29.7948)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	100.000 (0.0000)	75.000 (35.3553)	87.500 (25.0000)
Median	100.000	75.000	100.000
Q1, Q3	100.000, 100.000	50.000, 100.000	75.000, 100.000
Min, Max	100.00, 100.00	50.00, 100.00	50.00, 100.00
Change from Baseline			
n	2	2	4
Mean (SD)	8.333 (11.7851)	25.000 (106.0660)	16.667 (62.3610)
Median	8.333	25.000	8.333
Q1, Q3	0.000, 16.667	-50.000, 100.000	-25.000, 58.333
Min, Max	0.00, 16.67	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	94.444 (13.6083)	90.476 (18.8982)	92.308 (16.1236)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	100.000, 100.000
Min, Max	66.67, 100.00	50.00, 100.00	50.00, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	5.556 (13.6083)	11.905 (40.4995)	8.974 (30.1350)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	-16.67, 100.00	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	66.667 (20.4124)	70.000 (30.2255)	68.889 (26.6270)
Median	66.667	75.000	66.667
Q1, Q3	66.667, 83.333	33.333, 100.000	33.333, 100.000
Min, Max	33.33, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	-16.667 (26.3523)	-6.667 (25.0924)	-10.000 (25.0397)
Median	-16.667	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Fatigue			
Baseline			
n	35	32	67
Mean (SD)	22.857 (17.6595)	36.632 (26.5821)	29.436 (23.2509)
Median	22.222	27.778	22.222
Q1, Q3	11.111, 33.333	16.667, 55.556	11.111, 44.444
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	18.855 (22.3062)	25.794 (22.4380)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 38.889	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	32	28	60
Mean (SD)	-2.778 (24.4412)	-9.722 (25.2842)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-44.44, 66.67	-88.89, 33.33	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	17.625 (15.2918)	30.808 (25.1817)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 33.333	11.111, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	28	22	50
Mean (SD)	-5.556 (14.0220)	-7.323 (25.0447)	-6.333 (19.4407)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-11.111, 11.111	-11.111, 0.000
Min, Max	-33.33, 22.22	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	18.148 (18.5657)	30.409 (25.8841)	22.902 (22.2694)
Median	16.667	33.333	22.222
Q1, Q3	0.000, 33.333	11.111, 44.444	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-3.448 (17.5942)	-11.404 (22.5648)	-6.597 (19.8714)
Median	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-44.44, 44.44	-55.56, 33.33	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	15.638 (18.2988)	27.083 (21.8369)	19.897 (20.2219)
Median	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	5.556, 33.333	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	26	16	42
Mean (SD)	-4.701 (16.3822)	-12.847 (25.9565)	-7.804 (20.6438)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-33.33, 33.33	-88.89, 11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	11.111 (0.0000)	5.556 (6.4150)
Median	0.000	11.111	5.556
Q1, Q3	0.000, 0.000	11.111, 11.111	0.000, 11.111
Min, Max	0.00, 0.00	11.11, 11.11	0.00, 11.11
Change from Baseline			
n	2	2	4
Mean (SD)	-11.111 (15.7135)	-38.889 (54.9972)	-25.000 (36.7115)
Median	-11.111	-38.889	-11.111
Q1, Q3	-22.222, 0.000	-77.778, 0.000	-50.000, 0.000
Min, Max	-22.22, 0.00	-77.78, 0.00	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	7.407 (9.0722)	22.222 (30.7653)	15.385 (23.8041)
Median	5.556	11.111	11.111
Q1, Q3	0.000, 11.111	0.000, 22.222	0.000, 22.222
Min, Max	0.00, 22.22	0.00, 88.89	0.00, 88.89
Change from Baseline			
n	6	7	13
Mean (SD)	-7.407 (5.7378)	-15.079 (37.2283)	-11.538 (26.8801)
Median	-11.111	0.000	0.000
Q1, Q3	-11.111, 0.000	-38.889, 0.000	-11.111, 0.000
Min, Max	-11.11, 0.00	-88.89, 22.22	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	51.111 (24.3432)	43.333 (30.2935)	45.926 (27.8148)
Median	66.667	38.889	44.444
Q1, Q3	44.444, 66.667	11.111, 77.778	11.111, 66.667
Min, Max	11.11, 66.67	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	5	10	15
Mean (SD)	31.111 (24.0883)	0.556 (18.6017)	10.741 (24.7088)
Median	44.444	-2.778	11.111
Q1, Q3	11.111, 44.444	-11.111, 11.111	-11.111, 33.333
Min, Max	0.00, 55.56	-22.22, 33.33	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	35	32	67
Mean (SD)	2.381 (10.0187)	5.729 (10.8834)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	2.020 (5.5239)	3.571 (10.4990)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	32	28	60
Mean (SD)	-0.521 (9.9139)	-1.786 (8.2891)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	1.724 (5.1656)	6.061 (21.5445)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	0.595 (5.5224)	-0.758 (18.8823)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	1.667 (5.0855)	7.018 (11.5414)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	29	19	48
Mean (SD)	0.575 (8.3128)	-0.877 (8.7378)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	0.000 (0.0000)	6.250 (13.4371)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (0.0000)	-1.042 (7.3755)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-16.67, 16.67	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	8.333 (11.7851)	4.167 (8.3333)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 8.333
Min, Max	0.00, 0.00	0.00, 16.67	0.00, 16.67
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	0.000 (0.0000)	7.143 (13.1133)	3.846 (9.9857)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	6	7	13
Mean (SD)	0.000 (0.0000)	-2.381 (6.2994)	-1.282 (4.6225)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-16.67, 0.00	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	10.000 (22.3607)	6.667 (16.1015)	7.778 (17.6683)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	5	10	15
Mean (SD)	10.000 (22.3607)	1.667 (12.2977)	4.444 (16.0192)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	-16.67, 33.33	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Pain			
Baseline			
n	35	31	66
Mean (SD)	9.524 (17.2854)	20.430 (24.2325)	14.646 (21.3868)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	10.606 (19.0112)	19.048 (23.0022)	14.481 (21.1860)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	27	59
Mean (SD)	0.521 (22.1935)	-0.617 (19.8722)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 8.333	0.000, 16.667	-16.667, 16.667
Min, Max	-33.33, 50.00	-66.67, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	8.621 (13.8162)	21.212 (30.5080)	14.052 (23.1835)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	21	49
Mean (SD)	0.000 (19.2450)	-3.175 (20.8294)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	15.000 (23.7120)	24.561 (29.0638)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	18	47
Mean (SD)	6.322 (22.8929)	-0.926 (27.0996)	3.546 (24.5580)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 50.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	10.494 (17.3871)	25.000 (27.8887)	15.891 (22.6993)
Median	0.000	25.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	15	41
Mean (SD)	2.564 (22.9455)	1.111 (18.3297)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	16.667 (23.5702)	8.333 (16.6667)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	2	2	4
Mean (SD)	-8.333 (11.7851)	8.333 (35.3553)	0.000 (23.5702)
Median	-8.333	8.333	-8.333
Q1, Q3	-16.667, 0.000	-16.667, 33.333	-16.667, 16.667
Min, Max	-16.67, 0.00	-16.67, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	5.556 (13.6083)	26.190 (37.0899)	16.667 (29.6586)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	6	12
Mean (SD)	5.556 (13.6083)	8.333 (20.4124)	6.944 (16.6034)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	-16.67, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	10.000 (14.9071)	25.000 (25.1538)	20.000 (22.8869)
Median	0.000	25.000	16.667
Q1, Q3	0.000, 16.667	0.000, 50.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	5	9	14
Mean (SD)	10.000 (14.9071)	1.852 (25.6098)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	0.00, 33.33	-33.33, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	35	32	67
Mean (SD)	16.190 (24.7490)	32.292 (35.4028)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	14.141 (20.4639)	21.429 (26.0014)	17.486 (23.2591)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (19.8279)	-8.333 (29.5717)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	11.494 (18.4216)	19.697 (30.2705)	15.033 (24.3253)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	-3.571 (26.1985)	-15.152 (30.3895)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	29	19	48
Mean (SD)	8.046 (14.5165)	17.544 (23.2231)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	28	19	47
Mean (SD)	-7.143 (24.6074)	-21.053 (37.2024)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	13.580 (21.2016)	20.833 (26.8742)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (26.6667)	-20.833 (41.9435)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	2	2	4
Mean (SD)	-33.333 (47.1405)	-50.000 (70.7107)	-41.667 (50.0000)
Median	-33.333	-50.000	-33.333
Q1, Q3	-66.667, 0.000	-100.000, 0.000	-83.333, 0.000
Min, Max	-66.67, 0.00	-100.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	5.556 (13.6083)	19.048 (26.2265)	12.821 (21.6815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	6	7	13
Mean (SD)	-11.111 (17.2133)	-19.048 (37.7964)	-15.385 (29.2353)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-33.33, 0.00	-100.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	60.000 (36.5148)	23.333 (27.4424)	35.556 (34.4265)
Median	66.667	16.667	33.333
Q1, Q3	66.667, 66.667	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	33.333 (33.3333)	-6.667 (21.0819)	6.667 (31.3708)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 66.667	-33.333, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Insomnia			
Baseline			
n	35	32	67
Mean (SD)	15.238 (21.9072)	25.000 (26.7740)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	14.141 (20.4639)	22.619 (27.2974)	18.033 (24.0168)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-2.083 (20.6307)	-1.190 (19.2068)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	13.793 (18.9344)	27.273 (31.9331)	19.608 (25.9713)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	-3.571 (20.9630)	-1.515 (19.1824)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	10.000 (19.8654)	31.579 (32.3440)	18.367 (27.2686)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-5.747 (25.3060)	0.000 (22.2222)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	13.580 (21.2016)	33.333 (34.4265)	20.930 (28.1936)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (16.3299)	0.000 (17.2133)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	16.667 (23.5702)	8.333 (16.6667)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	2	2	4
Mean (SD)	-16.667 (23.5702)	-33.333 (0.0000)	-25.000 (16.6667)
Median	-16.667	-33.333	-33.333
Q1, Q3	-33.333, 0.000	-33.333, -33.333	-33.333, -16.667
Min, Max	-33.33, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	0.000 (0.0000)	38.095 (35.6348)	20.513 (32.0256)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 0.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	7	13
Mean (SD)	-5.556 (13.6083)	0.000 (19.2450)	-2.564 (16.4516)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	20.000 (29.8142)	30.000 (29.1865)	26.667 (28.7297)
Median	0.000	33.333	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	5	10	15
Mean (SD)	6.667 (14.9071)	16.667 (28.3279)	13.333 (24.5596)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	35	32	67
Mean (SD)	6.667 (15.7596)	19.792 (29.1571)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	8.081 (16.7297)	13.095 (20.9630)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (21.5599)	-8.333 (29.5717)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	6.897 (16.3768)	10.606 (23.8744)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	0.000 (22.2222)	-10.606 (29.7900)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	5.556 (15.3711)	10.526 (19.4131)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	-1.149 (22.6827)	-12.281 (33.7209)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	6.173 (16.1114)	18.750 (27.1314)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (22.0721)	-2.083 (33.2638)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	-50.000 (70.7107)	-25.000 (50.0000)
Median	0.000	-50.000	0.000
Q1, Q3	0.000, 0.000	-100.000, 0.000	-50.000, 0.000
Min, Max	0.00, 0.00	-100.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	0.000 (0.0000)	14.286 (26.2265)	7.692 (19.9715)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	6	7	13
Mean (SD)	-5.556 (13.6083)	-14.286 (42.4139)	-10.256 (31.5777)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	33.333 (40.8248)	30.000 (36.6835)	31.111 (36.6595)
Median	33.333	16.667	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	33.333 (40.8248)	0.000 (31.4270)	11.111 (37.0899)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	-66.67, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Constipation			
Baseline			
n	35	32	67
Mean (SD)	6.667 (17.7123)	11.458 (18.1775)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	9.091 (17.2255)	15.476 (27.9361)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	2.083 (18.8134)	4.762 (26.7811)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	9.195 (17.5855)	7.576 (17.6138)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	28	22	50
Mean (SD)	2.381 (20.1406)	-1.515 (19.1824)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	11.111 (18.2224)	5.263 (12.4878)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	3.448 (16.2930)	-5.263 (16.7153)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	8.642 (17.5231)	22.917 (39.8493)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (17.5898)	12.500 (38.2487)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	-16.667 (23.5702)	-8.333 (16.6667)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	0.00, 0.00	-33.33, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	0.000 (0.0000)	14.286 (17.8174)	7.692 (14.6176)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	6	7	13
Mean (SD)	-5.556 (13.6083)	4.762 (29.9912)	0.000 (23.5702)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	26.667 (43.4613)	20.000 (32.2031)	22.222 (34.8845)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	26.667 (43.4613)	6.667 (14.0546)	13.333 (27.6026)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	35	31	66
Mean (SD)	3.810 (13.4588)	10.753 (23.3921)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	5.051 (18.8584)	5.952 (13.0007)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	32	27	59
Mean (SD)	1.042 (10.3154)	-1.235 (19.5712)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	4.762 (14.9465)	10.606 (18.9300)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	27	21	48
Mean (SD)	2.469 (12.8300)	3.175 (20.8294)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	5.556 (15.3711)	5.263 (12.4878)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	18	47
Mean (SD)	3.448 (13.6418)	-1.852 (24.1786)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	7.407 (21.3504)	6.250 (13.4371)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	26	15	41
Mean (SD)	5.128 (20.4229)	0.000 (17.8174)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	5.556 (13.6083)	4.762 (12.5988)	5.128 (12.5178)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	6	6	12
Mean (SD)	5.556 (13.6083)	5.556 (13.6083)	5.556 (12.9750)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	20.000 (29.8142)	0.000 (0.0000)	6.667 (18.6871)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	5	9	14
Mean (SD)	20.000 (29.8142)	-3.704 (11.1111)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	35	32	67
Mean (SD)	21.905 (34.2452)	10.417 (26.0101)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	15.152 (27.7525)	8.333 (21.5166)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-5.208 (29.4628)	-2.381 (15.5253)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	15.476 (26.4219)	4.545 (15.5854)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	27	22	49
Mean (SD)	-4.938 (31.6278)	-1.515 (12.5030)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	10.000 (19.8654)	3.509 (10.5101)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	-9.195 (21.6329)	-3.509 (10.5101)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	16.049 (29.7717)	8.333 (22.7710)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	-2.564 (18.6740)	2.083 (14.7510)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 15			
n	2	2	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	2	2	4
Mean (SD)	-16.667 (23.5702)	0.000 (0.0000)	-8.333 (16.6667)
Median	-16.667	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	6	7	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	6	7	13
Mean (SD)	-11.111 (27.2166)	0.000 (0.0000)	-5.128 (18.4900)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 0.00	0.00, 0.00	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	10	15
Mean (SD)	53.333 (50.5525)	23.333 (35.3117)	33.333 (41.7855)
Median	66.667	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	5	10	15
Mean (SD)	6.667 (14.9071)	0.000 (27.2166)	2.222 (23.4577)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Global health status/QOL					
Baseline					
n	27	40	48	19	67
Mean (SD)	67.593 (22.9191)	65.000 (20.1667)	67.708 (21.3067)	61.842 (20.8455)	66.045 (21.1871)
Median	75.000	66.667	75.000	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 83.333	50.000, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	0.00, 100.00	25.00, 100.00	0.00, 100.00	25.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	75.000 (20.4124)	75.877 (14.8553)	76.550 (18.1170)	73.148 (14.1639)	75.546 (17.0014)
Median	83.333	75.000	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	6.522 (21.0153)	9.234 (19.5220)	7.738 (19.4254)	9.259 (21.7474)	8.194 (19.9748)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	0.000, 16.667	0.000, 25.000	0.000, 16.667
Min, Max	-41.67, 66.67	-33.33, 50.00	-41.67, 66.67	-33.33, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	72.083 (23.3012)	76.944 (18.3990)	75.926 (20.6807)	72.619 (20.2623)	75.000 (20.4124)
Median	83.333	83.333	83.333	70.833	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	66.667, 91.667	58.333, 91.667	66.667, 91.667
Min, Max	8.33, 100.00	33.33, 100.00	8.33, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	5.417 (10.9073)	9.483 (18.4633)	7.619 (16.7121)	8.333 (13.8675)	7.823 (15.8121)
Median	0.000	8.333	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-8.33, 41.67	-16.67, 66.67	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	68.860 (24.1909)	74.722 (19.8755)	72.059 (21.6027)	73.333 (22.3163)	72.449 (21.5974)
Median	66.667	83.333	79.167	83.333	83.333
Q1, Q3	58.333, 83.333	58.333, 83.333	66.667, 83.333	58.333, 91.667	58.333, 83.333
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	3.070 (20.2627)	6.897 (20.1764)	4.293 (19.4456)	7.778 (21.9276)	5.382 (20.0833)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667	0.000, 25.000	0.000, 16.667
Min, Max	-33.33, 50.00	-50.00, 41.67	-41.67, 50.00	-50.00, 41.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	74.479 (26.7825)	76.543 (15.5107)	76.149 (22.1292)	75.000 (16.0128)	75.775 (20.1527)
Median	83.333	83.333	83.333	79.167	83.333
Q1, Q3	66.667, 87.500	66.667, 83.333	66.667, 83.333	66.667, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	7.292 (13.5657)	7.051 (19.5352)	7.143 (14.6485)	7.143 (22.3743)	7.143 (17.3216)
Median	8.333	8.333	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667	-8.333, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 58.33	-16.67, 41.67	-33.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	80.556 (20.9718)	83.333 (-)	80.556 (20.9718)	83.333 (-)	81.250 (17.1796)
Median	83.333	83.333	83.333	83.333	83.333
Q1, Q3	58.333, 100.000	83.333, 83.333	58.333, 100.000	83.333, 83.333	70.833, 91.667
Min, Max	58.33, 100.00	83.33, 83.33	58.33, 100.00	83.33, 83.33	58.33, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-2.778 (20.9718)	58.333 (-)	-2.778 (20.9718)	58.333 (-)	12.500 (35.0264)
Median	0.000	58.333	0.000	58.333	8.333
Q1, Q3	-25.000, 16.667	58.333, 58.333	-25.000, 16.667	58.333, 58.333	-12.500, 37.500
Min, Max	-25.00, 16.67	58.33, 58.33	-25.00, 16.67	58.33, 58.33	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	68.750 (18.4780)	83.333 (12.5000)	75.000 (16.6667)	87.500 (8.3333)	78.846 (15.4468)
Median	75.000	83.333	75.000	83.333	83.333
Q1, Q3	58.333, 79.167	83.333, 83.333	75.000, 83.333	83.333, 91.667	75.000, 83.333
Min, Max	41.67, 83.33	58.33, 100.00	41.67, 100.00	83.33, 100.00	41.67, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	-6.250 (10.4859)	17.593 (20.1748)	3.704 (15.0872)	25.000 (26.3523)	10.256 (20.7370)
Median	-8.333	8.333	0.000	20.833	8.333
Q1, Q3	-12.500, 0.000	0.000, 33.333	-8.333, 8.333	4.167, 45.833	0.000, 16.667
Min, Max	-16.67, 8.33	0.00, 58.33	-16.67, 33.33	0.00, 58.33	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	54.762 (26.2895)	54.167 (26.7261)	52.564 (26.8709)	66.667 (11.7851)	54.444 (25.5625)
Median	66.667	54.167	50.000	66.667	58.333
Q1, Q3	25.000, 66.667	33.333, 70.833	33.333, 66.667	58.333, 75.000	33.333, 66.667
Min, Max	16.67, 91.67	16.67, 100.00	16.67, 100.00	58.33, 75.00	16.67, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-11.905 (40.4995)	-14.583 (18.7665)	-16.026 (31.0804)	4.167 (5.8926)	-13.333 (29.6808)
Median	0.000	-16.667	-16.667	4.167	-16.667
Q1, Q3	-50.000, 16.667	-29.167, 4.167	-33.333, 8.333	0.000, 8.333	-33.333, 8.333
Min, Max	-75.00, 41.67	-41.67, 8.33	-75.00, 41.67	0.00, 8.33	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Physical functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	86.667 (17.9267)	80.833 (20.5446)	87.083 (15.6442)	73.333 (25.0432)	83.184 (19.6041)
Median	93.333	86.667	93.333	80.000	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	86.667, 100.000	46.667, 93.333	80.000, 100.000
Min, Max	40.00, 100.00	20.00, 100.00	40.00, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	37	42	18	60
Mean (SD)	88.406 (17.6632)	84.324 (16.2706)	89.365 (15.0201)	77.778 (18.2932)	85.889 (16.7890)
Median	93.333	86.667	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000	73.333, 86.667	83.333, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	26.67, 100.00	26.67, 93.33	26.67, 100.00
Change from Baseline					
n	23	36	41	18	59
Mean (SD)	0.000 (13.6330)	2.222 (13.9841)	0.650 (11.7194)	2.963 (17.8918)	1.356 (13.7732)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-6.667, 0.000	-6.667, 6.667	0.000, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-33.33, 40.00	-26.67, 53.33	-33.33, 40.00	-26.67, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	86.000 (24.3656)	86.667 (12.9957)	87.778 (19.0238)	83.111 (15.7090)	86.405 (18.0843)
Median	93.333	86.667	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	46.67, 100.00	20.00, 100.00	46.67, 100.00	20.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	1.000 (13.3815)	3.778 (18.3356)	-0.381 (12.2012)	9.778 (22.5187)	2.667 (16.4406)
Median	0.000	0.000	0.000	6.667	0.000
Q1, Q3	-3.333, 6.667	-6.667, 6.667	-6.667, 6.667	-6.667, 26.667	-6.667, 6.667
Min, Max	-20.00, 33.33	-33.33, 53.33	-20.00, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	84.912 (24.5294)	84.667 (20.5032)	88.235 (19.2141)	76.889 (26.0484)	84.762 (21.9004)
Median	93.333	86.667	93.333	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	86.667, 100.000	80.000, 86.667	80.000, 100.000
Min, Max	0.00, 100.00	6.67, 100.00	0.00, 100.00	6.67, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.702 (12.3518)	2.069 (22.0464)	0.404 (11.0478)	4.000 (29.6862)	1.528 (18.6666)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667	-6.667, 13.333	0.000, 6.667
Min, Max	-40.00, 20.00	-73.33, 53.33	-40.00, 20.00	-73.33, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	26	29	13	42
Mean (SD)	82.083 (27.6184)	87.436 (16.8999)	87.586 (21.6556)	80.513 (20.9870)	85.397 (21.4508)
Median	90.000	93.333	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	86.667, 100.000	80.000, 93.333	86.667, 100.000
Min, Max	0.00, 100.00	20.00, 100.00	0.00, 100.00	20.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	-2.083 (14.5488)	4.800 (15.5778)	-0.238 (12.1014)	7.179 (20.4508)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-6.667, 3.333	0.000, 6.667	0.000, 6.667	0.000, 6.667	0.000, 6.667
Min, Max	-40.00, 26.67	-13.33, 60.00	-40.00, 26.67	-13.33, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	97.778 (3.8490)	93.333 (-)	97.778 (3.8490)	93.333 (-)	96.667 (3.8490)
Median	100.000	93.333	100.000	93.333	96.667
Q1, Q3	93.333, 100.000	93.333, 93.333	93.333, 100.000	93.333, 93.333	93.333, 100.000
Min, Max	93.33, 100.00	93.33, 93.33	93.33, 100.00	93.33, 93.33	93.33, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	60.000 (-)	0.000 (0.0000)	60.000 (-)	15.000 (30.0000)
Median	0.000	60.000	0.000	60.000	0.000
Q1, Q3	0.000, 0.000	60.000, 60.000	0.000, 0.000	60.000, 60.000	0.000, 30.000
Min, Max	0.00, 0.00	60.00, 60.00	0.00, 0.00	60.00, 60.00	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	76.667 (33.7749)	88.889 (11.5470)	83.704 (24.2925)	88.333 (6.3828)	85.128 (20.2125)
Median	90.000	93.333	93.333	90.000	93.333
Q1, Q3	56.667, 96.667	80.000, 100.000	80.000, 100.000	83.333, 93.333	80.000, 100.000
Min, Max	26.67, 100.00	66.67, 100.00	26.67, 100.00	80.00, 93.33	26.67, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	-1.667 (8.3887)	2.222 (24.2670)	-4.444 (11.0554)	13.333 (32.2031)	1.026 (20.3390)
Median	0.000	0.000	0.000	3.333	0.000
Q1, Q3	-6.667, 3.333	-13.333, 6.667	-13.333, 0.000	-6.667, 33.333	-13.333, 6.667
Min, Max	-13.33, 6.67	-26.67, 60.00	-26.67, 6.67	-13.33, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	82.857 (14.8360)	70.833 (19.1693)	78.462 (18.2886)	63.333 (4.7140)	76.444 (17.7936)
Median	86.667	73.333	80.000	63.333	80.000
Q1, Q3	66.667, 93.333	53.333, 83.333	66.667, 93.333	60.000, 66.667	60.000, 93.333
Min, Max	60.00, 100.00	46.67, 100.00	46.67, 100.00	60.00, 66.67	46.67, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-4.762 (17.9358)	-6.667 (11.8187)	-4.615 (15.2472)	-13.333 (0.0000)	-5.778 (14.4457)
Median	-6.667	-6.667	0.000	-13.333	-6.667
Q1, Q3	-20.000, 6.667	-16.667, 0.000	-20.000, 0.000	-13.333, -13.333	-20.000, 0.000
Min, Max	-26.67, 26.67	-20.00, 13.33	-26.67, 26.67	-13.33, -13.33	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	58.333 (-)	58.333 (-)	- (-)	58.333 (-)
Median	-	58.333	58.333	-	58.333
Q1, Q3	-, -	58.333, 58.333	58.333, 58.333	-, -	58.333, 58.333
Min, Max	-, -	58.33, 58.33	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	60.000 (-)	60.000 (-)	- (-)	60.000 (-)
Median	-	60.000	60.000	-	60.000
Q1, Q3	-, -	60.000, 60.000	60.000, 60.000	-, -	60.000, 60.000
Min, Max	-, -	60.00, 60.00	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-6.667 (-)	-6.667 (-)	- (-)	-6.667 (-)
Median	-	-6.667	-6.667	-	-6.667
Q1, Q3	-, -	-6.667, -6.667	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Role functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	87.037 (23.2661)	80.833 (26.5677)	87.500 (22.1482)	72.807 (30.0260)	83.333 (25.2929)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	87.681 (23.6864)	86.404 (20.8150)	89.535 (20.2574)	80.556 (24.4214)	86.885 (21.7551)
Median	100.000	100.000	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (26.1116)	3.604 (21.9199)	0.397 (21.9287)	6.481 (26.8978)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-50.00, 66.67	-66.67, 66.67	-50.00, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	90.000 (21.2201)	89.785 (15.9149)	92.130 (17.1298)	84.444 (19.3820)	89.869 (17.9748)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	91.667, 100.000	83.333, 100.000	91.667, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	5.000 (10.9491)	6.111 (24.5587)	2.857 (13.0895)	12.222 (30.5158)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	85.088 (25.3949)	87.222 (25.4023)	90.196 (20.5635)	77.778 (32.5300)	86.395 (25.1554)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.877 (23.2231)	2.299 (19.2746)	1.010 (19.0665)	3.333 (24.5596)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 33.33	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	83.333 (29.1865)	88.272 (22.5580)	88.506 (24.0302)	82.143 (27.3192)	86.434 (25.0015)
Median	100.000	100.000	100.000	91.667	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (14.7510)	3.846 (23.7148)	-1.786 (16.5672)	8.333 (26.7547)	1.587 (20.7611)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-33.33, 16.67	-50.00, 83.33	-50.00, 33.33	-33.33, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	5.556 (9.6225)	100.000 (-)	5.556 (9.6225)	100.000 (-)	29.167 (47.8714)
Median	0.000	100.000	0.000	100.000	8.333
Q1, Q3	0.000, 16.667	100.000, 100.000	0.000, 16.667	100.000, 100.000	0.000, 58.333
Min, Max	0.00, 16.67	100.00, 100.00	0.00, 16.67	100.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	75.000 (31.9142)	88.889 (16.6667)	81.481 (24.2161)	91.667 (16.6667)	84.615 (22.0075)
Median	83.333	100.000	100.000	100.000	100.000
Q1, Q3	50.000, 100.000	66.667, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	-8.333 (16.6667)	5.556 (39.0868)	-9.259 (18.8398)	25.000 (50.0000)	1.282 (33.6523)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 50.000	0.000, 0.000
Min, Max	-33.33, 0.00	-33.33, 100.00	-33.33, 16.67	0.00, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	66.667 (39.6746)	60.417 (26.6332)	62.821 (34.7969)	66.667 (0.0000)	63.333 (32.2441)
Median	83.333	66.667	66.667	66.667	66.667
Q1, Q3	33.333, 100.000	41.667, 75.000	33.333, 100.000	66.667, 66.667	33.333, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00	66.67, 66.67	0.00, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-11.905 (38.1448)	-14.583 (20.7737)	-14.103 (31.0661)	-8.333 (11.7851)	-13.333 (29.0047)
Median	0.000	-16.667	-16.667	-8.333	-16.667
Q1, Q3	-50.000, 0.000	-25.000, 0.000	-33.333, 0.000	-16.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 50.00	-50.00, 16.67	-66.67, 50.00	-16.67, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Emotional functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	85.185 (15.2145)	80.208 (19.4005)	84.201 (16.2392)	77.193 (21.1261)	82.214 (17.8786)
Median	91.667	83.333	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	58.33, 100.00	25.00, 100.00	41.67, 100.00	25.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	81.522 (27.2887)	86.404 (16.1428)	85.853 (21.7865)	81.481 (19.0792)	84.563 (20.9627)
Median	100.000	91.667	100.000	83.333	91.667
Q1, Q3	66.667, 100.000	75.000, 100.000	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	41.67, 100.00	16.67, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-3.261 (24.5848)	6.081 (13.4154)	1.786 (20.8667)	4.167 (13.4826)	2.500 (18.8724)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-25.00, 33.33	-75.00, 33.33	-25.00, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	83.333 (21.2889)	83.056 (22.6885)	84.954 (22.6971)	78.571 (19.8052)	83.167 (21.9183)
Median	91.667	91.667	91.667	83.333	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	83.333, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-0.417 (15.6429)	5.747 (20.9050)	2.143 (17.5435)	5.952 (22.7464)	3.231 (19.0042)
Median	0.000	8.333	0.000	8.333	0.000
Q1, Q3	-12.500, 8.333	0.000, 16.667	-8.333, 8.333	0.000, 25.000	0.000, 16.667
Min, Max	-25.00, 33.33	-50.00, 41.67	-41.67, 41.67	-50.00, 33.33	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	83.772 (22.6476)	82.222 (22.7148)	82.598 (23.4240)	83.333 (20.8928)	82.823 (22.4645)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	8.33, 100.00	16.67, 100.00	8.33, 100.00	41.67, 100.00	8.33, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.877 (19.8168)	2.586 (19.9334)	0.000 (19.3200)	6.111 (20.5255)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 16.667	-8.333, 16.667	0.000, 16.667	-8.333, 16.667
Min, Max	-50.00, 33.33	-41.67, 50.00	-50.00, 33.33	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	77.083 (30.0463)	86.420 (18.6551)	80.172 (27.4055)	88.690 (11.6057)	82.946 (23.6370)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	50.000, 100.000	83.333, 100.000	75.000, 100.000	83.333, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-7.292 (21.4897)	6.090 (13.4490)	-2.381 (19.3592)	7.738 (12.8537)	0.992 (17.9583)
Median	0.000	0.000	0.000	4.167	0.000
Q1, Q3	-20.833, 4.167	0.000, 16.667	-16.667, 12.500	0.000, 8.333	0.000, 8.333
Min, Max	-50.00, 25.00	-16.67, 41.67	-50.00, 25.00	-8.33, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	91.667 (14.4338)	83.333 (-)	91.667 (14.4338)	83.333 (-)	89.583 (12.5000)
Median	100.000	83.333	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	83.333, 83.333	75.000, 100.000	83.333, 83.333	79.167, 100.000
Min, Max	75.00, 100.00	83.33, 83.33	75.00, 100.00	83.33, 83.33	75.00, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	11.111 (12.7294)	8.333 (-)	11.111 (12.7294)	8.333 (-)	10.417 (10.4859)
Median	8.333	8.333	8.333	8.333	8.333
Q1, Q3	0.000, 25.000	8.333, 8.333	0.000, 25.000	8.333, 8.333	4.167, 16.667
Min, Max	0.00, 25.00	8.33, 8.33	0.00, 25.00	8.33, 8.33	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	81.250 (10.4859)	81.481 (29.3972)	77.778 (28.2597)	89.583 (12.5000)	81.410 (24.5689)
Median	83.333	91.667	83.333	91.667	83.333
Q1, Q3	75.000, 87.500	75.000, 100.000	75.000, 91.667	79.167, 100.000	75.000, 100.000
Min, Max	66.67, 91.67	8.33, 100.00	8.33, 100.00	75.00, 100.00	8.33, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	2.083 (7.9786)	0.926 (18.3733)	1.852 (18.5301)	0.000 (6.8041)	1.282 (15.5330)
Median	4.167	0.000	0.000	0.000	0.000
Q1, Q3	-4.167, 8.333	-8.333, 8.333	-8.333, 8.333	-4.167, 4.167	-8.333, 8.333
Min, Max	-8.33, 8.33	-33.33, 33.33	-33.33, 33.33	-8.33, 8.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	78.571 (31.1274)	75.000 (18.8982)	76.282 (26.3185)	79.167 (5.8926)	76.667 (24.4381)
Median	91.667	79.167	91.667	79.167	83.333
Q1, Q3	33.333, 100.000	70.833, 87.500	66.667, 91.667	75.000, 83.333	66.667, 91.667
Min, Max	33.33, 100.00	33.33, 91.67	33.33, 100.00	75.00, 83.33	33.33, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-8.333 (23.5702)	-13.542 (16.0217)	-12.179 (20.5861)	-4.167 (5.8926)	-11.111 (19.3307)
Median	0.000	-12.500	-8.333	-4.167	-8.333
Q1, Q3	-25.000, 0.000	-29.167, 0.000	-25.000, 0.000	-8.333, 0.000	-25.000, 0.000
Min, Max	-50.00, 25.00	-33.33, 8.33	-50.00, 25.00	-8.33, 0.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-13.889 (-)	-13.889 (-)	- (-)	-13.889 (-)
Median	-	-13.889	-13.889	-	-13.889
Q1, Q3	-, -	-13.889, -13.889	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cognitive functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	85.802 (20.5188)	89.583 (15.8732)	88.542 (17.9164)	86.842 (18.0696)	88.060 (17.8391)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	86.957 (20.0734)	85.088 (14.9018)	86.822 (17.6526)	83.333 (15.1248)	85.792 (16.8973)
Median	100.000	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (21.3201)	-5.856 (13.7303)	-2.381 (17.4885)	-6.481 (16.3088)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	81.667 (25.8764)	86.667 (21.1725)	83.796 (25.0352)	86.905 (17.5150)	84.667 (23.0449)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-4.167 (15.1744)	-5.172 (15.4967)	-5.714 (16.6386)	-2.381 (11.0499)	-4.762 (15.2145)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-66.67, 16.67	-66.67, 33.33	-33.33, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	85.088 (28.2705)	83.889 (22.5243)	86.275 (24.0897)	80.000 (26.1255)	84.354 (24.6288)
Median	100.000	83.333	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.000 (18.4257)	-8.046 (20.7119)	-2.525 (16.2025)	-10.000 (26.5772)	-4.861 (20.0349)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-100.00, 16.67	-33.33, 50.00	-100.00, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	80.208 (28.0335)	86.420 (18.5114)	83.333 (25.5883)	85.714 (14.4073)	84.109 (22.4060)
Median	100.000	83.333	100.000	83.333	83.333
Q1, Q3	58.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-6.250 (22.6691)	-4.487 (12.9595)	-5.952 (19.8836)	-3.571 (9.6489)	-5.159 (17.0636)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00	-16.67, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	83.333 (23.5702)	87.037 (33.1010)	79.630 (34.1339)	100.000 (0.0000)	85.897 (29.5382)
Median	91.667	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	100.000, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	-4.167 (15.9571)	-9.259 (22.2222)	-11.111 (23.5702)	0.000 (0.0000)	-7.692 (19.9715)
Median	-8.333	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 8.333	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 0.00	-66.67, 16.67	0.00, 0.00	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	73.810 (23.2879)	79.167 (23.1455)	74.359 (23.1894)	91.667 (11.7851)	76.667 (22.5374)
Median	83.333	83.333	83.333	91.667	83.333
Q1, Q3	50.000, 83.333	66.667, 100.000	66.667, 83.333	83.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	83.33, 100.00	33.33, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-11.905 (20.8928)	-10.417 (15.2688)	-12.821 (16.8790)	0.000 (23.5702)	-11.111 (17.4423)
Median	-16.667	-16.667	-16.667	0.000	-16.667
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67	-16.67, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Social functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	88.272 (19.5105)	82.917 (24.0155)	86.806 (20.6165)	80.702 (26.2133)	85.075 (22.3106)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	85.507 (23.1946)	91.228 (17.2148)	89.922 (20.2953)	87.037 (18.5729)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-2.174 (24.2589)	6.306 (24.3278)	2.381 (22.2609)	4.630 (29.5973)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 66.67	-50.00, 100.00	-50.00, 66.67	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	92.500 (17.5010)	91.667 (15.0032)	93.056 (15.1054)	89.286 (18.0303)	92.000 (15.8794)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	6.667 (23.1951)	6.897 (25.0068)	6.190 (21.0375)	8.333 (31.1805)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 83.33	-50.00, 100.00	-33.33, 83.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	83.333 (26.0579)	88.889 (21.1423)	87.255 (21.3433)	85.556 (27.3620)	86.735 (23.0688)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-1.754 (30.8795)	4.023 (26.9682)	0.505 (27.1585)	4.444 (31.7897)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 8.333
Min, Max	-66.67, 83.33	-83.33, 66.67	-66.67, 83.33	-83.33, 66.67	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	87.500 (15.5158)	94.444 (10.3362)	90.230 (13.7417)	95.238 (10.1875)	91.860 (12.7927)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (19.1243)	8.333 (24.1523)	0.595 (17.8483)	11.905 (29.5468)	4.365 (22.7093)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-8.333, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	83.333 (28.8675)	100.000 (-)	83.333 (28.8675)	100.000 (-)	87.500 (25.0000)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	50.000, 100.000	100.000, 100.000	50.000, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	100.00, 100.00	50.00, 100.00	100.00, 100.00	50.00, 100.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-11.111 (34.6944)	100.000 (-)	-11.111 (34.6944)	100.000 (-)	16.667 (62.3610)
Median	0.000	100.000	0.000	100.000	8.333
Q1, Q3	-50.000, 16.667	100.000, 100.000	-50.000, 16.667	100.000, 100.000	-25.000, 58.333
Min, Max	-50.00, 16.67	100.00, 100.00	-50.00, 16.67	100.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	87.500 (25.0000)	94.444 (11.7851)	88.889 (18.6339)	100.000 (0.0000)	92.308 (16.1236)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	75.000, 100.000	100.000, 100.000	83.333, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	50.00, 100.00	66.67, 100.00	50.00, 100.00	100.00, 100.00	50.00, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	-4.167 (8.3333)	14.815 (34.8055)	0.000 (14.4338)	29.167 (47.8714)	8.974 (30.1350)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	-8.333, 0.000	0.000, 16.667	0.000, 0.000	0.000, 58.333	0.000, 0.000
Min, Max	-16.67, 0.00	-16.67, 100.00	-16.67, 33.33	0.00, 100.00	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	66.667 (28.8675)	70.833 (26.3523)	69.231 (25.3185)	66.667 (47.1405)	68.889 (26.6270)
Median	66.667	75.000	66.667	66.667	66.667
Q1, Q3	33.333, 100.000	50.000, 91.667	50.000, 83.333	33.333, 100.000	33.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	-11.905 (28.4056)	-8.333 (23.5702)	-10.256 (25.0356)	-8.333 (35.3553)	-10.000 (25.0397)
Median	0.000	-8.333	0.000	-8.333	0.000
Q1, Q3	-50.000, 16.667	-33.333, 16.667	-33.333, 16.667	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Fatigue					
Baseline					
n	27	40	48	19	67
Mean (SD)	24.280 (24.6605)	32.917 (21.8772)	24.306 (20.7118)	42.398 (24.7907)	29.436 (23.2509)
Median	22.222	27.778	22.222	44.444	22.222
Q1, Q3	11.111, 33.333	16.667, 47.222	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 88.89	0.00, 100.00	0.00, 88.89	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	24.155 (26.0906)	20.760 (20.2043)	20.155 (21.9903)	26.543 (23.5360)	22.040 (22.4518)
Median	22.222	16.667	11.111	27.778	22.222
Q1, Q3	0.000, 44.444	0.000, 33.333	0.000, 22.222	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.966 (28.0118)	-10.360 (21.9958)	-2.646 (22.1964)	-13.889 (29.4127)	-6.019 (24.8724)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-11.111, 11.111	-22.222, 0.000	-11.111, 0.000	-33.333, 0.000	-22.222, 0.000
Min, Max	-55.56, 66.67	-88.89, 33.33	-55.56, 66.67	-88.89, 33.33	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	26.667 (24.0208)	21.147 (18.8899)	23.148 (22.7516)	23.704 (16.7283)	23.312 (20.9944)
Median	22.222	22.222	22.222	22.222	22.222
Q1, Q3	11.111, 27.778	0.000, 33.333	5.556, 33.333	11.111, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.556 (13.2331)	-10.926 (21.6636)	-0.952 (13.8388)	-18.889 (24.8274)	-6.333 (19.4407)
Median	0.000	-11.111	0.000	-11.111	0.000
Q1, Q3	-5.556, 11.111	-22.222, 0.000	-11.111, 11.111	-27.778, 0.000	-11.111, 0.000
Min, Max	-22.22, 22.22	-77.78, 33.33	-22.22, 33.33	-77.78, 11.11	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	22.222 (26.4497)	23.333 (19.6500)	20.915 (23.3333)	27.407 (19.6381)	22.902 (22.2694)
Median	11.111	22.222	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	22.222, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 77.78	0.00, 100.00	0.00, 77.78	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-4.678 (18.2633)	-7.854 (21.0775)	-4.040 (17.0824)	-12.222 (24.6850)	-6.597 (19.8714)
Median	0.000	0.000	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-11.111, 0.000	-33.333, 0.000	-19.444, 0.000
Min, Max	-44.44, 33.33	-55.56, 44.44	-44.44, 33.33	-55.56, 44.44	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	20.833 (24.3009)	19.342 (17.8611)	18.008 (20.6623)	23.810 (19.4204)	19.897 (20.2219)
Median	16.667	22.222	11.111	33.333	22.222
Q1, Q3	0.000, 38.889	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-3.472 (15.5655)	-10.470 (23.1115)	-5.159 (14.6541)	-13.095 (29.2033)	-7.804 (20.6438)
Median	0.000	0.000	0.000	-11.111	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-22.22, 33.33	-88.89, 33.33	-33.33, 33.33	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	3.704 (6.4150)	11.111 (-)	3.704 (6.4150)	11.111 (-)	5.556 (6.4150)
Median	0.000	11.111	0.000	11.111	5.556
Q1, Q3	0.000, 11.111	11.111, 11.111	0.000, 11.111	11.111, 11.111	0.000, 11.111
Min, Max	0.00, 11.11	11.11, 11.11	0.00, 11.11	11.11, 11.11	0.00, 11.11
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-7.407 (12.8300)	-77.778 (-)	-7.407 (12.8300)	-77.778 (-)	-25.000 (36.7115)
Median	0.000	-77.778	0.000	-77.778	-11.111
Q1, Q3	-22.222, 0.000	-77.778, -77.778	-22.222, 0.000	-77.778, -77.778	-50.000, 0.000
Min, Max	-22.22, 0.00	-77.78, -77.78	-22.22, 0.00	-77.78, -77.78	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	33.333 (37.4056)	7.407 (9.6225)	20.988 (26.8997)	2.778 (5.5556)	15.385 (23.8041)
Median	16.667	0.000	11.111	0.000	11.111
Q1, Q3	11.111, 55.556	0.000, 11.111	11.111, 22.222	0.000, 5.556	0.000, 22.222
Min, Max	11.11, 88.89	0.00, 22.22	0.00, 88.89	0.00, 11.11	0.00, 88.89
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	5.556 (11.1111)	-19.136 (28.7485)	-1.235 (10.3107)	-34.722 (39.6422)	-11.538 (26.8801)
Median	0.000	-11.111	0.000	-25.000	0.000
Q1, Q3	0.000, 11.111	-11.111, 0.000	-11.111, 0.000	-63.889, -5.556	-11.111, 0.000
Min, Max	0.00, 22.22	-88.89, 0.00	-11.11, 22.22	-88.89, 0.00	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	38.095 (27.8570)	52.778 (27.6983)	44.444 (29.3972)	55.556 (15.7135)	45.926 (27.8148)
Median	33.333	66.667	44.444	55.556	44.444
Q1, Q3	11.111, 66.667	27.778, 72.222	11.111, 66.667	44.444, 66.667	11.111, 66.667
Min, Max	0.00, 77.78	11.11, 77.78	0.00, 77.78	44.44, 66.67	0.00, 77.78
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	7.937 (31.2393)	13.194 (19.2307)	11.966 (26.2395)	2.778 (11.7851)	10.741 (24.7088)
Median	0.000	11.111	11.111	2.778	11.111
Q1, Q3	-22.222, 44.444	-2.778, 27.778	-11.111, 33.333	-5.556, 11.111	-11.111, 33.333
Min, Max	-22.22, 55.56	-11.11, 44.44	-22.22, 55.56	-5.56, 11.11	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Nausea and vomiting					
Baseline					
n	27	40	48	19	67
Mean (SD)	5.556 (13.0744)	2.917 (8.3440)	3.819 (10.4506)	4.386 (10.8896)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	4.348 (11.4783)	1.754 (5.1835)	3.488 (9.3139)	0.926 (3.9284)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-0.725 (9.3720)	-1.351 (9.1104)	0.000 (9.0167)	-3.704 (9.1386)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-33.33, 16.67	-33.33, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	5.833 (22.4748)	2.151 (5.6796)	4.167 (17.0783)	2.222 (5.8644)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	1.667 (17.8525)	-1.111 (8.6805)	1.429 (14.2179)	-3.333 (9.3435)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 16.67	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	3.509 (8.9217)	3.889 (8.4001)	3.431 (7.9766)	4.444 (9.8936)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-0.877 (6.7442)	0.575 (9.4310)	0.505 (7.7782)	-1.111 (9.8936)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	4.167 (12.9099)	1.235 (4.4480)	2.874 (10.0287)	1.190 (4.4544)	2.326 (8.5923)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	1.042 (4.1667)	-1.282 (4.5291)	0.595 (3.1497)	-2.381 (6.0523)	-0.397 (4.4904)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	-16.67, 0.00	0.00, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	16.667 (-)	0.000 (0.0000)	16.667 (-)	4.167 (8.3333)
Median	0.000	16.667	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	16.667, 16.667	0.000, 0.000	16.667, 16.667	0.000, 8.333
Min, Max	0.00, 0.00	16.67, 16.67	0.00, 0.00	16.67, 16.67	0.00, 16.67
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	8.333 (16.6667)	1.852 (5.5556)	3.704 (11.1111)	4.167 (8.3333)	3.846 (9.9857)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	0.000 (0.0000)	-1.852 (5.5556)	-1.852 (5.5556)	0.000 (0.0000)	-1.282 (4.6225)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-16.67, 0.00	-16.67, 0.00	0.00, 0.00	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	9.524 (18.8982)	6.250 (17.6777)	8.974 (18.7767)	0.000 (0.0000)	7.778 (17.6683)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	4.762 (20.8928)	4.167 (11.7851)	5.128 (17.1926)	0.000 (0.0000)	4.444 (16.0192)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 33.33	-16.67, 50.00	0.00, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Pain					
Baseline					
n	27	39	48	18	66
Mean (SD)	13.580 (23.5870)	15.385 (20.0090)	12.500 (19.8993)	20.370 (24.6250)	14.646 (21.3868)
Median	0.000	16.667	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	14.493 (22.0790)	14.474 (20.9285)	12.016 (18.6607)	20.370 (25.9181)	14.481 (21.1860)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	36	42	17	59
Mean (SD)	2.174 (24.2589)	-1.389 (18.8457)	0.000 (19.8231)	0.000 (24.2956)	0.000 (20.9908)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 8.333	0.000, 0.000	-16.667, 16.667	-16.667, 16.667
Min, Max	-66.67, 50.00	-33.33, 33.33	-66.67, 50.00	-33.33, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	14.167 (30.7199)	13.978 (17.2652)	13.426 (24.8230)	15.556 (19.3820)	14.052 (23.1835)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-1.667 (20.8728)	-1.149 (19.3808)	0.952 (18.4987)	-7.143 (22.3743)	-1.361 (19.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-50.00, 33.33	-66.67, 33.33	-50.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	17.544 (28.5848)	19.444 (24.7916)	16.667 (25.2929)	23.333 (28.0306)	18.707 (26.0503)
Median	0.000	16.667	0.000	16.667	16.667
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	28	33	14	47
Mean (SD)	0.877 (20.3925)	5.357 (27.2368)	4.040 (20.4253)	2.381 (33.2416)	3.546 (24.5580)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667	-33.333, 33.333	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	17.708 (28.8475)	14.815 (18.6816)	14.368 (25.4811)	19.048 (15.8210)	15.891 (22.6993)
Median	0.000	0.000	0.000	25.000	0.000
Q1, Q3	0.000, 25.000	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	3.125 (15.1764)	1.333 (24.4949)	4.167 (19.0435)	-2.564 (25.3185)	2.033 (21.1460)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-50.00, 66.67	-33.33, 66.67	-50.00, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-11.111 (9.6225)	33.333 (-)	-11.111 (9.6225)	33.333 (-)	0.000 (23.5702)
Median	-16.667	33.333	-16.667	33.333	-8.333
Q1, Q3	-16.667, 0.000	33.333, 33.333	-16.667, 0.000	33.333, 33.333	-16.667, 16.667
Min, Max	-16.67, 0.00	33.33, 33.33	-16.67, 0.00	33.33, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	29.167 (47.8714)	11.111 (18.6339)	22.222 (34.3592)	4.167 (8.3333)	16.667 (29.6586)
Median	8.333	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 58.333	0.000, 16.667	0.000, 33.333	0.000, 8.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 50.00	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline					
n	4	8	9	3	12
Mean (SD)	4.167 (20.9718)	8.333 (15.4303)	9.259 (18.8398)	0.000 (0.0000)	6.944 (16.6034)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 16.667
Min, Max	-16.67, 33.33	0.00, 33.33	-16.67, 33.33	0.00, 0.00	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	21.429 (18.5450)	18.750 (27.3680)	20.513 (23.7208)	16.667 (23.5702)	20.000 (22.8869)
Median	16.667	0.000	16.667	16.667	16.667
Q1, Q3	0.000, 33.333	0.000, 41.667	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	7	7	13	1	14
Mean (SD)	7.143 (28.6375)	2.381 (14.9956)	5.128 (22.9579)	0.000 (-)	4.762 (22.0998)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 33.333	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 50.00	-16.67, 33.33	-33.33, 50.00	0.00, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Dyspnoea					
Baseline					
n	27	40	48	19	67
Mean (SD)	17.284 (26.7473)	28.333 (33.3760)	20.833 (27.1803)	31.579 (39.2423)	23.881 (31.1432)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	20.290 (27.9594)	15.789 (20.1150)	18.605 (24.4542)	14.815 (20.5233)	17.486 (23.2591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	5.797 (19.2069)	-9.009 (26.8152)	0.794 (20.1459)	-12.963 (32.6176)	-3.333 (25.0799)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	18.333 (31.4838)	12.903 (18.6139)	13.889 (26.8742)	17.778 (17.2133)	15.033 (24.3253)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	-1.667 (22.8778)	-13.333 (31.0728)	-5.714 (26.1790)	-15.556 (33.0143)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	29	33	15	48
Mean (SD)	10.526 (19.4131)	12.644 (18.7163)	10.101 (17.6479)	15.556 (21.3313)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	28	32	15	47
Mean (SD)	-10.526 (29.5075)	-14.286 (31.9832)	-10.417 (24.5935)	-17.778 (41.5315)	-12.766 (30.7343)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	12.500 (20.6380)	18.519 (25.0356)	12.644 (20.7284)	23.810 (27.5140)	16.279 (23.4262)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-10.417 (33.8160)	-6.410 (35.3009)	-8.333 (28.1457)	-7.143 (45.6268)	-7.937 (34.3815)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 66.67	-100.00, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-22.222 (38.4900)	-100.000 (-)	-22.222 (38.4900)	-100.000 (-)	-41.667 (50.0000)
Median	0.000	-100.000	0.000	-100.000	-33.333
Q1, Q3	-66.667, 0.000	-100.000, -100.000	-66.667, 0.000	-100.000, -100.000	-83.333, 0.000
Min, Max	-66.67, 0.00	-100.00, -100.00	-66.67, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	16.667 (33.3333)	11.111 (16.6667)	14.815 (24.2161)	8.333 (16.6667)	12.821 (21.6815)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	0.000 (0.0000)	-22.222 (33.3333)	-7.407 (14.6986)	-33.333 (47.1405)	-15.385 (29.2353)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-66.667, 0.000	-33.333, 0.000
Min, Max	0.00, 0.00	-100.00, 0.00	-33.33, 0.00	-100.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	23.810 (31.7063)	45.833 (35.3553)	35.897 (34.5916)	33.333 (47.1405)	35.556 (34.4265)
Median	0.000	50.000	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	16.667, 66.667	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	9.524 (31.7063)	4.167 (33.0344)	7.692 (33.7580)	0.000 (0.0000)	6.667 (31.3708)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	-16.667, 16.667	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Insomnia					
Baseline					
n	27	40	48	19	67
Mean (SD)	18.519 (23.2661)	20.833 (25.8061)	18.750 (22.7082)	22.807 (29.5075)	19.900 (24.6591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	18.841 (22.0790)	17.544 (25.3940)	14.729 (20.9589)	25.926 (29.2735)	18.033 (24.0168)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (14.2134)	-2.703 (22.7417)	-4.762 (17.3774)	5.556 (23.5702)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	21.667 (31.1101)	18.280 (22.5071)	19.444 (28.0306)	20.000 (21.0819)	19.608 (25.9713)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.000 (18.7317)	-4.444 (20.9603)	-2.857 (20.4067)	-2.222 (19.7872)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	19.298 (27.9236)	17.778 (27.3102)	18.627 (26.1968)	17.778 (30.5158)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-3.509 (24.5823)	-3.448 (24.1438)	-4.040 (26.0309)	-2.222 (19.7872)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	22.917 (33.8160)	19.753 (24.9088)	24.138 (30.7274)	14.286 (21.5402)	20.930 (28.1936)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 50.000	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (19.1243)	1.282 (14.8497)	1.190 (16.9292)	-2.381 (15.8210)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-22.222 (19.2450)	-33.333 (-)	-22.222 (19.2450)	-33.333 (-)	-25.000 (16.6667)
Median	-33.333	-33.333	-33.333	-33.333	-33.333
Q1, Q3	-33.333, 0.000	-33.333, -33.333	-33.333, 0.000	-33.333, -33.333	-33.333, -16.667
Min, Max	-33.33, 0.00	-33.33, -33.33	-33.33, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	41.667 (41.9435)	11.111 (23.5702)	25.926 (36.4302)	8.333 (16.6667)	20.513 (32.0256)
Median	33.333	0.000	0.000	0.000	0.000
Q1, Q3	16.667, 66.667	0.000, 0.000	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	8.333 (16.6667)	-7.407 (14.6986)	0.000 (16.6667)	-8.333 (16.6667)	-2.564 (16.4516)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 0.00	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	23.810 (31.7063)	29.167 (27.8174)	28.205 (29.9572)	16.667 (23.5702)	26.667 (28.7297)
Median	0.000	33.333	33.333	16.667	33.333
Q1, Q3	0.000, 66.667	0.000, 50.000	0.000, 66.667	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	14.286 (26.2265)	12.500 (24.8008)	15.385 (25.8750)	0.000 (0.0000)	13.333 (24.5596)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Appetite loss					
Baseline					
n	27	40	48	19	67
Mean (SD)	9.877 (20.2860)	15.000 (26.0943)	9.722 (18.1383)	21.053 (33.7209)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	11.594 (23.8020)	9.649 (15.3202)	10.078 (19.9667)	11.111 (16.1690)	10.383 (18.7981)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	1.449 (23.5236)	-6.306 (27.0320)	0.000 (22.0863)	-11.111 (32.3381)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	10.000 (24.4232)	7.527 (16.5768)	7.407 (19.6979)	11.111 (20.5738)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.000 (18.7317)	-7.778 (29.9211)	-2.857 (18.7370)	-8.889 (38.7640)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	8.772 (18.7317)	6.667 (16.1411)	6.863 (15.9532)	8.889 (19.7872)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-1.754 (28.2705)	-8.046 (27.6818)	-3.030 (22.6134)	-11.111 (37.0899)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	14.583 (24.2479)	8.642 (19.8124)	11.494 (22.3178)	9.524 (20.3750)	10.853 (21.4808)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	6.250 (18.1302)	-3.846 (30.2977)	3.571 (18.8982)	-7.143 (37.3905)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	-100.000 (-)	0.000 (0.0000)	-100.000 (-)	-25.000 (50.0000)
Median	0.000	-100.000	0.000	-100.000	0.000
Q1, Q3	0.000, 0.000	-100.000, -100.000	0.000, 0.000	-100.000, -100.000	-50.000, 0.000
Min, Max	0.00, 0.00	-100.00, -100.00	0.00, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	25.000 (31.9142)	0.000 (0.0000)	11.111 (23.5702)	0.000 (0.0000)	7.692 (19.9715)
Median	16.667	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 50.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	8.333 (16.6667)	-18.519 (33.7931)	-3.704 (20.0308)	-25.000 (50.0000)	-10.256 (31.5777)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-33.333, 0.000	0.000, 0.000	-50.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-100.00, 0.00	-33.33, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	28.571 (35.6348)	33.333 (39.8410)	28.205 (32.9032)	50.000 (70.7107)	31.111 (36.6595)
Median	33.333	16.667	33.333	50.000	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333	0.000, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	14.286 (50.3953)	8.333 (23.5702)	12.821 (39.7643)	0.000 (0.0000)	11.111 (37.0899)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-66.67, 100.00	-33.33, 33.33	-66.67, 100.00	0.00, 0.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Constipation					
Baseline					
n	27	40	48	19	67
Mean (SD)	4.938 (12.0671)	11.667 (20.7412)	4.167 (11.1406)	21.053 (25.3629)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	10.145 (23.4301)	13.158 (22.6469)	9.302 (19.6875)	18.519 (28.5195)	12.022 (22.7977)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	5.797 (23.8941)	1.802 (22.1470)	5.556 (20.7144)	-1.852 (26.7455)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	10.000 (19.0414)	7.527 (16.5768)	8.333 (16.6667)	8.889 (19.7872)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	5.000 (22.3607)	-2.222 (17.3610)	4.762 (18.3340)	-8.889 (19.7872)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	7.018 (13.9618)	10.000 (17.8328)	5.882 (12.8984)	15.556 (21.3313)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	1.754 (17.4755)	-1.149 (16.6256)	2.020 (14.2872)	-4.444 (21.3313)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	18.750 (34.3592)	11.111 (24.4600)	13.793 (27.4834)	14.286 (31.2538)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	14.583 (32.1311)	0.000 (23.0940)	10.714 (27.2974)	-4.762 (25.6776)	5.556 (27.4644)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	-33.333 (-)	0.000 (0.0000)	-33.333 (-)	-8.333 (16.6667)
Median	0.000	-33.333	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-33.333, -33.333	0.000, 0.000	-33.333, -33.333	-16.667, 0.000
Min, Max	0.00, 0.00	-33.33, -33.33	0.00, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	16.667 (19.2450)	3.704 (11.1111)	11.111 (16.6667)	0.000 (0.0000)	7.692 (14.6176)
Median	16.667	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	8.333 (31.9142)	-3.704 (20.0308)	3.704 (26.0579)	-8.333 (16.6667)	0.000 (23.5702)
Median	16.667	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 33.333	0.000, 0.000	0.000, 33.333	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	28.571 (35.6348)	16.667 (35.6348)	17.949 (29.2353)	50.000 (70.7107)	22.222 (34.8845)
Median	33.333	0.000	0.000	50.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	23.810 (37.0899)	4.167 (11.7851)	12.821 (28.9906)	16.667 (23.5702)	13.333 (27.6026)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Diarrhoea					
Baseline					
n	27	39	48	18	66
Mean (SD)	7.407 (16.8790)	6.838 (20.4903)	8.333 (20.0472)	3.704 (15.7135)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	7.246 (22.3754)	4.386 (11.4190)	6.202 (18.1933)	3.704 (10.7794)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	23	36	42	17	59
Mean (SD)	0.000 (17.4078)	0.000 (13.8013)	0.000 (16.4622)	0.000 (11.7851)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	6.667 (17.4383)	7.778 (16.8002)	8.333 (18.4735)	4.762 (12.1046)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	20	28	35	13	48
Mean (SD)	3.333 (18.4169)	2.381 (15.5253)	4.762 (18.3340)	-2.564 (9.2450)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	1.754 (7.6472)	7.778 (16.8002)	4.902 (11.9830)	6.667 (18.6871)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	28	33	14	47
Mean (SD)	-1.754 (13.4884)	3.571 (20.9630)	1.010 (13.1362)	2.381 (27.6247)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	2.083 (8.3333)	9.877 (22.2933)	5.747 (12.8142)	9.524 (27.5140)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	0.000 (12.1716)	5.333 (22.9331)	2.381 (12.5988)	5.128 (29.9572)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	8.333 (16.6667)	3.704 (11.1111)	7.407 (14.6986)	0.000 (0.0000)	5.128 (12.5178)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	4	8	9	3	12
Mean (SD)	8.333 (16.6667)	4.167 (11.7851)	7.407 (14.6986)	0.000 (0.0000)	5.556 (12.9750)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	9.524 (25.1976)	4.167 (11.7851)	7.692 (19.9715)	0.000 (0.0000)	6.667 (18.6871)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	7	7	13	1	14
Mean (SD)	4.762 (29.9912)	4.762 (12.5988)	5.128 (22.9579)	0.000 (-)	4.762 (22.0998)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Financial Difficulties					
Baseline					
n	27	40	48	19	67
Mean (SD)	32.099 (39.7444)	5.833 (16.6880)	22.222 (34.6092)	1.754 (7.6472)	16.418 (30.9083)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	18.841 (31.5045)	7.895 (19.6581)	14.729 (25.5131)	5.556 (23.5702)	12.022 (25.1166)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-13.043 (27.9594)	1.802 (19.1581)	-7.143 (26.0661)	3.704 (15.7135)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 66.67	-66.67, 33.33	0.00, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	16.667 (27.5723)	6.667 (18.3620)	12.037 (24.1066)	7.143 (19.2978)	10.667 (22.7776)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-8.333 (28.3565)	0.000 (21.8218)	-6.667 (27.7712)	4.762 (12.1046)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-100.00, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	14.035 (23.0828)	3.333 (10.1710)	8.824 (18.9076)	4.444 (11.7289)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-12.281 (16.5198)	-3.448 (18.5695)	-11.111 (19.8373)	2.222 (8.6066)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 33.33	-66.67, 0.00	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	18.750 (32.1311)	9.877 (24.1343)	17.241 (31.6487)	4.762 (12.1046)	13.178 (27.3518)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-6.250 (21.8369)	2.564 (13.0744)	-2.381 (20.1406)	2.381 (8.9087)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 15					
n	3	1	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	3	1	3	1	4
Mean (SD)	-11.111 (19.2450)	0.000 (-)	-11.111 (19.2450)	0.000 (-)	-8.333 (16.6667)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	4	9	9	4	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	4	9	9	4	13
Mean (SD)	0.000 (0.0000)	-7.407 (22.2222)	-7.407 (22.2222)	0.000 (0.0000)	-5.128 (18.4900)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-66.67, 0.00	-66.67, 0.00	0.00, 0.00	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	8	13	2	15
Mean (SD)	66.667 (38.4900)	4.167 (11.7851)	38.462 (42.7008)	0.000 (0.0000)	33.333 (41.7855)
Median	66.667	0.000	33.333	0.000	0.000
Q1, Q3	33.333, 100.000	0.000, 0.000	0.000, 66.667	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	7	8	13	2	15
Mean (SD)	0.000 (33.3333)	4.167 (11.7851)	2.564 (25.3185)	0.000 (0.0000)	2.222 (23.4577)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	0.00, 33.33	-66.67, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	38	29	67
Mean (SD)	73.026 (17.8030)	56.897 (22.0557)	66.045 (21.1871)
Median	75.000	58.333	66.667
Q1, Q3	66.667, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	33.33, 100.00	0.00, 83.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	76.667 (18.7214)	74.038 (14.5920)	75.546 (17.0014)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	4.167 (17.4380)	13.462 (22.1205)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 25.000	0.000, 16.667
Min, Max	-41.67, 33.33	-16.67, 66.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	82.099 (15.2794)	66.667 (22.7525)	75.000 (20.4124)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	66.667, 91.667
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	7.372 (15.1524)	8.333 (16.8550)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	-8.333, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	75.617 (19.1884)	68.561 (24.1155)	72.449 (21.5974)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	2.244 (18.1900)	9.091 (21.9591)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 25.000	0.000, 16.667
Min, Max	-50.00, 33.33	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	78.667 (17.5264)	71.759 (23.2454)	75.775 (20.1527)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 83.333	66.667, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	4.861 (14.3112)	10.185 (20.7214)	7.143 (17.3216)
Median	0.000	12.500	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	80.556 (20.9718)	83.333 (-)	81.250 (17.1796)
Median	83.333	83.333	83.333
Q1, Q3	58.333, 100.000	83.333, 83.333	70.833, 91.667
Min, Max	58.33, 100.00	83.33, 83.33	58.33, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	-2.778 (20.9718)	58.333 (-)	12.500 (35.0264)
Median	0.000	58.333	8.333
Q1, Q3	-25.000, 16.667	58.333, 58.333	-12.500, 37.500
Min, Max	-25.00, 16.67	58.33, 58.33	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 18			
n	9	4	13
Mean (SD)	81.481 (17.0670)	72.917 (10.4859)	78.846 (15.4468)
Median	83.333	75.000	83.333
Q1, Q3	83.333, 83.333	66.667, 79.167	75.000, 83.333
Min, Max	41.67, 100.00	58.33, 83.33	41.67, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	4.630 (14.5004)	22.917 (29.1667)	10.256 (20.7370)
Median	0.000	20.833	8.333
Q1, Q3	0.000, 8.333	0.000, 45.833	0.000, 16.667
Min, Max	-16.67, 33.33	-8.33, 58.33	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	59.375 (29.6934)	48.810 (20.6540)	54.444 (25.5625)
Median	58.333	58.333	58.333
Q1, Q3	37.500, 83.333	33.333, 66.667	33.333, 66.667
Min, Max	16.67, 100.00	16.67, 66.67	16.67, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-19.792 (27.4359)	-5.952 (32.5300)	-13.333 (29.6808)
Median	-20.833	0.000	-16.667
Q1, Q3	-29.167, 4.167	-41.667, 16.667	-33.333, 8.333
Min, Max	-75.00, 8.33	-50.00, 41.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)
Median	-	-16.667	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)
Median	-	50.000	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	38	29	67
Mean (SD)	87.719 (14.8285)	77.241 (23.4702)	83.184 (19.6041)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	66.667, 93.333	80.000, 100.000
Min, Max	40.00, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	34	26	60
Mean (SD)	88.824 (15.6322)	82.051 (17.7658)	85.889 (16.7890)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	83.333, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	1.010 (11.4408)	1.795 (16.4986)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-20.00, 40.00	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	90.864 (16.3454)	81.389 (18.9563)	86.405 (18.0843)
Median	93.333	86.667	93.333
Q1, Q3	93.333, 100.000	76.667, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	3.077 (11.0322)	2.222 (21.0513)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-13.333, 13.333	-6.667, 6.667
Min, Max	-20.00, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	85.679 (19.8028)	83.636 (24.6651)	84.762 (21.9004)
Median	86.667	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-1.795 (15.6128)	5.455 (21.4438)	1.528 (18.6666)
Median	0.000	3.333	0.000
Q1, Q3	0.000, 0.000	-6.667, 13.333	0.000, 6.667
Min, Max	-73.33, 13.33	-40.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	24	18	42
Mean (SD)	89.167 (15.0763)	80.370 (27.4847)	85.397 (21.4508)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	86.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	2.319 (7.6828)	1.852 (21.9096)	2.114 (15.3796)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667
Min, Max	-13.33, 26.67	-40.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 15			
n	3	1	4
Mean (SD)	97.778 (3.8490)	93.333 (-)	96.667 (3.8490)
Median	100.000	93.333	96.667
Q1, Q3	93.333, 100.000	93.333, 93.333	93.333, 100.000
Min, Max	93.33, 100.00	93.33, 93.33	93.33, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	60.000 (-)	15.000 (30.0000)
Median	0.000	60.000	0.000
Q1, Q3	0.000, 0.000	60.000, 60.000	0.000, 30.000
Min, Max	0.00, 0.00	60.00, 60.00	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	86.667 (23.5702)	81.667 (11.3855)	85.128 (20.2125)
Median	93.333	83.333	93.333
Q1, Q3	86.667, 100.000	73.333, 90.000	80.000, 100.000
Min, Max	26.67, 100.00	66.67, 93.33	26.67, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	-1.481 (7.2860)	6.667 (38.1032)	1.026 (20.3390)
Median	0.000	-3.333	0.000
Q1, Q3	0.000, 0.000	-20.000, 33.333	-13.333, 6.667
Min, Max	-13.33, 6.67	-26.67, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	80.833 (17.6158)	71.429 (17.9358)	76.444 (17.7936)
Median	83.333	66.667	80.000
Q1, Q3	73.333, 93.333	60.000, 93.333	60.000, 93.333
Min, Max	46.67, 100.00	46.67, 93.33	46.67, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-4.167 (10.6533)	-7.619 (18.6304)	-5.778 (14.4457)
Median	0.000	-13.333	-6.667
Q1, Q3	-13.333, 0.000	-20.000, 6.667	-20.000, 0.000
Min, Max	-20.00, 13.33	-26.67, 26.67	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	58.333 (-)	58.333 (-)
Median	-	58.333	58.333
Q1, Q3	-, -	58.333, 58.333	58.333, 58.333
Min, Max	-, -	58.33, 58.33	58.33, 58.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)
Median	-	-8.333	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	60.000 (-)	60.000 (-)
Median	-	60.000	60.000
Q1, Q3	-, -	60.000, 60.000	60.000, 60.000
Min, Max	-, -	60.00, 60.00	60.00, 60.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-6.667 (-)	-6.667 (-)
Median	-	-6.667	-6.667
Q1, Q3	-, -	-6.667, -6.667	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Role functioning			
Baseline			
n	38	29	67
Mean (SD)	90.351 (19.6178)	74.138 (29.0683)	83.333 (25.2929)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	89.048 (20.9820)	83.974 (22.8428)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.490 (21.1159)	5.769 (26.2223)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	93.210 (16.8320)	86.111 (18.8220)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	75.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	3.205 (13.3493)	8.333 (25.5377)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 9			
n	27	22	49
Mean (SD)	87.654 (22.9234)	84.848 (28.1291)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-1.923 (19.6225)	6.061 (21.5445)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	92.667 (14.4978)	77.778 (33.3333)	86.434 (25.0015)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (9.8038)	-0.926 (29.9631)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	-16.67, 33.33	-50.00, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	5.556 (9.6225)	100.000 (-)	29.167 (47.8714)
Median	0.000	100.000	8.333
Q1, Q3	0.000, 16.667	100.000, 100.000	0.000, 58.333
Min, Max	0.00, 16.67	100.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	85.185 (24.2161)	83.333 (19.2450)	84.615 (22.0075)
Median	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	-1.852 (13.0289)	8.333 (63.0990)	1.282 (33.6523)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 50.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	70.833 (24.8008)	54.762 (39.3398)	63.333 (32.2441)
Median	75.000	66.667	66.667
Q1, Q3	50.000, 91.667	16.667, 100.000	33.333, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-14.583 (24.2956)	-11.905 (35.6348)	-13.333 (29.0047)
Median	-8.333	-16.667	-16.667
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-50.00, 16.67	-66.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)
Median	-	50.000	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	38	29	67
Mean (SD)	85.965 (15.5124)	77.299 (19.7826)	82.214 (17.8786)
Median	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 91.667	66.667, 100.000
Min, Max	50.00, 100.00	25.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	88.571 (18.8611)	79.167 (22.7608)	84.563 (20.9627)
Median	100.000	87.500	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	3.186 (18.0038)	1.603 (20.2785)	2.500 (18.8724)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-58.33, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	89.198 (14.3994)	76.087 (26.9802)	83.167 (21.9183)
Median	91.667	83.333	91.667
Q1, Q3	83.333, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	5.449 (14.3260)	0.725 (23.2891)	3.231 (19.0042)
Median	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-25.00, 33.33	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	86.111 (19.7473)	78.788 (25.2929)	82.823 (22.4645)
Median	91.667	87.500	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	1.603 (19.0057)	2.273 (20.9215)	1.910 (19.6932)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-8.333, 16.667	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	88.000 (18.0149)	75.926 (28.8518)	82.946 (23.6370)
Median	91.667	87.500	91.667
Q1, Q3	83.333, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (13.4408)	-2.315 (22.6521)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 12.500	-8.333, 8.333	0.000, 8.333
Min, Max	-25.00, 25.00	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	91.667 (14.4338)	83.333 (-)	89.583 (12.5000)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	83.333, 83.333	79.167, 100.000
Min, Max	75.00, 100.00	83.33, 83.33	75.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	11.111 (12.7294)	8.333 (-)	10.417 (10.4859)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 25.000	8.333, 8.333	4.167, 16.667
Min, Max	0.00, 25.00	8.33, 8.33	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	88.889 (12.5000)	64.583 (38.1123)	81.410 (24.5689)
Median	91.667	79.167	83.333
Q1, Q3	83.333, 100.000	41.667, 87.500	75.000, 100.000
Min, Max	66.67, 100.00	8.33, 91.67	8.33, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	3.704 (12.5769)	-4.167 (22.0479)	1.282 (15.5330)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-20.833, 12.500	-8.333, 8.333
Min, Max	-8.33, 33.33	-33.33, 16.67	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	79.167 (22.2718)	73.810 (28.2304)	76.667 (24.4381)
Median	83.333	83.333	83.333
Q1, Q3	70.833, 95.833	33.333, 91.667	66.667, 91.667
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-12.500 (16.0604)	-9.524 (23.7797)	-11.111 (19.3307)
Median	-8.333	0.000	-8.333
Q1, Q3	-29.167, 0.000	-25.000, 0.000	-25.000, 0.000
Min, Max	-33.33, 8.33	-50.00, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)
Median	-	77.778	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-13.889 (-)	-13.889 (-)
Median	-	-13.889	-13.889
Q1, Q3	-, -	-13.889, -13.889	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)
Median	-	-8.333	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	38	29	67
Mean (SD)	88.596 (15.5506)	87.356 (20.7284)	88.060 (17.8391)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	87.143 (15.7003)	83.974 (18.5477)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.980 (15.8599)	-7.051 (18.3624)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	88.889 (16.6667)	79.710 (28.4074)	84.667 (23.0449)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	-1.282 (11.4727)	-8.696 (18.0275)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-66.67, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	87.037 (22.8023)	81.061 (26.8720)	84.354 (24.6288)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-3.205 (24.0459)	-6.818 (14.2345)	-4.861 (20.0349)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	87.333 (17.5330)	79.630 (27.7451)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-2.083 (14.9980)	-9.259 (19.1504)	-5.159 (17.0636)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	94.444 (16.6667)	66.667 (45.1335)	85.897 (29.5382)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	41.667, 91.667	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (8.3333)	-25.000 (28.8675)	-7.692 (19.9715)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-41.667, -8.333	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 0.00	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	81.250 (22.6034)	71.429 (23.0022)	76.667 (22.5374)
Median	83.333	83.333	83.333
Q1, Q3	75.000, 100.000	50.000, 83.333	66.667, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-6.250 (12.4004)	-16.667 (21.5166)	-11.111 (17.4423)
Median	-8.333	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-16.67, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)
Median	-	-16.667	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Social functioning			
Baseline			
n	38	29	67
Mean (SD)	89.474 (16.1734)	79.310 (27.6942)	85.075 (22.3106)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	88.571 (21.6823)	89.744 (17.0469)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.980 (16.3820)	8.333 (31.7105)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 33.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	93.827 (15.4340)	89.855 (16.4679)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	3.846 (13.5873)	10.145 (32.0744)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	82.716 (27.9199)	91.667 (14.3187)	86.735 (23.0688)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-7.692 (25.4867)	12.879 (28.1398)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 8.333
Min, Max	-83.33, 16.67	-33.33, 83.33	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 12			
n	25	18	43
Mean (SD)	94.000 (10.6284)	88.889 (15.1248)	91.860 (12.7927)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (10.9668)	5.556 (32.8395)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 33.333	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	83.333 (28.8675)	100.000 (-)	87.500 (25.0000)
Median	100.000	100.000	100.000
Q1, Q3	50.000, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	100.00, 100.00	50.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (34.6944)	100.000 (-)	16.667 (62.3610)
Median	0.000	100.000	8.333
Q1, Q3	-50.000, 16.667	100.000, 100.000	-25.000, 58.333
Min, Max	-50.00, 16.67	100.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	94.444 (16.6667)	87.500 (15.9571)	92.308 (16.1236)
Median	100.000	91.667	100.000
Q1, Q3	100.000, 100.000	75.000, 100.000	100.000, 100.000
Min, Max	50.00, 100.00	66.67, 100.00	50.00, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (8.3333)	29.167 (51.5949)	8.974 (30.1350)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	-8.333, 66.667	0.000, 0.000
Min, Max	-16.67, 16.67	-16.67, 100.00	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	77.083 (25.0990)	59.524 (26.9725)	68.889 (26.6270)
Median	83.333	66.667	66.667
Q1, Q3	58.333, 100.000	33.333, 83.333	33.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-10.417 (23.4648)	-9.524 (28.6375)	-10.000 (25.0397)
Median	-8.333	0.000	0.000
Q1, Q3	-25.000, 8.333	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Fatigue			
Baseline			
n	38	29	67
Mean (SD)	21.491 (16.2445)	39.847 (26.9753)	29.436 (23.2509)
Median	22.222	33.333	22.222
Q1, Q3	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	17.778 (20.2023)	27.778 (24.3939)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 44.444	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	34	26	60
Mean (SD)	-3.758 (20.3192)	-8.974 (29.9826)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-44.44, 66.67	-88.89, 66.67	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 6			
n	27	24	51
Mean (SD)	19.342 (16.4783)	27.778 (24.7369)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	11.111, 22.222	5.556, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	26	24	50
Mean (SD)	-3.205 (12.7824)	-9.722 (24.5873)	-6.333 (19.4407)
Median	0.000	-5.556	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-11.111, 0.000
Min, Max	-27.78, 22.22	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 9			
n	27	22	49
Mean (SD)	20.576 (19.9009)	25.758 (25.0541)	22.902 (22.2694)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-2.350 (15.2488)	-11.616 (23.6268)	-6.597 (19.8714)
Median	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-33.33, 44.44	-55.56, 33.33	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 12			
n	25	18	43
Mean (SD)	18.667 (21.2084)	21.605 (19.2345)	19.897 (20.2219)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline			
n	24	18	42
Mean (SD)	-5.324 (11.5236)	-11.111 (28.7730)	-7.804 (20.6438)
Median	0.000	-5.556	0.000
Q1, Q3	-19.444, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-22.22, 11.11	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	3.704 (6.4150)	11.111 (-)	5.556 (6.4150)
Median	0.000	11.111	5.556
Q1, Q3	0.000, 11.111	11.111, 11.111	0.000, 11.111
Min, Max	0.00, 11.11	11.11, 11.11	0.00, 11.11
Change from Baseline			
n	3	1	4
Mean (SD)	-7.407 (12.8300)	-77.778 (-)	-25.000 (36.7115)
Median	0.000	-77.778	-11.111
Q1, Q3	-22.222, 0.000	-77.778, -77.778	-50.000, 0.000
Min, Max	-22.22, 0.00	-77.78, -77.78	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 18			
n	9	4	13
Mean (SD)	14.815 (28.3279)	16.667 (11.1111)	15.385 (23.8041)
Median	11.111	22.222	11.111
Q1, Q3	0.000, 11.111	11.111, 22.222	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 22.22	0.00, 88.89
Change from Baseline			
n	9	4	13
Mean (SD)	-5.556 (16.1971)	-25.000 (42.9134)	-11.538 (26.8801)
Median	0.000	-5.556	0.000
Q1, Q3	-11.111, 0.000	-50.000, 0.000	-11.111, 0.000
Min, Max	-38.89, 22.22	-88.89, 0.00	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Safety Follow-up			
n	8	7	15
Mean (SD)	36.111 (27.6983)	57.143 (25.1976)	45.926 (27.8148)
Median	38.889	66.667	44.444
Q1, Q3	11.111, 55.556	33.333, 77.778	11.111, 66.667
Min, Max	0.00, 77.78	11.11, 77.78	0.00, 77.78
Change from Baseline			
n	8	7	15
Mean (SD)	11.806 (23.0859)	9.524 (28.2760)	10.741 (24.7088)
Median	5.556	11.111	11.111
Q1, Q3	-8.333, 33.333	-22.222, 33.333	-11.111, 33.333
Min, Max	-11.11, 44.44	-22.22, 55.56	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)
Median	-	11.111	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)
Median	-	44.444	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)
Median	-	-11.111	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	38	29	67
Mean (SD)	3.070 (10.1455)	5.172 (11.0046)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	2.381 (9.1670)	3.205 (6.6986)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.490 (7.6600)	-1.923 (10.8801)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	5.556 (19.6116)	1.389 (4.7055)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	4.487 (13.7902)	-4.861 (10.4016)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	2.469 (6.0336)	5.303 (10.7722)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	26	22	48
Mean (SD)	1.282 (6.5372)	-1.515 (10.1693)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	2.000 (10.0000)	2.778 (6.3914)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	24	18	42
Mean (SD)	0.694 (3.4021)	-1.852 (5.3897)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	16.667 (-)	4.167 (8.3333)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	16.667, 16.667	0.000, 8.333
Min, Max	0.00, 0.00	16.67, 16.67	0.00, 16.67
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	3.704 (11.1111)	4.167 (8.3333)	3.846 (9.9857)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (0.0000)	-4.167 (8.3333)	-1.282 (4.6225)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-8.333, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-16.67, 0.00	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	12.500 (23.1455)	2.381 (6.2994)	7.778 (17.6683)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	8	7	15
Mean (SD)	10.417 (19.7956)	-2.381 (6.2994)	4.444 (16.0192)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	-16.67, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Pain			
Baseline			
n	37	29	66
Mean (SD)	11.261 (19.6631)	18.966 (23.0270)	14.646 (21.3868)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	12.381 (19.1071)	17.308 (23.7958)	14.481 (21.1860)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	0.000 (17.6777)	0.000 (24.9444)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 16.667	-16.667, 16.667
Min, Max	-33.33, 50.00	-66.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	11.728 (21.5900)	16.667 (25.0603)	14.052 (23.1835)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	24	49
Mean (SD)	0.000 (18.6339)	-2.778 (21.2341)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	18.519 (27.4770)	18.939 (24.8250)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	22	47
Mean (SD)	6.667 (23.0740)	0.000 (26.2265)	3.546 (24.5580)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 50.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	13.333 (20.9718)	19.444 (25.0816)	15.891 (22.6993)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	0.725 (23.2891)	3.704 (18.5729)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (9.6225)	33.333 (-)	0.000 (23.5702)
Median	-16.667	33.333	-8.333
Q1, Q3	-16.667, 0.000	33.333, 33.333	-16.667, 16.667
Min, Max	-16.67, 0.00	33.33, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	12.963 (33.1010)	25.000 (21.5166)	16.667 (29.6586)
Median	0.000	25.000	0.000
Q1, Q3	0.000, 0.000	8.333, 41.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline			
n	8	4	12
Mean (SD)	2.083 (13.9087)	16.667 (19.2450)	6.944 (16.6034)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-16.67, 33.33	0.00, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	18.750 (22.6034)	21.429 (24.9338)	20.000 (22.8869)
Median	8.333	16.667	16.667
Q1, Q3	0.000, 41.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	7	7	14
Mean (SD)	7.143 (21.2070)	2.381 (24.3975)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 33.333	0.000, 16.667
Min, Max	-16.67, 50.00	-33.33, 33.33	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	38	29	67
Mean (SD)	17.544 (24.1825)	32.184 (37.2494)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	12.381 (21.5202)	24.359 (24.1434)	17.486 (23.2591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-5.882 (17.3508)	0.000 (32.6599)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	9.877 (22.2933)	20.833 (25.6557)	15.033 (24.3253)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	-8.974 (25.9190)	-8.333 (31.4696)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-16.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 9			
n	26	22	48
Mean (SD)	10.256 (18.3042)	13.636 (19.6775)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	25	22	47
Mean (SD)	-8.000 (22.1108)	-18.182 (38.1133)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	0 (N = 39)	≥ 1 (N = 29)	Total (N = 68)
Cycle 12			
n	25	18	43
Mean (SD)	14.667 (23.7268)	18.519 (23.4931)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	24	18	42
Mean (SD)	-4.167 (24.6962)	-12.963 (44.4853)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	-22.222 (38.4900)	-100.000 (-)	-41.667 (50.0000)
Median	0.000	-100.000	-33.333
Q1, Q3	-66.667, 0.000	-100.000, -100.000	-83.333, 0.000
Min, Max	-66.67, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	14.815 (24.2161)	8.333 (16.6667)	12.821 (21.6815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	9	4	13
Mean (SD)	-7.407 (14.6986)	-33.333 (47.1405)	-15.385 (29.2353)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	-33.333, 0.000
Min, Max	-33.33, 0.00	-100.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	33.333 (30.8607)	38.095 (40.4995)	35.556 (34.4265)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	8.333 (38.8322)	4.762 (23.0022)	6.667 (31.3708)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Insomnia			
Baseline			
n	38	29	67
Mean (SD)	14.035 (19.9573)	27.586 (28.2688)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	10.476 (17.6595)	28.205 (27.7966)	18.033 (24.0168)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-4.902 (14.5235)	2.564 (24.8069)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	14.815 (23.2661)	25.000 (28.2330)	19.608 (25.9713)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	-2.564 (18.6740)	-2.778 (21.7954)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	12.346 (20.9765)	25.758 (32.4189)	18.367 (27.2686)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-3.846 (21.7602)	-3.030 (27.0392)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	13.333 (21.5166)	31.481 (33.2788)	20.930 (28.1936)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (15.4769)	1.852 (17.9768)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline			
n	3	1	4
Mean (SD)	-22.222 (19.2450)	-33.333 (-)	-25.000 (16.6667)
Median	-33.333	-33.333	-33.333
Q1, Q3	-33.333, 0.000	-33.333, -33.333	-33.333, -16.667
Min, Max	-33.33, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	14.815 (33.7931)	33.333 (27.2166)	20.513 (32.0256)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	16.667, 50.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (16.6667)	-8.333 (16.6667)	-2.564 (16.4516)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	25.000 (29.5468)	28.571 (29.9912)	26.667 (28.7297)
Median	16.667	33.333	33.333
Q1, Q3	0.000, 50.000	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	8	7	15
Mean (SD)	16.667 (30.8607)	9.524 (16.2650)	13.333 (24.5596)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	38	29	67
Mean (SD)	7.018 (15.8026)	20.690 (30.0975)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	8.571 (16.8478)	12.821 (21.2434)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	34	26	60
Mean (SD)	0.980 (15.3199)	-8.974 (34.7150)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	7.407 (21.3504)	9.722 (18.3344)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	0.000 (16.3299)	-9.722 (33.3031)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	3.704 (10.6752)	12.121 (21.9317)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	-2.564 (16.1192)	-9.091 (37.3484)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	9.333 (20.4577)	12.963 (23.2601)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	24	18	42
Mean (SD)	2.778 (16.7870)	-3.704 (35.9537)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	-100.000 (-)	-25.000 (50.0000)
Median	0.000	-100.000	0.000
Q1, Q3	0.000, 0.000	-100.000, -100.000	-50.000, 0.000
Min, Max	0.00, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	7.407 (22.2222)	8.333 (16.6667)	7.692 (19.9715)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (0.0000)	-33.333 (54.4331)	-10.256 (31.5777)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	29.167 (37.5331)	33.333 (38.4900)	31.111 (36.6595)
Median	16.667	33.333	33.333
Q1, Q3	0.000, 50.000	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	20.833 (39.5912)	0.000 (33.3333)	11.111 (37.0899)
Median	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	-33.33, 100.00	-66.67, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Constipation			
Baseline			
n	38	29	67
Mean (SD)	7.018 (17.6007)	11.494 (18.4216)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	8.571 (16.8478)	16.667 (28.6744)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	1.961 (16.2911)	5.128 (29.3520)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	6.173 (13.1949)	11.111 (21.2341)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	24	50
Mean (SD)	0.000 (16.3299)	1.389 (23.0084)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	7.407 (16.8790)	10.606 (15.8910)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	0.000 (16.3299)	0.000 (17.8174)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	6.667 (16.6667)	24.074 (37.5831)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (15.4769)	14.815 (36.5546)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	-33.333 (-)	-8.333 (16.6667)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-33.333, -33.333	-16.667, 0.000
Min, Max	0.00, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	3.704 (11.1111)	16.667 (19.2450)	7.692 (14.6176)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (16.6667)	0.000 (38.4900)	0.000 (23.5702)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	16.667 (35.6348)	28.571 (35.6348)	22.222 (34.8845)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	12.500 (35.3553)	14.286 (17.8174)	13.333 (27.6026)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	37	29	66
Mean (SD)	9.009 (21.7288)	4.598 (14.7038)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	6.667 (19.4701)	3.846 (10.8604)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	1.010 (15.5565)	-1.282 (14.8497)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	7.407 (19.2450)	7.246 (14.0580)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	25	23	48
Mean (SD)	4.000 (17.5330)	1.449 (15.8218)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	6.173 (16.1114)	4.545 (11.7083)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	25	22	47
Mean (SD)	4.000 (14.6566)	-1.515 (21.7666)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	8.000 (22.1108)	5.556 (12.7827)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	5.797 (21.6776)	0.000 (16.1690)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	0.000 (0.0000)	16.667 (19.2450)	5.128 (12.5178)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	8	4	12
Mean (SD)	0.000 (0.0000)	16.667 (19.2450)	5.556 (12.9750)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	12.500 (24.8008)	0.000 (0.0000)	6.667 (18.6871)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	7	7	14
Mean (SD)	14.286 (26.2265)	-4.762 (12.5988)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	38	29	67
Mean (SD)	14.912 (32.6022)	18.391 (28.9858)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	11.429 (26.7436)	12.821 (23.2416)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-1.961 (21.6199)	-6.410 (26.6987)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	8.642 (21.8632)	13.043 (24.0772)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	23	49
Mean (SD)	-2.564 (24.8069)	-4.348 (25.2350)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	8.642 (19.8124)	6.061 (13.1590)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	-2.564 (13.0744)	-12.121 (21.9317)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	10.667 (24.9444)	16.667 (30.7849)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (18.3344)	0.000 (16.1690)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (19.2450)	0.000 (-)	-8.333 (16.6667)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	9	4	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	9	4	13
Mean (SD)	0.000 (0.0000)	-16.667 (33.3333)	-5.128 (18.4900)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-66.67, 0.00	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	29.167 (45.2068)	38.095 (40.4995)	33.333 (41.7855)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	4.167 (11.7851)	0.000 (33.3333)	2.222 (23.4577)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	48	19	67
Mean (SD)	67.535 (22.2971)	62.281 (18.0808)	66.045 (21.1871)
Median	70.833	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	0.00, 100.00	25.00, 91.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	76.357 (18.4493)	73.611 (13.1762)	75.546 (17.0014)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	6.746 (20.2657)	11.574 (19.4152)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-41.67, 66.67	-16.67, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	76.905 (22.3320)	70.556 (14.7286)	75.000 (20.4124)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 91.667
Min, Max	8.33, 100.00	41.67, 100.00	8.33, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	7.353 (15.7266)	8.889 (16.5072)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	75.231 (22.7553)	64.744 (16.3702)	72.449 (21.5974)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	58.333, 83.333	58.333, 83.333
Min, Max	0.00, 100.00	33.33, 83.33	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	5.238 (19.9146)	5.769 (21.3504)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 50.00	-41.67, 41.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	77.020 (21.7537)	71.667 (13.7212)	75.775 (20.1527)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	50.00, 83.33	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	4.948 (13.3634)	14.167 (26.0727)	7.143 (17.3216)
Median	4.167	12.500	8.333
Q1, Q3	0.000, 16.667	-16.667, 33.333	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	80.556 (20.9718)	83.333 (-)	81.250 (17.1796)
Median	83.333	83.333	83.333
Q1, Q3	58.333, 100.000	83.333, 83.333	70.833, 91.667
Min, Max	58.33, 100.00	83.33, 83.33	58.33, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	-2.778 (20.9718)	58.333 (-)	12.500 (35.0264)
Median	0.000	58.333	8.333
Q1, Q3	-25.000, 16.667	58.333, 58.333	-12.500, 37.500
Min, Max	-25.00, 16.67	58.33, 58.33	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	80.303 (15.4887)	70.833 (17.6777)	78.846 (15.4468)
Median	83.333	70.833	83.333
Q1, Q3	75.000, 83.333	58.333, 83.333	75.000, 83.333
Min, Max	41.67, 100.00	58.33, 83.33	41.67, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	3.788 (13.6237)	45.833 (17.6777)	10.256 (20.7370)
Median	0.000	45.833	8.333
Q1, Q3	-8.333, 8.333	33.333, 58.333	0.000, 16.667
Min, Max	-16.67, 33.33	33.33, 58.33	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	60.417 (21.7078)	47.619 (29.5468)	54.444 (25.5625)
Median	66.667	50.000	58.333
Q1, Q3	45.833, 70.833	16.667, 66.667	33.333, 66.667
Min, Max	25.00, 91.67	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-4.167 (34.2145)	-23.810 (21.2070)	-13.333 (29.6808)
Median	4.167	-25.000	-16.667
Q1, Q3	-16.667, 12.500	-41.667, 0.000	-33.333, 8.333
Min, Max	-75.00, 41.67	-50.00, 8.33	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	48	19	67
Mean (SD)	83.611 (19.2512)	82.105 (20.9706)	83.184 (19.6041)
Median	90.000	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	33.33, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	17	60
Mean (SD)	85.736 (17.0018)	86.275 (16.7449)	85.889 (16.7890)
Median	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	86.667, 100.000	83.333, 100.000
Min, Max	26.67, 100.00	46.67, 100.00	26.67, 100.00
Change from Baseline			
n	42	17	59
Mean (SD)	-0.159 (10.5654)	5.098 (19.5120)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-6.667, 6.667
Min, Max	-26.67, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	85.556 (20.8090)	88.444 (8.8968)	86.405 (18.0843)
Median	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	66.67, 100.00	20.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	1.333 (14.1698)	5.778 (21.0618)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-33.33, 33.33	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	83.889 (24.8615)	87.179 (10.3500)	84.762 (21.9004)
Median	90.000	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	0.000 (17.5641)	5.641 (21.5761)	1.528 (18.6666)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667
Min, Max	-73.33, 40.00	-20.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	32	10	42
Mean (SD)	84.375 (23.9838)	88.667 (9.9629)	85.397 (21.4508)
Median	93.333	90.000	93.333
Q1, Q3	83.333, 100.000	86.667, 93.333	86.667, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	-1.075 (10.1976)	12.000 (23.6852)	2.114 (15.3796)
Median	0.000	6.667	0.000
Q1, Q3	0.000, 0.000	0.000, 26.667	0.000, 6.667
Min, Max	-40.00, 20.00	-20.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	97.778 (3.8490)	93.333 (-)	96.667 (3.8490)
Median	100.000	93.333	96.667
Q1, Q3	93.333, 100.000	93.333, 93.333	93.333, 100.000
Min, Max	93.33, 100.00	93.33, 93.33	93.33, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	60.000 (-)	15.000 (30.0000)
Median	0.000	60.000	0.000
Q1, Q3	0.000, 0.000	60.000, 60.000	0.000, 30.000
Min, Max	0.00, 0.00	60.00, 60.00	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	84.848 (21.9273)	86.667 (9.4281)	85.128 (20.2125)
Median	93.333	86.667	93.333
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	26.67, 100.00	80.00, 93.33	26.67, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	-3.030 (10.4833)	23.333 (51.8545)	1.026 (20.3390)
Median	0.000	23.333	0.000
Q1, Q3	-13.333, 6.667	-13.333, 60.000	-13.333, 6.667
Min, Max	-26.67, 6.67	-13.33, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	75.833 (18.4950)	77.143 (18.4017)	76.444 (17.7936)
Median	76.667	80.000	80.000
Q1, Q3	63.333, 90.000	60.000, 93.333	60.000, 93.333
Min, Max	46.67, 100.00	46.67, 100.00	46.67, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-3.333 (15.1186)	-8.571 (14.2539)	-5.778 (14.4457)
Median	-6.667	-6.667	-6.667
Q1, Q3	-13.333, 3.333	-20.000, 0.000	-20.000, 0.000
Min, Max	-20.00, 26.67	-26.67, 13.33	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	58.333 (-)	- (-)	58.333 (-)
Median	58.333	-	58.333
Q1, Q3	58.333, 58.333	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	< 3 (N = 49)	≥ 3 (N = 19)	Total (N = 68)
Survival Follow-up 2			
n	1	0	1
Mean (SD)	60.000 (-)	- (-)	60.000 (-)
Median	60.000	-	60.000
Q1, Q3	60.000, 60.000	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline			
n	1	0	1
Mean (SD)	-6.667 (-)	- (-)	-6.667 (-)
Median	-6.667	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Role functioning			
Baseline			
n	48	19	67
Mean (SD)	83.333 (24.7923)	83.333 (27.2166)	83.333 (25.2929)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.047 (22.3992)	88.889 (20.6116)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	0.397 (23.7101)	6.481 (22.9655)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	88.889 (19.9205)	92.222 (12.3871)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	4.286 (14.2014)	8.889 (30.1232)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	87.037 (26.4608)	84.615 (22.0075)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	2.381 (22.5582)	0.000 (15.2145)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	85.859 (27.0420)	88.333 (17.6558)	86.434 (25.0015)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (17.9605)	6.667 (28.5450)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-16.67, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	< 3 (N = 49)	≥ 3 (N = 19)	Total (N = 68)
Cycle 15			
n	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	5.556 (9.6225)	100.000 (-)	29.167 (47.8714)
Median	0.000	100.000	8.333
Q1, Q3	0.000, 16.667	100.000, 100.000	0.000, 58.333
Min, Max	0.00, 16.67	100.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	84.848 (22.9184)	83.333 (23.5702)	84.615 (22.0075)
Median	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	-4.545 (15.0756)	33.333 (94.2809)	1.282 (33.6523)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	-33.333, 100.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	64.583 (30.1287)	61.905 (36.9112)	63.333 (32.2441)
Median	66.667	66.667	66.667
Q1, Q3	41.667, 91.667	33.333, 100.000	33.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-6.250 (28.0836)	-21.429 (29.9912)	-13.333 (29.0047)
Median	-8.333	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-50.000, 0.000	-33.333, 0.000
Min, Max	-50.00, 50.00	-66.67, 16.67	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	48	19	67
Mean (SD)	82.986 (18.2702)	80.263 (17.1707)	82.214 (17.8786)
Median	83.333	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 91.667	66.667, 100.000
Min, Max	25.00, 100.00	41.67, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.047 (20.0628)	81.019 (23.1868)	84.563 (20.9627)
Median	100.000	87.500	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	2.976 (17.0506)	1.389 (23.0887)	2.500 (18.8724)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-58.33, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	85.476 (20.5463)	77.778 (24.7340)	83.167 (21.9183)
Median	91.667	83.333	91.667
Q1, Q3	83.333, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	4.657 (18.8239)	0.000 (19.6699)	3.231 (19.0042)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-50.00, 41.67	-41.67, 33.33	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	85.880 (21.2524)	74.359 (24.4053)	82.823 (22.4645)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	8.33, 100.00	16.67, 100.00	8.33, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	4.048 (19.9439)	-3.846 (18.5141)	1.910 (19.6932)
Median	0.000	-8.333	0.000
Q1, Q3	0.000, 16.667	-16.667, 8.333	-8.333, 16.667
Min, Max	-50.00, 50.00	-33.33, 25.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	86.364 (21.8321)	71.667 (26.9888)	82.946 (23.6370)
Median	100.000	87.500	91.667
Q1, Q3	83.333, 100.000	41.667, 91.667	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	1.823 (17.4204)	-1.667 (20.3367)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 12.500	-16.667, 8.333	0.000, 8.333
Min, Max	-50.00, 41.67	-41.67, 25.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	91.667 (14.4338)	83.333 (-)	89.583 (12.5000)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	83.333, 83.333	79.167, 100.000
Min, Max	75.00, 100.00	83.33, 83.33	75.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	11.111 (12.7294)	8.333 (-)	10.417 (10.4859)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 25.000	8.333, 8.333	4.167, 16.667
Min, Max	0.00, 25.00	8.33, 8.33	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	87.879 (11.9975)	45.833 (53.0330)	81.410 (24.5689)
Median	91.667	45.833	83.333
Q1, Q3	75.000, 100.000	8.333, 83.333	75.000, 100.000
Min, Max	66.67, 100.00	8.33, 83.33	8.33, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	3.788 (12.5630)	-12.500 (29.4628)	1.282 (15.5330)
Median	0.000	-12.500	0.000
Q1, Q3	-8.333, 8.333	-33.333, 8.333	-8.333, 8.333
Min, Max	-8.33, 33.33	-33.33, 8.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	81.250 (21.7078)	71.429 (27.9952)	76.667 (24.4381)
Median	87.500	83.333	83.333
Q1, Q3	75.000, 95.833	33.333, 91.667	66.667, 91.667
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-5.208 (16.0217)	-17.857 (21.7459)	-11.111 (19.3307)
Median	-4.167	-16.667	-8.333
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-25.000, 0.000
Min, Max	-25.00, 25.00	-50.00, 8.33	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	-13.889 (-)	- (-)	-13.889 (-)
Median	-13.889	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	48	19	67
Mean (SD)	89.236 (18.3509)	85.088 (16.5689)	88.060 (17.8391)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.822 (16.8867)	83.333 (17.1499)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-4.365 (16.0704)	-1.852 (19.7111)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	85.714 (22.1930)	82.222 (25.5625)	84.667 (23.0449)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	-3.922 (10.0995)	-6.667 (23.4013)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	83.333 (26.1255)	87.179 (20.5861)	84.354 (24.6288)
Median	91.667	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-6.190 (18.9968)	-1.282 (23.0353)	-4.861 (20.0349)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-100.00, 16.67	-33.33, 50.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	85.859 (20.8838)	78.333 (27.2732)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	-4.688 (10.5701)	-6.667 (30.6312)	-5.159 (17.0636)
Median	0.000	-8.333	0.000
Q1, Q3	-8.333, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	100.000 (0.0000)	100.000 (-)	100.000 (0.0000)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	92.424 (15.5700)	50.000 (70.7107)	85.897 (29.5382)
Median	100.000	50.000	100.000
Q1, Q3	83.333, 100.000	0.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	-3.030 (10.0504)	-33.333 (47.1405)	-7.692 (19.9715)
Median	0.000	-33.333	0.000
Q1, Q3	-16.667, 0.000	-66.667, 0.000	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 0.00	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	81.250 (22.6034)	71.429 (23.0022)	76.667 (22.5374)
Median	83.333	83.333	83.333
Q1, Q3	75.000, 100.000	50.000, 83.333	66.667, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	-8.333 (15.4303)	-14.286 (20.2498)	-11.111 (17.4423)
Median	-8.333	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Social functioning			
Baseline			
n	48	19	67
Mean (SD)	87.847 (18.7492)	78.070 (28.8956)	85.075 (22.3106)
Median	100.000	83.333	100.000
Q1, Q3	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	89.535 (19.9282)	87.963 (19.6419)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.397 (20.3253)	11.111 (31.3112)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 66.67	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	92.857 (16.3128)	90.000 (15.1710)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	3.922 (20.5394)	13.333 (30.3420)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-50.00, 83.33	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	90.278 (24.3568)	76.923 (16.0128)	86.735 (23.0688)
Median	100.000	66.667	100.000
Q1, Q3	100.000, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	1.429 (27.8216)	2.564 (31.0661)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 8.333
Min, Max	-83.33, 83.33	-33.33, 66.67	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	94.444 (10.7583)	83.333 (15.7135)	91.860 (12.7927)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	2.604 (15.3276)	10.000 (38.6501)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 33.333	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	< 3 (N = 49)	≥ 3 (N = 19)	Total (N = 68)
Cycle 15			
n	3	1	4
Mean (SD)	83.333 (28.8675)	100.000 (-)	87.500 (25.0000)
Median	100.000	100.000	100.000
Q1, Q3	50.000, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	100.00, 100.00	50.00, 100.00
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (34.6944)	100.000 (-)	16.667 (62.3610)
Median	0.000	100.000	8.333
Q1, Q3	-50.000, 16.667	100.000, 100.000	-25.000, 58.333
Min, Max	-50.00, 16.67	100.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	93.939 (15.4069)	83.333 (23.5702)	92.308 (16.1236)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	50.00, 100.00	66.67, 100.00	50.00, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	-1.515 (8.9893)	66.667 (47.1405)	8.974 (30.1350)
Median	0.000	66.667	0.000
Q1, Q3	0.000, 0.000	33.333, 100.000	0.000, 0.000
Min, Max	-16.67, 16.67	33.33, 100.00	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	77.083 (28.0836)	59.524 (23.2879)	68.889 (26.6270)
Median	83.333	66.667	66.667
Q1, Q3	58.333, 100.000	33.333, 66.667	33.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	0.000 (19.9205)	-21.429 (26.7261)	-10.000 (25.0397)
Median	8.333	-33.333	0.000
Q1, Q3	-16.667, 16.667	-50.000, 0.000	-33.333, 16.667
Min, Max	-33.33, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Fatigue			
Baseline			
n	48	19	67
Mean (SD)	29.514 (24.1796)	29.240 (21.3439)	29.436 (23.2509)
Median	22.222	22.222	22.222
Q1, Q3	11.111, 44.444	11.111, 44.444	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 88.89	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	< 3 (N = 49)	≥ 3 (N = 19)	Total (N = 68)
Cycle 3			
n	43	18	61
Mean (SD)	20.672 (22.6910)	25.309 (22.1586)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	11.111, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	42	18	60
Mean (SD)	-6.746 (22.5429)	-4.321 (30.2828)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 0.000	-22.222, 0.000
Min, Max	-55.56, 66.67	-88.89, 66.67	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	21.296 (22.4394)	28.148 (16.7283)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	22.222, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	35	15	50
Mean (SD)	-8.413 (15.5024)	-1.481 (26.5163)	-6.333 (19.4407)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 11.111	-11.111, 0.000
Min, Max	-66.67, 11.11	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	20.988 (24.1655)	28.205 (15.4596)	22.902 (22.2694)
Median	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	22.222, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-7.778 (18.4847)	-3.419 (23.7375)	-6.597 (19.8714)
Median	-11.111	0.000	0.000
Q1, Q3	-22.222, 0.000	0.000, 11.111	-19.444, 0.000
Min, Max	-44.44, 44.44	-55.56, 22.22	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	19.865 (21.4731)	20.000 (16.3970)	19.897 (20.2219)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 44.44	0.00, 77.78
Change from Baseline			
n	32	10	42
Mean (SD)	-5.729 (15.0324)	-14.444 (33.1476)	-7.804 (20.6438)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-33.33, 33.33	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	< 3 (N = 49)	≥ 3 (N = 19)	Total (N = 68)
Cycle 15			
n	3	1	4
Mean (SD)	3.704 (6.4150)	11.111 (-)	5.556 (6.4150)
Median	0.000	11.111	5.556
Q1, Q3	0.000, 11.111	11.111, 11.111	0.000, 11.111
Min, Max	0.00, 11.11	11.11, 11.11	0.00, 11.11
Change from Baseline			
n	3	1	4
Mean (SD)	-7.407 (12.8300)	-77.778 (-)	-25.000 (36.7115)
Median	0.000	-77.778	-11.111
Q1, Q3	-22.222, 0.000	-77.778, -77.778	-50.000, 0.000
Min, Max	-22.22, 0.00	-77.78, -77.78	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	16.162 (25.5138)	11.111 (15.7135)	15.385 (23.8041)
Median	11.111	11.111	11.111
Q1, Q3	0.000, 22.222	0.000, 22.222	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 22.22	0.00, 88.89
Change from Baseline			
n	11	2	13
Mean (SD)	-4.545 (14.6604)	-50.000 (54.9972)	-11.538 (26.8801)
Median	0.000	-50.000	0.000
Q1, Q3	-11.111, 0.000	-88.889, -11.111	-11.111, 0.000
Min, Max	-38.89, 22.22	-88.89, -11.11	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	43.056 (27.4986)	49.206 (29.9912)	45.926 (27.8148)
Median	44.444	66.667	44.444
Q1, Q3	22.222, 66.667	11.111, 77.778	11.111, 66.667
Min, Max	0.00, 77.78	11.11, 77.78	0.00, 77.78
Change from Baseline			
n	8	7	15
Mean (SD)	-0.694 (22.3089)	23.810 (21.6867)	10.741 (24.7088)
Median	-8.333	22.222	11.111
Q1, Q3	-16.667, 11.111	0.000, 44.444	-11.111, 33.333
Min, Max	-22.22, 44.44	0.00, 55.56	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	48	19	67
Mean (SD)	4.514 (11.7799)	2.632 (6.2439)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	3.488 (9.3139)	0.926 (3.9284)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	42	18	60
Mean (SD)	-1.190 (10.0087)	-0.926 (6.9363)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	3.241 (16.8181)	4.444 (7.6290)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-1.429 (14.7813)	3.333 (6.9007)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 16.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	3.241 (8.7464)	5.128 (8.0064)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	35	13	48
Mean (SD)	-1.429 (8.4515)	3.846 (7.3088)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	3.030 (9.7312)	0.000 (0.0000)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (4.2333)	-1.667 (5.2705)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	16.667 (-)	4.167 (8.3333)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	16.667, 16.667	0.000, 8.333
Min, Max	0.00, 0.00	16.67, 16.67	0.00, 16.67
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	3.030 (10.0504)	8.333 (11.7851)	3.846 (9.9857)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	11	2	13
Mean (SD)	-1.515 (5.0252)	0.000 (0.0000)	-1.282 (4.6225)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	0.00, 0.00	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	8.333 (17.8174)	7.143 (18.8982)	7.778 (17.6683)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	8	7	15
Mean (SD)	4.167 (19.4161)	4.762 (12.5988)	4.444 (16.0192)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 33.33	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Pain			
Baseline			
n	47	19	66
Mean (SD)	15.248 (23.2685)	13.158 (16.2721)	14.646 (21.3868)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 50.00	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	15.891 (23.2747)	11.111 (15.1248)	14.481 (21.1860)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline			
n	41	18	59
Mean (SD)	1.220 (22.4815)	-2.778 (17.3864)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	-16.667, 16.667
Min, Max	-66.67, 50.00	-33.33, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	16.204 (25.9689)	8.889 (13.8968)	14.052 (23.1835)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	-0.490 (19.8840)	-3.333 (20.1187)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	17.130 (27.4545)	23.077 (22.0883)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 25.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	34	13	47
Mean (SD)	0.000 (24.2740)	12.821 (23.7208)	3.546 (24.5580)
Median	0.000	16.667	0.000
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-16.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	16.162 (23.0055)	15.000 (22.8387)	15.891 (22.6993)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	0.538 (16.9334)	6.667 (31.6228)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 33.333	0.000, 16.667
Min, Max	-50.00, 33.33	-33.33, 66.67	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (9.6225)	33.333 (-)	0.000 (23.5702)
Median	-16.667	33.333	-8.333
Q1, Q3	-16.667, 0.000	33.333, 33.333	-16.667, 16.667
Min, Max	-16.67, 0.00	33.33, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	16.667 (31.6228)	16.667 (23.5702)	16.667 (29.6586)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	10	2	12
Mean (SD)	5.000 (15.8114)	16.667 (23.5702)	6.944 (16.6034)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-16.67, 33.33	0.00, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	12.500 (14.7734)	28.571 (28.4056)	20.000 (22.8869)
Median	8.333	33.333	16.667
Q1, Q3	0.000, 25.000	0.000, 50.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	7	7	14
Mean (SD)	-4.762 (15.8532)	14.286 (24.3975)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 16.67	-16.67, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	48	19	67
Mean (SD)	22.222 (30.2342)	28.070 (33.8172)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	16.279 (22.2683)	20.370 (25.9181)	17.486 (23.2591)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (21.4490)	-9.259 (31.9427)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	15.741 (27.0051)	13.333 (16.9031)	15.033 (24.3253)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-5.714 (23.5504)	-15.556 (37.5154)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	12	48
Mean (SD)	12.037 (19.7649)	11.111 (16.4122)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	12	47
Mean (SD)	-9.524 (26.2858)	-22.222 (41.0305)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	16.162 (23.7481)	16.667 (23.5702)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	10	42
Mean (SD)	-4.167 (30.2321)	-20.000 (44.9966)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	-22.222 (38.4900)	-100.000 (-)	-41.667 (50.0000)
Median	0.000	-100.000	-33.333
Q1, Q3	-66.667, 0.000	-100.000, -100.000	-83.333, 0.000
Min, Max	-66.67, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	15.152 (22.9184)	0.000 (0.0000)	12.821 (21.6815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	11	2	13
Mean (SD)	-6.061 (13.4840)	-66.667 (47.1405)	-15.385 (29.2353)
Median	0.000	-66.667	0.000
Q1, Q3	0.000, 0.000	-100.000, -33.333	-33.333, 0.000
Min, Max	-33.33, 0.00	-100.00, -33.33	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	37.500 (37.5331)	33.333 (33.3333)	35.556 (34.4265)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	4.167 (27.8174)	9.524 (37.0899)	6.667 (31.3708)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Insomnia			
Baseline			
n	48	19	67
Mean (SD)	20.139 (26.3990)	19.298 (20.2326)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	18.605 (25.5131)	16.667 (20.6116)	18.033 (24.0168)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (18.7526)	-3.704 (22.5467)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	20.370 (27.9203)	17.778 (21.3313)	19.608 (25.9713)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-1.905 (19.7084)	-4.444 (21.3313)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	17.593 (28.1562)	20.513 (25.5983)	18.367 (27.2686)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (25.2716)	-2.564 (21.3504)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	20.202 (28.7945)	23.333 (27.4424)	20.930 (28.1936)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (14.6647)	0.000 (22.2222)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	33.333 (-)	8.333 (16.6667)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline			
n	3	1	4
Mean (SD)	-22.222 (19.2450)	-33.333 (-)	-25.000 (16.6667)
Median	-33.333	-33.333	-33.333
Q1, Q3	-33.333, 0.000	-33.333, -33.333	-33.333, -16.667
Min, Max	-33.33, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	21.212 (34.2304)	16.667 (23.5702)	20.513 (32.0256)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	11	2	13
Mean (SD)	0.000 (14.9071)	-16.667 (23.5702)	-2.564 (16.4516)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	8.333 (15.4303)	47.619 (26.2265)	26.667 (28.7297)
Median	0.000	66.667	33.333
Q1, Q3	0.000, 16.667	33.333, 66.667	0.000, 66.667
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	8	7	15
Mean (SD)	0.000 (0.0000)	28.571 (29.9912)	13.333 (24.5596)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 0.00	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	48	19	67
Mean (SD)	11.111 (23.1485)	17.544 (25.7443)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	8.527 (17.9550)	14.815 (20.5233)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	42	18	60
Mean (SD)	-3.175 (21.8513)	-3.704 (34.0873)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	9.259 (21.9828)	6.667 (13.8013)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-0.952 (23.5504)	-13.333 (30.3420)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	6.481 (17.4928)	10.256 (16.0128)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (25.2716)	-10.256 (34.3851)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	10.101 (21.2211)	13.333 (23.3069)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	10	42
Mean (SD)	3.125 (19.6006)	-10.000 (41.7222)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	-100.000 (-)	-25.000 (50.0000)
Median	0.000	-100.000	0.000
Q1, Q3	0.000, 0.000	-100.000, -100.000	-50.000, 0.000
Min, Max	0.00, 0.00	-100.00, -100.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	9.091 (21.5557)	0.000 (0.0000)	7.692 (19.9715)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	11	2	13
Mean (SD)	0.000 (14.9071)	-66.667 (47.1405)	-10.256 (31.5777)
Median	0.000	-66.667	0.000
Q1, Q3	0.000, 0.000	-100.000, -33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, -33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	29.167 (45.2068)	33.333 (27.2166)	31.111 (36.6595)
Median	0.000	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	4.167 (45.2068)	19.048 (26.2265)	11.111 (37.0899)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	-66.67, 100.00	-33.33, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Constipation			
Baseline			
n	48	19	67
Mean (SD)	9.028 (19.1295)	8.772 (15.0805)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	13.178 (25.3437)	9.259 (15.3630)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	3.968 (24.6409)	1.852 (17.9768)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	6.481 (15.5726)	13.333 (21.0819)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	35	15	50
Mean (SD)	-1.905 (16.0531)	6.667 (25.8199)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	8.333 (16.6667)	10.256 (16.0128)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-0.952 (15.0939)	2.564 (21.3504)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	14.141 (31.2142)	13.333 (17.2133)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	6.250 (27.3534)	3.333 (29.1865)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	-33.333 (-)	-8.333 (16.6667)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-33.333, -33.333	-16.667, 0.000
Min, Max	0.00, 0.00	-33.33, -33.33	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	9.091 (15.5700)	0.000 (0.0000)	7.692 (14.6176)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline			
n	11	2	13
Mean (SD)	6.061 (20.1008)	-33.333 (0.0000)	0.000 (23.5702)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 33.333	-33.333, -33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, -33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	33.333 (43.6436)	9.524 (16.2650)	22.222 (34.8845)
Median	16.667	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	20.833 (35.3553)	4.762 (12.5988)	13.333 (27.6026)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	47	19	66
Mean (SD)	8.511 (21.3868)	3.509 (10.5101)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	6.977 (18.6277)	1.852 (7.8567)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	41	18	59
Mean (SD)	0.000 (16.6667)	0.000 (11.4332)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	9.524 (19.0826)	2.222 (8.6066)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	33	15	48
Mean (SD)	3.030 (19.2996)	2.222 (8.6066)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	7.407 (16.1562)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	34	13	47
Mean (SD)	1.961 (21.6199)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	7.071 (19.9958)	6.667 (14.0546)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	2.151 (20.9682)	6.667 (14.0546)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	0.00, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	3.030 (10.0504)	16.667 (23.5702)	5.128 (12.5178)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	10	2	12
Mean (SD)	3.333 (10.5409)	16.667 (23.5702)	5.556 (12.9750)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	8.333 (23.5702)	4.762 (12.5988)	6.667 (18.6871)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	7	7	14
Mean (SD)	4.762 (29.9912)	4.762 (12.5988)	4.762 (22.0998)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	48	19	67
Mean (SD)	12.500 (25.3813)	26.316 (40.9440)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	10.078 (21.2504)	16.667 (32.8395)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (18.7526)	-11.111 (32.3381)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	8.571 (20.3609)	15.556 (27.7936)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	34	15	49
Mean (SD)	0.000 (20.1008)	-11.111 (32.5300)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	4.630 (11.6912)	15.385 (25.8750)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (15.7003)	-15.385 (22.0075)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	10.101 (24.2740)	23.333 (35.3117)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	2.083 (14.5112)	-10.000 (22.4983)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 15			
n	3	1	4
Mean (SD)	0.000 (0.0000)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	3	1	4
Mean (SD)	-11.111 (19.2450)	0.000 (-)	-8.333 (16.6667)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	11	2	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	0.000 (0.0000)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	11	2	13
Mean (SD)	0.000 (0.0000)	-33.333 (47.1405)	-5.128 (18.4900)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-66.67, 0.00	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	8	7	15
Mean (SD)	29.167 (37.5331)	38.095 (48.7950)	33.333 (41.7855)
Median	16.667	0.000	0.000
Q1, Q3	0.000, 50.000	0.000, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	8	7	15
Mean (SD)	0.000 (30.8607)	4.762 (12.5988)	2.222 (23.4577)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Global health status/QOL					
Baseline					
n	26	25	12	4	67
Mean (SD)	66.346 (22.7890)	70.000 (16.6667)	59.722 (26.0713)	58.333 (21.5166)	66.045 (21.1871)
Median	66.667	75.000	62.500	58.333	66.667
Q1, Q3	50.000, 83.333	66.667, 83.333	45.833, 83.333	41.667, 75.000	50.000, 83.333
Min, Max	25.00, 100.00	25.00, 100.00	0.00, 91.67	33.33, 83.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	78.571 (18.1757)	74.667 (16.2233)	73.485 (16.5907)	70.833 (20.9718)	75.546 (17.0014)
Median	83.333	83.333	75.000	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	58.333, 83.333	58.333, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	25.00, 100.00	50.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	11.508 (23.4929)	4.514 (20.8484)	8.333 (12.9099)	12.500 (8.3333)	8.194 (19.9748)
Median	8.333	8.333	8.333	16.667	8.333
Q1, Q3	0.000, 16.667	-8.333, 12.500	0.000, 25.000	8.333, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-41.67, 50.00	-16.67, 25.00	0.00, 16.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	79.902 (14.4514)	76.587 (17.6027)	64.815 (29.6911)	66.667 (33.3333)	75.000 (20.4124)
Median	83.333	83.333	66.667	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 91.667	50.000, 83.333	33.333, 100.000	66.667, 91.667
Min, Max	50.00, 100.00	41.67, 100.00	8.33, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	12.745 (21.8735)	4.583 (11.9315)	6.481 (10.0154)	5.556 (9.6225)	7.823 (15.8121)
Median	0.000	0.000	8.333	0.000	8.333
Q1, Q3	0.000, 25.000	0.000, 8.333	8.333, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 33.33	-16.67, 16.67	0.00, 16.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	73.611 (15.9784)	76.587 (17.9929)	58.333 (36.6414)	69.444 (29.2657)	72.449 (21.5974)
Median	79.167	83.333	66.667	66.667	83.333
Q1, Q3	58.333, 83.333	66.667, 83.333	16.667, 91.667	41.667, 100.000	58.333, 83.333
Min, Max	41.67, 100.00	33.33, 100.00	0.00, 91.67	41.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	5.556 (16.9100)	3.750 (19.2086)	8.333 (29.2657)	8.333 (30.0463)	5.382 (20.0833)
Median	4.167	8.333	8.333	16.667	8.333
Q1, Q3	-8.333, 16.667	0.000, 12.500	0.000, 25.000	-25.000, 33.333	0.000, 16.667
Min, Max	-16.67, 50.00	-41.67, 41.67	-50.00, 41.67	-25.00, 33.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	75.000 (15.2145)	81.140 (15.9189)	63.889 (32.3465)	66.667 (47.1405)	75.775 (20.1527)
Median	79.167	83.333	75.000	66.667	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	66.667, 83.333	33.333, 100.000	66.667, 83.333
Min, Max	50.00, 100.00	50.00, 100.00	0.00, 83.33	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	3.125 (21.0544)	9.259 (15.8858)	11.111 (12.5462)	8.333 (11.7851)	7.143 (17.3216)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-12.500, 12.500	0.000, 16.667	0.000, 25.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 58.33	-16.67, 41.67	0.00, 25.00	0.00, 16.67	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	91.667 (11.7851)	70.833 (17.6777)	- (-)	- (-)	81.250 (17.1796)
Median	91.667	70.833	-	-	83.333
Q1, Q3	83.333, 100.000	58.333, 83.333	-, -	-, -	70.833, 91.667
Min, Max	83.33, 100.00	58.33, 83.33	-, -	-, -	58.33, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	37.500 (29.4628)	-12.500 (17.6777)	- (-)	- (-)	12.500 (35.0264)
Median	37.500	-12.500	-	-	8.333
Q1, Q3	16.667, 58.333	-25.000, 0.000	-, -	-, -	-12.500, 37.500
Min, Max	16.67, 58.33	-25.00, 0.00	-, -	-, -	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	85.000 (9.1287)	79.762 (12.5988)	- (-)	41.667 (-)	78.846 (15.4468)
Median	83.333	83.333	-	41.667	83.333
Q1, Q3	83.333, 83.333	75.000, 83.333	-, -	41.667, 41.667	75.000, 83.333
Min, Max	75.00, 100.00	58.33, 100.00	-, -	41.67, 41.67	41.67, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	13.333 (28.0129)	8.333 (18.0021)	- (-)	8.333 (-)	10.256 (20.7370)
Median	8.333	0.000	-	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 33.333	-, -	8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 58.33	-8.33, 33.33	-, -	8.33, 8.33	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	50.000 (17.4801)	48.333 (23.8630)	69.444 (45.8964)	66.667 (-)	54.444 (25.5625)
Median	54.167	50.000	91.667	66.667	58.333
Q1, Q3	33.333, 66.667	33.333, 66.667	16.667, 100.000	66.667, 66.667	33.333, 66.667
Min, Max	25.00, 66.67	16.67, 75.00	16.67, 100.00	66.67, 66.67	16.67, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-15.278 (39.2346)	-20.000 (28.0129)	-2.778 (19.2450)	0.000 (-)	-13.333 (29.6808)
Median	-16.667	-25.000	8.333	0.000	-16.667
Q1, Q3	-33.333, 8.333	-41.667, 0.000	-25.000, 8.333	0.000, 0.000	-33.333, 8.333
Min, Max	-75.00, 41.67	-50.00, 16.67	-25.00, 8.33	0.00, 0.00	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-16.667 (-)	- (-)	- (-)	- (-)	-16.667 (-)
Median	-16.667	-	-	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-, -	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-, -	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	50.000 (-)	- (-)	- (-)	- (-)	50.000 (-)
Median	50.000	-	-	-	50.000
Q1, Q3	50.000, 50.000	-, -	-, -	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	-, -	-, -	50.00, 50.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Physical functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	84.872 (18.5288)	86.667 (17.3205)	73.333 (22.9184)	80.000 (27.2166)	83.184 (19.6041)
Median	90.000	93.333	83.333	90.000	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	46.667, 90.000	63.333, 96.667	80.000, 100.000
Min, Max	33.33, 100.00	20.00, 100.00	40.00, 100.00	40.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	20	25	11	4	60
Mean (SD)	89.000 (11.9012)	85.867 (17.2477)	83.636 (16.6969)	76.667 (33.7749)	85.889 (16.7890)
Median	93.333	86.667	86.667	90.000	93.333
Q1, Q3	86.667, 100.000	86.667, 100.000	80.000, 93.333	56.667, 96.667	83.333, 100.000
Min, Max	60.00, 100.00	26.67, 100.00	46.67, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline					
n	20	24	11	4	59
Mean (SD)	2.667 (14.5739)	-1.667 (14.7442)	7.273 (10.5217)	-3.333 (6.6667)	1.356 (13.7732)
Median	0.000	0.000	6.667	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 3.333	0.000, 13.333	-6.667, 0.000	-6.667, 6.667
Min, Max	-20.00, 53.33	-33.33, 40.00	-6.67, 33.33	-13.33, 0.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	89.259 (10.5133)	87.302 (15.0414)	83.704 (25.1906)	71.111 (44.3889)	86.405 (18.0843)
Median	93.333	93.333	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	86.667, 100.000	80.000, 100.000	20.000, 100.000	80.000, 100.000
Min, Max	73.33, 100.00	46.67, 100.00	20.00, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	2.593 (15.8653)	0.667 (16.0263)	10.370 (18.8889)	-6.667 (13.3333)	2.667 (16.4406)
Median	0.000	0.000	6.667	-6.667	0.000
Q1, Q3	-6.667, 6.667	-10.000, 6.667	0.000, 20.000	-20.000, 6.667	-6.667, 6.667
Min, Max	-20.00, 53.33	-33.33, 33.33	-20.00, 40.00	-20.00, 6.67	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	90.370 (10.0254)	87.937 (17.2071)	61.905 (40.1321)	82.222 (25.2396)	84.762 (21.9004)
Median	86.667	93.333	86.667	93.333	86.667
Q1, Q3	86.667, 100.000	80.000, 100.000	6.667, 86.667	53.333, 100.000	80.000, 100.000
Min, Max	66.67, 100.00	26.67, 100.00	0.00, 86.67	53.33, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	3.704 (14.8583)	1.000 (8.7258)	-3.810 (42.1386)	4.444 (10.1835)	1.528 (18.6666)
Median	0.000	0.000	0.000	6.667	0.000
Q1, Q3	0.000, 6.667	0.000, 6.667	-40.000, 40.000	-6.667, 13.333	0.000, 6.667
Min, Max	-13.33, 53.33	-20.00, 20.00	-73.33, 46.67	-6.67, 13.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	18	6	2	42
Mean (SD)	90.833 (9.3887)	88.889 (19.1315)	66.667 (33.4664)	66.667 (47.1405)	85.397 (21.4508)
Median	93.333	93.333	80.000	66.667	93.333
Q1, Q3	86.667, 100.000	86.667, 100.000	66.667, 86.667	33.333, 100.000	86.667, 100.000
Min, Max	66.67, 100.00	20.00, 100.00	0.00, 86.67	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	2.917 (16.6833)	3.137 (10.3058)	-2.222 (25.8772)	0.000 (9.4281)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-3.333, 3.333	0.000, 6.667	-13.333, 0.000	-6.667, 6.667	0.000, 6.667
Min, Max	-13.33, 60.00	-20.00, 26.67	-40.00, 40.00	-6.67, 6.67	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	96.667 (4.7140)	96.667 (4.7140)	- (-)	- (-)	96.667 (3.8490)
Median	96.667	96.667	-	-	96.667
Q1, Q3	93.333, 100.000	93.333, 100.000	-, -	-, -	93.333, 100.000
Min, Max	93.33, 100.00	93.33, 100.00	-, -	-, -	93.33, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	30.000 (42.4264)	0.000 (0.0000)	- (-)	- (-)	15.000 (30.0000)
Median	30.000	0.000	-	-	0.000
Q1, Q3	0.000, 60.000	0.000, 0.000	-, -	-, -	0.000, 30.000
Min, Max	0.00, 60.00	0.00, 0.00	-, -	-, -	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	92.000 (14.4530)	88.571 (7.4180)	- (-)	26.667 (-)	85.128 (20.2125)
Median	100.000	86.667	-	26.667	93.333
Q1, Q3	93.333, 100.000	80.000, 93.333	-, -	26.667, 26.667	80.000, 100.000
Min, Max	66.67, 100.00	80.00, 100.00	-, -	26.67, 26.67	26.67, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	8.000 (31.7630)	-1.905 (8.3571)	- (-)	-13.333 (-)	1.026 (20.3390)
Median	0.000	0.000	-	-13.333	0.000
Q1, Q3	0.000, 6.667	-13.333, 6.667	-, -	-13.333, -13.333	-13.333, 6.667
Min, Max	-26.67, 60.00	-13.33, 6.67	-, -	-13.33, -13.33	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	71.111 (16.1475)	76.000 (12.9957)	82.222 (30.7920)	93.333 (-)	76.444 (17.7936)
Median	73.333	80.000	100.000	93.333	80.000
Q1, Q3	60.000, 86.667	66.667, 80.000	46.667, 100.000	93.333, 93.333	60.000, 93.333
Min, Max	46.67, 86.67	60.00, 93.33	46.67, 100.00	93.33, 93.33	46.67, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-6.667 (10.3280)	-10.667 (21.3957)	4.444 (7.6980)	-6.667 (-)	-5.778 (14.4457)
Median	-6.667	-20.000	0.000	-6.667	-6.667
Q1, Q3	-13.333, 0.000	-20.000, -13.333	0.000, 13.333	-6.667, -6.667	-20.000, 0.000
Min, Max	-20.00, 6.67	-26.67, 26.67	0.00, 13.33	-6.67, -6.67	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	58.333 (-)	- (-)	- (-)	- (-)	58.333 (-)
Median	58.333	-	-	-	58.333
Q1, Q3	58.333, 58.333	-, -	-, -	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	-, -	-, -	58.33, 58.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-8.333 (-)	- (-)	- (-)	- (-)	-8.333 (-)
Median	-8.333	-	-	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-, -	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-, -	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	60.000 (-)	- (-)	- (-)	- (-)	60.000 (-)
Median	60.000	-	-	-	60.000
Q1, Q3	60.000, 60.000	-, -	-, -	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	-, -	-, -	60.00, 60.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-6.667 (-)	- (-)	- (-)	- (-)	-6.667 (-)
Median	-6.667	-	-	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-, -	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-, -	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Role functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	83.333 (28.2843)	88.000 (21.7945)	76.389 (24.0563)	75.000 (31.9142)	83.333 (25.2929)
Median	100.000	100.000	83.333	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000	50.000, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	90.476 (16.3056)	84.667 (25.8736)	89.394 (17.1152)	75.000 (31.9142)	86.885 (21.7551)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	5.556 (25.9986)	-3.472 (25.5278)	9.091 (15.5700)	0.000 (0.0000)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 33.33	-16.67, 33.33	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	88.889 (16.1690)	94.444 (13.2637)	85.185 (22.7371)	77.778 (38.4900)	89.869 (17.9748)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	83.333, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	50.00, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	5.556 (28.5831)	6.667 (14.7097)	5.556 (14.4338)	0.000 (0.0000)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-16.67, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	89.815 (19.9172)	91.270 (17.9653)	66.667 (46.1479)	77.778 (19.2450)	86.395 (25.1554)
Median	100.000	100.000	83.333	66.667	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	0.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	6.481 (19.9172)	1.667 (14.2040)	-9.524 (31.7063)	0.000 (33.3333)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-33.333, 16.667	-33.333, 33.333	0.000, 16.667
Min, Max	-16.67, 66.67	-33.33, 33.33	-66.67, 16.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	88.542 (16.9080)	89.474 (25.5860)	75.000 (39.0868)	75.000 (35.3553)	86.434 (25.0015)
Median	100.000	100.000	91.667	75.000	100.000
Q1, Q3	75.000, 100.000	100.000, 100.000	66.667, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (30.3529)	0.926 (10.6523)	0.000 (18.2574)	8.333 (11.7851)	1.587 (20.7611)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	-8.333, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 83.33	-16.67, 33.33	-33.33, 16.67	0.00, 16.67	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	100.000 (0.0000)	100.000 (0.0000)	- (-)	- (-)	100.000 (0.0000)
Median	100.000	100.000	-	-	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	-, -	-, -	100.00, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	58.333 (58.9256)	0.000 (0.0000)	- (-)	- (-)	29.167 (47.8714)
Median	58.333	0.000	-	-	8.333
Q1, Q3	16.667, 100.000	0.000, 0.000	-, -	-, -	0.000, 58.333
Min, Max	16.67, 100.00	0.00, 0.00	-, -	-, -	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	93.333 (14.9071)	85.714 (17.8174)	- (-)	33.333 (-)	84.615 (22.0075)
Median	100.000	100.000	-	33.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	-, -	33.333, 33.333	66.667, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	-, -	33.33, 33.33	33.33, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	16.667 (50.0000)	-9.524 (16.2650)	- (-)	0.000 (-)	1.282 (33.6523)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 16.667	-33.333, 0.000	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 0.00	-, -	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	50.000 (23.5702)	63.333 (38.0058)	77.778 (38.4900)	100.000 (-)	63.333 (32.2441)
Median	50.000	66.667	100.000	100.000	66.667
Q1, Q3	33.333, 66.667	66.667, 83.333	33.333, 100.000	100.000, 100.000	33.333, 100.000
Min, Max	16.67, 83.33	0.00, 100.00	33.33, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-25.000 (20.4124)	-13.333 (43.1406)	5.556 (9.6225)	0.000 (-)	-13.333 (29.0047)
Median	-16.667	-16.667	0.000	0.000	-16.667
Q1, Q3	-50.000, -16.667	-33.333, 0.000	0.000, 16.667	0.000, 0.000	-33.333, 0.000
Min, Max	-50.00, 0.00	-66.67, 50.00	0.00, 16.67	0.00, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	50.000 (-)	- (-)	- (-)	- (-)	50.000 (-)
Median	50.000	-	-	-	50.000
Q1, Q3	50.000, 50.000	-, -	-, -	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	-, -	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Emotional functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	82.692 (15.7979)	84.667 (16.6110)	75.694 (24.4790)	83.333 (18.0021)	82.214 (17.8786)
Median	83.333	83.333	83.333	87.500	83.333
Q1, Q3	66.667, 100.000	75.000, 100.000	62.500, 95.833	70.833, 95.833	66.667, 100.000
Min, Max	50.00, 100.00	41.67, 100.00	25.00, 100.00	58.33, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	85.317 (13.4125)	83.000 (27.2675)	84.848 (18.5660)	89.583 (20.8333)	84.563 (20.9627)
Median	91.667	100.000	100.000	100.000	91.667
Q1, Q3	75.000, 91.667	66.667, 100.000	66.667, 100.000	79.167, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	58.33, 100.00	58.33, 100.00	16.67, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	3.968 (13.3383)	-1.736 (25.7706)	7.576 (10.8362)	6.250 (7.9786)	2.500 (18.8724)
Median	0.000	0.000	0.000	4.167	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 12.500	0.000, 16.667
Min, Max	-25.00, 25.00	-75.00, 33.33	0.00, 33.33	0.00, 16.67	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	91.176 (10.8135)	79.365 (25.7686)	79.630 (22.4811)	75.000 (36.3242)	83.167 (21.9183)
Median	91.667	83.333	83.333	91.667	91.667
Q1, Q3	91.667, 100.000	75.000, 100.000	75.000, 100.000	33.333, 100.000	75.000, 100.000
Min, Max	66.67, 100.00	0.00, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	11.275 (14.4161)	-3.750 (21.0254)	7.407 (17.8946)	-8.333 (14.4338)	3.231 (19.0042)
Median	8.333	0.000	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 12.500	0.000, 8.333	-25.000, 0.000	0.000, 16.667
Min, Max	-16.67, 41.67	-50.00, 33.33	-25.00, 33.33	-25.00, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	84.722 (20.8578)	86.508 (18.1575)	65.476 (33.1343)	86.111 (24.0563)	82.823 (22.4645)
Median	91.667	91.667	83.333	100.000	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	41.667, 91.667	58.333, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	8.33, 100.00	58.33, 100.00	8.33, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	3.704 (18.7916)	2.500 (16.0181)	-4.762 (33.9721)	2.778 (4.8113)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-8.333, 16.667	-41.667, 16.667	0.000, 8.333	-8.333, 16.667
Min, Max	-33.33, 33.33	-25.00, 25.00	-50.00, 50.00	0.00, 8.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	84.375 (24.6972)	84.211 (21.3175)	79.167 (28.2597)	70.833 (41.2479)	82.946 (23.6370)
Median	91.667	91.667	87.500	70.833	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	75.000, 100.000	41.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	25.00, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.604 (17.9296)	0.463 (16.7820)	1.389 (25.5042)	-8.333 (11.7851)	0.992 (17.9583)
Median	4.167	0.000	4.167	-8.333	0.000
Q1, Q3	0.000, 12.500	0.000, 16.667	-16.667, 8.333	-16.667, 0.000	0.000, 8.333
Min, Max	-50.00, 25.00	-41.67, 25.00	-33.33, 41.67	-16.67, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	91.667 (11.7851)	87.500 (17.6777)	- (-)	- (-)	89.583 (12.5000)
Median	91.667	87.500	-	-	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	-, -	-, -	79.167, 100.000
Min, Max	83.33, 100.00	75.00, 100.00	-, -	-, -	75.00, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	8.333 (0.0000)	12.500 (17.6777)	- (-)	- (-)	10.417 (10.4859)
Median	8.333	12.500	-	-	8.333
Q1, Q3	8.333, 8.333	0.000, 25.000	-, -	-, -	4.167, 16.667
Min, Max	8.33, 8.33	0.00, 25.00	-, -	-, -	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	88.333 (11.1803)	78.571 (32.2236)	- (-)	66.667 (-)	81.410 (24.5689)
Median	83.333	91.667	-	66.667	83.333
Q1, Q3	83.333, 100.000	75.000, 100.000	-, -	66.667, 66.667	75.000, 100.000
Min, Max	75.00, 100.00	8.33, 100.00	-, -	66.67, 66.67	8.33, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	11.667 (13.9443)	-7.143 (13.1133)	- (-)	8.333 (-)	1.282 (15.5330)
Median	8.333	-8.333	-	8.333	0.000
Q1, Q3	0.000, 16.667	-8.333, 0.000	-, -	8.333, 8.333	-8.333, 8.333
Min, Max	0.00, 33.33	-33.33, 8.33	-, -	8.33, 8.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	73.611 (21.9954)	78.333 (27.3861)	75.000 (36.3242)	91.667 (-)	76.667 (24.4381)
Median	79.167	83.333	91.667	91.667	83.333
Q1, Q3	66.667, 91.667	75.000, 100.000	33.333, 100.000	91.667, 91.667	66.667, 91.667
Min, Max	33.33, 91.67	33.33, 100.00	33.33, 100.00	91.67, 91.67	33.33, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-15.278 (14.3533)	-10.000 (27.2590)	-8.333 (22.0479)	0.000 (-)	-11.111 (19.3307)
Median	-16.667	-8.333	0.000	0.000	-8.333
Q1, Q3	-25.000, 0.000	-16.667, 0.000	-33.333, 8.333	0.000, 0.000	-25.000, 0.000
Min, Max	-33.33, 0.00	-50.00, 25.00	-33.33, 8.33	0.00, 0.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	77.778 (-)	- (-)	- (-)	- (-)	77.778 (-)
Median	77.778	-	-	-	77.778
Q1, Q3	77.778, 77.778	-, -	-, -	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	-, -	-, -	77.78, 77.78
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-13.889 (-)	- (-)	- (-)	- (-)	-13.889 (-)
Median	-13.889	-	-	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-, -	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-, -	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-8.333 (-)	- (-)	- (-)	- (-)	-8.333 (-)
Median	-8.333	-	-	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-, -	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-, -	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cognitive functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	86.538 (20.0107)	91.333 (13.7100)	83.333 (21.3201)	91.667 (16.6667)	88.060 (17.8391)
Median	100.000	100.000	83.333	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	88.889 (18.5093)	83.333 (16.6667)	83.333 (14.9071)	91.667 (16.6667)	85.792 (16.8973)
Median	100.000	83.333	83.333	100.000	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	50.00, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	1.587 (12.8071)	-8.333 (21.9793)	-4.545 (13.1041)	0.000 (0.0000)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-50.00, 50.00	-33.33, 16.67	0.00, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	87.255 (22.4609)	85.714 (24.3160)	83.333 (20.4124)	66.667 (28.8675)	84.667 (23.0449)
Median	100.000	100.000	83.333	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	33.333, 83.333	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	33.33, 100.00	33.33, 83.33	0.00, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	-0.980 (7.1458)	-6.667 (20.5196)	-1.852 (10.0154)	-22.222 (9.6225)	-4.762 (15.2145)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-33.333, -16.667	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 33.33	-16.67, 16.67	-33.33, -16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	84.259 (25.2259)	89.683 (17.0589)	71.429 (39.3398)	77.778 (25.4588)	84.354 (24.6288)
Median	91.667	100.000	83.333	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	33.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-3.704 (12.2014)	-2.500 (18.1570)	-11.905 (39.3398)	-11.111 (9.6225)	-4.861 (20.0349)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-33.33, 50.00	-100.00, 16.67	-16.67, 0.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	84.375 (15.4785)	86.842 (22.6207)	80.556 (32.3465)	66.667 (47.1405)	84.109 (22.4060)
Median	83.333	100.000	91.667	66.667	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-6.250 (10.3190)	-4.630 (21.9964)	0.000 (14.9071)	-16.667 (23.5702)	-5.159 (17.0636)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	-50.00, 50.00	-16.67, 16.67	-33.33, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	100.000 (0.0000)	100.000 (0.0000)	- (-)	- (-)	100.000 (0.0000)
Median	100.000	100.000	-	-	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	-, -	-, -	100.00, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	96.667 (7.4536)	83.333 (37.2678)	- (-)	50.000 (-)	85.897 (29.5382)
Median	100.000	100.000	-	50.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	-, -	50.000, 50.000	83.333, 100.000
Min, Max	83.33, 100.00	0.00, 100.00	-, -	50.00, 50.00	0.00, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	0.000 (11.7851)	-11.905 (24.9338)	- (-)	-16.667 (-)	-7.692 (19.9715)
Median	0.000	0.000	-	-16.667	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-, -	-16.667, -16.667	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 0.00	-, -	-16.67, -16.67	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	75.000 (25.2763)	76.667 (14.9071)	77.778 (38.4900)	83.333 (-)	76.667 (22.5374)
Median	75.000	83.333	100.000	83.333	83.333
Q1, Q3	66.667, 100.000	83.333, 83.333	33.333, 100.000	83.333, 83.333	66.667, 100.000
Min, Max	33.33, 100.00	50.00, 83.33	33.33, 100.00	83.33, 83.33	33.33, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-8.333 (17.4801)	-16.667 (23.5702)	-5.556 (9.6225)	-16.667 (-)	-11.111 (17.4423)
Median	-8.333	-16.667	0.000	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-16.667, -16.667	-16.667, 0.000	-16.667, -16.667	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 16.67	-16.67, 0.00	-16.67, -16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-16.667 (-)	- (-)	- (-)	- (-)	-16.667 (-)
Median	-16.667	-	-	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-, -	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-, -	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Social functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	82.051 (27.0485)	89.333 (17.2670)	83.333 (22.4733)	83.333 (19.2450)	85.075 (22.3106)
Median	100.000	100.000	91.667	83.333	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	33.33, 100.00	66.67, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	92.063 (16.3461)	88.000 (17.6908)	89.394 (21.4382)	79.167 (41.6667)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	58.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	8.730 (30.5592)	-1.389 (21.9335)	4.545 (7.7850)	-4.167 (34.3592)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 16.667	-25.000, 16.667	0.000, 0.000
Min, Max	-50.00, 100.00	-50.00, 66.67	0.00, 16.67	-50.00, 33.33	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	97.059 (8.8099)	89.683 (17.0589)	94.444 (11.7851)	72.222 (34.6944)	92.000 (15.8794)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000	33.333, 100.000	100.000, 100.000
Min, Max	66.67, 100.00	50.00, 100.00	66.67, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	14.706 (30.5518)	1.667 (20.1602)	7.407 (14.6986)	-5.556 (25.4588)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	0.000, 16.667	-33.333, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	-50.00, 33.33	-16.67, 33.33	-33.33, 16.67	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	90.741 (14.2598)	87.302 (19.6531)	85.714 (37.7964)	61.111 (41.9435)	86.735 (23.0688)
Median	100.000	100.000	100.000	66.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	16.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	33.33, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	7.407 (28.1350)	-0.833 (23.2423)	2.381 (42.4139)	-16.667 (28.8675)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 33.333	-50.000, 0.000	0.000, 8.333
Min, Max	-33.33, 83.33	-66.67, 50.00	-83.33, 50.00	-50.00, 0.00	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	90.625 (12.1240)	92.105 (14.0199)	100.000 (0.0000)	75.000 (11.7851)	91.860 (12.7927)
Median	100.000	100.000	100.000	75.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	100.00, 100.00	66.67, 83.33	66.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (30.3529)	5.556 (18.0775)	11.111 (13.6083)	-8.333 (11.7851)	4.365 (22.7093)
Median	0.000	0.000	8.333	-8.333	0.000
Q1, Q3	-16.667, 8.333	0.000, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-33.33, 33.33	0.00, 33.33	-16.67, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	100.000 (0.0000)	75.000 (35.3553)	- (-)	- (-)	87.500 (25.0000)
Median	100.000	75.000	-	-	100.000
Q1, Q3	100.000, 100.000	50.000, 100.000	-, -	-, -	75.000, 100.000
Min, Max	100.00, 100.00	50.00, 100.00	-, -	-, -	50.00, 100.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	58.333 (58.9256)	-25.000 (35.3553)	- (-)	- (-)	16.667 (62.3610)
Median	58.333	-25.000	-	-	8.333
Q1, Q3	16.667, 100.000	-50.000, 0.000	-, -	-, -	-25.000, 58.333
Min, Max	16.67, 100.00	-50.00, 0.00	-, -	-, -	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	96.667 (7.4536)	95.238 (12.5988)	- (-)	50.000 (-)	92.308 (16.1236)
Median	100.000	100.000	-	50.000	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	-, -	50.000, 50.000	100.000, 100.000
Min, Max	83.33, 100.00	66.67, 100.00	-, -	50.00, 50.00	50.00, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	16.667 (47.1405)	7.143 (13.1133)	- (-)	-16.667 (-)	8.974 (30.1350)
Median	0.000	0.000	-	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	-, -	-16.667, -16.667	0.000, 0.000
Min, Max	-16.67, 100.00	0.00, 33.33	-, -	-16.67, -16.67	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	63.889 (24.5327)	70.000 (29.8142)	77.778 (38.4900)	66.667 (-)	68.889 (26.6270)
Median	75.000	66.667	100.000	66.667	66.667
Q1, Q3	33.333, 83.333	50.000, 100.000	33.333, 100.000	66.667, 66.667	33.333, 100.000
Min, Max	33.33, 83.33	33.33, 100.00	33.33, 100.00	66.67, 66.67	33.33, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	-11.111 (22.7710)	-20.000 (34.1565)	5.556 (9.6225)	0.000 (-)	-10.000 (25.0397)
Median	-16.667	-33.333	0.000	0.000	0.000
Q1, Q3	-33.333, 16.667	-50.000, 16.667	0.000, 16.667	0.000, 0.000	-33.333, 16.667
Min, Max	-33.33, 16.67	-50.00, 16.67	0.00, 16.67	0.00, 0.00	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Fatigue					
Baseline					
n	26	25	12	4	67
Mean (SD)	31.624 (25.6649)	24.667 (17.5741)	37.037 (26.0937)	22.222 (30.0890)	29.436 (23.2509)
Median	22.222	22.222	27.778	11.111	22.222
Q1, Q3	11.111, 44.444	11.111, 33.333	16.667, 61.111	5.556, 38.889	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 55.56	0.00, 77.78	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	20.106 (16.3371)	24.444 (27.4049)	20.202 (19.1280)	22.222 (31.4270)	22.040 (22.4518)
Median	22.222	11.111	11.111	11.111	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	0.000, 33.333	0.000, 44.444	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 55.56	0.00, 66.67	0.00, 77.78
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-11.111 (24.0883)	1.157 (26.8182)	-14.141 (23.3550)	0.000 (9.0722)	-6.019 (24.8724)
Median	0.000	0.000	-11.111	0.000	0.000
Q1, Q3	-22.222, 0.000	-16.667, 11.111	-33.333, 0.000	-5.556, 5.556	-22.222, 0.000
Min, Max	-88.89, 22.22	-44.44, 66.67	-55.56, 22.22	-11.11, 11.11	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	19.136 (20.4544)	22.751 (18.4177)	29.630 (22.2222)	33.333 (40.0617)	23.312 (20.9944)
Median	11.111	22.222	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	11.111, 22.222	22.222, 33.333	0.000, 77.778	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-11.728 (19.2345)	-1.944 (16.2497)	-9.877 (26.3198)	7.407 (6.4150)	-6.333 (19.4407)
Median	-11.111	0.000	0.000	11.111	0.000
Q1, Q3	-22.222, 0.000	-11.111, 5.556	-22.222, 11.111	0.000, 11.111	-11.111, 0.000
Min, Max	-77.78, 11.11	-27.78, 33.33	-66.67, 11.11	0.00, 11.11	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	20.988 (16.1191)	17.460 (19.7426)	42.857 (32.9787)	25.926 (27.9623)	22.902 (22.2694)
Median	22.222	11.111	33.333	22.222	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	22.222, 77.778	0.000, 55.556	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 66.67	11.11, 100.00	0.00, 55.56	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-9.877 (18.2331)	-4.722 (14.7840)	-6.349 (36.7715)	0.000 (11.1111)	-6.597 (19.8714)
Median	-11.111	0.000	-11.111	0.000	0.000
Q1, Q3	-11.111, 0.000	-19.444, 0.000	-44.444, 33.333	-11.111, 11.111	-19.444, 0.000
Min, Max	-55.56, 22.22	-33.33, 22.22	-44.44, 44.44	-11.11, 11.11	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	22.917 (19.2316)	14.035 (17.7013)	24.074 (16.3551)	38.889 (54.9972)	19.897 (20.2219)
Median	22.222	0.000	27.778	38.889	22.222
Q1, Q3	5.556, 33.333	0.000, 33.333	11.111, 33.333	0.000, 77.778	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 44.44	0.00, 44.44	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.861 (25.9689)	-7.716 (15.8445)	-20.370 (17.8009)	5.556 (7.8567)	-7.804 (20.6438)
Median	0.000	-5.556	-22.222	5.556	0.000
Q1, Q3	-5.556, 5.556	-22.222, 0.000	-33.333, 0.000	0.000, 11.111	-22.222, 0.000
Min, Max	-88.89, 33.33	-33.33, 33.33	-44.44, 0.00	0.00, 11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	5.556 (7.8567)	5.556 (7.8567)	- (-)	- (-)	5.556 (6.4150)
Median	5.556	5.556	-	-	5.556
Q1, Q3	0.000, 11.111	0.000, 11.111	-, -	-, -	0.000, 11.111
Min, Max	0.00, 11.11	0.00, 11.11	-, -	-, -	0.00, 11.11
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-50.000 (39.2837)	0.000 (0.0000)	- (-)	- (-)	-25.000 (36.7115)
Median	-50.000	0.000	-	-	-11.111
Q1, Q3	-77.778, -22.222	0.000, 0.000	-, -	-, -	-50.000, 0.000
Min, Max	-77.78, -22.22	0.00, 0.00	-, -	-, -	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	6.667 (9.9381)	11.111 (9.0722)	- (-)	88.889 (-)	15.385 (23.8041)
Median	0.000	11.111	-	88.889	11.111
Q1, Q3	0.000, 11.111	0.000, 22.222	-, -	88.889, 88.889	0.000, 22.222
Min, Max	0.00, 22.22	0.00, 22.22	-, -	88.89, 88.89	0.00, 88.89
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	-20.000 (38.8094)	-10.317 (13.7693)	- (-)	22.222 (-)	-11.538 (26.8801)
Median	0.000	-11.111	-	22.222	0.000
Q1, Q3	-11.111, 0.000	-11.111, 0.000	-, -	22.222, 22.222	-11.111, 0.000
Min, Max	-88.89, 0.00	-38.89, 0.00	-, -	22.22, 22.22	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	55.556 (24.3432)	51.111 (20.1843)	29.630 (42.0660)	11.111 (-)	45.926 (27.8148)
Median	66.667	44.444	11.111	11.111	44.444
Q1, Q3	44.444, 66.667	33.333, 66.667	0.000, 77.778	11.111, 11.111	11.111, 66.667
Min, Max	11.11, 77.78	33.33, 77.78	0.00, 77.78	11.11, 11.11	0.00, 77.78
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	12.963 (27.5920)	14.444 (30.8321)	3.704 (16.9725)	0.000 (-)	10.741 (24.7088)
Median	11.111	11.111	0.000	0.000	11.111
Q1, Q3	-11.111, 44.444	-5.556, 33.333	-11.111, 22.222	0.000, 0.000	-11.111, 33.333
Min, Max	-22.22, 44.44	-22.22, 55.56	-11.11, 22.22	0.00, 0.00	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	11.111 (-)	- (-)	- (-)	- (-)	11.111 (-)
Median	11.111	-	-	-	11.111
Q1, Q3	11.111, 11.111	-, -	-, -	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	-, -	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	44.444 (-)	- (-)	- (-)	- (-)	44.444 (-)
Median	44.444	-	-	-	44.444
Q1, Q3	44.444, 44.444	-, -	-, -	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	-, -	-, -	44.44, 44.44
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-11.111 (-)	- (-)	- (-)	- (-)	-11.111 (-)
Median	-11.111	-	-	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-, -	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-, -	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Nausea and vomiting					
Baseline					
n	26	25	12	4	67
Mean (SD)	3.205 (8.1911)	3.333 (11.7851)	5.556 (10.8556)	8.333 (16.6667)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 8.333	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 50.00	0.00, 33.33	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	1.587 (5.0132)	3.333 (6.8041)	0.000 (0.0000)	12.500 (25.0000)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 25.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 0.00	0.00, 50.00	0.00, 50.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-1.587 (7.2739)	0.000 (9.8295)	-4.545 (10.7778)	4.167 (8.3333)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-33.33, 0.00	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	2.778 (6.3914)	0.794 (3.6370)	1.852 (5.5556)	33.333 (57.7350)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 100.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 16.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-0.926 (10.6523)	-0.833 (8.5070)	-3.704 (7.3493)	22.222 (38.4900)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-16.67, 0.00	0.00, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (7.1299)	2.381 (7.9682)	7.143 (13.1133)	5.556 (9.6225)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	0.000 (8.0845)	0.833 (3.7268)	0.000 (16.6667)	-5.556 (9.6225)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	0.00, 16.67	-33.33, 16.67	-16.67, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	1.042 (4.1667)	0.877 (3.8236)	2.778 (6.8041)	25.000 (35.3553)	2.326 (8.5923)
Median	0.000	0.000	0.000	25.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 50.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 16.67	0.00, 50.00	0.00, 50.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-1.042 (4.1667)	-0.926 (3.9284)	0.000 (0.0000)	8.333 (11.7851)	-0.397 (4.4904)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 0.00	-16.67, 0.00	0.00, 0.00	0.00, 16.67	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	8.333 (11.7851)	0.000 (0.0000)	- (-)	- (-)	4.167 (8.3333)
Median	8.333	0.000	-	-	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-, -	-, -	0.000, 8.333
Min, Max	0.00, 16.67	0.00, 0.00	-, -	-, -	0.00, 16.67
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	3.333 (7.4536)	0.000 (0.0000)	- (-)	33.333 (-)	3.846 (9.9857)
Median	0.000	0.000	-	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	33.333, 33.333	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 0.00	-, -	33.33, 33.33	0.00, 33.33
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	-3.333 (7.4536)	0.000 (0.0000)	- (-)	0.000 (-)	-1.282 (4.6225)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	0.00, 0.00	-, -	0.00, 0.00	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	11.111 (20.1843)	0.000 (0.0000)	16.667 (28.8675)	0.000 (-)	7.778 (17.6683)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 50.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	5.556 (22.7710)	0.000 (0.0000)	11.111 (19.2450)	0.000 (-)	4.444 (16.0192)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 0.00	0.00, 33.33	0.00, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Pain					
Baseline					
n	26	24	12	4	66
Mean (SD)	10.256 (20.5896)	11.806 (16.6516)	26.389 (25.0840)	25.000 (31.9142)	14.646 (21.3868)
Median	0.000	0.000	33.333	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 33.333	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 66.67	0.00, 83.33	0.00, 66.67	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	12.698 (16.5871)	18.000 (25.8736)	9.091 (11.4592)	16.667 (33.3333)	14.481 (21.1860)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	0.794 (22.6545)	6.522 (21.1650)	-12.121 (13.1041)	-8.333 (16.6667)	0.000 (20.9908)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667
Min, Max	-66.67, 33.33	-33.33, 50.00	-33.33, 0.00	-33.33, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	12.963 (15.7135)	11.111 (17.7430)	16.667 (32.2749)	33.333 (57.7350)	14.052 (23.1835)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667	0.000, 100.000	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	19	9	3	49
Mean (SD)	-0.926 (25.2259)	0.000 (13.6083)	-9.259 (18.8398)	11.111 (19.2450)	-1.361 (19.7896)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-16.667, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-33.33, 16.67	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	20.370 (21.0474)	10.317 (14.4108)	35.714 (45.5710)	27.778 (48.1125)	18.707 (26.0503)
Median	16.667	0.000	16.667	0.000	16.667
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 100.000	0.000, 83.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 50.00	0.00, 100.00	0.00, 83.33	0.00, 100.00
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	6.481 (30.3244)	0.000 (13.6083)	4.762 (36.9112)	5.556 (9.6225)	3.546 (24.5580)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-33.333, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 16.67	-33.33, 66.67	0.00, 16.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	15.625 (20.6099)	9.649 (13.9618)	30.556 (37.1434)	33.333 (47.1405)	15.891 (22.6993)
Median	0.000	0.000	25.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	5.208 (26.3303)	0.000 (18.6339)	0.000 (18.2574)	0.000 (0.0000)	2.033 (21.1460)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-33.33, 16.67	0.00, 0.00	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	16.667 (23.5702)	0.000 (0.0000)	- (-)	- (-)	8.333 (16.6667)
Median	16.667	0.000	-	-	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	-, -	-, -	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 0.00	-, -	-, -	0.00, 33.33
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	16.667 (23.5702)	-16.667 (0.0000)	- (-)	- (-)	0.000 (23.5702)
Median	16.667	-16.667	-	-	-8.333
Q1, Q3	0.000, 33.333	-16.667, -16.667	-, -	-, -	-16.667, 16.667
Min, Max	0.00, 33.33	-16.67, -16.67	-, -	-, -	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	10.000 (22.3607)	9.524 (13.1133)	- (-)	100.000 (-)	16.667 (29.6586)
Median	0.000	0.000	-	100.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	-, -	100.000, 100.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 33.33	-, -	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	5	6	0	1	12
Mean (SD)	6.667 (14.9071)	2.778 (16.3865)	- (-)	33.333 (-)	6.944 (16.6034)
Median	0.000	0.000	-	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	33.333, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	-16.67, 33.33	-, -	33.33, 33.33	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	8.333 (13.9443)	40.000 (19.0029)	16.667 (28.8675)	0.000 (-)	20.000 (22.8869)
Median	0.000	33.333	0.000	0.000	16.667
Q1, Q3	0.000, 16.667	33.333, 50.000	0.000, 50.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 33.33	16.67, 66.67	0.00, 50.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	6	4	3	1	14
Mean (SD)	-2.778 (16.3865)	25.000 (28.8675)	-5.556 (9.6225)	0.000 (-)	4.762 (22.0998)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	8.333, 41.667	-16.667, 0.000	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 16.67	-16.67, 50.00	-16.67, 0.00	0.00, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Dyspnoea					
Baseline					
n	26	25	12	4	67
Mean (SD)	25.641 (34.3934)	18.667 (21.6880)	33.333 (40.2015)	16.667 (33.3333)	23.881 (31.1432)
Median	0.000	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	15.873 (20.0528)	18.667 (21.6880)	12.121 (22.4733)	33.333 (47.1405)	17.486 (23.2591)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-6.349 (29.0957)	1.389 (23.0084)	-15.152 (17.4078)	16.667 (19.2450)	-3.333 (25.0799)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-33.33, 0.00	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	11.111 (16.1690)	14.286 (19.9205)	18.519 (33.7931)	33.333 (57.7350)	15.033 (24.3253)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-12.963 (32.6176)	-3.333 (26.2690)	-18.519 (24.2161)	11.111 (19.2450)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000	0.000, 33.333	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	17	21	7	3	48
Mean (SD)	11.765 (16.4197)	12.698 (19.6531)	4.762 (12.5988)	22.222 (38.4900)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	20	7	3	47
Mean (SD)	-13.725 (31.3112)	-5.000 (16.3120)	-38.095 (52.4531)	0.000 (0.0000)	-12.766 (30.7343)
Median	0.000	0.000	-33.333	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-100.000, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	20.833 (26.8742)	14.035 (20.2326)	5.556 (13.6083)	33.333 (47.1405)	16.279 (23.4262)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.167 (38.2487)	-3.704 (19.4328)	-33.333 (55.7773)	0.000 (0.0000)	-7.937 (34.3815)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-100.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-83.333 (23.5702)	0.000 (0.0000)	- (-)	- (-)	-41.667 (50.0000)
Median	-83.333	0.000	-	-	-33.333
Q1, Q3	-100.000, -66.667	0.000, 0.000	-, -	-, -	-83.333, 0.000
Min, Max	-100.00, -66.67	0.00, 0.00	-, -	-, -	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	6.667 (14.9071)	9.524 (16.2650)	- (-)	66.667 (-)	12.821 (21.6815)
Median	0.000	0.000	-	66.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-, -	66.667, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 33.33	-, -	66.67, 66.67	0.00, 66.67
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	-26.667 (43.4613)	-9.524 (16.2650)	- (-)	0.000 (-)	-15.385 (29.2353)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-, -	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 0.00	-33.33, 0.00	-, -	0.00, 0.00	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	50.000 (34.9603)	40.000 (36.5148)	11.111 (19.2450)	0.000 (-)	35.556 (34.4265)
Median	50.000	66.667	0.000	0.000	33.333
Q1, Q3	33.333, 66.667	0.000, 66.667	0.000, 33.333	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	22.222 (34.4265)	6.667 (27.8887)	-22.222 (19.2450)	0.000 (-)	6.667 (31.3708)
Median	0.000	0.000	-33.333	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 33.333	-33.333, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Insomnia					
Baseline					
n	26	25	12	4	67
Mean (SD)	21.795 (26.5703)	17.333 (19.5316)	22.222 (29.5875)	16.667 (33.3333)	19.900 (24.6591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 50.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	15.873 (20.0528)	18.667 (25.6038)	21.212 (26.9680)	16.667 (33.3333)	18.033 (24.0168)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-7.937 (17.9653)	1.389 (25.0201)	3.030 (10.0504)	0.000 (0.0000)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	0.00, 33.33	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	14.815 (20.5233)	17.460 (20.0528)	29.630 (35.1364)	33.333 (57.7350)	19.608 (25.9713)
Median	0.000	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-9.259 (15.3630)	0.000 (24.1825)	0.000 (16.6667)	11.111 (19.2450)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 33.33	-33.33, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	16.667 (26.1968)	17.460 (24.9868)	28.571 (40.4995)	11.111 (19.2450)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-7.407 (18.2773)	1.667 (27.5193)	-4.762 (29.9912)	-11.111 (19.2450)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 33.33	-33.33, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	20.833 (26.8742)	15.789 (23.2231)	33.333 (42.1637)	33.333 (47.1405)	20.930 (28.1936)
Median	0.000	0.000	16.667	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.167 (16.6667)	1.852 (17.9768)	5.556 (13.6083)	0.000 (0.0000)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	16.667 (23.5702)	0.000 (0.0000)	- (-)	- (-)	8.333 (16.6667)
Median	16.667	0.000	-	-	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	-, -	-, -	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 0.00	-, -	-, -	0.00, 33.33
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-16.667 (23.5702)	-33.333 (0.0000)	- (-)	- (-)	-25.000 (16.6667)
Median	-16.667	-33.333	-	-	-33.333
Q1, Q3	-33.333, 0.000	-33.333, -33.333	-, -	-, -	-33.333, -16.667
Min, Max	-33.33, 0.00	-33.33, -33.33	-, -	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	20.000 (29.8142)	9.524 (16.2650)	- (-)	100.000 (-)	20.513 (32.0256)
Median	0.000	0.000	-	100.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	-, -	100.000, 100.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	-, -	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	-13.333 (18.2574)	0.000 (0.0000)	- (-)	33.333 (-)	-2.564 (16.4516)
Median	0.000	0.000	-	33.333	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-, -	33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-, -	33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	11.111 (17.2133)	46.667 (29.8142)	33.333 (33.3333)	0.000 (-)	26.667 (28.7297)
Median	0.000	66.667	33.333	0.000	33.333
Q1, Q3	0.000, 33.333	33.333, 66.667	0.000, 66.667	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	0.000 (0.0000)	26.667 (27.8887)	22.222 (38.4900)	0.000 (-)	13.333 (24.5596)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 66.667	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 0.00	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Appetite loss					
Baseline					
n	26	25	12	4	67
Mean (SD)	15.385 (30.1563)	8.000 (14.5297)	16.667 (22.4733)	16.667 (33.3333)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	9.524 (15.4303)	12.000 (21.2568)	6.061 (13.4840)	16.667 (33.3333)	10.383 (18.7981)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-9.524 (35.1866)	4.167 (17.8899)	-9.091 (21.5557)	0.000 (0.0000)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	3.704 (10.7794)	11.111 (19.2450)	3.704 (11.1111)	33.333 (57.7350)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 100.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-11.111 (30.2495)	3.333 (21.3574)	-14.815 (24.2161)	11.111 (19.2450)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	9.259 (19.1504)	6.349 (13.4125)	9.524 (25.1976)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-5.556 (34.7728)	-1.667 (17.0139)	-9.524 (31.7063)	-22.222 (38.4900)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-66.67, 33.33	-66.67, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	12.500 (23.9598)	7.018 (13.9618)	11.111 (27.2166)	33.333 (47.1405)	10.853 (21.4808)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	0.000 (36.5148)	0.000 (19.8030)	0.000 (21.0819)	0.000 (0.0000)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-50.000 (70.7107)	0.000 (0.0000)	- (-)	- (-)	-25.000 (50.0000)
Median	-50.000	0.000	-	-	0.000
Q1, Q3	-100.000, 0.000	0.000, 0.000	-, -	-, -	-50.000, 0.000
Min, Max	-100.00, 0.00	0.00, 0.00	-, -	-, -	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	0.000 (0.0000)	4.762 (12.5988)	- (-)	66.667 (-)	7.692 (19.9715)
Median	0.000	0.000	-	66.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	66.667, 66.667	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	-, -	66.67, 66.67	0.00, 66.67
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	-26.667 (43.4613)	0.000 (19.2450)	- (-)	0.000 (-)	-10.256 (31.5777)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 0.00	-33.33, 33.33	-, -	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	38.889 (49.0653)	33.333 (23.5702)	22.222 (38.4900)	0.000 (-)	31.111 (36.6595)
Median	16.667	33.333	0.000	0.000	33.333
Q1, Q3	0.000, 100.000	33.333, 33.333	0.000, 66.667	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	11.111 (54.4331)	20.000 (18.2574)	0.000 (33.3333)	0.000 (-)	11.111 (37.0899)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	-33.333, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-66.67, 100.00	0.00, 33.33	-33.33, 33.33	0.00, 0.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Constipation					
Baseline					
n	26	25	12	4	67
Mean (SD)	11.538 (20.9599)	5.333 (15.7527)	11.111 (16.4122)	8.333 (16.6667)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	11.111 (16.1015)	17.333 (30.6111)	6.061 (13.4840)	0.000 (0.0000)	12.022 (22.7977)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	0.000 (18.2574)	12.500 (27.4742)	-6.061 (13.4840)	-8.333 (16.6667)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 0.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	7.407 (14.2598)	14.286 (22.5374)	0.000 (0.0000)	0.000 (0.0000)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-1.852 (17.9768)	8.333 (21.2889)	-7.407 (14.6986)	-11.111 (19.2450)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	7.407 (18.2773)	11.111 (16.1015)	4.762 (12.5988)	11.111 (19.2450)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-1.852 (13.8725)	5.000 (16.3120)	-9.524 (16.2650)	0.000 (33.3333)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	14.583 (29.7365)	14.035 (25.6178)	16.667 (40.8248)	0.000 (0.0000)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	6.250 (21.8369)	7.407 (24.4028)	5.556 (49.0653)	-16.667 (23.5702)	5.556 (27.4644)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-33.333, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 100.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-16.667 (23.5702)	0.000 (0.0000)	- (-)	- (-)	-8.333 (16.6667)
Median	-16.667	0.000	-	-	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-, -	-, -	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-, -	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	6.667 (14.9071)	9.524 (16.2650)	- (-)	0.000 (-)	7.692 (14.6176)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-, -	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	-, -	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	0.000 (23.5702)	4.762 (23.0022)	- (-)	-33.333 (-)	0.000 (23.5702)
Median	0.000	0.000	-	-33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-, -	-33.333, -33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-, -	-33.33, -33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	38.889 (49.0653)	13.333 (18.2574)	11.111 (19.2450)	0.000 (-)	22.222 (34.8845)
Median	16.667	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	22.222 (40.3687)	13.333 (18.2574)	0.000 (0.0000)	0.000 (-)	13.333 (27.6026)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Diarrhoea					
Baseline					
n	26	24	12	4	66
Mean (SD)	7.692 (21.7208)	5.556 (16.0514)	11.111 (21.7113)	0.000 (0.0000)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	3.175 (10.0264)	6.667 (21.5166)	9.091 (15.5700)	0.000 (0.0000)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	0.000 (14.9071)	1.449 (15.8218)	-3.030 (17.9787)	0.000 (0.0000)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	3.922 (11.0702)	6.349 (13.4125)	11.111 (23.5702)	22.222 (38.4900)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	19	9	3	48
Mean (SD)	0.000 (16.6667)	3.509 (10.5101)	0.000 (16.6667)	22.222 (38.4900)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	-33.33, 33.33	0.00, 33.33	-33.33, 33.33	0.00, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (10.7794)	4.762 (11.9523)	14.286 (26.2265)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	0.000 (11.4332)	3.509 (15.2944)	0.000 (38.4900)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	4.167 (11.3855)	8.772 (24.4498)	11.111 (17.2133)	0.000 (0.0000)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	2.083 (8.3333)	7.843 (27.7123)	-5.556 (13.6083)	0.000 (0.0000)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 100.00	-33.33, 0.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	0.000 (0.0000)	9.524 (16.2650)	- (-)	0.000 (-)	5.128 (12.5178)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-, -	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	-, -	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	5	6	0	1	12
Mean (SD)	0.000 (0.0000)	11.111 (17.2133)	- (-)	0.000 (-)	5.556 (12.9750)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-, -	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	-, -	0.00, 0.00	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	16.667 (27.8887)	0.000 (0.0000)	0.000 (0.0000)	0.000 (-)	6.667 (18.6871)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	6	4	3	1	14
Mean (SD)	11.111 (34.4265)	0.000 (0.0000)	0.000 (0.0000)	0.000 (-)	4.762 (22.0998)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 0.00	0.00, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Financial Difficulties					
Baseline					
n	26	25	12	4	67
Mean (SD)	11.538 (24.8414)	25.333 (40.0000)	2.778 (9.6225)	33.333 (27.2166)	16.418 (30.9083)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 0.000	16.667, 50.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	6.349 (17.0589)	20.000 (33.3333)	3.030 (10.0504)	16.667 (19.2450)	12.022 (25.1166)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-3.175 (10.0264)	-5.556 (33.5740)	3.030 (10.0504)	-16.667 (33.3333)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 66.67	0.00, 33.33	-66.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	5.882 (17.6198)	12.698 (24.6671)	3.704 (11.1111)	44.444 (38.4900)	10.667 (22.7776)
Median	0.000	0.000	0.000	66.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	-1.961 (14.2915)	-8.333 (33.9849)	0.000 (16.6667)	11.111 (19.2450)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (10.7794)	9.524 (21.4550)	4.762 (12.5988)	22.222 (19.2450)	7.483 (17.0312)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-3.704 (10.7794)	-11.667 (22.3607)	0.000 (19.2450)	-11.111 (19.2450)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 0.00	-33.33, 33.33	-33.33, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	8.333 (22.7710)	19.298 (33.9131)	5.556 (13.6083)	16.667 (23.5702)	13.178 (27.3518)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (14.7510)	-3.704 (19.4328)	0.000 (21.0819)	0.000 (0.0000)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-33.33, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 15					
n	2	2	0	0	4
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	-, -	0.00, 0.00
Change from Baseline					
n	2	2	0	0	4
Mean (SD)	-16.667 (23.5702)	0.000 (0.0000)	- (-)	- (-)	-8.333 (16.6667)
Median	-16.667	0.000	-	-	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-, -	-, -	-16.667, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-, -	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	5	7	0	1	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	0.000 (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline					
n	5	7	0	1	13
Mean (SD)	0.000 (0.0000)	-9.524 (25.1976)	- (-)	0.000 (-)	-5.128 (18.4900)
Median	0.000	0.000	-	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-66.67, 0.00	-, -	0.00, 0.00	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	6	5	3	1	15
Mean (SD)	33.333 (42.1637)	46.667 (50.5525)	0.000 (0.0000)	66.667 (-)	33.333 (41.7855)
Median	16.667	33.333	0.000	66.667	0.000
Q1, Q3	0.000, 66.667	0.000, 100.000	0.000, 0.000	66.667, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 0.00	66.67, 66.67	0.00, 100.00
Change from Baseline					
n	6	5	3	1	15
Mean (SD)	11.111 (17.2133)	-6.667 (36.5148)	0.000 (0.0000)	0.000 (-)	2.222 (23.4577)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	0.00, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Global health status/QOL				
Baseline				
n	33	27	7	67
Mean (SD)	64.394 (22.7525)	67.284 (20.4027)	69.048 (18.4556)	66.045 (21.1871)
Median	66.667	66.667	75.000	66.667
Q1, Q3	50.000, 83.333	58.333, 83.333	50.000, 83.333	50.000, 83.333
Min, Max	25.00, 100.00	0.00, 100.00	50.00, 91.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	74.713 (16.1348)	77.667 (17.9570)	71.429 (18.5450)	75.546 (17.0014)
Median	75.000	83.333	66.667	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	58.333, 91.667	66.667, 83.333
Min, Max	33.33, 100.00	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	10.632 (21.8100)	6.944 (16.0514)	2.381 (25.3285)	8.194 (19.9748)
Median	8.333	8.333	0.000	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-33.33, 66.67	-41.67, 33.33	-33.33, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	78.261 (19.9018)	72.222 (20.8031)	72.222 (25.4588)	75.000 (20.4124)
Median	83.333	83.333	66.667	83.333
Q1, Q3	66.667, 100.000	66.667, 83.333	50.000, 100.000	66.667, 91.667
Min, Max	33.33, 100.00	8.33, 100.00	50.00, 100.00	8.33, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	11.957 (20.0734)	4.710 (9.9956)	0.000 (8.3333)	7.823 (15.8121)
Median	8.333	0.000	0.000	8.333
Q1, Q3	0.000, 25.000	0.000, 8.333	-8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 33.33	-8.33, 8.33	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	69.565 (21.4100)	73.551 (22.5647)	86.111 (12.7294)	72.449 (21.5974)
Median	75.000	83.333	83.333	83.333
Q1, Q3	50.000, 83.333	58.333, 91.667	75.000, 100.000	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	75.00, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	5.797 (24.6740)	5.303 (15.9665)	2.778 (9.6225)	5.382 (20.0833)
Median	8.333	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-50.00, 50.00	-33.33, 41.67	-8.33, 8.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	77.917 (16.5069)	72.083 (23.9204)	86.111 (12.7294)	75.775 (20.1527)
Median	83.333	83.333	83.333	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	75.000, 100.000	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	75.00, 100.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	12.917 (18.0308)	1.754 (16.0965)	2.778 (9.6225)	7.143 (17.3216)
Median	8.333	0.000	8.333	8.333
Q1, Q3	0.000, 20.833	-16.667, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 58.33	-33.33, 25.00	-8.33, 8.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	83.333 (-)	80.556 (20.9718)	- (-)	81.250 (17.1796)
Median	83.333	83.333	-	83.333
Q1, Q3	83.333, 83.333	58.333, 100.000	-, -	70.833, 91.667
Min, Max	83.33, 83.33	58.33, 100.00	-, -	58.33, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	58.333 (-)	-2.778 (20.9718)	- (-)	12.500 (35.0264)
Median	58.333	0.000	-	8.333
Q1, Q3	58.333, 58.333	-25.000, 16.667	-, -	-12.500, 37.500
Min, Max	58.33, 58.33	-25.00, 16.67	-, -	-25.00, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	77.778 (18.6339)	81.250 (4.1667)	- (-)	78.846 (15.4468)
Median	83.333	83.333	-	83.333
Q1, Q3	75.000, 83.333	79.167, 83.333	-, -	75.000, 83.333
Min, Max	41.67, 100.00	75.00, 83.33	-, -	41.67, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	15.741 (21.4267)	-2.083 (14.2319)	- (-)	10.256 (20.7370)
Median	8.333	-4.167	-	8.333
Q1, Q3	0.000, 33.333	-12.500, 8.333	-, -	0.000, 16.667
Min, Max	-8.33, 58.33	-16.67, 16.67	-, -	-16.67, 58.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	57.500 (27.6246)	25.000 (11.7851)	63.889 (4.8113)	54.444 (25.5625)
Median	58.333	25.000	66.667	58.333
Q1, Q3	33.333, 75.000	16.667, 33.333	58.333, 66.667	33.333, 66.667
Min, Max	16.67, 100.00	16.67, 33.33	58.33, 66.67	16.67, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-14.167 (32.6433)	-33.333 (23.5702)	2.778 (17.3472)	-13.333 (29.6808)
Median	-12.500	-33.333	8.333	-16.667
Q1, Q3	-33.333, 8.333	-50.000, -16.667	-16.667, 16.667	-33.333, 8.333
Min, Max	-75.00, 41.67	-50.00, -16.67	-16.67, 16.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Physical functioning				
Baseline				
n	33	27	7	67
Mean (SD)	81.616 (21.9235)	84.198 (18.4111)	86.667 (12.7657)	83.184 (19.6041)
Median	86.667	93.333	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	73.333, 100.000	80.000, 100.000
Min, Max	20.00, 100.00	40.00, 100.00	66.67, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	24	7	60
Mean (SD)	85.747 (18.6636)	87.500 (15.2673)	80.952 (14.6204)	85.889 (16.7890)
Median	93.333	93.333	86.667	93.333
Q1, Q3	86.667, 93.333	83.333, 100.000	66.667, 93.333	83.333, 100.000
Min, Max	26.67, 100.00	46.67, 100.00	60.00, 100.00	26.67, 100.00
Change from Baseline				
n	29	23	7	59
Mean (SD)	3.908 (14.6404)	0.290 (11.8028)	-5.714 (15.1186)	1.356 (13.7732)
Median	0.000	0.000	-6.667	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-20.000, 0.000	-6.667, 6.667
Min, Max	-13.33, 53.33	-33.33, 33.33	-26.67, 20.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	84.058 (18.5035)	89.722 (17.5812)	80.000 (19.6261)	86.405 (18.0843)
Median	86.667	93.333	83.333	93.333
Q1, Q3	80.000, 93.333	86.667, 100.000	66.667, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	20.00, 100.00	53.33, 100.00	20.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	2.899 (17.5034)	5.507 (14.3058)	-15.000 (13.7437)	2.667 (16.4406)
Median	0.000	0.000	-13.333	0.000
Q1, Q3	-6.667, 6.667	0.000, 13.333	-23.333, -6.667	-6.667, 6.667
Min, Max	-20.00, 53.33	-20.00, 40.00	-33.33, 0.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	82.609 (24.0151)	86.087 (21.2644)	91.111 (7.6980)	84.762 (21.9004)
Median	86.667	86.667	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	86.667, 100.000	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	86.67, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	2.029 (21.4085)	2.121 (16.8889)	-6.667 (6.6667)	1.528 (18.6666)
Median	0.000	0.000	-6.667	0.000
Q1, Q3	0.000, 6.667	0.000, 6.667	-13.333, 0.000	0.000, 6.667
Min, Max	-73.33, 53.33	-40.00, 46.67	-13.33, 0.00	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	19	20	3	42
Mean (SD)	83.860 (21.9219)	85.333 (22.7470)	95.556 (3.8490)	85.397 (21.4508)
Median	86.667	93.333	93.333	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	93.333, 100.000	86.667, 100.000
Min, Max	20.00, 100.00	0.00, 100.00	93.33, 100.00	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	4.912 (16.7542)	0.000 (15.0718)	-2.222 (3.8490)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	0.000, 0.000	-6.667, 0.000	0.000, 6.667
Min, Max	-13.33, 60.00	-40.00, 40.00	-6.67, 0.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	93.333 (-)	97.778 (3.8490)	- (-)	96.667 (3.8490)
Median	93.333	100.000	-	96.667
Q1, Q3	93.333, 93.333	93.333, 100.000	-, -	93.333, 100.000
Min, Max	93.33, 93.33	93.33, 100.00	-, -	93.33, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	60.000 (-)	0.000 (0.0000)	- (-)	15.000 (30.0000)
Median	60.000	0.000	-	0.000
Q1, Q3	60.000, 60.000	0.000, 0.000	-, -	0.000, 30.000
Min, Max	60.00, 60.00	0.00, 0.00	-, -	0.00, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	79.259 (21.9708)	98.333 (3.3333)	- (-)	85.128 (20.2125)
Median	86.667	100.000	-	93.333
Q1, Q3	80.000, 93.333	96.667, 100.000	-, -	80.000, 100.000
Min, Max	26.67, 100.00	93.33, 100.00	-, -	26.67, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	0.741 (24.8203)	1.667 (3.3333)	- (-)	1.026 (20.3390)
Median	0.000	0.000	-	0.000
Q1, Q3	-13.333, 6.667	0.000, 3.333	-, -	-13.333, 6.667
Min, Max	-26.67, 60.00	0.00, 6.67	-, -	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	80.000 (16.6296)	53.333 (9.4281)	80.000 (17.6383)	76.444 (17.7936)
Median	80.000	53.333	86.667	80.000
Q1, Q3	66.667, 93.333	46.667, 60.000	60.000, 93.333	60.000, 93.333
Min, Max	46.67, 100.00	46.67, 60.00	60.00, 93.33	46.67, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-5.333 (11.2437)	-23.333 (4.7140)	4.444 (20.3670)	-5.778 (14.4457)
Median	-3.333	-23.333	0.000	-6.667
Q1, Q3	-13.333, 0.000	-26.667, -20.000	-13.333, 26.667	-20.000, 0.000
Min, Max	-20.00, 13.33	-26.67, -20.00	-13.33, 26.67	-26.67, 26.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	58.333 (-)	- (-)	58.333 (-)
Median	-	58.333	-	58.333
Q1, Q3	-, -	58.333, 58.333	-, -	58.333, 58.333
Min, Max	-, -	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	60.000 (-)	- (-)	60.000 (-)
Median	-	60.000	-	60.000
Q1, Q3	-, -	60.000, 60.000	-, -	60.000, 60.000
Min, Max	-, -	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-6.667 (-)	- (-)	-6.667 (-)
Median	-	-6.667	-	-6.667
Q1, Q3	-, -	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Role functioning				
Baseline				
n	33	27	7	67
Mean (SD)	80.808 (28.9039)	85.802 (22.0255)	85.714 (20.2498)	83.333 (25.2929)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	50.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	85.057 (22.4248)	89.333 (20.9054)	85.714 (24.3975)	86.885 (21.7551)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	5.172 (27.1326)	-0.694 (19.3363)	0.000 (21.5166)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	-16.667, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-66.67, 33.33	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	90.580 (18.6854)	90.278 (17.6634)	83.333 (19.2450)	89.869 (17.9748)
Median	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	10.145 (25.9852)	3.623 (11.1877)	-8.333 (16.6667)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	84.783 (27.9398)	86.957 (24.0772)	94.444 (9.6225)	86.395 (25.1554)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	5.072 (25.8369)	-0.758 (14.9755)	-5.556 (9.6225)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 16.67	-16.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	83.333 (26.4906)	87.500 (25.2907)	100.000 (0.0000)	86.434 (25.0015)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	3.333 (25.7064)	0.000 (16.6667)	0.000 (0.0000)	1.587 (20.7611)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 83.33	-33.33, 33.33	0.00, 0.00	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	100.000 (-)	100.000 (0.0000)	- (-)	100.000 (0.0000)
Median	100.000	100.000	-	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	100.000 (-)	5.556 (9.6225)	- (-)	29.167 (47.8714)
Median	100.000	0.000	-	8.333
Q1, Q3	100.000, 100.000	0.000, 16.667	-, -	0.000, 58.333
Min, Max	100.00, 100.00	0.00, 16.67	-, -	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	81.481 (24.2161)	91.667 (16.6667)	- (-)	84.615 (22.0075)
Median	100.000	100.000	-	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	-, -	66.667, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	-, -	33.33, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	3.704 (38.8889)	-4.167 (20.9718)	- (-)	1.282 (33.6523)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	-16.667, 8.333	-, -	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 16.67	-, -	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	68.333 (26.5855)	8.333 (11.7851)	83.333 (16.6667)	63.333 (32.2441)
Median	66.667	8.333	83.333	66.667
Q1, Q3	50.000, 100.000	0.000, 16.667	66.667, 100.000	33.333, 100.000
Min, Max	33.33, 100.00	0.00, 16.67	66.67, 100.00	0.00, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-13.333 (23.3069)	-41.667 (35.3553)	5.556 (38.4900)	-13.333 (29.0047)
Median	0.000	-41.667	-16.667	-16.667
Q1, Q3	-33.333, 0.000	-66.667, -16.667	-16.667, 50.000	-33.333, 0.000
Min, Max	-50.00, 16.67	-66.67, -16.67	-16.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Emotional functioning				
Baseline				
n	33	27	7	67
Mean (SD)	82.323 (16.6351)	80.247 (20.6916)	89.286 (10.4464)	82.214 (17.8786)
Median	83.333	83.333	83.333	83.333
Q1, Q3	66.667, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	41.67, 100.00	25.00, 100.00	75.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	86.782 (17.6098)	80.667 (25.7660)	89.286 (13.3631)	84.563 (20.9627)
Median	100.000	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	41.67, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	5.172 (13.6229)	0.000 (25.0603)	0.000 (12.7294)	2.500 (18.8724)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	-8.333, 16.667	0.000, 16.667
Min, Max	-25.00, 33.33	-75.00, 33.33	-16.67, 16.67	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	84.420 (25.0384)	83.333 (17.3762)	72.222 (34.6944)	83.167 (21.9183)
Median	91.667	83.333	83.333	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	33.333, 100.000	75.000, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	3.623 (19.9156)	5.435 (15.2025)	-16.667 (33.3333)	3.231 (19.0042)
Median	0.000	8.333	-16.667	0.000
Q1, Q3	-8.333, 16.667	0.000, 8.333	-50.000, 16.667	0.000, 16.667
Min, Max	-41.67, 41.67	-25.00, 33.33	-50.00, 16.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	82.971 (19.2141)	80.435 (26.1851)	100.000 (0.0000)	82.823 (22.4645)
Median	91.667	91.667	100.000	91.667
Q1, Q3	66.667, 100.000	75.000, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	100.00, 100.00	8.33, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	1.812 (17.2175)	1.515 (23.3781)	5.556 (9.6225)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-16.667, 16.667	0.000, 16.667	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	0.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.917 (24.8497)	80.833 (24.0461)	97.222 (4.8113)	82.946 (23.6370)
Median	91.667	91.667	100.000	91.667
Q1, Q3	79.167, 100.000	70.833, 100.000	91.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	25.00, 100.00	91.67, 100.00	16.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	2.083 (16.4181)	-0.439 (20.6891)	2.778 (12.7294)	0.992 (17.9583)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 16.667	-8.333, 16.667	0.000, 8.333
Min, Max	-50.00, 25.00	-41.67, 41.67	-8.33, 16.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	83.333 (-)	91.667 (14.4338)	- (-)	89.583 (12.5000)
Median	83.333	100.000	-	91.667
Q1, Q3	83.333, 83.333	75.000, 100.000	-, -	79.167, 100.000
Min, Max	83.33, 83.33	75.00, 100.00	-, -	75.00, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	8.333 (-)	11.111 (12.7294)	- (-)	10.417 (10.4859)
Median	8.333	8.333	-	8.333
Q1, Q3	8.333, 8.333	0.000, 25.000	-, -	4.167, 16.667
Min, Max	8.33, 8.33	0.00, 25.00	-, -	0.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	77.778 (28.8675)	89.583 (7.9786)	- (-)	81.410 (24.5689)
Median	83.333	87.500	-	83.333
Q1, Q3	75.000, 100.000	83.333, 95.833	-, -	75.000, 100.000
Min, Max	8.33, 100.00	83.33, 100.00	-, -	8.33, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	-1.852 (14.2995)	8.333 (18.0021)	- (-)	1.282 (15.5330)
Median	0.000	4.167	-	0.000
Q1, Q3	-8.333, 8.333	-4.167, 20.833	-, -	-8.333, 8.333
Min, Max	-33.33, 16.67	-8.33, 33.33	-, -	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	76.667 (25.0924)	62.500 (41.2479)	86.111 (12.7294)	76.667 (24.4381)
Median	87.500	62.500	83.333	83.333
Q1, Q3	66.667, 91.667	33.333, 91.667	75.000, 100.000	66.667, 91.667
Min, Max	33.33, 100.00	33.33, 91.67	75.00, 100.00	33.33, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-11.667 (14.8032)	-25.000 (35.3553)	0.000 (25.0000)	-11.111 (19.3307)
Median	-8.333	-25.000	0.000	-8.333
Q1, Q3	-25.000, 0.000	-50.000, 0.000	-25.000, 25.000	-25.000, 0.000
Min, Max	-33.33, 8.33	-50.00, 0.00	-25.00, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-13.889 (-)	- (-)	-13.889 (-)
Median	-	-13.889	-	-13.889
Q1, Q3	-, -	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cognitive functioning				
Baseline				
n	33	27	7	67
Mean (SD)	85.859 (20.4639)	89.506 (16.1114)	92.857 (8.9087)	88.060 (17.8391)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	83.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	85.057 (16.8707)	87.333 (17.5330)	83.333 (16.6667)	85.792 (16.8973)
Median	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.724 (16.2720)	-4.167 (17.2016)	-9.524 (21.2070)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-50.00, 16.67	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	79.710 (28.4074)	88.889 (17.4917)	88.889 (9.6225)	84.667 (23.0449)
Median	83.333	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	-8.696 (18.7147)	-0.725 (10.6343)	-5.556 (9.6225)	-4.762 (15.2145)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-66.67, 33.33	-33.33, 16.67	-16.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	78.261 (30.3327)	89.855 (17.9359)	88.889 (9.6225)	84.354 (24.6288)
Median	83.333	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (25.9852)	0.000 (11.5011)	0.000 (0.0000)	-4.861 (20.0349)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	0.00, 0.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.500 (23.8630)	85.000 (22.8778)	88.889 (9.6225)	84.109 (22.4060)
Median	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	83.33, 100.00	16.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-7.500 (19.8496)	-3.509 (15.2944)	0.000 (0.0000)	-5.159 (17.0636)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	0.00, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	100.000 (-)	100.000 (0.0000)	- (-)	100.000 (0.0000)
Median	100.000	100.000	-	100.000
Q1, Q3	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	79.630 (34.1339)	100.000 (0.0000)	- (-)	85.897 (29.5382)
Median	100.000	100.000	-	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	-, -	83.333, 100.000
Min, Max	0.00, 100.00	100.00, 100.00	-, -	0.00, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	-12.963 (21.6951)	4.167 (8.3333)	- (-)	-7.692 (19.9715)
Median	0.000	0.000	-	0.000
Q1, Q3	-16.667, 0.000	0.000, 8.333	-, -	-16.667, 0.000
Min, Max	-66.67, 0.00	0.00, 16.67	-, -	-66.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	75.000 (23.8953)	58.333 (11.7851)	94.444 (9.6225)	76.667 (22.5374)
Median	83.333	58.333	100.000	83.333
Q1, Q3	66.667, 83.333	50.000, 66.667	83.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	50.00, 66.67	83.33, 100.00	33.33, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-8.333 (11.7851)	-41.667 (11.7851)	0.000 (16.6667)	-11.111 (17.4423)
Median	-16.667	-41.667	0.000	-16.667
Q1, Q3	-16.667, 0.000	-50.000, -33.333	-16.667, 16.667	-16.667, 0.000
Min, Max	-16.67, 16.67	-50.00, -33.33	-16.67, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Social functioning				
Baseline				
n	33	27	7	67
Mean (SD)	78.788 (27.0906)	90.741 (14.8593)	92.857 (13.1133)	85.075 (22.3106)
Median	83.333	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	66.67, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	86.782 (23.7293)	91.333 (14.5297)	90.476 (18.8982)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	8.046 (30.7385)	-1.389 (12.9255)	-2.381 (24.3975)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 100.00	-33.33, 33.33	-50.00, 33.33	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	89.855 (17.9359)	95.139 (11.5042)	83.333 (28.8675)	92.000 (15.8794)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	50.000, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	12.319 (30.2420)	4.348 (12.5302)	-16.667 (28.8675)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-50.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-50.00, 0.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	81.884 (27.9398)	89.855 (17.9359)	100.000 (0.0000)	86.735 (23.0688)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	4.348 (34.5305)	-0.758 (23.2750)	0.000 (0.0000)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 8.333
Min, Max	-83.33, 83.33	-66.67, 50.00	0.00, 0.00	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	90.000 (13.6797)	92.500 (12.6526)	100.000 (0.0000)	91.860 (12.7927)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	100.00, 100.00	66.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	10.000 (28.3049)	-0.877 (16.1720)	0.000 (0.0000)	4.365 (22.7093)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 0.000	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-33.33, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	100.000 (-)	83.333 (28.8675)	- (-)	87.500 (25.0000)
Median	100.000	100.000	-	100.000
Q1, Q3	100.000, 100.000	50.000, 100.000	-, -	75.000, 100.000
Min, Max	100.00, 100.00	50.00, 100.00	-, -	50.00, 100.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	100.000 (-)	-11.111 (34.6944)	- (-)	16.667 (62.3610)
Median	100.000	0.000	-	8.333
Q1, Q3	100.000, 100.000	-50.000, 16.667	-, -	-25.000, 58.333
Min, Max	100.00, 100.00	-50.00, 16.67	-, -	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	88.889 (18.6339)	100.000 (0.0000)	- (-)	92.308 (16.1236)
Median	100.000	100.000	-	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	50.00, 100.00	100.00, 100.00	-, -	50.00, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	12.963 (36.1111)	0.000 (0.0000)	- (-)	8.974 (30.1350)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-16.67, 100.00	0.00, 0.00	-, -	-16.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	70.000 (25.8199)	58.333 (35.3553)	72.222 (34.6944)	68.889 (26.6270)
Median	66.667	58.333	83.333	66.667
Q1, Q3	50.000, 100.000	33.333, 83.333	33.333, 100.000	33.333, 100.000
Min, Max	33.33, 100.00	33.33, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	-8.333 (23.8953)	-16.667 (47.1405)	-11.111 (25.4588)	-10.000 (25.0397)
Median	0.000	-16.667	-16.667	0.000
Q1, Q3	-33.333, 16.667	-50.000, 16.667	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Fatigue				
Baseline				
n	33	27	7	67
Mean (SD)	30.471 (25.6144)	26.337 (21.6043)	36.508 (17.8174)	29.436 (23.2509)
Median	22.222	22.222	22.222	22.222
Q1, Q3	11.111, 44.444	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 77.78	22.22, 55.56	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	21.456 (20.9835)	20.889 (23.8566)	28.571 (25.5452)	22.040 (22.4518)
Median	22.222	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	0.000, 33.333	0.000, 55.556	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 66.67	0.00, 77.78
Change from Baseline				
n	29	24	7	60
Mean (SD)	-9.387 (25.0706)	-1.389 (27.0806)	-7.937 (13.9285)	-6.019 (24.8724)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-16.667, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-88.89, 33.33	-55.56, 66.67	-22.22, 11.11	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	28.502 (21.9238)	18.981 (18.9581)	19.444 (26.2545)	23.312 (20.9944)
Median	22.222	22.222	11.111	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	0.000, 38.889	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline				
n	23	23	4	50
Mean (SD)	-4.106 (21.3344)	-7.729 (18.7831)	-11.111 (12.8300)	-6.333 (19.4407)
Median	0.000	0.000	-11.111	0.000
Q1, Q3	-11.111, 11.111	-22.222, 0.000	-22.222, 0.000	-11.111, 0.000
Min, Max	-77.78, 33.33	-66.67, 22.22	-22.22, 0.00	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	25.604 (23.0733)	21.256 (22.7002)	14.815 (12.8300)	22.902 (22.2694)
Median	22.222	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 22.222	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 22.22	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	-7.488 (21.1621)	-5.556 (19.9205)	-7.407 (12.8300)	-6.597 (19.8714)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-55.56, 44.44	-44.44, 33.33	-22.22, 0.00	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	22.778 (21.1664)	19.444 (20.0308)	3.704 (6.4150)	19.897 (20.2219)
Median	22.222	11.111	0.000	22.222
Q1, Q3	0.000, 33.333	0.000, 38.889	0.000, 11.111	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 11.11	0.00, 77.78
Change from Baseline				
n	20	19	3	42
Mean (SD)	-7.500 (22.0958)	-6.433 (20.7261)	-18.519 (6.4150)	-7.804 (20.6438)
Median	0.000	0.000	-22.222	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-22.222, -11.111	-22.222, 0.000
Min, Max	-88.89, 11.11	-44.44, 33.33	-22.22, -11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	11.111 (-)	3.704 (6.4150)	- (-)	5.556 (6.4150)
Median	11.111	0.000	-	5.556
Q1, Q3	11.111, 11.111	0.000, 11.111	-, -	0.000, 11.111
Min, Max	11.11, 11.11	0.00, 11.11	-, -	0.00, 11.11
Change from Baseline				
n	1	3	0	4
Mean (SD)	-77.778 (-)	-7.407 (12.8300)	- (-)	-25.000 (36.7115)
Median	-77.778	0.000	-	-11.111
Q1, Q3	-77.778, -77.778	-22.222, 0.000	-, -	-50.000, 0.000
Min, Max	-77.78, -77.78	-22.22, 0.00	-, -	-77.78, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	18.519 (28.3279)	8.333 (5.5556)	- (-)	15.385 (23.8041)
Median	11.111	11.111	-	11.111
Q1, Q3	0.000, 22.222	5.556, 11.111	-, -	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 11.11	-, -	0.00, 88.89
Change from Baseline				
n	9	4	0	13
Mean (SD)	-14.198 (32.2881)	-5.556 (6.4150)	- (-)	-11.538 (26.8801)
Median	0.000	-5.556	-	0.000
Q1, Q3	-11.111, 0.000	-11.111, 0.000	-, -	-11.111, 0.000
Min, Max	-88.89, 22.22	-11.11, 0.00	-, -	-88.89, 22.22

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	44.444 (30.0890)	66.667 (0.0000)	37.037 (27.9623)	45.926 (27.8148)
Median	44.444	66.667	33.333	44.444
Q1, Q3	11.111, 77.778	66.667, 66.667	11.111, 66.667	11.111, 66.667
Min, Max	0.00, 77.78	66.67, 66.67	11.11, 66.67	0.00, 77.78
Change from Baseline				
n	10	2	3	15
Mean (SD)	11.667 (23.4901)	33.333 (31.4270)	-7.407 (16.9725)	10.741 (24.7088)
Median	5.556	33.333	-11.111	11.111
Q1, Q3	-5.556, 33.333	11.111, 55.556	-22.222, 11.111	-11.111, 33.333
Min, Max	-22.22, 44.44	11.11, 55.56	-22.22, 11.11	-22.22, 55.56

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Nausea and vomiting				
Baseline				
n	33	27	7	67
Mean (SD)	5.051 (10.6106)	3.704 (11.6330)	0.000 (0.0000)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 50.00	0.00, 0.00	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	4.023 (10.5927)	0.667 (3.3333)	4.762 (8.1325)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 16.67	0.00, 50.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.149 (8.8316)	-2.778 (9.4110)	4.762 (8.1325)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 0.00	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	6.522 (21.1650)	1.389 (4.7055)	0.000 (0.0000)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	0.725 (18.4489)	-0.725 (6.1098)	0.000 (0.0000)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-16.67, 16.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	5.072 (9.3133)	2.899 (8.1838)	0.000 (0.0000)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline				
n	23	22	3	48
Mean (SD)	-0.725 (7.9109)	0.758 (9.5912)	0.000 (0.0000)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	0.00, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	4.167 (11.9392)	0.833 (3.7268)	0.000 (0.0000)	2.326 (8.5923)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 0.00	0.00, 50.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-0.833 (6.5672)	0.000 (0.0000)	0.000 (0.0000)	-0.397 (4.4904)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	0.00, 0.00	0.00, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	16.667 (-)	0.000 (0.0000)	- (-)	4.167 (8.3333)
Median	16.667	0.000	-	0.000
Q1, Q3	16.667, 16.667	0.000, 0.000	-, -	0.000, 8.333
Min, Max	16.67, 16.67	0.00, 0.00	-, -	0.00, 16.67
Change from Baseline				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	5.556 (11.7851)	0.000 (0.0000)	- (-)	3.846 (9.9857)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	-, -	0.00, 33.33
Change from Baseline				
n	9	4	0	13
Mean (SD)	-1.852 (5.5556)	0.000 (0.0000)	- (-)	-1.282 (4.6225)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-16.67, 0.00	0.00, 0.00	-, -	-16.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	11.667 (20.8611)	0.000 (0.0000)	0.000 (0.0000)	7.778 (17.6683)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 0.00	0.00, 50.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	6.667 (19.5631)	0.000 (0.0000)	0.000 (0.0000)	4.444 (16.0192)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 0.00	0.00, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Pain				
Baseline				
n	32	27	7	66
Mean (SD)	16.146 (21.3708)	14.815 (23.2661)	7.143 (13.1133)	14.646 (21.3868)
Median	8.333	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 83.33	0.00, 33.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	17.241 (23.3515)	9.333 (18.6835)	21.429 (18.5450)	14.481 (21.1860)
Median	16.667	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 50.00	0.00, 100.00
Change from Baseline				
n	28	24	7	59
Mean (SD)	-0.595 (21.5080)	-3.472 (20.8394)	14.286 (14.9956)	0.000 (20.9908)
Median	0.000	0.000	16.667	0.000
Q1, Q3	-8.333, 16.667	-16.667, 0.000	0.000, 33.333	-16.667, 16.667
Min, Max	-66.67, 33.33	-33.33, 50.00	0.00, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	15.217 (25.5807)	12.500 (22.1163)	16.667 (19.2450)	14.052 (23.1835)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	22	23	4	49
Mean (SD)	-2.273 (20.7629)	-2.899 (19.2355)	12.500 (15.9571)	-1.361 (19.7896)
Median	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 25.000	0.000, 0.000
Min, Max	-66.67, 33.33	-50.00, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	22.464 (29.5628)	15.217 (23.5236)	16.667 (16.6667)	18.707 (26.0503)
Median	16.667	0.000	16.667	16.667
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	22	22	3	47
Mean (SD)	4.545 (29.6281)	0.758 (19.5703)	16.667 (16.6667)	3.546 (24.5580)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 33.33	0.00, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	15.833 (22.6045)	15.000 (24.1220)	22.222 (19.2450)	15.891 (22.6993)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 25.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	-0.877 (21.1357)	1.754 (20.7087)	22.222 (19.2450)	2.033 (21.1460)
Median	0.000	0.000	33.333	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 66.67	-50.00, 33.33	0.00, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	33.333 (-)	0.000 (0.0000)	- (-)	8.333 (16.6667)
Median	33.333	0.000	-	0.000
Q1, Q3	33.333, 33.333	0.000, 0.000	-, -	0.000, 16.667
Min, Max	33.33, 33.33	0.00, 0.00	-, -	0.00, 33.33
Change from Baseline				
n	1	3	0	4
Mean (SD)	33.333 (-)	-11.111 (9.6225)	- (-)	0.000 (23.5702)
Median	33.333	-16.667	-	-8.333
Q1, Q3	33.333, 33.333	-16.667, 0.000	-, -	-16.667, 16.667
Min, Max	33.33, 33.33	-16.67, 0.00	-, -	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	24.074 (33.4489)	0.000 (0.0000)	- (-)	16.667 (29.6586)
Median	16.667	0.000	-	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	-, -	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 0.00	-, -	0.00, 100.00
Change from Baseline				
n	8	4	0	12
Mean (SD)	12.500 (17.2516)	-4.167 (8.3333)	- (-)	6.944 (16.6034)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 33.333	-8.333, 0.000	-, -	0.000, 16.667
Min, Max	0.00, 33.33	-16.67, 0.00	-, -	-16.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	25.000 (25.1538)	16.667 (23.5702)	5.556 (9.6225)	20.000 (22.8869)
Median	25.000	16.667	0.000	16.667
Q1, Q3	0.000, 50.000	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 16.67	0.00, 66.67
Change from Baseline				
n	9	2	3	14
Mean (SD)	5.556 (25.0000)	16.667 (23.5702)	-5.556 (9.6225)	4.762 (22.0998)
Median	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 50.00	0.00, 33.33	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Dyspnoea				
Baseline				
n	33	27	7	67
Mean (SD)	22.222 (30.8070)	29.630 (33.7580)	9.524 (16.2650)	23.881 (31.1432)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	17.241 (26.1569)	18.667 (21.6880)	14.286 (17.8174)	17.486 (23.2591)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-4.598 (30.5039)	-4.167 (20.4124)	4.762 (12.5988)	-3.333 (25.0799)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	15.942 (24.3492)	13.889 (23.9094)	16.667 (33.3333)	15.033 (24.3253)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	-8.696 (27.0005)	-13.043 (27.9594)	16.667 (33.3333)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	0.000, 33.333	-33.333, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	0.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	22	3	48
Mean (SD)	14.493 (22.0790)	10.606 (15.8910)	0.000 (0.0000)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	21	3	47
Mean (SD)	-8.696 (25.0603)	-19.048 (37.3741)	0.000 (0.0000)	-12.766 (30.7343)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	16.667 (22.9416)	16.667 (25.3629)	11.111 (19.2450)	16.279 (23.4262)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	20	19	3	42
Mean (SD)	-6.667 (27.7836)	-12.281 (41.8854)	11.111 (19.2450)	-7.937 (34.3815)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 66.67	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	-100.000 (-)	-22.222 (38.4900)	- (-)	-41.667 (50.0000)
Median	-100.000	0.000	-	-33.333
Q1, Q3	-100.000, -100.000	-66.667, 0.000	-, -	-83.333, 0.000
Min, Max	-100.00, -100.00	-66.67, 0.00	-, -	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	14.815 (24.2161)	8.333 (16.6667)	- (-)	12.821 (21.6815)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	-, -	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	-, -	0.00, 66.67
Change from Baseline				
n	9	4	0	13
Mean (SD)	-18.519 (33.7931)	-8.333 (16.6667)	- (-)	-15.385 (29.2353)
Median	0.000	0.000	-	0.000
Q1, Q3	-33.333, 0.000	-16.667, 0.000	-, -	-33.333, 0.000
Min, Max	-100.00, 0.00	-33.33, 0.00	-, -	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	33.333 (31.4270)	83.333 (23.5702)	11.111 (19.2450)	35.556 (34.4265)
Median	33.333	83.333	0.000	33.333
Q1, Q3	0.000, 66.667	66.667, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 66.67	66.67, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	10.000 (35.3117)	16.667 (23.5702)	-11.111 (19.2450)	6.667 (31.3708)
Median	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	-33.333, 0.000	0.000, 33.333
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Insomnia				
Baseline				
n	33	27	7	67
Mean (SD)	19.192 (25.0421)	19.753 (24.9088)	23.810 (25.1976)	19.900 (24.6591)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	18.391 (26.1045)	17.333 (23.8048)	19.048 (17.8174)	18.033 (24.0168)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.149 (16.6256)	-1.389 (20.8031)	-4.762 (29.9912)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	23.188 (27.4042)	18.056 (25.9676)	8.333 (16.6667)	19.608 (25.9713)
Median	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	0.000 (17.4078)	-2.899 (19.8811)	-16.667 (33.3333)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	21.739 (25.8369)	17.391 (29.9319)	0.000 (0.0000)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	0.000 (20.1008)	-4.545 (25.8106)	-22.222 (38.4900)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	20.000 (25.1312)	21.667 (31.1101)	22.222 (38.4900)	20.930 (28.1936)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-3.333 (14.9071)	3.509 (18.9044)	0.000 (0.0000)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	33.333 (-)	0.000 (0.0000)	- (-)	8.333 (16.6667)
Median	33.333	0.000	-	0.000
Q1, Q3	33.333, 33.333	0.000, 0.000	-, -	0.000, 16.667
Min, Max	33.33, 33.33	0.00, 0.00	-, -	0.00, 33.33
Change from Baseline				
n	1	3	0	4
Mean (SD)	-33.333 (-)	-22.222 (19.2450)	- (-)	-25.000 (16.6667)
Median	-33.333	-33.333	-	-33.333
Q1, Q3	-33.333, -33.333	-33.333, 0.000	-, -	-33.333, -16.667
Min, Max	-33.33, -33.33	-33.33, 0.00	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	25.926 (36.4302)	8.333 (16.6667)	- (-)	20.513 (32.0256)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	-, -	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	-, -	0.00, 100.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	0.000 (16.6667)	-8.333 (16.6667)	- (-)	-2.564 (16.4516)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-, -	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-, -	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	26.667 (30.6312)	33.333 (47.1405)	22.222 (19.2450)	26.667 (28.7297)
Median	16.667	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	10	2	3	15
Mean (SD)	16.667 (28.3279)	16.667 (23.5702)	0.000 (0.0000)	13.333 (24.5596)
Median	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Appetite loss				
Baseline				
n	33	27	7	67
Mean (SD)	14.141 (25.0421)	8.642 (17.5231)	23.810 (37.0899)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	8.046 (17.0321)	9.333 (18.0534)	23.810 (25.1976)	10.383 (18.7981)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline				
n	29	24	7	60
Mean (SD)	-8.046 (26.2091)	1.389 (23.0084)	0.000 (33.3333)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	-66.67, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	8.696 (22.9567)	6.944 (13.8284)	16.667 (33.3333)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	-8.696 (28.8104)	-2.899 (19.8811)	8.333 (41.9435)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-16.667, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-33.33, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	5.797 (12.9184)	10.145 (21.1650)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (30.8708)	0.000 (25.1976)	-11.111 (19.2450)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	-33.33, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	10.000 (19.0414)	13.333 (25.1312)	0.000 (0.0000)	10.853 (21.4808)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	20	19	3	42
Mean (SD)	-3.333 (28.4081)	5.263 (25.4906)	-11.111 (19.2450)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-33.33, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	-100.000 (-)	0.000 (0.0000)	- (-)	-25.000 (50.0000)
Median	-100.000	0.000	-	0.000
Q1, Q3	-100.000, -100.000	0.000, 0.000	-, -	-50.000, 0.000
Min, Max	-100.00, -100.00	0.00, 0.00	-, -	-100.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	11.111 (23.5702)	0.000 (0.0000)	- (-)	7.692 (19.9715)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	-, -	0.00, 66.67
Change from Baseline				
n	9	4	0	13
Mean (SD)	-14.815 (37.6796)	0.000 (0.0000)	- (-)	-10.256 (31.5777)
Median	0.000	0.000	-	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-100.00, 33.33	0.00, 0.00	-, -	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	30.000 (36.6835)	16.667 (23.5702)	44.444 (50.9175)	31.111 (36.6595)
Median	16.667	16.667	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 33.333	0.000, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	13.333 (44.9966)	16.667 (23.5702)	0.000 (0.0000)	11.111 (37.0899)
Median	16.667	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-66.67, 100.00	0.00, 33.33	0.00, 0.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Constipation				
Baseline				
n	33	27	7	67
Mean (SD)	10.101 (15.5565)	7.407 (19.2450)	9.524 (25.1976)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	12.644 (22.5617)	6.667 (16.6667)	28.571 (35.6348)	12.022 (22.7977)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	3.448 (22.4401)	-1.389 (11.9547)	19.048 (42.4139)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	10.145 (18.6265)	8.333 (17.7203)	0.000 (0.0000)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	23	4	50
Mean (SD)	1.449 (18.7441)	0.000 (22.4733)	0.000 (0.0000)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	10.145 (15.6824)	7.246 (17.2812)	11.111 (19.2450)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	0.000 (20.1008)	-1.515 (12.5030)	11.111 (19.2450)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	15.000 (31.4838)	15.000 (27.5193)	0.000 (0.0000)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	5.000 (29.1698)	7.018 (28.4994)	0.000 (0.0000)	5.556 (27.4644)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 100.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	-33.333 (-)	0.000 (0.0000)	- (-)	-8.333 (16.6667)
Median	-33.333	0.000	-	0.000
Q1, Q3	-33.333, -33.333	0.000, 0.000	-, -	-16.667, 0.000
Min, Max	-33.33, -33.33	0.00, 0.00	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	7.407 (14.6986)	8.333 (16.6667)	- (-)	7.692 (14.6176)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	-, -	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	-, -	0.00, 33.33
Change from Baseline				
n	9	4	0	13
Mean (SD)	-3.704 (26.0579)	8.333 (16.6667)	- (-)	0.000 (23.5702)
Median	0.000	0.000	-	0.000
Q1, Q3	-33.333, 0.000	0.000, 16.667	-, -	0.000, 0.000
Min, Max	-33.33, 33.33	0.00, 33.33	-, -	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	16.667 (32.3942)	16.667 (23.5702)	44.444 (50.9175)	22.222 (34.8845)
Median	0.000	16.667	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	10.000 (31.6228)	16.667 (23.5702)	22.222 (19.2450)	13.333 (27.6026)
Median	0.000	16.667	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Diarrhoea				
Baseline				
n	32	27	7	66
Mean (SD)	5.208 (19.1380)	11.111 (20.6725)	0.000 (0.0000)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	2.299 (8.5960)	8.000 (22.1108)	9.524 (16.2650)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	28	24	7	59
Mean (SD)	1.190 (11.0448)	-4.167 (17.8899)	9.524 (16.2650)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	8.696 (18.0275)	6.944 (16.9659)	0.000 (0.0000)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	22	23	3	48
Mean (SD)	6.061 (19.6163)	0.000 (14.2134)	0.000 (0.0000)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	8.696 (18.0275)	2.899 (9.6035)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	22	22	3	47
Mean (SD)	7.576 (20.3977)	-4.545 (15.5854)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 0.00	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	8.333 (23.8783)	6.667 (13.6797)	0.000 (0.0000)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	8.772 (24.4498)	-1.754 (13.4884)	0.000 (0.0000)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	7.407 (14.6986)	0.000 (0.0000)	- (-)	5.128 (12.5178)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	-, -	0.00, 33.33
Change from Baseline				
n	8	4	0	12
Mean (SD)	8.333 (15.4303)	0.000 (0.0000)	- (-)	5.556 (12.9750)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	-, -	0.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	10.000 (22.4983)	0.000 (0.0000)	0.000 (0.0000)	6.667 (18.6871)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	9	2	3	14
Mean (SD)	7.407 (27.7778)	0.000 (0.0000)	0.000 (0.0000)	4.762 (22.0998)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Financial Difficulties				
Baseline				
n	33	27	7	67
Mean (SD)	25.253 (36.3531)	6.173 (16.1114)	14.286 (37.7964)	16.418 (30.9083)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	14.943 (24.5373)	9.333 (28.0872)	9.524 (16.2650)	12.022 (25.1166)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-10.345 (25.3600)	4.167 (17.8899)	-4.762 (29.9912)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	13.043 (26.0906)	8.333 (20.2640)	11.111 (19.2450)	10.667 (22.7776)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	23	23	3	49
Mean (SD)	-10.145 (30.8708)	1.449 (15.8218)	11.111 (19.2450)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	13.043 (21.8792)	2.899 (9.6035)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (23.4301)	-4.545 (11.7083)	0.000 (0.0000)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	23.333 (34.3698)	5.000 (16.3120)	0.000 (0.0000)	13.178 (27.3518)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	1.667 (22.8778)	-3.509 (10.5101)	0.000 (0.0000)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 15				
n	1	3	0	4
Mean (SD)	0.000 (-)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	1	3	0	4
Mean (SD)	0.000 (-)	-11.111 (19.2450)	- (-)	-8.333 (16.6667)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-, -	-16.667, 0.000
Min, Max	0.00, 0.00	-33.33, 0.00	-, -	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	9	4	0	13
Mean (SD)	0.000 (0.0000)	0.000 (0.0000)	- (-)	0.000 (0.0000)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	9	4	0	13
Mean (SD)	-7.407 (22.2222)	0.000 (0.0000)	- (-)	-5.128 (18.4900)
Median	0.000	0.000	-	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-66.67, 0.00	0.00, 0.00	-, -	-66.67, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	10	2	3	15
Mean (SD)	33.333 (44.4444)	50.000 (70.7107)	22.222 (19.2450)	33.333 (41.7855)
Median	0.000	50.000	33.333	0.000
Q1, Q3	0.000, 66.667	0.000, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	10	2	3	15
Mean (SD)	3.333 (10.5409)	16.667 (23.5702)	-11.111 (50.9175)	2.222 (23.4577)
Median	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-66.667, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-eortc.sas 04AUG2022 00:32 t-14-02-01-06-06-eortc-sum-region.rtf

Figure 14.2.1.7.1:
EORTC QLQ-C30 Questionnaire - Global Health Status Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-01-meanot-qol-ghs.rtf

Figure 14.2.1.7.2:
EORTC QLQ-C30 Questionnaire - Cognitive Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-02-meanot-qol-cog.rtf

Figure 14.2.1.7.3:
EORTC QLQ-C30 Questionnaire - Emotional Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-03-meanot-qol-emo.rtf

Figure 14.2.1.7.4:
EORTC QLQ-C30 Questionnaire - Physical Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-04-meanot-qol-phy.rtf

Figure 14.2.1.7.5:
EORTC QLQ-C30 Questionnaire - Role Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-05-meanot-qol-rol.rtf

Figure 14.2.1.7.6:
EORTC QLQ-C30 Questionnaire - Social Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-06-meanot-qol-soc.rtf

Figure 14.2.1.7.7:
EORTC QLQ-C30 Questionnaire - Appetite Loss Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-07-meanot-qol-app.rtf

Figure 14.2.1.7.8:
EORTC QLQ-C30 Questionnaire - Constipation Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-08-meanot-qol-con.rtf

Figure 14.2.1.7.9:
EORTC QLQ-C30 Questionnaire - Diarrhoea Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-09-meanot-qol-dia.rtf

Figure 14.2.1.7.10:
EORTC QLQ-C30 Questionnaire - Dyspnoea Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-10-meanot-qol-dys.rtf

Figure 14.2.1.7.11:
EORTC QLQ-C30 Questionnaire - Fatigue Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-11-meanot-qol-fat.rtf

Figure 14.2.1.7.12:
EORTC QLQ-C30 Questionnaire - Financial Difficulties Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-12-meanot-qol-fin.rtf

Figure 14.2.1.7.13:
EORTC QLQ-C30 Questionnaire - Nausea and Vomiting Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-13-meanot-qol-nau.rtf

Figure 14.2.1.7.14:
EORTC QLQ-C30 Questionnaire - Pain Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-14-meanot-qol-pai.rtf

Figure 14.2.1.7.15:
EORTC QLQ-C30 Questionnaire - Insomnia Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/f-meanot-qol.sas 21JUL2022 06:33 f-14-02-01-07-15-meanot-qol-ins.rtf

Table 14.3.1.2.1.1:
Overall Summary of Treatment-Emergent Adverse Events by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36) n (%)	**Female (N = 32) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	33 (91.7)	32 (100.0)	65 (95.6)
Grade 3 or Higher	20 (55.6)	7 (21.9)	27 (39.7)
Grade 2 or Lower	32 (88.9)	32 (100.0)	64 (94.1)
Serious	17 (47.2)	9 (28.1)	26 (38.2)
Leading to Death	3 (8.3)	0 (0.0)	3 (4.4)
Leading to Treatment Discontinuation	4 (11.1)	0 (0.0)	4 (5.9)
Leading to Dose Modification	13 (36.1)	7 (21.9)	20 (29.4)
Leading to Dose Interruption	13 (36.1)	7 (21.9)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-01-ae-sum-sex.rtf

Table 14.3.1.2.1.2:
Overall Summary of Treatment-Emergent Adverse Events by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27) n (%)	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	27 (100.0)	38 (92.7)	48 (98.0)	17 (89.5)	65 (95.6)
Grade 3 or Higher	9 (33.3)	18 (43.9)	18 (36.7)	9 (47.4)	27 (39.7)
Grade 2 or Lower	27 (100.0)	37 (90.2)	48 (98.0)	16 (84.2)	64 (94.1)
Serious	10 (37.0)	16 (39.0)	18 (36.7)	8 (42.1)	26 (38.2)
Leading to Death	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Leading to Treatment Discontinuation	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)
Leading to Dose Modification	7 (25.9)	13 (31.7)	14 (28.6)	6 (31.6)	20 (29.4)
Leading to Dose Interruption	7 (25.9)	13 (31.7)	14 (28.6)	6 (31.6)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-02-ae-sum-age.rtf

Table 14.3.1.2.1.3:
Overall Summary of Treatment-Emergent Adverse Events by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39) n (%)	**≥ 1 (N = 29) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	37 (94.9)	28 (96.6)	65 (95.6)
Grade 3 or Higher	14 (35.9)	13 (44.8)	27 (39.7)
Grade 2 or Lower	36 (92.3)	28 (96.6)	64 (94.1)
Serious	13 (33.3)	13 (44.8)	26 (38.2)
Leading to Death	0 (0.0)	3 (10.3)	3 (4.4)
Leading to Treatment Discontinuation	1 (2.6)	3 (10.3)	4 (5.9)
Leading to Dose Modification	10 (25.6)	10 (34.5)	20 (29.4)
Leading to Dose Interruption	10 (25.6)	10 (34.5)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-03-ae-sum-ecog.rtf

Table 14.3.1.2.1.4:
Overall Summary of Treatment-Emergent Adverse Events by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49) n (%)	≥ 3 (N = 19) n (%)	Total (N = 68) n (%)
Patients with at Least One TEAE	46 (93.9)	19 (100.0)	65 (95.6)
Grade 3 or Higher	19 (38.8)	8 (42.1)	27 (39.7)
Grade 2 or Lower	46 (93.9)	18 (94.7)	64 (94.1)
Serious	19 (38.8)	7 (36.8)	26 (38.2)
Leading to Death	2 (4.1)	1 (5.3)	3 (4.4)
Leading to Treatment Discontinuation	3 (6.1)	1 (5.3)	4 (5.9)
Leading to Dose Modification	15 (30.6)	5 (26.3)	20 (29.4)
Leading to Dose Interruption	15 (30.6)	5 (26.3)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-04-ae-sum-pst.rtf

Table 14.3.1.2.1.5:
Overall Summary of Treatment-Emergent Adverse Events by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26) n (%)	NMZL (N = 26) n (%)	SMZL (N = 12) n (%)	Unknown (N = 4) n (%)	Total (N = 68) n (%)
Patients with at Least One TEAE	26 (100.0)	23 (88.5)	12 (100.0)	4 (100.0)	65 (95.6)
Grade 3 or Higher	9 (34.6)	9 (34.6)	7 (58.3)	2 (50.0)	27 (39.7)
Grade 2 or Lower	25 (96.2)	23 (88.5)	12 (100.0)	4 (100.0)	64 (94.1)
Serious	10 (38.5)	8 (30.8)	6 (50.0)	2 (50.0)	26 (38.2)
Leading to Death	0 (0.0)	2 (7.7)	0 (0.0)	1 (25.0)	3 (4.4)
Leading to Treatment Discontinuation	1 (3.8)	2 (7.7)	0 (0.0)	1 (25.0)	4 (5.9)
Leading to Dose Modification	7 (26.9)	7 (26.9)	6 (50.0)	0 (0.0)	20 (29.4)
Leading to Dose Interruption	7 (26.9)	7 (26.9)	6 (50.0)	0 (0.0)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-05-ae-sum-mzltype.rtf

Table 14.3.1.2.1.6:
Overall Summary of Treatment-Emergent Adverse Events by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33) n (%)	**Europe (N = 28) n (%)**	**North America (N = 7) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	32 (97.0)	27 (96.4)	6 (85.7)	65 (95.6)
Grade 3 or Higher	12 (36.4)	12 (42.9)	3 (42.9)	27 (39.7)
Grade 2 or Lower	31 (93.9)	27 (96.4)	6 (85.7)	64 (94.1)
Serious	14 (42.4)	10 (35.7)	2 (28.6)	26 (38.2)
Leading to Death	1 (3.0)	1 (3.6)	1 (14.3)	3 (4.4)
Leading to Treatment Discontinuation	2 (6.1)	1 (3.6)	1 (14.3)	4 (5.9)
Leading to Dose Modification	8 (24.2)	11 (39.3)	1 (14.3)	20 (29.4)
Leading to Dose Interruption	8 (24.2)	11 (39.3)	1 (14.3)	20 (29.4)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 23.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-ae-sum.sas 04AUG2022 00:27 t-14-03-01-02-01-06-ae-sum-region.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	27 (75.0)	22 (68.8)	49 (72.1)
Anemia	3 (8.3)	1 (3.1)	4 (5.9)
Anaemia	3 (8.3)	1 (3.1)	4 (5.9)
Atrial Fibrillation and Flutter	1 (2.8)	1 (3.1)	2 (2.9)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)
Hemorrhage	12 (33.3)	13 (40.6)	25 (36.8)
Petechiae/Purpura/Contusion	10 (27.8)	8 (25.0)	18 (26.5)
Contusion	9 (25.0)	5 (15.6)	14 (20.6)
Epistaxis	0 (0.0)	3 (9.4)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male (N = 36)** **n (%)**	**Female (N = 32)** **n (%)**	**Total (N = 68)** **n (%)**
Petechiae	1 (2.8)	2 (6.3)	3 (4.4)
Haematuria	1 (2.8)	1 (3.1)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.8)	1 (3.1)	2 (2.9)
Purpura	0 (0.0)	2 (6.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.8)	0 (0.0)	1 (1.5)
Ecchymosis	1 (2.8)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.8)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (3.1)	1 (1.5)
Haemorrhage urinary tract	1 (2.8)	0 (0.0)	1 (1.5)
Melaena	1 (2.8)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Pulmonary haematoma	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hypertension	2 (5.6)	0 (0.0)	2 (2.9)
Hypertension	1 (2.8)	0 (0.0)	1 (1.5)
Prehypertension	1 (2.8)	0 (0.0)	1 (1.5)
Infections	17 (47.2)	14 (43.8)	31 (45.6)
Upper respiratory tract infection	6 (16.7)	2 (6.3)	8 (11.8)
COVID-19 pneumonia	2 (5.6)	2 (6.3)	4 (5.9)
Oral herpes	1 (2.8)	2 (6.3)	3 (4.4)
Tonsillitis	3 (8.3)	0 (0.0)	3 (4.4)
Urinary tract infection	2 (5.6)	1 (3.1)	3 (4.4)
COVID-19	2 (5.6)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.8)	1 (3.1)	2 (2.9)
Pneumonia	2 (5.6)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Respiratory syncytial virus infection	1 (2.8)	1 (3.1)	2 (2.9)
Bacteraemia	1 (2.8)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Cellulitis	1 (2.8)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.8)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.1)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.1)	1 (1.5)
Gastroenteritis	1 (2.8)	0 (0.0)	1 (1.5)
Gingivitis	1 (2.8)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	1 (3.1)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Nasal herpes	1 (2.8)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (3.1)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.1)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.1)	1 (1.5)
Oral infection	0 (0.0)	1 (3.1)	1 (1.5)
Orchitis	1 (2.8)	0 (0.0)	1 (1.5)
Otitis media	1 (2.8)	0 (0.0)	1 (1.5)
Parotitis	1 (2.8)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.1)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Skin infection	1 (2.8)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	1 (3.1)	1 (1.5)
Tinea versicolour	1 (2.8)	0 (0.0)	1 (1.5)
Tooth abscess	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.1)	1 (1.5)
Opportunistic Infections	1 (2.8)	1 (3.1)	2 (2.9)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Neutropenia	6 (16.7)	3 (9.4)	9 (13.2)
Neutropenia	4 (11.1)	1 (3.1)	5 (7.4)
Neutrophil count decreased	2 (5.6)	2 (6.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	5 (13.9)	0 (0.0)	5 (7.4)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	1 (2.8)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	7 (19.4)	3 (9.4)	10 (14.7)
Thrombocytopenia	5 (13.9)	1 (3.1)	6 (8.8)
Platelet count decreased	2 (5.6)	2 (6.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE of Special Interest	19 (70.4)	30 (73.2)	36 (73.5)	13 (68.4)	49 (72.1)
Anemia	3 (11.1)	1 (2.4)	4 (8.2)	0 (0.0)	4 (5.9)
Anaemia	3 (11.1)	1 (2.4)	4 (8.2)	0 (0.0)	4 (5.9)
Atrial Fibrillation and Flutter	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	6 (22.2)	19 (46.3)	18 (36.7)	7 (36.8)	25 (36.8)
Petechiae/Purpura/Contusion	4 (14.8)	14 (34.1)	11 (22.4)	7 (36.8)	18 (26.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Contusion	3 (11.1)	11 (26.8)	9 (18.4)	5 (26.3)	14 (20.6)
Epistaxis	0 (0.0)	3 (7.3)	3 (6.1)	0 (0.0)	3 (4.4)
Petechiae	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Haematuria	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Diarrhoea haemorrhagic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Mouth haemorrhage	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Pulmonary haematoma	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Hypertension	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Hypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Prehypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Infections	13 (48.1)	18 (43.9)	23 (46.9)	8 (42.1)	31 (45.6)
Upper respiratory tract infection	4 (14.8)	4 (9.8)	6 (12.2)	2 (10.5)	8 (11.8)
COVID-19 pneumonia	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Oral herpes	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.7)	2 (4.9)	2 (4.1)	1 (5.3)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Urinary tract infection	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
COVID-19	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Gastroenteritis viral	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Pneumonia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Respiratory syncytial virus infection	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis escherichia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Gingivitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Lower respiratory tract infection	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Oral candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Otitis media	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Rhinitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tinea cruris	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tooth abscess	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Opportunistic Infections	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	4 (14.8)	5 (12.2)	7 (14.3)	2 (10.5)	9 (13.2)
Neutropenia	3 (11.1)	2 (4.9)	4 (8.2)	1 (5.3)	5 (7.4)
Neutrophil count decreased	1 (3.7)	3 (7.3)	3 (6.1)	1 (5.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (7.4)	3 (7.3)	3 (6.1)	2 (10.5)	5 (7.4)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Acute myeloid leukaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Skin Cancers	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	5 (18.5)	5 (12.2)	9 (18.4)	1 (5.3)	10 (14.7)
Thrombocytopenia	3 (11.1)	3 (7.3)	5 (10.2)	1 (5.3)	6 (8.8)
Platelet count decreased	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	30 (76.9)	19 (65.5)	49 (72.1)
Anemia	0 (0.0)	4 (13.8)	4 (5.9)
Anaemia	0 (0.0)	4 (13.8)	4 (5.9)
Atrial Fibrillation and Flutter	2 (5.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	17 (43.6)	8 (27.6)	25 (36.8)
Petechiae/Purpura/Contusion	11 (28.2)	7 (24.1)	18 (26.5)
Contusion	9 (23.1)	5 (17.2)	14 (20.6)
Epistaxis	2 (5.1)	1 (3.4)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	3 (7.7)	0 (0.0)	3 (4.4)
Haematuria	2 (5.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.6)	1 (3.4)	2 (2.9)
Purpura	0 (0.0)	2 (6.9)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.6)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (3.4)	1 (1.5)
Gingival bleeding	1 (2.6)	0 (0.0)	1 (1.5)
Haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (2.6)	0 (0.0)	1 (1.5)
Melaena	1 (2.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.4)	1 (1.5)
Pulmonary haematoma	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hypertension	0 (0.0)	2 (6.9)	2 (2.9)
Hypertension	0 (0.0)	1 (3.4)	1 (1.5)
Prehypertension	0 (0.0)	1 (3.4)	1 (1.5)
Infections	17 (43.6)	14 (48.3)	31 (45.6)
Upper respiratory tract infection	3 (7.7)	5 (17.2)	8 (11.8)
COVID-19 pneumonia	1 (2.6)	3 (10.3)	4 (5.9)
Oral herpes	2 (5.1)	1 (3.4)	3 (4.4)
Tonsillitis	1 (2.6)	2 (6.9)	3 (4.4)
Urinary tract infection	2 (5.1)	1 (3.4)	3 (4.4)
COVID-19	1 (2.6)	1 (3.4)	2 (2.9)
Gastroenteritis viral	2 (5.1)	0 (0.0)	2 (2.9)
Pneumonia	0 (0.0)	2 (6.9)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Respiratory syncytial virus infection	1 (2.6)	1 (3.4)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.4)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Cellulitis	1 (2.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.6)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.4)	1 (1.5)
Cystitis escherichia	1 (2.6)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (2.6)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Infected bite	1 (2.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)
Lymph gland infection	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Nasal herpes	1 (2.6)	0 (0.0)	1 (1.5)
Nasopharyngitis	1 (2.6)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.4)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.4)	1 (1.5)
Oral infection	0 (0.0)	1 (3.4)	1 (1.5)
Orchitis	1 (2.6)	0 (0.0)	1 (1.5)
Otitis media	1 (2.6)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.4)	1 (1.5)
Rhinitis	1 (2.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Skin infection	1 (2.6)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.6)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.4)	1 (1.5)
Tooth abscess	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.4)	1 (1.5)
Opportunistic Infections	2 (5.1)	0 (0.0)	2 (2.9)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Neutropenia	4 (10.3)	5 (17.2)	9 (13.2)
Neutropenia	2 (5.1)	3 (10.3)	5 (7.4)
Neutrophil count decreased	2 (5.1)	2 (6.9)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	3 (7.7)	2 (6.9)	5 (7.4)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.4)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	5 (12.8)	5 (17.2)	10 (14.7)
Thrombocytopenia	2 (5.1)	4 (13.8)	6 (8.8)
Platelet count decreased	3 (7.7)	1 (3.4)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	32 (65.3)	17 (89.5)	49 (72.1)
Anemia	2 (4.1)	2 (10.5)	4 (5.9)
Anaemia	2 (4.1)	2 (10.5)	4 (5.9)
Atrial Fibrillation and Flutter	1 (2.0)	1 (5.3)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	17 (34.7)	8 (42.1)	25 (36.8)
Petechiae/Purpura/Contusion	12 (24.5)	6 (31.6)	18 (26.5)
Contusion	9 (18.4)	5 (26.3)	14 (20.6)
Epistaxis	1 (2.0)	2 (10.5)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	2 (4.1)	1 (5.3)	3 (4.4)
Haematuria	1 (2.0)	1 (5.3)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	1 (2.0)	1 (5.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (5.3)	1 (1.5)
Gingival bleeding	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (5.3)	1 (1.5)
Melaena	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)
Pulmonary haematoma	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hypertension	2 (4.1)	0 (0.0)	2 (2.9)
Hypertension	1 (2.0)	0 (0.0)	1 (1.5)
Prehypertension	1 (2.0)	0 (0.0)	1 (1.5)
Infections	21 (42.9)	10 (52.6)	31 (45.6)
Upper respiratory tract infection	4 (8.2)	4 (21.1)	8 (11.8)
COVID-19 pneumonia	2 (4.1)	2 (10.5)	4 (5.9)
Oral herpes	2 (4.1)	1 (5.3)	3 (4.4)
Tonsillitis	2 (4.1)	1 (5.3)	3 (4.4)
Urinary tract infection	3 (6.1)	0 (0.0)	3 (4.4)
COVID-19	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.0)	1 (5.3)	2 (2.9)
Pneumonia	0 (0.0)	2 (10.5)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Respiratory syncytial virus infection	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (5.3)	1 (1.5)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	1 (2.0)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis escherichia	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (5.3)	1 (1.5)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (5.3)	1 (1.5)
Lymph gland infection	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Nasal herpes	1 (2.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (5.3)	1 (1.5)
Onychomycosis	1 (2.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (5.3)	1 (1.5)
Rhinitis	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	1 (2.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (5.3)	1 (1.5)
Tooth abscess	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Vulvovaginal candidiasis	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (2.0)	1 (5.3)	2 (2.9)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Neutropenia	4 (8.2)	5 (26.3)	9 (13.2)
Neutropenia	2 (4.1)	3 (15.8)	5 (7.4)
Neutrophil count decreased	2 (4.1)	2 (10.5)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	3 (6.1)	2 (10.5)	5 (7.4)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (5.3)	1 (1.5)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	3 (6.1)	7 (36.8)	10 (14.7)
Thrombocytopenia	1 (2.0)	5 (26.3)	6 (8.8)
Platelet count decreased	2 (4.1)	2 (10.5)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	17 (65.4)	18 (69.2)	11 (91.7)	3 (75.0)	49 (72.1)
Anemia	0 (0.0)	2 (7.7)	0 (0.0)	2 (50.0)	4 (5.9)
Anaemia	0 (0.0)	2 (7.7)	0 (0.0)	2 (50.0)	4 (5.9)
Atrial Fibrillation and Flutter	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	9 (34.6)	10 (38.5)	5 (41.7)	1 (25.0)	25 (36.8)
Petechiae/Purpura/Contusion	5 (19.2)	8 (30.8)	5 (41.7)	0 (0.0)	18 (26.5)
Contusion	4 (15.4)	6 (23.1)	4 (33.3)	0 (0.0)	14 (20.6)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Epistaxis	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
Petechiae	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)
Haematuria	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Haematoma	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Melaena	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Hypertension	1 (3.8)	0 (0.0)	1 (8.3)	0 (0.0)	2 (2.9)
Hypertension	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Prehypertension	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Infections	8 (30.8)	13 (50.0)	8 (66.7)	2 (50.0)	31 (45.6)
Upper respiratory tract infection	0 (0.0)	5 (19.2)	2 (16.7)	1 (25.0)	8 (11.8)
COVID-19 pneumonia	0 (0.0)	2 (7.7)	2 (16.7)	0 (0.0)	4 (5.9)
Oral herpes	0 (0.0)	1 (3.8)	2 (16.7)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)
Urinary tract infection	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
COVID-19	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Pneumonia	0 (0.0)	1 (3.8)	0 (0.0)	1 (25.0)	2 (2.9)
Respiratory syncytial virus infection	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Lower respiratory tract infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tinea cruris	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	4 (15.4)	2 (7.7)	2 (16.7)	1 (25.0)	9 (13.2)
Neutropenia	1 (3.8)	2 (7.7)	2 (16.7)	0 (0.0)	5 (7.4)
Neutrophil count decreased	3 (11.5)	0 (0.0)	0 (0.0)	1 (25.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (7.7)	3 (11.5)	0 (0.0)	0 (0.0)	5 (7.4)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	2 (7.7)	4 (15.4)	2 (16.7)	2 (50.0)	10 (14.7)
Thrombocytopenia	1 (3.8)	2 (7.7)	2 (16.7)	1 (25.0)	6 (8.8)
Platelet count decreased	1 (3.8)	2 (7.7)	0 (0.0)	1 (25.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	21 (63.6)	24 (85.7)	4 (57.1)	49 (72.1)
Anemia	2 (6.1)	1 (3.6)	1 (14.3)	4 (5.9)
Anaemia	2 (6.1)	1 (3.6)	1 (14.3)	4 (5.9)
Atrial Fibrillation and Flutter	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	12 (36.4)	12 (42.9)	1 (14.3)	25 (36.8)
Petechiae/Purpura/Contusion	9 (27.3)	8 (28.6)	1 (14.3)	18 (26.5)
Contusion	7 (21.2)	6 (21.4)	1 (14.3)	14 (20.6)
Epistaxis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	2 (6.1)	1 (3.6)	0 (0.0)	3 (4.4)
Haematuria	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Ecchymosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Pulmonary haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hypertension	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Hypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Prehypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infections	12 (36.4)	16 (57.1)	3 (42.9)	31 (45.6)
Upper respiratory tract infection	5 (15.2)	3 (10.7)	0 (0.0)	8 (11.8)
COVID-19 pneumonia	0 (0.0)	3 (10.7)	1 (14.3)	4 (5.9)
Oral herpes	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Urinary tract infection	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
COVID-19	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Gastroenteritis viral	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Pneumonia	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gastroenteritis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infected bite	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Nasal herpes	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Onychomycosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Otitis media	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Parotitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Skin infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	5 (15.2)	4 (14.3)	0 (0.0)	9 (13.2)
Neutropenia	1 (3.0)	4 (14.3)	0 (0.0)	5 (7.4)
Neutrophil count decreased	4 (12.1)	0 (0.0)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (6.1)	3 (10.7)	0 (0.0)	5 (7.4)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	5 (15.2)	5 (17.9)	0 (0.0)	10 (14.7)
Thrombocytopenia	1 (3.0)	5 (17.9)	0 (0.0)	6 (8.8)
Platelet count decreased	4 (12.1)	0 (0.0)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 00:38 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	23 (63.9)	21 (65.6)	44 (64.7)
Anemia	2 (5.6)	0 (0.0)	2 (2.9)
Anaemia	2 (5.6)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (3.1)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)
Hemorrhage	12 (33.3)	13 (40.6)	25 (36.8)
Petechiae/Purpura/Contusion	10 (27.8)	8 (25.0)	18 (26.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	9 (25.0)	5 (15.6)	14 (20.6)
Epistaxis	0 (0.0)	3 (9.4)	3 (4.4)
Petechiae	1 (2.8)	2 (6.3)	3 (4.4)
Haematuria	1 (2.8)	1 (3.1)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.8)	1 (3.1)	2 (2.9)
Purpura	0 (0.0)	2 (6.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.8)	0 (0.0)	1 (1.5)
Ecchymosis	1 (2.8)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.8)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (3.1)	1 (1.5)
Haemorrhage urinary tract	1 (2.8)	0 (0.0)	1 (1.5)
Melaena	1 (2.8)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.8)	0 (0.0)	1 (1.5)
Hypertension	2 (5.6)	0 (0.0)	2 (2.9)
Hypertension	1 (2.8)	0 (0.0)	1 (1.5)
Prehypertension	1 (2.8)	0 (0.0)	1 (1.5)
Infections	15 (41.7)	14 (43.8)	29 (42.6)
Upper respiratory tract infection	6 (16.7)	2 (6.3)	8 (11.8)
Oral herpes	1 (2.8)	2 (6.3)	3 (4.4)
Tonsillitis	3 (8.3)	0 (0.0)	3 (4.4)
Urinary tract infection	2 (5.6)	1 (3.1)	3 (4.4)
COVID-19	2 (5.6)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.8)	1 (3.1)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Bacteraemia	1 (2.8)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.1)	1 (1.5)
Cellulitis	1 (2.8)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.8)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.1)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.1)	1 (1.5)
Gastroenteritis	1 (2.8)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	1 (3.1)	1 (1.5)
Lower respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.8)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.8)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (3.1)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral candidiasis	0 (0.0)	1 (3.1)	1 (1.5)
Oral infection	0 (0.0)	1 (3.1)	1 (1.5)
Orchitis	1 (2.8)	0 (0.0)	1 (1.5)
Otitis media	1 (2.8)	0 (0.0)	1 (1.5)
Parotitis	1 (2.8)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.1)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.1)	1 (1.5)
Skin infection	1 (2.8)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	1 (3.1)	1 (1.5)
Tinea versicolour	1 (2.8)	0 (0.0)	1 (1.5)
Tooth abscess	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	0 (0.0)	1 (3.1)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Neutropenia	0 (0.0)	3 (9.4)	3 (4.4)
Neutrophil count decreased	0 (0.0)	2 (6.3)	2 (2.9)
Neutropenia	0 (0.0)	1 (3.1)	1 (1.5)
Second Primary Malignancies	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin Cancers	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)
Thrombocytopenia	5 (13.9)	3 (9.4)	8 (11.8)
Platelet count decreased	2 (5.6)	2 (6.3)	4 (5.9)
Thrombocytopenia	3 (8.3)	1 (3.1)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	17 (63.0)	27 (65.9)	33 (67.3)	11 (57.9)	44 (64.7)
Anemia	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Anaemia	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hemorrhage	6 (22.2)	19 (46.3)	18 (36.7)	7 (36.8)	25 (36.8)
Petechiae/Purpura/Contusion	4 (14.8)	14 (34.1)	11 (22.4)	7 (36.8)	18 (26.5)
Contusion	3 (11.1)	11 (26.8)	9 (18.4)	5 (26.3)	14 (20.6)
Epistaxis	0 (0.0)	3 (7.3)	3 (6.1)	0 (0.0)	3 (4.4)
Petechiae	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Haematuria	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Diarrhoea haemorrhagic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Gingival bleeding	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Pulmonary haematoma	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Hypertension	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Hypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Prehypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Infections	13 (48.1)	16 (39.0)	22 (44.9)	7 (36.8)	29 (42.6)
Upper respiratory tract infection	4 (14.8)	4 (9.8)	6 (12.2)	2 (10.5)	8 (11.8)
Oral herpes	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.7)	2 (4.9)	2 (4.1)	1 (5.3)	3 (4.4)
Urinary tract infection	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
COVID-19	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Gastroenteritis viral	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Bacteraemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cellulitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Conjunctivitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis escherichia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Oral candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Oral infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Rhinitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tinea cruris	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tooth abscess	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Vulvovaginal candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	0 (0.0)	3 (7.3)	2 (4.1)	1 (5.3)	3 (4.4)
Neutrophil count decreased	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Neutropenia	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Second Primary Malignancies	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Skin Cancers	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Thrombocytopenia	3 (11.1)	5 (12.2)	7 (14.3)	1 (5.3)	8 (11.8)
Platelet count decreased	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)
Thrombocytopenia	1 (3.7)	3 (7.3)	3 (6.1)	1 (5.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	28 (71.8)	16 (55.2)	44 (64.7)
Anemia	0 (0.0)	2 (6.9)	2 (2.9)
Anaemia	0 (0.0)	2 (6.9)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	17 (43.6)	8 (27.6)	25 (36.8)
Petechiae/Purpura/Contusion	11 (28.2)	7 (24.1)	18 (26.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	9 (23.1)	5 (17.2)	14 (20.6)
Epistaxis	2 (5.1)	1 (3.4)	3 (4.4)
Petechiae	3 (7.7)	0 (0.0)	3 (4.4)
Haematuria	2 (5.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.6)	1 (3.4)	2 (2.9)
Purpura	0 (0.0)	2 (6.9)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.6)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (3.4)	1 (1.5)
Gingival bleeding	1 (2.6)	0 (0.0)	1 (1.5)
Haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (2.6)	0 (0.0)	1 (1.5)
Melaena	1 (2.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	2 (6.9)	2 (2.9)
Hypertension	0 (0.0)	1 (3.4)	1 (1.5)
Prehypertension	0 (0.0)	1 (3.4)	1 (1.5)
Infections	17 (43.6)	12 (41.4)	29 (42.6)
Upper respiratory tract infection	3 (7.7)	5 (17.2)	8 (11.8)
Oral herpes	2 (5.1)	1 (3.4)	3 (4.4)
Tonsillitis	1 (2.6)	2 (6.9)	3 (4.4)
Urinary tract infection	2 (5.1)	1 (3.4)	3 (4.4)
COVID-19	1 (2.6)	1 (3.4)	2 (2.9)
Gastroenteritis viral	2 (5.1)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Bacteraemia	0 (0.0)	1 (3.4)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.4)	1 (1.5)
Cellulitis	1 (2.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.6)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.4)	1 (1.5)
Cystitis escherichia	1 (2.6)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.6)	0 (0.0)	1 (1.5)
Infected bite	1 (2.6)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)
Lymph gland infection	1 (2.6)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.6)	0 (0.0)	1 (1.5)
Nasopharyngitis	1 (2.6)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral candidiasis	0 (0.0)	1 (3.4)	1 (1.5)
Oral infection	0 (0.0)	1 (3.4)	1 (1.5)
Orchitis	1 (2.6)	0 (0.0)	1 (1.5)
Otitis media	1 (2.6)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.4)	1 (1.5)
Respiratory syncytial virus infection	1 (2.6)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.6)	0 (0.0)	1 (1.5)
Skin infection	1 (2.6)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.6)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.4)	1 (1.5)
Tooth abscess	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Neutropenia	1 (2.6)	2 (6.9)	3 (4.4)
Neutrophil count decreased	1 (2.6)	1 (3.4)	2 (2.9)
Neutropenia	0 (0.0)	1 (3.4)	1 (1.5)
Second Primary Malignancies	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin Cancers	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	5 (12.8)	3 (10.3)	8 (11.8)
Platelet count decreased	3 (7.7)	1 (3.4)	4 (5.9)
Thrombocytopenia	2 (5.1)	2 (6.9)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	28 (57.1)	16 (84.2)	44 (64.7)
Anemia	1 (2.0)	1 (5.3)	2 (2.9)
Anaemia	1 (2.0)	1 (5.3)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	17 (34.7)	8 (42.1)	25 (36.8)
Petechiae/Purpura/Contusion	12 (24.5)	6 (31.6)	18 (26.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	9 (18.4)	5 (26.3)	14 (20.6)
Epistaxis	1 (2.0)	2 (10.5)	3 (4.4)
Petechiae	2 (4.1)	1 (5.3)	3 (4.4)
Haematuria	1 (2.0)	1 (5.3)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	1 (2.0)	1 (5.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (5.3)	1 (1.5)
Gingival bleeding	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (5.3)	1 (1.5)
Melaena	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	2 (4.1)	0 (0.0)	2 (2.9)
Hypertension	1 (2.0)	0 (0.0)	1 (1.5)
Prehypertension	1 (2.0)	0 (0.0)	1 (1.5)
Infections	19 (38.8)	10 (52.6)	29 (42.6)
Upper respiratory tract infection	4 (8.2)	4 (21.1)	8 (11.8)
Oral herpes	2 (4.1)	1 (5.3)	3 (4.4)
Tonsillitis	2 (4.1)	1 (5.3)	3 (4.4)
Urinary tract infection	3 (6.1)	0 (0.0)	3 (4.4)
COVID-19	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.0)	1 (5.3)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Bacteraemia	0 (0.0)	1 (5.3)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (5.3)	1 (1.5)
Cellulitis	1 (2.0)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis escherichia	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (2.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (5.3)	1 (1.5)
Lymph gland infection	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (5.3)	1 (1.5)
Onychomycosis	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral candidiasis	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (5.3)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	1 (2.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (5.3)	1 (1.5)
Tooth abscess	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Vulvovaginal candidiasis	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Neutropenia	2 (4.1)	1 (5.3)	3 (4.4)
Neutrophil count decreased	2 (4.1)	0 (0.0)	2 (2.9)
Neutropenia	0 (0.0)	1 (5.3)	1 (1.5)
Second Primary Malignancies	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin Cancers	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	3 (6.1)	5 (26.3)	8 (11.8)
Platelet count decreased	2 (4.1)	2 (10.5)	4 (5.9)
Thrombocytopenia	1 (2.0)	3 (15.8)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	14 (53.8)	16 (61.5)	11 (91.7)	3 (75.0)	44 (64.7)
Anemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	2 (2.9)
Anaemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	9 (34.6)	10 (38.5)	5 (41.7)	1 (25.0)	25 (36.8)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Petechiae/Purpura/Contusion	5 (19.2)	8 (30.8)	5 (41.7)	0 (0.0)	18 (26.5)
Contusion	4 (15.4)	6 (23.1)	4 (33.3)	0 (0.0)	14 (20.6)
Epistaxis	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
Petechiae	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)
Haematuria	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Ecchymosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Haematoma	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Melaena	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Hypertension	1 (3.8)	0 (0.0)	1 (8.3)	0 (0.0)	2 (2.9)
Hypertension	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Prehypertension	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Infections	7 (26.9)	12 (46.2)	8 (66.7)	2 (50.0)	29 (42.6)
Upper respiratory tract infection	0 (0.0)	5 (19.2)	2 (16.7)	1 (25.0)	8 (11.8)
Oral herpes	0 (0.0)	1 (3.8)	2 (16.7)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Urinary tract infection	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
COVID-19	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Lymph gland infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasopharyngitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Tinea cruris	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	2 (7.7)	0 (0.0)	1 (8.3)	0 (0.0)	3 (4.4)
Neutrophil count decreased	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Neutropenia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Second Primary Malignancies	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	2 (7.7)	2 (7.7)	2 (16.7)	2 (50.0)	8 (11.8)
Platelet count decreased	1 (3.8)	2 (7.7)	0 (0.0)	1 (25.0)	4 (5.9)
Thrombocytopenia	1 (3.8)	0 (0.0)	2 (16.7)	1 (25.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	19 (57.6)	23 (82.1)	2 (28.6)	44 (64.7)
Anemia	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Anaemia	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	12 (36.4)	12 (42.9)	1 (14.3)	25 (36.8)
Petechiae/Purpura/Contusion	9 (27.3)	8 (28.6)	1 (14.3)	18 (26.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	7 (21.2)	6 (21.4)	1 (14.3)	14 (20.6)
Epistaxis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Petechiae	2 (6.1)	1 (3.6)	0 (0.0)	3 (4.4)
Haematuria	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Ecchymosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific (N = 33) n (%)**	**Europe (N = 28) n (%)**	**North America (N = 7) n (%)**	**Total (N = 68) n (%)**
Pulmonary haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Hypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Prehypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infections	12 (36.4)	15 (53.6)	2 (28.6)	29 (42.6)
Upper respiratory tract infection	5 (15.2)	3 (10.7)	0 (0.0)	8 (11.8)
Oral herpes	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Tonsillitis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Urinary tract infection	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
COVID-19	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Gastroenteritis viral	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Bacteraemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gastroenteritis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infected bite	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Nasopharyngitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Onychomycosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Otitis media	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Parotitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Skin infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Vulvovaginal candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	2 (6.1)	1 (3.6)	0 (0.0)	3 (4.4)
Neutrophil count decreased	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Neutropenia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Second Primary Malignancies	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific (N = 33)** **n (%)**	**Europe (N = 28)** **n (%)**	**North America (N = 7)** **n (%)**	**Total (N = 68)** **n (%)**
Skin Cancers	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	5 (15.2)	3 (10.7)	0 (0.0)	8 (11.8)
Platelet count decreased	4 (12.1)	0 (0.0)	0 (0.0)	4 (5.9)
Thrombocytopenia	1 (3.0)	3 (10.7)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 00:39 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	14 (38.9)	4 (12.5)	18 (26.5)
Anemia	1 (2.8)	1 (3.1)	2 (2.9)
Anaemia	1 (2.8)	1 (3.1)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.8)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Hypertension	1 (2.8)	0 (0.0)	1 (1.5)
Hypertension	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	9 (25.0)	2 (6.3)	11 (16.2)
COVID-19 pneumonia	2 (5.6)	1 (3.1)	3 (4.4)
Pneumonia	2 (5.6)	0 (0.0)	2 (2.9)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Gingivitis	1 (2.8)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (2.8)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Tonsillitis	1 (2.8)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (2.8)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Neutropenia	6 (16.7)	1 (3.1)	7 (10.3)
Neutropenia	4 (11.1)	1 (3.1)	5 (7.4)
Neutrophil count decreased	2 (5.6)	0 (0.0)	2 (2.9)
Second Primary Malignancies	3 (8.3)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	1 (2.8)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	3 (8.3)	0 (0.0)	3 (4.4)
Thrombocytopenia	2 (5.6)	0 (0.0)	2 (2.9)
Platelet count decreased	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	8 (29.6)	10 (24.4)	13 (26.5)	5 (26.3)	18 (26.5)
Anemia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Anaemia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Hypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Infections	6 (22.2)	5 (12.2)	9 (18.4)	2 (10.5)	11 (16.2)
COVID-19 pneumonia	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Pneumonia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Upper respiratory tract infection	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	4 (14.8)	3 (7.3)	5 (10.2)	2 (10.5)	7 (10.3)
Neutropenia	3 (11.1)	2 (4.9)	4 (8.2)	1 (5.3)	5 (7.4)
Neutrophil count decreased	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27)** **n (%)**	**≥ 65 years (N = 41)** **n (%)**	**< 75 years (N = 49)** **n (%)**	**≥ 75 years (N = 19)** **n (%)**	**Total (N = 68)** **n (%)**
Second Primary Malignancies	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Thrombocytopenia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Platelet count decreased	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	6 (15.4)	12 (41.4)	18 (26.5)
Anemia	0 (0.0)	2 (6.9)	2 (2.9)
Anaemia	0 (0.0)	2 (6.9)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.6)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	1 (3.4)	1 (1.5)
Hypertension	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	3 (7.7)	8 (27.6)	11 (16.2)
COVID-19 pneumonia	1 (2.6)	2 (6.9)	3 (4.4)
Pneumonia	0 (0.0)	2 (6.9)	2 (2.9)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Gingivitis	1 (2.6)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.4)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.4)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (2.6)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Neutropenia	3 (7.7)	4 (13.8)	7 (10.3)
Neutropenia	2 (5.1)	3 (10.3)	5 (7.4)
Neutrophil count decreased	1 (2.6)	1 (3.4)	2 (2.9)
Second Primary Malignancies	1 (2.6)	2 (6.9)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.4)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	0 (0.0)	3 (10.3)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (6.9)	2 (2.9)
Platelet count decreased	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	12 (24.5)	6 (31.6)	18 (26.5)
Anemia	1 (2.0)	1 (5.3)	2 (2.9)
Anaemia	1 (2.0)	1 (5.3)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (5.3)	1 (1.5)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Hypertension	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	7 (14.3)	4 (21.1)	11 (16.2)
COVID-19 pneumonia	2 (4.1)	1 (5.3)	3 (4.4)
Pneumonia	0 (0.0)	2 (10.5)	2 (2.9)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (5.3)	1 (1.5)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	1 (2.0)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	2 (4.1)	5 (26.3)	7 (10.3)
Neutropenia	2 (4.1)	3 (15.8)	5 (7.4)
Neutrophil count decreased	0 (0.0)	2 (10.5)	2 (2.9)
Second Primary Malignancies	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (5.3)	1 (1.5)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	1 (2.0)	2 (10.5)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (10.5)	2 (2.9)
Platelet count decreased	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	5 (19.2)	6 (23.1)	5 (41.7)	2 (50.0)	18 (26.5)
Anemia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Anaemia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hypertension	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	2 (7.7)	5 (19.2)	3 (25.0)	1 (25.0)	11 (16.2)
COVID-19 pneumonia	0 (0.0)	2 (7.7)	1 (8.3)	0 (0.0)	3 (4.4)
Pneumonia	0 (0.0)	1 (3.8)	0 (0.0)	1 (25.0)	2 (2.9)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Opportunistic Infections	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	2 (7.7)	2 (7.7)	2 (16.7)	1 (25.0)	7 (10.3)
Neutropenia	1 (3.8)	2 (7.7)	2 (16.7)	0 (0.0)	5 (7.4)
Neutrophil count decreased	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)
Second Primary Malignancies	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Thrombocytopenia	0 (0.0)	2 (7.7)	0 (0.0)	1 (25.0)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Platelet count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	5 (15.2)	10 (35.7)	3 (42.9)	18 (26.5)
Anemia	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Anaemia	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	2 (6.1)	7 (25.0)	2 (28.6)	11 (16.2)
COVID-19 pneumonia	0 (0.0)	2 (7.1)	1 (14.3)	3 (4.4)
Pneumonia	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Neutropenia	3 (9.1)	4 (14.3)	0 (0.0)	7 (10.3)
Neutropenia	1 (3.0)	4 (14.3)	0 (0.0)	5 (7.4)
Neutrophil count decreased	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Second Primary Malignancies	0 (0.0)	3 (10.7)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Platelet count decreased	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 00:40 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	11 (30.6)	4 (12.5)	15 (22.1)
Anemia	1 (2.8)	0 (0.0)	1 (1.5)
Anaemia	1 (2.8)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	1 (2.8)	1 (3.1)	2 (2.9)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	7 (19.4)	3 (9.4)	10 (14.7)
COVID-19 pneumonia	2 (5.6)	1 (3.1)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Pneumonia	1 (2.8)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (2.8)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Tonsillitis	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Urinary tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (3.1)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (5.6)	0 (0.0)	2 (2.9)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (2.8)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Serious TEAE of Special Interest	6 (22.2)	9 (22.0)	11 (22.4)	4 (21.1)	15 (22.1)
Anemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Anaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	5 (18.5)	5 (12.2)	7 (14.3)	3 (15.8)	10 (14.7)
COVID-19 pneumonia	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Pneumonia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Urinary tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Second Primary Malignancies	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Platelet count decreased	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	6 (15.4)	9 (31.0)	15 (22.1)
Anemia	0 (0.0)	1 (3.4)	1 (1.5)
Anaemia	0 (0.0)	1 (3.4)	1 (1.5)
Atrial Fibrillation and Flutter	2 (5.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	3 (7.7)	7 (24.1)	10 (14.7)
COVID-19 pneumonia	1 (2.6)	2 (6.9)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Pneumonia	0 (0.0)	1 (3.4)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.4)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.4)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Urinary tract infection	1 (2.6)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	1 (2.6)	1 (3.4)	2 (2.9)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	0 (0.0)	1 (3.4)	1 (1.5)
Platelet count decreased	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	11 (22.4)	4 (21.1)	15 (22.1)
Anemia	0 (0.0)	1 (5.3)	1 (1.5)
Anaemia	0 (0.0)	1 (5.3)	1 (1.5)
Atrial Fibrillation and Flutter	1 (2.0)	1 (5.3)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	7 (14.3)	3 (15.8)	10 (14.7)
COVID-19 pneumonia	2 (4.1)	1 (5.3)	3 (4.4)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia	0 (0.0)	1 (5.3)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Urinary tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (4.1)	0 (0.0)	2 (2.9)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (2.0)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	6 (23.1)	5 (19.2)	3 (25.0)	1 (25.0)	15 (22.1)
Anemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Anaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	3 (11.5)	4 (15.4)	3 (25.0)	0 (0.0)	10 (14.7)
COVID-19 pneumonia	0 (0.0)	2 (7.7)	1 (8.3)	0 (0.0)	3 (4.4)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pneumonia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Urinary tract infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Opportunistic Infections	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Second Primary Malignancies	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Platelet count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	4 (12.1)	9 (32.1)	2 (28.6)	15 (22.1)
Anemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Anaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	1 (3.0)	7 (25.0)	2 (28.6)	10 (14.7)
COVID-19 pneumonia	0 (0.0)	2 (7.1)	1 (14.3)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Pneumonia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Urinary tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 18JAN2021. Data extraction: 05FEB2021.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20210118_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 00:39 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
ORR by IRC (months)	
n	68
Mean (SD)	18.31 (10.186)
Median	22.70
Q1, Q3	7.44, 27.58
Min, Max	0.0, 28.7
PFS by IRC (months)	
n	68
Mean (SD)	19.76 (9.233)
Median	25.36
Q1, Q3	10.64, 27.58
Min, Max	0.0, 28.7

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
OS (months)	
n	68
Mean (SD)	25.46 (7.646)
Median	28.04
Q1, Q3	24.85, 30.49
Min, Max	1.6, 32.9
AE (months)	
n	68
Mean (SD)	19.39 (11.039)
Median	24.38
Q1, Q3	7.69, 29.31
Min, Max	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.3.5.10:
Observation Period
Safety Analysis Set

	Zanubrutinib (N = 68)
EQ VAS (months)	
n	68
Mean (SD)	18.39 (10.859)
Median	24.10
Q1, Q3	8.25, 27.68
Min, Max	0.0, 32.0
QLQ-C30 (months)	
n	68
Mean (SD)	18.46 (10.783)
Median	24.10
Q1, Q3	8.67, 27.68
Min, Max	0.0, 32.0

Source: ADSL,ADRSIRC,ADTTEIRC,ADTTE,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.
Observation period of EQ VAS is defined as the time from the first dose to last EQ VAS assessment.
Observation period of QLQ-C30 is defined as the time from the first dose to last QLQ-C30 assessment.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-obserprd.sas 29SEP2022 19:15 t-14-03-05-10-obserprd.rtf

Table 14.2.1.1.10.1:
Analysis of Overall Survival by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	7 (19.4)	6 (18.8)	13 (19.1)
Death	7 (19.4)	6 (18.8)	13 (19.1)
Censored, n (%)	29 (80.6)	26 (81.3)	55 (80.9)
Alive	29 (80.6)	26 (81.3)	55 (80.9)
Follow-up Time (months) [a]			
Median (95% CI)	28.78 (27.63, 30.39)	28.55 (27.10, 30.55)	28.68 (27.89, 30.36)
(Min, Max)	(3.6, 32.1)	(1.6, 32.9)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each gender group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-01-ef-os-grp-sex.rtf

Table 14.2.1.1.10.1:
Analysis of Overall Survival by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (16.0, NE)	NE (13.8, NE)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(3.6 ,32.1^{+})	(1.6^{+} ,32.9^{+})	(1.6^{+} ,32.9^{+})

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each gender group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-01-ef-os-grp-sex.rtf

Table 14.2.1.1.10.1:
Analysis of Overall Survival by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	100.0 (NE, NE)	96.8 (79.2, 99.5)	98.5 (89.9, 99.8)
6 Month	97.2 (81.9, 99.6)	96.8 (79.2, 99.5)	97.0 (88.6, 99.2)
9 Month	97.2 (81.9, 99.6)	93.5 (76.6, 98.3)	95.5 (86.8, 98.5)
12 Month	94.4 (79.3, 98.6)	93.5 (76.6, 98.3)	94.0 (84.8, 97.7)
15 Month	94.4 (79.3, 98.6)	90.3 (72.9, 96.8)	92.5 (82.9, 96.8)
18 Month	82.8 (65.7, 91.9)	90.3 (72.9, 96.8)	86.4 (75.5, 92.7)
24 Month	82.8 (65.7, 91.9)	87.1 (69.2, 95.0)	84.9 (73.7, 91.6)
30 Month	79.8 (62.1, 89.8)	79.3 (59.5, 90.2)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each gender group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-01-ef-os-grp-sex.rtf

Table 14.2.1.1.10.2:
Analysis of Overall Survival by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Overall Survival					
Events, n (%)	4 (14.8)	9 (22.0)	9 (18.4)	4 (21.1)	13 (19.1)
Death	4 (14.8)	9 (22.0)	9 (18.4)	4 (21.1)	13 (19.1)
Censored, n (%)	23 (85.2)	32 (78.0)	40 (81.6)	15 (78.9)	55 (80.9)
Alive	23 (85.2)	32 (78.0)	40 (81.6)	15 (78.9)	55 (80.9)
Follow-up Time (months) [a]					
Median (95% CI)	29.01 (27.10, 30.39)	28.62 (27.63, 30.42)	29.01 (28.19, 30.39)	27.79 (24.90, 31.05)	28.68 (27.89, 30.36)
(Min, Max)	(1.6, 32.8)	(2.8, 32.9)	(1.6, 32.9)	(6.4, 32.2)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-02-ef-os-grp-age.rtf

Table 14.2.1.1.10.2:
Analysis of Overall Survival by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
OS (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (15.5, NE)	NE (13.8, NE)	NE (16.5, NE)	NE (6.4, NE)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(1.6^{+} ,32.8^{+})	(2.8 ,32.9^{+})	(1.6^{+} ,32.9^{+})	(6.4 ,32.2^{+})	(1.6^{+} ,32.9^{+})

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-02-ef-os-grp-age.rtf

Table 14.2.1.1.10.2:
Analysis of Overall Survival by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]					
3 Month	100.0 (NE, NE)	97.6 (83.9, 99.7)	97.9 (86.1, 99.7)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	100.0 (NE, NE)	95.1 (81.9, 98.8)	95.8 (84.4, 98.9)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	100.0 (NE, NE)	92.7 (79.0, 97.6)	95.8 (84.4, 98.9)	94.7 (68.1, 99.2)	95.5 (86.8, 98.5)
12 Month	100.0 (NE, NE)	90.2 (76.1, 96.2)	95.8 (84.4, 98.9)	89.5 (64.1, 97.3)	94.0 (84.8, 97.7)
15 Month	100.0 (NE, NE)	87.8 (73.2, 94.7)	95.8 (84.4, 98.9)	84.2 (58.7, 94.6)	92.5 (82.9, 96.8)
18 Month	88.0 (67.3, 96.0)	85.4 (70.3, 93.1)	87.3 (73.9, 94.1)	84.2 (58.7, 94.6)	86.4 (75.5, 92.7)
24 Month	84.0 (62.8, 93.7)	85.4 (70.3, 93.1)	85.2 (71.4, 92.6)	84.2 (58.7, 94.6)	84.9 (73.7, 91.6)
30 Month	84.0 (62.8, 93.7)	77.0 (60.3, 87.4)	80.5 (65.8, 89.4)	77.7 (50.7, 91.1)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-02-ef-os-grp-age.rtf

Table 14.2.1.1.10.3:
Analysis of Overall Survival by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	4 (10.3)	9 (31.0)	13 (19.1)
Death	4 (10.3)	9 (31.0)	13 (19.1)
Censored, n (%)	35 (89.7)	20 (69.0)	55 (80.9)
Alive	35 (89.7)	20 (69.0)	55 (80.9)
Follow-up Time (months) [a]			
Median (95% CI)	28.78 (27.63, 30.36)	28.62 (27.10, 30.62)	28.68 (27.89, 30.36)
(Min, Max)	(1.6, 32.9)	(3.6, 32.8)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-03-ef-os-grp-ecog.rtf

Table 14.2.1.1.10.3:
Analysis of Overall Survival by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (24.9, NE)	NE (NE, NE)
Q1 (95% CI)	NE (26.5, NE)	19.6 (10.3, NE)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(1.6+ ,32.9+)	(3.6 ,32.8+)	(1.6+ ,32.9+)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-03-ef-os-grp-ecog.rtf

Table 14.2.1.1.10.3:
Analysis of Overall Survival by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	97.4 (82.8, 99.6)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	97.4 (82.8, 99.6)	96.6 (77.9, 99.5)	97.0 (88.6, 99.2)
9 Month	97.4 (82.8, 99.6)	93.1 (75.1, 98.2)	95.5 (86.8, 98.5)
12 Month	97.4 (82.8, 99.6)	89.5 (70.9, 96.5)	94.0 (84.8, 97.7)
15 Month	97.4 (82.8, 99.6)	85.9 (66.7, 94.5)	92.5 (82.9, 96.8)
18 Month	94.7 (80.6, 98.7)	75.2 (54.9, 87.3)	86.4 (75.5, 92.7)
24 Month	94.7 (80.6, 98.7)	71.6 (51.2, 84.7)	84.9 (73.7, 91.6)
30 Month	88.8 (72.8, 95.7)	67.6 (46.9, 81.7)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-03-ef-os-grp-ecog.rtf

Table 14.2.1.1.10.4:
Analysis of Overall Survival by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Overall Survival			
Events, n (%)	9 (18.4)	4 (21.1)	13 (19.1)
Death	9 (18.4)	4 (21.1)	13 (19.1)
Censored, n (%)	40 (81.6)	15 (78.9)	55 (80.9)
Alive	40 (81.6)	15 (78.9)	55 (80.9)
Follow-up Time (months) [a]			
Median (95% CI)	29.50 (27.79, 30.42)	28.52 (26.28, 30.36)	28.68 (27.89, 30.36)
(Min, Max)	(2.8, 32.9)	(1.6, 32.7)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-04-ef-os-grp-pst.rtf

Table 14.2.1.1.10.4:
Analysis of Overall Survival by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
OS (months) [b]			
Median (95% CI)	NE (NE, NE)	NE (26.5, NE)	NE (NE, NE)
Q1 (95% CI)	NE (16.1, NE)	NE (13.8, NE)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(2.8 ,32.9^{+})	(1.6^{+} ,32.7^{+})	(1.6^{+} ,32.9^{+})

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-04-ef-os-grp-pst.rtf

Table 14.2.1.1.10.4:
Analysis of Overall Survival by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	98.0 (86.4, 99.7)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	95.9 (84.7, 99.0)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	93.9 (82.2, 98.0)	100.0 (NE, NE)	95.5 (86.8, 98.5)
12 Month	91.8 (79.7, 96.9)	100.0 (NE, NE)	94.0 (84.8, 97.7)
15 Month	91.8 (79.7, 96.9)	94.1 (65.0, 99.1)	92.5 (82.9, 96.8)
18 Month	87.8 (74.8, 94.3)	82.4 (54.7, 93.9)	86.4 (75.5, 92.7)
24 Month	85.7 (72.3, 92.9)	82.4 (54.7, 93.9)	84.9 (73.7, 91.6)
30 Month	81.0 (66.5, 89.6)	75.5 (46.9, 90.1)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-04-ef-os-grp-pst.rtf

Table 14.2.1.1.10.5:
Analysis of Overall Survival by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Overall Survival					
Events, n (%)	6 (23.1)	5 (19.2)	1 (8.3)	1 (25.0)	13 (19.1)
Death	6 (23.1)	5 (19.2)	1 (8.3)	1 (25.0)	13 (19.1)
Censored, n (%)	20 (76.9)	21 (80.8)	11 (91.7)	3 (75.0)	55 (80.9)
Alive	20 (76.9)	21 (80.8)	11 (91.7)	3 (75.0)	55 (80.9)
Follow-up Time (months) [a]					
Median (95% CI)	30.55 (27.63, 30.82)	28.68 (27.56, 29.80)	27.60 (24.41, 29.11)	28.55 (10.22, 30.59)	28.68 (27.89, 30.36)
(Min, Max)	(1.6, 32.9)	(10.3, 32.7)	(13.8, 32.1)	(3.6, 30.6)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-05-ef-os-grp-mzltype.rtf

Table 14.2.1.1.10.5:
Analysis of Overall Survival by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
OS (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (3.6, NE)	NE (NE, NE)
Q1 (95% CI)	26.5 (2.8, NE)	NE (15.5, NE)	NE (13.8, NE)	NE (3.6, NE)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (3.6, NE)	NE (NE, NE)
Range	(1.6^{+} ,32.9^{+})	(10.3 ,32.7^{+})	(13.8 ,32.1^{+})	(3.6 ,30.6^{+})	(1.6^{+} ,32.9^{+})

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-05-ef-os-grp-mzltype.rtf

Table 14.2.1.1.10.5:
Analysis of Overall Survival by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]					
3 Month	96.0 (74.8, 99.4)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	96.0 (74.8, 99.4)	100.0 (NE, NE)	100.0 (NE, NE)	75.0 (12.8, 96.1)	97.0 (88.6, 99.2)
9 Month	92.0 (71.6, 97.9)	100.0 (NE, NE)	100.0 (NE, NE)	75.0 (12.8, 96.1)	95.5 (86.8, 98.5)
12 Month	92.0 (71.6, 97.9)	96.2 (75.7, 99.4)	100.0 (NE, NE)	75.0 (12.8, 96.1)	94.0 (84.8, 97.7)
15 Month	92.0 (71.6, 97.9)	96.2 (75.7, 99.4)	91.7 (53.9, 98.8)	75.0 (12.8, 96.1)	92.5 (82.9, 96.8)
18 Month	88.0 (67.3, 96.0)	84.6 (64.0, 93.9)	91.7 (53.9, 98.8)	75.0 (12.8, 96.1)	86.4 (75.5, 92.7)
24 Month	88.0 (67.3, 96.0)	80.8 (59.8, 91.5)	91.7 (53.9, 98.8)	75.0 (12.8, 96.1)	84.9 (73.7, 91.6)
30 Month	74.8 (52.2, 87.8)	80.8 (59.8, 91.5)	91.7 (53.9, 98.8)	75.0 (12.8, 96.1)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-05-ef-os-grp-mzltype.rtf

Table 14.2.1.1.10.6:
Analysis of Overall Survival by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Overall Survival				
Events, n (%)	3 (9.1)	5 (17.9)	5 (71.4)	13 (19.1)
Death	3 (9.1)	5 (17.9)	5 (71.4)	13 (19.1)
Censored, n (%)	30 (90.9)	23 (82.1)	2 (28.6)	55 (80.9)
Alive	30 (90.9)	23 (82.1)	2 (28.6)	55 (80.9)
Follow-up Time (months) [a]				
Median (95% CI)	28.55 (27.40, 30.55)	29.67 (27.63, 30.39)	29.21 (27.79, 30.62)	28.68 (27.89, 30.36)
(Min, Max)	(1.6, 32.9)	(13.8, 32.1)	(6.4, 30.6)	(1.6, 32.9)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each geographic region group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-06-ef-os-grp-region.rtf

Table 14.2.1.1.10.6:
Analysis of Overall Survival by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
OS (months) [b]				
Median (95% CI)	NE (NE, NE)	NE (NE, NE)	19.6 (6.4, NE)	NE (NE, NE)
Q1 (95% CI)	NE (16.1, NE)	NE (15.5, NE)	10.3 (6.4, 19.6)	NE (19.6, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (16.0, NE)	NE (NE, NE)
Range	(1.6^{+} ,32.9^{+})	(13.8 ,32.1^{+})	(6.4 ,30.6^{+})	(1.6^{+} ,32.9^{+})

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each geographic region group or total.
OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-06-ef-os-grp-region.rtf

Table 14.2.1.1.10.6:
Analysis of Overall Survival by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]				
3 Month	96.9 (79.8, 99.6)	100.0 (NE, NE)	100.0 (NE, NE)	98.5 (89.9, 99.8)
6 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	100.0 (NE, NE)	97.0 (88.6, 99.2)
9 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	85.7 (33.4, 97.9)	95.5 (86.8, 98.5)
12 Month	93.8 (77.3, 98.4)	100.0 (NE, NE)	71.4 (25.8, 92.0)	94.0 (84.8, 97.7)
15 Month	93.8 (77.3, 98.4)	96.4 (77.2, 99.5)	71.4 (25.8, 92.0)	92.5 (82.9, 96.8)
18 Month	90.5 (73.4, 96.8)	89.1 (70.0, 96.4)	57.1 (17.2, 83.7)	86.4 (75.5, 92.7)
24 Month	90.5 (73.4, 96.8)	89.1 (70.0, 96.4)	42.9 (9.8, 73.4)	84.9 (73.7, 91.6)
30 Month	90.5 (73.4, 96.8)	81.4 (60.9, 91.8)	28.6 (4.1, 61.2)	79.7 (67.5, 87.7)
36 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: OS, overall survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each geographic region group or total.

OS is defined as the time from study treatment start to death due to any cause.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-os-grp.sas 26AUG2022 02:08 t-14-02-01-01-10-06-ef-os-grp-region.rtf

Figure 14.2.1.1.3.1:
Kaplan-Meier Plot of Overall Survival
Safety Analysis Set



Source: ADSL,ADTTE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: CI, confidence interval.
Note: Confidence intervals were calculated using a generalized Brookmeyer and Crowley method.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-ef-km-os.sas 26AUG2022 02:08 f-14-02-01-01-03-01-ef-km-os.rtf

Table 14.2.1.2.10.1:
Analysis of Progression Free Survival by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	11 (30.6)	11 (34.4)	22 (32.4)
Progressive disease	7 (19.4)	11 (34.4)	18 (26.5)
Death	4 (11.1)	0 (0.0)	4 (5.9)
Censored, n (%)	25 (69.4)	21 (65.6)	46 (67.6)
No documented disease progression/death	24 (66.7)	17 (53.1)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	1 (2.8)	2 (6.3)	3 (4.4)
No baseline/post-baseline assessment	0 (0.0)	1 (3.1)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each gender group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-01-ef-pfs-grp-irc-sex.rtf

Table 14.2.1.2.10.1:
Analysis of Progression Free Survival by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Follow-up Time (months) [a]			
Median (95% CI)	27.60 (27.14, 27.63)	23.23 (9.33, 27.43)	27.40 (25.99, 27.60)
(Min, Max)	(0.82, 28.68)	(0.03, 27.73)	(0.03, 28.68)
PFS (months) [b]			
Median (95% CI)	NE (27.4, NE)	NE (16.5, NE)	NE (27.4, NE)
Q1 (95% CI)	22.3 (4.9, NE)	5.6 (2.7, 27.6)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (27.6, NE)	NE (NE, NE)
Range	(0.82 ,28.68^{+})	(0.03^{+} ,27.73^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each gender group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-01-ef-pfs-grp-irc-sex.rtf

Table 14.2.1.2.10.1:
Analysis of Progression Free Survival by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	94.4 (79.57, 98.58)	80.6 (61.91, 90.80)	88.1 (77.54, 93.84)
6 Month	86.0 (69.61, 93.93)	73.6 (53.99, 85.87)	80.3 (68.41, 88.04)
9 Month	86.0 (69.61, 93.93)	73.6 (53.99, 85.87)	80.3 (68.41, 88.04)
12 Month	86.0 (69.61, 93.93)	73.6 (53.99, 85.87)	80.3 (68.41, 88.04)
15 Month	86.0 (69.61, 93.93)	73.6 (53.99, 85.87)	80.3 (68.41, 88.04)
18 Month	76.8 (58.84, 87.69)	63.4 (41.64, 78.91)	70.8 (57.55, 80.63)
24 Month	73.6 (55.28, 85.35)	63.4 (41.64, 78.91)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each gender group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-01-ef-pfs-grp-irc-sex.rtf

Table 14.2.1.2.10.2:
Analysis of Progression Free Survival by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Progression-free Survival					
Events, n (%)	11 (40.7)	11 (26.8)	16 (32.7)	6 (31.6)	22 (32.4)
Progressive disease	9 (33.3)	9 (22.0)	13 (26.5)	5 (26.3)	18 (26.5)
Death	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Censored, n (%)	16 (59.3)	30 (73.2)	33 (67.3)	13 (68.4)	46 (67.6)
No documented disease progression/death	14 (51.9)	27 (65.9)	29 (59.2)	12 (63.2)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	3 (7.3)	2 (4.1)	1 (5.3)	3 (4.4)
No baseline/post-baseline assessment	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each age group or total.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-02-ef-pfs-grp-irc-age.rtf

Table 14.2.1.2.10.2:
Analysis of Progression Free Survival by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Follow-up Time (months) [a]					
Median (95% CI)	27.40 (27.10, 27.73)	27.37 (22.14, 27.60)	27.40 (26.28, 27.63)	27.37 (16.46, 27.60)	27.40 (25.99, 27.60)
(Min, Max)	(0.03, 28.68)	(1.84, 27.73)	(0.03, 28.68)	(2.56, 27.63)	(0.03, 28.68)
PFS (months) [b]					
Median (95% CI)	NE (5.8, NE)	NE (27.4, NE)	NE (22.3, NE)	NE (17.4, NE)	NE (27.4, NE)
Q1 (95% CI)	5.6 (2.7, 27.6)	22.3 (5.4, NE)	15.5 (2.8, NE)	24.9 (2.6, NE)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (27.4, NE)	NE (NE, NE)
Range	(0.03^{+} ,28.68^{+})	(1.84 ,27.73^{+})	(0.03^{+} ,28.68^{+})	(2.56 ,27.63^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each age group or total.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-02-ef-pfs-grp-irc-age.rtf

Table 14.2.1.2.10.2:
Analysis of Progression Free Survival by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]					
3 Month	84.6 (64.04, 93.93)	90.2 (76.06, 96.22)	85.4 (71.83, 92.77)	94.7 (68.12, 99.24)	88.1 (77.54, 93.84)
6 Month	68.8 (47.18, 83.05)	87.7 (72.85, 94.68)	76.7 (61.82, 86.37)	89.2 (63.15, 97.18)	80.3 (68.41, 88.04)
9 Month	68.8 (47.18, 83.05)	87.7 (72.85, 94.68)	76.7 (61.82, 86.37)	89.2 (63.15, 97.18)	80.3 (68.41, 88.04)
12 Month	68.8 (47.18, 83.05)	87.7 (72.85, 94.68)	76.7 (61.82, 86.37)	89.2 (63.15, 97.18)	80.3 (68.41, 88.04)
15 Month	68.8 (47.18, 83.05)	87.7 (72.85, 94.68)	76.7 (61.82, 86.37)	89.2 (63.15, 97.18)	80.3 (68.41, 88.04)
18 Month	60.2 (38.55, 76.35)	77.8 (60.03, 88.37)	68.8 (52.75, 80.30)	75.9 (47.37, 90.32)	70.8 (57.55, 80.63)
24 Month	60.2 (38.55, 76.35)	74.1 (55.52, 85.82)	66.1 (49.90, 78.16)	75.9 (47.37, 90.32)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-02-ef-pfs-grp-irc-age.rtf

Table 14.2.1.2.10.3:
Analysis of Progression Free Survival by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	9 (23.1)	13 (44.8)	22 (32.4)
Progressive disease	9 (23.1)	9 (31.0)	18 (26.5)
Death	0 (0.0)	4 (13.8)	4 (5.9)
Censored, n (%)	30 (76.9)	16 (55.2)	46 (67.6)
No documented disease progression/death	26 (66.7)	15 (51.7)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	2 (5.1)	1 (3.4)	3 (4.4)
No baseline/post-baseline assessment	1 (2.6)	0 (0.0)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-03-ef-pfs-grp-irc-ecog.rtf

Table 14.2.1.2.10.3:
Analysis of Progression Free Survival by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Follow-up Time (months) [a]			
Median (95% CI)	27.40 (25.66, 27.63)	27.37 (23.23, 27.63)	27.40 (25.99, 27.60)
(Min, Max)	(0.03, 28.68)	(2.56, 28.55)	(0.03, 28.68)
PFS (months) [b]			
Median (95% CI)	NE (27.6, NE)	24.9 (16.0, NE)	NE (27.4, NE)
Q1 (95% CI)	27.6 (3.0, NE)	15.5 (2.8, 17.4)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(0.03^{+} ,28.68^{+})	(2.56 ,28.55^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-03-ef-pfs-grp-irc-ecog.rtf

Table 14.2.1.2.10.3:
Analysis of Progression Free Survival by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	89.5 (74.34, 95.91)	86.2 (67.31, 94.59)	88.1 (77.54, 93.84)
6 Month	81.0 (64.13, 90.46)	79.2 (59.36, 90.06)	80.3 (68.41, 88.04)
9 Month	81.0 (64.13, 90.46)	79.2 (59.36, 90.06)	80.3 (68.41, 88.04)
12 Month	81.0 (64.13, 90.46)	79.2 (59.36, 90.06)	80.3 (68.41, 88.04)
15 Month	81.0 (64.13, 90.46)	79.2 (59.36, 90.06)	80.3 (68.41, 88.04)
18 Month	81.0 (64.13, 90.46)	58.3 (37.16, 74.56)	70.8 (57.55, 80.63)
24 Month	81.0 (64.13, 90.46)	53.8 (32.84, 70.87)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each ECOG group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-03-ef-pfs-grp-irc-ecog.rtf

Table 14.2.1.2.10.4:
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Progression-free Survival			
Events, n (%)	14 (28.6)	8 (42.1)	22 (32.4)
Progressive disease	12 (24.5)	6 (31.6)	18 (26.5)
Death	2 (4.1)	2 (10.5)	4 (5.9)
Censored, n (%)	35 (71.4)	11 (57.9)	46 (67.6)
No documented disease progression/death	32 (65.3)	9 (47.4)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	2 (4.1)	1 (5.3)	3 (4.4)
No baseline/post-baseline assessment	0 (0.0)	1 (5.3)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.
[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.
[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-04-ef-pfs-grp-irc-pst.rtf

Table 14.2.1.2.10.4:
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Follow-up Time (months) [a]			
Median (95% CI)	27.40 (25.99, 27.63)	27.43 (8.18, 27.66)	27.40 (25.99, 27.60)
(Min, Max)	(0.82, 28.55)	(0.03, 28.68)	(0.03, 28.68)
PFS (months) [b]			
Median (95% CI)	NE (27.6, NE)	27.4 (15.5, NE)	NE (27.4, NE)
Q1 (95% CI)	22.3 (2.8, NE)	15.5 (2.8, 17.4)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (17.4, NE)	NE (NE, NE)
Range	(0.82 ,28.55^{+})	(0.03^{+} ,28.68^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-04-ef-pfs-grp-irc-pst.rtf

Table 14.2.1.2.10.4:
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]			
3 Month	87.8 (74.76, 94.30)	88.9 (62.42, 97.10)	88.1 (77.54, 93.84)
6 Month	81.3 (67.03, 89.79)	77.4 (50.33, 90.87)	80.3 (68.41, 88.04)
9 Month	81.3 (67.03, 89.79)	77.4 (50.33, 90.87)	80.3 (68.41, 88.04)
12 Month	81.3 (67.03, 89.79)	77.4 (50.33, 90.87)	80.3 (68.41, 88.04)
15 Month	81.3 (67.03, 89.79)	77.4 (50.33, 90.87)	80.3 (68.41, 88.04)
18 Month	76.5 (61.45, 86.27)	51.6 (23.08, 74.17)	70.8 (57.55, 80.63)
24 Month	73.8 (58.36, 84.30)	51.6 (23.08, 74.17)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each prior line of therapy group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-04-ef-pfs-grp-irc-pst.rtf

Table 14.2.1.2.10.5:
Analysis of Progression Free Survival by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Progression-free Survival					
Events, n (%)	8 (30.8)	7 (26.9)	4 (33.3)	3 (75.0)	22 (32.4)
Progressive disease	7 (26.9)	4 (15.4)	4 (33.3)	3 (75.0)	18 (26.5)
Death	1 (3.8)	3 (11.5)	0 (0.0)	0 (0.0)	4 (5.9)
Censored, n (%)	18 (69.2)	19 (73.1)	8 (66.7)	1 (25.0)	46 (67.6)
No documented disease progression/death	15 (57.7)	18 (69.2)	7 (58.3)	1 (25.0)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
No baseline/post-baseline assessment	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile. MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-05-ef-pfs-grp-irc-mzltype.rtf

Table 14.2.1.2.10.5:
Analysis of Progression Free Survival by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Follow-up Time (months) [a]					
Median (95% CI)	27.43 (14.36, 27.63)	27.37 (25.79, 27.56)	27.50 (5.45, 27.70)	28.55 (NE, NE)	27.40 (25.99, 27.60)
(Min, Max)	(0.03, 27.73)	(2.73, 28.68)	(2.96, 27.70)	(2.76, 28.55)	(0.03, 28.68)
PFS (months) [b]					
Median (95% CI)	NE (24.9, NE)	NE (16.5, NE)	NE (5.4, NE)	15.6 (2.8, NE)	NE (27.4, NE)
Q1 (95% CI)	22.3 (0.8, NE)	16.5 (2.8, NE)	5.6 (3.0, NE)	3.2 (2.8, 27.6)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (2.8, NE)	NE (NE, NE)
Range	(0.03^{+} ,27.73^{+})	(2.73 ,28.68^{+})	(2.96 ,27.70^{+})	(2.76 ,28.55^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile. MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-05-ef-pfs-grp-irc-mzltype.rtf

Table 14.2.1.2.10.5:
Analysis of Progression Free Survival by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]					
3 Month	84.0 (62.81, 93.67)	92.3 (72.60, 98.02)	91.7 (53.90, 98.78)	75.0 (12.79, 96.05)	88.1 (77.54, 93.84)
6 Month	80.0 (58.44, 91.15)	88.1 (67.46, 96.01)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	80.3 (68.41, 88.04)
9 Month	80.0 (58.44, 91.15)	88.1 (67.46, 96.01)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	80.3 (68.41, 88.04)
12 Month	80.0 (58.44, 91.15)	88.1 (67.46, 96.01)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	80.3 (68.41, 88.04)
15 Month	80.0 (58.44, 91.15)	88.1 (67.46, 96.01)	74.1 (39.07, 90.86)	50.0 (5.78, 84.49)	80.3 (68.41, 88.04)
18 Month	80.0 (58.44, 91.15)	70.2 (47.27, 84.63)	63.5 (28.87, 84.70)	50.0 (5.78, 84.49)	70.8 (57.55, 80.63)
24 Month	74.3 (50.89, 87.74)	70.2 (47.27, 84.63)	63.5 (28.87, 84.70)	50.0 (5.78, 84.49)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile. MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-05-ef-pfs-grp-irc-mzltype.rtf

Table 14.2.1.2.10.6:
Analysis of Progression Free Survival by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Progression-free Survival				
Events, n (%)	12 (36.4)	7 (25.0)	3 (42.9)	22 (32.4)
Progressive disease	12 (36.4)	4 (14.3)	2 (28.6)	18 (26.5)
Death	0 (0.0)	3 (10.7)	1 (14.3)	4 (5.9)
Censored, n (%)	21 (63.6)	21 (75.0)	4 (57.1)	46 (67.6)
No documented disease progression/death	20 (60.6)	19 (67.9)	2 (28.6)	41 (60.3)
Progressive disease/death after non-protocol anti-cancer therapy	0 (0.0)	1 (3.6)	2 (28.6)	3 (4.4)
No baseline/post-baseline assessment	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.

Percentages are based on N for each geographic region group or total.

PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-06-ef-pfs-grp-irc-region.rtf

Table 14.2.1.2.10.6:
Analysis of Progression Free Survival by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Follow-up Time (months) [a]				
Median (95% CI)	26.28 (16.46, 27.56)	27.60 (27.10, 27.63)	27.56 (5.32, 27.60)	27.40 (25.99, 27.60)
(Min, Max)	(0.03, 28.68)	(4.01, 27.73)	(2.56, 27.60)	(0.03, 28.68)
PFS (months) [b]				
Median (95% CI)	NE (16.5, NE)	NE (24.9, NE)	16.0 (2.6, NE)	NE (27.4, NE)
Q1 (95% CI)	5.2 (2.8, 27.6)	24.9 (5.8, NE)	2.7 (2.6, NE)	16.5 (4.9, 27.6)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (16.0, NE)	NE (NE, NE)
Range	(0.03^{+} ,28.68^{+})	(4.01^{+} ,27.73^{+})	(2.56 ,27.60^{+})	(0.03^{+} ,28.68^{+})

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each geographic region group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-06-ef-pfs-grp-irc-region.rtf

Table 14.2.1.2.10.6:
Analysis of Progression Free Survival by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Event Free Rate at, % (95% CI) [c]				
3 Month	81.3 (62.95, 91.11)	100.0 (NE, NE)	71.4 (25.82, 91.98)	88.1 (77.54, 93.84)
6 Month	71.9 (52.91, 84.26)	92.4 (73.02, 98.06)	71.4 (25.82, 91.98)	80.3 (68.41, 88.04)
9 Month	71.9 (52.91, 84.26)	92.4 (73.02, 98.06)	71.4 (25.82, 91.98)	80.3 (68.41, 88.04)
12 Month	71.9 (52.91, 84.26)	92.4 (73.02, 98.06)	71.4 (25.82, 91.98)	80.3 (68.41, 88.04)
15 Month	71.9 (52.91, 84.26)	92.4 (73.02, 98.06)	71.4 (25.82, 91.98)	80.3 (68.41, 88.04)
18 Month	67.9 (48.32, 81.35)	79.8 (58.04, 91.10)	47.6 (7.51, 80.85)	70.8 (57.55, 80.63)
24 Month	67.9 (48.32, 81.35)	75.4 (53.09, 88.17)	47.6 (7.51, 80.85)	68.8 (55.29, 78.99)
30 Month	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; PFS, progression-free survival; CI, confidence interval; NE, Not Estimable; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
Percentages are based on N for each geographic region group or total.
PFS is defined as the time from study treatment start to PD or death of any cause, whichever occurs first.

[a] Median follow-up time is estimated by the reverse Kaplan-Meier method.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-pfs-grp-irc.sas 26AUG2022 01:58 t-14-02-01-02-10-06-ef-pfs-grp-irc-region.rtf

Figure 14.2.1.2.1.1:
Kaplan-Meier Plot of Progression Free Survival by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set



Source: ADSL,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: CI, confidence interval; IRC, independent review committee.
Note: Confidence intervals were calculated using a generalized Brookmeyer and Crowley method.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-ef-km-pfs-irc.sas 26AUG2022 02:02 f-14-02-01-02-01-01-ef-km-pfs-irc.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	12 (33.3)	5 (15.6)	17 (25.0)
Partial Response	18 (50.0)	10 (31.3)	28 (41.2)
Stable Disease	3 (8.3)	10 (31.3)	13 (19.1)
Non Progressive Disease	1 (2.8)	0 (0.0)	1 (1.5)
Progressive Disease	2 (5.6)	6 (18.8)	8 (11.8)
Discontinued Study Prior to First Assessment	0 (0.0)	1 (3.1)	1 (1.5)
Overall Response Rate, n (%)	30 (83.3)	15 (46.9)	45 (66.2)
(95% CI [a])	(67.19, 93.63)	(29.09, 65.26)	(53.68, 77.21)
Complete Response Rate, n (%)	12 (33.3)	5 (15.6)	17 (25.0)
(95% CI [a])	(18.56, 50.97)	(5.28, 32.79)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each gender group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Time to Response (months)			
n	30	15	45
Mean (SD)	3.45 (1.770)	3.31 (1.150)	3.40 (1.578)
Median	2.81	2.79	2.79
Q1, Q3	2.69, 3.65	2.63, 3.78	2.66, 3.65
Min, Max	1.7, 11.1	2.6, 6.3	1.7, 11.1
Time to Complete Response (months)			
n	12	5	17
Mean (SD)	4.85 (4.162)	3.92 (1.788)	4.57 (3.592)
Median	2.92	2.79	2.86
Q1, Q3	2.81, 4.68	2.56, 5.32	2.79, 5.32
Min, Max	2.7, 16.9	2.6, 6.3	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each gender group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.1:
Analysis of Disease Response by Gender and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	36	32	68
Mean (SD)	25.42 (7.249)	25.52 (8.188)	25.46 (7.646)
Median	28.53	27.76	28.04
Q1, Q3	24.41, 30.41	24.87, 30.57	24.85, 30.49
Min, Max	3.6, 32.1	1.6, 32.9	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each gender group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-01-ef-rsp-grp-irc-sex.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Best Overall Response, n (%)					
Complete Response	7 (25.9)	10 (24.4)	13 (26.5)	4 (21.1)	17 (25.0)
Partial Response	8 (29.6)	20 (48.8)	15 (30.6)	13 (68.4)	28 (41.2)
Stable Disease	6 (22.2)	7 (17.1)	12 (24.5)	1 (5.3)	13 (19.1)
Non Progressive Disease	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Progressive Disease	4 (14.8)	4 (9.8)	7 (14.3)	1 (5.3)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	15 (55.6)	30 (73.2)	28 (57.1)	17 (89.5)	45 (66.2)
(95% CI [a])	(35.33, 74.52)	(57.06, 85.78)	(42.21, 71.18)	(66.86, 98.70)	(53.68, 77.21)
Complete Response Rate, n (%)	7 (25.9)	10 (24.4)	13 (26.5)	4 (21.1)	17 (25.0)
(95% CI [a])	(11.11, 46.28)	(12.36, 40.30)	(14.95, 41.08)	(6.05, 45.57)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each age group or total.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Time to Response (months)					
n	15	30	28	17	45
Mean (SD)	3.32 (1.096)	3.45 (1.786)	3.46 (1.791)	3.31 (1.190)	3.40 (1.578)
Median	2.79	2.79	2.79	2.79	2.79
Q1, Q3	2.73, 3.65	2.66, 3.68	2.71, 3.32	2.66, 3.68	2.66, 3.65
Min, Max	2.6, 6.3	1.7, 11.1	1.8, 11.1	1.7, 5.6	1.7, 11.1
Time to Complete Response (months)					
n	7	10	13	4	17
Mean (SD)	4.47 (2.300)	4.65 (4.404)	4.86 (4.047)	3.65 (1.336)	4.57 (3.592)
Median	2.99	2.86	2.86	3.25	2.86
Q1, Q3	2.79, 6.34	2.73, 3.84	2.79, 5.32	2.69, 4.60	2.79, 5.32
Min, Max	2.6, 8.5	2.6, 16.9	2.6, 16.9	2.6, 5.5	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.2:
Analysis of Disease Response by Age and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Study Follow-up Time (months)					
n	27	41	49	19	68
Mean (SD)	25.56 (7.560)	25.40 (7.796)	25.73 (7.727)	24.78 (7.597)	25.46 (7.646)
Median	28.55	27.79	28.52	27.56	28.04
Q1, Q3	24.41, 30.55	24.90, 30.42	25.79, 30.42	23.95, 30.62	24.85, 30.49
Min, Max	1.6, 32.8	2.8, 32.9	1.6, 32.9	6.4, 32.2	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-02-ef-rsp-grp-irc-age.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	9 (23.1)	8 (27.6)	17 (25.0)
Partial Response	16 (41.0)	12 (41.4)	28 (41.2)
Stable Disease	8 (20.5)	5 (17.2)	13 (19.1)
Non Progressive Disease	1 (2.6)	0 (0.0)	1 (1.5)
Progressive Disease	4 (10.3)	4 (13.8)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (2.6)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	25 (64.1)	20 (69.0)	45 (66.2)
(95% CI [a])	(47.18, 78.80)	(49.17, 84.72)	(53.68, 77.21)
Complete Response Rate, n (%)	9 (23.1)	8 (27.6)	17 (25.0)
(95% CI [a])	(11.13, 39.33)	(12.73, 47.24)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each ECOG group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Time to Response (months)			
n	25	20	45
Mean (SD)	3.50 (1.821)	3.28 (1.244)	3.40 (1.578)
Median	2.79	2.79	2.79
Q1, Q3	2.69, 2.99	2.66, 3.81	2.66, 3.65
Min, Max	2.6, 11.1	1.7, 6.3	1.7, 11.1
Time to Complete Response (months)			
n	9	8	17
Mean (SD)	5.36 (4.742)	3.69 (1.450)	4.57 (3.592)
Median	2.99	2.84	2.86
Q1, Q3	2.73, 5.32	2.79, 4.68	2.79, 5.32
Min, Max	2.6, 16.9	2.6, 6.3	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each ECOG group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.3:
Analysis of Disease Response by ECOG Performance Status and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	39	29	68
Mean (SD)	26.88 (6.828)	23.56 (8.373)	25.46 (7.646)
Median	28.55	27.10	28.04
Q1, Q3	26.55, 30.59	16.53, 30.42	24.85, 30.49
Min, Max	1.6, 32.9	3.6, 32.8	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each ECOG group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-03-ef-rsp-grp-irc-ecog.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Best Overall Response, n (%)			
Complete Response	15 (30.6)	2 (10.5)	17 (25.0)
Partial Response	21 (42.9)	7 (36.8)	28 (41.2)
Stable Disease	6 (12.2)	7 (36.8)	13 (19.1)
Non Progressive Disease	1 (2.0)	0 (0.0)	1 (1.5)
Progressive Disease	6 (12.2)	2 (10.5)	8 (11.8)
Discontinued Study Prior to First Assessment	0 (0.0)	1 (5.3)	1 (1.5)
Overall Response Rate, n (%)	36 (73.5)	9 (47.4)	45 (66.2)
(95% CI [a])	(58.92, 85.05)	(24.45, 71.14)	(53.68, 77.21)
Complete Response Rate, n (%)	15 (30.6)	2 (10.5)	17 (25.0)
(95% CI [a])	(18.25, 45.42)	(1.30, 33.14)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Time to Response (months)			
n	36	9	45
Mean (SD)	3.50 (1.722)	3.03 (0.726)	3.40 (1.578)
Median	2.79	2.83	2.79
Q1, Q3	2.66, 3.38	2.73, 3.65	2.66, 3.65
Min, Max	1.7, 11.1	1.8, 4.3	1.7, 11.1
Time to Complete Response (months)			
n	15	2	17
Mean (SD)	4.75 (3.800)	3.27 (0.581)	4.57 (3.592)
Median	2.86	3.27	2.86
Q1, Q3	2.73, 5.52	2.86, 3.68	2.79, 5.32
Min, Max	2.6, 16.9	2.9, 3.7	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.4:
Analysis of Disease Response by Prior Line of Therapy for MZL and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Study Follow-up Time (months)			
n	49	19	68
Mean (SD)	25.95 (7.341)	24.21 (8.463)	25.46 (7.646)
Median	28.19	27.60	28.04
Q1, Q3	24.87, 30.59	16.53, 28.68	24.85, 30.49
Min, Max	2.8, 32.9	1.6, 32.7	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each prior line of therapy group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-04-ef-rsp-grp-irc-pst.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Best Overall Response, n (%)					
Complete Response	10 (38.5)	5 (19.2)	1 (8.3)	1 (25.0)	17 (25.0)
Partial Response	6 (23.1)	14 (53.8)	7 (58.3)	1 (25.0)	28 (41.2)
Stable Disease	4 (15.4)	5 (19.2)	3 (25.0)	1 (25.0)	13 (19.1)
Non Progressive Disease	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive Disease	4 (15.4)	2 (7.7)	1 (8.3)	1 (25.0)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	16 (61.5)	19 (73.1)	8 (66.7)	2 (50.0)	45 (66.2)
(95% CI [a])	(40.57, 79.77)	(52.21, 88.43)	(34.89, 90.08)	(6.76, 93.24)	(53.68, 77.21)
Complete Response Rate, n (%)	10 (38.5)	5 (19.2)	1 (8.3)	1 (25.0)	17 (25.0)
(95% CI [a])	(20.23, 59.43)	(6.55, 39.35)	(0.21, 38.48)	(0.63, 80.59)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Time to Response (months)					
n	16	19	8	2	45
Mean (SD)	3.00 (0.719)	3.24 (1.104)	4.78 (2.941)	2.69 (0.139)	3.40 (1.578)
Median	2.81	2.79	3.55	2.69	2.79
Q1, Q3	2.68, 2.92	2.66, 3.78	2.73, 5.95	2.60, 2.79	2.66, 3.65
Min, Max	2.6, 5.5	1.7, 5.6	2.7, 11.1	2.6, 2.8	1.7, 11.1
Time to Complete Response (months)					
n	10	5	1	1	17
Mean (SD)	5.12 (4.547)	3.49 (1.137)	6.34 (--)	2.79 (--)	4.57 (3.592)
Median	2.86	2.99	6.34	2.79	2.86
Q1, Q3	2.79, 5.52	2.73, 3.84	6.34, 6.34	2.79, 2.79	2.79, 5.32
Min, Max	2.6, 16.9	2.6, 5.3	6.3, 6.3	2.8, 2.8	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.5:
Analysis of Disease Response by MZL Subtype and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Study Follow-up Time (months)					
n	26	26	12	4	68
Mean (SD)	25.35 (9.088)	26.27 (5.769)	26.39 (4.729)	18.23 (13.392)	25.46 (7.646)
Median	28.35	28.06	27.10	19.38	28.04
Q1, Q3	24.87, 30.72	25.79, 29.80	24.41, 29.06	6.90, 29.57	24.85, 30.49
Min, Max	1.6, 32.9	10.3, 32.7	13.8, 32.1	3.6, 30.6	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.

Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.

For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-05-ef-rsp-grp-irc-mzltype.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Best Overall Response, n (%)				
Complete Response	6 (18.2)	10 (35.7)	1 (14.3)	17 (25.0)
Partial Response	12 (36.4)	13 (46.4)	3 (42.9)	28 (41.2)
Stable Disease	7 (21.2)	5 (17.9)	1 (14.3)	13 (19.1)
Non Progressive Disease	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Progressive Disease	6 (18.2)	0 (0.0)	2 (28.6)	8 (11.8)
Discontinued Study Prior to First Assessment	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Overall Response Rate, n (%)	18 (54.5)	23 (82.1)	4 (57.1)	45 (66.2)
(95% CI [a])	(36.35, 71.89)	(63.11, 93.94)	(18.41, 90.10)	(53.68, 77.21)
Complete Response Rate, n (%)	6 (18.2)	10 (35.7)	1 (14.3)	17 (25.0)
(95% CI [a])	(6.98, 35.46)	(18.64, 55.93)	(0.36, 57.87)	(15.29, 36.98)

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each geographic region group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Time to Response (months)				
n	18	23	4	45
Mean (SD)	2.85 (0.469)	3.88 (1.985)	3.17 (1.639)	3.40 (1.578)
Median	2.78	2.86	2.73	2.79
Q1, Q3	2.63, 2.89	2.73, 5.32	2.18, 4.16	2.66, 3.65
Min, Max	1.8, 3.8	2.6, 11.1	1.7, 5.5	1.7, 11.1
Time to Complete Response (months)				
n	6	10	1	17
Mean (SD)	3.04 (0.572)	5.40 (4.508)	5.52 (--)	4.57 (3.592)
Median	2.79	2.92	5.52	2.86
Q1, Q3	2.56, 3.68	2.83, 6.34	5.52, 5.52	2.79, 5.32
Min, Max	2.6, 3.8	2.7, 16.9	5.5, 5.5	2.6, 16.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each geographic region group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.

[a] 2-sided Clopper-Pearson 95% CI

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.2.7.6:
Analysis of Disease Response by Geographic Region and by IRC based on Lugano Classification (Cheson et al 2014)
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Study Follow-up Time (months)				
n	33	28	7	68
Mean (SD)	25.40 (8.601)	27.06 (5.193)	19.39 (9.061)	25.46 (7.646)
Median	28.19	28.90	19.58	28.04
Q1, Q3	24.90, 30.59	26.58, 30.41	10.28, 27.79	24.85, 30.49
Min, Max	1.6, 32.9	13.8, 32.1	6.4, 30.6	1.6, 32.9

Source: ADSL,ADRSIRC,ADTTEIRC. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: IRC, independent review committee; CI, confidence interval; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Percentages are based on N for each geographic region group or total.
Overall Response Rate is defined as the proportion of patients who achieved at least a best overall response of PR or better.
Time to Response is defined as time from the first dose date to the date of earliest qualifying response (PR or CR). Only responders are included in the analysis.
For 061019-002 patient, modified PET+CT+Clinical response per IRC at Cycle 3 is non-PD due to missing PET scan at that visit but with time point response of SD by CT per IRC.
[a] 2-sided Clopper-Pearson 95% CI
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ef-rsp-grp-irc.sas 26AUG2022 02:05 t-14-02-01-02-07-06-ef-rsp-grp-irc-region.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	35	31	66
Mean (SD)	80.1 (16.42)	71.5 (21.66)	76.1 (19.39)
Median	85.0	80.0	80.0
Q1, Q3	70.0, 95.0	70.0, 85.0	70.0, 90.0
Min, Max	50, 100	0, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	80.6 (13.80)	75.4 (17.86)	78.2 (15.87)
Median	85.0	80.0	80.0
Q1, Q3	75.0, 90.0	67.5, 88.0	70.0, 90.0
Min, Max	50, 98	30, 100	30, 100
Change from Baseline			
n	32	27	59
Mean (SD)	0.7 (19.21)	1.6 (16.49)	1.1 (17.87)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 14.0	-4.0, 5.0	-5.0, 10.0
Min, Max	-45, 40	-40, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	30	21	51
Mean (SD)	79.8 (16.05)	74.8 (22.35)	77.7 (18.85)
Median	82.5	80.0	80.0
Q1, Q3	70.0, 90.0	75.0, 87.0	70.0, 90.0
Min, Max	40, 100	0, 100	0, 100
Change from Baseline			
n	29	21	50
Mean (SD)	0.1 (15.90)	5.1 (15.53)	2.2 (15.78)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 10.0	-5.0, 13.0	-5.0, 10.0
Min, Max	-35, 39	-25, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	18	48
Mean (SD)	77.5 (17.90)	72.8 (21.64)	75.7 (19.30)
Median	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 85.0	65.0, 90.0
Min, Max	20, 100	0, 95	0, 100
Change from Baseline			
n	29	18	47
Mean (SD)	-3.4 (15.53)	5.9 (16.22)	0.2 (16.28)
Median	0.0	0.0	0.0
Q1, Q3	-15.0, 5.0	-3.0, 15.0	-10.0, 10.0
Min, Max	-45, 25	-20, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	80.8 (15.39)	77.3 (22.07)	79.5 (17.99)
Median	90.0	80.0	85.0
Q1, Q3	70.0, 95.0	79.0, 87.5	70.0, 90.0
Min, Max	50, 100	0, 100	0, 100
Change from Baseline			
n	26	16	42
Mean (SD)	-1.2 (13.91)	9.2 (17.88)	2.8 (16.15)
Median	0.0	5.0	0.0
Q1, Q3	-8.0, 10.0	0.0, 12.0	-5.0, 10.0
Min, Max	-45, 20	-15, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	21	13	34
Mean (SD)	83.6 (13.24)	76.6 (25.44)	80.9 (18.80)
Median	90.0	80.0	86.5
Q1, Q3	80.0, 95.0	75.0, 90.0	78.0, 90.0
Min, Max	50, 100	0, 100	0, 100
Change from Baseline			
n	20	13	33
Mean (SD)	3.9 (17.89)	8.3 (17.72)	5.6 (17.68)
Median	3.5	0.0	2.0
Q1, Q3	-2.5, 17.5	0.0, 10.0	0.0, 15.0
Min, Max	-45, 35	-10, 55	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	85.5 (12.15)	74.1 (25.20)	81.4 (18.48)
Median	88.0	80.0	85.0
Q1, Q3	80.0, 95.0	78.0, 85.0	79.0, 95.0
Min, Max	50, 100	0, 100	0, 100
Change from Baseline			
n	22	13	35
Mean (SD)	6.0 (14.90)	5.4 (16.39)	5.8 (15.24)
Median	5.0	0.0	0.0
Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	-20, 38	-15, 45	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	81.1 (17.02)	71.2 (29.56)	78.0 (21.62)
Median	90.0	75.0	83.0
Q1, Q3	70.0, 92.5	70.0, 83.0	70.0, 90.0
Min, Max	40, 98	0, 100	0, 100
Change from Baseline			
n	19	9	28
Mean (SD)	0.4 (18.84)	4.2 (17.37)	1.6 (18.15)
Median	2.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-5.0, 0.0	-5.0, 10.0
Min, Max	-40, 48	-10, 45	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	5	11	16
Mean (SD)	47.4 (26.90)	73.6 (10.74)	65.4 (20.68)
Median	52.0	75.0	70.0
Q1, Q3	40.0, 70.0	70.0, 80.0	58.5, 77.5
Min, Max	5, 70	50, 90	5, 90
Change from Baseline			
n	5	10	15
Mean (SD)	-33.6 (32.48)	-3.0 (13.17)	-13.2 (25.21)
Median	-20.0	-5.0	-5.0
Q1, Q3	-30.0, -20.0	-5.0, 5.0	-20.0, 0.0
Min, Max	-90, -8	-25, 20	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	80.0 (-)	- (-)	80.0 (-)
Median	80.0	-	80.0
Q1, Q3	80.0, 80.0	-, -	80.0, 80.0
Min, Max	80, 80	-, -	80, 80
Change from Baseline			
n	1	0	1
Mean (SD)	20.0 (-)	- (-)	20.0 (-)
Median	20.0	-	20.0
Q1, Q3	20.0, 20.0	-, -	20.0, 20.0
Min, Max	20, 20	-, -	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	90.0 (-)	- (-)	90.0 (-)
Median	90.0	-	90.0
Q1, Q3	90.0, 90.0	-, -	90.0, 90.0
Min, Max	90, 90	-, -	90, 90
Change from Baseline			
n	1	0	1
Mean (SD)	30.0 (-)	- (-)	30.0 (-)
Median	30.0	-	30.0
Q1, Q3	30.0, 30.0	-, -	30.0, 30.0
Min, Max	30, 30	-, -	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36)	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	60.0 (-)	- (-)	60.0 (-)
Median	60.0	-	60.0
Q1, Q3	60.0, 60.0	-, -	60.0, 60.0
Min, Max	60, 60	-, -	60, 60
Change from Baseline			
n	1	0	1
Mean (SD)	0.0 (-)	- (-)	0.0 (-)
Median	0.0	-	0.0
Q1, Q3	0.0, 0.0	-, -	0.0, 0.0
Min, Max	0, 0	-, -	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-01-eq5d-vas-sex.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
EQ-5D-5L					
EQ VAS Score					
Baseline					
n	26	40	47	19	66
Mean (SD)	77.6 (22.30)	75.1 (17.47)	77.4 (18.54)	72.8 (21.51)	76.1 (19.39)
Median	81.5	80.0	80.0	80.0	80.0
Q1, Q3	70.0, 95.0	70.0, 87.5	70.0, 90.0	50.0, 90.0	70.0, 90.0
Min, Max	0, 100	30, 100	0, 100	30, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	76.8 (18.01)	79.0 (14.62)	79.0 (15.68)	76.3 (16.63)	78.2 (15.87)
Median	80.0	80.0	80.0	80.0	80.0
Q1, Q3	60.0, 90.0	70.0, 90.0	70.0, 90.0	65.0, 90.0	70.0, 90.0
Min, Max	30, 96	45, 100	30, 100	45, 98	30, 100
Change from Baseline					
n	22	37	41	18	59
Mean (SD)	-2.1 (21.76)	3.0 (15.12)	0.8 (17.58)	1.7 (19.03)	1.1 (17.87)
Median	0.0	5.0	0.0	0.0	0.0
Q1, Q3	-10.0, 1.0	-5.0, 10.0	-5.0, 10.0	-10.0, 13.0	-5.0, 10.0
Min, Max	-45, 40	-35, 40	-45, 40	-35, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	74.1 (22.26)	80.1 (16.25)	77.6 (19.81)	78.1 (16.96)	77.7 (18.85)
Median	80.0	80.0	82.5	80.0	80.0
Q1, Q3	68.0, 87.5	75.0, 93.0	72.5, 90.0	65.0, 93.0	70.0, 90.0
Min, Max	0, 95	40, 100	0, 100	45, 100	0, 100
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	-2.4 (14.09)	5.2 (16.34)	1.0 (14.94)	5.1 (17.81)	2.2 (15.78)
Median	0.0	4.0	0.0	3.0	0.0
Q1, Q3	-12.5, 2.5	-5.0, 13.0	-10.0, 10.0	-5.0, 13.0	-5.0, 10.0
Min, Max	-25, 30	-35, 40	-25, 39	-35, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	18	30	33	15	48
Mean (SD)	74.4 (21.69)	76.5 (18.06)	76.4 (18.89)	74.3 (20.78)	75.7 (19.30)
Median	80.0	80.0	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0	65.0, 90.0	65.0, 90.0
Min, Max	0, 95	20, 100	0, 95	20, 100	0, 100
Change from Baseline					
n	18	29	32	15	47
Mean (SD)	-1.0 (14.88)	0.9 (17.30)	0.1 (14.18)	0.5 (20.63)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0	0.0
Q1, Q3	-15.0, 10.0	-5.0, 10.0	-12.5, 10.0	-5.0, 10.0	-10.0, 10.0
Min, Max	-25, 30	-45, 40	-25, 30	-45, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	78.1 (23.23)	80.3 (14.47)	80.0 (19.46)	78.5 (15.11)	79.5 (17.99)
Median	85.0	80.0	85.0	79.0	85.0
Q1, Q3	80.0, 90.0	70.0, 94.0	80.0, 90.0	70.0, 94.0	70.0, 90.0
Min, Max	0, 95	50, 100	0, 100	50, 100	0, 100
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	2.2 (9.99)	3.1 (19.17)	2.7 (10.93)	2.9 (23.98)	2.8 (16.15)
Median	0.0	0.0	0.0	-1.5	0.0
Q1, Q3	-2.5, 5.0	-8.0, 10.0	-2.5, 10.0	-10.0, 14.0	-5.0, 10.0
Min, Max	-15, 30	-45, 50	-20, 30	-45, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	23	22	12	34
Mean (SD)	73.5 (26.42)	84.5 (13.10)	80.6 (20.84)	81.5 (15.19)	80.9 (18.80)
Median	80.0	90.0	85.0	86.5	86.5
Q1, Q3	70.0, 90.0	80.0, 95.0	78.0, 95.0	77.5, 90.0	78.0, 90.0
Min, Max	0, 95	50, 100	0, 100	50, 100	0, 100
Change from Baseline					
n	11	22	21	12	33
Mean (SD)	2.7 (15.71)	7.0 (18.77)	6.2 (13.41)	4.6 (24.10)	5.6 (17.68)
Median	0.0	5.0	0.0	3.5	2.0
Q1, Q3	-10.0, 10.0	0.0, 20.0	0.0, 20.0	-5.0, 9.0	0.0, 15.0
Min, Max	-20, 30	-45, 55	-20, 30	-45, 55	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	79.1 (24.06)	83.0 (13.62)	79.4 (20.93)	85.7 (10.67)	81.4 (18.48)
Median	85.0	80.0	85.0	80.0	85.0
Q1, Q3	80.0, 90.0	75.0, 95.0	78.0, 90.0	80.0, 98.0	79.0, 95.0
Min, Max	0, 95	50, 100	0, 100	70, 100	0, 100
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	3.5 (15.08)	7.5 (15.52)	4.3 (13.40)	9.1 (18.95)	5.8 (15.24)
Median	0.0	5.0	0.0	5.0	0.0
Q1, Q3	-5.0, 10.0	0.0, 12.5	-2.5, 10.0	0.0, 30.0	0.0, 10.0
Min, Max	-20, 38	-20, 45	-20, 38	-20, 45	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	76.1 (26.55)	79.6 (17.41)	78.0 (22.88)	77.9 (18.68)	78.0 (21.62)
Median	83.0	85.0	86.5	80.0	83.0
Q1, Q3	70.0, 95.0	70.0, 90.0	70.0, 95.0	70.0, 90.0	70.0, 90.0
Min, Max	0, 98	40, 100	0, 100	40, 95	0, 100
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-0.3 (20.47)	3.3 (16.41)	0.9 (16.54)	3.9 (23.72)	1.6 (18.15)
Median	0.0	3.0	0.0	2.0	0.0
Q1, Q3	-5.0, 0.0	-5.0, 10.0	-5.0, 10.0	-10.0, 20.0	-5.0, 10.0
Min, Max	-40, 48	-30, 45	-40, 48	-30, 45	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	6	10	12	4	16
Mean (SD)	62.5 (28.77)	67.2 (15.62)	63.5 (20.93)	71.3 (21.75)	65.4 (20.68)
Median	70.0	70.0	70.0	77.5	70.0
Q1, Q3	70.0, 75.0	52.0, 80.0	58.5, 72.5	57.5, 85.0	58.5, 77.5
Min, Max	5, 85	40, 90	5, 85	40, 90	5, 90
Change from Baseline					
n	5	10	11	4	15
Mean (SD)	-24.0 (40.84)	-7.8 (12.27)	-15.3 (28.10)	-7.5 (16.58)	-13.2 (25.21)
Median	-20.0	-5.0	-8.0	-5.0	-5.0
Q1, Q3	-25.0, -5.0	-20.0, 0.0	-20.0, 0.0	-17.5, 2.5	-20.0, 0.0
Min, Max	-90, 20	-30, 10	-90, 20	-30, 10	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	40, 40	-, -	40, 40
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	40, 40	-, -	40, 40
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	80.0 (-)	80.0 (-)	- (-)	80.0 (-)
Median	-	80.0	80.0	-	80.0
Q1, Q3	-, -	80.0, 80.0	80.0, 80.0	-, -	80.0, 80.0
Min, Max	-, -	80, 80	80, 80	-, -	80, 80
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	20.0 (-)	20.0 (-)	- (-)	20.0 (-)
Median	-	20.0	20.0	-	20.0
Q1, Q3	-, -	20.0, 20.0	20.0, 20.0	-, -	20.0, 20.0
Min, Max	-, -	20, 20	20, 20	-, -	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	90.0 (-)	90.0 (-)	- (-)	90.0 (-)
Median	-	90.0	90.0	-	90.0
Q1, Q3	-, -	90.0, 90.0	90.0, 90.0	-, -	90.0, 90.0
Min, Max	-, -	90, 90	90, 90	-, -	90, 90
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	30.0 (-)	30.0 (-)	- (-)	30.0 (-)
Median	-	30.0	30.0	-	30.0
Q1, Q3	-, -	30.0, 30.0	30.0, 30.0	-, -	30.0, 30.0
Min, Max	-, -	30, 30	30, 30	-, -	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27)	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	60.0 (-)	60.0 (-)	- (-)	60.0 (-)
Median	-	60.0	60.0	-	60.0
Q1, Q3	-, -	60.0, 60.0	60.0, 60.0	-, -	60.0, 60.0
Min, Max	-, -	60, 60	60, 60	-, -	60, 60
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.0 (-)	0.0 (-)	- (-)	0.0 (-)
Median	-	0.0	0.0	-	0.0
Q1, Q3	-, -	0.0, 0.0	0.0, 0.0	-, -	0.0, 0.0
Min, Max	-, -	0, 0	0, 0	-, -	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-02-eq5d-vas-age.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	39	27	66
Mean (SD)	81.8 (13.98)	67.8 (23.09)	76.1 (19.39)
Median	83.0	75.0	80.0
Q1, Q3	70.0, 95.0	50.0, 85.0	70.0, 90.0
Min, Max	50, 100	0, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	81.3 (15.93)	74.0 (15.10)	78.2 (15.87)
Median	85.0	77.5	80.0
Q1, Q3	75.0, 95.0	65.0, 85.0	70.0, 90.0
Min, Max	30, 100	45, 95	30, 100
Change from Baseline			
n	35	24	59
Mean (SD)	-0.3 (17.33)	3.1 (18.81)	1.1 (17.87)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-7.5, 12.5	-5.0, 10.0
Min, Max	-45, 40	-35, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	28	23	51
Mean (SD)	84.8 (12.27)	69.0 (21.91)	77.7 (18.85)
Median	85.0	75.0	80.0
Q1, Q3	80.0, 91.5	60.0, 85.0	70.0, 90.0
Min, Max	45, 100	0, 95	0, 100
Change from Baseline			
n	28	22	50
Mean (SD)	2.9 (13.77)	1.3 (18.33)	2.2 (15.78)
Median	1.5	0.0	0.0
Q1, Q3	-5.0, 10.0	-10.0, 5.0	-5.0, 10.0
Min, Max	-25, 39	-35, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	21	48
Mean (SD)	79.6 (17.54)	70.7 (20.69)	75.7 (19.30)
Median	80.0	75.0	80.0
Q1, Q3	70.0, 90.0	60.0, 80.0	65.0, 90.0
Min, Max	20, 100	0, 95	0, 100
Change from Baseline			
n	27	20	47
Mean (SD)	-2.1 (12.41)	3.3 (20.34)	0.2 (16.28)
Median	0.0	0.0	0.0
Q1, Q3	-10.0, 5.0	-7.5, 17.5	-10.0, 10.0
Min, Max	-30, 20	-45, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	83.6 (12.69)	73.8 (22.63)	79.5 (17.99)
Median	90.0	80.0	85.0
Q1, Q3	70.0, 95.0	70.0, 90.0	70.0, 90.0
Min, Max	60, 100	0, 95	0, 100
Change from Baseline			
n	25	17	42
Mean (SD)	1.1 (9.49)	5.2 (22.87)	2.8 (16.15)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-5.0, 20.0	-5.0, 10.0
Min, Max	-20, 20	-45, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	22	12	34
Mean (SD)	86.6 (9.88)	70.4 (26.24)	80.9 (18.80)
Median	90.0	77.5	86.5
Q1, Q3	80.0, 95.0	62.5, 90.0	78.0, 90.0
Min, Max	60, 100	0, 95	0, 100
Change from Baseline			
n	22	11	33
Mean (SD)	5.5 (13.39)	5.9 (24.98)	5.6 (17.68)
Median	1.0	5.0	2.0
Q1, Q3	0.0, 15.0	-5.0, 20.0	0.0, 15.0
Min, Max	-20, 35	-45, 55	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	84.7 (12.72)	76.1 (24.67)	81.4 (18.48)
Median	86.5	82.5	85.0
Q1, Q3	78.0, 95.0	80.0, 90.0	79.0, 95.0
Min, Max	55, 100	0, 95	0, 100
Change from Baseline			
n	22	13	35
Mean (SD)	3.5 (12.94)	9.6 (18.42)	5.8 (15.24)
Median	2.5	0.0	0.0
Q1, Q3	-5.0, 10.0	0.0, 25.0	0.0, 10.0
Min, Max	-20, 38	-20, 45	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	81.6 (16.09)	68.5 (31.43)	78.0 (21.62)
Median	90.0	77.5	83.0
Q1, Q3	70.0, 90.0	60.0, 87.5	70.0, 90.0
Min, Max	40, 100	0, 98	0, 100
Change from Baseline			
n	21	7	28
Mean (SD)	-0.8 (17.33)	9.0 (19.92)	1.6 (18.15)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 5.0	-10.0, 20.0	-5.0, 10.0
Min, Max	-40, 48	-10, 45	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	8	8	16
Mean (SD)	61.3 (28.38)	69.6 (8.43)	65.4 (20.68)
Median	70.0	70.0	70.0
Q1, Q3	45.0, 82.5	67.5, 75.0	58.5, 77.5
Min, Max	5, 90	52, 80	5, 90
Change from Baseline			
n	8	7	15
Mean (SD)	-23.1 (29.99)	-1.9 (12.35)	-13.2 (25.21)
Median	-20.0	-5.0	-5.0
Q1, Q3	-27.5, -5.0	-8.0, 5.0	-20.0, 0.0
Min, Max	-90, 10	-20, 20	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)
Median	-	40.0	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0
Min, Max	-, -	40, 40	40, 40
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)
Median	-	-20.0	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	40.0 (-)	40.0 (-)
Median	-	40.0	40.0
Q1, Q3	-, -	40.0, 40.0	40.0, 40.0
Min, Max	-, -	40, 40	40, 40
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-20.0 (-)	-20.0 (-)
Median	-	-20.0	-20.0
Q1, Q3	-, -	-20.0, -20.0	-20.0, -20.0
Min, Max	-, -	-20, -20	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	80.0 (-)	80.0 (-)
Median	-	80.0	80.0
Q1, Q3	-, -	80.0, 80.0	80.0, 80.0
Min, Max	-, -	80, 80	80, 80
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	20.0 (-)	20.0 (-)
Median	-	20.0	20.0
Q1, Q3	-, -	20.0, 20.0	20.0, 20.0
Min, Max	-, -	20, 20	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	90.0 (-)	90.0 (-)
Median	-	90.0	90.0
Q1, Q3	-, -	90.0, 90.0	90.0, 90.0
Min, Max	-, -	90, 90	90, 90
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	30.0 (-)	30.0 (-)
Median	-	30.0	30.0
Q1, Q3	-, -	30.0, 30.0	30.0, 30.0
Min, Max	-, -	30, 30	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39)	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	60.0 (-)	60.0 (-)
Median	-	60.0	60.0
Q1, Q3	-, -	60.0, 60.0	60.0, 60.0
Min, Max	-, -	60, 60	60, 60
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.0 (-)	0.0 (-)
Median	-	0.0	0.0
Q1, Q3	-, -	0.0, 0.0	0.0, 0.0
Min, Max	-, -	0, 0	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-03-eq5d-vas-ecog.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
EQ-5D-5L			
EQ VAS Score			
Baseline			
n	48	18	66
Mean (SD)	76.7 (19.28)	74.4 (20.14)	76.1 (19.39)
Median	80.0	80.0	80.0
Q1, Q3	70.0, 91.5	60.0, 90.0	70.0, 90.0
Min, Max	0, 100	30, 100	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	78.4 (16.25)	77.7 (15.39)	78.2 (15.87)
Median	80.0	77.5	80.0
Q1, Q3	70.0, 90.0	65.0, 90.0	70.0, 90.0
Min, Max	30, 100	45, 100	30, 100
Change from Baseline			
n	42	17	59
Mean (SD)	-0.1 (17.63)	4.0 (18.66)	1.1 (17.87)
Median	0.0	5.0	0.0
Q1, Q3	-8.0, 10.0	0.0, 10.0	-5.0, 10.0
Min, Max	-45, 40	-40, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	37	14	51
Mean (SD)	79.2 (19.79)	73.8 (16.13)	77.7 (18.85)
Median	85.0	72.5	80.0
Q1, Q3	75.0, 90.0	65.0, 85.0	70.0, 90.0
Min, Max	0, 100	40, 100	0, 100
Change from Baseline			
n	37	13	50
Mean (SD)	1.5 (11.88)	4.1 (24.26)	2.2 (15.78)
Median	0.0	0.0	0.0
Q1, Q3	-5.0, 10.0	-15.0, 30.0	-5.0, 10.0
Min, Max	-35, 25	-24, 40	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	35	13	48
Mean (SD)	78.1 (21.53)	69.2 (9.09)	75.7 (19.30)
Median	80.0	70.0	80.0
Q1, Q3	75.0, 90.0	60.0, 75.0	65.0, 90.0
Min, Max	0, 100	60, 90	0, 100
Change from Baseline			
n	35	12	47
Mean (SD)	0.5 (14.69)	-0.8 (20.98)	0.2 (16.28)
Median	0.0	-7.5	0.0
Q1, Q3	-5.0, 10.0	-15.0, 12.5	-10.0, 10.0
Min, Max	-45, 30	-25, 40	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	81.2 (18.79)	73.8 (14.41)	79.5 (17.99)
Median	85.0	74.0	85.0
Q1, Q3	80.0, 90.0	60.0, 85.0	70.0, 90.0
Min, Max	0, 100	50, 95	0, 100
Change from Baseline			
n	33	9	42
Mean (SD)	2.1 (12.93)	5.3 (25.66)	2.8 (16.15)
Median	0.0	-5.0	0.0
Q1, Q3	-3.0, 10.0	-15.0, 10.0	-5.0, 10.0
Min, Max	-45, 30	-20, 50	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	28	6	34
Mean (SD)	80.8 (20.53)	81.7 (7.53)	80.9 (18.80)
Median	89.0	80.0	86.5
Q1, Q3	76.5, 95.0	80.0, 90.0	78.0, 90.0
Min, Max	0, 100	70, 90	0, 100
Change from Baseline			
n	28	5	33
Mean (SD)	3.4 (14.87)	18.0 (27.97)	5.6 (17.68)
Median	0.0	20.0	2.0
Q1, Q3	-2.5, 10.0	5.0, 30.0	0.0, 15.0
Min, Max	-45, 35	-20, 55	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	82.2 (19.10)	77.2 (15.75)	81.4 (18.48)
Median	85.0	80.0	85.0
Q1, Q3	80.0, 95.0	70.0, 88.0	79.0, 95.0
Min, Max	0, 100	50, 95	0, 100
Change from Baseline			
n	30	5	35
Mean (SD)	4.0 (12.48)	16.6 (25.94)	5.8 (15.24)
Median	0.0	10.0	0.0
Q1, Q3	0.0, 10.0	10.0, 38.0	0.0, 10.0
Min, Max	-20, 30	-20, 45	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	78.9 (22.72)	74.7 (18.18)	78.0 (21.62)
Median	90.0	75.0	83.0
Q1, Q3	70.0, 95.0	60.0, 90.0	70.0, 90.0
Min, Max	0, 100	50, 98	0, 100
Change from Baseline			
n	23	5	28
Mean (SD)	-1.0 (11.46)	13.6 (35.81)	1.6 (18.15)
Median	0.0	10.0	0.0
Q1, Q3	-5.0, 5.0	5.0, 45.0	-5.0, 10.0
Min, Max	-30, 20	-40, 48	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	5	16
Mean (SD)	65.6 (24.73)	65.0 (8.66)	65.4 (20.68)
Median	75.0	70.0	70.0
Q1, Q3	52.0, 80.0	65.0, 70.0	58.5, 77.5
Min, Max	5, 90	50, 70	5, 90
Change from Baseline			
n	10	5	15
Mean (SD)	-11.8 (30.32)	-16.0 (11.94)	-13.2 (25.21)
Median	-5.0	-20.0	-5.0
Q1, Q3	-8.0, 0.0	-20.0, -20.0	-20.0, 0.0
Min, Max	-90, 20	-25, 5	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	40.0 (-)	- (-)	40.0 (-)
Median	40.0	-	40.0
Q1, Q3	40.0, 40.0	-, -	40.0, 40.0
Min, Max	40, 40	-, -	40, 40
Change from Baseline			
n	1	0	1
Mean (SD)	-20.0 (-)	- (-)	-20.0 (-)
Median	-20.0	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	80.0 (-)	- (-)	80.0 (-)
Median	80.0	-	80.0
Q1, Q3	80.0, 80.0	-, -	80.0, 80.0
Min, Max	80, 80	-, -	80, 80
Change from Baseline			
n	1	0	1
Mean (SD)	20.0 (-)	- (-)	20.0 (-)
Median	20.0	-	20.0
Q1, Q3	20.0, 20.0	-, -	20.0, 20.0
Min, Max	20, 20	-, -	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	90.0 (-)	- (-)	90.0 (-)
Median	90.0	-	90.0
Q1, Q3	90.0, 90.0	-, -	90.0, 90.0
Min, Max	90, 90	-, -	90, 90
Change from Baseline			
n	1	0	1
Mean (SD)	30.0 (-)	- (-)	30.0 (-)
Median	30.0	-	30.0
Q1, Q3	30.0, 30.0	-, -	30.0, 30.0
Min, Max	30, 30	-, -	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49)	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	60.0 (-)	- (-)	60.0 (-)
Median	60.0	-	60.0
Q1, Q3	60.0, 60.0	-, -	60.0, 60.0
Min, Max	60, 60	-, -	60, 60
Change from Baseline			
n	1	0	1
Mean (SD)	0.0 (-)	- (-)	0.0 (-)
Median	0.0	-	0.0
Q1, Q3	0.0, 0.0	-, -	0.0, 0.0
Min, Max	0, 0	-, -	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-04-eq5d-vas-pst.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
EQ-5D-5L					
EQ VAS Score					
Baseline					
n	26	24	12	4	66
Mean (SD)	75.4 (18.76)	82.8 (12.76)	63.8 (26.89)	77.5 (18.48)	76.1 (19.39)
Median	80.0	81.5	72.5	80.0	80.0
Q1, Q3	60.0, 90.0	77.5, 94.0	50.0, 80.0	62.5, 92.5	70.0, 90.0
Min, Max	35, 100	50, 100	0, 90	55, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	80.4 (13.79)	77.8 (16.65)	77.4 (13.91)	71.3 (28.39)	78.2 (15.87)
Median	80.0	85.0	80.0	82.5	80.0
Q1, Q3	75.0, 90.0	60.0, 90.0	70.0, 86.0	52.5, 90.0	70.0, 90.0
Min, Max	50, 100	50, 95	45, 100	30, 90	30, 100
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	4.0 (15.55)	-3.5 (20.22)	7.8 (12.02)	-6.3 (24.96)	1.1 (17.87)
Median	0.0	0.0	5.0	-2.5	0.0
Q1, Q3	-5.0, 5.0	-15.0, 10.0	0.0, 15.0	-22.5, 10.0	-5.0, 10.0
Min, Max	-15, 40	-45, 40	-10, 30	-40, 20	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	83.0 (12.16)	78.8 (16.37)	67.2 (29.49)	70.0 (25.00)	77.7 (18.85)
Median	85.0	80.0	75.0	70.0	80.0
Q1, Q3	75.0, 90.0	75.0, 90.0	60.0, 85.0	45.0, 95.0	70.0, 90.0
Min, Max	50, 100	40, 100	0, 100	45, 95	0, 100
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	5.8 (17.14)	-0.2 (15.05)	6.1 (12.19)	-15.0 (13.23)	2.2 (15.78)
Median	0.0	0.0	5.0	-20.0	0.0
Q1, Q3	-10.0, 17.0	-5.0, 7.5	0.0, 10.0	-25.0, 0.0	-5.0, 10.0
Min, Max	-20, 40	-35, 30	-5, 35	-25, 0	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	20	7	3	48
Mean (SD)	76.7 (14.04)	80.0 (14.23)	57.9 (34.86)	83.3 (10.41)	75.7 (19.30)
Median	80.0	80.0	70.0	80.0	80.0
Q1, Q3	65.0, 90.0	65.0, 92.5	20.0, 80.0	75.0, 95.0	65.0, 90.0
Min, Max	50, 95	60, 100	0, 95	75, 95	0, 100
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	-0.6 (18.30)	-0.6 (13.62)	5.0 (21.02)	-1.7 (12.58)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0	0.0
Q1, Q3	-10.0, 10.0	-5.0, 10.0	0.0, 15.0	-15.0, 10.0	-10.0, 10.0
Min, Max	-45, 30	-25, 25	-30, 40	-15, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	80.0 (13.73)	82.8 (14.32)	65.0 (32.71)	87.5 (10.61)	79.5 (17.99)
Median	80.0	90.0	75.0	87.5	85.0
Q1, Q3	70.0, 92.5	80.0, 90.0	70.0, 80.0	80.0, 95.0	70.0, 90.0
Min, Max	50, 100	50, 100	0, 90	80, 95	0, 100
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	0.0 (20.06)	2.0 (10.02)	11.7 (21.37)	5.0 (7.07)	2.8 (16.15)
Median	0.0	0.0	5.0	5.0	0.0
Q1, Q3	-11.5, 10.0	-5.0, 10.0	0.0, 20.0	0.0, 10.0	-5.0, 10.0
Min, Max	-45, 43	-15, 20	-10, 50	0, 10	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	6	1	34
Mean (SD)	84.2 (13.62)	86.1 (9.22)	65.0 (34.50)	60.0 (-)	80.9 (18.80)
Median	90.0	90.0	77.5	60.0	86.5
Q1, Q3	80.0, 92.5	80.0, 95.0	55.0, 85.0	60.0, 60.0	78.0, 90.0
Min, Max	50, 100	70, 100	0, 95	60, 60	0, 100
Change from Baseline					
n	12	14	6	1	33
Mean (SD)	7.9 (24.35)	3.6 (12.37)	8.3 (14.72)	-10.0 (-)	5.6 (17.68)
Median	2.5	3.5	2.5	-10.0	2.0
Q1, Q3	0.0, 20.0	-5.0, 10.0	0.0, 15.0	-10.0, -10.0	0.0, 15.0
Min, Max	-45, 55	-20, 30	-5, 35	-10, -10	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	83.2 (11.54)	86.0 (13.27)	68.3 (33.71)	75.0 (28.28)	81.4 (18.48)
Median	85.0	89.0	80.0	75.0	85.0
Q1, Q3	75.0, 95.0	80.0, 95.0	80.0, 80.0	55.0, 95.0	79.0, 95.0
Min, Max	60, 100	50, 100	0, 90	55, 95	0, 100
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	5.0 (16.76)	6.0 (14.36)	11.7 (14.72)	-7.5 (10.61)	5.8 (15.24)
Median	0.0	5.0	5.0	-7.5	0.0
Q1, Q3	-5.0, 10.0	0.0, 10.0	0.0, 30.0	-15.0, 0.0	0.0, 10.0
Min, Max	-20, 45	-20, 38	0, 30	-15, 0	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	83.0 (12.04)	79.1 (20.66)	58.8 (40.08)	82.5 (17.68)	78.0 (21.62)
Median	80.0	90.0	72.5	82.5	83.0
Q1, Q3	75.0, 90.0	60.0, 95.0	35.0, 82.5	70.0, 95.0	70.0, 90.0
Min, Max	60, 100	40, 98	0, 90	70, 95	0, 100
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	3.0 (15.84)	-1.1 (24.12)	6.3 (11.09)	0.0 (0.00)	1.6 (18.15)
Median	0.0	0.0	5.0	0.0	0.0
Q1, Q3	-10.0, 10.0	-20.0, 15.0	-2.5, 15.0	0.0, 0.0	-5.0, 10.0
Min, Max	-10, 45	-40, 48	-5, 20	0, 0	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	6	2	1	16
Mean (SD)	60.3 (25.86)	70.0 (17.03)	67.5 (24.75)	70.0 (-)	65.4 (20.68)
Median	70.0	72.5	67.5	70.0	70.0
Q1, Q3	52.0, 75.0	65.0, 80.0	50.0, 85.0	70.0, 70.0	58.5, 77.5
Min, Max	5, 80	40, 90	50, 85	70, 70	5, 90
Change from Baseline					
n	7	5	2	1	15
Mean (SD)	-15.4 (34.99)	-9.0 (17.82)	-12.5 (10.61)	-20.0 (-)	-13.2 (25.21)
Median	-5.0	-5.0	-12.5	-20.0	-5.0
Q1, Q3	-20.0, 0.0	-25.0, 5.0	-20.0, -5.0	-20.0, -20.0	-20.0, 0.0
Min, Max	-90, 20	-30, 10	-20, -5	-20, -20	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	40.0 (-)	- (-)	- (-)	- (-)	40.0 (-)
Median	40.0	-	-	-	40.0
Q1, Q3	40.0, 40.0	-, -	-, -	-, -	40.0, 40.0
Min, Max	40, 40	-, -	-, -	-, -	40, 40
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-20.0 (-)	- (-)	- (-)	- (-)	-20.0 (-)
Median	-20.0	-	-	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-, -	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-, -	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	40.0 (-)	- (-)	- (-)	- (-)	40.0 (-)
Median	40.0	-	-	-	40.0
Q1, Q3	40.0, 40.0	-, -	-, -	-, -	40.0, 40.0
Min, Max	40, 40	-, -	-, -	-, -	40, 40
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-20.0 (-)	- (-)	- (-)	- (-)	-20.0 (-)
Median	-20.0	-	-	-	-20.0
Q1, Q3	-20.0, -20.0	-, -	-, -	-, -	-20.0, -20.0
Min, Max	-20, -20	-, -	-, -	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	80.0 (-)	- (-)	- (-)	- (-)	80.0 (-)
Median	80.0	-	-	-	80.0
Q1, Q3	80.0, 80.0	-, -	-, -	-, -	80.0, 80.0
Min, Max	80, 80	-, -	-, -	-, -	80, 80
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	20.0 (-)	- (-)	- (-)	- (-)	20.0 (-)
Median	20.0	-	-	-	20.0
Q1, Q3	20.0, 20.0	-, -	-, -	-, -	20.0, 20.0
Min, Max	20, 20	-, -	-, -	-, -	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	90.0 (-)	- (-)	- (-)	- (-)	90.0 (-)
Median	90.0	-	-	-	90.0
Q1, Q3	90.0, 90.0	-, -	-, -	-, -	90.0, 90.0
Min, Max	90, 90	-, -	-, -	-, -	90, 90
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	30.0 (-)	- (-)	- (-)	- (-)	30.0 (-)
Median	30.0	-	-	-	30.0
Q1, Q3	30.0, 30.0	-, -	-, -	-, -	30.0, 30.0
Min, Max	30, 30	-, -	-, -	-, -	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26)	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	60.0 (-)	- (-)	- (-)	- (-)	60.0 (-)
Median	60.0	-	-	-	60.0
Q1, Q3	60.0, 60.0	-, -	-, -	-, -	60.0, 60.0
Min, Max	60, 60	-, -	-, -	-, -	60, 60
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.0 (-)	- (-)	- (-)	- (-)	0.0 (-)
Median	0.0	-	-	-	0.0
Q1, Q3	0.0, 0.0	-, -	-, -	-, -	0.0, 0.0
Min, Max	0, 0	-, -	-, -	-, -	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-05-eq5d-vas-mzltype.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
EQ-5D-5L				
EQ VAS Score				
Baseline				
n	32	28	6	66
Mean (SD)	75.1 (19.18)	75.6 (21.35)	83.3 (8.76)	76.1 (19.39)
Median	80.0	80.0	82.5	80.0
Q1, Q3	57.5, 90.0	70.0, 90.0	80.0, 90.0	70.0, 90.0
Min, Max	35, 100	0, 100	70, 95	0, 100

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	78.8 (17.13)	78.6 (14.38)	74.3 (17.42)	78.2 (15.87)
Median	80.0	80.0	80.0	80.0
Q1, Q3	75.0, 90.0	70.0, 90.0	50.0, 85.0	70.0, 90.0
Min, Max	30, 100	45, 96	50, 95	30, 100
Change from Baseline				
n	28	25	6	59
Mean (SD)	3.8 (21.01)	-0.5 (14.60)	-5.0 (14.14)	1.1 (17.87)
Median	0.0	0.0	-2.5	0.0
Q1, Q3	-5.0, 16.5	-10.0, 5.0	-10.0, 5.0	-5.0, 10.0
Min, Max	-40, 40	-45, 30	-30, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	24	23	4	51
Mean (SD)	78.5 (17.26)	77.4 (20.59)	75.0 (22.73)	77.7 (18.85)
Median	82.5	80.0	77.5	80.0
Q1, Q3	70.0, 91.5	75.0, 90.0	60.0, 90.0	70.0, 90.0
Min, Max	40, 100	0, 99	45, 100	0, 100
Change from Baseline				
n	23	23	4	50
Mean (SD)	4.3 (16.82)	2.0 (14.04)	-8.8 (18.87)	2.2 (15.78)
Median	0.0	0.0	-2.5	0.0
Q1, Q3	-5.0, 17.0	-5.0, 10.0	-22.5, 5.0	-5.0, 10.0
Min, Max	-25, 40	-24, 39	-35, 5	-35, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	22	23	3	48
Mean (SD)	76.8 (18.49)	73.5 (21.08)	85.0 (8.66)	75.7 (19.30)
Median	80.0	80.0	80.0	80.0
Q1, Q3	65.0, 90.0	60.0, 90.0	80.0, 95.0	65.0, 90.0
Min, Max	20, 100	0, 95	80, 95	0, 100
Change from Baseline				
n	21	23	3	47
Mean (SD)	2.5 (17.26)	-1.9 (16.28)	0.0 (10.00)	0.2 (16.28)
Median	0.0	0.0	0.0	0.0
Q1, Q3	-10.0, 15.0	-5.0, 5.0	-10.0, 10.0	-10.0, 10.0
Min, Max	-30, 30	-45, 40	-10, 10	-45, 40

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.9 (13.00)	75.1 (22.24)	86.7 (10.41)	79.5 (17.99)
Median	82.5	82.5	90.0	85.0
Q1, Q3	79.0, 92.0	66.0, 90.0	75.0, 95.0	70.0, 90.0
Min, Max	50, 100	0, 95	75, 95	0, 100
Change from Baseline				
n	19	20	3	42
Mean (SD)	7.8 (14.26)	-1.9 (17.00)	1.7 (17.56)	2.8 (16.15)
Median	10.0	0.0	0.0	0.0
Q1, Q3	0.0, 14.0	-9.0, 2.5	-15.0, 20.0	-5.0, 10.0
Min, Max	-20, 43	-45, 50	-15, 20	-45, 50

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	16	16	2	34
Mean (SD)	84.9 (11.06)	76.4 (24.73)	85.0 (7.07)	80.9 (18.80)
Median	89.0	80.0	85.0	86.5
Q1, Q3	80.0, 90.0	72.5, 95.0	80.0, 90.0	78.0, 90.0
Min, Max	60, 100	0, 95	80, 90	0, 100
Change from Baseline				
n	15	16	2	33
Mean (SD)	12.3 (19.39)	0.9 (14.97)	-7.5 (3.54)	5.6 (17.68)
Median	8.0	0.0	-7.5	2.0
Q1, Q3	0.0, 30.0	-2.5, 7.5	-10.0, -5.0	0.0, 15.0
Min, Max	-20, 55	-45, 20	-10, -5	-45, 55

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	83.3 (15.32)	79.0 (21.74)	85.0 (21.21)	81.4 (18.48)
Median	85.0	80.0	85.0	85.0
Q1, Q3	80.0, 95.0	78.0, 90.0	70.0, 100.0	79.0, 95.0
Min, Max	50, 100	0, 95	70, 100	0, 100
Change from Baseline				
n	16	17	2	35
Mean (SD)	10.2 (18.99)	3.2 (9.34)	-7.5 (17.68)	5.8 (15.24)
Median	7.5	0.0	-7.5	0.0
Q1, Q3	0.0, 27.5	0.0, 5.0	-20.0, 5.0	0.0, 10.0
Min, Max	-20, 45	-10, 30	-20, 5	-20, 45

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	80.9 (17.61)	74.7 (25.73)	85.0 (7.07)	78.0 (21.62)
Median	85.0	83.0	85.0	83.0
Q1, Q3	65.0, 96.5	70.0, 90.0	80.0, 90.0	70.0, 90.0
Min, Max	50, 100	0, 98	80, 90	0, 100
Change from Baseline				
n	11	15	2	28
Mean (SD)	5.3 (24.85)	0.2 (12.98)	-7.5 (3.54)	1.6 (18.15)
Median	0.0	0.0	-7.5	0.0
Q1, Q3	-10.0, 18.0	-5.0, 10.0	-10.0, -5.0	-5.0, 10.0
Min, Max	-40, 48	-30, 20	-10, -5	-40, 48

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	11	2	3	16
Mean (SD)	65.9 (22.78)	46.0 (8.49)	76.7 (2.89)	65.4 (20.68)
Median	70.0	46.0	75.0	70.0
Q1, Q3	65.0, 80.0	40.0, 52.0	75.0, 80.0	58.5, 77.5
Min, Max	5, 90	40, 52	75, 80	5, 90
Change from Baseline				
n	11	2	2	15
Mean (SD)	-13.6 (29.08)	-19.0 (15.56)	-5.0 (0.00)	-13.2 (25.21)
Median	-5.0	-19.0	-5.0	-5.0
Q1, Q3	-20.0, 5.0	-30.0, -8.0	-5.0, -5.0	-20.0, 0.0
Min, Max	-90, 20	-30, -8	-5, -5	-90, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	-, -	40, 40
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	40.0 (-)	- (-)	40.0 (-)
Median	-	40.0	-	40.0
Q1, Q3	-, -	40.0, 40.0	-, -	40.0, 40.0
Min, Max	-, -	40, 40	-, -	40, 40
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-20.0 (-)	- (-)	-20.0 (-)
Median	-	-20.0	-	-20.0
Q1, Q3	-, -	-20.0, -20.0	-, -	-20.0, -20.0
Min, Max	-, -	-20, -20	-, -	-20, -20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	80.0 (-)	- (-)	80.0 (-)
Median	-	80.0	-	80.0
Q1, Q3	-, -	80.0, 80.0	-, -	80.0, 80.0
Min, Max	-, -	80, 80	-, -	80, 80
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	20.0 (-)	- (-)	20.0 (-)
Median	-	20.0	-	20.0
Q1, Q3	-, -	20.0, 20.0	-, -	20.0, 20.0
Min, Max	-, -	20, 20	-, -	20, 20

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	90.0 (-)	- (-)	90.0 (-)
Median	-	90.0	-	90.0
Q1, Q3	-, -	90.0, 90.0	-, -	90.0, 90.0
Min, Max	-, -	90, 90	-, -	90, 90
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	30.0 (-)	- (-)	30.0 (-)
Median	-	30.0	-	30.0
Q1, Q3	-, -	30.0, 30.0	-, -	30.0, 30.0
Min, Max	-, -	30, 30	-, -	30, 30

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.5.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33)	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	60.0 (-)	- (-)	60.0 (-)
Median	-	60.0	-	60.0
Q1, Q3	-, -	60.0, 60.0	-, -	60.0, 60.0
Min, Max	-, -	60, 60	-, -	60, 60
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.0 (-)	- (-)	0.0 (-)
Median	-	0.0	-	0.0
Q1, Q3	-, -	0.0, 0.0	-, -	0.0, 0.0
Min, Max	-, -	0, 0	-, -	0, 0

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-vas.sas 26AUG2022 01:59 t-14-02-01-05-06-eq5d-vas-region.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	36	32	68
Patients who completed questionnaire, n	35	31	66
Compliance Rate (%) [a]	97.2	96.9	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	34	29	63
Patients who completed questionnaire, n	33	28	61
Compliance Rate (%) [a]	97.1	96.6	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	31	22	53
Patients who completed questionnaire, n	30	21	51
Compliance Rate (%) [a]	96.8	95.5	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	30	19	49
Patients who completed questionnaire, n	30	18	48
Compliance Rate (%) [a]	100.0	94.7	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	29	17	46
Patients who completed questionnaire, n	27	16	43
Compliance Rate (%) [a]	93.1	94.1	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	24	15	39
Patients who completed questionnaire, n	21	13	34
Compliance Rate (%) [a]	87.5	86.7	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.1:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
Patients expected to complete questionnaire at visit, n	24	13	37
Patients who completed questionnaire, n	23	13	36
Compliance Rate (%) [a]	95.8	100.0	97.3
Cycle 30			
Patients expected to complete questionnaire at visit, n	20	9	29
Patients who completed questionnaire, n	20	9	29
Compliance Rate (%) [a]	100.0	100.0	100.0
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	4	3	7
Patients who completed questionnaire, n	1	0	1
Compliance Rate (%) [a]	25.0	0.0	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-01-eq5d-comprate-sex.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Baseline					
Patients expected to complete questionnaire at visit, n	27	41	49	19	68
Patients who completed questionnaire, n	26	40	47	19	66
Compliance Rate (%) [a]	96.3	97.6	95.9	100.0	97.1
Cycle 03					
Patients expected to complete questionnaire at visit, n	25	38	45	18	63
Patients who completed questionnaire, n	23	38	43	18	61
Compliance Rate (%) [a]	92.0	100.0	95.6	100.0	96.8
Cycle 06					
Patients expected to complete questionnaire at visit, n	20	33	36	17	53
Patients who completed questionnaire, n	20	31	36	15	51
Compliance Rate (%) [a]	100.0	93.9	100.0	88.2	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 09					
Patients expected to complete questionnaire at visit, n	19	30	34	15	49
Patients who completed questionnaire, n	18	30	33	15	48
Compliance Rate (%) [a]	94.7	100.0	97.1	100.0	98.0
Cycle 12					
Patients expected to complete questionnaire at visit, n	17	29	31	15	46
Patients who completed questionnaire, n	16	27	29	14	43
Compliance Rate (%) [a]	94.1	93.1	93.5	93.3	93.5
Cycle 18					
Patients expected to complete questionnaire at visit, n	15	24	26	13	39
Patients who completed questionnaire, n	11	23	22	12	34
Compliance Rate (%) [a]	73.3	95.8	84.6	92.3	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.2:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
Patients expected to complete questionnaire at visit, n	15	22	26	11	37
Patients who completed questionnaire, n	15	21	25	11	36
Compliance Rate (%) [a]	100.0	95.5	96.2	100.0	97.3
Cycle 30					
Patients expected to complete questionnaire at visit, n	13	16	22	7	29
Patients who completed questionnaire, n	13	16	22	7	29
Compliance Rate (%) [a]	100.0	100.0	100.0	100.0	100.0
Safety Follow-up					
Patients expected to complete questionnaire at visit, n	4	3	6	1	7
Patients who completed questionnaire, n	0	1	1	0	1
Compliance Rate (%) [a]	0.0	33.3	16.7	0.0	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-02-eq5d-comprate-age.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	39	29	68
Patients who completed questionnaire, n	39	27	66
Compliance Rate (%) [a]	100.0	93.1	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	36	27	63
Patients who completed questionnaire, n	35	26	61
Compliance Rate (%) [a]	97.2	96.3	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	29	24	53
Patients who completed questionnaire, n	28	23	51
Compliance Rate (%) [a]	96.6	95.8	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	27	22	49
Patients who completed questionnaire, n	27	21	48
Compliance Rate (%) [a]	100.0	95.5	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	27	19	46
Patients who completed questionnaire, n	25	18	43
Compliance Rate (%) [a]	92.6	94.7	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	24	15	39
Patients who completed questionnaire, n	22	12	34
Compliance Rate (%) [a]	91.7	80.0	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.3:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
Patients expected to complete questionnaire at visit, n	23	14	37
Patients who completed questionnaire, n	22	14	36
Compliance Rate (%) [a]	95.7	100.0	97.3
Cycle 30			
Patients expected to complete questionnaire at visit, n	21	8	29
Patients who completed questionnaire, n	21	8	29
Compliance Rate (%) [a]	100.0	100.0	100.0
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	3	4	7
Patients who completed questionnaire, n	0	1	1
Compliance Rate (%) [a]	0.0	25.0	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-03-eq5d-comprate-ecog.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Baseline			
Patients expected to complete questionnaire at visit, n	49	19	68
Patients who completed questionnaire, n	48	18	66
Compliance Rate (%) [a]	98.0	94.7	97.1
Cycle 03			
Patients expected to complete questionnaire at visit, n	45	18	63
Patients who completed questionnaire, n	43	18	61
Compliance Rate (%) [a]	95.6	100.0	96.8
Cycle 06			
Patients expected to complete questionnaire at visit, n	38	15	53
Patients who completed questionnaire, n	37	14	51
Compliance Rate (%) [a]	97.4	93.3	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 09			
Patients expected to complete questionnaire at visit, n	36	13	49
Patients who completed questionnaire, n	35	13	48
Compliance Rate (%) [a]	97.2	100.0	98.0
Cycle 12			
Patients expected to complete questionnaire at visit, n	35	11	46
Patients who completed questionnaire, n	33	10	43
Compliance Rate (%) [a]	94.3	90.9	93.5
Cycle 18			
Patients expected to complete questionnaire at visit, n	33	6	39
Patients who completed questionnaire, n	28	6	34
Compliance Rate (%) [a]	84.8	100.0	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.4:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
Patients expected to complete questionnaire at visit, n	31	6	37
Patients who completed questionnaire, n	30	6	36
Compliance Rate (%) [a]	96.8	100.0	97.3
Cycle 30			
Patients expected to complete questionnaire at visit, n	23	6	29
Patients who completed questionnaire, n	23	6	29
Compliance Rate (%) [a]	100.0	100.0	100.0
Safety Follow-up			
Patients expected to complete questionnaire at visit, n	4	3	7
Patients who completed questionnaire, n	1	0	1
Compliance Rate (%) [a]	25.0	0.0	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-04-eq5d-comprate-pst.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Baseline					
Patients expected to complete questionnaire at visit, n	26	26	12	4	68
Patients who completed questionnaire, n	26	24	12	4	66
Compliance Rate (%) [a]	100.0	92.3	100.0	100.0	97.1
Cycle 03					
Patients expected to complete questionnaire at visit, n	21	26	12	4	63
Patients who completed questionnaire, n	21	25	11	4	61
Compliance Rate (%) [a]	100.0	96.2	91.7	100.0	96.8
Cycle 06					
Patients expected to complete questionnaire at visit, n	18	22	10	3	53
Patients who completed questionnaire, n	18	21	9	3	51
Compliance Rate (%) [a]	100.0	95.5	90.0	100.0	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 09					
Patients expected to complete questionnaire at visit, n	18	21	7	3	49
Patients who completed questionnaire, n	18	20	7	3	48
Compliance Rate (%) [a]	100.0	95.2	100.0	100.0	98.0
Cycle 12					
Patients expected to complete questionnaire at visit, n	17	20	7	2	46
Patients who completed questionnaire, n	16	19	6	2	43
Compliance Rate (%) [a]	94.1	95.0	85.7	100.0	93.5
Cycle 18					
Patients expected to complete questionnaire at visit, n	14	17	6	2	39
Patients who completed questionnaire, n	12	15	6	1	34
Compliance Rate (%) [a]	85.7	88.2	100.0	50.0	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.5:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
Patients expected to complete questionnaire at visit, n	14	15	6	2	37
Patients who completed questionnaire, n	14	14	6	2	36
Compliance Rate (%) [a]	100.0	93.3	100.0	100.0	97.3
Cycle 30					
Patients expected to complete questionnaire at visit, n	11	12	4	2	29
Patients who completed questionnaire, n	11	12	4	2	29
Compliance Rate (%) [a]	100.0	100.0	100.0	100.0	100.0
Safety Follow-up					
Patients expected to complete questionnaire at visit, n	4	2	0	1	7
Patients who completed questionnaire, n	1	0	0	0	1
Compliance Rate (%) [a]	25.0	0.0	-	0.0	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-05-eq5d-comprate-mzltype.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Baseline				
Patients expected to complete questionnaire at visit, n	33	28	7	68
Patients who completed questionnaire, n	32	28	6	66
Compliance Rate (%) [a]	97.0	100.0	85.7	97.1
Cycle 03				
Patients expected to complete questionnaire at visit, n	29	27	7	63
Patients who completed questionnaire, n	29	25	7	61
Compliance Rate (%) [a]	100.0	92.6	100.0	96.8
Cycle 06				
Patients expected to complete questionnaire at visit, n	25	24	4	53
Patients who completed questionnaire, n	24	23	4	51
Compliance Rate (%) [a]	96.0	95.8	100.0	96.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-06-eq5d-comprate-region.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 09				
Patients expected to complete questionnaire at visit, n	23	23	3	49
Patients who completed questionnaire, n	22	23	3	48
Compliance Rate (%) [a]	95.7	100.0	100.0	98.0
Cycle 12				
Patients expected to complete questionnaire at visit, n	20	23	3	46
Patients who completed questionnaire, n	20	20	3	43
Compliance Rate (%) [a]	100.0	87.0	100.0	93.5
Cycle 18				
Patients expected to complete questionnaire at visit, n	19	18	2	39
Patients who completed questionnaire, n	16	16	2	34
Compliance Rate (%) [a]	84.2	88.9	100.0	87.2

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-06-eq5d-comprate-region.rtf

Table 14.2.1.7.6:
Summary of EQ-5D-5L Visual Analogue Scale (VAS) Score Compliance Rate by Visit and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
Patients expected to complete questionnaire at visit, n	17	18	2	37
Patients who completed questionnaire, n	17	17	2	36
Compliance Rate (%) [a]	100.0	94.4	100.0	97.3
Cycle 30				
Patients expected to complete questionnaire at visit, n	12	15	2	29
Patients who completed questionnaire, n	12	15	2	29
Compliance Rate (%) [a]	100.0	100.0	100.0	100.0
Safety Follow-up				
Patients expected to complete questionnaire at visit, n	3	4	0	7
Patients who completed questionnaire, n	0	1	0	1
Compliance Rate (%) [a]	0.0	25.0	-	14.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eq5d-comprate.sas 26AUG2022 02:10 t-14-02-01-07-06-eq5d-comprate-region.rtf

Figure 14.2.1.8.1:
EQ-5D-5L Questionnaire - EQ-5D Score Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EQ-5D-5L, 5-level EQ-5D version.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-08-01-meanot-qol-eq5d.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Baseline	
Patients expected to complete questionnaire at visit, n	68
Patients who completed questionnaire, n	66
Compliance Rate (%) [a]	97.1
Cycle 03	
Patients expected to complete questionnaire at visit, n	63
Patients who completed questionnaire, n	60
Compliance Rate (%) [a]	95.2
Cycle 06	
Patients expected to complete questionnaire at visit, n	53
Patients who completed questionnaire, n	50
Compliance Rate (%) [a]	94.3

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:21 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Cycle 09	
Patients expected to complete questionnaire at visit, n	49
Patients who completed questionnaire, n	48
Compliance Rate (%) [a]	98.0
Cycle 12	
Patients expected to complete questionnaire at visit, n	46
Patients who completed questionnaire, n	42
Compliance Rate (%) [a]	91.3
Cycle 18	
Patients expected to complete questionnaire at visit, n	39
Patients who completed questionnaire, n	33
Compliance Rate (%) [a]	84.6

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:21 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.9:
Summary of EORTC QLQ-C30 Compliance Rate by Visit
Safety Analysis Set

Visit	Total (N = 68)
Cycle 24	
Patients expected to complete questionnaire at visit, n	37
Patients who completed questionnaire, n	36
Compliance Rate (%) [a]	97.3
Cycle 30	
Patients expected to complete questionnaire at visit, n	29
Patients who completed questionnaire, n	29
Compliance Rate (%) [a]	100.0
Safety Follow-up	
Patients expected to complete questionnaire at visit, n	7
Patients who completed questionnaire, n	2
Compliance Rate (%) [a]	28.6

Source: ADSL,ADQS,SV,VE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Patients should complete the EQ-5D-5L and EORTC QLQ-C30 questionnaires before the first dose of study drug, and before performing any other procedures. The questionnaires are to be completed on Cycle 1 Day 1, end of Cycle 3, then every 12 weeks for 12 months, followed by every 24 weeks thereafter. Patient-reported outcomes will continue to be assessed until disease progression, death, or withdrawal of consent, regardless of study treatment discontinuation.

[a] Compliance rate = the number of patients who completed questionnaire / number of patients expected to complete questionnaire at each visit.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc-comprate-all.sas 20SEP2022 23:21 t-14-02-01-09-eortc-comprate-all.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	35	32	67
Mean (SD)	69.524 (18.6276)	62.240 (23.3779)	66.045 (21.1871)
Median	66.667	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 83.333	50.000, 83.333
Min, Max	25.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	75.253 (17.6143)	75.893 (16.5644)	75.546 (17.0014)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 83.333	62.500, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	5.990 (18.8413)	10.714 (21.2589)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-41.67, 50.00	-33.33, 66.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	77.679 (16.6749)	71.591 (24.3513)	75.000 (20.4124)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 87.500	58.333, 91.667	66.667, 91.667
Min, Max	41.67, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	6.481 (11.8604)	9.470 (19.8032)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-16.67, 66.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	76.667 (19.2533)	65.789 (23.8783)	72.449 (21.5974)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	4.598 (17.6195)	6.579 (23.8273)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 25.000	0.000, 16.667
Min, Max	-50.00, 41.67	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	79.012 (15.2210)	70.313 (26.1705)	75.775 (20.1527)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	66.667, 83.333
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	4.487 (17.0344)	11.458 (17.4470)	7.143 (17.3216)
Median	4.167	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 20.833	0.000, 16.667
Min, Max	-33.33, 41.67	-16.67, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	80.833 (14.3321)	69.872 (26.6880)	76.515 (20.4607)
Median	83.333	75.000	83.333
Q1, Q3	75.000, 83.333	66.667, 83.333	75.000, 83.333
Min, Max	41.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	9.649 (19.4966)	12.179 (17.5513)	10.677 (18.4811)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 20.833
Min, Max	-33.33, 41.67	-8.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	81.159 (15.5329)	67.949 (28.2282)	76.389 (21.5933)
Median	83.333	66.667	83.333
Q1, Q3	75.000, 91.667	58.333, 83.333	66.667, 87.500
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	9.091 (17.0412)	9.615 (23.2852)	9.286 (19.2561)
Median	12.500	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-25.00, 50.00	-25.00, 66.67	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	77.083 (17.9088)	64.815 (32.4834)	73.276 (23.5048)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 91.667	41.667, 83.333	66.667, 83.333
Min, Max	41.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	4.825 (20.8455)	9.259 (20.6006)	6.250 (20.4910)
Median	8.333	0.000	4.167
Q1, Q3	-8.333, 16.667	0.000, 8.333	-8.333, 16.667
Min, Max	-33.33, 41.67	-8.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	43.056 (21.3546)	63.889 (22.8448)	56.944 (23.9570)
Median	41.667	66.667	66.667
Q1, Q3	25.000, 66.667	54.167, 75.000	33.333, 66.667
Min, Max	16.67, 66.67	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-29.167 (29.6975)	-1.389 (22.4265)	-10.648 (27.6837)
Median	-25.000	4.167	0.000
Q1, Q3	-50.000, 0.000	-20.833, 8.333	-25.000, 8.333
Min, Max	-75.00, 0.00	-41.67, 41.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	35	32	67
Mean (SD)	88.762 (13.6023)	77.083 (23.2757)	83.184 (19.6041)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	63.333, 93.333	80.000, 100.000
Min, Max	46.67, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	32	28	60
Mean (SD)	89.583 (12.5510)	81.667 (20.0103)	85.889 (16.7890)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	76.667, 93.333	83.333, 100.000
Min, Max	53.33, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	31	28	59
Mean (SD)	0.000 (14.4016)	2.857 (13.1379)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-6.667, 6.667
Min, Max	-33.33, 40.00	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	90.805 (11.4661)	80.606 (23.2683)	86.405 (18.0843)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	73.333, 93.333	80.000, 100.000
Min, Max	53.33, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	1.905 (14.1546)	3.636 (19.2700)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-13.333, 13.333	-6.667, 6.667
Min, Max	-33.33, 33.33	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	88.222 (18.5020)	79.298 (26.0004)	84.762 (21.9004)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-0.690 (17.4888)	4.912 (20.3479)	1.528 (18.6666)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 13.333	0.000, 6.667
Min, Max	-73.33, 40.00	-40.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	26	16	42
Mean (SD)	91.538 (10.7592)	75.417 (29.8856)	85.397 (21.4508)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000
Min, Max	66.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	16	41
Mean (SD)	1.600 (9.6762)	2.917 (21.9047)	2.114 (15.3796)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-3.333, 6.667	0.000, 6.667
Min, Max	-20.00, 26.67	-40.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	92.333 (8.1721)	77.949 (24.5530)	86.667 (17.7951)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	73.333, 93.333	86.667, 100.000
Min, Max	80.00, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	3.158 (12.8368)	0.000 (20.3670)	1.875 (16.0853)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-13.333, 0.000	-6.667, 6.667
Min, Max	-13.33, 33.33	-26.67, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	87.899 (15.5880)	77.436 (27.8273)	84.120 (21.0762)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	66.667, 93.333	80.000, 96.667
Min, Max	26.67, 100.00	6.67, 100.00	6.67, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-1.742 (19.3852)	-1.538 (22.6330)	-1.667 (20.3202)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 0.000	-13.333, 0.000	-6.667, 0.000
Min, Max	-66.67, 40.00	-33.33, 60.00	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	89.833 (10.1148)	81.481 (21.0232)	87.241 (14.5315)
Median	93.333	93.333	93.333
Q1, Q3	81.667, 100.000	66.667, 100.000	80.000, 100.000
Min, Max	66.67, 100.00	46.67, 100.00	46.67, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	-1.228 (15.0395)	8.889 (23.5702)	2.024 (18.3998)
Median	-6.667	6.667	0.000
Q1, Q3	-6.667, 0.000	0.000, 6.667	-6.667, 6.667
Min, Max	-26.67, 33.33	-20.00, 66.67	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	71.111 (18.2168)	72.222 (22.1717)	71.852 (20.3955)
Median	70.000	73.333	73.333
Q1, Q3	60.000, 86.667	60.000, 90.000	60.000, 86.667
Min, Max	46.67, 93.33	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-16.667 (12.4722)	-3.889 (16.6869)	-8.148 (16.2586)
Median	-16.667	0.000	-10.000
Q1, Q3	-26.667, -6.667	-16.667, 6.667	-20.000, 0.000
Min, Max	-33.33, 0.00	-33.33, 26.67	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	58.333 (-)	- (-)	58.333 (-)
Median	58.333	-	58.333
Q1, Q3	58.333, 58.333	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	60.000 (-)	- (-)	60.000 (-)
Median	60.000	-	60.000
Q1, Q3	60.000, 60.000	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline			
n	1	0	1
Mean (SD)	-6.667 (-)	- (-)	-6.667 (-)
Median	-6.667	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	73.333 (-)	- (-)	73.333 (-)
Median	73.333	-	73.333
Q1, Q3	73.333, 73.333	-, -	73.333, 73.333
Min, Max	73.33, 73.33	-, -	73.33, 73.33
Change from Baseline			
n	1	0	1
Mean (SD)	6.667 (-)	- (-)	6.667 (-)
Median	6.667	-	6.667
Q1, Q3	6.667, 6.667	-, -	6.667, 6.667
Min, Max	6.67, 6.67	-, -	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	86.667 (-)	- (-)	86.667 (-)
Median	86.667	-	86.667
Q1, Q3	86.667, 86.667	-, -	86.667, 86.667
Min, Max	86.67, 86.67	-, -	86.67, 86.67
Change from Baseline			
n	1	0	1
Mean (SD)	20.000 (-)	- (-)	20.000 (-)
Median	20.000	-	20.000
Q1, Q3	20.000, 20.000	-, -	20.000, 20.000
Min, Max	20.00, 20.00	-, -	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Role functioning			
Baseline			
n	35	32	67
Mean (SD)	88.571 (18.8611)	77.604 (30.1161)	83.333 (25.2929)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	58.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	87.374 (22.8333)	86.310 (20.8135)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	75.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-2.604 (22.0416)	7.738 (24.2085)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	92.529 (13.7914)	86.364 (22.2042)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	1.786 (14.5857)	10.606 (24.9579)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	88.333 (22.3821)	83.333 (29.3972)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-2.874 (18.4030)	8.772 (22.4766)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	93.210 (14.8059)	75.000 (33.8843)	86.434 (25.0015)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	58.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.923 (12.7601)	1.042 (30.1040)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	-33.33, 33.33	-50.00, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	90.833 (12.6526)	75.641 (30.8936)	84.848 (22.5784)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	66.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	-3.509 (15.2944)	-1.282 (33.6523)	-2.604 (23.9883)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	92.029 (19.3777)	78.205 (24.8929)	87.037 (22.2222)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-0.758 (25.4469)	0.000 (34.0207)	-0.476 (28.4357)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-83.33, 33.33	-33.33, 100.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	92.500 (16.6447)	81.481 (29.3972)	89.080 (21.4901)
Median	100.000	100.000	100.000
Q1, Q3	91.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	-2.632 (19.4549)	9.259 (30.1744)	1.190 (23.5390)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-66.67, 33.33	-16.67, 83.33	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	41.667 (34.5607)	68.056 (27.9414)	59.259 (31.9427)
Median	41.667	66.667	66.667
Q1, Q3	16.667, 50.000	50.000, 91.667	33.333, 83.333
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-41.667 (27.3861)	-4.167 (22.6134)	-16.667 (29.7044)
Median	-50.000	0.000	-16.667
Q1, Q3	-66.667, -16.667	-16.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 0.00	-33.33, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	35	32	67
Mean (SD)	83.810 (18.1838)	80.469 (17.6598)	82.214 (17.8786)
Median	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	25.00, 100.00	41.67, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	84.343 (24.2740)	84.821 (16.6749)	84.563 (20.9627)
Median	100.000	91.667	91.667
Q1, Q3	75.000, 100.000	70.833, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.302 (23.8639)	3.869 (10.9906)	2.500 (18.8724)
Median	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 12.500	0.000, 16.667
Min, Max	-75.00, 33.33	-25.00, 25.00	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	83.631 (22.9602)	82.576 (21.0362)	83.167 (21.9183)
Median	91.667	91.667	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	1.543 (20.2860)	5.303 (17.5454)	3.231 (19.0042)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 33.33	-25.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	87.500 (18.9208)	75.439 (25.9798)	82.823 (22.4645)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	3.736 (17.8988)	-0.877 (22.3770)	1.910 (19.6932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 8.333	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	88.272 (18.5274)	73.958 (28.8475)	82.946 (23.6370)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	54.167, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	2.885 (16.3201)	-2.083 (20.5255)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 8.333	0.000, 8.333
Min, Max	-41.67, 25.00	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	85.000 (22.3933)	77.564 (22.6652)	82.071 (22.4499)
Median	91.667	83.333	91.667
Q1, Q3	79.167, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	8.33, 100.00	25.00, 100.00	8.33, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	2.632 (19.8475)	1.282 (18.2720)	2.083 (18.9321)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-8.333, 8.333	-8.333, 12.500
Min, Max	-33.33, 41.67	-41.67, 33.33	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	87.319 (19.6030)	80.769 (23.6645)	84.954 (21.0649)
Median	91.667	83.333	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	25.00, 100.00	16.67, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	4.545 (18.3166)	3.205 (17.5259)	4.048 (17.7781)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	0.000, 8.333	0.000, 8.333
Min, Max	-33.33, 41.67	-41.67, 33.33	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	82.917 (24.9963)	79.630 (25.7226)	81.897 (24.8077)
Median	95.833	91.667	91.667
Q1, Q3	75.000, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	8.33, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	0.877 (21.3175)	-2.778 (12.5000)	-0.298 (18.7690)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 8.333	-8.333, 0.000	-8.333, 8.333
Min, Max	-50.00, 41.67	-25.00, 16.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	69.444 (26.7014)	75.694 (23.4247)	73.611 (23.9570)
Median	79.167	79.167	79.167
Q1, Q3	41.667, 91.667	66.667, 95.833	58.333, 91.667
Min, Max	33.33, 91.67	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-16.667 (20.4124)	-5.556 (17.5282)	-9.259 (18.7190)
Median	-8.333	-4.167	-8.333
Q1, Q3	-33.333, 0.000	-20.833, 4.167	-25.000, 0.000
Min, Max	-50.00, 0.00	-33.33, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	-13.889 (-)	- (-)	-13.889 (-)
Median	-13.889	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	8.333 (-)	- (-)	8.333 (-)
Median	8.333	-	8.333
Q1, Q3	8.333, 8.333	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	8.333 (-)	- (-)	8.333 (-)
Median	8.333	-	8.333
Q1, Q3	8.333, 8.333	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	91.667 (-)	- (-)	91.667 (-)
Median	91.667	-	91.667
Q1, Q3	91.667, 91.667	-, -	91.667, 91.667
Min, Max	91.67, 91.67	-, -	91.67, 91.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	35	32	67
Mean (SD)	90.952 (14.2014)	84.896 (20.8937)	88.060 (17.8391)
Median	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	86.364 (16.9018)	85.119 (17.1769)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-4.167 (21.1667)	-2.976 (11.1606)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-8.333, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-33.33, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	85.714 (21.1375)	83.333 (25.7172)	84.667 (23.0449)
Median	83.333	100.000	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	-4.938 (17.7920)	-4.545 (11.7083)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-66.67, 33.33	-33.33, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	85.556 (23.4616)	81.579 (27.1568)	84.014 (24.7579)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-5.172 (24.8421)	-5.263 (11.1840)	-5.208 (20.3853)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	85.802 (20.5188)	81.250 (25.7301)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	-3.846 (19.0366)	-7.292 (13.5657)	-5.159 (17.0636)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-33.33, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	84.167 (24.4680)	83.333 (20.4124)	83.838 (22.6250)
Median	91.667	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	-6.140 (24.9756)	-5.128 (12.5178)	-5.729 (20.5696)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-8.333, 0.000
Min, Max	-66.67, 50.00	-33.33, 16.67	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	88.406 (15.4354)	79.487 (28.9906)	85.185 (21.3726)
Median	83.333	100.000	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-3.030 (15.9665)	-8.974 (12.9375)	-5.238 (15.0008)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-33.33, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	85.000 (21.5618)	85.185 (19.4444)	85.057 (20.5793)
Median	91.667	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	-5.263 (20.8260)	-1.852 (15.4660)	-4.167 (19.0435)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-16.67, 33.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	69.444 (12.5462)	79.167 (23.7038)	75.926 (20.7870)
Median	66.667	83.333	83.333
Q1, Q3	66.667, 83.333	75.000, 100.000	66.667, 83.333
Min, Max	50.00, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-25.000 (13.9443)	-5.556 (14.7938)	-12.037 (16.9636)
Median	-16.667	0.000	-16.667
Q1, Q3	-33.333, -16.667	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, -16.67	-33.33, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Social functioning			
Baseline			
n	35	32	67
Mean (SD)	87.619 (17.7781)	82.292 (26.4160)	85.075 (22.3106)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	88.889 (18.4780)	89.286 (21.3795)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (22.7726)	5.357 (26.4706)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 66.67	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	91.071 (15.3707)	93.182 (16.7925)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	100.000, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	27	22	49
Mean (SD)	4.321 (17.6581)	9.848 (30.2805)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 33.33	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	87.222 (22.1815)	85.965 (25.0081)	86.735 (23.0688)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	0.000 (24.3975)	4.386 (34.1755)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 8.333
Min, Max	-83.33, 50.00	-66.67, 83.33	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	91.358 (13.3736)	92.708 (12.1240)	91.860 (12.7927)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (16.9464)	9.375 (29.7948)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	90.833 (15.7419)	87.179 (22.7240)	89.394 (18.5490)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	4.386 (17.4290)	3.846 (34.1252)	4.167 (25.0448)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	92.754 (15.7523)	89.744 (19.8821)	91.667 (17.1362)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	6.061 (15.8910)	5.128 (33.5994)	5.714 (23.5504)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-16.67, 50.00	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	94.167 (13.5455)	81.481 (25.6098)	90.230 (18.6431)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	7.018 (20.2727)	3.704 (41.4811)	5.952 (28.0411)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 50.00	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	61.111 (22.7710)	70.833 (27.6385)	67.593 (25.8656)
Median	66.667	75.000	66.667
Q1, Q3	33.333, 83.333	41.667, 100.000	33.333, 83.333
Min, Max	33.33, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	-22.222 (27.2166)	-6.944 (22.9826)	-12.037 (24.7903)
Median	-25.000	0.000	-8.333
Q1, Q3	-50.000, 0.000	-25.000, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Fatigue			
Baseline			
n	35	32	67
Mean (SD)	22.857 (17.6595)	36.632 (26.5821)	29.436 (23.2509)
Median	22.222	27.778	22.222
Q1, Q3	11.111, 33.333	16.667, 55.556	11.111, 44.444
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	18.855 (22.3062)	25.794 (22.4380)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 38.889	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	32	28	60
Mean (SD)	-2.778 (24.4412)	-9.722 (25.2842)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-44.44, 66.67	-88.89, 33.33	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	17.625 (15.2918)	30.808 (25.1817)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 33.333	11.111, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	28	22	50
Mean (SD)	-5.556 (14.0220)	-7.323 (25.0447)	-6.333 (19.4407)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-11.111, 11.111	-11.111, 0.000
Min, Max	-33.33, 22.22	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	18.148 (18.5657)	30.409 (25.8841)	22.902 (22.2694)
Median	16.667	33.333	22.222
Q1, Q3	0.000, 33.333	11.111, 44.444	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-3.448 (17.5942)	-11.404 (22.5648)	-6.597 (19.8714)
Median	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-44.44, 44.44	-55.56, 33.33	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	15.638 (18.2988)	27.083 (21.8369)	19.897 (20.2219)
Median	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	5.556, 33.333	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	26	16	42
Mean (SD)	-4.701 (16.3822)	-12.847 (25.9565)	-7.804 (20.6438)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-33.33, 33.33	-88.89, 11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	15.000 (14.0892)	21.368 (23.7708)	17.508 (18.4320)
Median	11.111	22.222	11.111
Q1, Q3	0.000, 27.778	11.111, 22.222	0.000, 22.222
Min, Max	0.00, 44.44	0.00, 88.89	0.00, 88.89
Change from Baseline			
n	19	13	32
Mean (SD)	-8.187 (16.0768)	-16.667 (29.9176)	-11.632 (22.6816)
Median	-11.111	0.000	0.000
Q1, Q3	-11.111, 0.000	-38.889, 0.000	-22.222, 0.000
Min, Max	-44.44, 33.33	-88.89, 22.22	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	17.874 (16.6630)	29.060 (29.5851)	21.914 (22.4569)
Median	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	11.111, 33.333	0.000, 33.333
Min, Max	0.00, 44.44	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-3.535 (15.8574)	-6.838 (23.8041)	-4.762 (18.9188)
Median	0.000	0.000	0.000
Q1, Q3	-11.111, 0.000	-11.111, 0.000	-11.111, 0.000
Min, Max	-44.44, 22.22	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	19.444 (23.3278)	25.926 (26.0579)	21.456 (23.9287)
Median	22.222	11.111	22.222
Q1, Q3	0.000, 22.222	11.111, 55.556	0.000, 22.222
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	-1.754 (25.1915)	-11.111 (31.4270)	-4.762 (27.1204)
Median	0.000	-11.111	0.000
Q1, Q3	-22.222, 11.111	-11.111, 0.000	-11.111, 5.556
Min, Max	-55.56, 66.67	-88.89, 22.22	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	59.259 (29.5369)	43.519 (28.9968)	48.765 (29.3079)
Median	66.667	38.889	55.556
Q1, Q3	44.444, 66.667	16.667, 72.222	22.222, 66.667
Min, Max	11.11, 100.00	0.00, 77.78	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	37.037 (25.9788)	2.315 (17.9565)	13.889 (26.2833)
Median	44.444	0.000	11.111
Q1, Q3	11.111, 55.556	-11.111, 16.667	-5.556, 33.333
Min, Max	0.00, 66.67	-22.22, 33.33	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-22.222 (-)	- (-)	-22.222 (-)
Median	-22.222	-	-22.222
Q1, Q3	-22.222, -22.222	-, -	-22.222, -22.222
Min, Max	-22.22, -22.22	-, -	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	35	32	67
Mean (SD)	2.381 (10.0187)	5.729 (10.8834)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	2.020 (5.5239)	3.571 (10.4990)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	32	28	60
Mean (SD)	-0.521 (9.9139)	-1.786 (8.2891)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	1.724 (5.1656)	6.061 (21.5445)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	0.595 (5.5224)	-0.758 (18.8823)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	1.667 (5.0855)	7.018 (11.5414)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	29	19	48
Mean (SD)	0.575 (8.3128)	-0.877 (8.7378)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	0.000 (0.0000)	6.250 (13.4371)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (0.0000)	-1.042 (7.3755)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-16.67, 16.67	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	0.833 (3.7268)	3.846 (9.9857)	2.020 (6.9191)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	19	13	32
Mean (SD)	-0.877 (8.7378)	-2.564 (6.2589)	-1.563 (7.7591)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	0.000 (0.0000)	3.846 (9.9857)	1.389 (6.1399)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	22	13	35
Mean (SD)	-1.515 (7.1067)	-2.564 (6.2589)	-1.905 (6.7294)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-16.67, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	3.333 (11.5975)	1.852 (5.5556)	2.874 (10.0287)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	19	9	28
Mean (SD)	1.754 (14.5877)	-5.556 (8.3333)	-0.595 (13.2110)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 50.00	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	8.333 (20.4124)	8.333 (15.0756)	8.333 (16.4197)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	6	12	18
Mean (SD)	8.333 (20.4124)	0.000 (12.3091)	2.778 (15.3925)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	-16.67, 33.33	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Pain			
Baseline			
n	35	31	66
Mean (SD)	9.524 (17.2854)	20.430 (24.2325)	14.646 (21.3868)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	10.606 (19.0112)	19.048 (23.0022)	14.481 (21.1860)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	27	59
Mean (SD)	0.521 (22.1935)	-0.617 (19.8722)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 8.333	0.000, 16.667	-16.667, 16.667
Min, Max	-33.33, 50.00	-66.67, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	8.621 (13.8162)	21.212 (30.5080)	14.052 (23.1835)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	21	49
Mean (SD)	0.000 (19.2450)	-3.175 (20.8294)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	15.000 (23.7120)	24.561 (29.0638)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	18	47
Mean (SD)	6.322 (22.8929)	-0.926 (27.0996)	3.546 (24.5580)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 50.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	10.494 (17.3871)	25.000 (27.8887)	15.891 (22.6993)
Median	0.000	25.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	15	41
Mean (SD)	2.564 (22.9455)	1.111 (18.3297)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	7.500 (11.4389)	24.359 (37.0281)	14.141 (25.7260)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	12	31
Mean (SD)	0.877 (17.9795)	4.167 (21.4676)	2.151 (19.1204)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	-8.333, 25.000	-16.667, 16.667
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	8.696 (22.9567)	28.205 (30.7202)	15.741 (27.2974)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	0.758 (28.3950)	7.692 (17.5005)	3.333 (24.8525)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-16.667, 0.000
Min, Max	-33.33, 100.00	-16.67, 50.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	10.000 (19.0414)	24.074 (33.4489)	14.368 (24.6902)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 83.33	0.00, 83.33
Change from Baseline			
n	19	9	28
Mean (SD)	3.509 (24.5823)	0.000 (14.4338)	2.381 (21.6188)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 0.000	-8.333, 8.333
Min, Max	-33.33, 66.67	-16.67, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	16.667 (21.0819)	29.167 (25.7464)	25.000 (24.4214)
Median	8.333	33.333	25.000
Q1, Q3	0.000, 33.333	0.000, 50.000	0.000, 50.000
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	6	11	17
Mean (SD)	16.667 (21.0819)	3.030 (23.3550)	7.843 (22.9111)
Median	8.333	0.000	0.000
Q1, Q3	0.000, 33.333	-16.667, 16.667	0.000, 16.667
Min, Max	0.00, 50.00	-33.33, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	35	32	67
Mean (SD)	16.190 (24.7490)	32.292 (35.4028)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	14.141 (20.4639)	21.429 (26.0014)	17.486 (23.2591)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (19.8279)	-8.333 (29.5717)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	11.494 (18.4216)	19.697 (30.2705)	15.033 (24.3253)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	-3.571 (26.1985)	-15.152 (30.3895)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	29	19	48
Mean (SD)	8.046 (14.5165)	17.544 (23.2231)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	28	19	47
Mean (SD)	-7.143 (24.6074)	-21.053 (37.2024)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	13.580 (21.2016)	20.833 (26.8742)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (26.6667)	-20.833 (41.9435)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	6.667 (13.6797)	12.821 (21.6815)	9.091 (17.2255)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	19	13	32
Mean (SD)	-10.526 (15.9189)	-17.949 (39.9430)	-13.542 (27.9007)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-33.33, 0.00	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	8.696 (14.9659)	15.385 (22.0075)	11.111 (17.8174)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	22	13	35
Mean (SD)	-7.576 (20.3977)	-12.821 (42.0283)	-9.524 (29.7829)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	11.667 (24.8387)	14.815 (24.2161)	12.644 (24.2569)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	-5.263 (25.4906)	-22.222 (40.8248)	-10.714 (31.4970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	61.111 (32.7731)	30.556 (33.2068)	40.741 (35.3425)
Median	66.667	33.333	33.333
Q1, Q3	66.667, 66.667	0.000, 50.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	33.333 (29.8142)	-2.778 (22.2853)	9.259 (29.8264)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 66.667	-16.667, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-66.667 (-)	- (-)	-66.667 (-)
Median	-66.667	-	-66.667
Q1, Q3	-66.667, -66.667	-, -	-66.667, -66.667
Min, Max	-66.67, -66.67	-, -	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	-33.333 (-)	- (-)	-33.333 (-)
Median	-33.333	-	-33.333
Q1, Q3	-33.333, -33.333	-, -	-33.333, -33.333
Min, Max	-33.33, -33.33	-, -	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Insomnia			
Baseline			
n	35	32	67
Mean (SD)	15.238 (21.9072)	25.000 (26.7740)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	14.141 (20.4639)	22.619 (27.2974)	18.033 (24.0168)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-2.083 (20.6307)	-1.190 (19.2068)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	13.793 (18.9344)	27.273 (31.9331)	19.608 (25.9713)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	-3.571 (20.9630)	-1.515 (19.1824)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	10.000 (19.8654)	31.579 (32.3440)	18.367 (27.2686)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	19	48
Mean (SD)	-5.747 (25.3060)	0.000 (22.2222)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	13.580 (21.2016)	33.333 (34.4265)	20.930 (28.1936)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	0.000 (16.3299)	0.000 (17.2133)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	8.333 (14.8087)	35.897 (34.5916)	19.192 (27.6766)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	-3.509 (18.9044)	0.000 (13.6083)	-2.083 (16.8005)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	5.797 (12.9184)	30.769 (34.5916)	14.815 (25.7515)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-6.061 (16.7027)	-7.692 (24.1670)	-6.667 (19.4701)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	8.333 (14.8087)	22.222 (28.8675)	12.644 (20.7284)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	19	9	28
Mean (SD)	-5.263 (16.7153)	-11.111 (16.6667)	-7.143 (16.6225)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	22.222 (27.2166)	36.111 (30.0112)	31.481 (29.0868)
Median	16.667	33.333	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	6	12	18
Mean (SD)	11.111 (17.2133)	16.667 (26.5908)	14.815 (23.4931)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	35	32	67
Mean (SD)	6.667 (15.7596)	19.792 (29.1571)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	8.081 (16.7297)	13.095 (20.9630)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	28	60
Mean (SD)	1.042 (21.5599)	-8.333 (29.5717)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	6.897 (16.3768)	10.606 (23.8744)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	28	22	50
Mean (SD)	0.000 (22.2222)	-10.606 (29.7900)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	5.556 (15.3711)	10.526 (19.4131)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	-1.149 (22.6827)	-12.281 (33.7209)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	6.173 (16.1114)	18.750 (27.1314)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (22.0721)	-2.083 (33.2638)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	3.333 (10.2598)	15.385 (25.8750)	8.081 (18.6903)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	19	13	32
Mean (SD)	-3.509 (18.9044)	-2.564 (34.5916)	-3.125 (25.9022)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	4.348 (11.4783)	15.385 (25.8750)	8.333 (18.4735)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	22	13	35
Mean (SD)	-1.515 (19.1824)	-2.564 (25.3185)	-1.905 (21.3021)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	6.667 (23.1951)	14.815 (24.2161)	9.195 (23.3954)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	0.000 (29.3972)	-7.407 (40.0617)	-2.381 (32.6202)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 100.00	-100.00, 33.33	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	44.444 (45.5420)	30.556 (33.2068)	35.185 (36.9989)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 100.000	0.000, 50.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	44.444 (45.5420)	0.000 (28.4268)	14.815 (39.9709)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 100.00	-66.67, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Constipation			
Baseline			
n	35	32	67
Mean (SD)	6.667 (17.7123)	11.458 (18.1775)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	9.091 (17.2255)	15.476 (27.9361)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	2.083 (18.8134)	4.762 (26.7811)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	29	22	51
Mean (SD)	9.195 (17.5855)	7.576 (17.6138)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	28	22	50
Mean (SD)	2.381 (20.1406)	-1.515 (19.1824)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	11.111 (18.2224)	5.263 (12.4878)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	3.448 (16.2930)	-5.263 (16.7153)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	8.642 (17.5231)	22.917 (39.8493)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	1.282 (17.5898)	12.500 (38.2487)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	6.667 (13.6797)	15.385 (29.2353)	10.101 (21.2211)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	0.000 (19.2450)	7.692 (27.7350)	3.125 (22.9685)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	2.899 (9.6035)	17.949 (32.2473)	8.333 (21.6392)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-4.545 (15.5854)	10.256 (31.5777)	0.952 (23.5504)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	10.000 (24.4232)	3.704 (11.1111)	8.046 (21.1854)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	19	9	28
Mean (SD)	3.509 (15.2944)	-3.704 (20.0308)	1.190 (16.9292)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	38.889 (49.0653)	19.444 (30.0112)	25.926 (37.1458)
Median	16.667	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	27.778 (38.9682)	5.556 (12.9750)	12.963 (25.9181)
Median	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	35	31	66
Mean (SD)	3.810 (13.4588)	10.753 (23.3921)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	5.051 (18.8584)	5.952 (13.0007)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	32	27	59
Mean (SD)	1.042 (10.3154)	-1.235 (19.5712)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	4.762 (14.9465)	10.606 (18.9300)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	27	21	48
Mean (SD)	2.469 (12.8300)	3.175 (20.8294)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	5.556 (15.3711)	5.263 (12.4878)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	18	47
Mean (SD)	3.448 (13.6418)	-1.852 (24.1786)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	7.407 (21.3504)	6.250 (13.4371)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	26	15	41
Mean (SD)	5.128 (20.4229)	0.000 (17.8174)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	10.000 (19.0414)	2.564 (9.2450)	7.071 (16.1537)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	19	12	31
Mean (SD)	7.018 (21.0201)	-5.556 (23.9247)	2.151 (22.6658)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	5.797 (12.9184)	10.256 (21.0142)	7.407 (16.1562)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	22	13	35
Mean (SD)	3.030 (9.8082)	2.564 (31.8025)	2.857 (20.4067)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	1.667 (7.4536)	3.704 (11.1111)	2.299 (8.5960)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	19	9	28
Mean (SD)	-1.754 (7.6472)	3.704 (11.1111)	0.000 (9.0722)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	16.667 (27.8887)	2.778 (9.6225)	7.407 (18.2773)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	6	11	17
Mean (SD)	16.667 (27.8887)	0.000 (14.9071)	5.882 (21.1978)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	35	32	67
Mean (SD)	21.905 (34.2452)	10.417 (26.0101)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 3			
n	33	28	61
Mean (SD)	15.152 (27.7525)	8.333 (21.5166)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	28	60
Mean (SD)	-5.208 (29.4628)	-2.381 (15.5253)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 6			
n	28	22	50
Mean (SD)	15.476 (26.4219)	4.545 (15.5854)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	27	22	49
Mean (SD)	-4.938 (31.6278)	-1.515 (12.5030)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 9			
n	30	19	49
Mean (SD)	10.000 (19.8654)	3.509 (10.5101)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	19	48
Mean (SD)	-9.195 (21.6329)	-3.509 (10.5101)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 12			
n	27	16	43
Mean (SD)	16.049 (29.7717)	8.333 (22.7710)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	26	16	42
Mean (SD)	-2.564 (18.6740)	2.083 (14.7510)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 18			
n	20	13	33
Mean (SD)	8.333 (18.3373)	15.385 (37.5534)	11.111 (27.2166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	13	32
Mean (SD)	-10.526 (22.3679)	7.692 (27.7350)	-3.125 (25.9022)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 0.00	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 24			
n	23	13	36
Mean (SD)	5.797 (16.3675)	15.385 (32.2473)	9.259 (23.3824)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	22	13	35
Mean (SD)	-13.636 (26.5455)	7.692 (24.1670)	-5.714 (27.3989)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 0.00	-33.33, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Cycle 30			
n	20	9	29
Mean (SD)	10.000 (21.8982)	11.111 (23.5702)	10.345 (22.0091)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	19	9	28
Mean (SD)	-8.772 (24.4498)	3.704 (20.0308)	-4.762 (23.5078)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Safety Follow-up			
n	6	12	18
Mean (SD)	50.000 (45.9468)	19.444 (33.2068)	29.630 (39.4221)
Median	50.000	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	6	12	18
Mean (SD)	5.556 (13.6083)	0.000 (24.6183)	1.852 (21.3046)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.1:
Summary of EORTC QLQ-C30 by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**Male (N = 36)**	**Female (N = 32)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-01-eortc-sum-sex.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Global health status/QOL					
Baseline					
n	27	40	48	19	67
Mean (SD)	67.593 (22.9191)	65.000 (20.1667)	67.708 (21.3067)	61.842 (20.8455)	66.045 (21.1871)
Median	75.000	66.667	75.000	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 83.333	50.000, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	0.00, 100.00	25.00, 100.00	0.00, 100.00	25.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	75.000 (20.4124)	75.877 (14.8553)	76.550 (18.1170)	73.148 (14.1639)	75.546 (17.0014)
Median	83.333	75.000	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	6.522 (21.0153)	9.234 (19.5220)	7.738 (19.4254)	9.259 (21.7474)	8.194 (19.9748)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	0.000, 16.667	0.000, 25.000	0.000, 16.667
Min, Max	-41.67, 66.67	-33.33, 50.00	-41.67, 66.67	-33.33, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	72.083 (23.3012)	76.944 (18.3990)	75.926 (20.6807)	72.619 (20.2623)	75.000 (20.4124)
Median	83.333	83.333	83.333	70.833	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	66.667, 91.667	58.333, 91.667	66.667, 91.667
Min, Max	8.33, 100.00	33.33, 100.00	8.33, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	5.417 (10.9073)	9.483 (18.4633)	7.619 (16.7121)	8.333 (13.8675)	7.823 (15.8121)
Median	0.000	8.333	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-8.33, 41.67	-16.67, 66.67	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	68.860 (24.1909)	74.722 (19.8755)	72.059 (21.6027)	73.333 (22.3163)	72.449 (21.5974)
Median	66.667	83.333	79.167	83.333	83.333
Q1, Q3	58.333, 83.333	58.333, 83.333	66.667, 83.333	58.333, 91.667	58.333, 83.333
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	3.070 (20.2627)	6.897 (20.1764)	4.293 (19.4456)	7.778 (21.9276)	5.382 (20.0833)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667	0.000, 25.000	0.000, 16.667
Min, Max	-33.33, 50.00	-50.00, 41.67	-41.67, 50.00	-50.00, 41.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	74.479 (26.7825)	76.543 (15.5107)	76.149 (22.1292)	75.000 (16.0128)	75.775 (20.1527)
Median	83.333	83.333	83.333	79.167	83.333
Q1, Q3	66.667, 87.500	66.667, 83.333	66.667, 83.333	66.667, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	7.292 (13.5657)	7.051 (19.5352)	7.143 (14.6485)	7.143 (22.3743)	7.143 (17.3216)
Median	8.333	8.333	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667	-8.333, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 58.33	-16.67, 41.67	-33.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	65.152 (27.8434)	82.197 (12.9344)	72.348 (23.0577)	84.848 (10.4205)	76.515 (20.4607)
Median	75.000	83.333	79.167	83.333	83.333
Q1, Q3	41.667, 83.333	75.000, 83.333	66.667, 83.333	75.000, 100.000	75.000, 83.333
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00	75.00, 100.00	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	0.758 (19.8797)	15.873 (15.7905)	6.746 (17.2037)	18.182 (19.2996)	10.677 (18.4811)
Median	0.000	16.667	8.333	8.333	8.333
Q1, Q3	-16.667, 16.667	0.000, 25.000	0.000, 16.667	0.000, 33.333	0.000, 20.833
Min, Max	-33.33, 33.33	0.00, 58.33	-33.33, 33.33	0.00, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	71.111 (28.3240)	80.159 (14.7846)	74.333 (23.9260)	81.061 (14.9494)	76.389 (21.5933)
Median	83.333	83.333	83.333	83.333	83.333
Q1, Q3	50.000, 91.667	66.667, 83.333	66.667, 83.333	66.667, 91.667	66.667, 87.500
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	1.667 (15.4945)	15.000 (20.1602)	6.597 (15.5377)	15.152 (25.5000)	9.286 (19.2561)
Median	0.000	16.667	0.000	8.333	0.000
Q1, Q3	-8.333, 16.667	0.000, 25.000	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-25.00, 33.33	-16.67, 66.67	-25.00, 33.33	-16.67, 66.67	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	69.872 (28.5730)	76.042 (18.9724)	73.864 (25.3671)	71.429 (17.9100)	73.276 (23.5048)
Median	83.333	79.167	83.333	83.333	83.333
Q1, Q3	50.000, 83.333	66.667, 87.500	66.667, 91.667	50.000, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	41.67, 100.00	0.00, 100.00	41.67, 83.33	0.00, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	0.641 (19.9715)	11.111 (20.3313)	4.762 (18.5539)	10.714 (26.6642)	6.250 (20.4910)
Median	0.000	8.333	0.000	8.333	4.167
Q1, Q3	-8.333, 8.333	-8.333, 16.667	0.000, 16.667	-8.333, 33.333	-8.333, 16.667
Min, Max	-33.33, 41.67	-16.67, 58.33	-33.33, 41.67	-16.67, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	54.762 (26.2895)	58.333 (23.5702)	54.167 (26.5039)	66.667 (6.8041)	56.944 (23.9570)
Median	66.667	66.667	58.333	66.667	66.667
Q1, Q3	25.000, 66.667	33.333, 75.000	33.333, 66.667	62.500, 70.833	33.333, 66.667
Min, Max	16.67, 91.67	16.67, 100.00	16.67, 100.00	58.33, 75.00	16.67, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-11.905 (40.4995)	-9.848 (17.8022)	-14.286 (30.5625)	2.083 (4.1667)	-10.648 (27.6837)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	-50.000, 16.667	-25.000, 8.333	-33.333, 8.333	0.000, 4.167	-25.000, 8.333
Min, Max	-75.00, 41.67	-41.67, 8.33	-75.00, 41.67	0.00, 8.33	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Physical functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	86.667 (17.9267)	80.833 (20.5446)	87.083 (15.6442)	73.333 (25.0432)	83.184 (19.6041)
Median	93.333	86.667	93.333	80.000	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	86.667, 100.000	46.667, 93.333	80.000, 100.000
Min, Max	40.00, 100.00	20.00, 100.00	40.00, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	37	42	18	60
Mean (SD)	88.406 (17.6632)	84.324 (16.2706)	89.365 (15.0201)	77.778 (18.2932)	85.889 (16.7890)
Median	93.333	86.667	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000	73.333, 86.667	83.333, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	26.67, 100.00	26.67, 93.33	26.67, 100.00
Change from Baseline					
n	23	36	41	18	59
Mean (SD)	0.000 (13.6330)	2.222 (13.9841)	0.650 (11.7194)	2.963 (17.8918)	1.356 (13.7732)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-6.667, 0.000	-6.667, 6.667	0.000, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-33.33, 40.00	-26.67, 53.33	-33.33, 40.00	-26.67, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	86.000 (24.3656)	86.667 (12.9957)	87.778 (19.0238)	83.111 (15.7090)	86.405 (18.0843)
Median	93.333	86.667	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	46.67, 100.00	20.00, 100.00	46.67, 100.00	20.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	1.000 (13.3815)	3.778 (18.3356)	-0.381 (12.2012)	9.778 (22.5187)	2.667 (16.4406)
Median	0.000	0.000	0.000	6.667	0.000
Q1, Q3	-3.333, 6.667	-6.667, 6.667	-6.667, 6.667	-6.667, 26.667	-6.667, 6.667
Min, Max	-20.00, 33.33	-33.33, 53.33	-20.00, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	84.912 (24.5294)	84.667 (20.5032)	88.235 (19.2141)	76.889 (26.0484)	84.762 (21.9004)
Median	93.333	86.667	93.333	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	86.667, 100.000	80.000, 86.667	80.000, 100.000
Min, Max	0.00, 100.00	6.67, 100.00	0.00, 100.00	6.67, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.702 (12.3518)	2.069 (22.0464)	0.404 (11.0478)	4.000 (29.6862)	1.528 (18.6666)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667	-6.667, 13.333	0.000, 6.667
Min, Max	-40.00, 20.00	-73.33, 53.33	-40.00, 20.00	-73.33, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	26	29	13	42
Mean (SD)	82.083 (27.6184)	87.436 (16.8999)	87.586 (21.6556)	80.513 (20.9870)	85.397 (21.4508)
Median	90.000	93.333	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	86.667, 100.000	80.000, 93.333	86.667, 100.000
Min, Max	0.00, 100.00	20.00, 100.00	0.00, 100.00	20.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	-2.083 (14.5488)	4.800 (15.5778)	-0.238 (12.1014)	7.179 (20.4508)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-6.667, 3.333	0.000, 6.667	0.000, 6.667	0.000, 6.667	0.000, 6.667
Min, Max	-40.00, 26.67	-13.33, 60.00	-40.00, 26.67	-13.33, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	78.788 (26.4690)	90.606 (10.0072)	85.152 (20.8732)	89.697 (9.1232)	86.667 (17.7951)
Median	86.667	93.333	86.667	93.333	86.667
Q1, Q3	80.000, 93.333	86.667, 100.000	86.667, 100.000	80.000, 100.000	86.667, 100.000
Min, Max	26.67, 100.00	66.67, 100.00	26.67, 100.00	73.33, 100.00	26.67, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-0.606 (12.8078)	3.175 (17.7162)	-1.270 (12.2237)	7.879 (21.0435)	1.875 (16.0853)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-13.333, 6.667	-6.667, 6.667	-13.333, 0.000	-6.667, 6.667	-6.667, 6.667
Min, Max	-13.33, 26.67	-26.67, 60.00	-26.67, 26.67	-13.33, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	84.444 (26.3874)	83.889 (17.0239)	83.267 (24.4025)	86.061 (10.9360)	84.120 (21.0762)
Median	93.333	86.667	93.333	93.333	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	80.000, 100.000	80.000, 93.333	80.000, 96.667
Min, Max	6.67, 100.00	26.67, 100.00	6.67, 100.00	60.00, 93.33	6.67, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	0.444 (15.0062)	-3.250 (23.8077)	-4.375 (18.8934)	4.242 (22.9536)	-1.667 (20.3202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-12.500, 0.000	-9.167, 0.000	-6.667, 6.667	-6.667, 0.000
Min, Max	-33.33, 40.00	-66.67, 60.00	-66.67, 40.00	-20.00, 60.00	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	87.179 (17.9426)	87.292 (11.6885)	87.424 (15.7336)	86.667 (10.8866)	87.241 (14.5315)
Median	93.333	86.667	93.333	86.667	93.333
Q1, Q3	80.000, 100.000	80.000, 100.000	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	46.67, 100.00	66.67, 100.00	46.67, 100.00	66.67, 100.00	46.67, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	5.641 (10.8342)	-1.111 (23.0137)	0.476 (11.8456)	6.667 (31.9722)	2.024 (18.3998)
Median	6.667	-6.667	0.000	-6.667	0.000
Q1, Q3	0.000, 6.667	-10.000, 0.000	-6.667, 6.667	-6.667, 33.333	-6.667, 6.667
Min, Max	-13.33, 33.33	-26.67, 66.67	-20.00, 33.33	-26.67, 66.67	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	82.857 (14.8360)	64.848 (20.8893)	77.143 (18.2507)	53.333 (18.0534)	71.852 (20.3955)
Median	86.667	60.000	80.000	60.000	73.333
Q1, Q3	66.667, 93.333	46.667, 80.000	60.000, 93.333	43.333, 63.333	60.000, 86.667
Min, Max	60.00, 100.00	26.67, 100.00	46.67, 100.00	26.67, 66.67	26.67, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-4.762 (17.9358)	-10.303 (15.5959)	-6.667 (16.5380)	-13.333 (16.3299)	-8.148 (16.2586)
Median	-6.667	-13.333	-3.333	-13.333	-10.000
Q1, Q3	-20.000, 6.667	-20.000, 0.000	-20.000, 0.000	-23.333, -3.333	-20.000, 0.000
Min, Max	-26.67, 26.67	-33.33, 13.33	-33.33, 26.67	-33.33, 6.67	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	58.333 (-)	58.333 (-)	- (-)	58.333 (-)
Median	-	58.333	58.333	-	58.333
Q1, Q3	-, -	58.333, 58.333	58.333, 58.333	-, -	58.333, 58.333
Min, Max	-, -	58.33, 58.33	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	60.000 (-)	60.000 (-)	- (-)	60.000 (-)
Median	-	60.000	60.000	-	60.000
Q1, Q3	-, -	60.000, 60.000	60.000, 60.000	-, -	60.000, 60.000
Min, Max	-, -	60.00, 60.00	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-6.667 (-)	-6.667 (-)	- (-)	-6.667 (-)
Median	-	-6.667	-6.667	-	-6.667
Q1, Q3	-, -	-6.667, -6.667	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	73.333 (-)	73.333 (-)	- (-)	73.333 (-)
Median	-	73.333	73.333	-	73.333
Q1, Q3	-, -	73.333, 73.333	73.333, 73.333	-, -	73.333, 73.333
Min, Max	-, -	73.33, 73.33	73.33, 73.33	-, -	73.33, 73.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	6.667 (-)	6.667 (-)	- (-)	6.667 (-)
Median	-	6.667	6.667	-	6.667
Q1, Q3	-, -	6.667, 6.667	6.667, 6.667	-, -	6.667, 6.667
Min, Max	-, -	6.67, 6.67	6.67, 6.67	-, -	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	86.667 (-)	86.667 (-)	- (-)	86.667 (-)
Median	-	86.667	86.667	-	86.667
Q1, Q3	-, -	86.667, 86.667	86.667, 86.667	-, -	86.667, 86.667
Min, Max	-, -	86.67, 86.67	86.67, 86.67	-, -	86.67, 86.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	20.000 (-)	20.000 (-)	- (-)	20.000 (-)
Median	-	20.000	20.000	-	20.000
Q1, Q3	-, -	20.000, 20.000	20.000, 20.000	-, -	20.000, 20.000
Min, Max	-, -	20.00, 20.00	20.00, 20.00	-, -	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Role functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	87.037 (23.2661)	80.833 (26.5677)	87.500 (22.1482)	72.807 (30.0260)	83.333 (25.2929)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	87.681 (23.6864)	86.404 (20.8150)	89.535 (20.2574)	80.556 (24.4214)	86.885 (21.7551)
Median	100.000	100.000	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (26.1116)	3.604 (21.9199)	0.397 (21.9287)	6.481 (26.8978)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-50.00, 66.67	-66.67, 66.67	-50.00, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	90.000 (21.2201)	89.785 (15.9149)	92.130 (17.1298)	84.444 (19.3820)	89.869 (17.9748)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	91.667, 100.000	83.333, 100.000	91.667, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	5.000 (10.9491)	6.111 (24.5587)	2.857 (13.0895)	12.222 (30.5158)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	85.088 (25.3949)	87.222 (25.4023)	90.196 (20.5635)	77.778 (32.5300)	86.395 (25.1554)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.877 (23.2231)	2.299 (19.2746)	1.010 (19.0665)	3.333 (24.5596)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 33.33	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	83.333 (29.1865)	88.272 (22.5580)	88.506 (24.0302)	82.143 (27.3192)	86.434 (25.0015)
Median	100.000	100.000	100.000	91.667	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (14.7510)	3.846 (23.7148)	-1.786 (16.5672)	8.333 (26.7547)	1.587 (20.7611)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-33.33, 16.67	-50.00, 83.33	-50.00, 33.33	-33.33, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	75.758 (32.7987)	89.394 (14.1285)	84.091 (25.9615)	86.364 (14.5644)	84.848 (22.5784)
Median	83.333	100.000	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-9.091 (13.6700)	0.794 (27.6266)	-5.556 (16.9422)	3.030 (34.0083)	-2.604 (23.9883)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	86.667 (24.5596)	87.302 (21.0190)	86.000 (24.8514)	89.394 (15.4069)	87.037 (22.2222)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	0.000 (16.6667)	-0.833 (35.2414)	-3.472 (24.0667)	6.061 (36.7217)	-0.476 (28.4357)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 8.333	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	-33.33, 33.33	-83.33, 100.00	-83.33, 33.33	-33.33, 100.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	89.744 (25.9437)	88.542 (17.9699)	89.394 (20.9215)	88.095 (24.9338)	89.080 (21.4901)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	5.128 (12.5178)	-2.222 (30.1232)	0.000 (12.9099)	4.762 (43.7949)	1.190 (23.5390)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 33.33	-66.67, 83.33	-16.67, 33.33	-66.67, 83.33	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	66.667 (39.6746)	54.545 (26.9680)	63.095 (33.4476)	45.833 (25.0000)	59.259 (31.9427)
Median	83.333	66.667	66.667	50.000	66.667
Q1, Q3	33.333, 100.000	33.333, 66.667	33.333, 100.000	25.000, 66.667	33.333, 83.333
Min, Max	0.00, 100.00	16.67, 100.00	0.00, 100.00	16.67, 66.67	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-11.905 (38.1448)	-19.697 (24.5155)	-15.476 (30.2866)	-20.833 (31.5495)	-16.667 (29.7044)
Median	0.000	-16.667	-16.667	-8.333	-16.667
Q1, Q3	-50.000, 0.000	-33.333, 0.000	-33.333, 0.000	-41.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 50.00	-66.67, 16.67	-66.67, 50.00	-66.67, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Emotional functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	85.185 (15.2145)	80.208 (19.4005)	84.201 (16.2392)	77.193 (21.1261)	82.214 (17.8786)
Median	91.667	83.333	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	58.33, 100.00	25.00, 100.00	41.67, 100.00	25.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	81.522 (27.2887)	86.404 (16.1428)	85.853 (21.7865)	81.481 (19.0792)	84.563 (20.9627)
Median	100.000	91.667	100.000	83.333	91.667
Q1, Q3	66.667, 100.000	75.000, 100.000	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	41.67, 100.00	16.67, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-3.261 (24.5848)	6.081 (13.4154)	1.786 (20.8667)	4.167 (13.4826)	2.500 (18.8724)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-25.00, 33.33	-75.00, 33.33	-25.00, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	83.333 (21.2889)	83.056 (22.6885)	84.954 (22.6971)	78.571 (19.8052)	83.167 (21.9183)
Median	91.667	91.667	91.667	83.333	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	83.333, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-0.417 (15.6429)	5.747 (20.9050)	2.143 (17.5435)	5.952 (22.7464)	3.231 (19.0042)
Median	0.000	8.333	0.000	8.333	0.000
Q1, Q3	-12.500, 8.333	0.000, 16.667	-8.333, 8.333	0.000, 25.000	0.000, 16.667
Min, Max	-25.00, 33.33	-50.00, 41.67	-41.67, 41.67	-50.00, 33.33	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	83.772 (22.6476)	82.222 (22.7148)	82.598 (23.4240)	83.333 (20.8928)	82.823 (22.4645)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	8.33, 100.00	16.67, 100.00	8.33, 100.00	41.67, 100.00	8.33, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.877 (19.8168)	2.586 (19.9334)	0.000 (19.3200)	6.111 (20.5255)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 16.667	-8.333, 16.667	0.000, 16.667	-8.333, 16.667
Min, Max	-50.00, 33.33	-41.67, 50.00	-50.00, 33.33	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	77.083 (30.0463)	86.420 (18.6551)	80.172 (27.4055)	88.690 (11.6057)	82.946 (23.6370)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	50.000, 100.000	83.333, 100.000	75.000, 100.000	83.333, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-7.292 (21.4897)	6.090 (13.4490)	-2.381 (19.3592)	7.738 (12.8537)	0.992 (17.9583)
Median	0.000	0.000	0.000	4.167	0.000
Q1, Q3	-20.833, 4.167	0.000, 16.667	-16.667, 12.500	0.000, 8.333	0.000, 8.333
Min, Max	-50.00, 25.00	-16.67, 41.67	-50.00, 25.00	-8.33, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	75.000 (23.5702)	85.606 (21.5445)	80.303 (25.5295)	85.606 (14.9494)	82.071 (22.4499)
Median	83.333	91.667	87.500	91.667	91.667
Q1, Q3	66.667, 91.667	75.000, 100.000	75.000, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	25.00, 100.00	8.33, 100.00	8.33, 100.00	58.33, 100.00	8.33, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-6.818 (17.8022)	6.746 (18.1848)	-1.587 (19.2965)	9.091 (16.8550)	2.083 (18.9321)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 8.333	0.000, 16.667	-8.333, 8.333	0.000, 25.000	-8.333, 12.500
Min, Max	-41.67, 16.67	-33.33, 41.67	-41.67, 33.33	-8.33, 41.67	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	84.444 (23.1169)	85.317 (20.0528)	83.333 (23.6927)	88.636 (13.5773)	84.954 (21.0649)
Median	100.000	91.667	91.667	91.667	91.667
Q1, Q3	66.667, 100.000	75.000, 100.000	75.000, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	25.00, 100.00	16.67, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	0.000 (20.4124)	7.083 (15.3600)	0.694 (17.8758)	11.364 (15.9307)	4.048 (17.7781)
Median	0.000	4.167	0.000	8.333	0.000
Q1, Q3	-8.333, 8.333	0.000, 12.500	-8.333, 8.333	0.000, 25.000	0.000, 8.333
Min, Max	-41.67, 33.33	-25.00, 41.67	-41.67, 33.33	-8.33, 41.67	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	83.333 (23.8145)	80.729 (26.3029)	81.439 (26.0915)	83.333 (22.0479)	81.897 (24.8077)
Median	100.000	91.667	95.833	91.667	91.667
Q1, Q3	75.000, 100.000	70.833, 100.000	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00	41.67, 100.00	8.33, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-1.282 (20.9293)	0.556 (17.3853)	-3.571 (18.3658)	9.524 (17.6308)	-0.298 (18.7690)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 8.333	-8.333, 8.333	-16.667, 8.333	0.000, 25.000	-8.333, 8.333
Min, Max	-50.00, 33.33	-33.33, 41.67	-50.00, 33.33	-8.33, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	78.571 (31.1274)	70.455 (19.1353)	76.190 (25.2883)	64.583 (18.4780)	73.611 (23.9570)
Median	91.667	75.000	87.500	66.667	79.167
Q1, Q3	33.333, 100.000	58.333, 83.333	66.667, 91.667	50.000, 79.167	58.333, 91.667
Min, Max	33.33, 100.00	33.33, 91.67	33.33, 100.00	41.67, 83.33	33.33, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-8.333 (23.5702)	-9.848 (16.1667)	-10.119 (21.2279)	-6.250 (4.1667)	-9.259 (18.7190)
Median	0.000	-8.333	-4.167	-8.333	-8.333
Q1, Q3	-25.000, 0.000	-25.000, 0.000	-25.000, 0.000	-8.333, -4.167	-25.000, 0.000
Min, Max	-50.00, 25.00	-33.33, 16.67	-50.00, 25.00	-8.33, 0.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-13.889 (-)	-13.889 (-)	- (-)	-13.889 (-)
Median	-	-13.889	-13.889	-	-13.889
Q1, Q3	-, -	-13.889, -13.889	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	8.333 (-)	8.333 (-)	- (-)	8.333 (-)
Median	-	8.333	8.333	-	8.333
Q1, Q3	-, -	8.333, 8.333	8.333, 8.333	-, -	8.333, 8.333
Min, Max	-, -	8.33, 8.33	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	8.333 (-)	8.333 (-)	- (-)	8.333 (-)
Median	-	8.333	8.333	-	8.333
Q1, Q3	-, -	8.333, 8.333	8.333, 8.333	-, -	8.333, 8.333
Min, Max	-, -	8.33, 8.33	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	91.667 (-)	91.667 (-)	- (-)	91.667 (-)
Median	-	91.667	91.667	-	91.667
Q1, Q3	-, -	91.667, 91.667	91.667, 91.667	-, -	91.667, 91.667
Min, Max	-, -	91.67, 91.67	91.67, 91.67	-, -	91.67, 91.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cognitive functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	85.802 (20.5188)	89.583 (15.8732)	88.542 (17.9164)	86.842 (18.0696)	88.060 (17.8391)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	86.957 (20.0734)	85.088 (14.9018)	86.822 (17.6526)	83.333 (15.1248)	85.792 (16.8973)
Median	100.000	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (21.3201)	-5.856 (13.7303)	-2.381 (17.4885)	-6.481 (16.3088)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	81.667 (25.8764)	86.667 (21.1725)	83.796 (25.0352)	86.905 (17.5150)	84.667 (23.0449)
Median	91.667	91.667	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-4.167 (15.1744)	-5.172 (15.4967)	-5.714 (16.6386)	-2.381 (11.0499)	-4.762 (15.2145)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-66.67, 16.67	-66.67, 33.33	-33.33, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	85.088 (28.2705)	83.333 (22.7429)	86.275 (24.0897)	78.889 (26.3272)	84.014 (24.7579)
Median	100.000	83.333	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	0.000 (18.4257)	-8.621 (21.1854)	-2.525 (16.2025)	-11.111 (27.2166)	-5.208 (20.3853)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-100.00, 16.67	-33.33, 50.00	-100.00, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	80.208 (28.0335)	86.420 (18.5114)	83.333 (25.5883)	85.714 (14.4073)	84.109 (22.4060)
Median	100.000	83.333	100.000	83.333	83.333
Q1, Q3	58.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-6.250 (22.6691)	-4.487 (12.9595)	-5.952 (19.8836)	-3.571 (9.6489)	-5.159 (17.0636)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00	-16.67, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	80.303 (22.1337)	85.606 (23.1715)	82.576 (25.4469)	86.364 (16.3608)	83.838 (22.6250)
Median	83.333	91.667	91.667	83.333	83.333
Q1, Q3	50.000, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-1.515 (24.1000)	-7.937 (18.7224)	-4.762 (22.4492)	-7.576 (17.2621)	-5.729 (20.5696)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-8.333, 0.000
Min, Max	-33.33, 50.00	-66.67, 0.00	-66.67, 50.00	-50.00, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	83.333 (27.4585)	86.508 (16.3461)	86.000 (24.8514)	83.333 (10.5409)	85.185 (21.3726)
Median	100.000	83.333	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 83.333	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-3.333 (19.1071)	-6.667 (11.3426)	-2.778 (16.7870)	-10.606 (8.4087)	-5.238 (15.0008)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-33.33, 16.67	-33.33, 50.00	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	89.744 (16.0128)	81.250 (23.4718)	87.121 (21.1644)	78.571 (18.5450)	85.057 (20.5793)
Median	100.000	83.333	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	3.846 (19.4292)	-11.111 (16.2650)	-0.794 (19.3478)	-14.286 (14.9956)	-4.167 (19.0435)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-16.67, 50.00	-50.00, 0.00	-50.00, 50.00	-33.33, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	73.810 (23.2879)	77.273 (20.1008)	73.810 (22.3743)	83.333 (13.6083)	75.926 (20.7870)
Median	83.333	83.333	83.333	83.333	83.333
Q1, Q3	50.000, 83.333	66.667, 100.000	66.667, 83.333	75.000, 91.667	66.667, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-11.905 (20.8928)	-12.121 (15.0756)	-14.286 (17.1184)	-4.167 (15.9571)	-12.037 (16.9636)
Median	-16.667	-16.667	-16.667	-8.333	-16.667
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 8.333	-16.667, 0.000
Min, Max	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67	-16.67, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Social functioning					
Baseline					
n	27	40	48	19	67
Mean (SD)	88.272 (19.5105)	82.917 (24.0155)	86.806 (20.6165)	80.702 (26.2133)	85.075 (22.3106)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	85.507 (23.1946)	91.228 (17.2148)	89.922 (20.2953)	87.037 (18.5729)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-2.174 (24.2589)	6.306 (24.3278)	2.381 (22.2609)	4.630 (29.5973)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 66.67	-50.00, 100.00	-50.00, 66.67	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	92.500 (17.5010)	91.667 (15.0032)	93.056 (15.1054)	89.286 (18.0303)	92.000 (15.8794)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	6.667 (23.1951)	6.897 (25.0068)	6.190 (21.0375)	8.333 (31.1805)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 83.33	-50.00, 100.00	-33.33, 83.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	83.333 (26.0579)	88.889 (21.1423)	87.255 (21.3433)	85.556 (27.3620)	86.735 (23.0688)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-1.754 (30.8795)	4.023 (26.9682)	0.505 (27.1585)	4.444 (31.7897)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667	0.000, 8.333
Min, Max	-66.67, 83.33	-83.33, 66.67	-66.67, 83.33	-83.33, 66.67	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	87.500 (15.5158)	94.444 (10.3362)	90.230 (13.7417)	95.238 (10.1875)	91.860 (12.7927)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (19.1243)	8.333 (24.1523)	0.595 (17.8483)	11.905 (29.5468)	4.365 (22.7093)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-8.333, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	83.333 (21.0819)	92.424 (16.8461)	84.091 (20.8784)	100.000 (0.0000)	89.394 (18.5490)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	100.000, 100.000	66.667, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00	100.00, 100.00	33.33, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-4.545 (16.8175)	8.730 (27.6983)	-2.381 (18.4735)	16.667 (31.6228)	4.167 (25.0448)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-16.667, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 33.33	0.00, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	90.000 (19.7203)	92.857 (15.4303)	89.333 (19.7672)	96.970 (6.7420)	91.667 (17.1362)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	83.33, 100.00	33.33, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	0.000 (18.8982)	10.000 (26.1574)	2.083 (17.2454)	13.636 (33.1815)	5.714 (23.5504)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 100.00	-33.33, 33.33	-16.67, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	85.897 (23.4186)	93.750 (13.4371)	87.121 (20.5299)	100.000 (0.0000)	90.230 (18.6431)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	91.667, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	100.00, 100.00	33.33, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-2.564 (22.4084)	13.333 (30.9890)	0.000 (21.7307)	23.810 (38.3178)	5.952 (28.0411)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-16.667, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 100.00	-33.33, 50.00	0.00, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	66.667 (28.8675)	68.182 (25.2262)	70.238 (24.6155)	58.333 (31.9142)	67.593 (25.8656)
Median	66.667	66.667	75.000	50.000	66.667
Q1, Q3	33.333, 100.000	33.333, 83.333	50.000, 83.333	33.333, 83.333	33.333, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	-11.905 (28.4056)	-12.121 (23.6771)	-10.714 (24.1143)	-16.667 (30.4290)	-12.037 (24.7903)
Median	0.000	-16.667	-8.333	-16.667	-8.333
Q1, Q3	-50.000, 16.667	-33.333, 16.667	-33.333, 16.667	-41.667, 8.333	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Fatigue					
Baseline					
n	27	40	48	19	67
Mean (SD)	24.280 (24.6605)	32.917 (21.8772)	24.306 (20.7118)	42.398 (24.7907)	29.436 (23.2509)
Median	22.222	27.778	22.222	44.444	22.222
Q1, Q3	11.111, 33.333	16.667, 47.222	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 88.89	0.00, 100.00	0.00, 88.89	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	24.155 (26.0906)	20.760 (20.2043)	20.155 (21.9903)	26.543 (23.5360)	22.040 (22.4518)
Median	22.222	16.667	11.111	27.778	22.222
Q1, Q3	0.000, 44.444	0.000, 33.333	0.000, 22.222	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.966 (28.0118)	-10.360 (21.9958)	-2.646 (22.1964)	-13.889 (29.4127)	-6.019 (24.8724)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-11.111, 11.111	-22.222, 0.000	-11.111, 0.000	-33.333, 0.000	-22.222, 0.000
Min, Max	-55.56, 66.67	-88.89, 33.33	-55.56, 66.67	-88.89, 33.33	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	26.667 (24.0208)	21.147 (18.8899)	23.148 (22.7516)	23.704 (16.7283)	23.312 (20.9944)
Median	22.222	22.222	22.222	22.222	22.222
Q1, Q3	11.111, 27.778	0.000, 33.333	5.556, 33.333	11.111, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.556 (13.2331)	-10.926 (21.6636)	-0.952 (13.8388)	-18.889 (24.8274)	-6.333 (19.4407)
Median	0.000	-11.111	0.000	-11.111	0.000
Q1, Q3	-5.556, 11.111	-22.222, 0.000	-11.111, 11.111	-27.778, 0.000	-11.111, 0.000
Min, Max	-22.22, 22.22	-77.78, 33.33	-22.22, 33.33	-77.78, 11.11	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	22.222 (26.4497)	23.333 (19.6500)	20.915 (23.3333)	27.407 (19.6381)	22.902 (22.2694)
Median	11.111	22.222	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	22.222, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 77.78	0.00, 100.00	0.00, 77.78	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-4.678 (18.2633)	-7.854 (21.0775)	-4.040 (17.0824)	-12.222 (24.6850)	-6.597 (19.8714)
Median	0.000	0.000	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-11.111, 0.000	-33.333, 0.000	-19.444, 0.000
Min, Max	-44.44, 33.33	-55.56, 44.44	-44.44, 33.33	-55.56, 44.44	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	20.833 (24.3009)	19.342 (17.8611)	18.008 (20.6623)	23.810 (19.4204)	19.897 (20.2219)
Median	16.667	22.222	11.111	33.333	22.222
Q1, Q3	0.000, 38.889	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-3.472 (15.5655)	-10.470 (23.1115)	-5.159 (14.6541)	-13.095 (29.2033)	-7.804 (20.6438)
Median	0.000	0.000	0.000	-11.111	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-22.22, 33.33	-88.89, 33.33	-33.33, 33.33	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	26.263 (24.9804)	13.131 (12.6623)	17.677 (20.1870)	17.172 (15.2053)	17.508 (18.4320)
Median	22.222	11.111	11.111	11.111	11.111
Q1, Q3	11.111, 33.333	0.000, 22.222	0.000, 22.222	0.000, 33.333	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 44.44	0.00, 88.89	0.00, 44.44	0.00, 88.89
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-3.030 (23.3550)	-16.138 (21.5097)	-6.878 (18.0795)	-20.707 (28.3378)	-11.632 (22.6816)
Median	0.000	-11.111	0.000	-11.111	0.000
Q1, Q3	0.000, 0.000	-22.222, 0.000	-11.111, 0.000	-38.889, 0.000	-22.222, 0.000
Min, Max	-44.44, 33.33	-88.89, 0.00	-44.44, 33.33	-88.89, 0.00	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	23.704 (29.9520)	20.635 (15.8253)	21.778 (25.3535)	22.222 (14.9071)	21.914 (22.4569)
Median	11.111	22.222	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	11.111, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 44.44	0.00, 100.00	0.00, 44.44	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-0.741 (14.8280)	-7.778 (21.3574)	-0.463 (13.6984)	-14.141 (25.3815)	-4.762 (18.9188)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-11.111, 0.000	-16.667, 0.000	-11.111, 0.000	-33.333, 0.000	-11.111, 0.000
Min, Max	-22.22, 33.33	-66.67, 22.22	-22.22, 33.33	-66.67, 22.22	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	20.513 (21.6815)	22.222 (26.2937)	19.697 (20.5543)	26.984 (33.8583)	21.456 (23.9287)
Median	11.111	22.222	11.111	22.222	22.222
Q1, Q3	11.111, 22.222	0.000, 27.778	0.000, 33.333	0.000, 22.222	0.000, 22.222
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-4.274 (14.7255)	-5.185 (35.1029)	-2.116 (15.5631)	-12.698 (49.0354)	-4.762 (27.1204)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-11.111, 0.000	-22.222, 11.111	-11.111, 11.111	-55.556, 0.000	-11.111, 5.556
Min, Max	-33.33, 22.22	-88.89, 66.67	-33.33, 22.22	-88.89, 66.67	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	38.095 (27.8570)	55.556 (29.3972)	42.857 (28.8616)	69.444 (22.9061)	48.765 (29.3079)
Median	33.333	66.667	38.889	66.667	55.556
Q1, Q3	11.111, 66.667	22.222, 77.778	11.111, 66.667	55.556, 83.333	22.222, 66.667
Min, Max	0.00, 77.78	11.11, 100.00	0.00, 77.78	44.44, 100.00	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	7.937 (31.2393)	17.677 (23.4150)	11.111 (25.4121)	23.611 (30.8904)	13.889 (26.2833)
Median	0.000	11.111	5.556	16.667	11.111
Q1, Q3	-22.222, 44.444	0.000, 33.333	-11.111, 33.333	2.778, 44.444	-5.556, 33.333
Min, Max	-22.22, 55.56	-11.11, 66.67	-22.22, 55.56	-5.56, 66.67	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-22.222 (-)	-22.222 (-)	- (-)	-22.222 (-)
Median	-	-22.222	-22.222	-	-22.222
Q1, Q3	-, -	-22.222, -22.222	-22.222, -22.222	-, -	-22.222, -22.222
Min, Max	-, -	-22.22, -22.22	-22.22, -22.22	-, -	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Nausea and vomiting					
Baseline					
n	27	40	48	19	67
Mean (SD)	5.556 (13.0744)	2.917 (8.3440)	3.819 (10.4506)	4.386 (10.8896)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	4.348 (11.4783)	1.754 (5.1835)	3.488 (9.3139)	0.926 (3.9284)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-0.725 (9.3720)	-1.351 (9.1104)	0.000 (9.0167)	-3.704 (9.1386)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-33.33, 16.67	-33.33, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	5.833 (22.4748)	2.151 (5.6796)	4.167 (17.0783)	2.222 (5.8644)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	1.667 (17.8525)	-1.111 (8.6805)	1.429 (14.2179)	-3.333 (9.3435)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 16.67	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	3.509 (8.9217)	3.889 (8.4001)	3.431 (7.9766)	4.444 (9.8936)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-0.877 (6.7442)	0.575 (9.4310)	0.505 (7.7782)	-1.111 (9.8936)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	4.167 (12.9099)	1.235 (4.4480)	2.874 (10.0287)	1.190 (4.4544)	2.326 (8.5923)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	1.042 (4.1667)	-1.282 (4.5291)	0.595 (3.1497)	-2.381 (6.0523)	-0.397 (4.4904)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	-16.67, 0.00	0.00, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	3.030 (10.0504)	1.515 (4.9041)	2.273 (7.7927)	1.515 (5.0252)	2.020 (6.9191)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-1.515 (5.0252)	-1.587 (8.9826)	-0.794 (6.4035)	-3.030 (10.0504)	-1.563 (7.7591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	-33.33, 16.67	-16.67, 16.67	-33.33, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	2.222 (8.6066)	0.794 (3.6370)	1.333 (6.6667)	1.515 (5.0252)	1.389 (6.1399)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-1.111 (4.3033)	-2.500 (8.1560)	-1.389 (4.7055)	-3.030 (10.0504)	-1.905 (6.7294)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	-33.33, 0.00	-16.67, 0.00	-33.33, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	2.564 (6.2589)	3.125 (12.5000)	1.515 (4.9041)	7.143 (18.8982)	2.874 (10.0287)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 50.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-1.282 (8.2258)	0.000 (16.6667)	-0.794 (6.4035)	0.000 (25.4588)	-0.595 (13.2110)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 50.00	-16.67, 16.67	-33.33, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	9.524 (18.8982)	7.576 (15.5700)	9.524 (18.1568)	4.167 (8.3333)	8.333 (16.4197)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 8.333	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	4.762 (20.8928)	1.515 (11.6775)	4.762 (16.5748)	-4.167 (8.3333)	2.778 (15.3925)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-8.333, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	-16.67, 33.33	-16.67, 50.00	-16.67, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Pain					
Baseline					
n	27	39	48	18	66
Mean (SD)	13.580 (23.5870)	15.385 (20.0090)	12.500 (19.8993)	20.370 (24.6250)	14.646 (21.3868)
Median	0.000	16.667	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	14.493 (22.0790)	14.474 (20.9285)	12.016 (18.6607)	20.370 (25.9181)	14.481 (21.1860)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	36	42	17	59
Mean (SD)	2.174 (24.2589)	-1.389 (18.8457)	0.000 (19.8231)	0.000 (24.2956)	0.000 (20.9908)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 8.333	0.000, 0.000	-16.667, 16.667	-16.667, 16.667
Min, Max	-66.67, 50.00	-33.33, 33.33	-66.67, 50.00	-33.33, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	14.167 (30.7199)	13.978 (17.2652)	13.426 (24.8230)	15.556 (19.3820)	14.052 (23.1835)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-1.667 (20.8728)	-1.149 (19.3808)	0.952 (18.4987)	-7.143 (22.3743)	-1.361 (19.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-50.00, 33.33	-66.67, 33.33	-50.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	17.544 (28.5848)	19.444 (24.7916)	16.667 (25.2929)	23.333 (28.0306)	18.707 (26.0503)
Median	0.000	16.667	0.000	16.667	16.667
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	19	28	33	14	47
Mean (SD)	0.877 (20.3925)	5.357 (27.2368)	4.040 (20.4253)	2.381 (33.2416)	3.546 (24.5580)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667	-33.333, 33.333	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	17.708 (28.8475)	14.815 (18.6816)	14.368 (25.4811)	19.048 (15.8210)	15.891 (22.6993)
Median	0.000	0.000	0.000	25.000	0.000
Q1, Q3	0.000, 25.000	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	3.125 (15.1764)	1.333 (24.4949)	4.167 (19.0435)	-2.564 (25.3185)	2.033 (21.1460)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-50.00, 66.67	-33.33, 66.67	-50.00, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	24.242 (38.9898)	9.091 (14.2977)	17.424 (30.6358)	7.576 (8.7039)	14.141 (25.7260)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 50.00	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline					
n	11	20	21	10	31
Mean (SD)	4.545 (19.8479)	0.833 (19.0989)	3.968 (18.9332)	-1.667 (19.9536)	2.151 (19.1204)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667	-16.667, 16.667	-16.667, 16.667
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 16.67	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	17.778 (28.4986)	14.286 (27.0214)	18.000 (30.7770)	10.606 (17.1152)	15.741 (27.2974)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	1.111 (16.0192)	5.000 (30.1555)	4.861 (26.6844)	0.000 (21.0819)	3.333 (24.8525)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	-8.333, 8.333	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00	-33.33, 50.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	15.385 (27.6063)	13.542 (22.9482)	15.152 (25.1499)	11.905 (24.9338)	14.368 (24.6902)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 25.000	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 66.67	0.00, 83.33	0.00, 66.67	0.00, 83.33
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-3.846 (13.8675)	7.778 (25.8711)	1.587 (18.1848)	4.762 (31.4970)	2.381 (21.6188)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 0.000	-16.667, 16.667	-8.333, 8.333
Min, Max	-33.33, 16.67	-33.33, 66.67	-33.33, 50.00	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	21.429 (18.5450)	27.273 (28.1590)	21.429 (23.0464)	37.500 (28.4638)	25.000 (24.4214)
Median	16.667	33.333	16.667	41.667	25.000
Q1, Q3	0.000, 33.333	0.000, 50.000	0.000, 33.333	16.667, 58.333	0.000, 50.000
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	7	10	14	3	17
Mean (SD)	7.143 (28.6375)	8.333 (19.6419)	5.952 (22.2718)	16.667 (28.8675)	7.843 (22.9111)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 33.333	0.000, 16.667	0.000, 16.667	0.000, 50.000	0.000, 16.667
Min, Max	-33.33, 50.00	-16.67, 50.00	-33.33, 50.00	0.00, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Dyspnoea					
Baseline					
n	27	40	48	19	67
Mean (SD)	17.284 (26.7473)	28.333 (33.3760)	20.833 (27.1803)	31.579 (39.2423)	23.881 (31.1432)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	20.290 (27.9594)	15.789 (20.1150)	18.605 (24.4542)	14.815 (20.5233)	17.486 (23.2591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	5.797 (19.2069)	-9.009 (26.8152)	0.794 (20.1459)	-12.963 (32.6176)	-3.333 (25.0799)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	18.333 (31.4838)	12.903 (18.6139)	13.889 (26.8742)	17.778 (17.2133)	15.033 (24.3253)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	-1.667 (22.8778)	-13.333 (31.0728)	-5.714 (26.1790)	-15.556 (33.0143)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	29	33	15	48
Mean (SD)	10.526 (19.4131)	12.644 (18.7163)	10.101 (17.6479)	15.556 (21.3313)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	28	32	15	47
Mean (SD)	-10.526 (29.5075)	-14.286 (31.9832)	-10.417 (24.5935)	-17.778 (41.5315)	-12.766 (30.7343)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	12.500 (20.6380)	18.519 (25.0356)	12.644 (20.7284)	23.810 (27.5140)	16.279 (23.4262)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-10.417 (33.8160)	-6.410 (35.3009)	-8.333 (28.1457)	-7.143 (45.6268)	-7.937 (34.3815)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 66.67	-100.00, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	9.091 (21.5557)	9.091 (15.1947)	7.576 (17.6138)	12.121 (16.8175)	9.091 (17.2255)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-12.121 (34.2304)	-14.286 (24.8807)	-11.111 (26.5274)	-18.182 (31.1400)	-13.542 (27.9007)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 0.00	-100.00, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	8.889 (19.7872)	12.698 (16.5871)	9.333 (18.0534)	15.152 (17.4078)	11.111 (17.8174)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-13.333 (32.8537)	-6.667 (27.7836)	-9.722 (28.6224)	-9.091 (33.6350)	-9.524 (29.7829)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	10.256 (21.0142)	14.583 (27.1314)	10.606 (18.9300)	19.048 (37.7964)	12.644 (24.2569)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-15.385 (25.8750)	-6.667 (36.0775)	-9.524 (23.9046)	-14.286 (50.3953)	-10.714 (31.4970)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 0.00	-100.00, 66.67	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	23.810 (31.7063)	51.515 (34.5242)	35.714 (33.2416)	58.333 (41.9435)	40.741 (35.3425)
Median	0.000	66.667	33.333	66.667	33.333
Q1, Q3	0.000, 66.667	33.333, 66.667	0.000, 66.667	33.333, 83.333	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	9.524 (31.7063)	9.091 (30.1511)	7.143 (32.4987)	16.667 (19.2450)	9.259 (29.8264)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 66.67	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-66.667 (-)	-66.667 (-)	- (-)	-66.667 (-)
Median	-	-66.667	-66.667	-	-66.667
Q1, Q3	-, -	-66.667, -66.667	-66.667, -66.667	-, -	-66.667, -66.667
Min, Max	-, -	-66.67, -66.67	-66.67, -66.67	-, -	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	-33.333 (-)	-33.333 (-)	- (-)	-33.333 (-)
Median	-	-33.333	-33.333	-	-33.333
Q1, Q3	-, -	-33.333, -33.333	-33.333, -33.333	-, -	-33.333, -33.333
Min, Max	-, -	-33.33, -33.33	-33.33, -33.33	-, -	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Insomnia					
Baseline					
n	27	40	48	19	67
Mean (SD)	18.519 (23.2661)	20.833 (25.8061)	18.750 (22.7082)	22.807 (29.5075)	19.900 (24.6591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	18.841 (22.0790)	17.544 (25.3940)	14.729 (20.9589)	25.926 (29.2735)	18.033 (24.0168)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	0.000 (14.2134)	-2.703 (22.7417)	-4.762 (17.3774)	5.556 (23.5702)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	21.667 (31.1101)	18.280 (22.5071)	19.444 (28.0306)	20.000 (21.0819)	19.608 (25.9713)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.000 (18.7317)	-4.444 (20.9603)	-2.857 (20.4067)	-2.222 (19.7872)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	19.298 (27.9236)	17.778 (27.3102)	18.627 (26.1968)	17.778 (30.5158)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-3.509 (24.5823)	-3.448 (24.1438)	-4.040 (26.0309)	-2.222 (19.7872)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	22.917 (33.8160)	19.753 (24.9088)	24.138 (30.7274)	14.286 (21.5402)	20.930 (28.1936)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 50.000	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-2.083 (19.1243)	1.282 (14.8497)	1.190 (16.9292)	-2.381 (15.8210)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	30.303 (34.8155)	13.636 (22.2042)	19.697 (30.2705)	18.182 (22.9184)	19.192 (27.6766)
Median	33.333	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	0.000 (14.9071)	-3.175 (17.9653)	-3.175 (14.5479)	0.000 (21.0819)	-2.083 (16.8005)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	22.222 (32.5300)	9.524 (18.6871)	16.000 (27.4199)	12.121 (22.4733)	14.815 (25.7515)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-4.444 (17.2133)	-8.333 (21.2889)	-6.944 (16.9659)	-6.061 (25.0252)	-6.667 (19.4701)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	15.385 (25.8750)	10.417 (15.9571)	12.121 (21.9317)	14.286 (17.8174)	12.644 (20.7284)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-10.256 (16.0128)	-4.444 (17.2133)	-7.937 (14.5479)	-4.762 (23.0022)	-7.143 (16.6225)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	23.810 (31.7063)	36.364 (27.7070)	30.952 (30.5625)	33.333 (27.2166)	31.481 (29.0868)
Median	0.000	33.333	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667	16.667, 50.000	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	14.286 (26.2265)	15.152 (22.9184)	14.286 (25.1976)	16.667 (19.2450)	14.815 (23.4931)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Appetite loss					
Baseline					
n	27	40	48	19	67
Mean (SD)	9.877 (20.2860)	15.000 (26.0943)	9.722 (18.1383)	21.053 (33.7209)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	11.594 (23.8020)	9.649 (15.3202)	10.078 (19.9667)	11.111 (16.1690)	10.383 (18.7981)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	1.449 (23.5236)	-6.306 (27.0320)	0.000 (22.0863)	-11.111 (32.3381)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	10.000 (24.4232)	7.527 (16.5768)	7.407 (19.6979)	11.111 (20.5738)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	0.000 (18.7317)	-7.778 (29.9211)	-2.857 (18.7370)	-8.889 (38.7640)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	8.772 (18.7317)	6.667 (16.1411)	6.863 (15.9532)	8.889 (19.7872)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-1.754 (28.2705)	-8.046 (27.6818)	-3.030 (22.6134)	-11.111 (37.0899)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	14.583 (24.2479)	8.642 (19.8124)	11.494 (22.3178)	9.524 (20.3750)	10.853 (21.4808)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	6.250 (18.1302)	-3.846 (30.2977)	3.571 (18.8982)	-7.143 (37.3905)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	18.182 (27.3400)	3.030 (9.8082)	9.091 (21.0362)	6.061 (13.4840)	8.081 (18.6903)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	9.091 (15.5700)	-9.524 (28.1718)	1.587 (16.5871)	-12.121 (37.3355)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	11.111 (24.1249)	6.349 (13.4125)	6.667 (19.2450)	12.121 (16.8175)	8.333 (18.4735)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	4.444 (11.7289)	-6.667 (25.5924)	0.000 (13.9010)	-6.061 (32.7217)	-1.905 (21.3021)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	7.692 (19.9715)	10.417 (26.4400)	6.061 (16.7027)	19.048 (37.7964)	9.195 (23.3954)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	0.000 (13.6083)	-4.444 (43.4004)	0.000 (14.9071)	-9.524 (62.9941)	-2.381 (32.6202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 100.00	-33.33, 33.33	-100.00, 100.00	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	28.571 (35.6348)	39.394 (38.9249)	28.571 (31.6421)	58.333 (50.0000)	35.185 (36.9989)
Median	33.333	33.333	33.333	66.667	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333	16.667, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	14.286 (50.3953)	15.152 (34.5242)	11.905 (38.3576)	25.000 (50.0000)	14.815 (39.9709)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 50.000	0.000, 33.333
Min, Max	-66.67, 100.00	-33.33, 100.00	-66.67, 100.00	0.00, 100.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Constipation					
Baseline					
n	27	40	48	19	67
Mean (SD)	4.938 (12.0671)	11.667 (20.7412)	4.167 (11.1406)	21.053 (25.3629)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	10.145 (23.4301)	13.158 (22.6469)	9.302 (19.6875)	18.519 (28.5195)	12.022 (22.7977)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	5.797 (23.8941)	1.802 (22.1470)	5.556 (20.7144)	-1.852 (26.7455)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	31	36	15	51
Mean (SD)	10.000 (19.0414)	7.527 (16.5768)	8.333 (16.6667)	8.889 (19.7872)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	20	30	35	15	50
Mean (SD)	5.000 (22.3607)	-2.222 (17.3610)	4.762 (18.3340)	-8.889 (19.7872)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	7.018 (13.9618)	10.000 (17.8328)	5.882 (12.8984)	15.556 (21.3313)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	1.754 (17.4755)	-1.149 (16.6256)	2.020 (14.2872)	-4.444 (21.3313)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	18.750 (34.3592)	11.111 (24.4600)	13.793 (27.4834)	14.286 (31.2538)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	14.583 (32.1311)	0.000 (23.0940)	10.714 (27.2974)	-4.762 (25.6776)	5.556 (27.4644)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00	-33.33, 66.67	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	18.182 (31.1400)	6.061 (13.1590)	10.606 (23.8744)	9.091 (15.5700)	10.101 (21.2211)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	12.121 (26.9680)	-1.587 (19.6531)	6.349 (22.6545)	-3.030 (23.3550)	3.125 (22.9685)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	15.556 (30.5158)	3.175 (10.0264)	10.667 (24.9444)	3.030 (10.0504)	8.333 (21.6392)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	11.111 (27.2166)	-6.667 (17.4383)	6.944 (24.0353)	-12.121 (16.8175)	0.952 (23.5504)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	-16.667, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	2.564 (9.2450)	12.500 (26.8742)	3.030 (9.8082)	23.810 (37.0899)	8.046 (21.1854)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	0.000 (13.6083)	2.222 (19.7872)	0.000 (14.9071)	4.762 (23.0022)	1.190 (16.9292)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	28.571 (35.6348)	24.242 (39.6958)	16.667 (28.4950)	58.333 (50.0000)	25.926 (37.1458)
Median	33.333	0.000	0.000	66.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	16.667, 100.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	23.810 (37.0899)	6.061 (13.4840)	11.905 (28.0632)	16.667 (19.2450)	12.963 (25.9181)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Diarrhoea					
Baseline					
n	27	39	48	18	66
Mean (SD)	7.407 (16.8790)	6.838 (20.4903)	8.333 (20.0472)	3.704 (15.7135)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	7.246 (22.3754)	4.386 (11.4190)	6.202 (18.1933)	3.704 (10.7794)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	23	36	42	17	59
Mean (SD)	0.000 (17.4078)	0.000 (13.8013)	0.000 (16.4622)	0.000 (11.7851)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	6.667 (17.4383)	7.778 (16.8002)	8.333 (18.4735)	4.762 (12.1046)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	20	28	35	13	48
Mean (SD)	3.333 (18.4169)	2.381 (15.5253)	4.762 (18.3340)	-2.564 (9.2450)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	1.754 (7.6472)	7.778 (16.8002)	4.902 (11.9830)	6.667 (18.6871)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	19	28	33	14	47
Mean (SD)	-1.754 (13.4884)	3.571 (20.9630)	1.010 (13.1362)	2.381 (27.6247)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	2.083 (8.3333)	9.877 (22.2933)	5.747 (12.8142)	9.524 (27.5140)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	25	28	13	41
Mean (SD)	0.000 (12.1716)	5.333 (22.9331)	2.381 (12.5988)	5.128 (29.9572)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	3.030 (10.0504)	9.091 (18.3494)	6.061 (13.1590)	9.091 (21.5557)	7.071 (16.1537)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	11	20	21	10	31
Mean (SD)	0.000 (14.9071)	3.333 (26.2690)	1.587 (16.5871)	3.333 (33.1476)	2.151 (22.6658)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	6.667 (18.6871)	7.937 (14.5479)	8.000 (17.4271)	6.061 (13.4840)	7.407 (16.1562)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	4.444 (21.3313)	1.667 (20.1602)	4.167 (17.8899)	0.000 (25.8199)	2.857 (20.4067)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	2.564 (9.2450)	2.083 (8.3333)	3.030 (9.8082)	0.000 (0.0000)	2.299 (8.5960)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	2.564 (9.2450)	-2.222 (8.6066)	0.000 (10.5409)	0.000 (0.0000)	0.000 (9.0722)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 0.00	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	9.524 (25.1976)	6.061 (13.4840)	9.524 (20.3750)	0.000 (0.0000)	7.407 (18.2773)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	7	10	14	3	17
Mean (SD)	4.762 (29.9912)	6.667 (14.0546)	7.143 (23.3098)	0.000 (0.0000)	5.882 (21.1978)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Financial Difficulties					
Baseline					
n	27	40	48	19	67
Mean (SD)	32.099 (39.7444)	5.833 (16.6880)	22.222 (34.6092)	1.754 (7.6472)	16.418 (30.9083)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 3					
n	23	38	43	18	61
Mean (SD)	18.841 (31.5045)	7.895 (19.6581)	14.729 (25.5131)	5.556 (23.5702)	12.022 (25.1166)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	23	37	42	18	60
Mean (SD)	-13.043 (27.9594)	1.802 (19.1581)	-7.143 (26.0661)	3.704 (15.7135)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 66.67	-66.67, 33.33	0.00, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 6					
n	20	30	36	14	50
Mean (SD)	16.667 (27.5723)	6.667 (18.3620)	12.037 (24.1066)	7.143 (19.2978)	10.667 (22.7776)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	20	29	35	14	49
Mean (SD)	-8.333 (28.3565)	0.000 (21.8218)	-6.667 (27.7712)	4.762 (12.1046)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-100.00, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 9					
n	19	30	34	15	49
Mean (SD)	14.035 (23.0828)	3.333 (10.1710)	8.824 (18.9076)	4.444 (11.7289)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	19	29	33	15	48
Mean (SD)	-12.281 (16.5198)	-3.448 (18.5695)	-11.111 (19.8373)	2.222 (8.6066)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 33.33	-66.67, 0.00	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 12					
n	16	27	29	14	43
Mean (SD)	18.750 (32.1311)	9.877 (24.1343)	17.241 (31.6487)	4.762 (12.1046)	13.178 (27.3518)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	26	28	14	42
Mean (SD)	-6.250 (21.8369)	2.564 (13.0744)	-2.381 (20.1406)	2.381 (8.9087)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 18					
n	11	22	22	11	33
Mean (SD)	18.182 (34.5242)	7.576 (22.8448)	15.152 (32.0833)	3.030 (10.0504)	11.111 (27.2166)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	11	21	21	11	32
Mean (SD)	-6.061 (32.7217)	-1.587 (22.3014)	-4.762 (32.1208)	0.000 (0.0000)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 66.67	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 24					
n	15	21	25	11	36
Mean (SD)	17.778 (33.0143)	3.175 (10.0264)	12.000 (27.0117)	3.030 (10.0504)	9.259 (23.3824)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	15	20	24	11	35
Mean (SD)	-4.444 (37.5154)	-6.667 (17.4383)	-8.333 (32.9690)	0.000 (0.0000)	-5.714 (27.3989)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-66.67, 0.00	-100.00, 66.67	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Cycle 30					
n	13	16	22	7	29
Mean (SD)	12.821 (21.6815)	8.333 (22.7710)	10.606 (21.5445)	9.524 (25.1976)	10.345 (22.0091)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	13	15	21	7	28
Mean (SD)	-10.256 (25.0356)	0.000 (21.8218)	-7.937 (25.6141)	4.762 (12.5988)	-4.762 (23.5078)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 33.33	-66.67, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Safety Follow-up					
n	7	11	14	4	18
Mean (SD)	66.667 (38.4900)	6.061 (13.4840)	35.714 (42.2938)	8.333 (16.6667)	29.630 (39.4221)
Median	66.667	0.000	16.667	0.000	0.000
Q1, Q3	33.333, 100.000	0.000, 0.000	0.000, 66.667	0.000, 16.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	7	11	14	4	18
Mean (SD)	0.000 (33.3333)	3.030 (10.0504)	2.381 (24.3349)	0.000 (0.0000)	1.852 (21.3046)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	0.00, 33.33	-66.67, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 1					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 2					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 5					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 6					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.2:
Summary of EORTC QLQ-C30 by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**< 65 years (N = 27)**	**≥ 65 years (N = 41)**	**< 75 years (N = 49)**	**≥ 75 years (N = 19)**	**Total (N = 68)**
Survival Follow-up 7					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline					
n	0	1	1	0	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-02-eortc-sum-age.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	38	29	67
Mean (SD)	73.026 (17.8030)	56.897 (22.0557)	66.045 (21.1871)
Median	75.000	58.333	66.667
Q1, Q3	66.667, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	33.33, 100.00	0.00, 83.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.
Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.
The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	76.667 (18.7214)	74.038 (14.5920)	75.546 (17.0014)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	4.167 (17.4380)	13.462 (22.1205)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 25.000	0.000, 16.667
Min, Max	-41.67, 33.33	-16.67, 66.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	82.099 (15.2794)	66.667 (22.7525)	75.000 (20.4124)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	66.667, 91.667
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	7.372 (15.1524)	8.333 (16.8550)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	-8.333, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	75.617 (19.1884)	68.561 (24.1155)	72.449 (21.5974)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	2.244 (18.1900)	9.091 (21.9591)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 25.000	0.000, 16.667
Min, Max	-50.00, 33.33	-41.67, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	78.667 (17.5264)	71.759 (23.2454)	75.775 (20.1527)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 83.333	66.667, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	4.861 (14.3112)	10.185 (20.7214)	7.143 (17.3216)
Median	0.000	12.500	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	78.571 (16.9909)	72.917 (25.8992)	76.515 (20.4607)
Median	83.333	75.000	83.333
Q1, Q3	75.000, 83.333	70.833, 83.333	75.000, 83.333
Min, Max	41.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	6.250 (17.0729)	18.056 (19.0803)	10.677 (18.4811)
Median	8.333	16.667	8.333
Q1, Q3	0.000, 16.667	4.167, 29.167	0.000, 20.833
Min, Max	-33.33, 33.33	-8.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	79.924 (17.3775)	70.833 (26.7047)	76.389 (21.5933)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	66.667, 87.500
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	7.540 (18.4287)	11.905 (20.8562)	9.286 (19.2561)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-25.00, 50.00	-16.67, 66.67	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	75.794 (19.8789)	66.667 (31.8105)	73.276 (23.5048)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 91.667	54.167, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	2.917 (18.7853)	14.583 (23.4648)	6.250 (20.4910)
Median	4.167	4.167	4.167
Q1, Q3	-8.333, 12.500	0.000, 29.167	-8.333, 16.667
Min, Max	-33.33, 41.67	-8.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	60.185 (27.8817)	53.704 (20.4596)	56.944 (23.9570)
Median	66.667	66.667	66.667
Q1, Q3	50.000, 75.000	33.333, 66.667	33.333, 66.667
Min, Max	16.67, 100.00	16.67, 75.00	16.67, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-17.593 (26.4983)	-3.704 (28.5990)	-10.648 (27.6837)
Median	-16.667	0.000	0.000
Q1, Q3	-25.000, 0.000	-16.667, 8.333	-25.000, 8.333
Min, Max	-75.00, 8.33	-50.00, 41.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)
Median	-	-16.667	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)
Median	-	50.000	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)
Median	-	16.667	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)
Median	-	16.667	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	16.667 (-)	16.667 (-)
Median	-	16.667	16.667
Q1, Q3	-, -	16.667, 16.667	16.667, 16.667
Min, Max	-, -	16.67, 16.67	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	38	29	67
Mean (SD)	87.719 (14.8285)	77.241 (23.4702)	83.184 (19.6041)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	66.667, 93.333	80.000, 100.000
Min, Max	40.00, 100.00	20.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	34	26	60
Mean (SD)	88.824 (15.6322)	82.051 (17.7658)	85.889 (16.7890)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 93.333	83.333, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	1.010 (11.4408)	1.795 (16.4986)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-20.00, 40.00	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	90.864 (16.3454)	81.389 (18.9563)	86.405 (18.0843)
Median	93.333	86.667	93.333
Q1, Q3	93.333, 100.000	76.667, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	3.077 (11.0322)	2.222 (21.0513)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-13.333, 13.333	-6.667, 6.667
Min, Max	-20.00, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	85.679 (19.8028)	83.636 (24.6651)	84.762 (21.9004)
Median	86.667	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-1.795 (15.6128)	5.455 (21.4438)	1.528 (18.6666)
Median	0.000	3.333	0.000
Q1, Q3	0.000, 0.000	-6.667, 13.333	0.000, 6.667
Min, Max	-73.33, 13.33	-40.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	24	18	42
Mean (SD)	89.167 (15.0763)	80.370 (27.4847)	85.397 (21.4508)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	86.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	2.319 (7.6828)	1.852 (21.9096)	2.114 (15.3796)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667
Min, Max	-13.33, 26.67	-40.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	89.524 (15.9960)	81.667 (20.3256)	86.667 (17.7951)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	76.667, 96.667	86.667, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	0.667 (9.4032)	3.889 (23.8613)	1.875 (16.0853)
Median	0.000	0.000	0.000
Q1, Q3	-3.333, 6.667	-13.333, 13.333	-6.667, 6.667
Min, Max	-13.33, 26.67	-26.67, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	89.773 (13.8233)	75.238 (27.3538)	84.120 (21.0762)
Median	93.333	86.667	93.333
Q1, Q3	86.667, 100.000	66.667, 93.333	80.000, 96.667
Min, Max	40.00, 100.00	6.67, 100.00	6.67, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	0.397 (10.7484)	-4.762 (29.7486)	-1.667 (20.3202)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 0.000	-20.000, 6.667	-6.667, 0.000
Min, Max	-13.33, 40.00	-66.67, 60.00	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	88.413 (13.0648)	84.167 (18.4950)	87.241 (14.5315)
Median	93.333	86.667	93.333
Q1, Q3	83.333, 100.000	76.667, 100.000	80.000, 100.000
Min, Max	53.33, 100.00	46.67, 100.00	46.67, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-1.833 (12.6803)	11.667 (26.8446)	2.024 (18.3998)
Median	0.000	6.667	0.000
Q1, Q3	-6.667, 0.000	-3.333, 20.000	-6.667, 6.667
Min, Max	-26.67, 33.33	-20.00, 66.67	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	78.519 (17.8816)	65.185 (21.5452)	71.852 (20.3955)
Median	80.000	60.000	73.333
Q1, Q3	66.667, 86.667	60.000, 80.000	60.000, 86.667
Min, Max	46.67, 100.00	26.67, 93.33	26.67, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-7.407 (13.9222)	-8.889 (19.1485)	-8.148 (16.2586)
Median	0.000	-13.333	-10.000
Q1, Q3	-13.333, 0.000	-20.000, 6.667	-20.000, 0.000
Min, Max	-33.33, 13.33	-33.33, 26.67	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	58.333 (-)	58.333 (-)
Median	-	58.333	58.333
Q1, Q3	-, -	58.333, 58.333	58.333, 58.333
Min, Max	-, -	58.33, 58.33	58.33, 58.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)
Median	-	-8.333	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	60.000 (-)	60.000 (-)
Median	-	60.000	60.000
Q1, Q3	-, -	60.000, 60.000	60.000, 60.000
Min, Max	-, -	60.00, 60.00	60.00, 60.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-6.667 (-)	-6.667 (-)
Median	-	-6.667	-6.667
Q1, Q3	-, -	-6.667, -6.667	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	73.333 (-)	73.333 (-)
Median	-	73.333	73.333
Q1, Q3	-, -	73.333, 73.333	73.333, 73.333
Min, Max	-, -	73.33, 73.33	73.33, 73.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	6.667 (-)	6.667 (-)
Median	-	6.667	6.667
Q1, Q3	-, -	6.667, 6.667	6.667, 6.667
Min, Max	-, -	6.67, 6.67	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)
Median	-	77.778	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)
Median	-	11.111	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	86.667 (-)	86.667 (-)
Median	-	86.667	86.667
Q1, Q3	-, -	86.667, 86.667	86.667, 86.667
Min, Max	-, -	86.67, 86.67	86.67, 86.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	20.000 (-)	20.000 (-)
Median	-	20.000	20.000
Q1, Q3	-, -	20.000, 20.000	20.000, 20.000
Min, Max	-, -	20.00, 20.00	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Role functioning			
Baseline			
n	38	29	67
Mean (SD)	90.351 (19.6178)	74.138 (29.0683)	83.333 (25.2929)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	89.048 (20.9820)	83.974 (22.8428)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.490 (21.1159)	5.769 (26.2223)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	93.210 (16.8320)	86.111 (18.8220)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	75.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	3.205 (13.3493)	8.333 (25.5377)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	87.654 (22.9234)	84.848 (28.1291)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-1.923 (19.6225)	6.061 (21.5445)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	92.667 (14.4978)	77.778 (33.3333)	86.434 (25.0015)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (9.8038)	-0.926 (29.9631)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 0.000
Min, Max	-16.67, 33.33	-50.00, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	89.683 (17.8545)	76.389 (27.9414)	84.848 (22.5784)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	-2.500 (9.7857)	-2.778 (38.1606)	-2.604 (23.9883)
Median	0.000	-8.333	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	93.182 (15.9854)	77.381 (27.4307)	87.037 (22.2222)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	1.587 (14.8181)	-3.571 (41.9496)	-0.476 (28.4357)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 16.667	0.000, 0.000
Min, Max	-33.33, 33.33	-83.33, 100.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	90.476 (18.6871)	85.417 (28.7815)	89.080 (21.4901)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-2.500 (18.9451)	10.417 (32.0435)	1.190 (23.5390)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-8.333, 16.667	0.000, 0.000
Min, Max	-66.67, 33.33	-16.67, 83.33	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	66.667 (26.3523)	51.852 (36.7465)	59.259 (31.9427)
Median	66.667	66.667	66.667
Q1, Q3	50.000, 83.333	16.667, 66.667	33.333, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-20.370 (28.5990)	-12.963 (32.0349)	-16.667 (29.7044)
Median	-16.667	-16.667	-16.667
Q1, Q3	-50.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 16.67	-66.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	50.000 (-)	50.000 (-)
Median	-	50.000	50.000
Q1, Q3	-, -	50.000, 50.000	50.000, 50.000
Min, Max	-, -	50.00, 50.00	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	38	29	67
Mean (SD)	85.965 (15.5124)	77.299 (19.7826)	82.214 (17.8786)
Median	91.667	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 91.667	66.667, 100.000
Min, Max	50.00, 100.00	25.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	88.571 (18.8611)	79.167 (22.7608)	84.563 (20.9627)
Median	100.000	87.500	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	3.186 (18.0038)	1.603 (20.2785)	2.500 (18.8724)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-58.33, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	89.198 (14.3994)	76.087 (26.9802)	83.167 (21.9183)
Median	91.667	83.333	91.667
Q1, Q3	83.333, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	5.449 (14.3260)	0.725 (23.2891)	3.231 (19.0042)
Median	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-25.00, 33.33	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	86.111 (19.7473)	78.788 (25.2929)	82.823 (22.4645)
Median	91.667	87.500	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	1.603 (19.0057)	2.273 (20.9215)	1.910 (19.6932)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-8.333, 16.667	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	88.000 (18.0149)	75.926 (28.8518)	82.946 (23.6370)
Median	91.667	87.500	91.667
Q1, Q3	83.333, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (13.4408)	-2.315 (22.6521)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 12.500	-8.333, 8.333	0.000, 8.333
Min, Max	-25.00, 25.00	-50.00, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	88.095 (13.3259)	71.528 (30.8668)	82.071 (22.4499)
Median	91.667	79.167	91.667
Q1, Q3	83.333, 100.000	54.167, 95.833	75.000, 100.000
Min, Max	58.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	2.500 (14.5849)	1.389 (25.3345)	2.083 (18.9321)
Median	0.000	0.000	0.000
Q1, Q3	-4.167, 8.333	-12.500, 20.833	-8.333, 12.500
Min, Max	-33.33, 33.33	-41.67, 41.67	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	89.773 (14.5324)	77.381 (27.4307)	84.954 (21.0649)
Median	100.000	87.500	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	4.762 (15.2688)	2.976 (21.5844)	4.048 (17.7781)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-8.333, 8.333	0.000, 8.333
Min, Max	-33.33, 33.33	-41.67, 41.67	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	84.127 (21.3933)	76.042 (33.1655)	81.897 (24.8077)
Median	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	58.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-0.833 (18.5158)	1.042 (20.6239)	-0.298 (18.7690)
Median	0.000	0.000	0.000
Q1, Q3	-12.500, 8.333	-4.167, 4.167	-8.333, 8.333
Min, Max	-50.00, 33.33	-33.33, 41.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	75.000 (24.2956)	72.222 (25.0000)	73.611 (23.9570)
Median	75.000	83.333	79.167
Q1, Q3	66.667, 91.667	58.333, 91.667	58.333, 91.667
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-12.037 (15.0872)	-6.481 (22.3521)	-9.259 (18.7190)
Median	-8.333	0.000	-8.333
Q1, Q3	-25.000, 0.000	-16.667, 0.000	-25.000, 0.000
Min, Max	-33.33, 8.33	-50.00, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	77.778 (-)	77.778 (-)
Median	-	77.778	77.778
Q1, Q3	-, -	77.778, 77.778	77.778, 77.778
Min, Max	-, -	77.78, 77.78	77.78, 77.78
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-13.889 (-)	-13.889 (-)
Median	-	-13.889	-13.889
Q1, Q3	-, -	-13.889, -13.889	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-8.333 (-)	-8.333 (-)
Median	-	-8.333	-8.333
Q1, Q3	-, -	-8.333, -8.333	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	8.333 (-)	8.333 (-)
Median	-	8.333	8.333
Q1, Q3	-, -	8.333, 8.333	8.333, 8.333
Min, Max	-, -	8.33, 8.33	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	8.333 (-)	8.333 (-)
Median	-	8.333	8.333
Q1, Q3	-, -	8.333, 8.333	8.333, 8.333
Min, Max	-, -	8.33, 8.33	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	91.667 (-)	91.667 (-)
Median	-	91.667	91.667
Q1, Q3	-, -	91.667, 91.667	91.667, 91.667
Min, Max	-, -	91.67, 91.67	91.67, 91.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	38	29	67
Mean (SD)	88.596 (15.5506)	87.356 (20.7284)	88.060 (17.8391)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	87.143 (15.7003)	83.974 (18.5477)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.980 (15.8599)	-7.051 (18.3624)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	88.889 (16.6667)	79.710 (28.4074)	84.667 (23.0449)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	-1.282 (11.4727)	-8.696 (18.0275)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-66.67, 16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	87.037 (22.8023)	80.303 (27.0392)	84.014 (24.7579)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-3.205 (24.0459)	-7.576 (15.1947)	-5.208 (20.3853)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	87.333 (17.5330)	79.630 (27.7451)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-2.083 (14.9980)	-9.259 (19.1504)	-5.159 (17.0636)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	91.270 (13.5596)	70.833 (29.4092)	83.838 (22.6250)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	50.000, 91.667	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	0.833 (14.7840)	-16.667 (24.6183)	-5.729 (20.5696)
Median	0.000	-8.333	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-8.333, 0.000
Min, Max	-33.33, 50.00	-66.67, 16.67	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	90.152 (15.1353)	77.381 (27.4307)	85.185 (21.3726)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-0.794 (15.3444)	-11.905 (12.1046)	-5.238 (15.0008)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-33.33, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	89.683 (16.2243)	72.917 (26.6332)	85.057 (20.5793)
Median	100.000	75.000	100.000
Q1, Q3	83.333, 100.000	66.667, 91.667	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-0.833 (15.7419)	-12.500 (24.8008)	-4.167 (19.0435)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-25.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-50.00, 33.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	79.630 (21.6951)	72.222 (20.4124)	75.926 (20.7870)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 100.000	66.667, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-7.407 (12.1081)	-16.667 (20.4124)	-12.037 (16.9636)
Median	-16.667	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-16.67, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	83.333 (-)	83.333 (-)
Median	-	83.333	83.333
Q1, Q3	-, -	83.333, 83.333	83.333, 83.333
Min, Max	-, -	83.33, 83.33	83.33, 83.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-16.667 (-)	-16.667 (-)
Median	-	-16.667	-16.667
Q1, Q3	-, -	-16.667, -16.667	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Social functioning			
Baseline			
n	38	29	67
Mean (SD)	89.474 (16.1734)	79.310 (27.6942)	85.075 (22.3106)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	88.571 (21.6823)	89.744 (17.0469)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.980 (16.3820)	8.333 (31.7105)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 33.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	93.827 (15.4340)	89.855 (16.4679)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	26	23	49
Mean (SD)	3.846 (13.5873)	10.145 (32.0744)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-50.00, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	82.716 (27.9199)	91.667 (14.3187)	86.735 (23.0688)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-7.692 (25.4867)	12.879 (28.1398)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 8.333
Min, Max	-83.33, 16.67	-33.33, 83.33	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	94.000 (10.6284)	88.889 (15.1248)	91.860 (12.7927)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	3.472 (10.9668)	5.556 (32.8395)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 33.333	0.000, 16.667
Min, Max	-16.67, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	87.302 (21.0190)	93.056 (13.2160)	89.394 (18.5490)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	91.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	-3.333 (11.5975)	16.667 (35.5335)	4.167 (25.0448)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	91.667 (16.0604)	91.667 (19.3373)	91.667 (17.1362)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	1.587 (13.8491)	11.905 (32.9650)	5.714 (23.5504)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	87.302 (21.0190)	97.917 (5.8926)	90.230 (18.6431)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	83.33, 100.00	33.33, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-3.333 (17.6052)	29.167 (36.4605)	5.952 (28.0411)
Median	0.000	16.667	0.000
Q1, Q3	-16.667, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	-33.33, 33.33	0.00, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	72.222 (27.6385)	62.963 (24.6894)	67.593 (25.8656)
Median	83.333	66.667	66.667
Q1, Q3	50.000, 100.000	33.333, 83.333	33.333, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	-14.815 (25.6098)	-9.259 (25.1538)	-12.037 (24.7903)
Median	-16.667	0.000	-8.333
Q1, Q3	-33.333, 0.000	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Fatigue			
Baseline			
n	38	29	67
Mean (SD)	21.491 (16.2445)	39.847 (26.9753)	29.436 (23.2509)
Median	22.222	33.333	22.222
Q1, Q3	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	17.778 (20.2023)	27.778 (24.3939)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 44.444	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	34	26	60
Mean (SD)	-3.758 (20.3192)	-8.974 (29.9826)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-44.44, 66.67	-88.89, 66.67	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	19.342 (16.4783)	27.778 (24.7369)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	11.111, 22.222	5.556, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	26	24	50
Mean (SD)	-3.205 (12.7824)	-9.722 (24.5873)	-6.333 (19.4407)
Median	0.000	-5.556	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-11.111, 0.000
Min, Max	-27.78, 22.22	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	20.576 (19.9009)	25.758 (25.0541)	22.902 (22.2694)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-2.350 (15.2488)	-11.616 (23.6268)	-6.597 (19.8714)
Median	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-33.33, 44.44	-55.56, 33.33	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	18.667 (21.2084)	21.605 (19.2345)	19.897 (20.2219)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline			
n	24	18	42
Mean (SD)	-5.324 (11.5236)	-11.111 (28.7730)	-7.804 (20.6438)
Median	0.000	-5.556	0.000
Q1, Q3	-19.444, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-22.22, 11.11	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	16.402 (20.6735)	19.444 (14.3117)	17.508 (18.4320)
Median	11.111	22.222	11.111
Q1, Q3	0.000, 22.222	11.111, 22.222	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 44.44	0.00, 88.89
Change from Baseline			
n	20	12	32
Mean (SD)	-5.833 (17.6121)	-21.296 (27.4049)	-11.632 (22.6816)
Median	0.000	-11.111	0.000
Q1, Q3	-11.111, 0.000	-38.889, 0.000	-22.222, 0.000
Min, Max	-44.44, 33.33	-88.89, 0.00	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	16.162 (18.3785)	30.952 (25.8488)	21.914 (22.4569)
Median	11.111	27.778	22.222
Q1, Q3	0.000, 33.333	11.111, 44.444	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-4.233 (12.4108)	-5.556 (26.4198)	-4.762 (18.9188)
Median	0.000	0.000	0.000
Q1, Q3	-11.111, 0.000	-11.111, 11.111	-11.111, 0.000
Min, Max	-22.22, 22.22	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	21.693 (25.2093)	20.833 (21.7712)	21.456 (23.9287)
Median	22.222	16.667	22.222
Q1, Q3	0.000, 22.222	5.556, 27.778	0.000, 22.222
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	1.667 (22.0092)	-20.833 (33.3002)	-4.762 (27.1204)
Median	0.000	-5.556	0.000
Q1, Q3	-11.111, 11.111	-33.333, 0.000	-11.111, 5.556
Min, Max	-33.33, 66.67	-88.89, 0.00	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	43.210 (33.5385)	54.321 (25.1197)	48.765 (29.3079)
Median	44.444	66.667	55.556
Q1, Q3	11.111, 66.667	33.333, 66.667	22.222, 66.667
Min, Max	0.00, 100.00	11.11, 77.78	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	17.901 (28.2976)	9.877 (25.1197)	13.889 (26.2833)
Median	11.111	11.111	11.111
Q1, Q3	-5.556, 44.444	0.000, 22.222	-5.556, 33.333
Min, Max	-11.11, 66.67	-22.22, 55.56	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	11.111 (-)	11.111 (-)
Median	-	11.111	11.111
Q1, Q3	-, -	11.111, 11.111	11.111, 11.111
Min, Max	-, -	11.11, 11.11	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)
Median	-	44.444	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)
Median	-	-11.111	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)
Median	-	44.444	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)
Median	-	-11.111	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-22.222 (-)	-22.222 (-)
Median	-	-22.222	-22.222
Q1, Q3	-, -	-22.222, -22.222	-22.222, -22.222
Min, Max	-, -	-22.22, -22.22	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	44.444 (-)	44.444 (-)
Median	-	44.444	44.444
Q1, Q3	-, -	44.444, 44.444	44.444, 44.444
Min, Max	-, -	44.44, 44.44	44.44, 44.44
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-11.111 (-)	-11.111 (-)
Median	-	-11.111	-11.111
Q1, Q3	-, -	-11.111, -11.111	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	38	29	67
Mean (SD)	3.070 (10.1455)	5.172 (11.0046)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	2.381 (9.1670)	3.205 (6.6986)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	34	26	60
Mean (SD)	-0.490 (7.6600)	-1.923 (10.8801)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	5.556 (19.6116)	1.389 (4.7055)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	4.487 (13.7902)	-4.861 (10.4016)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	2.469 (6.0336)	5.303 (10.7722)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	26	22	48
Mean (SD)	1.282 (6.5372)	-1.515 (10.1693)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	2.000 (10.0000)	2.778 (6.3914)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	24	18	42
Mean (SD)	0.694 (3.4021)	-1.852 (5.3897)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	2.381 (7.9682)	1.389 (4.8113)	2.020 (6.9191)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	20	12	32
Mean (SD)	0.833 (3.7268)	-5.556 (10.8556)	-1.563 (7.7591)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-8.333, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	-33.33, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	1.515 (7.1067)	1.190 (4.4544)	1.389 (6.1399)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	21	14	35
Mean (SD)	0.000 (0.0000)	-4.762 (10.1875)	-1.905 (6.7294)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	-33.33, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	3.968 (11.6723)	0.000 (0.0000)	2.874 (10.0287)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline			
n	20	8	28
Mean (SD)	2.500 (12.4193)	-8.333 (12.5988)	-0.595 (13.2110)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	-33.33, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	11.111 (22.0479)	5.556 (8.3333)	8.333 (16.4197)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	9	9	18
Mean (SD)	9.259 (18.8398)	-3.704 (7.3493)	2.778 (15.3925)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	-16.67, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Pain			
Baseline			
n	37	29	66
Mean (SD)	11.261 (19.6631)	18.966 (23.0270)	14.646 (21.3868)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 83.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	12.381 (19.1071)	17.308 (23.7958)	14.481 (21.1860)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	0.000 (17.6777)	0.000 (24.9444)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 16.667	-16.667, 16.667
Min, Max	-33.33, 50.00	-66.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	11.728 (21.5900)	16.667 (25.0603)	14.052 (23.1835)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	24	49
Mean (SD)	0.000 (18.6339)	-2.778 (21.2341)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	18.519 (27.4770)	18.939 (24.8250)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	25	22	47
Mean (SD)	6.667 (23.0740)	0.000 (26.2265)	3.546 (24.5580)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 50.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	13.333 (20.9718)	19.444 (25.0816)	15.891 (22.6993)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	0.725 (23.2891)	3.704 (18.5729)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	9.524 (22.7128)	22.222 (29.5875)	14.141 (25.7260)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	19	12	31
Mean (SD)	0.000 (15.7135)	5.556 (23.9247)	2.151 (19.1204)
Median	0.000	8.333	0.000
Q1, Q3	-16.667, 16.667	-8.333, 25.000	-16.667, 16.667
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	7.576 (15.1947)	28.571 (36.6483)	15.741 (27.2974)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-3.175 (14.5479)	13.095 (33.4476)	3.333 (24.8525)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	11.905 (22.4492)	20.833 (30.5375)	14.368 (24.6902)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 83.33	0.00, 83.33
Change from Baseline			
n	20	8	28
Mean (SD)	2.500 (21.1338)	2.083 (24.2956)	2.381 (21.6188)
Median	0.000	0.000	0.000
Q1, Q3	-8.333, 8.333	-8.333, 8.333	-8.333, 8.333
Min, Max	-33.33, 66.67	-33.33, 50.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	22.222 (23.5702)	27.778 (26.3523)	25.000 (24.4214)
Median	16.667	33.333	25.000
Q1, Q3	0.000, 50.000	0.000, 33.333	0.000, 50.000
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	8	9	17
Mean (SD)	12.500 (24.8008)	3.704 (21.6951)	7.843 (22.9111)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 50.00	-33.33, 33.33	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	38	29	67
Mean (SD)	17.544 (24.1825)	32.184 (37.2494)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	12.381 (21.5202)	24.359 (24.1434)	17.486 (23.2591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-5.882 (17.3508)	0.000 (32.6599)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	9.877 (22.2933)	20.833 (25.6557)	15.033 (24.3253)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	-8.974 (25.9190)	-8.333 (31.4696)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-16.667, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	26	22	48
Mean (SD)	10.256 (18.3042)	13.636 (19.6775)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	25	22	47
Mean (SD)	-8.000 (22.1108)	-18.182 (38.1133)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	14.667 (23.7268)	18.519 (23.4931)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	24	18	42
Mean (SD)	-4.167 (24.6962)	-12.963 (44.4853)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	7.937 (17.9653)	11.111 (16.4122)	9.091 (17.2255)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	20	12	32
Mean (SD)	-8.333 (14.8087)	-22.222 (41.0305)	-13.542 (27.9007)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-33.33, 0.00	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	9.091 (18.3494)	14.286 (17.1184)	11.111 (17.8174)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	21	14	35
Mean (SD)	-4.762 (19.1071)	-16.667 (40.8248)	-9.524 (29.7829)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	14.286 (27.0214)	8.333 (15.4303)	12.644 (24.2569)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	-1.667 (25.3052)	-33.333 (35.6348)	-10.714 (31.4970)
Median	0.000	-33.333	0.000
Q1, Q3	0.000, 0.000	-50.000, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	37.037 (30.9320)	44.444 (40.8248)	40.741 (35.3425)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	11.111 (37.2678)	7.407 (22.2222)	9.259 (29.8264)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	100.000 (-)	100.000 (-)
Median	-	100.000	100.000
Q1, Q3	-, -	100.000, 100.000	100.000, 100.000
Min, Max	-, -	100.00, 100.00	100.00, 100.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-66.667 (-)	-66.667 (-)
Median	-	-66.667	-66.667
Q1, Q3	-, -	-66.667, -66.667	-66.667, -66.667
Min, Max	-, -	-66.67, -66.67	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	-33.333 (-)	-33.333 (-)
Median	-	-33.333	-33.333
Q1, Q3	-, -	-33.333, -33.333	-33.333, -33.333
Min, Max	-, -	-33.33, -33.33	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Insomnia			
Baseline			
n	38	29	67
Mean (SD)	14.035 (19.9573)	27.586 (28.2688)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	10.476 (17.6595)	28.205 (27.7966)	18.033 (24.0168)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-4.902 (14.5235)	2.564 (24.8069)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	14.815 (23.2661)	25.000 (28.2330)	19.608 (25.9713)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	-2.564 (18.6740)	-2.778 (21.7954)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	12.346 (20.9765)	25.758 (32.4189)	18.367 (27.2686)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	22	48
Mean (SD)	-3.846 (21.7602)	-3.030 (27.0392)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	13.333 (21.5166)	31.481 (33.2788)	20.930 (28.1936)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (15.4769)	1.852 (17.9768)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	11.111 (24.3432)	33.333 (28.4268)	19.192 (27.6766)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	-1.667 (17.0139)	-2.778 (17.1643)	-2.083 (16.8005)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	7.576 (17.6138)	26.190 (32.4987)	14.815 (25.7515)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-6.349 (17.0589)	-7.143 (23.3098)	-6.667 (19.4701)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	7.937 (17.9653)	25.000 (23.5702)	12.644 (20.7284)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	20	8	28
Mean (SD)	-6.667 (13.6797)	-8.333 (23.5702)	-7.143 (16.6225)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	25.926 (27.7778)	37.037 (30.9320)	31.481 (29.0868)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	9	9	18
Mean (SD)	18.519 (29.3972)	11.111 (16.6667)	14.815 (23.4931)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	38	29	67
Mean (SD)	7.018 (15.8026)	20.690 (30.0975)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	8.571 (16.8478)	12.821 (21.2434)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	34	26	60
Mean (SD)	0.980 (15.3199)	-8.974 (34.7150)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	7.407 (21.3504)	9.722 (18.3344)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	26	24	50
Mean (SD)	0.000 (16.3299)	-9.722 (33.3031)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	3.704 (10.6752)	12.121 (21.9317)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	-2.564 (16.1192)	-9.091 (37.3484)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	9.333 (20.4577)	12.963 (23.2601)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	24	18	42
Mean (SD)	2.778 (16.7870)	-3.704 (35.9537)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	4.762 (15.9364)	13.889 (22.2853)	8.081 (18.6903)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	20	12	32
Mean (SD)	0.000 (0.0000)	-8.333 (42.9352)	-3.125 (25.9022)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	0.00, 0.00	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	6.061 (16.7027)	11.905 (21.1108)	8.333 (18.4735)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	21	14	35
Mean (SD)	1.587 (7.2739)	-7.143 (32.4987)	-1.905 (21.3021)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	9.524 (23.9046)	8.333 (23.5702)	9.195 (23.3954)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	5.000 (24.8387)	-20.833 (43.4157)	-2.381 (32.6202)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-50.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-100.00, 33.33	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	37.037 (42.3099)	33.333 (33.3333)	35.185 (36.9989)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	29.630 (45.4742)	0.000 (28.8675)	14.815 (39.9709)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-33.33, 100.00	-66.67, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	33.333 (-)	33.333 (-)
Median	-	33.333	33.333
Q1, Q3	-, -	33.333, 33.333	33.333, 33.333
Min, Max	-, -	33.33, 33.33	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	66.667 (-)	66.667 (-)
Median	-	66.667	66.667
Q1, Q3	-, -	66.667, 66.667	66.667, 66.667
Min, Max	-, -	66.67, 66.67	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Constipation			
Baseline			
n	38	29	67
Mean (SD)	7.018 (17.6007)	11.494 (18.4216)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	8.571 (16.8478)	16.667 (28.6744)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	1.961 (16.2911)	5.128 (29.3520)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	24	51
Mean (SD)	6.173 (13.1949)	11.111 (21.2341)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	24	50
Mean (SD)	0.000 (16.3299)	1.389 (23.0084)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	7.407 (16.8790)	10.606 (15.8910)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	0.000 (16.3299)	0.000 (17.8174)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	6.667 (16.6667)	24.074 (37.5831)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (15.4769)	14.815 (36.5546)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	6.349 (13.4125)	16.667 (30.1511)	10.101 (21.2211)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	1.667 (17.0139)	5.556 (31.2479)	3.125 (22.9685)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	4.545 (11.7083)	14.286 (31.2538)	8.333 (21.6392)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-1.587 (16.5871)	4.762 (31.6421)	0.952 (23.5504)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	7.937 (23.3447)	8.333 (15.4303)	8.046 (21.1854)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	20	8	28
Mean (SD)	3.333 (14.9071)	-4.167 (21.3623)	1.190 (16.9292)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	25.926 (43.3903)	25.926 (32.3942)	25.926 (37.1458)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	14.815 (33.7931)	11.111 (16.6667)	12.963 (25.9181)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	37	29	66
Mean (SD)	9.009 (21.7288)	4.598 (14.7038)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	6.667 (19.4701)	3.846 (10.8604)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	33	26	59
Mean (SD)	1.010 (15.5565)	-1.282 (14.8497)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	7.407 (19.2450)	7.246 (14.0580)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	25	23	48
Mean (SD)	4.000 (17.5330)	1.449 (15.8218)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	6.173 (16.1114)	4.545 (11.7083)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	25	22	47
Mean (SD)	4.000 (14.6566)	-1.515 (21.7666)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	8.000 (22.1108)	5.556 (12.7827)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	23	18	41
Mean (SD)	5.797 (21.6776)	0.000 (16.1690)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	3.175 (10.0264)	13.889 (22.2853)	7.071 (16.1537)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	19	12	31
Mean (SD)	0.000 (11.1111)	5.556 (34.3286)	2.151 (22.6658)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	7.576 (17.6138)	7.143 (14.1938)	7.407 (16.1562)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	21	14	35
Mean (SD)	4.762 (15.9364)	0.000 (26.1488)	2.857 (20.4067)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	1.587 (7.2739)	4.167 (11.7851)	2.299 (8.5960)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33
Change from Baseline			
n	20	8	28
Mean (SD)	-1.667 (7.4536)	4.167 (11.7851)	0.000 (9.0722)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	11.111 (23.5702)	3.704 (11.1111)	7.407 (18.2773)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	8	9	17
Mean (SD)	12.500 (24.8008)	0.000 (16.6667)	5.882 (21.1978)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	38	29	67
Mean (SD)	14.912 (32.6022)	18.391 (28.9858)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 3			
n	35	26	61
Mean (SD)	11.429 (26.7436)	12.821 (23.2416)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	26	60
Mean (SD)	-1.961 (21.6199)	-6.410 (26.6987)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 6			
n	27	23	50
Mean (SD)	8.642 (21.8632)	13.043 (24.0772)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	26	23	49
Mean (SD)	-2.564 (24.8069)	-4.348 (25.2350)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 9			
n	27	22	49
Mean (SD)	8.642 (19.8124)	6.061 (13.1590)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	26	22	48
Mean (SD)	-2.564 (13.0744)	-12.121 (21.9317)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 12			
n	25	18	43
Mean (SD)	10.667 (24.9444)	16.667 (30.7849)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	24	18	42
Mean (SD)	-1.389 (18.3344)	0.000 (16.1690)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 18			
n	21	12	33
Mean (SD)	11.111 (26.5274)	11.111 (29.5875)	11.111 (27.2166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	20	12	32
Mean (SD)	-1.667 (22.8778)	-5.556 (31.2479)	-3.125 (25.9022)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 24			
n	22	14	36
Mean (SD)	6.061 (16.7027)	14.286 (31.2538)	9.259 (23.3824)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	21	14	35
Mean (SD)	-7.937 (25.6141)	-2.381 (30.5625)	-5.714 (27.3989)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Cycle 30			
n	21	8	29
Mean (SD)	12.698 (24.6671)	4.167 (11.7851)	10.345 (22.0091)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	20	8	28
Mean (SD)	-1.667 (22.8778)	-12.500 (24.8008)	-4.762 (23.5078)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Safety Follow-up			
n	9	9	18
Mean (SD)	29.630 (42.3099)	29.630 (38.8889)	29.630 (39.4221)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	9	9	18
Mean (SD)	3.704 (11.1111)	0.000 (28.8675)	1.852 (21.3046)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 1			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 2			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 5			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 6			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.3:
Summary of EORTC QLQ-C30 by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**0 (N = 39)**	**≥ 1 (N = 29)**	**Total (N = 68)**
Survival Follow-up 7			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00
Change from Baseline			
n	0	1	1
Mean (SD)	- (-)	0.000 (-)	0.000 (-)
Median	-	0.000	0.000
Q1, Q3	-, -	0.000, 0.000	0.000, 0.000
Min, Max	-, -	0.00, 0.00	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-03-eortc-sum-ecog.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Global health status/QOL			
Baseline			
n	48	19	67
Mean (SD)	67.535 (22.2971)	62.281 (18.0808)	66.045 (21.1871)
Median	70.833	66.667	66.667
Q1, Q3	50.000, 83.333	50.000, 75.000	50.000, 83.333
Min, Max	0.00, 100.00	25.00, 91.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	76.357 (18.4493)	73.611 (13.1762)	75.546 (17.0014)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	6.746 (20.2657)	11.574 (19.4152)	8.194 (19.9748)
Median	8.333	8.333	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-41.67, 66.67	-16.67, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	76.905 (22.3320)	70.556 (14.7286)	75.000 (20.4124)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 91.667
Min, Max	8.33, 100.00	41.67, 100.00	8.33, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	7.353 (15.7266)	8.889 (16.5072)	7.823 (15.8121)
Median	0.000	8.333	8.333
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 41.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	75.231 (22.7553)	64.744 (16.3702)	72.449 (21.5974)
Median	83.333	66.667	83.333
Q1, Q3	66.667, 91.667	58.333, 83.333	58.333, 83.333
Min, Max	0.00, 100.00	33.33, 83.33	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	5.238 (19.9146)	5.769 (21.3504)	5.382 (20.0833)
Median	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-50.00, 50.00	-41.67, 41.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	77.020 (21.7537)	71.667 (13.7212)	75.775 (20.1527)
Median	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	50.00, 83.33	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	4.948 (13.3634)	14.167 (26.0727)	7.143 (17.3216)
Median	4.167	12.500	8.333
Q1, Q3	0.000, 16.667	-16.667, 33.333	0.000, 16.667
Min, Max	-33.33, 33.33	-16.67, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	78.086 (21.2016)	69.444 (16.3865)	76.515 (20.4607)
Median	83.333	75.000	83.333
Q1, Q3	75.000, 83.333	58.333, 83.333	75.000, 83.333
Min, Max	0.00, 100.00	41.67, 83.33	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	8.654 (14.0398)	19.444 (31.9142)	10.677 (18.4811)
Median	8.333	29.167	8.333
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 20.833
Min, Max	-16.67, 41.67	-33.33, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	77.222 (22.4177)	72.222 (18.0021)	76.389 (21.5933)
Median	83.333	79.167	83.333
Q1, Q3	66.667, 91.667	50.000, 83.333	66.667, 87.500
Min, Max	0.00, 100.00	50.00, 91.67	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	6.609 (15.6505)	22.222 (30.1232)	9.286 (19.2561)
Median	0.000	25.000	0.000
Q1, Q3	0.000, 16.667	8.333, 33.333	0.000, 16.667
Min, Max	-25.00, 50.00	-25.00, 66.67	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	73.188 (25.4947)	73.611 (15.2904)	73.276 (23.5048)
Median	83.333	75.000	83.333
Q1, Q3	50.000, 91.667	66.667, 83.333	66.667, 83.333
Min, Max	0.00, 100.00	50.00, 91.67	0.00, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	1.515 (14.6918)	23.611 (30.0077)	6.250 (20.4910)
Median	0.000	29.167	4.167
Q1, Q3	-8.333, 8.333	8.333, 41.667	-8.333, 16.667
Min, Max	-33.33, 33.33	-25.00, 58.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	62.879 (18.7689)	47.619 (29.5468)	56.944 (23.9570)
Median	66.667	50.000	66.667
Q1, Q3	58.333, 75.000	16.667, 66.667	33.333, 66.667
Min, Max	25.00, 91.67	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-2.273 (28.8894)	-23.810 (21.2070)	-10.648 (27.6837)
Median	0.000	-25.000	0.000
Q1, Q3	-16.667, 8.333	-41.667, 0.000	-25.000, 8.333
Min, Max	-75.00, 41.67	-50.00, 8.33	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	16.667 (-)	- (-)	16.667 (-)
Median	16.667	-	16.667
Q1, Q3	16.667, 16.667	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Physical functioning			
Baseline			
n	48	19	67
Mean (SD)	83.611 (19.2512)	82.105 (20.9706)	83.184 (19.6041)
Median	90.000	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	33.33, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	17	60
Mean (SD)	85.736 (17.0018)	86.275 (16.7449)	85.889 (16.7890)
Median	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	86.667, 100.000	83.333, 100.000
Min, Max	26.67, 100.00	46.67, 100.00	26.67, 100.00
Change from Baseline			
n	42	17	59
Mean (SD)	-0.159 (10.5654)	5.098 (19.5120)	1.356 (13.7732)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-6.667, 6.667
Min, Max	-26.67, 33.33	-33.33, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	85.556 (20.8090)	88.444 (8.8968)	86.405 (18.0843)
Median	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	66.67, 100.00	20.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	1.333 (14.1698)	5.778 (21.0618)	2.667 (16.4406)
Median	0.000	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 6.667	-6.667, 6.667
Min, Max	-33.33, 33.33	-20.00, 53.33	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	83.889 (24.8615)	87.179 (10.3500)	84.762 (21.9004)
Median	90.000	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	0.000 (17.5641)	5.641 (21.5761)	1.528 (18.6666)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	-6.667, 6.667	0.000, 6.667
Min, Max	-73.33, 40.00	-20.00, 53.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	32	10	42
Mean (SD)	84.375 (23.9838)	88.667 (9.9629)	85.397 (21.4508)
Median	93.333	90.000	93.333
Q1, Q3	83.333, 100.000	86.667, 93.333	86.667, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	-1.075 (10.1976)	12.000 (23.6852)	2.114 (15.3796)
Median	0.000	6.667	0.000
Q1, Q3	0.000, 0.000	0.000, 26.667	0.000, 6.667
Min, Max	-40.00, 20.00	-20.00, 60.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	86.667 (19.5680)	86.667 (5.9628)	86.667 (17.7951)
Median	93.333	86.667	86.667
Q1, Q3	86.667, 100.000	80.000, 93.333	86.667, 100.000
Min, Max	26.67, 100.00	80.00, 93.33	26.67, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	0.513 (11.6120)	7.778 (29.6398)	1.875 (16.0853)
Median	0.000	-6.667	0.000
Q1, Q3	0.000, 6.667	-13.333, 26.667	-6.667, 6.667
Min, Max	-26.67, 33.33	-13.33, 60.00	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	84.944 (20.1550)	80.000 (26.9979)	84.120 (21.0762)
Median	93.333	90.000	93.333
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 96.667
Min, Max	6.67, 100.00	26.67, 100.00	6.67, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	-2.241 (12.0702)	1.111 (44.5055)	-1.667 (20.3202)
Median	0.000	-6.667	0.000
Q1, Q3	-6.667, 0.000	-13.333, 40.000	-6.667, 0.000
Min, Max	-33.33, 33.33	-66.67, 60.00	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	87.246 (15.6880)	87.222 (9.9815)	87.241 (14.5315)
Median	93.333	88.333	93.333
Q1, Q3	80.000, 100.000	80.000, 93.333	80.000, 100.000
Min, Max	46.67, 100.00	73.33, 100.00	46.67, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	0.303 (11.9039)	8.333 (34.2377)	2.024 (18.3998)
Median	0.000	-8.333	0.000
Q1, Q3	-6.667, 6.667	-13.333, 33.333	-6.667, 6.667
Min, Max	-26.67, 33.33	-20.00, 66.67	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	68.485 (21.7237)	77.143 (18.4017)	71.852 (20.3955)
Median	66.667	80.000	73.333
Q1, Q3	60.000, 86.667	60.000, 93.333	60.000, 86.667
Min, Max	26.67, 100.00	46.67, 100.00	26.67, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-7.879 (18.0907)	-8.571 (14.2539)	-8.148 (16.2586)
Median	-13.333	-6.667	-10.000
Q1, Q3	-20.000, 6.667	-20.000, 0.000	-20.000, 0.000
Min, Max	-33.33, 26.67	-26.67, 13.33	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	58.333 (-)	- (-)	58.333 (-)
Median	58.333	-	58.333
Q1, Q3	58.333, 58.333	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	60.000 (-)	- (-)	60.000 (-)
Median	60.000	-	60.000
Q1, Q3	60.000, 60.000	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline			
n	1	0	1
Mean (SD)	-6.667 (-)	- (-)	-6.667 (-)
Median	-6.667	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	73.333 (-)	- (-)	73.333 (-)
Median	73.333	-	73.333
Q1, Q3	73.333, 73.333	-, -	73.333, 73.333
Min, Max	73.33, 73.33	-, -	73.33, 73.33
Change from Baseline			
n	1	0	1
Mean (SD)	6.667 (-)	- (-)	6.667 (-)
Median	6.667	-	6.667
Q1, Q3	6.667, 6.667	-, -	6.667, 6.667
Min, Max	6.67, 6.67	-, -	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	86.667 (-)	- (-)	86.667 (-)
Median	86.667	-	86.667
Q1, Q3	86.667, 86.667	-, -	86.667, 86.667
Min, Max	86.67, 86.67	-, -	86.67, 86.67
Change from Baseline			
n	1	0	1
Mean (SD)	20.000 (-)	- (-)	20.000 (-)
Median	20.000	-	20.000
Q1, Q3	20.000, 20.000	-, -	20.000, 20.000
Min, Max	20.00, 20.00	-, -	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Role functioning			
Baseline			
n	48	19	67
Mean (SD)	83.333 (24.7923)	83.333 (27.2166)	83.333 (25.2929)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.047 (22.3992)	88.889 (20.6116)	86.885 (21.7551)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	0.397 (23.7101)	6.481 (22.9655)	2.222 (23.4635)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	88.889 (19.9205)	92.222 (12.3871)	89.869 (17.9748)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	4.286 (14.2014)	8.889 (30.1232)	5.667 (20.0933)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	87.037 (26.4608)	84.615 (22.0075)	86.395 (25.1554)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	2.381 (22.5582)	0.000 (15.2145)	1.736 (20.6970)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	85.859 (27.0420)	88.333 (17.6558)	86.434 (25.0015)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (17.9605)	6.667 (28.5450)	1.587 (20.7611)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 33.33	-16.67, 83.33	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	85.185 (24.1670)	83.333 (14.9071)	84.848 (22.5784)
Median	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	-5.128 (15.4698)	8.333 (46.8449)	-2.604 (23.9883)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	87.778 (20.0255)	83.333 (33.3333)	87.037 (22.2222)
Median	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	-2.299 (18.2162)	8.333 (59.3951)	-0.476 (28.4357)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-83.33, 100.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	89.130 (23.3597)	88.889 (13.6083)	89.080 (21.4901)
Median	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-2.273 (17.2865)	13.889 (38.6101)	1.190 (23.5390)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 33.333	0.000, 0.000
Min, Max	-66.67, 16.67	-16.67, 83.33	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	57.576 (30.1511)	61.905 (36.9112)	59.259 (31.9427)
Median	66.667	66.667	66.667
Q1, Q3	33.333, 83.333	33.333, 100.000	33.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-13.636 (30.5670)	-21.429 (29.9912)	-16.667 (29.7044)
Median	-16.667	-16.667	-16.667
Q1, Q3	-33.333, 0.000	-50.000, 0.000	-33.333, 0.000
Min, Max	-66.67, 50.00	-66.67, 16.67	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	50.000 (-)	- (-)	50.000 (-)
Median	50.000	-	50.000
Q1, Q3	50.000, 50.000	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Emotional functioning			
Baseline			
n	48	19	67
Mean (SD)	82.986 (18.2702)	80.263 (17.1707)	82.214 (17.8786)
Median	83.333	83.333	83.333
Q1, Q3	75.000, 100.000	66.667, 91.667	66.667, 100.000
Min, Max	25.00, 100.00	41.67, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.047 (20.0628)	81.019 (23.1868)	84.563 (20.9627)
Median	100.000	87.500	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	2.976 (17.0506)	1.389 (23.0887)	2.500 (18.8724)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-75.00, 33.33	-58.33, 33.33	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	85.476 (20.5463)	77.778 (24.7340)	83.167 (21.9183)
Median	91.667	83.333	91.667
Q1, Q3	83.333, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	4.657 (18.8239)	0.000 (19.6699)	3.231 (19.0042)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 16.667
Min, Max	-50.00, 41.67	-41.67, 33.33	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	85.880 (21.2524)	74.359 (24.4053)	82.823 (22.4645)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	66.667, 91.667	75.000, 100.000
Min, Max	8.33, 100.00	16.67, 100.00	8.33, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	4.048 (19.9439)	-3.846 (18.5141)	1.910 (19.6932)
Median	0.000	-8.333	0.000
Q1, Q3	0.000, 16.667	-16.667, 8.333	-8.333, 16.667
Min, Max	-50.00, 50.00	-33.33, 25.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	86.364 (21.8321)	71.667 (26.9888)	82.946 (23.6370)
Median	100.000	87.500	91.667
Q1, Q3	83.333, 100.000	41.667, 91.667	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	1.823 (17.4204)	-1.667 (20.3367)	0.992 (17.9583)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 12.500	-16.667, 8.333	0.000, 8.333
Min, Max	-50.00, 41.67	-41.67, 25.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	83.642 (19.8124)	75.000 (33.3333)	82.071 (22.4499)
Median	91.667	83.333	91.667
Q1, Q3	75.000, 100.000	83.333, 91.667	75.000, 100.000
Min, Max	25.00, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	1.923 (18.9015)	2.778 (20.8611)	2.083 (18.9321)
Median	0.000	8.333	0.000
Q1, Q3	-8.333, 8.333	-8.333, 16.667	-8.333, 12.500
Min, Max	-41.67, 41.67	-33.33, 25.00	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	86.944 (18.9124)	75.000 (29.8142)	84.954 (21.0649)
Median	100.000	83.333	91.667
Q1, Q3	75.000, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	25.00, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	4.310 (16.9061)	2.778 (23.3730)	4.048 (17.7781)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 25.000	0.000, 8.333
Min, Max	-41.67, 41.67	-25.00, 33.33	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	83.696 (22.5404)	75.000 (33.7474)	81.897 (24.8077)
Median	100.000	87.500	91.667
Q1, Q3	66.667, 100.000	75.000, 91.667	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	8.33, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-1.136 (17.3082)	2.778 (25.0924)	-0.298 (18.7690)
Median	0.000	4.167	0.000
Q1, Q3	-8.333, 8.333	-16.667, 25.000	-8.333, 8.333
Min, Max	-50.00, 41.67	-33.33, 33.33	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	75.000 (22.3607)	71.429 (27.9952)	73.611 (23.9570)
Median	75.000	83.333	79.167
Q1, Q3	58.333, 91.667	33.333, 91.667	58.333, 91.667
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-3.788 (15.0756)	-17.857 (21.7459)	-9.259 (18.7190)
Median	-8.333	-16.667	-8.333
Q1, Q3	-8.333, 0.000	-33.333, 0.000	-25.000, 0.000
Min, Max	-25.00, 25.00	-50.00, 8.33	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	77.778 (-)	- (-)	77.778 (-)
Median	77.778	-	77.778
Q1, Q3	77.778, 77.778	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline			
n	1	0	1
Mean (SD)	-13.889 (-)	- (-)	-13.889 (-)
Median	-13.889	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-8.333 (-)	- (-)	-8.333 (-)
Median	-8.333	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	8.333 (-)	- (-)	8.333 (-)
Median	8.333	-	8.333
Q1, Q3	8.333, 8.333	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	8.333 (-)	- (-)	8.333 (-)
Median	8.333	-	8.333
Q1, Q3	8.333, 8.333	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	91.667 (-)	- (-)	91.667 (-)
Median	91.667	-	91.667
Q1, Q3	91.667, 91.667	-, -	91.667, 91.667
Min, Max	91.67, 91.67	-, -	91.67, 91.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cognitive functioning			
Baseline			
n	48	19	67
Mean (SD)	89.236 (18.3509)	85.088 (16.5689)	88.060 (17.8391)
Median	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	86.822 (16.8867)	83.333 (17.1499)	85.792 (16.8973)
Median	83.333	83.333	83.333
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-4.365 (16.0704)	-1.852 (19.7111)	-3.611 (17.1104)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	85.714 (22.1930)	82.222 (25.5625)	84.667 (23.0449)
Median	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	-3.922 (10.0995)	-6.667 (23.4013)	-4.762 (15.2145)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	82.870 (26.2727)	87.179 (20.5861)	84.014 (24.7579)
Median	91.667	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-6.667 (19.4701)	-1.282 (23.0353)	-5.208 (20.3853)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-100.00, 16.67	-33.33, 50.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	85.859 (20.8838)	78.333 (27.2732)	84.109 (22.4060)
Median	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	-4.688 (10.5701)	-6.667 (30.6312)	-5.159 (17.0636)
Median	0.000	-8.333	0.000
Q1, Q3	-8.333, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	84.568 (17.8586)	80.556 (40.0231)	83.838 (22.6250)
Median	83.333	100.000	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	-6.410 (15.6893)	-2.778 (37.1434)	-5.729 (20.5696)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-8.333, 0.000
Min, Max	-50.00, 16.67	-66.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	85.556 (20.8687)	83.333 (25.8199)	85.185 (21.3726)
Median	91.667	91.667	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	-6.322 (11.2809)	0.000 (27.8887)	-5.238 (15.0008)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-33.33, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	86.232 (17.1536)	80.556 (32.3465)	85.057 (20.5793)
Median	100.000	91.667	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-4.545 (14.7122)	-2.778 (32.3465)	-4.167 (19.0435)
Median	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-50.00, 50.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	78.788 (19.8479)	71.429 (23.0022)	75.926 (20.7870)
Median	83.333	83.333	83.333
Q1, Q3	66.667, 100.000	50.000, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-10.606 (15.4069)	-14.286 (20.2498)	-12.037 (16.9636)
Median	-16.667	-16.667	-16.667
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	83.333 (-)	- (-)	83.333 (-)
Median	83.333	-	83.333
Q1, Q3	83.333, 83.333	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline			
n	1	0	1
Mean (SD)	-16.667 (-)	- (-)	-16.667 (-)
Median	-16.667	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Social functioning			
Baseline			
n	48	19	67
Mean (SD)	87.847 (18.7492)	78.070 (28.8956)	85.075 (22.3106)
Median	100.000	83.333	100.000
Q1, Q3	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	89.535 (19.9282)	87.963 (19.6419)	89.071 (19.6933)
Median	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.397 (20.3253)	11.111 (31.3112)	3.056 (24.4510)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 66.67	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	92.857 (16.3128)	90.000 (15.1710)	92.000 (15.8794)
Median	100.000	100.000	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	3.922 (20.5394)	13.333 (30.3420)	6.803 (24.0366)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-50.00, 83.33	-33.33, 100.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	90.278 (24.3568)	76.923 (16.0128)	86.735 (23.0688)
Median	100.000	66.667	100.000
Q1, Q3	100.000, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	1.429 (27.8216)	2.564 (31.0661)	1.736 (28.4010)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 8.333
Min, Max	-83.33, 83.33	-33.33, 66.67	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	94.444 (10.7583)	83.333 (15.7135)	91.860 (12.7927)
Median	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	66.67, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	2.604 (15.3276)	10.000 (38.6501)	4.365 (22.7093)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 33.333	0.000, 16.667
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	92.593 (16.8790)	75.000 (20.4124)	89.394 (18.5490)
Median	100.000	66.667	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	0.641 (18.5477)	19.444 (42.7092)	4.167 (25.0448)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 50.00	-16.67, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	93.889 (14.1715)	80.556 (26.7014)	91.667 (17.1362)
Median	100.000	91.667	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	1.724 (17.4488)	25.000 (39.0868)	5.714 (23.5504)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 50.00	0.00, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	91.304 (18.7147)	86.111 (19.4841)	90.230 (18.6431)
Median	100.000	91.667	100.000
Q1, Q3	100.000, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-0.758 (19.5703)	30.556 (41.3880)	5.952 (28.0411)
Median	0.000	25.000	0.000
Q1, Q3	0.000, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	-33.33, 50.00	-16.67, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	72.727 (27.1546)	59.524 (23.2879)	67.593 (25.8656)
Median	83.333	66.667	66.667
Q1, Q3	33.333, 100.000	33.333, 66.667	33.333, 83.333
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	-6.061 (22.6969)	-21.429 (26.7261)	-12.037 (24.7903)
Median	0.000	-33.333	-8.333
Q1, Q3	-16.667, 16.667	-50.000, 0.000	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Fatigue			
Baseline			
n	48	19	67
Mean (SD)	29.514 (24.1796)	29.240 (21.3439)	29.436 (23.2509)
Median	22.222	22.222	22.222
Q1, Q3	11.111, 44.444	11.111, 44.444	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 88.89	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	20.672 (22.6910)	25.309 (22.1586)	22.040 (22.4518)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	11.111, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	42	18	60
Mean (SD)	-6.746 (22.5429)	-4.321 (30.2828)	-6.019 (24.8724)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 0.000	-22.222, 0.000
Min, Max	-55.56, 66.67	-88.89, 66.67	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	21.296 (22.4394)	28.148 (16.7283)	23.312 (20.9944)
Median	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	22.222, 33.333	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline			
n	35	15	50
Mean (SD)	-8.413 (15.5024)	-1.481 (26.5163)	-6.333 (19.4407)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 11.111	-11.111, 0.000
Min, Max	-66.67, 11.11	-77.78, 33.33	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	20.988 (24.1655)	28.205 (15.4596)	22.902 (22.2694)
Median	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	22.222, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-7.778 (18.4847)	-3.419 (23.7375)	-6.597 (19.8714)
Median	-11.111	0.000	0.000
Q1, Q3	-22.222, 0.000	0.000, 11.111	-19.444, 0.000
Min, Max	-44.44, 44.44	-55.56, 22.22	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	19.865 (21.4731)	20.000 (16.3970)	19.897 (20.2219)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 44.44	0.00, 77.78
Change from Baseline			
n	32	10	42
Mean (SD)	-5.729 (15.0324)	-14.444 (33.1476)	-7.804 (20.6438)
Median	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-33.33, 33.33	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	17.695 (19.3089)	16.667 (15.3156)	17.508 (18.4320)
Median	11.111	16.667	11.111
Q1, Q3	0.000, 22.222	0.000, 33.333	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 33.33	0.00, 88.89
Change from Baseline			
n	26	6	32
Mean (SD)	-10.043 (16.1795)	-18.519 (42.5523)	-11.632 (22.6816)
Median	0.000	-5.556	0.000
Q1, Q3	-22.222, 0.000	-44.444, 0.000	-22.222, 0.000
Min, Max	-44.44, 22.22	-88.89, 33.33	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	20.000 (23.9554)	31.481 (8.3641)	21.914 (22.4569)
Median	11.111	33.333	22.222
Q1, Q3	0.000, 33.333	22.222, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	22.22, 44.44	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	-4.981 (15.3116)	-3.704 (33.4566)	-4.762 (18.9188)
Median	0.000	5.556	0.000
Q1, Q3	-11.111, 0.000	-11.111, 22.222	-11.111, 0.000
Min, Max	-44.44, 33.33	-66.67, 22.22	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	21.739 (26.2677)	20.370 (12.9894)	21.456 (23.9287)
Median	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	11.111, 33.333	0.000, 22.222
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-2.020 (22.1258)	-14.815 (41.9680)	-4.762 (27.1204)
Median	0.000	-5.556	0.000
Q1, Q3	-11.111, 0.000	-33.333, 22.222	-11.111, 5.556
Min, Max	-55.56, 66.67	-88.89, 22.22	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	48.485 (30.3367)	49.206 (29.9912)	48.765 (29.3079)
Median	44.444	66.667	55.556
Q1, Q3	22.222, 66.667	11.111, 77.778	22.222, 66.667
Min, Max	0.00, 100.00	11.11, 77.78	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	7.576 (27.9188)	23.810 (21.6867)	13.889 (26.2833)
Median	0.000	22.222	11.111
Q1, Q3	-11.111, 22.222	0.000, 44.444	-5.556, 33.333
Min, Max	-22.22, 66.67	0.00, 55.56	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	11.111 (-)	- (-)	11.111 (-)
Median	11.111	-	11.111
Q1, Q3	11.111, 11.111	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-22.222 (-)	- (-)	-22.222 (-)
Median	-22.222	-	-22.222
Q1, Q3	-22.222, -22.222	-, -	-22.222, -22.222
Min, Max	-22.22, -22.22	-, -	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	44.444 (-)	- (-)	44.444 (-)
Median	44.444	-	44.444
Q1, Q3	44.444, 44.444	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline			
n	1	0	1
Mean (SD)	-11.111 (-)	- (-)	-11.111 (-)
Median	-11.111	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Nausea and vomiting			
Baseline			
n	48	19	67
Mean (SD)	4.514 (11.7799)	2.632 (6.2439)	3.980 (10.4967)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	3.488 (9.3139)	0.926 (3.9284)	2.732 (8.1538)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00
Change from Baseline			
n	42	18	60
Mean (SD)	-1.190 (10.0087)	-0.926 (6.9363)	-1.111 (9.1373)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	-16.67, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	3.241 (16.8181)	4.444 (7.6290)	3.595 (14.6491)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-1.429 (14.7813)	3.333 (6.9007)	0.000 (13.0410)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 16.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	3.241 (8.7464)	5.128 (8.0064)	3.741 (8.5156)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	35	13	48
Mean (SD)	-1.429 (8.4515)	3.846 (7.3088)	0.000 (8.4215)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 16.67	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	3.030 (9.7312)	0.000 (0.0000)	2.326 (8.5923)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (4.2333)	-1.667 (5.2705)	-0.397 (4.4904)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-16.67, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	1.235 (6.4150)	5.556 (8.6066)	2.020 (6.9191)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	26	6	32
Mean (SD)	-2.564 (7.7349)	2.778 (6.8041)	-1.563 (7.7591)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	1.111 (6.0858)	2.778 (6.8041)	1.389 (6.1399)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline			
n	29	6	35
Mean (SD)	-2.299 (7.3519)	0.000 (0.0000)	-1.905 (6.7294)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	3.623 (11.1877)	0.000 (0.0000)	2.874 (10.0287)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline			
n	22	6	28
Mean (SD)	0.000 (14.5479)	-2.778 (6.8041)	-0.595 (13.2110)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 50.00	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	9.091 (15.5700)	7.143 (18.8982)	8.333 (16.4197)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 50.00	0.00, 50.00
Change from Baseline			
n	11	7	18
Mean (SD)	1.515 (17.4078)	4.762 (12.5988)	2.778 (15.3925)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 33.33	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Pain			
Baseline			
n	47	19	66
Mean (SD)	15.248 (23.2685)	13.158 (16.2721)	14.646 (21.3868)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 50.00	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	15.891 (23.2747)	11.111 (15.1248)	14.481 (21.1860)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline			
n	41	18	59
Mean (SD)	1.220 (22.4815)	-2.778 (17.3864)	0.000 (20.9908)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	-16.667, 16.667
Min, Max	-66.67, 50.00	-33.33, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	16.204 (25.9689)	8.889 (13.8968)	14.052 (23.1835)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	34	15	49
Mean (SD)	-0.490 (19.8840)	-3.333 (20.1187)	-1.361 (19.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	17.130 (27.4545)	23.077 (22.0883)	18.707 (26.0503)
Median	0.000	16.667	16.667
Q1, Q3	0.000, 25.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	34	13	47
Mean (SD)	0.000 (24.2740)	12.821 (23.7208)	3.546 (24.5580)
Median	0.000	16.667	0.000
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-16.67, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	16.162 (23.0055)	15.000 (22.8387)	15.891 (22.6993)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	0.538 (16.9334)	6.667 (31.6228)	2.033 (21.1460)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 33.333	0.000, 16.667
Min, Max	-50.00, 33.33	-33.33, 66.67	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	14.815 (27.4770)	11.111 (17.2133)	14.141 (25.7260)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	25	6	31
Mean (SD)	2.667 (18.4341)	0.000 (23.5702)	2.151 (19.1204)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	-16.667, 16.667
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	14.444 (25.0415)	22.222 (38.9682)	15.741 (27.2974)
Median	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	1.724 (18.0084)	11.111 (47.9197)	3.333 (24.8525)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	-16.667, 0.000
Min, Max	-33.33, 50.00	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	14.493 (25.7731)	13.889 (22.1527)	14.368 (24.6902)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 50.00	0.00, 83.33
Change from Baseline			
n	22	6	28
Mean (SD)	2.273 (20.1157)	2.778 (28.7067)	2.381 (21.6188)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	-8.333, 8.333
Min, Max	-33.33, 66.67	-33.33, 50.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	22.727 (22.6969)	28.571 (28.4056)	25.000 (24.4214)
Median	16.667	33.333	25.000
Q1, Q3	0.000, 33.333	0.000, 50.000	0.000, 50.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	10	7	17
Mean (SD)	3.333 (21.9427)	14.286 (24.3975)	7.843 (22.9111)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 50.00	-16.67, 50.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Dyspnoea			
Baseline			
n	48	19	67
Mean (SD)	22.222 (30.2342)	28.070 (33.8172)	23.881 (31.1432)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	16.279 (22.2683)	20.370 (25.9181)	17.486 (23.2591)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (21.4490)	-9.259 (31.9427)	-3.333 (25.0799)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	15.741 (27.0051)	13.333 (16.9031)	15.033 (24.3253)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-5.714 (23.5504)	-15.556 (37.5154)	-8.667 (28.4202)
Median	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	12	48
Mean (SD)	12.037 (19.7649)	11.111 (16.4122)	11.806 (18.8180)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	12	47
Mean (SD)	-9.524 (26.2858)	-22.222 (41.0305)	-12.766 (30.7343)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	16.162 (23.7481)	16.667 (23.5702)	16.279 (23.4262)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	10	42
Mean (SD)	-4.167 (30.2321)	-20.000 (44.9966)	-7.937 (34.3815)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	11.111 (18.4900)	0.000 (0.0000)	9.091 (17.2255)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	26	6	32
Mean (SD)	-10.256 (24.5298)	-27.778 (38.9682)	-13.542 (27.9007)
Median	0.000	-16.667	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	12.222 (18.5351)	5.556 (13.6083)	11.111 (17.8174)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	6	35
Mean (SD)	-6.897 (27.2835)	-22.222 (40.3687)	-9.524 (29.7829)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	15.942 (26.3419)	0.000 (0.0000)	12.644 (24.2569)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	-6.061 (28.4268)	-27.778 (38.9682)	-10.714 (31.4970)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000
Min, Max	-66.67, 66.67	-100.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	45.455 (37.3355)	33.333 (33.3333)	40.741 (35.3425)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	9.091 (26.2082)	9.524 (37.0899)	9.259 (29.8264)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	-33.333, 33.333	0.000, 33.333
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	100.000 (-)	- (-)	100.000 (-)
Median	100.000	-	100.000
Q1, Q3	100.000, 100.000	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	-66.667 (-)	- (-)	-66.667 (-)
Median	-66.667	-	-66.667
Q1, Q3	-66.667, -66.667	-, -	-66.667, -66.667
Min, Max	-66.67, -66.67	-, -	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	-33.333 (-)	- (-)	-33.333 (-)
Median	-33.333	-	-33.333
Q1, Q3	-33.333, -33.333	-, -	-33.333, -33.333
Min, Max	-33.33, -33.33	-, -	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Insomnia			
Baseline			
n	48	19	67
Mean (SD)	20.139 (26.3990)	19.298 (20.2326)	19.900 (24.6591)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	18.605 (25.5131)	16.667 (20.6116)	18.033 (24.0168)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (18.7526)	-3.704 (22.5467)	-1.667 (19.8155)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	20.370 (27.9203)	17.778 (21.3313)	19.608 (25.9713)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-1.905 (19.7084)	-4.444 (21.3313)	-2.667 (20.0227)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	17.593 (28.1562)	20.513 (25.5983)	18.367 (27.2686)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (25.2716)	-2.564 (21.3504)	-3.472 (24.0563)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	20.202 (28.7945)	23.333 (27.4424)	20.930 (28.1936)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	0.000 (14.6647)	0.000 (22.2222)	0.000 (16.4622)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	19.753 (29.6118)	16.667 (18.2574)	19.192 (27.6766)
Median	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	0.000 (16.3299)	-11.111 (17.2133)	-2.083 (16.8005)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	16.667 (27.3336)	5.556 (13.6083)	14.815 (25.7515)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	-3.448 (16.2930)	-22.222 (27.2166)	-6.667 (19.4701)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	13.043 (21.8792)	11.111 (17.2133)	12.644 (20.7284)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	22	6	28
Mean (SD)	-4.545 (15.5854)	-16.667 (18.2574)	-7.143 (16.6225)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	21.212 (26.9680)	47.619 (26.2265)	31.481 (29.0868)
Median	0.000	66.667	33.333
Q1, Q3	0.000, 33.333	33.333, 66.667	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	11	7	18
Mean (SD)	6.061 (13.4840)	28.571 (29.9912)	14.815 (23.4931)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Appetite loss			
Baseline			
n	48	19	67
Mean (SD)	11.111 (23.1485)	17.544 (25.7443)	12.935 (23.8932)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	8.527 (17.9550)	14.815 (20.5233)	10.383 (18.7981)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	42	18	60
Mean (SD)	-3.175 (21.8513)	-3.704 (34.0873)	-3.333 (25.8199)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	9.259 (21.9828)	6.667 (13.8013)	8.497 (19.8249)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	35	15	50
Mean (SD)	-0.952 (23.5504)	-13.333 (30.3420)	-4.667 (26.0907)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	6.481 (17.4928)	10.256 (16.0128)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (25.2716)	-10.256 (34.3851)	-5.556 (27.7896)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	10.101 (21.2211)	13.333 (23.3069)	10.853 (21.4808)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	32	10	42
Mean (SD)	3.125 (19.6006)	-10.000 (41.7222)	0.000 (26.5444)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	9.877 (20.2860)	0.000 (0.0000)	8.081 (18.6903)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	26	6	32
Mean (SD)	1.282 (19.9572)	-22.222 (40.3687)	-3.125 (25.9022)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	8.889 (19.4431)	5.556 (13.6083)	8.333 (18.4735)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	29	6	35
Mean (SD)	1.149 (18.8620)	-16.667 (27.8887)	-1.905 (21.3021)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	11.594 (25.8369)	0.000 (0.0000)	9.195 (23.3954)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	3.030 (28.9299)	-22.222 (40.3687)	-2.381 (32.6202)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 100.00	-100.00, 0.00	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	36.364 (43.3450)	33.333 (27.2166)	35.185 (36.9989)
Median	33.333	33.333	33.333
Q1, Q3	0.000, 100.000	0.000, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	12.121 (47.7790)	19.048 (26.2265)	14.815 (39.9709)
Median	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	-66.67, 100.00	-33.33, 33.33	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline			
n	1	0	1
Mean (SD)	33.333 (-)	- (-)	33.333 (-)
Median	33.333	-	33.333
Q1, Q3	33.333, 33.333	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline			
n	1	0	1
Mean (SD)	66.667 (-)	- (-)	66.667 (-)
Median	66.667	-	66.667
Q1, Q3	66.667, 66.667	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Constipation			
Baseline			
n	48	19	67
Mean (SD)	9.028 (19.1295)	8.772 (15.0805)	8.955 (17.9619)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	13.178 (25.3437)	9.259 (15.3630)	12.022 (22.7977)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	3.968 (24.6409)	1.852 (17.9768)	3.333 (22.7158)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	36	15	51
Mean (SD)	6.481 (15.5726)	13.333 (21.0819)	8.497 (17.4396)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	35	15	50
Mean (SD)	-1.905 (16.0531)	6.667 (25.8199)	0.667 (19.6223)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	8.333 (16.6667)	10.256 (16.0128)	8.844 (16.3519)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-0.952 (15.0939)	2.564 (21.3504)	0.000 (16.8430)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	14.141 (31.2142)	13.333 (17.2133)	13.953 (28.3894)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	6.250 (27.3534)	3.333 (29.1865)	5.556 (27.4644)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	11.111 (22.6455)	5.556 (13.6083)	10.101 (21.2211)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	5.128 (22.4941)	-5.556 (25.0924)	3.125 (22.9685)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	8.889 (23.0497)	5.556 (13.6083)	8.333 (21.6392)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	2.299 (23.4538)	-5.556 (25.0924)	0.952 (23.5504)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	8.696 (22.9567)	5.556 (13.6083)	8.046 (21.1854)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	22	6	28
Mean (SD)	3.030 (14.2134)	-5.556 (25.0924)	1.190 (16.9292)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	36.364 (43.3450)	9.524 (16.2650)	25.926 (37.1458)
Median	33.333	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	18.182 (31.1400)	4.762 (12.5988)	12.963 (25.9181)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Diarrhoea			
Baseline			
n	47	19	66
Mean (SD)	8.511 (21.3868)	3.509 (10.5101)	7.071 (18.9603)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	6.977 (18.6277)	1.852 (7.8567)	5.464 (16.3076)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	41	18	59
Mean (SD)	0.000 (16.6667)	0.000 (11.4332)	0.000 (15.1620)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	9.524 (19.0826)	2.222 (8.6066)	7.333 (16.8897)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	33	15	48
Mean (SD)	3.030 (19.2996)	2.222 (8.6066)	2.778 (16.6075)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	7.407 (16.1562)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	34	13	47
Mean (SD)	1.961 (21.6199)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	7.071 (19.9958)	6.667 (14.0546)	6.977 (18.6277)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline			
n	31	10	41
Mean (SD)	2.151 (20.9682)	6.667 (14.0546)	3.252 (19.4435)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	0.00, 33.33	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	7.407 (16.8790)	5.556 (13.6083)	7.071 (16.1537)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	25	6	31
Mean (SD)	1.333 (24.4949)	5.556 (13.6083)	2.151 (22.6658)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	0.00, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	8.889 (17.3610)	0.000 (0.0000)	7.407 (16.1562)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline			
n	29	6	35
Mean (SD)	3.448 (22.4401)	0.000 (0.0000)	2.857 (20.4067)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	2.899 (9.6035)	0.000 (0.0000)	2.299 (8.5960)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline			
n	22	6	28
Mean (SD)	0.000 (10.2869)	0.000 (0.0000)	0.000 (9.0722)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	9.091 (21.5557)	4.762 (12.5988)	7.407 (18.2773)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline			
n	10	7	17
Mean (SD)	6.667 (26.2937)	4.762 (12.5988)	5.882 (21.1978)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Financial Difficulties			
Baseline			
n	48	19	67
Mean (SD)	12.500 (25.3813)	26.316 (40.9440)	16.418 (30.9083)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 3			
n	43	18	61
Mean (SD)	10.078 (21.2504)	16.667 (32.8395)	12.022 (25.1166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	42	18	60
Mean (SD)	-0.794 (18.7526)	-11.111 (32.3381)	-3.889 (23.8417)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 6			
n	35	15	50
Mean (SD)	8.571 (20.3609)	15.556 (27.7936)	10.667 (22.7776)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	34	15	49
Mean (SD)	0.000 (20.1008)	-11.111 (32.5300)	-3.401 (24.7627)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-100.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 9			
n	36	13	49
Mean (SD)	4.630 (11.6912)	15.385 (25.8750)	7.483 (17.0312)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	35	13	48
Mean (SD)	-3.810 (15.7003)	-15.385 (22.0075)	-6.944 (18.1383)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 12			
n	33	10	43
Mean (SD)	10.101 (24.2740)	23.333 (35.3117)	13.178 (27.3518)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	32	10	42
Mean (SD)	2.083 (14.5112)	-10.000 (22.4983)	-0.794 (17.2470)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 18			
n	27	6	33
Mean (SD)	9.877 (27.4482)	16.667 (27.8887)	11.111 (27.2166)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	26	6	32
Mean (SD)	2.564 (20.9191)	-27.778 (32.7731)	-3.125 (25.9022)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 24			
n	30	6	36
Mean (SD)	8.889 (23.0497)	11.111 (27.2166)	9.259 (23.3824)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline			
n	29	6	35
Mean (SD)	0.000 (19.9205)	-33.333 (42.1637)	-5.714 (27.3989)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Cycle 30			
n	23	6	29
Mean (SD)	8.696 (20.6397)	16.667 (27.8887)	10.345 (22.0091)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline			
n	22	6	28
Mean (SD)	1.515 (16.1909)	-27.778 (32.7731)	-4.762 (23.5078)
Median	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Safety Follow-up			
n	11	7	18
Mean (SD)	24.242 (33.6350)	38.095 (48.7950)	29.630 (39.4221)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline			
n	11	7	18
Mean (SD)	0.000 (25.8199)	4.762 (12.5988)	1.852 (21.3046)
Median	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 1			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 2			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 5			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 6			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.4:
Summary of EORTC QLQ-C30 by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
Scale/Visit	**< 3 (N = 49)**	**≥ 3 (N = 19)**	**Total (N = 68)**
Survival Follow-up 7			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline			
n	1	0	1
Mean (SD)	0.000 (-)	- (-)	0.000 (-)
Median	0.000	-	0.000
Q1, Q3	0.000, 0.000	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-04-eortc-sum-pst.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Global health status/QOL					
Baseline					
n	26	25	12	4	67
Mean (SD)	66.346 (22.7890)	70.000 (16.6667)	59.722 (26.0713)	58.333 (21.5166)	66.045 (21.1871)
Median	66.667	75.000	62.500	58.333	66.667
Q1, Q3	50.000, 83.333	66.667, 83.333	45.833, 83.333	41.667, 75.000	50.000, 83.333
Min, Max	25.00, 100.00	25.00, 100.00	0.00, 91.67	33.33, 83.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	78.571 (18.1757)	74.667 (16.2233)	73.485 (16.5907)	70.833 (20.9718)	75.546 (17.0014)
Median	83.333	83.333	75.000	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	58.333, 83.333	58.333, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	25.00, 100.00	50.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	11.508 (23.4929)	4.514 (20.8484)	8.333 (12.9099)	12.500 (8.3333)	8.194 (19.9748)
Median	8.333	8.333	8.333	16.667	8.333
Q1, Q3	0.000, 16.667	-8.333, 12.500	0.000, 25.000	8.333, 16.667	0.000, 16.667
Min, Max	-33.33, 66.67	-41.67, 50.00	-16.67, 25.00	0.00, 16.67	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	79.902 (14.4514)	76.587 (17.6027)	64.815 (29.6911)	66.667 (33.3333)	75.000 (20.4124)
Median	83.333	83.333	66.667	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 91.667	50.000, 83.333	33.333, 100.000	66.667, 91.667
Min, Max	50.00, 100.00	41.67, 100.00	8.33, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	12.745 (21.8735)	4.583 (11.9315)	6.481 (10.0154)	5.556 (9.6225)	7.823 (15.8121)
Median	0.000	0.000	8.333	0.000	8.333
Q1, Q3	0.000, 25.000	0.000, 8.333	8.333, 8.333	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 33.33	-16.67, 16.67	0.00, 16.67	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	73.611 (15.9784)	76.587 (17.9929)	58.333 (36.6414)	69.444 (29.2657)	72.449 (21.5974)
Median	79.167	83.333	66.667	66.667	83.333
Q1, Q3	58.333, 83.333	66.667, 83.333	16.667, 91.667	41.667, 100.000	58.333, 83.333
Min, Max	41.67, 100.00	33.33, 100.00	0.00, 91.67	41.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	5.556 (16.9100)	3.750 (19.2086)	8.333 (29.2657)	8.333 (30.0463)	5.382 (20.0833)
Median	4.167	8.333	8.333	16.667	8.333
Q1, Q3	-8.333, 16.667	0.000, 12.500	0.000, 25.000	-25.000, 33.333	0.000, 16.667
Min, Max	-16.67, 50.00	-41.67, 41.67	-50.00, 41.67	-25.00, 33.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	75.000 (15.2145)	81.140 (15.9189)	63.889 (32.3465)	66.667 (47.1405)	75.775 (20.1527)
Median	79.167	83.333	75.000	66.667	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	66.667, 83.333	33.333, 100.000	66.667, 83.333
Min, Max	50.00, 100.00	50.00, 100.00	0.00, 83.33	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	3.125 (21.0544)	9.259 (15.8858)	11.111 (12.5462)	8.333 (11.7851)	7.143 (17.3216)
Median	0.000	8.333	8.333	8.333	8.333
Q1, Q3	-12.500, 12.500	0.000, 16.667	0.000, 25.000	0.000, 16.667	0.000, 16.667
Min, Max	-33.33, 58.33	-16.67, 41.67	0.00, 25.00	0.00, 16.67	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	81.250 (14.7046)	79.444 (15.7065)	63.333 (35.6487)	41.667 (-)	76.515 (20.4607)
Median	83.333	83.333	75.000	41.667	83.333
Q1, Q3	75.000, 91.667	75.000, 83.333	75.000, 83.333	41.667, 41.667	75.000, 83.333
Min, Max	50.00, 100.00	41.67, 100.00	0.00, 83.33	41.67, 41.67	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	12.500 (18.2920)	6.548 (19.6602)	18.333 (18.0662)	8.333 (-)	10.677 (18.4811)
Median	12.500	8.333	25.000	8.333	8.333
Q1, Q3	0.000, 16.667	-8.333, 16.667	0.000, 25.000	8.333, 8.333	0.000, 20.833
Min, Max	-16.67, 58.33	-33.33, 33.33	0.00, 41.67	8.33, 8.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	81.548 (15.0422)	79.167 (16.9053)	61.111 (32.7731)	66.667 (47.1405)	76.389 (21.5933)
Median	83.333	83.333	75.000	66.667	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	50.000, 83.333	33.333, 100.000	66.667, 87.500
Min, Max	50.00, 100.00	50.00, 100.00	0.00, 83.33	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	10.714 (21.2908)	6.410 (21.5579)	12.500 (12.6381)	8.333 (11.7851)	9.286 (19.2561)
Median	4.167	0.000	12.500	8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	-16.67, 66.67	-25.00, 50.00	0.00, 33.33	0.00, 16.67	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	79.545 (15.9703)	76.389 (18.0604)	50.000 (37.8838)	66.667 (47.1405)	73.276 (23.5048)
Median	83.333	83.333	58.333	66.667	83.333
Q1, Q3	75.000, 83.333	58.333, 91.667	20.833, 79.167	33.333, 100.000	66.667, 83.333
Min, Max	41.67, 100.00	50.00, 100.00	0.00, 83.33	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	8.333 (19.3649)	3.788 (25.9175)	6.250 (14.2319)	8.333 (11.7851)	6.250 (20.4910)
Median	8.333	0.000	4.167	8.333	4.167
Q1, Q3	0.000, 16.667	-16.667, 33.333	-4.167, 16.667	0.000, 16.667	-8.333, 16.667
Min, Max	-16.67, 58.33	-33.33, 41.67	-8.33, 25.00	0.00, 16.67	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	53.571 (18.5450)	53.571 (21.4396)	69.444 (45.8964)	66.667 (-)	56.944 (23.9570)
Median	58.333	66.667	91.667	66.667	66.667
Q1, Q3	33.333, 66.667	33.333, 66.667	16.667, 100.000	66.667, 66.667	33.333, 66.667
Min, Max	25.00, 75.00	16.67, 75.00	16.67, 100.00	66.67, 66.67	16.67, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-11.905 (36.9112)	-14.286 (24.8674)	-2.778 (19.2450)	0.000 (-)	-10.648 (27.6837)
Median	-16.667	0.000	8.333	0.000	0.000
Q1, Q3	-33.333, 8.333	-41.667, 0.000	-25.000, 8.333	0.000, 0.000	-25.000, 8.333
Min, Max	-75.00, 41.67	-50.00, 16.67	-25.00, 8.33	0.00, 0.00	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-16.667 (-)	- (-)	- (-)	- (-)	-16.667 (-)
Median	-16.667	-	-	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-, -	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-, -	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	50.000 (-)	- (-)	- (-)	- (-)	50.000 (-)
Median	50.000	-	-	-	50.000
Q1, Q3	50.000, 50.000	-, -	-, -	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	-, -	-, -	50.00, 50.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	16.667 (-)	- (-)	- (-)	- (-)	16.667 (-)
Median	16.667	-	-	-	16.667
Q1, Q3	16.667, 16.667	-, -	-, -	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	-, -	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	16.667 (-)	- (-)	- (-)	- (-)	16.667 (-)
Median	16.667	-	-	-	16.667
Q1, Q3	16.667, 16.667	-, -	-, -	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	-, -	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	16.667 (-)	- (-)	- (-)	- (-)	16.667 (-)
Median	16.667	-	-	-	16.667
Q1, Q3	16.667, 16.667	-, -	-, -	-, -	16.667, 16.667
Min, Max	16.67, 16.67	-, -	-, -	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Physical functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	84.872 (18.5288)	86.667 (17.3205)	73.333 (22.9184)	80.000 (27.2166)	83.184 (19.6041)
Median	90.000	93.333	83.333	90.000	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	46.667, 90.000	63.333, 96.667	80.000, 100.000
Min, Max	33.33, 100.00	20.00, 100.00	40.00, 100.00	40.00, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	20	25	11	4	60
Mean (SD)	89.000 (11.9012)	85.867 (17.2477)	83.636 (16.6969)	76.667 (33.7749)	85.889 (16.7890)
Median	93.333	86.667	86.667	90.000	93.333
Q1, Q3	86.667, 100.000	86.667, 100.000	80.000, 93.333	56.667, 96.667	83.333, 100.000
Min, Max	60.00, 100.00	26.67, 100.00	46.67, 100.00	26.67, 100.00	26.67, 100.00
Change from Baseline					
n	20	24	11	4	59
Mean (SD)	2.667 (14.5739)	-1.667 (14.7442)	7.273 (10.5217)	-3.333 (6.6667)	1.356 (13.7732)
Median	0.000	0.000	6.667	0.000	0.000
Q1, Q3	-6.667, 6.667	-6.667, 3.333	0.000, 13.333	-6.667, 0.000	-6.667, 6.667
Min, Max	-20.00, 53.33	-33.33, 40.00	-6.67, 33.33	-13.33, 0.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	89.259 (10.5133)	87.302 (15.0414)	83.704 (25.1906)	71.111 (44.3889)	86.405 (18.0843)
Median	93.333	93.333	93.333	93.333	93.333
Q1, Q3	80.000, 100.000	86.667, 100.000	80.000, 100.000	20.000, 100.000	80.000, 100.000
Min, Max	73.33, 100.00	46.67, 100.00	20.00, 100.00	20.00, 100.00	20.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	2.593 (15.8653)	0.667 (16.0263)	10.370 (18.8889)	-6.667 (13.3333)	2.667 (16.4406)
Median	0.000	0.000	6.667	-6.667	0.000
Q1, Q3	-6.667, 6.667	-10.000, 6.667	0.000, 20.000	-20.000, 6.667	-6.667, 6.667
Min, Max	-20.00, 53.33	-33.33, 33.33	-20.00, 40.00	-20.00, 6.67	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	90.370 (10.0254)	87.937 (17.2071)	61.905 (40.1321)	82.222 (25.2396)	84.762 (21.9004)
Median	86.667	93.333	86.667	93.333	86.667
Q1, Q3	86.667, 100.000	80.000, 100.000	6.667, 86.667	53.333, 100.000	80.000, 100.000
Min, Max	66.67, 100.00	26.67, 100.00	0.00, 86.67	53.33, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	3.704 (14.8583)	1.000 (8.7258)	-3.810 (42.1386)	4.444 (10.1835)	1.528 (18.6666)
Median	0.000	0.000	0.000	6.667	0.000
Q1, Q3	0.000, 6.667	0.000, 6.667	-40.000, 40.000	-6.667, 13.333	0.000, 6.667
Min, Max	-13.33, 53.33	-20.00, 20.00	-73.33, 46.67	-6.67, 13.33	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	18	6	2	42
Mean (SD)	90.833 (9.3887)	88.889 (19.1315)	66.667 (33.4664)	66.667 (47.1405)	85.397 (21.4508)
Median	93.333	93.333	80.000	66.667	93.333
Q1, Q3	86.667, 100.000	86.667, 100.000	66.667, 86.667	33.333, 100.000	86.667, 100.000
Min, Max	66.67, 100.00	20.00, 100.00	0.00, 86.67	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	2.917 (16.6833)	3.137 (10.3058)	-2.222 (25.8772)	0.000 (9.4281)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-3.333, 3.333	0.000, 6.667	-13.333, 0.000	-6.667, 6.667	0.000, 6.667
Min, Max	-13.33, 60.00	-20.00, 26.67	-40.00, 40.00	-6.67, 6.67	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	91.667 (9.8985)	92.000 (8.0475)	70.667 (25.2102)	26.667 (-)	86.667 (17.7951)
Median	93.333	93.333	80.000	26.667	86.667
Q1, Q3	86.667, 100.000	86.667, 100.000	73.333, 86.667	26.667, 26.667	86.667, 100.000
Min, Max	66.67, 100.00	80.00, 100.00	26.67, 86.67	26.67, 26.67	26.67, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	1.111 (20.4660)	3.333 (11.9114)	2.667 (18.0123)	-13.333 (-)	1.875 (16.0853)
Median	0.000	3.333	0.000	-13.333	0.000
Q1, Q3	-6.667, 0.000	0.000, 6.667	-6.667, 0.000	-13.333, -13.333	-6.667, 6.667
Min, Max	-26.67, 60.00	-13.33, 26.67	-13.33, 33.33	-13.33, -13.33	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	90.952 (9.2845)	87.619 (18.6478)	65.833 (31.7586)	66.667 (37.7124)	84.120 (21.0762)
Median	93.333	93.333	74.167	66.667	93.333
Q1, Q3	86.667, 100.000	86.667, 100.000	60.000, 80.000	40.000, 93.333	80.000, 96.667
Min, Max	66.67, 100.00	26.67, 100.00	6.67, 100.00	40.00, 93.33	6.67, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-0.476 (19.4742)	-2.051 (22.6707)	-4.167 (23.9849)	0.000 (0.0000)	-1.667 (20.3202)
Median	0.000	0.000	-9.167	0.000	0.000
Q1, Q3	-13.333, 0.000	0.000, 0.000	-20.000, 13.333	0.000, 0.000	-6.667, 0.000
Min, Max	-26.67, 60.00	-66.67, 40.00	-33.33, 33.33	0.00, 0.00	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	93.030 (10.5887)	87.778 (10.9483)	75.000 (19.9072)	76.667 (32.9983)	87.241 (14.5315)
Median	100.000	90.000	80.000	76.667	93.333
Q1, Q3	86.667, 100.000	80.000, 96.667	63.333, 86.667	53.333, 100.000	80.000, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	46.67, 93.33	53.33, 100.00	46.67, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	2.121 (22.5227)	-2.424 (16.1308)	10.000 (16.7774)	10.000 (4.7140)	2.024 (18.3998)
Median	0.000	0.000	6.667	10.000	0.000
Q1, Q3	-6.667, 0.000	-13.333, 0.000	0.000, 20.000	6.667, 13.333	-6.667, 6.667
Min, Max	-20.00, 66.67	-26.67, 33.33	-6.67, 33.33	6.67, 13.33	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	69.524 (15.3271)	66.667 (21.4303)	82.222 (30.7920)	93.333 (-)	71.852 (20.3955)
Median	66.667	66.667	100.000	93.333	73.333
Q1, Q3	60.000, 86.667	60.000, 80.000	46.667, 100.000	93.333, 93.333	60.000, 86.667
Min, Max	46.67, 86.67	26.67, 93.33	46.67, 100.00	93.33, 93.33	26.67, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-10.476 (13.8013)	-11.429 (20.9812)	4.444 (7.6980)	-6.667 (-)	-8.148 (16.2586)
Median	-13.333	-20.000	0.000	-6.667	-10.000
Q1, Q3	-20.000, 0.000	-26.667, 6.667	0.000, 13.333	-6.667, -6.667	-20.000, 0.000
Min, Max	-33.33, 6.67	-33.33, 26.67	0.00, 13.33	-6.67, -6.67	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	58.333 (-)	- (-)	- (-)	- (-)	58.333 (-)
Median	58.333	-	-	-	58.333
Q1, Q3	58.333, 58.333	-, -	-, -	-, -	58.333, 58.333
Min, Max	58.33, 58.33	-, -	-, -	-, -	58.33, 58.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-8.333 (-)	- (-)	- (-)	- (-)	-8.333 (-)
Median	-8.333	-	-	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-, -	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-, -	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	60.000 (-)	- (-)	- (-)	- (-)	60.000 (-)
Median	60.000	-	-	-	60.000
Q1, Q3	60.000, 60.000	-, -	-, -	-, -	60.000, 60.000
Min, Max	60.00, 60.00	-, -	-, -	-, -	60.00, 60.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-6.667 (-)	- (-)	- (-)	- (-)	-6.667 (-)
Median	-6.667	-	-	-	-6.667
Q1, Q3	-6.667, -6.667	-, -	-, -	-, -	-6.667, -6.667
Min, Max	-6.67, -6.67	-, -	-, -	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	73.333 (-)	- (-)	- (-)	- (-)	73.333 (-)
Median	73.333	-	-	-	73.333
Q1, Q3	73.333, 73.333	-, -	-, -	-, -	73.333, 73.333
Min, Max	73.33, 73.33	-, -	-, -	-, -	73.33, 73.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	6.667 (-)	- (-)	- (-)	- (-)	6.667 (-)
Median	6.667	-	-	-	6.667
Q1, Q3	6.667, 6.667	-, -	-, -	-, -	6.667, 6.667
Min, Max	6.67, 6.67	-, -	-, -	-, -	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	77.778 (-)	- (-)	- (-)	- (-)	77.778 (-)
Median	77.778	-	-	-	77.778
Q1, Q3	77.778, 77.778	-, -	-, -	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	-, -	-, -	77.78, 77.78
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	11.111 (-)	- (-)	- (-)	- (-)	11.111 (-)
Median	11.111	-	-	-	11.111
Q1, Q3	11.111, 11.111	-, -	-, -	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	-, -	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	86.667 (-)	- (-)	- (-)	- (-)	86.667 (-)
Median	86.667	-	-	-	86.667
Q1, Q3	86.667, 86.667	-, -	-, -	-, -	86.667, 86.667
Min, Max	86.67, 86.67	-, -	-, -	-, -	86.67, 86.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	20.000 (-)	- (-)	- (-)	- (-)	20.000 (-)
Median	20.000	-	-	-	20.000
Q1, Q3	20.000, 20.000	-, -	-, -	-, -	20.000, 20.000
Min, Max	20.00, 20.00	-, -	-, -	-, -	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Role functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	83.333 (28.2843)	88.000 (21.7945)	76.389 (24.0563)	75.000 (31.9142)	83.333 (25.2929)
Median	100.000	100.000	83.333	83.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000	50.000, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	16.67, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	90.476 (16.3056)	84.667 (25.8736)	89.394 (17.1152)	75.000 (31.9142)	86.885 (21.7551)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	50.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	5.556 (25.9986)	-3.472 (25.5278)	9.091 (15.5700)	0.000 (0.0000)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-8.333, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 66.67	-66.67, 33.33	-16.67, 33.33	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	88.889 (16.1690)	94.444 (13.2637)	85.185 (22.7371)	77.778 (38.4900)	89.869 (17.9748)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	83.333, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	50.00, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	5.556 (28.5831)	6.667 (14.7097)	5.556 (14.4338)	0.000 (0.0000)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-16.67, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	89.815 (19.9172)	91.270 (17.9653)	66.667 (46.1479)	77.778 (19.2450)	86.395 (25.1554)
Median	100.000	100.000	83.333	66.667	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	0.000, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	0.00, 100.00	66.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	6.481 (19.9172)	1.667 (14.2040)	-9.524 (31.7063)	0.000 (33.3333)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-33.333, 16.667	-33.333, 33.333	0.000, 16.667
Min, Max	-16.67, 66.67	-33.33, 33.33	-66.67, 16.67	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	88.542 (16.9080)	89.474 (25.5860)	75.000 (39.0868)	75.000 (35.3553)	86.434 (25.0015)
Median	100.000	100.000	91.667	75.000	100.000
Q1, Q3	75.000, 100.000	100.000, 100.000	66.667, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (30.3529)	0.926 (10.6523)	0.000 (18.2574)	8.333 (11.7851)	1.587 (20.7611)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	-8.333, 16.667	0.000, 0.000	0.000, 16.667	0.000, 16.667	0.000, 0.000
Min, Max	-50.00, 83.33	-16.67, 33.33	-33.33, 16.67	0.00, 16.67	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	90.278 (13.2160)	88.889 (14.9956)	70.000 (41.4997)	33.333 (-)	84.848 (22.5784)
Median	100.000	100.000	83.333	33.333	100.000
Q1, Q3	83.333, 100.000	66.667, 100.000	66.667, 100.000	33.333, 33.333	66.667, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	0.00, 100.00	33.33, 33.33	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	1.389 (34.4204)	-4.762 (16.5748)	-6.667 (14.9071)	0.000 (-)	-2.604 (23.9883)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	-33.33, 0.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	88.095 (15.2312)	90.476 (23.3098)	83.333 (27.8887)	66.667 (47.1405)	87.037 (22.2222)
Median	100.000	100.000	100.000	66.667	100.000
Q1, Q3	66.667, 100.000	100.000, 100.000	66.667, 100.000	33.333, 100.000	75.000, 100.000
Min, Max	66.67, 100.00	16.67, 100.00	33.33, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	0.000 (34.5916)	-5.128 (29.1743)	8.333 (13.9443)	0.000 (0.0000)	-0.476 (28.4357)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-83.33, 33.33	0.00, 33.33	0.00, 0.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	92.424 (11.4592)	91.667 (19.4625)	79.167 (41.6667)	75.000 (35.3553)	89.080 (21.4901)
Median	100.000	100.000	100.000	75.000	100.000
Q1, Q3	83.333, 100.000	91.667, 100.000	58.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	33.33, 100.00	16.67, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	7.576 (27.2475)	-6.061 (23.8895)	0.000 (13.6083)	8.333 (11.7851)	1.190 (23.5390)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	-8.333, 8.333	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 83.33	-66.67, 33.33	-16.67, 16.67	0.00, 16.67	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	52.381 (22.4198)	52.381 (36.5510)	77.778 (38.4900)	100.000 (-)	59.259 (31.9427)
Median	50.000	66.667	100.000	100.000	66.667
Q1, Q3	33.333, 66.667	16.667, 83.333	33.333, 100.000	100.000, 100.000	33.333, 83.333
Min, Max	16.67, 83.33	0.00, 100.00	33.33, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-26.190 (18.8982)	-19.048 (41.3080)	5.556 (9.6225)	0.000 (-)	-16.667 (29.7044)
Median	-16.667	-16.667	0.000	0.000	-16.667
Q1, Q3	-50.000, -16.667	-66.667, 0.000	0.000, 16.667	0.000, 0.000	-33.333, 0.000
Min, Max	-50.00, 0.00	-66.67, 50.00	0.00, 16.67	0.00, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	50.000 (-)	- (-)	- (-)	- (-)	50.000 (-)
Median	50.000	-	-	-	50.000
Q1, Q3	50.000, 50.000	-, -	-, -	-, -	50.000, 50.000
Min, Max	50.00, 50.00	-, -	-, -	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Emotional functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	82.692 (15.7979)	84.667 (16.6110)	75.694 (24.4790)	83.333 (18.0021)	82.214 (17.8786)
Median	83.333	83.333	83.333	87.500	83.333
Q1, Q3	66.667, 100.000	75.000, 100.000	62.500, 95.833	70.833, 95.833	66.667, 100.000
Min, Max	50.00, 100.00	41.67, 100.00	25.00, 100.00	58.33, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	85.317 (13.4125)	83.000 (27.2675)	84.848 (18.5660)	89.583 (20.8333)	84.563 (20.9627)
Median	91.667	100.000	100.000	100.000	91.667
Q1, Q3	75.000, 91.667	66.667, 100.000	66.667, 100.000	79.167, 100.000	75.000, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	58.33, 100.00	58.33, 100.00	16.67, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	3.968 (13.3383)	-1.736 (25.7706)	7.576 (10.8362)	6.250 (7.9786)	2.500 (18.8724)
Median	0.000	0.000	0.000	4.167	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 16.667	0.000, 12.500	0.000, 16.667
Min, Max	-25.00, 25.00	-75.00, 33.33	0.00, 33.33	0.00, 16.67	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	91.176 (10.8135)	79.365 (25.7686)	79.630 (22.4811)	75.000 (36.3242)	83.167 (21.9183)
Median	91.667	83.333	83.333	91.667	91.667
Q1, Q3	91.667, 100.000	75.000, 100.000	75.000, 100.000	33.333, 100.000	75.000, 100.000
Min, Max	66.67, 100.00	0.00, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	11.275 (14.4161)	-3.750 (21.0254)	7.407 (17.8946)	-8.333 (14.4338)	3.231 (19.0042)
Median	8.333	0.000	8.333	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 12.500	0.000, 8.333	-25.000, 0.000	0.000, 16.667
Min, Max	-16.67, 41.67	-50.00, 33.33	-25.00, 33.33	-25.00, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	84.722 (20.8578)	86.508 (18.1575)	65.476 (33.1343)	86.111 (24.0563)	82.823 (22.4645)
Median	91.667	91.667	83.333	100.000	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	41.667, 91.667	58.333, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	8.33, 100.00	58.33, 100.00	8.33, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	3.704 (18.7916)	2.500 (16.0181)	-4.762 (33.9721)	2.778 (4.8113)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-8.333, 16.667	-41.667, 16.667	0.000, 8.333	-8.333, 16.667
Min, Max	-33.33, 33.33	-25.00, 25.00	-50.00, 50.00	0.00, 8.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	84.375 (24.6972)	84.211 (21.3175)	79.167 (28.2597)	70.833 (41.2479)	82.946 (23.6370)
Median	91.667	91.667	87.500	70.833	91.667
Q1, Q3	83.333, 100.000	66.667, 100.000	75.000, 100.000	41.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	25.00, 100.00	41.67, 100.00	16.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.604 (17.9296)	0.463 (16.7820)	1.389 (25.5042)	-8.333 (11.7851)	0.992 (17.9583)
Median	4.167	0.000	4.167	-8.333	0.000
Q1, Q3	0.000, 12.500	0.000, 16.667	-16.667, 8.333	-16.667, 0.000	0.000, 8.333
Min, Max	-50.00, 25.00	-41.67, 25.00	-33.33, 41.67	-16.67, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	86.806 (21.1591)	82.778 (24.4922)	71.667 (20.9165)	66.667 (-)	82.071 (22.4499)
Median	91.667	91.667	75.000	66.667	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	66.667, 75.000	66.667, 66.667	75.000, 100.000
Min, Max	25.00, 100.00	8.33, 100.00	41.67, 100.00	66.67, 66.67	8.33, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	4.861 (18.9558)	-2.976 (16.2141)	8.333 (27.6385)	8.333 (-)	2.083 (18.9321)
Median	4.167	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 16.667	-8.333, 8.333	-16.667, 33.333	8.333, 8.333	-8.333, 12.500
Min, Max	-41.67, 33.33	-33.33, 25.00	-16.67, 41.67	8.33, 8.33	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	85.119 (20.1963)	87.500 (24.1854)	83.333 (15.8114)	70.833 (29.4628)	84.954 (21.0649)
Median	91.667	100.000	83.333	70.833	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	66.667, 100.000	50.000, 91.667	75.000, 100.000
Min, Max	25.00, 100.00	16.67, 100.00	66.67, 100.00	50.00, 91.67	16.67, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	1.190 (14.9276)	3.846 (20.5861)	15.278 (17.8081)	-8.333 (0.0000)	4.048 (17.7781)
Median	4.167	0.000	8.333	-8.333	0.000
Q1, Q3	0.000, 8.333	0.000, 25.000	0.000, 33.333	-8.333, -8.333	0.000, 8.333
Min, Max	-41.67, 25.00	-33.33, 33.33	0.00, 41.67	-8.33, -8.33	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	90.909 (13.6700)	79.167 (30.2556)	72.917 (20.8333)	66.667 (47.1405)	81.897 (24.8077)
Median	100.000	95.833	70.833	66.667	91.667
Q1, Q3	83.333, 100.000	62.500, 100.000	58.333, 87.500	33.333, 100.000	75.000, 100.000
Min, Max	58.33, 100.00	8.33, 100.00	50.00, 100.00	33.33, 100.00	8.33, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	4.545 (10.7778)	-4.545 (22.7802)	4.167 (25.9094)	-12.500 (17.6777)	-0.298 (18.7690)
Median	0.000	0.000	-4.167	-12.500	0.000
Q1, Q3	0.000, 8.333	-16.667, 8.333	-12.500, 20.833	-25.000, 0.000	-8.333, 8.333
Min, Max	-16.67, 25.00	-50.00, 33.33	-16.67, 41.67	-25.00, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	73.810 (20.0858)	70.238 (26.7261)	75.000 (36.3242)	91.667 (-)	73.611 (23.9570)
Median	75.000	75.000	91.667	91.667	79.167
Q1, Q3	66.667, 91.667	41.667, 100.000	33.333, 100.000	91.667, 91.667	58.333, 91.667
Min, Max	33.33, 91.67	33.33, 100.00	33.33, 100.00	91.67, 91.67	33.33, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-10.714 (17.8174)	-9.524 (22.2718)	-8.333 (22.0479)	0.000 (-)	-9.259 (18.7190)
Median	-8.333	-8.333	0.000	0.000	-8.333
Q1, Q3	-25.000, 0.000	-16.667, 0.000	-33.333, 8.333	0.000, 0.000	-25.000, 0.000
Min, Max	-33.33, 16.67	-50.00, 25.00	-33.33, 8.33	0.00, 0.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	77.778 (-)	- (-)	- (-)	- (-)	77.778 (-)
Median	77.778	-	-	-	77.778
Q1, Q3	77.778, 77.778	-, -	-, -	-, -	77.778, 77.778
Min, Max	77.78, 77.78	-, -	-, -	-, -	77.78, 77.78
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-13.889 (-)	- (-)	- (-)	- (-)	-13.889 (-)
Median	-13.889	-	-	-	-13.889
Q1, Q3	-13.889, -13.889	-, -	-, -	-, -	-13.889, -13.889
Min, Max	-13.89, -13.89	-, -	-, -	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-8.333 (-)	- (-)	- (-)	- (-)	-8.333 (-)
Median	-8.333	-	-	-	-8.333
Q1, Q3	-8.333, -8.333	-, -	-, -	-, -	-8.333, -8.333
Min, Max	-8.33, -8.33	-, -	-, -	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	8.333 (-)	- (-)	- (-)	- (-)	8.333 (-)
Median	8.333	-	-	-	8.333
Q1, Q3	8.333, 8.333	-, -	-, -	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	-, -	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	8.333 (-)	- (-)	- (-)	- (-)	8.333 (-)
Median	8.333	-	-	-	8.333
Q1, Q3	8.333, 8.333	-, -	-, -	-, -	8.333, 8.333
Min, Max	8.33, 8.33	-, -	-, -	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	91.667 (-)	- (-)	- (-)	- (-)	91.667 (-)
Median	91.667	-	-	-	91.667
Q1, Q3	91.667, 91.667	-, -	-, -	-, -	91.667, 91.667
Min, Max	91.67, 91.67	-, -	-, -	-, -	91.67, 91.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cognitive functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	86.538 (20.0107)	91.333 (13.7100)	83.333 (21.3201)	91.667 (16.6667)	88.060 (17.8391)
Median	100.000	100.000	83.333	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	88.889 (18.5093)	83.333 (16.6667)	83.333 (14.9071)	91.667 (16.6667)	85.792 (16.8973)
Median	100.000	83.333	83.333	100.000	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	50.00, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	1.587 (12.8071)	-8.333 (21.9793)	-4.545 (13.1041)	0.000 (0.0000)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-50.00, 50.00	-33.33, 16.67	0.00, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	87.255 (22.4609)	85.714 (24.3160)	83.333 (20.4124)	66.667 (28.8675)	84.667 (23.0449)
Median	100.000	100.000	83.333	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	33.333, 83.333	83.333, 100.000
Min, Max	16.67, 100.00	0.00, 100.00	33.33, 100.00	33.33, 83.33	0.00, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	-0.980 (7.1458)	-6.667 (20.5196)	-1.852 (10.0154)	-22.222 (9.6225)	-4.762 (15.2145)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-33.333, -16.667	-16.667, 0.000
Min, Max	-16.67, 16.67	-66.67, 33.33	-16.67, 16.67	-33.33, -16.67	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	83.333 (25.5655)	89.683 (17.0589)	71.429 (39.3398)	77.778 (25.4588)	84.014 (24.7579)
Median	91.667	100.000	83.333	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	33.333, 100.000	50.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	0.00, 100.00	50.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-4.630 (13.7740)	-2.500 (18.1570)	-11.905 (39.3398)	-11.111 (9.6225)	-5.208 (20.3853)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-33.33, 50.00	-100.00, 16.67	-16.67, 0.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	84.375 (15.4785)	86.842 (22.6207)	80.556 (32.3465)	66.667 (47.1405)	84.109 (22.4060)
Median	83.333	100.000	91.667	66.667	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-6.250 (10.3190)	-4.630 (21.9964)	0.000 (14.9071)	-16.667 (23.5702)	-5.159 (17.0636)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 0.00	-50.00, 50.00	-16.67, 16.67	-33.33, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	86.111 (18.5773)	86.667 (26.1255)	76.667 (19.0029)	50.000 (-)	83.838 (22.6250)
Median	91.667	100.000	83.333	50.000	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 83.333	50.000, 50.000	83.333, 100.000
Min, Max	50.00, 100.00	0.00, 100.00	50.00, 100.00	50.00, 50.00	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	-6.944 (18.0604)	-4.762 (24.8315)	-3.333 (18.2574)	-16.667 (-)	-5.729 (20.5696)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-8.333, 0.000	0.000, 0.000	0.000, 0.000	-16.667, -16.667	-8.333, 0.000
Min, Max	-50.00, 16.67	-66.67, 50.00	-33.33, 16.67	-16.67, -16.67	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	89.286 (15.4797)	89.286 (18.0303)	72.222 (29.1865)	66.667 (47.1405)	85.185 (21.3726)
Median	100.000	100.000	83.333	66.667	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 83.333	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	33.33, 100.00	16.67, 100.00	33.33, 100.00	16.67, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-4.762 (12.1046)	-1.282 (18.5861)	-11.111 (8.6066)	-16.667 (23.5702)	-5.238 (15.0008)
Median	0.000	0.000	-16.667	-16.667	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-33.333, 0.000	-16.667, 0.000
Min, Max	-33.33, 16.67	-33.33, 50.00	-16.67, 0.00	-33.33, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	90.909 (13.6700)	84.722 (26.0713)	79.167 (15.9571)	66.667 (23.5702)	85.057 (20.5793)
Median	100.000	100.000	75.000	66.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 91.667	50.000, 83.333	83.333, 100.000
Min, Max	66.67, 100.00	16.67, 100.00	66.67, 100.00	50.00, 83.33	16.67, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-3.030 (10.0504)	-4.545 (24.8226)	0.000 (27.2166)	-16.667 (0.0000)	-4.167 (19.0435)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667	-16.667, -16.667	-16.667, 0.000
Min, Max	-16.67, 16.67	-50.00, 50.00	-33.33, 33.33	-16.67, -16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	73.810 (23.2879)	76.190 (13.1133)	77.778 (38.4900)	83.333 (-)	75.926 (20.7870)
Median	66.667	83.333	100.000	83.333	83.333
Q1, Q3	66.667, 100.000	66.667, 83.333	33.333, 100.000	83.333, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	50.00, 83.33	33.33, 100.00	83.33, 83.33	33.33, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-11.905 (18.5450)	-14.286 (20.2498)	-5.556 (9.6225)	-16.667 (-)	-12.037 (16.9636)
Median	-16.667	-16.667	0.000	-16.667	-16.667
Q1, Q3	-33.333, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, -16.667	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, 16.67	-16.67, 0.00	-16.67, -16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	83.333 (-)	- (-)	- (-)	- (-)	83.333 (-)
Median	83.333	-	-	-	83.333
Q1, Q3	83.333, 83.333	-, -	-, -	-, -	83.333, 83.333
Min, Max	83.33, 83.33	-, -	-, -	-, -	83.33, 83.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-16.667 (-)	- (-)	- (-)	- (-)	-16.667 (-)
Median	-16.667	-	-	-	-16.667
Q1, Q3	-16.667, -16.667	-, -	-, -	-, -	-16.667, -16.667
Min, Max	-16.67, -16.67	-, -	-, -	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Social functioning					
Baseline					
n	26	25	12	4	67
Mean (SD)	82.051 (27.0485)	89.333 (17.2670)	83.333 (22.4733)	83.333 (19.2450)	85.075 (22.3106)
Median	100.000	100.000	91.667	83.333	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	75.000, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	33.33, 100.00	66.67, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	92.063 (16.3461)	88.000 (17.6908)	89.394 (21.4382)	79.167 (41.6667)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	58.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	33.33, 100.00	16.67, 100.00	16.67, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	8.730 (30.5592)	-1.389 (21.9335)	4.545 (7.7850)	-4.167 (34.3592)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 16.667	-25.000, 16.667	0.000, 0.000
Min, Max	-50.00, 100.00	-50.00, 66.67	0.00, 16.67	-50.00, 33.33	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	97.059 (8.8099)	89.683 (17.0589)	94.444 (11.7851)	72.222 (34.6944)	92.000 (15.8794)
Median	100.000	100.000	100.000	83.333	100.000
Q1, Q3	100.000, 100.000	66.667, 100.000	100.000, 100.000	33.333, 100.000	100.000, 100.000
Min, Max	66.67, 100.00	50.00, 100.00	66.67, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	14.706 (30.5518)	1.667 (20.1602)	7.407 (14.6986)	-5.556 (25.4588)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	0.000, 16.667	-33.333, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	-50.00, 33.33	-16.67, 33.33	-33.33, 16.67	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	90.741 (14.2598)	87.302 (19.6531)	85.714 (37.7964)	61.111 (41.9435)	86.735 (23.0688)
Median	100.000	100.000	100.000	66.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	16.667, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	33.33, 100.00	0.00, 100.00	16.67, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	7.407 (28.1350)	-0.833 (23.2423)	2.381 (42.4139)	-16.667 (28.8675)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 33.333	-50.000, 0.000	0.000, 8.333
Min, Max	-33.33, 83.33	-66.67, 50.00	-83.33, 50.00	-50.00, 0.00	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	90.625 (12.1240)	92.105 (14.0199)	100.000 (0.0000)	75.000 (11.7851)	91.860 (12.7927)
Median	100.000	100.000	100.000	75.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	100.00, 100.00	66.67, 83.33	66.67, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (30.3529)	5.556 (18.0775)	11.111 (13.6083)	-8.333 (11.7851)	4.365 (22.7093)
Median	0.000	0.000	8.333	-8.333	0.000
Q1, Q3	-16.667, 8.333	0.000, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-33.33, 33.33	0.00, 33.33	-16.67, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	87.500 (21.4676)	91.111 (16.5072)	96.667 (7.4536)	50.000 (-)	89.394 (18.5490)
Median	100.000	100.000	100.000	50.000	100.000
Q1, Q3	75.000, 100.000	83.333, 100.000	100.000, 100.000	50.000, 50.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	83.33, 100.00	50.00, 50.00	33.33, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	1.389 (33.6788)	4.762 (15.2312)	13.333 (27.3861)	-16.667 (-)	4.167 (25.0448)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	-8.333, 0.000	0.000, 16.667	0.000, 33.333	-16.667, -16.667	0.000, 0.000
Min, Max	-33.33, 100.00	-16.67, 33.33	-16.67, 50.00	-16.67, -16.67	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	94.048 (10.5554)	90.476 (19.2978)	97.222 (6.8041)	66.667 (47.1405)	91.667 (17.1362)
Median	100.000	100.000	100.000	66.667	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	33.33, 100.00	83.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	7.143 (29.7527)	3.846 (13.8675)	13.889 (24.5327)	-16.667 (23.5702)	5.714 (23.5504)
Median	0.000	0.000	8.333	-16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 33.333	-33.333, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-16.67, 50.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	92.424 (15.5700)	88.889 (17.8848)	100.000 (0.0000)	66.667 (47.1405)	90.230 (18.6431)
Median	100.000	100.000	100.000	66.667	100.000
Q1, Q3	83.333, 100.000	75.000, 100.000	100.000, 100.000	33.333, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	50.00, 100.00	100.00, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	9.091 (31.9406)	1.515 (25.2262)	20.833 (25.0000)	-16.667 (23.5702)	5.952 (28.0411)
Median	0.000	0.000	16.667	-16.667	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 41.667	-33.333, 0.000	0.000, 16.667
Min, Max	-16.67, 100.00	-33.33, 50.00	0.00, 50.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	66.667 (23.5702)	64.286 (27.9361)	77.778 (38.4900)	66.667 (-)	67.593 (25.8656)
Median	83.333	66.667	100.000	66.667	66.667
Q1, Q3	33.333, 83.333	33.333, 100.000	33.333, 100.000	66.667, 66.667	33.333, 83.333
Min, Max	33.33, 83.33	33.33, 100.00	33.33, 100.00	66.67, 66.67	33.33, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	-11.905 (20.8928)	-21.429 (31.4970)	5.556 (9.6225)	0.000 (-)	-12.037 (24.7903)
Median	-16.667	-33.333	0.000	0.000	-8.333
Q1, Q3	-33.333, 16.667	-50.000, 16.667	0.000, 16.667	0.000, 0.000	-33.333, 16.667
Min, Max	-33.33, 16.67	-50.00, 16.67	0.00, 16.67	0.00, 0.00	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Fatigue					
Baseline					
n	26	25	12	4	67
Mean (SD)	31.624 (25.6649)	24.667 (17.5741)	37.037 (26.0937)	22.222 (30.0890)	29.436 (23.2509)
Median	22.222	22.222	27.778	11.111	22.222
Q1, Q3	11.111, 44.444	11.111, 33.333	16.667, 61.111	5.556, 38.889	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 55.56	0.00, 77.78	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	20.106 (16.3371)	24.444 (27.4049)	20.202 (19.1280)	22.222 (31.4270)	22.040 (22.4518)
Median	22.222	11.111	11.111	11.111	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	0.000, 33.333	0.000, 44.444	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 77.78	0.00, 55.56	0.00, 66.67	0.00, 77.78
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-11.111 (24.0883)	1.157 (26.8182)	-14.141 (23.3550)	0.000 (9.0722)	-6.019 (24.8724)
Median	0.000	0.000	-11.111	0.000	0.000
Q1, Q3	-22.222, 0.000	-16.667, 11.111	-33.333, 0.000	-5.556, 5.556	-22.222, 0.000
Min, Max	-88.89, 22.22	-44.44, 66.67	-55.56, 22.22	-11.11, 11.11	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	19.136 (20.4544)	22.751 (18.4177)	29.630 (22.2222)	33.333 (40.0617)	23.312 (20.9944)
Median	11.111	22.222	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	11.111, 22.222	22.222, 33.333	0.000, 77.778	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-11.728 (19.2345)	-1.944 (16.2497)	-9.877 (26.3198)	7.407 (6.4150)	-6.333 (19.4407)
Median	-11.111	0.000	0.000	11.111	0.000
Q1, Q3	-22.222, 0.000	-11.111, 5.556	-22.222, 11.111	0.000, 11.111	-11.111, 0.000
Min, Max	-77.78, 11.11	-27.78, 33.33	-66.67, 11.11	0.00, 11.11	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	20.988 (16.1191)	17.460 (19.7426)	42.857 (32.9787)	25.926 (27.9623)	22.902 (22.2694)
Median	22.222	11.111	33.333	22.222	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	22.222, 77.778	0.000, 55.556	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 66.67	11.11, 100.00	0.00, 55.56	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-9.877 (18.2331)	-4.722 (14.7840)	-6.349 (36.7715)	0.000 (11.1111)	-6.597 (19.8714)
Median	-11.111	0.000	-11.111	0.000	0.000
Q1, Q3	-11.111, 0.000	-19.444, 0.000	-44.444, 33.333	-11.111, 11.111	-19.444, 0.000
Min, Max	-55.56, 22.22	-33.33, 22.22	-44.44, 44.44	-11.11, 11.11	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	22.917 (19.2316)	14.035 (17.7013)	24.074 (16.3551)	38.889 (54.9972)	19.897 (20.2219)
Median	22.222	0.000	27.778	38.889	22.222
Q1, Q3	5.556, 33.333	0.000, 33.333	11.111, 33.333	0.000, 77.778	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 44.44	0.00, 44.44	0.00, 77.78	0.00, 77.78
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.861 (25.9689)	-7.716 (15.8445)	-20.370 (17.8009)	5.556 (7.8567)	-7.804 (20.6438)
Median	0.000	-5.556	-22.222	5.556	0.000
Q1, Q3	-5.556, 5.556	-22.222, 0.000	-33.333, 0.000	0.000, 11.111	-22.222, 0.000
Min, Max	-88.89, 33.33	-33.33, 33.33	-44.44, 0.00	0.00, 11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	12.963 (14.0812)	14.074 (12.9213)	24.444 (12.1716)	88.889 (-)	17.508 (18.4320)
Median	11.111	11.111	22.222	88.889	11.111
Q1, Q3	0.000, 16.667	0.000, 22.222	22.222, 22.222	88.889, 88.889	0.000, 22.222
Min, Max	0.00, 44.44	0.00, 33.33	11.11, 44.44	88.89, 88.89	0.00, 88.89
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	-12.963 (25.4404)	-7.540 (18.9475)	-26.667 (20.1843)	22.222 (-)	-11.632 (22.6816)
Median	0.000	0.000	-33.333	22.222	0.000
Q1, Q3	-16.667, 0.000	-11.111, 0.000	-44.444, -11.111	22.222, 22.222	-22.222, 0.000
Min, Max	-88.89, 0.00	-44.44, 33.33	-44.44, 0.00	22.22, 22.22	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	19.841 (18.5815)	17.460 (16.1394)	33.333 (35.1364)	33.333 (47.1405)	21.914 (22.4569)
Median	22.222	16.667	27.778	33.333	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	11.111, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 55.56	0.00, 44.44	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-5.556 (22.1151)	0.000 (9.0722)	-14.815 (27.8148)	0.000 (0.0000)	-4.762 (18.9188)
Median	0.000	0.000	-22.222	0.000	0.000
Q1, Q3	-11.111, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-11.111, 0.000
Min, Max	-66.67, 22.22	-11.11, 22.22	-44.44, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	16.162 (17.4721)	22.222 (28.4268)	30.556 (24.6373)	27.778 (39.2837)	21.456 (23.9287)
Median	11.111	16.667	22.222	27.778	22.222
Q1, Q3	0.000, 22.222	0.000, 27.778	16.667, 44.444	0.000, 55.556	0.000, 22.222
Min, Max	0.00, 55.56	0.00, 100.00	11.11, 66.67	0.00, 55.56	0.00, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-9.091 (30.5579)	4.040 (25.9500)	-16.667 (26.4497)	-5.556 (7.8567)	-4.762 (27.1204)
Median	0.000	0.000	-5.556	-5.556	0.000
Q1, Q3	-22.222, 11.111	-11.111, 11.111	-33.333, 0.000	-11.111, 0.000	-11.111, 5.556
Min, Max	-88.89, 22.22	-33.33, 66.67	-55.56, 0.00	-11.11, 0.00	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	50.794 (25.5452)	60.317 (24.7266)	29.630 (42.0660)	11.111 (-)	48.765 (29.3079)
Median	66.667	66.667	11.111	11.111	55.556
Q1, Q3	22.222, 66.667	33.333, 77.778	0.000, 77.778	11.111, 11.111	22.222, 66.667
Min, Max	11.11, 77.78	33.33, 100.00	0.00, 77.78	11.11, 11.11	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	11.111 (25.6600)	23.016 (31.8220)	3.704 (16.9725)	0.000 (-)	13.889 (26.2833)
Median	11.111	22.222	0.000	0.000	11.111
Q1, Q3	-11.111, 44.444	-5.556, 55.556	-11.111, 22.222	0.000, 0.000	-5.556, 33.333
Min, Max	-22.22, 44.44	-22.22, 66.67	-11.11, 22.22	0.00, 0.00	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	11.111 (-)	- (-)	- (-)	- (-)	11.111 (-)
Median	11.111	-	-	-	11.111
Q1, Q3	11.111, 11.111	-, -	-, -	-, -	11.111, 11.111
Min, Max	11.11, 11.11	-, -	-, -	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	44.444 (-)	- (-)	- (-)	- (-)	44.444 (-)
Median	44.444	-	-	-	44.444
Q1, Q3	44.444, 44.444	-, -	-, -	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	-, -	-, -	44.44, 44.44
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-11.111 (-)	- (-)	- (-)	- (-)	-11.111 (-)
Median	-11.111	-	-	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-, -	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-, -	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	44.444 (-)	- (-)	- (-)	- (-)	44.444 (-)
Median	44.444	-	-	-	44.444
Q1, Q3	44.444, 44.444	-, -	-, -	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	-, -	-, -	44.44, 44.44
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-11.111 (-)	- (-)	- (-)	- (-)	-11.111 (-)
Median	-11.111	-	-	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-, -	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-, -	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-22.222 (-)	- (-)	- (-)	- (-)	-22.222 (-)
Median	-22.222	-	-	-	-22.222
Q1, Q3	-22.222, -22.222	-, -	-, -	-, -	-22.222, -22.222
Min, Max	-22.22, -22.22	-, -	-, -	-, -	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	44.444 (-)	- (-)	- (-)	- (-)	44.444 (-)
Median	44.444	-	-	-	44.444
Q1, Q3	44.444, 44.444	-, -	-, -	-, -	44.444, 44.444
Min, Max	44.44, 44.44	-, -	-, -	-, -	44.44, 44.44
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-11.111 (-)	- (-)	- (-)	- (-)	-11.111 (-)
Median	-11.111	-	-	-	-11.111
Q1, Q3	-11.111, -11.111	-, -	-, -	-, -	-11.111, -11.111
Min, Max	-11.11, -11.11	-, -	-, -	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Nausea and vomiting					
Baseline					
n	26	25	12	4	67
Mean (SD)	3.205 (8.1911)	3.333 (11.7851)	5.556 (10.8556)	8.333 (16.6667)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 8.333	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 50.00	0.00, 33.33	0.00, 33.33	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	1.587 (5.0132)	3.333 (6.8041)	0.000 (0.0000)	12.500 (25.0000)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 25.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 0.00	0.00, 50.00	0.00, 50.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-1.587 (7.2739)	0.000 (9.8295)	-4.545 (10.7778)	4.167 (8.3333)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 8.333	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	-33.33, 0.00	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	2.778 (6.3914)	0.794 (3.6370)	1.852 (5.5556)	33.333 (57.7350)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 100.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 16.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-0.926 (10.6523)	-0.833 (8.5070)	-3.704 (7.3493)	22.222 (38.4900)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	-33.33, 16.67	-33.33, 16.67	-16.67, 0.00	0.00, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (7.1299)	2.381 (7.9682)	7.143 (13.1133)	5.556 (9.6225)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 33.33	0.00, 33.33	0.00, 16.67	0.00, 33.33
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	0.000 (8.0845)	0.833 (3.7268)	0.000 (16.6667)	-5.556 (9.6225)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	0.00, 16.67	-33.33, 16.67	-16.67, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	1.042 (4.1667)	0.877 (3.8236)	2.778 (6.8041)	25.000 (35.3553)	2.326 (8.5923)
Median	0.000	0.000	0.000	25.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 50.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 16.67	0.00, 16.67	0.00, 50.00	0.00, 50.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-1.042 (4.1667)	-0.926 (3.9284)	0.000 (0.0000)	8.333 (11.7851)	-0.397 (4.4904)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 0.00	-16.67, 0.00	0.00, 0.00	0.00, 16.67	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	2.778 (6.4875)	0.000 (0.0000)	0.000 (0.0000)	33.333 (-)	2.020 (6.9191)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	33.333, 33.333	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 0.00	0.00, 0.00	33.33, 33.33	0.00, 33.33
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	0.000 (7.1067)	0.000 (0.0000)	-10.000 (14.9071)	0.000 (-)	-1.563 (7.7591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	0.00, 0.00	-33.33, 0.00	0.00, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	1.190 (4.4544)	0.000 (0.0000)	0.000 (0.0000)	16.667 (23.5702)	1.389 (6.1399)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 0.00	0.00, 0.00	0.00, 33.33	0.00, 33.33
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-1.190 (4.4544)	0.000 (0.0000)	-8.333 (13.9443)	0.000 (0.0000)	-1.905 (6.7294)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	0.00, 0.00	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	0.000 (0.0000)	5.556 (14.7938)	0.000 (0.0000)	8.333 (11.7851)	2.874 (10.0287)
Median	0.000	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 50.00	0.00, 0.00	0.00, 16.67	0.00, 50.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-1.515 (5.0252)	6.061 (15.4069)	-12.500 (15.9571)	-8.333 (11.7851)	-0.595 (13.2110)
Median	0.000	0.000	-8.333	-8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-25.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	0.00, 50.00	-33.33, 0.00	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	11.905 (18.5450)	2.381 (6.2994)	16.667 (28.8675)	0.000 (-)	8.333 (16.4197)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 50.000	0.000, 0.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	4.762 (20.8928)	-2.381 (6.2994)	11.111 (19.2450)	0.000 (-)	2.778 (15.3925)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	-16.67, 0.00	0.00, 33.33	0.00, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Pain					
Baseline					
n	26	24	12	4	66
Mean (SD)	10.256 (20.5896)	11.806 (16.6516)	26.389 (25.0840)	25.000 (31.9142)	14.646 (21.3868)
Median	0.000	0.000	33.333	16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 33.333	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 83.33	0.00, 66.67	0.00, 83.33	0.00, 66.67	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	12.698 (16.5871)	18.000 (25.8736)	9.091 (11.4592)	16.667 (33.3333)	14.481 (21.1860)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	0.794 (22.6545)	6.522 (21.1650)	-12.121 (13.1041)	-8.333 (16.6667)	0.000 (20.9908)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-16.667, 0.000	-16.667, 0.000	-16.667, 16.667
Min, Max	-66.67, 33.33	-33.33, 50.00	-33.33, 0.00	-33.33, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	12.963 (15.7135)	11.111 (17.7430)	16.667 (32.2749)	33.333 (57.7350)	14.052 (23.1835)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667	0.000, 100.000	0.000, 16.667
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	19	9	3	49
Mean (SD)	-0.926 (25.2259)	0.000 (13.6083)	-9.259 (18.8398)	11.111 (19.2450)	-1.361 (19.7896)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-16.667, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-33.33, 16.67	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	20.370 (21.0474)	10.317 (14.4108)	35.714 (45.5710)	27.778 (48.1125)	18.707 (26.0503)
Median	16.667	0.000	16.667	0.000	16.667
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 100.000	0.000, 83.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 50.00	0.00, 100.00	0.00, 83.33	0.00, 100.00
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	6.481 (30.3244)	0.000 (13.6083)	4.762 (36.9112)	5.556 (9.6225)	3.546 (24.5580)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-33.333, 33.333	0.000, 16.667	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 16.67	-33.33, 66.67	0.00, 16.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	15.625 (20.6099)	9.649 (13.9618)	30.556 (37.1434)	33.333 (47.1405)	15.891 (22.6993)
Median	0.000	0.000	25.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	5.208 (26.3303)	0.000 (18.6339)	0.000 (18.2574)	0.000 (0.0000)	2.033 (21.1460)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-50.00, 66.67	-33.33, 33.33	-33.33, 16.67	0.00, 0.00	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	12.500 (17.5882)	7.778 (10.6657)	20.000 (44.7214)	100.000 (-)	14.141 (25.7260)
Median	0.000	0.000	0.000	100.000	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 0.000	100.000, 100.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 33.33	0.00, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	12	13	5	1	31
Mean (SD)	5.556 (17.8848)	1.282 (17.2958)	-10.000 (22.3607)	33.333 (-)	2.151 (19.1204)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	-8.333, 16.667	0.000, 16.667	-33.333, 0.000	33.333, 33.333	-16.667, 16.667
Min, Max	-16.67, 33.33	-33.33, 33.33	-33.33, 16.67	33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	11.905 (21.1108)	14.286 (28.3877)	25.000 (39.0868)	25.000 (35.3553)	15.741 (27.2974)
Median	0.000	0.000	8.333	25.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 33.333	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	4.762 (21.1108)	7.692 (32.3575)	-5.556 (17.2133)	-8.333 (11.7851)	3.333 (24.8525)
Median	0.000	0.000	0.000	-8.333	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-16.67, 50.00	-33.33, 100.00	-33.33, 16.67	-16.67, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	12.121 (16.8175)	11.111 (22.8448)	20.833 (41.6667)	33.333 (47.1405)	14.368 (24.6902)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	0.000, 41.667	0.000, 66.667	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 66.67	0.00, 83.33	0.00, 66.67	0.00, 83.33
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	4.545 (15.0756)	4.545 (29.8988)	-8.333 (16.6667)	0.000 (0.0000)	2.381 (21.6188)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	-16.667, 0.000	0.000, 0.000	-8.333, 8.333
Min, Max	-16.67, 33.33	-33.33, 66.67	-33.33, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	11.905 (15.8532)	45.238 (18.5450)	16.667 (28.8675)	0.000 (-)	25.000 (24.4214)
Median	0.000	50.000	0.000	0.000	25.000
Q1, Q3	0.000, 33.333	33.333, 66.667	0.000, 50.000	0.000, 0.000	0.000, 50.000
Min, Max	0.00, 33.33	16.67, 66.67	0.00, 50.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	7	6	3	1	17
Mean (SD)	0.000 (16.6667)	25.000 (27.3861)	-5.556 (9.6225)	0.000 (-)	7.843 (22.9111)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 50.000	-16.667, 0.000	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 16.67	-16.67, 50.00	-16.67, 0.00	0.00, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Dyspnoea					
Baseline					
n	26	25	12	4	67
Mean (SD)	25.641 (34.3934)	18.667 (21.6880)	33.333 (40.2015)	16.667 (33.3333)	23.881 (31.1432)
Median	0.000	0.000	16.667	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	15.873 (20.0528)	18.667 (21.6880)	12.121 (22.4733)	33.333 (47.1405)	17.486 (23.2591)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-6.349 (29.0957)	1.389 (23.0084)	-15.152 (17.4078)	16.667 (19.2450)	-3.333 (25.0799)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-33.33, 0.00	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	11.111 (16.1690)	14.286 (19.9205)	18.519 (33.7931)	33.333 (57.7350)	15.033 (24.3253)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-12.963 (32.6176)	-3.333 (26.2690)	-18.519 (24.2161)	11.111 (19.2450)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-33.333, 0.000	0.000, 33.333	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	17	21	7	3	48
Mean (SD)	11.765 (16.4197)	12.698 (19.6531)	4.762 (12.5988)	22.222 (38.4900)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	20	7	3	47
Mean (SD)	-13.725 (31.3112)	-5.000 (16.3120)	-38.095 (52.4531)	0.000 (0.0000)	-12.766 (30.7343)
Median	0.000	0.000	-33.333	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-100.000, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	20.833 (26.8742)	14.035 (20.2326)	5.556 (13.6083)	33.333 (47.1405)	16.279 (23.4262)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.167 (38.2487)	-3.704 (19.4328)	-33.333 (55.7773)	0.000 (0.0000)	-7.937 (34.3815)
Median	0.000	0.000	-16.667	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-100.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	8.333 (15.0756)	6.667 (13.8013)	6.667 (14.9071)	66.667 (-)	9.091 (17.2255)
Median	0.000	0.000	0.000	66.667	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	66.667, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	66.67, 66.67	0.00, 66.67
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	-11.111 (32.8244)	-9.524 (15.6269)	-33.333 (40.8248)	0.000 (-)	-13.542 (27.9007)
Median	0.000	0.000	-33.333	0.000	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 0.00	-100.00, 0.00	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	14.286 (17.1184)	2.381 (8.9087)	11.111 (17.2133)	50.000 (23.5702)	11.111 (17.8174)
Median	0.000	0.000	0.000	50.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	33.333, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	33.33, 66.67	0.00, 66.67
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-9.524 (33.1497)	-7.692 (14.6176)	-22.222 (45.5420)	16.667 (23.5702)	-9.524 (29.7829)
Median	0.000	0.000	-16.667	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 0.00	-100.00, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	6.061 (13.4840)	13.889 (30.0112)	16.667 (19.2450)	33.333 (47.1405)	12.644 (24.2569)
Median	0.000	0.000	16.667	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-18.182 (37.6051)	3.030 (23.3550)	-33.333 (27.2166)	0.000 (0.0000)	-10.714 (31.4970)
Median	0.000	0.000	-33.333	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	-50.000, -16.667	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	47.619 (32.5300)	52.381 (37.7964)	11.111 (19.2450)	0.000 (-)	40.741 (35.3425)
Median	33.333	66.667	0.000	0.000	33.333
Q1, Q3	33.333, 66.667	0.000, 66.667	0.000, 33.333	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	19.048 (32.5300)	14.286 (26.2265)	-22.222 (19.2450)	0.000 (-)	9.259 (29.8264)
Median	0.000	33.333	-33.333	0.000	0.000
Q1, Q3	0.000, 66.667	0.000, 33.333	-33.333, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	-33.33, 33.33	-33.33, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	100.000 (-)	- (-)	- (-)	- (-)	100.000 (-)
Median	100.000	-	-	-	100.000
Q1, Q3	100.000, 100.000	-, -	-, -	-, -	100.000, 100.000
Min, Max	100.00, 100.00	-, -	-, -	-, -	100.00, 100.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-66.667 (-)	- (-)	- (-)	- (-)	-66.667 (-)
Median	-66.667	-	-	-	-66.667
Q1, Q3	-66.667, -66.667	-, -	-, -	-, -	-66.667, -66.667
Min, Max	-66.67, -66.67	-, -	-, -	-, -	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	-33.333 (-)	- (-)	- (-)	- (-)	-33.333 (-)
Median	-33.333	-	-	-	-33.333
Q1, Q3	-33.333, -33.333	-, -	-, -	-, -	-33.333, -33.333
Min, Max	-33.33, -33.33	-, -	-, -	-, -	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Insomnia					
Baseline					
n	26	25	12	4	67
Mean (SD)	21.795 (26.5703)	17.333 (19.5316)	22.222 (29.5875)	16.667 (33.3333)	19.900 (24.6591)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 50.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	15.873 (20.0528)	18.667 (25.6038)	21.212 (26.9680)	16.667 (33.3333)	18.033 (24.0168)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-7.937 (17.9653)	1.389 (25.0201)	3.030 (10.0504)	0.000 (0.0000)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	0.00, 33.33	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	14.815 (20.5233)	17.460 (20.0528)	29.630 (35.1364)	33.333 (57.7350)	19.608 (25.9713)
Median	0.000	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-9.259 (15.3630)	0.000 (24.1825)	0.000 (16.6667)	11.111 (19.2450)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 33.33	-33.33, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	16.667 (26.1968)	17.460 (24.9868)	28.571 (40.4995)	11.111 (19.2450)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-7.407 (18.2773)	1.667 (27.5193)	-4.762 (29.9912)	-11.111 (19.2450)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 33.33	-33.33, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	20.833 (26.8742)	15.789 (23.2231)	33.333 (42.1637)	33.333 (47.1405)	20.930 (28.1936)
Median	0.000	0.000	16.667	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	-4.167 (16.6667)	1.852 (17.9768)	5.556 (13.6083)	0.000 (0.0000)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	19.444 (26.4320)	8.889 (15.2579)	33.333 (33.3333)	100.000 (-)	19.192 (27.6766)
Median	0.000	0.000	33.333	100.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	100.000, 100.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	100.00, 100.00	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	-2.778 (17.1643)	0.000 (13.0744)	-13.333 (18.2574)	33.333 (-)	-2.083 (16.8005)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 0.00	33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	9.524 (20.3750)	7.143 (14.1938)	38.889 (38.9682)	33.333 (47.1405)	14.815 (25.7515)
Median	0.000	0.000	33.333	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-11.905 (21.1108)	-5.128 (18.4900)	0.000 (21.0819)	0.000 (0.0000)	-6.667 (19.4701)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 0.00	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	9.091 (15.5700)	5.556 (12.9750)	33.333 (27.2166)	33.333 (47.1405)	12.644 (20.7284)
Median	0.000	0.000	33.333	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	16.667, 50.000	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-6.061 (20.1008)	-9.091 (15.5700)	-8.333 (16.6667)	0.000 (0.0000)	-7.143 (16.6225)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-33.33, 33.33	-33.33, 0.00	-33.33, 0.00	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	19.048 (26.2265)	47.619 (26.2265)	33.333 (33.3333)	0.000 (-)	31.481 (29.0868)
Median	0.000	66.667	33.333	0.000	33.333
Q1, Q3	0.000, 33.333	33.333, 66.667	0.000, 66.667	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	0.000 (0.0000)	28.571 (23.0022)	22.222 (38.4900)	0.000 (-)	14.815 (23.4931)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 66.667	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 0.00	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Appetite loss					
Baseline					
n	26	25	12	4	67
Mean (SD)	15.385 (30.1563)	8.000 (14.5297)	16.667 (22.4733)	16.667 (33.3333)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	9.524 (15.4303)	12.000 (21.2568)	6.061 (13.4840)	16.667 (33.3333)	10.383 (18.7981)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-9.524 (35.1866)	4.167 (17.8899)	-9.091 (21.5557)	0.000 (0.0000)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	3.704 (10.7794)	11.111 (19.2450)	3.704 (11.1111)	33.333 (57.7350)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 100.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 100.00	0.00, 100.00
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-11.111 (30.2495)	3.333 (21.3574)	-14.815 (24.2161)	11.111 (19.2450)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-66.67, 0.00	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	9.259 (19.1504)	6.349 (13.4125)	9.524 (25.1976)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-5.556 (34.7728)	-1.667 (17.0139)	-9.524 (31.7063)	-22.222 (38.4900)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-66.67, 33.33	-66.67, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	12.500 (23.9598)	7.018 (13.9618)	11.111 (27.2166)	33.333 (47.1405)	10.853 (21.4808)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	0.000 (36.5148)	0.000 (19.8030)	0.000 (21.0819)	0.000 (0.0000)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	5.556 (12.9750)	4.444 (11.7289)	13.333 (29.8142)	66.667 (-)	8.081 (18.6903)
Median	0.000	0.000	0.000	66.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	66.667, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	66.67, 66.67	0.00, 66.67
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	-5.556 (34.3286)	0.000 (13.0744)	-6.667 (36.5148)	0.000 (-)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	-66.67, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	7.143 (14.1938)	4.762 (12.1046)	11.111 (27.2166)	33.333 (47.1405)	8.333 (18.4735)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	-2.381 (24.3349)	0.000 (13.6083)	-5.556 (32.7731)	0.000 (0.0000)	-1.905 (21.3021)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	-66.67, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	3.030 (10.0504)	11.111 (29.5875)	16.667 (33.3333)	16.667 (23.5702)	9.195 (23.3954)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-6.061 (32.7217)	6.061 (32.7217)	-8.333 (41.9435)	-16.667 (23.5702)	-2.381 (32.6202)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 16.667	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 100.00	-66.67, 33.33	-33.33, 0.00	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	38.095 (44.8395)	42.857 (31.7063)	22.222 (38.4900)	0.000 (-)	35.185 (36.9989)
Median	33.333	33.333	0.000	0.000	33.333
Q1, Q3	0.000, 100.000	33.333, 66.667	0.000, 66.667	0.000, 0.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	9.524 (49.8675)	28.571 (35.6348)	0.000 (33.3333)	0.000 (-)	14.815 (39.9709)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	-33.333, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	-66.67, 100.00	0.00, 100.00	-33.33, 33.33	0.00, 0.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	33.333 (-)	- (-)	- (-)	- (-)	33.333 (-)
Median	33.333	-	-	-	33.333
Q1, Q3	33.333, 33.333	-, -	-, -	-, -	33.333, 33.333
Min, Max	33.33, 33.33	-, -	-, -	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	66.667 (-)	- (-)	- (-)	- (-)	66.667 (-)
Median	66.667	-	-	-	66.667
Q1, Q3	66.667, 66.667	-, -	-, -	-, -	66.667, 66.667
Min, Max	66.67, 66.67	-, -	-, -	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Constipation					
Baseline					
n	26	25	12	4	67
Mean (SD)	11.538 (20.9599)	5.333 (15.7527)	11.111 (16.4122)	8.333 (16.6667)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	11.111 (16.1015)	17.333 (30.6111)	6.061 (13.4840)	0.000 (0.0000)	12.022 (22.7977)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	0.000 (18.2574)	12.500 (27.4742)	-6.061 (13.4840)	-8.333 (16.6667)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	-16.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 100.00	-33.33, 0.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	18	21	9	3	51
Mean (SD)	7.407 (14.2598)	14.286 (22.5374)	0.000 (0.0000)	0.000 (0.0000)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	20	9	3	50
Mean (SD)	-1.852 (17.9768)	8.333 (21.2889)	-7.407 (14.6986)	-11.111 (19.2450)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	7.407 (18.2773)	11.111 (16.1015)	4.762 (12.5988)	11.111 (19.2450)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-1.852 (13.8725)	5.000 (16.3120)	-9.524 (16.2650)	0.000 (33.3333)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 0.00	-33.33, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	14.583 (29.7365)	14.035 (25.6178)	16.667 (40.8248)	0.000 (0.0000)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	6.250 (21.8369)	7.407 (24.4028)	5.556 (49.0653)	-16.667 (23.5702)	5.556 (27.4644)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-33.333, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 66.67	-33.33, 100.00	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	13.889 (30.0112)	11.111 (16.2650)	0.000 (0.0000)	0.000 (-)	10.101 (21.2211)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	8.333 (25.1259)	4.762 (22.0998)	-6.667 (14.9071)	-33.333 (-)	3.125 (22.9685)
Median	0.000	0.000	0.000	-33.333	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	-33.333, -33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 0.00	-33.33, -33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	9.524 (27.5140)	7.143 (14.1938)	11.111 (27.2166)	0.000 (0.0000)	8.333 (21.6392)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	4.762 (22.0998)	0.000 (19.2450)	0.000 (36.5148)	-16.667 (23.5702)	0.952 (23.5504)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 66.67	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	6.061 (13.4840)	11.111 (29.5875)	8.333 (16.6667)	0.000 (0.0000)	8.046 (21.1854)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	3.030 (17.9787)	3.030 (17.9787)	0.000 (0.0000)	-16.667 (23.5702)	1.190 (16.9292)
Median	0.000	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-33.33, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	33.333 (47.1405)	28.571 (35.6348)	11.111 (19.2450)	0.000 (-)	25.926 (37.1458)
Median	0.000	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 100.000	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	19.048 (37.7964)	14.286 (17.8174)	0.000 (0.0000)	0.000 (-)	12.963 (25.9181)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Diarrhoea					
Baseline					
n	26	24	12	4	66
Mean (SD)	7.692 (21.7208)	5.556 (16.0514)	11.111 (21.7113)	0.000 (0.0000)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	3.175 (10.0264)	6.667 (21.5166)	9.091 (15.5700)	0.000 (0.0000)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	21	23	11	4	59
Mean (SD)	0.000 (14.9071)	1.449 (15.8218)	-3.030 (17.9787)	0.000 (0.0000)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	3.922 (11.0702)	6.349 (13.4125)	11.111 (23.5702)	22.222 (38.4900)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	19	9	3	48
Mean (SD)	0.000 (16.6667)	3.509 (10.5101)	0.000 (16.6667)	22.222 (38.4900)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	-33.33, 33.33	0.00, 33.33	-33.33, 33.33	0.00, 66.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (10.7794)	4.762 (11.9523)	14.286 (26.2265)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	18	19	7	3	47
Mean (SD)	0.000 (11.4332)	3.509 (15.2944)	0.000 (38.4900)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	4.167 (11.3855)	8.772 (24.4498)	11.111 (17.2133)	0.000 (0.0000)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	16	17	6	2	41
Mean (SD)	2.083 (8.3333)	7.843 (27.7123)	-5.556 (13.6083)	0.000 (0.0000)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 100.00	-33.33, 0.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	0.000 (0.0000)	8.889 (15.2579)	20.000 (29.8142)	0.000 (-)	7.071 (16.1537)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	12	13	5	1	31
Mean (SD)	-2.778 (9.6225)	7.692 (19.9715)	0.000 (47.1405)	0.000 (-)	2.151 (22.6658)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-33.33, 33.33	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	4.762 (12.1046)	4.762 (12.1046)	11.111 (17.2133)	33.333 (47.1405)	7.407 (16.1562)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	2.381 (8.9087)	2.564 (16.4516)	-5.556 (32.7731)	33.333 (47.1405)	2.857 (20.4067)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 33.33	-66.67, 33.33	0.00, 66.67	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	0.000 (0.0000)	2.778 (9.6225)	8.333 (16.6667)	0.000 (0.0000)	2.299 (8.5960)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 0.00	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	-3.030 (10.0504)	3.030 (10.0504)	0.000 (0.0000)	0.000 (0.0000)	0.000 (9.0722)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	0.00, 33.33	0.00, 0.00	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	19.048 (26.2265)	0.000 (0.0000)	0.000 (0.0000)	0.000 (-)	7.407 (18.2773)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline					
n	7	6	3	1	17
Mean (SD)	14.286 (32.5300)	0.000 (0.0000)	0.000 (0.0000)	0.000 (-)	5.882 (21.1978)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 0.00	0.00, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Financial Difficulties					
Baseline					
n	26	25	12	4	67
Mean (SD)	11.538 (24.8414)	25.333 (40.0000)	2.778 (9.6225)	33.333 (27.2166)	16.418 (30.9083)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 66.667	0.000, 0.000	16.667, 50.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 3					
n	21	25	11	4	61
Mean (SD)	6.349 (17.0589)	20.000 (33.3333)	3.030 (10.0504)	16.667 (19.2450)	12.022 (25.1166)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	21	24	11	4	60
Mean (SD)	-3.175 (10.0264)	-5.556 (33.5740)	3.030 (10.0504)	-16.667 (33.3333)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 66.67	0.00, 33.33	-66.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 6					
n	17	21	9	3	50
Mean (SD)	5.882 (17.6198)	12.698 (24.6671)	3.704 (11.1111)	44.444 (38.4900)	10.667 (22.7776)
Median	0.000	0.000	0.000	66.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 66.667	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67	0.00, 66.67
Change from Baseline					
n	17	20	9	3	49
Mean (SD)	-1.961 (14.2915)	-8.333 (33.9849)	0.000 (16.6667)	11.111 (19.2450)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 9					
n	18	21	7	3	49
Mean (SD)	3.704 (10.7794)	9.524 (21.4550)	4.762 (12.5988)	22.222 (19.2450)	7.483 (17.0312)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 33.33	0.00, 66.67
Change from Baseline					
n	18	20	7	3	48
Mean (SD)	-3.704 (10.7794)	-11.667 (22.3607)	0.000 (19.2450)	-11.111 (19.2450)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 0.00	-66.67, 0.00	-33.33, 33.33	-33.33, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 12					
n	16	19	6	2	43
Mean (SD)	8.333 (22.7710)	19.298 (33.9131)	5.556 (13.6083)	16.667 (23.5702)	13.178 (27.3518)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	16	18	6	2	42
Mean (SD)	2.083 (14.7510)	-3.704 (19.4328)	0.000 (21.0819)	0.000 (0.0000)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-33.33, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 18					
n	12	15	5	1	33
Mean (SD)	16.667 (38.9249)	11.111 (20.5738)	0.000 (0.0000)	0.000 (-)	11.111 (27.2166)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 100.00
Change from Baseline					
n	12	14	5	1	32
Mean (SD)	11.111 (25.9500)	-14.286 (25.1976)	-6.667 (14.9071)	0.000 (-)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 0.00	-33.33, 0.00	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 24					
n	14	14	6	2	36
Mean (SD)	7.143 (26.7261)	9.524 (20.3750)	11.111 (27.2166)	16.667 (23.5702)	9.259 (23.3824)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline					
n	14	13	6	2	35
Mean (SD)	0.000 (22.6455)	-17.949 (32.2473)	5.556 (13.6083)	0.000 (47.1405)	-5.714 (27.3989)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-100.00, 0.00	0.00, 33.33	-33.33, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Cycle 30					
n	11	12	4	2	29
Mean (SD)	6.061 (20.1008)	13.889 (26.4320)	0.000 (0.0000)	33.333 (0.0000)	10.345 (22.0091)
Median	0.000	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 16.667	0.000, 0.000	33.333, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	33.33, 33.33	0.00, 66.67
Change from Baseline					
n	11	11	4	2	28
Mean (SD)	0.000 (14.9071)	-12.121 (30.8139)	-8.333 (16.6667)	16.667 (23.5702)	-4.762 (23.5078)
Median	0.000	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	-16.667, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 33.33	-33.33, 0.00	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Safety Follow-up					
n	7	7	3	1	18
Mean (SD)	28.571 (40.4995)	38.095 (44.8395)	0.000 (0.0000)	66.667 (-)	29.630 (39.4221)
Median	0.000	33.333	0.000	66.667	0.000
Q1, Q3	0.000, 66.667	0.000, 100.000	0.000, 0.000	66.667, 66.667	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 0.00	66.67, 66.67	0.00, 100.00
Change from Baseline					
n	7	7	3	1	18
Mean (SD)	9.524 (16.2650)	-4.762 (29.9912)	0.000 (0.0000)	0.000 (-)	1.852 (21.3046)
Median	0.000	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 33.33	0.00, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 1					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 2					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 5					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 6					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.5:
Summary of EORTC QLQ-C30 by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
Scale/Visit	**MALT (N = 26)**	**NMZL (N = 26)**	**SMZL (N = 12)**	**Unknown (N = 4)**	**Total (N = 68)**
Survival Follow-up 7					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00
Change from Baseline					
n	1	0	0	0	1
Mean (SD)	0.000 (-)	- (-)	- (-)	- (-)	0.000 (-)
Median	0.000	-	-	-	0.000
Q1, Q3	0.000, 0.000	-, -	-, -	-, -	0.000, 0.000
Min, Max	0.00, 0.00	-, -	-, -	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-05-eortc-sum-mzltype.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Global health status/QOL				
Baseline				
n	33	27	7	67
Mean (SD)	64.394 (22.7525)	67.284 (20.4027)	69.048 (18.4556)	66.045 (21.1871)
Median	66.667	66.667	75.000	66.667
Q1, Q3	50.000, 83.333	58.333, 83.333	50.000, 83.333	50.000, 83.333
Min, Max	25.00, 100.00	0.00, 100.00	50.00, 91.67	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	74.713 (16.1348)	77.667 (17.9570)	71.429 (18.5450)	75.546 (17.0014)
Median	75.000	83.333	66.667	83.333
Q1, Q3	66.667, 83.333	66.667, 91.667	58.333, 91.667	66.667, 83.333
Min, Max	33.33, 100.00	25.00, 100.00	50.00, 100.00	25.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	10.632 (21.8100)	6.944 (16.0514)	2.381 (25.3285)	8.194 (19.9748)
Median	8.333	8.333	0.000	8.333
Q1, Q3	0.000, 16.667	0.000, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-33.33, 66.67	-41.67, 33.33	-33.33, 50.00	-41.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	78.261 (19.9018)	72.222 (20.8031)	72.222 (25.4588)	75.000 (20.4124)
Median	83.333	83.333	66.667	83.333
Q1, Q3	66.667, 100.000	66.667, 83.333	50.000, 100.000	66.667, 91.667
Min, Max	33.33, 100.00	8.33, 100.00	50.00, 100.00	8.33, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	11.957 (20.0734)	4.710 (9.9956)	0.000 (8.3333)	7.823 (15.8121)
Median	8.333	0.000	0.000	8.333
Q1, Q3	0.000, 25.000	0.000, 8.333	-8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 66.67	-16.67, 33.33	-8.33, 8.33	-16.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	69.565 (21.4100)	73.551 (22.5647)	86.111 (12.7294)	72.449 (21.5974)
Median	75.000	83.333	83.333	83.333
Q1, Q3	50.000, 83.333	58.333, 91.667	75.000, 100.000	58.333, 83.333
Min, Max	16.67, 100.00	0.00, 100.00	75.00, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	5.797 (24.6740)	5.303 (15.9665)	2.778 (9.6225)	5.382 (20.0833)
Median	8.333	8.333	8.333	8.333
Q1, Q3	-8.333, 16.667	0.000, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-50.00, 50.00	-33.33, 41.67	-8.33, 8.33	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	77.917 (16.5069)	72.083 (23.9204)	86.111 (12.7294)	75.775 (20.1527)
Median	83.333	83.333	83.333	83.333
Q1, Q3	66.667, 83.333	58.333, 83.333	75.000, 100.000	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	75.00, 100.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	12.917 (18.0308)	1.754 (16.0965)	2.778 (9.6225)	7.143 (17.3216)
Median	8.333	0.000	8.333	8.333
Q1, Q3	0.000, 20.833	-16.667, 16.667	-8.333, 8.333	0.000, 16.667
Min, Max	-16.67, 58.33	-33.33, 25.00	-8.33, 8.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	73.333 (18.4197)	77.604 (22.9167)	91.667 (11.7851)	76.515 (20.4607)
Median	75.000	83.333	91.667	83.333
Q1, Q3	58.333, 83.333	75.000, 83.333	83.333, 100.000	75.000, 83.333
Min, Max	41.67, 100.00	0.00, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	12.222 (21.5626)	10.000 (16.7261)	4.167 (5.8926)	10.677 (18.4811)
Median	8.333	16.667	4.167	8.333
Q1, Q3	0.000, 33.333	0.000, 25.000	0.000, 8.333	0.000, 20.833
Min, Max	-33.33, 58.33	-16.67, 41.67	0.00, 8.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	76.961 (20.7351)	75.980 (24.0951)	75.000 (11.7851)	76.389 (21.5933)
Median	83.333	83.333	75.000	83.333
Q1, Q3	66.667, 91.667	66.667, 83.333	66.667, 83.333	66.667, 87.500
Min, Max	33.33, 100.00	0.00, 100.00	66.67, 83.33	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	13.725 (22.6195)	7.292 (14.2319)	-12.500 (5.8926)	9.286 (19.2561)
Median	8.333	4.167	-12.500	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	-16.667, -8.333	0.000, 16.667
Min, Max	-25.00, 66.67	-25.00, 33.33	-16.67, -8.33	-25.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	75.000 (22.1906)	71.111 (26.5149)	79.167 (5.8926)	73.276 (23.5048)
Median	83.333	75.000	79.167	83.333
Q1, Q3	58.333, 87.500	50.000, 91.667	75.000, 83.333	66.667, 83.333
Min, Max	33.33, 100.00	0.00, 100.00	75.00, 83.33	0.00, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	15.278 (23.7924)	0.595 (15.8331)	-8.333 (0.0000)	6.250 (20.4910)
Median	8.333	4.167	-8.333	4.167
Q1, Q3	0.000, 37.500	-8.333, 8.333	-8.333, -8.333	-8.333, 16.667
Min, Max	-25.00, 58.33	-33.33, 25.00	-8.33, -8.33	-33.33, 58.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	59.722 (25.5824)	38.889 (25.4588)	63.889 (4.8113)	56.944 (23.9570)
Median	66.667	33.333	66.667	66.667
Q1, Q3	41.667, 75.000	16.667, 66.667	58.333, 66.667	33.333, 66.667
Min, Max	16.67, 100.00	16.67, 66.67	58.33, 66.67	16.67, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-11.111 (30.4290)	-22.222 (25.4588)	2.778 (17.3472)	-10.648 (27.6837)
Median	0.000	-16.667	8.333	0.000
Q1, Q3	-29.167, 8.333	-50.000, 0.000	-16.667, 16.667	-25.000, 8.333
Min, Max	-75.00, 41.67	-50.00, 0.00	-16.67, 16.67	-75.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	-, -	50.00, 50.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	16.667 (-)	- (-)	16.667 (-)
Median	-	16.667	-	16.667
Q1, Q3	-, -	16.667, 16.667	-, -	16.667, 16.667
Min, Max	-, -	16.67, 16.67	-, -	16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Physical functioning				
Baseline				
n	33	27	7	67
Mean (SD)	81.616 (21.9235)	84.198 (18.4111)	86.667 (12.7657)	83.184 (19.6041)
Median	86.667	93.333	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 93.333	73.333, 100.000	80.000, 100.000
Min, Max	20.00, 100.00	40.00, 100.00	66.67, 100.00	20.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	24	7	60
Mean (SD)	85.747 (18.6636)	87.500 (15.2673)	80.952 (14.6204)	85.889 (16.7890)
Median	93.333	93.333	86.667	93.333
Q1, Q3	86.667, 93.333	83.333, 100.000	66.667, 93.333	83.333, 100.000
Min, Max	26.67, 100.00	46.67, 100.00	60.00, 100.00	26.67, 100.00
Change from Baseline				
n	29	23	7	59
Mean (SD)	3.908 (14.6404)	0.290 (11.8028)	-5.714 (15.1186)	1.356 (13.7732)
Median	0.000	0.000	-6.667	0.000
Q1, Q3	-6.667, 6.667	0.000, 6.667	-20.000, 0.000	-6.667, 6.667
Min, Max	-13.33, 53.33	-33.33, 33.33	-26.67, 20.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	84.058 (18.5035)	89.722 (17.5812)	80.000 (19.6261)	86.405 (18.0843)
Median	86.667	93.333	83.333	93.333
Q1, Q3	80.000, 93.333	86.667, 100.000	66.667, 93.333	80.000, 100.000
Min, Max	20.00, 100.00	20.00, 100.00	53.33, 100.00	20.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	2.899 (17.5034)	5.507 (14.3058)	-15.000 (13.7437)	2.667 (16.4406)
Median	0.000	0.000	-13.333	0.000
Q1, Q3	-6.667, 6.667	0.000, 13.333	-23.333, -6.667	-6.667, 6.667
Min, Max	-20.00, 53.33	-20.00, 40.00	-33.33, 0.00	-33.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	82.609 (24.0151)	86.087 (21.2644)	91.111 (7.6980)	84.762 (21.9004)
Median	86.667	86.667	86.667	86.667
Q1, Q3	80.000, 100.000	80.000, 100.000	86.667, 100.000	80.000, 100.000
Min, Max	6.67, 100.00	0.00, 100.00	86.67, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	2.029 (21.4085)	2.121 (16.8889)	-6.667 (6.6667)	1.528 (18.6666)
Median	0.000	0.000	-6.667	0.000
Q1, Q3	0.000, 6.667	0.000, 6.667	-13.333, 0.000	0.000, 6.667
Min, Max	-73.33, 53.33	-40.00, 46.67	-13.33, 0.00	-73.33, 53.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	19	20	3	42
Mean (SD)	83.860 (21.9219)	85.333 (22.7470)	95.556 (3.8490)	85.397 (21.4508)
Median	86.667	93.333	93.333	93.333
Q1, Q3	86.667, 100.000	80.000, 100.000	93.333, 100.000	86.667, 100.000
Min, Max	20.00, 100.00	0.00, 100.00	93.33, 100.00	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	4.912 (16.7542)	0.000 (15.0718)	-2.222 (3.8490)	2.114 (15.3796)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 6.667	0.000, 0.000	-6.667, 0.000	0.000, 6.667
Min, Max	-13.33, 60.00	-40.00, 40.00	-6.67, 0.00	-40.00, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	83.111 (17.7936)	88.333 (18.4592)	100.000 (0.0000)	86.667 (17.7951)
Median	86.667	93.333	100.000	86.667
Q1, Q3	80.000, 93.333	86.667, 100.000	100.000, 100.000	86.667, 100.000
Min, Max	26.67, 100.00	26.67, 100.00	100.00, 100.00	26.67, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	1.333 (21.4106)	2.222 (10.5910)	3.333 (4.7140)	1.875 (16.0853)
Median	0.000	0.000	3.333	0.000
Q1, Q3	-13.333, 6.667	0.000, 6.667	0.000, 6.667	-6.667, 6.667
Min, Max	-26.67, 60.00	-13.33, 33.33	0.00, 6.67	-26.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	81.961 (20.3804)	85.980 (23.3858)	86.667 (0.0000)	84.120 (21.0762)
Median	86.667	93.333	86.667	93.333
Q1, Q3	80.000, 93.333	80.000, 100.000	86.667, 86.667	80.000, 96.667
Min, Max	26.67, 100.00	6.67, 100.00	86.67, 86.67	6.67, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	-1.176 (25.8452)	-1.146 (14.5643)	-10.000 (4.7140)	-1.667 (20.3202)
Median	0.000	0.000	-10.000	0.000
Q1, Q3	-6.667, 0.000	-5.833, 3.333	-13.333, -6.667	-6.667, 0.000
Min, Max	-66.67, 60.00	-33.33, 33.33	-13.33, -6.67	-66.67, 60.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	85.556 (15.2642)	88.222 (15.2683)	90.000 (4.7140)	87.241 (14.5315)
Median	90.000	93.333	90.000	93.333
Q1, Q3	76.667, 100.000	80.000, 100.000	86.667, 93.333	80.000, 100.000
Min, Max	53.33, 100.00	46.67, 100.00	86.67, 93.33	46.67, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	5.000 (24.4743)	0.714 (13.2161)	-6.667 (0.0000)	2.024 (18.3998)
Median	0.000	0.000	-6.667	0.000
Q1, Q3	-10.000, 10.000	-6.667, 6.667	-6.667, -6.667	-6.667, 6.667
Min, Max	-20.00, 66.67	-26.67, 33.33	-6.67, -6.67	-26.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	73.889 (21.9197)	55.556 (7.6980)	80.000 (17.6383)	71.852 (20.3955)
Median	80.000	60.000	86.667	73.333
Q1, Q3	63.333, 90.000	46.667, 60.000	60.000, 93.333	60.000, 86.667
Min, Max	26.67, 100.00	46.67, 60.00	60.00, 93.33	26.67, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-6.667 (13.6330)	-26.667 (6.6667)	4.444 (20.3670)	-8.148 (16.2586)
Median	-3.333	-26.667	0.000	-10.000
Q1, Q3	-16.667, 3.333	-33.333, -20.000	-13.333, 26.667	-20.000, 0.000
Min, Max	-33.33, 13.33	-33.33, -20.00	-13.33, 26.67	-33.33, 26.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	58.333 (-)	- (-)	58.333 (-)
Median	-	58.333	-	58.333
Q1, Q3	-, -	58.333, 58.333	-, -	58.333, 58.333
Min, Max	-, -	58.33, 58.33	-, -	58.33, 58.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	60.000 (-)	- (-)	60.000 (-)
Median	-	60.000	-	60.000
Q1, Q3	-, -	60.000, 60.000	-, -	60.000, 60.000
Min, Max	-, -	60.00, 60.00	-, -	60.00, 60.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-6.667 (-)	- (-)	-6.667 (-)
Median	-	-6.667	-	-6.667
Q1, Q3	-, -	-6.667, -6.667	-, -	-6.667, -6.667
Min, Max	-, -	-6.67, -6.67	-, -	-6.67, -6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	73.333 (-)	- (-)	73.333 (-)
Median	-	73.333	-	73.333
Q1, Q3	-, -	73.333, 73.333	-, -	73.333, 73.333
Min, Max	-, -	73.33, 73.33	-, -	73.33, 73.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	6.667 (-)	- (-)	6.667 (-)
Median	-	6.667	-	6.667
Q1, Q3	-, -	6.667, 6.667	-, -	6.667, 6.667
Min, Max	-, -	6.67, 6.67	-, -	6.67, 6.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	86.667 (-)	- (-)	86.667 (-)
Median	-	86.667	-	86.667
Q1, Q3	-, -	86.667, 86.667	-, -	86.667, 86.667
Min, Max	-, -	86.67, 86.67	-, -	86.67, 86.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	20.000 (-)	- (-)	20.000 (-)
Median	-	20.000	-	20.000
Q1, Q3	-, -	20.000, 20.000	-, -	20.000, 20.000
Min, Max	-, -	20.00, 20.00	-, -	20.00, 20.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Role functioning				
Baseline				
n	33	27	7	67
Mean (SD)	80.808 (28.9039)	85.802 (22.0255)	85.714 (20.2498)	83.333 (25.2929)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	66.667, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	50.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	85.057 (22.4248)	89.333 (20.9054)	85.714 (24.3975)	86.885 (21.7551)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	33.33, 100.00	33.33, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	5.172 (27.1326)	-0.694 (19.3363)	0.000 (21.5166)	2.222 (23.4635)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	-16.667, 16.667	0.000, 16.667
Min, Max	-50.00, 66.67	-66.67, 33.33	-33.33, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	90.580 (18.6854)	90.278 (17.6634)	83.333 (19.2450)	89.869 (17.9748)
Median	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	66.67, 100.00	33.33, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	10.145 (25.9852)	3.623 (11.1877)	-8.333 (16.6667)	5.667 (20.0933)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-33.33, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	84.783 (27.9398)	86.957 (24.0772)	94.444 (9.6225)	86.395 (25.1554)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	5.072 (25.8369)	-0.758 (14.9755)	-5.556 (9.6225)	1.736 (20.6970)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-16.667, 0.000	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 16.67	-16.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	83.333 (26.4906)	87.500 (25.2907)	100.000 (0.0000)	86.434 (25.0015)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	0.00, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	3.333 (25.7064)	0.000 (16.6667)	0.000 (0.0000)	1.587 (20.7611)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 83.33	-33.33, 33.33	0.00, 0.00	-50.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	84.444 (20.3800)	84.375 (26.1539)	91.667 (11.7851)	84.848 (22.5784)
Median	100.000	100.000	91.667	100.000
Q1, Q3	66.667, 100.000	75.000, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	33.33, 100.00	0.00, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	2.222 (31.4129)	-6.667 (15.1710)	-8.333 (11.7851)	-2.604 (23.9883)
Median	0.000	0.000	-8.333	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 100.00	-33.33, 16.67	-16.67, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	86.275 (25.8436)	88.235 (19.3332)	83.333 (23.5702)	87.037 (22.2222)
Median	100.000	100.000	83.333	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	33.33, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	2.941 (37.8389)	-2.083 (14.7510)	-16.667 (23.5702)	-0.476 (28.4357)
Median	0.000	0.000	-16.667	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-83.33, 100.00	-33.33, 16.67	-33.33, 0.00	-83.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	91.667 (15.0756)	85.556 (26.6270)	100.000 (0.0000)	89.080 (21.4901)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	50.00, 100.00	16.67, 100.00	100.00, 100.00	16.67, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	9.722 (27.0226)	-5.952 (20.2623)	0.000 (0.0000)	1.190 (23.5390)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 83.33	-66.67, 16.67	0.00, 0.00	-66.67, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	63.889 (28.2783)	16.667 (16.6667)	83.333 (16.6667)	59.259 (31.9427)
Median	66.667	16.667	83.333	66.667
Q1, Q3	41.667, 91.667	0.000, 33.333	66.667, 100.000	33.333, 83.333
Min, Max	16.67, 100.00	0.00, 33.33	66.67, 100.00	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-13.889 (22.2853)	-50.000 (28.8675)	5.556 (38.4900)	-16.667 (29.7044)
Median	0.000	-66.667	-16.667	-16.667
Q1, Q3	-33.333, 0.000	-66.667, -16.667	-16.667, 50.000	-33.333, 0.000
Min, Max	-50.00, 16.67	-66.67, -16.67	-16.67, 50.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	50.000 (-)	- (-)	50.000 (-)
Median	-	50.000	-	50.000
Q1, Q3	-, -	50.000, 50.000	-, -	50.000, 50.000
Min, Max	-, -	50.00, 50.00	-, -	50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Emotional functioning				
Baseline				
n	33	27	7	67
Mean (SD)	82.323 (16.6351)	80.247 (20.6916)	89.286 (10.4464)	82.214 (17.8786)
Median	83.333	83.333	83.333	83.333
Q1, Q3	66.667, 100.000	66.667, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	41.67, 100.00	25.00, 100.00	75.00, 100.00	25.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	86.782 (17.6098)	80.667 (25.7660)	89.286 (13.3631)	84.563 (20.9627)
Median	100.000	91.667	91.667	91.667
Q1, Q3	75.000, 100.000	66.667, 100.000	75.000, 100.000	75.000, 100.000
Min, Max	41.67, 100.00	16.67, 100.00	66.67, 100.00	16.67, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	5.172 (13.6229)	0.000 (25.0603)	0.000 (12.7294)	2.500 (18.8724)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	-8.333, 16.667	0.000, 16.667
Min, Max	-25.00, 33.33	-75.00, 33.33	-16.67, 16.67	-75.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	84.420 (25.0384)	83.333 (17.3762)	72.222 (34.6944)	83.167 (21.9183)
Median	91.667	83.333	83.333	91.667
Q1, Q3	83.333, 100.000	75.000, 100.000	33.333, 100.000	75.000, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	33.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	3.623 (19.9156)	5.435 (15.2025)	-16.667 (33.3333)	3.231 (19.0042)
Median	0.000	8.333	-16.667	0.000
Q1, Q3	-8.333, 16.667	0.000, 8.333	-50.000, 16.667	0.000, 16.667
Min, Max	-41.67, 41.67	-25.00, 33.33	-50.00, 16.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	82.971 (19.2141)	80.435 (26.1851)	100.000 (0.0000)	82.823 (22.4645)
Median	91.667	91.667	100.000	91.667
Q1, Q3	66.667, 100.000	75.000, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	33.33, 100.00	8.33, 100.00	100.00, 100.00	8.33, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	1.812 (17.2175)	1.515 (23.3781)	5.556 (9.6225)	1.910 (19.6932)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-8.333, 16.667	-16.667, 16.667	0.000, 16.667	-8.333, 16.667
Min, Max	-41.67, 33.33	-50.00, 50.00	0.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.917 (24.8497)	80.833 (24.0461)	97.222 (4.8113)	82.946 (23.6370)
Median	91.667	91.667	100.000	91.667
Q1, Q3	79.167, 100.000	70.833, 100.000	91.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	25.00, 100.00	91.67, 100.00	16.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	2.083 (16.4181)	-0.439 (20.6891)	2.778 (12.7294)	0.992 (17.9583)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 8.333	-16.667, 16.667	-8.333, 16.667	0.000, 8.333
Min, Max	-50.00, 25.00	-41.67, 41.67	-8.33, 16.67	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	78.333 (27.2408)	83.854 (18.3759)	95.833 (5.8926)	82.071 (22.4499)
Median	83.333	87.500	95.833	91.667
Q1, Q3	75.000, 100.000	70.833, 100.000	91.667, 100.000	75.000, 100.000
Min, Max	8.33, 100.00	41.67, 100.00	91.67, 100.00	8.33, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	1.111 (19.3820)	3.889 (20.1351)	-4.167 (5.8926)	2.083 (18.9321)
Median	0.000	0.000	-4.167	0.000
Q1, Q3	-8.333, 16.667	-8.333, 8.333	-8.333, 0.000	-8.333, 12.500
Min, Max	-41.67, 25.00	-33.33, 41.67	-8.33, 0.00	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	81.373 (26.9273)	87.255 (14.4691)	95.833 (5.8926)	84.954 (21.0649)
Median	91.667	91.667	95.833	91.667
Q1, Q3	75.000, 100.000	75.000, 100.000	91.667, 100.000	75.000, 100.000
Min, Max	16.67, 100.00	66.67, 100.00	91.67, 100.00	16.67, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	0.980 (18.3717)	8.333 (17.7430)	-4.167 (5.8926)	4.048 (17.7781)
Median	0.000	8.333	-4.167	0.000
Q1, Q3	-8.333, 8.333	0.000, 20.833	-8.333, 0.000	0.000, 8.333
Min, Max	-41.67, 33.33	-33.33, 41.67	-8.33, 0.00	-41.67, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	79.167 (30.6701)	81.667 (20.9402)	100.000 (0.0000)	81.897 (24.8077)
Median	95.833	91.667	100.000	91.667
Q1, Q3	66.667, 100.000	66.667, 100.000	100.000, 100.000	75.000, 100.000
Min, Max	8.33, 100.00	41.67, 100.00	100.00, 100.00	8.33, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-2.083 (19.1765)	1.190 (20.3750)	0.000 (0.0000)	-0.298 (18.7690)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 4.167	-8.333, 8.333	0.000, 0.000	-8.333, 8.333
Min, Max	-33.33, 33.33	-50.00, 41.67	0.00, 0.00	-50.00, 41.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	75.000 (23.3008)	55.556 (31.5495)	86.111 (12.7294)	73.611 (23.9570)
Median	79.167	41.667	83.333	79.167
Q1, Q3	62.500, 91.667	33.333, 91.667	75.000, 100.000	58.333, 91.667
Min, Max	33.33, 100.00	33.33, 91.67	75.00, 100.00	33.33, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-9.028 (15.6744)	-19.444 (26.7879)	0.000 (25.0000)	-9.259 (18.7190)
Median	-8.333	-8.333	0.000	-8.333
Q1, Q3	-20.833, 0.000	-50.000, 0.000	-25.000, 25.000	-25.000, 0.000
Min, Max	-33.33, 16.67	-50.00, 0.00	-25.00, 25.00	-50.00, 25.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	77.778 (-)	- (-)	77.778 (-)
Median	-	77.778	-	77.778
Q1, Q3	-, -	77.778, 77.778	-, -	77.778, 77.778
Min, Max	-, -	77.78, 77.78	-, -	77.78, 77.78
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-13.889 (-)	- (-)	-13.889 (-)
Median	-	-13.889	-	-13.889
Q1, Q3	-, -	-13.889, -13.889	-, -	-13.889, -13.889
Min, Max	-, -	-13.89, -13.89	-, -	-13.89, -13.89

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-8.333 (-)	- (-)	-8.333 (-)
Median	-	-8.333	-	-8.333
Q1, Q3	-, -	-8.333, -8.333	-, -	-8.333, -8.333
Min, Max	-, -	-8.33, -8.33	-, -	-8.33, -8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	8.333 (-)	- (-)	8.333 (-)
Median	-	8.333	-	8.333
Q1, Q3	-, -	8.333, 8.333	-, -	8.333, 8.333
Min, Max	-, -	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	8.333 (-)	- (-)	8.333 (-)
Median	-	8.333	-	8.333
Q1, Q3	-, -	8.333, 8.333	-, -	8.333, 8.333
Min, Max	-, -	8.33, 8.33	-, -	8.33, 8.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	91.667 (-)	- (-)	91.667 (-)
Median	-	91.667	-	91.667
Q1, Q3	-, -	91.667, 91.667	-, -	91.667, 91.667
Min, Max	-, -	91.67, 91.67	-, -	91.67, 91.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cognitive functioning				
Baseline				
n	33	27	7	67
Mean (SD)	85.859 (20.4639)	89.506 (16.1114)	92.857 (8.9087)	88.060 (17.8391)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	33.33, 100.00	83.33, 100.00	33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	85.057 (16.8707)	87.333 (17.5330)	83.333 (16.6667)	85.792 (16.8973)
Median	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	50.00, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.724 (16.2720)	-4.167 (17.2016)	-9.524 (21.2070)	-3.611 (17.1104)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-50.00, 16.67	-50.00, 16.67	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	79.710 (28.4074)	88.889 (17.4917)	88.889 (9.6225)	84.667 (23.0449)
Median	83.333	100.000	83.333	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	-8.696 (18.7147)	-0.725 (10.6343)	-5.556 (9.6225)	-4.762 (15.2145)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-66.67, 33.33	-33.33, 16.67	-16.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	78.261 (30.3327)	89.130 (18.5379)	88.889 (9.6225)	84.014 (24.7579)
Median	83.333	100.000	83.333	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	83.33, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (25.9852)	-0.758 (13.0903)	0.000 (0.0000)	-5.208 (20.3853)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-100.00, 50.00	-33.33, 16.67	0.00, 0.00	-100.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	82.500 (23.8630)	85.000 (22.8778)	88.889 (9.6225)	84.109 (22.4060)
Median	83.333	100.000	83.333	83.333
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	16.67, 100.00	83.33, 100.00	16.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-7.500 (19.8496)	-3.509 (15.2944)	0.000 (0.0000)	-5.159 (17.0636)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	-16.667, 0.000	0.000, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-50.00, 16.67	0.00, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	82.222 (28.4986)	85.417 (18.1302)	83.333 (0.0000)	83.838 (22.6250)
Median	100.000	91.667	83.333	83.333
Q1, Q3	83.333, 100.000	75.000, 100.000	83.333, 83.333	83.333, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	83.33, 83.33	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	-6.667 (24.2343)	-5.556 (18.5450)	0.000 (0.0000)	-5.729 (20.5696)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	-8.333, 0.000
Min, Max	-66.67, 50.00	-50.00, 16.67	0.00, 0.00	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	83.333 (22.8218)	88.235 (21.0528)	75.000 (11.7851)	85.185 (21.3726)
Median	83.333	100.000	75.000	91.667
Q1, Q3	83.333, 100.000	83.333, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	33.33, 100.00	16.67, 100.00	66.67, 83.33	16.67, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	-6.863 (19.5956)	-3.125 (9.0651)	-8.333 (11.7851)	-5.238 (15.0008)
Median	0.000	0.000	-8.333	0.000
Q1, Q3	-16.667, 0.000	-8.333, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-33.33, 50.00	-16.67, 16.67	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	80.556 (25.4588)	90.000 (16.4268)	75.000 (11.7851)	85.057 (20.5793)
Median	83.333	100.000	75.000	100.000
Q1, Q3	75.000, 100.000	83.333, 100.000	66.667, 83.333	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	66.67, 83.33	16.67, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-6.944 (22.9826)	-1.190 (16.6208)	-8.333 (11.7851)	-4.167 (19.0435)
Median	-8.333	0.000	-8.333	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	-16.667, 0.000	-16.667, 0.000
Min, Max	-50.00, 50.00	-33.33, 33.33	-16.67, 0.00	-50.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	75.000 (21.9043)	61.111 (9.6225)	94.444 (9.6225)	75.926 (20.7870)
Median	83.333	66.667	100.000	83.333
Q1, Q3	66.667, 83.333	50.000, 66.667	83.333, 100.000	66.667, 83.333
Min, Max	33.33, 100.00	50.00, 66.67	83.33, 100.00	33.33, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-9.722 (13.2160)	-33.333 (16.6667)	0.000 (16.6667)	-12.037 (16.9636)
Median	-16.667	-33.333	0.000	-16.667
Q1, Q3	-16.667, 0.000	-50.000, -16.667	-16.667, 16.667	-16.667, 0.000
Min, Max	-33.33, 16.67	-50.00, -16.67	-16.67, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	83.333 (-)	- (-)	83.333 (-)
Median	-	83.333	-	83.333
Q1, Q3	-, -	83.333, 83.333	-, -	83.333, 83.333
Min, Max	-, -	83.33, 83.33	-, -	83.33, 83.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-16.667 (-)	- (-)	-16.667 (-)
Median	-	-16.667	-	-16.667
Q1, Q3	-, -	-16.667, -16.667	-, -	-16.667, -16.667
Min, Max	-, -	-16.67, -16.67	-, -	-16.67, -16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Social functioning				
Baseline				
n	33	27	7	67
Mean (SD)	78.788 (27.0906)	90.741 (14.8593)	92.857 (13.1133)	85.075 (22.3106)
Median	83.333	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	83.333, 100.000	66.667, 100.000
Min, Max	0.00, 100.00	50.00, 100.00	66.67, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	86.782 (23.7293)	91.333 (14.5297)	90.476 (18.8982)	89.071 (19.6933)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	16.67, 100.00	50.00, 100.00	50.00, 100.00	16.67, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	8.046 (30.7385)	-1.389 (12.9255)	-2.381 (24.3975)	3.056 (24.4510)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-50.00, 100.00	-33.33, 33.33	-50.00, 33.33	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	89.855 (17.9359)	95.139 (11.5042)	83.333 (28.8675)	92.000 (15.8794)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	50.000, 100.000	100.000, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	50.00, 100.00	33.33, 100.00
Change from Baseline				
n	23	23	3	49
Mean (SD)	12.319 (30.2420)	4.348 (12.5302)	-16.667 (28.8675)	6.803 (24.0366)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	-50.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 33.33	-50.00, 0.00	-50.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	81.884 (27.9398)	89.855 (17.9359)	100.000 (0.0000)	86.735 (23.0688)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	0.00, 100.00	33.33, 100.00	100.00, 100.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	4.348 (34.5305)	-0.758 (23.2750)	0.000 (0.0000)	1.736 (28.4010)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 8.333
Min, Max	-83.33, 83.33	-66.67, 50.00	0.00, 0.00	-83.33, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	90.000 (13.6797)	92.500 (12.6526)	100.000 (0.0000)	91.860 (12.7927)
Median	100.000	100.000	100.000	100.000
Q1, Q3	83.333, 100.000	83.333, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	66.67, 100.00	66.67, 100.00	100.00, 100.00	66.67, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	10.000 (28.3049)	-0.877 (16.1720)	0.000 (0.0000)	4.365 (22.7093)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 0.000	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-33.33, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	81.111 (23.4577)	95.833 (9.6225)	100.000 (0.0000)	89.394 (18.5490)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	100.000, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	100.00, 100.00	33.33, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	4.444 (33.0143)	4.444 (17.2133)	0.000 (0.0000)	4.167 (25.0448)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 100.00	-16.67, 50.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	87.255 (23.2210)	96.078 (7.2873)	91.667 (11.7851)	91.667 (17.1362)
Median	100.000	100.000	91.667	100.000
Q1, Q3	83.333, 100.000	100.000, 100.000	83.333, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	83.33, 100.00	83.33, 100.00	33.33, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	7.843 (29.5320)	5.208 (16.9080)	-8.333 (11.7851)	5.714 (23.5504)
Median	0.000	0.000	-8.333	0.000
Q1, Q3	0.000, 16.667	0.000, 8.333	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-16.67, 50.00	-16.67, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	83.333 (24.6183)	94.444 (12.0624)	100.000 (0.0000)	90.230 (18.6431)
Median	100.000	100.000	100.000	100.000
Q1, Q3	66.667, 100.000	100.000, 100.000	100.000, 100.000	83.333, 100.000
Min, Max	33.33, 100.00	66.67, 100.00	100.00, 100.00	33.33, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	8.333 (36.5839)	4.762 (22.0998)	0.000 (0.0000)	5.952 (28.0411)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 16.667	0.000, 16.667	0.000, 0.000	0.000, 16.667
Min, Max	-33.33, 100.00	-33.33, 50.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	70.833 (23.7038)	50.000 (28.8675)	72.222 (34.6944)	67.593 (25.8656)
Median	66.667	33.333	83.333	66.667
Q1, Q3	58.333, 91.667	33.333, 83.333	33.333, 100.000	33.333, 83.333
Min, Max	33.33, 100.00	33.33, 83.33	33.33, 100.00	33.33, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	-8.333 (21.9043)	-27.778 (38.4900)	-11.111 (25.4588)	-12.037 (24.7903)
Median	0.000	-50.000	-16.667	-8.333
Q1, Q3	-25.000, 8.333	-50.000, 16.667	-33.333, 16.667	-33.333, 16.667
Min, Max	-50.00, 16.67	-50.00, 16.67	-33.33, 16.67	-50.00, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Fatigue				
Baseline				
n	33	27	7	67
Mean (SD)	30.471 (25.6144)	26.337 (21.6043)	36.508 (17.8174)	29.436 (23.2509)
Median	22.222	22.222	22.222	22.222
Q1, Q3	11.111, 44.444	11.111, 33.333	22.222, 55.556	11.111, 44.444
Min, Max	0.00, 100.00	0.00, 77.78	22.22, 55.56	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	21.456 (20.9835)	20.889 (23.8566)	28.571 (25.5452)	22.040 (22.4518)
Median	22.222	11.111	22.222	22.222
Q1, Q3	0.000, 22.222	0.000, 33.333	0.000, 55.556	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 66.67	0.00, 77.78
Change from Baseline				
n	29	24	7	60
Mean (SD)	-9.387 (25.0706)	-1.389 (27.0806)	-7.937 (13.9285)	-6.019 (24.8724)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-16.667, 0.000	-22.222, 0.000	-22.222, 0.000
Min, Max	-88.89, 33.33	-55.56, 66.67	-22.22, 11.11	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	28.502 (21.9238)	18.981 (18.9581)	19.444 (26.2545)	23.312 (20.9944)
Median	22.222	22.222	11.111	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	0.000, 38.889	11.111, 33.333
Min, Max	0.00, 77.78	0.00, 77.78	0.00, 55.56	0.00, 77.78
Change from Baseline				
n	23	23	4	50
Mean (SD)	-4.106 (21.3344)	-7.729 (18.7831)	-11.111 (12.8300)	-6.333 (19.4407)
Median	0.000	0.000	-11.111	0.000
Q1, Q3	-11.111, 11.111	-22.222, 0.000	-22.222, 0.000	-11.111, 0.000
Min, Max	-77.78, 33.33	-66.67, 22.22	-22.22, 0.00	-77.78, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	25.604 (23.0733)	21.256 (22.7002)	14.815 (12.8300)	22.902 (22.2694)
Median	22.222	22.222	22.222	22.222
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 22.222	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 100.00	0.00, 22.22	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	-7.488 (21.1621)	-5.556 (19.9205)	-7.407 (12.8300)	-6.597 (19.8714)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-22.222, 0.000	-11.111, 0.000	-22.222, 0.000	-19.444, 0.000
Min, Max	-55.56, 44.44	-44.44, 33.33	-22.22, 0.00	-55.56, 44.44

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	22.778 (21.1664)	19.444 (20.0308)	3.704 (6.4150)	19.897 (20.2219)
Median	22.222	11.111	0.000	22.222
Q1, Q3	0.000, 33.333	0.000, 38.889	0.000, 11.111	0.000, 33.333
Min, Max	0.00, 77.78	0.00, 55.56	0.00, 11.11	0.00, 77.78
Change from Baseline				
n	20	19	3	42
Mean (SD)	-7.500 (22.0958)	-6.433 (20.7261)	-18.519 (6.4150)	-7.804 (20.6438)
Median	0.000	0.000	-22.222	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	-22.222, -11.111	-22.222, 0.000
Min, Max	-88.89, 11.11	-44.44, 33.33	-22.22, -11.11	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	20.000 (23.8307)	15.278 (13.3795)	16.667 (7.8567)	17.508 (18.4320)
Median	11.111	11.111	16.667	11.111
Q1, Q3	0.000, 33.333	5.556, 22.222	11.111, 22.222	0.000, 22.222
Min, Max	0.00, 88.89	0.00, 44.44	11.11, 22.22	0.00, 88.89
Change from Baseline				
n	15	15	2	32
Mean (SD)	-12.222 (29.2619)	-11.852 (16.5161)	-5.556 (7.8567)	-11.632 (22.6816)
Median	0.000	0.000	-5.556	0.000
Q1, Q3	-22.222, 0.000	-22.222, 0.000	-11.111, 0.000	-22.222, 0.000
Min, Max	-88.89, 33.33	-44.44, 0.00	-11.11, 0.00	-88.89, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	24.183 (19.7341)	18.301 (25.7424)	33.333 (15.7135)	21.914 (22.4569)
Median	22.222	11.111	33.333	22.222
Q1, Q3	11.111, 33.333	0.000, 33.333	22.222, 44.444	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	22.22, 44.44	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	-4.575 (18.8639)	-6.944 (19.4047)	11.111 (15.7135)	-4.762 (18.9188)
Median	0.000	0.000	11.111	0.000
Q1, Q3	-11.111, 0.000	-22.222, 0.000	0.000, 22.222	-11.111, 0.000
Min, Max	-66.67, 22.22	-44.44, 33.33	0.00, 22.22	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	18.519 (20.2860)	23.704 (28.4418)	22.222 (0.0000)	21.456 (23.9287)
Median	11.111	22.222	22.222	22.222
Q1, Q3	0.000, 27.778	0.000, 33.333	22.222, 22.222	0.000, 22.222
Min, Max	0.00, 55.56	0.00, 100.00	22.22, 22.22	0.00, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-10.185 (28.9968)	-0.794 (27.7228)	0.000 (0.0000)	-4.762 (27.1204)
Median	-5.556	0.000	0.000	0.000
Q1, Q3	-11.111, 0.000	-22.222, 11.111	0.000, 0.000	-11.111, 5.556
Min, Max	-88.89, 22.22	-55.56, 66.67	0.00, 0.00	-88.89, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	44.444 (28.8189)	77.778 (19.2450)	37.037 (27.9623)	48.765 (29.3079)
Median	44.444	66.667	33.333	55.556
Q1, Q3	16.667, 72.222	66.667, 100.000	11.111, 66.667	22.222, 66.667
Min, Max	0.00, 77.78	66.67, 100.00	11.11, 66.67	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	11.574 (21.7704)	44.444 (29.3972)	-7.407 (16.9725)	13.889 (26.2833)
Median	5.556	55.556	-11.111	11.111
Q1, Q3	-2.778, 27.778	11.111, 66.667	-22.222, 11.111	-5.556, 33.333
Min, Max	-22.22, 44.44	11.11, 66.67	-22.22, 11.11	-22.22, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	11.111 (-)	- (-)	11.111 (-)
Median	-	11.111	-	11.111
Q1, Q3	-, -	11.111, 11.111	-, -	11.111, 11.111
Min, Max	-, -	11.11, 11.11	-, -	11.11, 11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-22.222 (-)	- (-)	-22.222 (-)
Median	-	-22.222	-	-22.222
Q1, Q3	-, -	-22.222, -22.222	-, -	-22.222, -22.222
Min, Max	-, -	-22.22, -22.22	-, -	-22.22, -22.22

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	44.444 (-)	- (-)	44.444 (-)
Median	-	44.444	-	44.444
Q1, Q3	-, -	44.444, 44.444	-, -	44.444, 44.444
Min, Max	-, -	44.44, 44.44	-, -	44.44, 44.44
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-11.111 (-)	- (-)	-11.111 (-)
Median	-	-11.111	-	-11.111
Q1, Q3	-, -	-11.111, -11.111	-, -	-11.111, -11.111
Min, Max	-, -	-11.11, -11.11	-, -	-11.11, -11.11

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Nausea and vomiting				
Baseline				
n	33	27	7	67
Mean (SD)	5.051 (10.6106)	3.704 (11.6330)	0.000 (0.0000)	3.980 (10.4967)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 50.00	0.00, 0.00	0.00, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	4.023 (10.5927)	0.667 (3.3333)	4.762 (8.1325)	2.732 (8.1538)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 16.67	0.00, 50.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.149 (8.8316)	-2.778 (9.4110)	4.762 (8.1325)	-1.111 (9.1373)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 16.667	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 0.00	0.00, 16.67	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	6.522 (21.1650)	1.389 (4.7055)	0.000 (0.0000)	3.595 (14.6491)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 16.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	0.725 (18.4489)	-0.725 (6.1098)	0.000 (0.0000)	0.000 (13.0410)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-16.67, 16.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	5.072 (9.3133)	2.899 (8.1838)	0.000 (0.0000)	3.741 (8.5156)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline				
n	23	22	3	48
Mean (SD)	-0.725 (7.9109)	0.758 (9.5912)	0.000 (0.0000)	0.000 (8.4215)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	-33.33, 16.67	0.00, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	4.167 (11.9392)	0.833 (3.7268)	0.000 (0.0000)	2.326 (8.5923)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 50.00	0.00, 16.67	0.00, 0.00	0.00, 50.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-0.833 (6.5672)	0.000 (0.0000)	0.000 (0.0000)	-0.397 (4.4904)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 16.67	0.00, 0.00	0.00, 0.00	-16.67, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	3.333 (9.3435)	1.042 (4.1667)	0.000 (0.0000)	2.020 (6.9191)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 16.67	0.00, 0.00	0.00, 33.33
Change from Baseline				
n	15	15	2	32
Mean (SD)	-1.111 (4.3033)	-2.222 (10.6657)	0.000 (0.0000)	-1.563 (7.7591)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	-33.33, 16.67	0.00, 0.00	-33.33, 16.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	2.941 (8.8099)	0.000 (0.0000)	0.000 (0.0000)	1.389 (6.1399)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 0.00	0.00, 0.00	0.00, 33.33
Change from Baseline				
n	17	16	2	35
Mean (SD)	-0.980 (4.0423)	-3.125 (9.0651)	0.000 (0.0000)	-1.905 (6.7294)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	-33.33, 0.00	0.00, 0.00	-33.33, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	1.389 (4.8113)	4.444 (13.3135)	0.000 (0.0000)	2.874 (10.0287)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 16.67	0.00, 50.00	0.00, 0.00	0.00, 50.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-2.778 (6.4875)	1.190 (17.8602)	0.000 (0.0000)	-0.595 (13.2110)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 0.00	-33.33, 50.00	0.00, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	12.500 (18.9697)	0.000 (0.0000)	0.000 (0.0000)	8.333 (16.4197)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 16.667
Min, Max	0.00, 50.00	0.00, 0.00	0.00, 0.00	0.00, 50.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	4.167 (18.9697)	0.000 (0.0000)	0.000 (0.0000)	2.778 (15.3925)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-16.67, 50.00	0.00, 0.00	0.00, 0.00	-16.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Pain				
Baseline				
n	32	27	7	66
Mean (SD)	16.146 (21.3708)	14.815 (23.2661)	7.143 (13.1133)	14.646 (21.3868)
Median	8.333	0.000	0.000	0.000
Q1, Q3	0.000, 25.000	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 83.33	0.00, 33.33	0.00, 83.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	17.241 (23.3515)	9.333 (18.6835)	21.429 (18.5450)	14.481 (21.1860)
Median	16.667	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 50.00	0.00, 100.00
Change from Baseline				
n	28	24	7	59
Mean (SD)	-0.595 (21.5080)	-3.472 (20.8394)	14.286 (14.9956)	0.000 (20.9908)
Median	0.000	0.000	16.667	0.000
Q1, Q3	-8.333, 16.667	-16.667, 0.000	0.000, 33.333	-16.667, 16.667
Min, Max	-66.67, 33.33	-33.33, 50.00	0.00, 33.33	-66.67, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	15.217 (25.5807)	12.500 (22.1163)	16.667 (19.2450)	14.052 (23.1835)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	22	23	4	49
Mean (SD)	-2.273 (20.7629)	-2.899 (19.2355)	12.500 (15.9571)	-1.361 (19.7896)
Median	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 0.000	-16.667, 16.667	0.000, 25.000	0.000, 0.000
Min, Max	-66.67, 33.33	-50.00, 33.33	0.00, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	22.464 (29.5628)	15.217 (23.5236)	16.667 (16.6667)	18.707 (26.0503)
Median	16.667	0.000	16.667	16.667
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	22	22	3	47
Mean (SD)	4.545 (29.6281)	0.758 (19.5703)	16.667 (16.6667)	3.546 (24.5580)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 16.667	-16.667, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-66.67, 66.67	-33.33, 33.33	0.00, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	15.833 (22.6045)	15.000 (24.1220)	22.222 (19.2450)	15.891 (22.6993)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 25.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	-0.877 (21.1357)	1.754 (20.7087)	22.222 (19.2450)	2.033 (21.1460)
Median	0.000	0.000	33.333	0.000
Q1, Q3	-16.667, 0.000	0.000, 16.667	0.000, 33.333	0.000, 16.667
Min, Max	-33.33, 66.67	-50.00, 33.33	0.00, 33.33	-50.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	16.667 (28.1718)	11.458 (25.6174)	16.667 (0.0000)	14.141 (25.7260)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	16.667, 16.667	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	16.67, 16.67	0.00, 100.00
Change from Baseline				
n	14	15	2	31
Mean (SD)	3.571 (21.8567)	-1.111 (17.2133)	16.667 (0.0000)	2.151 (19.1204)
Median	0.000	0.000	16.667	0.000
Q1, Q3	-16.667, 33.333	-16.667, 16.667	16.667, 16.667	-16.667, 16.667
Min, Max	-33.33, 33.33	-33.33, 16.67	16.67, 16.67	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	18.627 (28.1873)	11.765 (26.8514)	25.000 (35.3553)	15.741 (27.2974)
Median	16.667	0.000	25.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 50.000	0.000, 16.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 50.00	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	4.902 (30.4849)	-1.042 (15.4785)	25.000 (35.3553)	3.333 (24.8525)
Median	0.000	0.000	25.000	0.000
Q1, Q3	-16.667, 0.000	-8.333, 0.000	0.000, 50.000	-16.667, 0.000
Min, Max	-33.33, 100.00	-33.33, 33.33	0.00, 50.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	15.278 (25.0840)	14.444 (26.6270)	8.333 (11.7851)	14.368 (24.6902)
Median	0.000	0.000	8.333	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 16.667	0.000, 16.667
Min, Max	0.00, 66.67	0.00, 83.33	0.00, 16.67	0.00, 83.33
Change from Baseline				
n	12	14	2	28
Mean (SD)	1.389 (21.8562)	2.381 (23.4404)	8.333 (11.7851)	2.381 (21.6188)
Median	0.000	0.000	8.333	0.000
Q1, Q3	-8.333, 0.000	-16.667, 16.667	0.000, 16.667	-8.333, 8.333
Min, Max	-33.33, 50.00	-33.33, 66.67	0.00, 16.67	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	29.167 (25.7464)	27.778 (25.4588)	5.556 (9.6225)	25.000 (24.4214)
Median	33.333	33.333	0.000	25.000
Q1, Q3	0.000, 50.000	0.000, 50.000	0.000, 16.667	0.000, 50.000
Min, Max	0.00, 66.67	0.00, 50.00	0.00, 16.67	0.00, 66.67
Change from Baseline				
n	11	3	3	17
Mean (SD)	6.061 (22.6969)	27.778 (25.4588)	-5.556 (9.6225)	7.843 (22.9111)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 50.000	-16.667, 0.000	0.000, 16.667
Min, Max	-33.33, 50.00	0.00, 50.00	-16.67, 0.00	-33.33, 50.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Dyspnoea				
Baseline				
n	33	27	7	67
Mean (SD)	22.222 (30.8070)	29.630 (33.7580)	9.524 (16.2650)	23.881 (31.1432)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	17.241 (26.1569)	18.667 (21.6880)	14.286 (17.8174)	17.486 (23.2591)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-4.598 (30.5039)	-4.167 (20.4124)	4.762 (12.5988)	-3.333 (25.0799)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-16.667, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	15.942 (24.3492)	13.889 (23.9094)	16.667 (33.3333)	15.033 (24.3253)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	-8.696 (27.0005)	-13.043 (27.9594)	16.667 (33.3333)	-8.667 (28.4202)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	0.000, 33.333	-33.333, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	0.00, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	22	3	48
Mean (SD)	14.493 (22.0790)	10.606 (15.8910)	0.000 (0.0000)	11.806 (18.8180)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	21	3	47
Mean (SD)	-8.696 (25.0603)	-19.048 (37.3741)	0.000 (0.0000)	-12.766 (30.7343)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	16.667 (22.9416)	16.667 (25.3629)	11.111 (19.2450)	16.279 (23.4262)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	20	19	3	42
Mean (SD)	-6.667 (27.7836)	-12.281 (41.8854)	11.111 (19.2450)	-7.937 (34.3815)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 66.67	0.00, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	11.111 (20.5738)	8.333 (14.9071)	0.000 (0.0000)	9.091 (17.2255)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	15	15	2	32
Mean (SD)	-13.333 (30.3420)	-15.556 (27.7936)	0.000 (0.0000)	-13.542 (27.9007)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-100.00, 0.00	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	13.725 (20.6116)	9.804 (15.6556)	0.000 (0.0000)	11.111 (17.8174)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	17	16	2	35
Mean (SD)	-5.882 (29.4281)	-14.583 (32.1311)	0.000 (0.0000)	-9.524 (29.7829)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-100.00, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	8.333 (20.7194)	17.778 (27.7936)	0.000 (0.0000)	12.644 (24.2569)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-13.889 (33.2068)	-9.524 (33.1497)	0.000 (0.0000)	-10.714 (31.4970)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	-33.333, 0.000	0.000, 0.000	-33.333, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	38.889 (34.3286)	77.778 (19.2450)	11.111 (19.2450)	40.741 (35.3425)
Median	33.333	66.667	0.000	33.333
Q1, Q3	0.000, 66.667	66.667, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	66.67, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	11.111 (32.8244)	22.222 (19.2450)	-11.111 (19.2450)	9.259 (29.8264)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	-33.333, 0.000	0.000, 33.333
Min, Max	-33.33, 66.67	0.00, 33.33	-33.33, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	100.000 (-)	- (-)	100.000 (-)
Median	-	100.000	-	100.000
Q1, Q3	-, -	100.000, 100.000	-, -	100.000, 100.000
Min, Max	-, -	100.00, 100.00	-, -	100.00, 100.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-66.667 (-)	- (-)	-66.667 (-)
Median	-	-66.667	-	-66.667
Q1, Q3	-, -	-66.667, -66.667	-, -	-66.667, -66.667
Min, Max	-, -	-66.67, -66.67	-, -	-66.67, -66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	-33.333 (-)	- (-)	-33.333 (-)
Median	-	-33.333	-	-33.333
Q1, Q3	-, -	-33.333, -33.333	-, -	-33.333, -33.333
Min, Max	-, -	-33.33, -33.33	-, -	-33.33, -33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Insomnia				
Baseline				
n	33	27	7	67
Mean (SD)	19.192 (25.0421)	19.753 (24.9088)	23.810 (25.1976)	19.900 (24.6591)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	18.391 (26.1045)	17.333 (23.8048)	19.048 (17.8174)	18.033 (24.0168)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-1.149 (16.6256)	-1.389 (20.8031)	-4.762 (29.9912)	-1.667 (19.8155)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	23.188 (27.4042)	18.056 (25.9676)	8.333 (16.6667)	19.608 (25.9713)
Median	33.333	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 16.667	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	0.000 (17.4078)	-2.899 (19.8811)	-16.667 (33.3333)	-2.667 (20.0227)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	-66.67, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	21.739 (25.8369)	17.391 (29.9319)	0.000 (0.0000)	18.367 (27.2686)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	23	22	3	48
Mean (SD)	0.000 (20.1008)	-4.545 (25.8106)	-22.222 (38.4900)	-3.472 (24.0563)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-66.667, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-66.67, 66.67	-66.67, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	20.000 (25.1312)	21.667 (31.1101)	22.222 (38.4900)	20.930 (28.1936)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 66.667	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	-3.333 (14.9071)	3.509 (18.9044)	0.000 (0.0000)	0.000 (16.4622)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	22.222 (32.5300)	16.667 (24.3432)	16.667 (23.5702)	19.192 (27.6766)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	-2.222 (15.2579)	-4.444 (17.2133)	16.667 (23.5702)	-2.083 (16.8005)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	15.686 (23.9143)	15.686 (29.1492)	0.000 (0.0000)	14.815 (25.7515)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	-7.843 (18.7432)	-6.250 (21.8369)	0.000 (0.0000)	-6.667 (19.4701)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	-33.333, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 0.00	-33.33, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	13.889 (22.2853)	11.111 (20.5738)	16.667 (23.5702)	12.644 (20.7284)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	12	14	2	28
Mean (SD)	-8.333 (15.0756)	-9.524 (15.6269)	16.667 (23.5702)	-7.143 (16.6225)
Median	0.000	0.000	16.667	0.000
Q1, Q3	-16.667, 0.000	-33.333, 0.000	0.000, 33.333	-16.667, 0.000
Min, Max	-33.33, 0.00	-33.33, 0.00	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	33.333 (31.7821)	33.333 (33.3333)	22.222 (19.2450)	31.481 (29.0868)
Median	33.333	33.333	33.333	33.333
Q1, Q3	0.000, 66.667	0.000, 66.667	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	12	3	3	18
Mean (SD)	16.667 (26.5908)	22.222 (19.2450)	0.000 (0.0000)	14.815 (23.4931)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Appetite loss				
Baseline				
n	33	27	7	67
Mean (SD)	14.141 (25.0421)	8.642 (17.5231)	23.810 (37.0899)	12.935 (23.8932)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	8.046 (17.0321)	9.333 (18.0534)	23.810 (25.1976)	10.383 (18.7981)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 66.67	0.00, 66.67
Change from Baseline				
n	29	24	7	60
Mean (SD)	-8.046 (26.2091)	1.389 (23.0084)	0.000 (33.3333)	-3.333 (25.8199)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	-66.67, 33.33	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	8.696 (22.9567)	6.944 (13.8284)	16.667 (33.3333)	8.497 (19.8249)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 66.67	0.00, 100.00
Change from Baseline				
n	23	23	4	50
Mean (SD)	-8.696 (28.8104)	-2.899 (19.8811)	8.333 (41.9435)	-4.667 (26.0907)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-16.667, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	-33.33, 66.67	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	5.797 (12.9184)	10.145 (21.1650)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (30.8708)	0.000 (25.1976)	-11.111 (19.2450)	-5.556 (27.7896)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 66.67	-33.33, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	10.000 (19.0414)	13.333 (25.1312)	0.000 (0.0000)	10.853 (21.4808)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 16.667	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	20	19	3	42
Mean (SD)	-3.333 (28.4081)	5.263 (25.4906)	-11.111 (19.2450)	0.000 (26.5444)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-33.333, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 66.67	-33.33, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	8.889 (19.7872)	6.250 (18.1302)	16.667 (23.5702)	8.081 (18.6903)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	15	15	2	32
Mean (SD)	-6.667 (31.3708)	0.000 (21.8218)	0.000 (0.0000)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 33.33	0.00, 0.00	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	7.843 (18.7432)	7.843 (18.7432)	16.667 (23.5702)	8.333 (18.4735)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	17	16	2	35
Mean (SD)	-5.882 (21.1978)	2.083 (22.6691)	0.000 (0.0000)	-1.905 (21.3021)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-66.67, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	5.556 (12.9750)	11.111 (29.9912)	16.667 (23.5702)	9.195 (23.3954)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-11.111 (32.8244)	4.762 (34.2368)	0.000 (0.0000)	-2.381 (32.6202)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 33.33	-66.67, 100.00	0.00, 0.00	-100.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	30.556 (33.2068)	44.444 (50.9175)	44.444 (50.9175)	35.185 (36.9989)
Median	33.333	33.333	33.333	33.333
Q1, Q3	0.000, 50.000	0.000, 100.000	0.000, 100.000	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	11.111 (41.0305)	44.444 (50.9175)	0.000 (0.0000)	14.815 (39.9709)
Median	0.000	33.333	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 100.000	0.000, 0.000	0.000, 33.333
Min, Max	-66.67, 100.00	0.00, 100.00	0.00, 0.00	-66.67, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	33.333 (-)	- (-)	33.333 (-)
Median	-	33.333	-	33.333
Q1, Q3	-, -	33.333, 33.333	-, -	33.333, 33.333
Min, Max	-, -	33.33, 33.33	-, -	33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	66.667 (-)	- (-)	66.667 (-)
Median	-	66.667	-	66.667
Q1, Q3	-, -	66.667, 66.667	-, -	66.667, 66.667
Min, Max	-, -	66.67, 66.67	-, -	66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Constipation				
Baseline				
n	33	27	7	67
Mean (SD)	10.101 (15.5565)	7.407 (19.2450)	9.524 (25.1976)	8.955 (17.9619)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 66.67	0.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	12.644 (22.5617)	6.667 (16.6667)	28.571 (35.6348)	12.022 (22.7977)
Median	0.000	0.000	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	3.448 (22.4401)	-1.389 (11.9547)	19.048 (42.4139)	3.333 (22.7158)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	-33.33, 100.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	4	51
Mean (SD)	10.145 (18.6265)	8.333 (17.7203)	0.000 (0.0000)	8.497 (17.4396)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	23	4	50
Mean (SD)	1.449 (18.7441)	0.000 (22.4733)	0.000 (0.0000)	0.667 (19.6223)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	10.145 (15.6824)	7.246 (17.2812)	11.111 (19.2450)	8.844 (16.3519)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	0.000 (20.1008)	-1.515 (12.5030)	11.111 (19.2450)	0.000 (16.8430)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	15.000 (31.4838)	15.000 (27.5193)	0.000 (0.0000)	13.953 (28.3894)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 33.333	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	5.000 (29.1698)	7.018 (28.4994)	0.000 (0.0000)	5.556 (27.4644)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 100.00	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	13.333 (27.6026)	6.250 (13.4371)	16.667 (23.5702)	10.101 (21.2211)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	4.444 (27.7936)	0.000 (17.8174)	16.667 (23.5702)	3.125 (22.9685)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	0.00, 33.33	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	9.804 (25.7248)	7.843 (18.7432)	0.000 (0.0000)	8.333 (21.6392)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	0.000 (26.3523)	2.083 (22.6691)	0.000 (0.0000)	0.952 (23.5504)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 66.67	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	5.556 (12.9750)	8.889 (26.6270)	16.667 (23.5702)	8.046 (21.1854)
Median	0.000	0.000	16.667	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	12	14	2	28
Mean (SD)	-2.778 (22.2853)	2.381 (8.9087)	16.667 (23.5702)	1.190 (16.9292)
Median	0.000	0.000	16.667	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	0.00, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	16.667 (30.1511)	44.444 (50.9175)	44.444 (50.9175)	25.926 (37.1458)
Median	0.000	33.333	33.333	0.000
Q1, Q3	0.000, 33.333	0.000, 100.000	0.000, 100.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 100.00	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	8.333 (28.8675)	22.222 (19.2450)	22.222 (19.2450)	12.963 (25.9181)
Median	0.000	33.333	33.333	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 33.333	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 33.33	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Diarrhoea				
Baseline				
n	32	27	7	66
Mean (SD)	5.208 (19.1380)	11.111 (20.6725)	0.000 (0.0000)	7.071 (18.9603)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	2.299 (8.5960)	8.000 (22.1108)	9.524 (16.2650)	5.464 (16.3076)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	28	24	7	59
Mean (SD)	1.190 (11.0448)	-4.167 (17.8899)	9.524 (16.2650)	0.000 (15.1620)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-33.33, 33.33	-33.33, 33.33	0.00, 33.33	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	8.696 (18.0275)	6.944 (16.9659)	0.000 (0.0000)	7.333 (16.8897)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	22	23	3	48
Mean (SD)	6.061 (19.6163)	0.000 (14.2134)	0.000 (0.0000)	2.778 (16.6075)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-33.33, 33.33	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	8.696 (18.0275)	2.899 (9.6035)	0.000 (0.0000)	5.442 (14.1862)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	22	22	3	47
Mean (SD)	7.576 (20.3977)	-4.545 (15.5854)	0.000 (0.0000)	1.418 (18.3333)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	-66.67, 0.00	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	8.333 (23.8783)	6.667 (13.6797)	0.000 (0.0000)	6.977 (18.6277)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	19	19	3	41
Mean (SD)	8.772 (24.4498)	-1.754 (13.4884)	0.000 (0.0000)	3.252 (19.4435)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	-33.33, 33.33	0.00, 0.00	-33.33, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	6.667 (13.8013)	8.333 (19.2450)	0.000 (0.0000)	7.071 (16.1537)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	14	15	2	31
Mean (SD)	7.143 (14.1938)	-2.222 (29.4572)	0.000 (0.0000)	2.151 (22.6658)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-66.67, 66.67	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	7.843 (18.7432)	7.843 (14.5746)	0.000 (0.0000)	7.407 (16.1562)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	17	16	2	35
Mean (SD)	7.843 (18.7432)	-2.083 (22.6691)	0.000 (0.0000)	2.857 (20.4067)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	-66.67, 33.33	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	2.778 (9.6225)	2.222 (8.6066)	0.000 (0.0000)	2.299 (8.5960)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	0.00, 0.00	0.00, 33.33
Change from Baseline				
n	12	14	2	28
Mean (SD)	2.778 (9.6225)	-2.381 (8.9087)	0.000 (0.0000)	0.000 (9.0722)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 33.33	-33.33, 0.00	0.00, 0.00	-33.33, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	11.111 (21.7113)	0.000 (0.0000)	0.000 (0.0000)	7.407 (18.2773)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 16.667	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 0.00	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	11	3	3	17
Mean (SD)	9.091 (26.2082)	0.000 (0.0000)	0.000 (0.0000)	5.882 (21.1978)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-33.33, 66.67	0.00, 0.00	0.00, 0.00	-33.33, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Financial Difficulties				
Baseline				
n	33	27	7	67
Mean (SD)	25.253 (36.3531)	6.173 (16.1114)	14.286 (37.7964)	16.418 (30.9083)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 33.333
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 100.00	0.00, 100.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 3				
n	29	25	7	61
Mean (SD)	14.943 (24.5373)	9.333 (28.0872)	9.524 (16.2650)	12.022 (25.1166)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	29	24	7	60
Mean (SD)	-10.345 (25.3600)	4.167 (17.8899)	-4.762 (29.9912)	-3.889 (23.8417)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 66.67	-66.67, 33.33	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 6				
n	23	24	3	50
Mean (SD)	13.043 (26.0906)	8.333 (20.2640)	11.111 (19.2450)	10.667 (22.7776)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 33.33	0.00, 66.67
Change from Baseline				
n	23	23	3	49
Mean (SD)	-10.145 (30.8708)	1.449 (15.8218)	11.111 (19.2450)	-3.401 (24.7627)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 33.333	0.000, 0.000
Min, Max	-100.00, 33.33	-33.33, 33.33	0.00, 33.33	-100.00, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 9				
n	23	23	3	49
Mean (SD)	13.043 (21.8792)	2.899 (9.6035)	0.000 (0.0000)	7.483 (17.0312)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 33.33	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	23	22	3	48
Mean (SD)	-10.145 (23.4301)	-4.545 (11.7083)	0.000 (0.0000)	-6.944 (18.1383)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 12				
n	20	20	3	43
Mean (SD)	23.333 (34.3698)	5.000 (16.3120)	0.000 (0.0000)	13.178 (27.3518)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	20	19	3	42
Mean (SD)	1.667 (22.8778)	-3.509 (10.5101)	0.000 (0.0000)	-0.794 (17.2470)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 0.00	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 18				
n	15	16	2	33
Mean (SD)	22.222 (37.0899)	2.083 (8.3333)	0.000 (0.0000)	11.111 (27.2166)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 33.33	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	15	15	2	32
Mean (SD)	-4.444 (37.5154)	-2.222 (8.6066)	0.000 (0.0000)	-3.125 (25.9022)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 66.67	-33.33, 0.00	0.00, 0.00	-66.67, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 24				
n	17	17	2	36
Mean (SD)	13.725 (29.0087)	5.882 (17.6198)	0.000 (0.0000)	9.259 (23.3824)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 100.00	0.00, 66.67	0.00, 0.00	0.00, 100.00
Change from Baseline				
n	17	16	2	35
Mean (SD)	-11.765 (37.1580)	0.000 (12.1716)	0.000 (0.0000)	-5.714 (27.3989)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-33.333, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-100.00, 66.67	-33.33, 33.33	0.00, 0.00	-100.00, 66.67

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Cycle 30				
n	12	15	2	29
Mean (SD)	19.444 (26.4320)	4.444 (17.2133)	0.000 (0.0000)	10.345 (22.0091)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 33.333	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	0.00, 66.67	0.00, 66.67	0.00, 0.00	0.00, 66.67
Change from Baseline				
n	12	14	2	28
Mean (SD)	-8.333 (32.1769)	-2.381 (15.8210)	0.000 (0.0000)	-4.762 (23.5078)
Median	0.000	0.000	0.000	0.000
Q1, Q3	-16.667, 0.000	0.000, 0.000	0.000, 0.000	0.000, 0.000
Min, Max	-66.67, 33.33	-33.33, 33.33	0.00, 0.00	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Safety Follow-up				
n	12	3	3	18
Mean (SD)	27.778 (42.2435)	44.444 (50.9175)	22.222 (19.2450)	29.630 (39.4221)
Median	0.000	33.333	33.333	0.000
Q1, Q3	0.000, 66.667	0.000, 100.000	0.000, 33.333	0.000, 66.667
Min, Max	0.00, 100.00	0.00, 100.00	0.00, 33.33	0.00, 100.00
Change from Baseline				
n	12	3	3	18
Mean (SD)	2.778 (9.6225)	11.111 (19.2450)	-11.111 (50.9175)	1.852 (21.3046)
Median	0.000	0.000	0.000	0.000
Q1, Q3	0.000, 0.000	0.000, 33.333	-66.667, 33.333	0.000, 0.000
Min, Max	0.00, 33.33	0.00, 33.33	-66.67, 33.33	-66.67, 33.33

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 1				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 2				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 5				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 6				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Table 14.2.1.6.6:
Summary of EORTC QLQ-C30 by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
Scale/Visit	**Asia Pacific (N = 33)**	**Europe (N = 28)**	**North America (N = 7)**	**Total (N = 68)**
Survival Follow-up 7				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00
Change from Baseline				
n	0	1	0	1
Mean (SD)	- (-)	0.000 (-)	- (-)	0.000 (-)
Median	-	0.000	-	0.000
Q1, Q3	-, -	0.000, 0.000	-, -	0.000, 0.000
Min, Max	-, -	0.00, 0.00	-, -	0.00, 0.00

Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30; Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile; SD, standard deviation.

Only patients with data at both baseline and corresponding postbaseline visit are included in the summary statistics for change from baseline.

The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue,Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-eortc.sas 26AUG2022 02:02 t-14-02-01-06-06-eortc-sum-region.rtf

Figure 14.2.1.7.1:
EORTC QLQ-C30 Questionnaire - Global Health Status Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-01-meanot-qol-ghs.rtf

Figure 14.2.1.7.2:
EORTC QLQ-C30 Questionnaire - Cognitive Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-02-meanot-qol-cog.rtf

Figure 14.2.1.7.3:
EORTC QLQ-C30 Questionnaire - Emotional Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-03-meanot-qol-emo.rtf

Figure 14.2.1.7.4:
EORTC QLQ-C30 Questionnaire - Physical Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-04-meanot-qol-phy.rtf

Figure 14.2.1.7.5:
EORTC QLQ-C30 Questionnaire - Role Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-05-meanot-qol-rol.rtf

Figure 14.2.1.7.6:
EORTC QLQ-C30 Questionnaire - Social Functioning Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-06-meanot-qol-soc.rtf

Figure 14.2.1.7.7:
EORTC QLQ-C30 Questionnaire - Appetite Loss Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-07-meanot-qol-app.rtf

Figure 14.2.1.7.8:
EORTC QLQ-C30 Questionnaire - Constipation Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-08-meanot-qol-con.rtf

Figure 14.2.1.7.9:
EORTC QLQ-C30 Questionnaire - Diarrhoea Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-09-meanot-qol-dia.rtf

Figure 14.2.1.7.10:
EORTC QLQ-C30 Questionnaire - Dyspnoea Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-10-meanot-qol-dys.rtf

Figure 14.2.1.7.11:
EORTC QLQ-C30 Questionnaire - Fatigue Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-11-meanot-qol-fat.rtf

Figure 14.2.1.7.12:
EORTC QLQ-C30 Questionnaire - Financial Difficulties Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-12-meanot-qol-fin.rtf

Figure 14.2.1.7.13:
EORTC QLQ-C30 Questionnaire - Nausea and Vomiting Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-13-meanot-qol-nau.rtf

Figure 14.2.1.7.14:
EORTC QLQ-C30 Questionnaire - Pain Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-14-meanot-qol-pai.rtf

Figure 14.2.1.7.15:
EORTC QLQ-C30 Questionnaire - Insomnia Mean Over Time: Change from Baseline
Safety Analysis Set



Source: ADSL,ADQS. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Only patients with data at both baseline and corresponding post-baseline visit are included in the summary statistics for change from baseline.
The bars represent the 95% confidence interval for the mean.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/f-meanot-qol.sas 26AUG2022 02:09 f-14-02-01-07-15-meanot-qol-ins.rtf

Table 14.3.1.2.1.1:
Overall Summary of Treatment-Emergent Adverse Events by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
	Male (N = 36) n (%)	**Female (N = 32) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	36 (100.0)	32 (100.0)	68 (100.0)
Grade 3 or Higher	25 (69.4)	8 (25.0)	33 (48.5)
Grade 2 or Lower	33 (91.7)	32 (100.0)	65 (95.6)
Serious	20 (55.6)	10 (31.3)	30 (44.1)
Leading to Death	5 (13.9)	0 (0.0)	5 (7.4)
Leading to Treatment Discontinuation	5 (13.9)	0 (0.0)	5 (7.4)
Leading to Dose Modification	18 (50.0)	7 (21.9)	25 (36.8)
Leading to Dose Interruption	18 (50.0)	7 (21.9)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-01-ae-sum-sex.rtf

Table 14.3.1.2.1.2:
Overall Summary of Treatment-Emergent Adverse Events by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
	< 65 years (N = 27) n (%)	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	27 (100.0)	41 (100.0)	49 (100.0)	19 (100.0)	68 (100.0)
Grade 3 or Higher	12 (44.4)	21 (51.2)	22 (44.9)	11 (57.9)	33 (48.5)
Grade 2 or Lower	27 (100.0)	38 (92.7)	49 (100.0)	16 (84.2)	65 (95.6)
Serious	11 (40.7)	19 (46.3)	20 (40.8)	10 (52.6)	30 (44.1)
Leading to Death	2 (7.4)	3 (7.3)	4 (8.2)	1 (5.3)	5 (7.4)
Leading to Treatment Discontinuation	2 (7.4)	3 (7.3)	4 (8.2)	1 (5.3)	5 (7.4)
Leading to Dose Modification	8 (29.6)	17 (41.5)	17 (34.7)	8 (42.1)	25 (36.8)
Leading to Dose Interruption	8 (29.6)	17 (41.5)	17 (34.7)	8 (42.1)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-02-ae-sum-age.rtf

Table 14.3.1.2.1.3:
Overall Summary of Treatment-Emergent Adverse Events by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
	0 (N = 39) n (%)	**≥ 1 (N = 29) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	39 (100.0)	29 (100.0)	68 (100.0)
Grade 3 or Higher	20 (51.3)	13 (44.8)	33 (48.5)
Grade 2 or Lower	36 (92.3)	29 (100.0)	65 (95.6)
Serious	17 (43.6)	13 (44.8)	30 (44.1)
Leading to Death	0 (0.0)	5 (17.2)	5 (7.4)
Leading to Treatment Discontinuation	1 (2.6)	4 (13.8)	5 (7.4)
Leading to Dose Modification	15 (38.5)	10 (34.5)	25 (36.8)
Leading to Dose Interruption	15 (38.5)	10 (34.5)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-03-ae-sum-ecog.rtf

Table 14.3.1.2.1.4:
Overall Summary of Treatment-Emergent Adverse Events by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
	< 3 (N = 49) n (%)	**≥ 3 (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	49 (100.0)	19 (100.0)	68 (100.0)
Grade 3 or Higher	24 (49.0)	9 (47.4)	33 (48.5)
Grade 2 or Lower	47 (95.9)	18 (94.7)	65 (95.6)
Serious	23 (46.9)	7 (36.8)	30 (44.1)
Leading to Death	3 (6.1)	2 (10.5)	5 (7.4)
Leading to Treatment Discontinuation	4 (8.2)	1 (5.3)	5 (7.4)
Leading to Dose Modification	19 (38.8)	6 (31.6)	25 (36.8)
Leading to Dose Interruption	19 (38.8)	6 (31.6)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-04-ae-sum-pst.rtf

Table 14.3.1.2.1.5:
Overall Summary of Treatment-Emergent Adverse Events by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
	MALT (N = 26) n (%)	**NMZL (N = 26) n (%)**	**SMZL (N = 12) n (%)**	**Unknown (N = 4) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	26 (100.0)	26 (100.0)	12 (100.0)	4 (100.0)	68 (100.0)
Grade 3 or Higher	9 (34.6)	14 (53.8)	7 (58.3)	3 (75.0)	33 (48.5)
Grade 2 or Lower	25 (96.2)	24 (92.3)	12 (100.0)	4 (100.0)	65 (95.6)
Serious	10 (38.5)	11 (42.3)	6 (50.0)	3 (75.0)	30 (44.1)
Leading to Death	1 (3.8)	3 (11.5)	0 (0.0)	1 (25.0)	5 (7.4)
Leading to Treatment Discontinuation	2 (7.7)	2 (7.7)	0 (0.0)	1 (25.0)	5 (7.4)
Leading to Dose Modification	8 (30.8)	10 (38.5)	7 (58.3)	0 (0.0)	25 (36.8)
Leading to Dose Interruption	8 (30.8)	10 (38.5)	7 (58.3)	0 (0.0)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-05-ae-sum-mzltype.rtf

Table 14.3.1.2.1.6:
Overall Summary of Treatment-Emergent Adverse Events by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
	Asia Pacific (N = 33) n (%)	**Europe (N = 28) n (%)**	**North America (N = 7) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE	33 (100.0)	28 (100.0)	7 (100.0)	68 (100.0)
Grade 3 or Higher	14 (42.4)	15 (53.6)	4 (57.1)	33 (48.5)
Grade 2 or Lower	32 (97.0)	27 (96.4)	6 (85.7)	65 (95.6)
Serious	15 (45.5)	12 (42.9)	3 (42.9)	30 (44.1)
Leading to Death	1 (3.0)	3 (10.7)	1 (14.3)	5 (7.4)
Leading to Treatment Discontinuation	2 (6.1)	2 (7.1)	1 (14.3)	5 (7.4)
Leading to Dose Modification	9 (27.3)	14 (50.0)	2 (28.6)	25 (36.8)
Leading to Dose Interruption	9 (27.3)	14 (50.0)	2 (28.6)	25 (36.8)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Source: ADSL,ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Notes: Adverse events were classified based on MedDRA Version 24.0.

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-ae-sum.sas 26AUG2022 02:01 t-14-03-01-02-01-06-ae-sum-region.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	31 (86.1)	23 (71.9)	54 (79.4)
Anemia	3 (8.3)	1 (3.1)	4 (5.9)
Anaemia	3 (8.3)	1 (3.1)	4 (5.9)
Atrial Fibrillation and Flutter	1 (2.8)	1 (3.1)	2 (2.9)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)
Hemorrhage	15 (41.7)	13 (40.6)	28 (41.2)
Petechiae/Purpura/Contusion	12 (33.3)	8 (25.0)	20 (29.4)
Contusion	11 (30.6)	5 (15.6)	16 (23.5)
Epistaxis	0 (0.0)	3 (9.4)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	1 (2.8)	2 (6.3)	3 (4.4)
Ecchymosis	2 (5.6)	0 (0.0)	2 (2.9)
Haematuria	1 (2.8)	1 (3.1)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.8)	1 (3.1)	2 (2.9)
Purpura	0 (0.0)	2 (6.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.8)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gingival bleeding	1 (2.8)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (3.1)	1 (1.5)
Haemorrhage urinary tract	1 (2.8)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (2.8)	0 (0.0)	1 (1.5)
Melaena	1 (2.8)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Procedural haemorrhage	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.8)	0 (0.0)	1 (1.5)
Major Hemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Hypertension	4 (11.1)	0 (0.0)	4 (5.9)
Hypertension	3 (8.3)	0 (0.0)	3 (4.4)
Prehypertension	1 (2.8)	0 (0.0)	1 (1.5)
Infections	22 (61.1)	16 (50.0)	38 (55.9)
Upper respiratory tract infection	6 (16.7)	3 (9.4)	9 (13.2)
COVID-19	4 (11.1)	2 (6.3)	6 (8.8)
COVID-19 pneumonia	3 (8.3)	2 (6.3)	5 (7.4)
Pneumonia	5 (13.9)	0 (0.0)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male (N = 36)** **n (%)**	**Female (N = 32)** **n (%)**	**Total (N = 68)** **n (%)**
Tonsillitis	3 (8.3)	1 (3.1)	4 (5.9)
Urinary tract infection	2 (5.6)	2 (6.3)	4 (5.9)
Lower respiratory tract infection	2 (5.6)	1 (3.1)	3 (4.4)
Oral herpes	1 (2.8)	2 (6.3)	3 (4.4)
Cellulitis	1 (2.8)	1 (3.1)	2 (2.9)
Gastroenteritis viral	1 (2.8)	1 (3.1)	2 (2.9)
Herpes zoster	1 (2.8)	1 (3.1)	2 (2.9)
Nasopharyngitis	1 (2.8)	1 (3.1)	2 (2.9)
Respiratory syncytial virus infection	1 (2.8)	1 (3.1)	2 (2.9)
Vulvovaginal candidiasis	0 (0.0)	2 (6.3)	2 (2.9)
Bacteraemia	1 (2.8)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Conjunctivitis	1 (2.8)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male (N = 36)** **n (%)**	**Female (N = 32)** **n (%)**	**Total (N = 68)** **n (%)**
Cystitis escherichia	0 (0.0)	1 (3.1)	1 (1.5)
Gastroenteritis	1 (2.8)	0 (0.0)	1 (1.5)
Gingivitis	1 (2.8)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	1 (3.1)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.8)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.8)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.1)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.1)	1 (1.5)
Oral infection	0 (0.0)	1 (3.1)	1 (1.5)
Orchitis	1 (2.8)	0 (0.0)	1 (1.5)
Otitis media	1 (2.8)	0 (0.0)	1 (1.5)
Parotitis	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male (N = 36)** **n (%)**	**Female (N = 32)** **n (%)**	**Total (N = 68)** **n (%)**
Pneumonia fungal	1 (2.8)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	1 (3.1)	1 (1.5)
Respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.1)	1 (1.5)
Septic encephalopathy	1 (2.8)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Skin infection	1 (2.8)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	1 (3.1)	1 (1.5)
Tinea versicolour	1 (2.8)	0 (0.0)	1 (1.5)
Tooth abscess	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Wound infection	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (5.6)	1 (3.1)	3 (4.4)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Neutropenia	7 (19.4)	4 (12.5)	11 (16.2)
Neutropenia	5 (13.9)	1 (3.1)	6 (8.8)
Neutrophil count decreased	2 (5.6)	3 (9.4)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	5 (13.9)	0 (0.0)	5 (7.4)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	1 (2.8)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.8)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.1:
TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	8 (22.2)	3 (9.4)	11 (16.2)
Thrombocytopenia	6 (16.7)	1 (3.1)	7 (10.3)
Platelet count decreased	2 (5.6)	2 (6.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-01-teae-si-eoipt-sex.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One TEAE of Special Interest	21 (77.8)	33 (80.5)	39 (79.6)	15 (78.9)	54 (79.4)
Anemia	3 (11.1)	1 (2.4)	4 (8.2)	0 (0.0)	4 (5.9)
Anaemia	3 (11.1)	1 (2.4)	4 (8.2)	0 (0.0)	4 (5.9)
Atrial Fibrillation and Flutter	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	7 (25.9)	21 (51.2)	19 (38.8)	9 (47.4)	28 (41.2)
Petechiae/Purpura/Contusion	4 (14.8)	16 (39.0)	11 (22.4)	9 (47.4)	20 (29.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Contusion	3 (11.1)	13 (31.7)	9 (18.4)	7 (36.8)	16 (23.5)
Epistaxis	0 (0.0)	3 (7.3)	3 (6.1)	0 (0.0)	3 (4.4)
Petechiae	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Ecchymosis	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Haematuria	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Diarrhoea haemorrhagic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Increased tendency to bruise	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Procedural haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Major Hemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	2 (7.4)	2 (4.9)	2 (4.1)	2 (10.5)	4 (5.9)
Hypertension	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Prehypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category Preferred Term	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Infections	14 (51.9)	24 (58.5)	27 (55.1)	11 (57.9)	38 (55.9)
Upper respiratory tract infection	4 (14.8)	5 (12.2)	7 (14.3)	2 (10.5)	9 (13.2)
COVID-19	3 (11.1)	3 (7.3)	5 (10.2)	1 (5.3)	6 (8.8)
COVID-19 pneumonia	2 (7.4)	3 (7.3)	4 (8.2)	1 (5.3)	5 (7.4)
Pneumonia	2 (7.4)	3 (7.3)	3 (6.1)	2 (10.5)	5 (7.4)
Tonsillitis	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Urinary tract infection	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Lower respiratory tract infection	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Oral herpes	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Cellulitis	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Herpes zoster	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Nasopharyngitis	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Respiratory syncytial virus infection	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis escherichia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Infected bite	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Oral candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Respiratory tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Rhinitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tinea cruris	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tooth abscess	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Wound infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	6 (22.2)	5 (12.2)	9 (18.4)	2 (10.5)	11 (16.2)
Neutropenia	4 (14.8)	2 (4.9)	5 (10.2)	1 (5.3)	6 (8.8)
Neutrophil count decreased	2 (7.4)	3 (7.3)	4 (8.2)	1 (5.3)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (7.4)	3 (7.3)	3 (6.1)	2 (10.5)	5 (7.4)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Acute myeloid leukaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Skin Cancers	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.2:
TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	5 (18.5)	6 (14.6)	9 (18.4)	2 (10.5)	11 (16.2)
Thrombocytopenia	3 (11.1)	4 (9.8)	5 (10.2)	2 (10.5)	7 (10.3)
Platelet count decreased	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-02-teae-si-eoipt-age.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	32 (82.1)	22 (75.9)	54 (79.4)
Anemia	0 (0.0)	4 (13.8)	4 (5.9)
Anaemia	0 (0.0)	4 (13.8)	4 (5.9)
Atrial Fibrillation and Flutter	2 (5.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	19 (48.7)	9 (31.0)	28 (41.2)
Petechiae/Purpura/Contusion	12 (30.8)	8 (27.6)	20 (29.4)
Contusion	10 (25.6)	6 (20.7)	16 (23.5)
Epistaxis	2 (5.1)	1 (3.4)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	3 (7.7)	0 (0.0)	3 (4.4)
Ecchymosis	1 (2.6)	1 (3.4)	2 (2.9)
Haematuria	2 (5.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.6)	1 (3.4)	2 (2.9)
Purpura	0 (0.0)	2 (6.9)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.6)	0 (0.0)	1 (1.5)
Haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (2.6)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (2.6)	0 (0.0)	1 (1.5)
Melaena	1 (2.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.4)	1 (1.5)
Procedural haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Major Hemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Hypertension	2 (5.1)	2 (6.9)	4 (5.9)
Hypertension	2 (5.1)	1 (3.4)	3 (4.4)
Prehypertension	0 (0.0)	1 (3.4)	1 (1.5)
Infections	21 (53.8)	17 (58.6)	38 (55.9)
Upper respiratory tract infection	3 (7.7)	6 (20.7)	9 (13.2)
COVID-19	4 (10.3)	2 (6.9)	6 (8.8)
COVID-19 pneumonia	2 (5.1)	3 (10.3)	5 (7.4)
Pneumonia	1 (2.6)	4 (13.8)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event.
Percentages are based on N for each ECOG group or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tonsillitis	1 (2.6)	3 (10.3)	4 (5.9)
Urinary tract infection	3 (7.7)	1 (3.4)	4 (5.9)
Lower respiratory tract infection	0 (0.0)	3 (10.3)	3 (4.4)
Oral herpes	2 (5.1)	1 (3.4)	3 (4.4)
Cellulitis	2 (5.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	2 (5.1)	0 (0.0)	2 (2.9)
Herpes zoster	1 (2.6)	1 (3.4)	2 (2.9)
Nasopharyngitis	2 (5.1)	0 (0.0)	2 (2.9)
Respiratory syncytial virus infection	1 (2.6)	1 (3.4)	2 (2.9)
Vulvovaginal candidiasis	1 (2.6)	1 (3.4)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.4)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Conjunctivitis	1 (2.6)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Cystitis escherichia	1 (2.6)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (2.6)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Infected bite	1 (2.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Lymph gland infection	1 (2.6)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.6)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.4)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.4)	1 (1.5)
Oral infection	0 (0.0)	1 (3.4)	1 (1.5)
Orchitis	1 (2.6)	0 (0.0)	1 (1.5)
Otitis media	1 (2.6)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pneumonia fungal	0 (0.0)	1 (3.4)	1 (1.5)
Pyelonephritis	1 (2.6)	0 (0.0)	1 (1.5)
Respiratory tract infection	1 (2.6)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.6)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.4)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Skin infection	1 (2.6)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.6)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.4)	1 (1.5)
Tooth abscess	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Wound infection	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (5.1)	1 (3.4)	3 (4.4)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.4)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Neutropenia	5 (12.8)	6 (20.7)	11 (16.2)
Neutropenia	3 (7.7)	3 (10.3)	6 (8.8)
Neutrophil count decreased	2 (5.1)	3 (10.3)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	3 (7.7)	2 (6.9)	5 (7.4)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.4)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.4)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.3:
TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	6 (15.4)	5 (17.2)	11 (16.2)
Thrombocytopenia	3 (7.7)	4 (13.8)	7 (10.3)
Platelet count decreased	3 (7.7)	1 (3.4)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-03-teae-si-eoipt-ecog.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	36 (73.5)	18 (94.7)	54 (79.4)
Anemia	2 (4.1)	2 (10.5)	4 (5.9)
Anaemia	2 (4.1)	2 (10.5)	4 (5.9)
Atrial Fibrillation and Flutter	1 (2.0)	1 (5.3)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	19 (38.8)	9 (47.4)	28 (41.2)
Petechiae/Purpura/Contusion	14 (28.6)	6 (31.6)	20 (29.4)
Contusion	11 (22.4)	5 (26.3)	16 (23.5)
Epistaxis	1 (2.0)	2 (10.5)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	2 (4.1)	1 (5.3)	3 (4.4)
Ecchymosis	1 (2.0)	1 (5.3)	2 (2.9)
Haematuria	1 (2.0)	1 (5.3)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	1 (2.0)	1 (5.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (5.3)	1 (1.5)
Increased tendency to bruise	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)
Procedural haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Major Hemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	3 (6.1)	1 (5.3)	4 (5.9)
Hypertension	2 (4.1)	1 (5.3)	3 (4.4)
Prehypertension	1 (2.0)	0 (0.0)	1 (1.5)
Infections	26 (53.1)	12 (63.2)	38 (55.9)
Upper respiratory tract infection	5 (10.2)	4 (21.1)	9 (13.2)
COVID-19	5 (10.2)	1 (5.3)	6 (8.8)
COVID-19 pneumonia	3 (6.1)	2 (10.5)	5 (7.4)
Pneumonia	3 (6.1)	2 (10.5)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event.
Percentages are based on N for each prior line of therapy group or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tonsillitis	3 (6.1)	1 (5.3)	4 (5.9)
Urinary tract infection	4 (8.2)	0 (0.0)	4 (5.9)
Lower respiratory tract infection	2 (4.1)	1 (5.3)	3 (4.4)
Oral herpes	2 (4.1)	1 (5.3)	3 (4.4)
Cellulitis	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.0)	1 (5.3)	2 (2.9)
Herpes zoster	1 (2.0)	1 (5.3)	2 (2.9)
Nasopharyngitis	1 (2.0)	1 (5.3)	2 (2.9)
Respiratory syncytial virus infection	2 (4.1)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (5.3)	1 (1.5)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Cystitis escherichia	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (5.3)	1 (1.5)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	1 (2.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pneumonia fungal	1 (2.0)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	1 (2.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (5.3)	1 (1.5)
Tooth abscess	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Wound infection	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (4.1)	1 (5.3)	3 (4.4)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Neutropenia	6 (12.2)	5 (26.3)	11 (16.2)
Neutropenia	3 (6.1)	3 (15.8)	6 (8.8)
Neutrophil count decreased	3 (6.1)	2 (10.5)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	3 (6.1)	2 (10.5)	5 (7.4)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (5.3)	1 (1.5)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.0)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.4:
TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	4 (8.2)	7 (36.8)	11 (16.2)
Thrombocytopenia	2 (4.1)	5 (26.3)	7 (10.3)
Platelet count decreased	2 (4.1)	2 (10.5)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-04-teae-si-eoipt-pst.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	19 (73.1)	21 (80.8)	11 (91.7)	3 (75.0)	54 (79.4)
Anemia	0 (0.0)	2 (7.7)	0 (0.0)	2 (50.0)	4 (5.9)
Anaemia	0 (0.0)	2 (7.7)	0 (0.0)	2 (50.0)	4 (5.9)
Atrial Fibrillation and Flutter	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	10 (38.5)	12 (46.2)	5 (41.7)	1 (25.0)	28 (41.2)
Petechiae/Purpura/Contusion	6 (23.1)	9 (34.6)	5 (41.7)	0 (0.0)	20 (29.4)
Contusion	5 (19.2)	7 (26.9)	4 (33.3)	0 (0.0)	16 (23.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Epistaxis	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
Petechiae	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)
Ecchymosis	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Haematuria	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gingival bleeding	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Haematoma	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Melaena	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Mouth haemorrhage	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Procedural haemorrhage	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Major Hemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Hypertension	2 (7.7)	1 (3.8)	1 (8.3)	0 (0.0)	4 (5.9)
Hypertension	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
Prehypertension	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Infections	13 (50.0)	15 (57.7)	8 (66.7)	2 (50.0)	38 (55.9)
Upper respiratory tract infection	1 (3.8)	5 (19.2)	2 (16.7)	1 (25.0)	9 (13.2)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
COVID-19	3 (11.5)	1 (3.8)	2 (16.7)	0 (0.0)	6 (8.8)
COVID-19 pneumonia	0 (0.0)	3 (11.5)	2 (16.7)	0 (0.0)	5 (7.4)
Pneumonia	0 (0.0)	3 (11.5)	1 (8.3)	1 (25.0)	5 (7.4)
Tonsillitis	1 (3.8)	1 (3.8)	2 (16.7)	0 (0.0)	4 (5.9)
Urinary tract infection	2 (7.7)	2 (7.7)	0 (0.0)	0 (0.0)	4 (5.9)
Lower respiratory tract infection	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
Oral herpes	0 (0.0)	1 (3.8)	2 (16.7)	0 (0.0)	3 (4.4)
Cellulitis	0 (0.0)	0 (0.0)	1 (8.3)	1 (25.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Herpes zoster	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Nasopharyngitis	1 (3.8)	0 (0.0)	1 (8.3)	0 (0.0)	2 (2.9)
Respiratory syncytial virus infection	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	1 (25.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Bacteraemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Oral candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Respiratory tract infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tinea versicolour	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Wound infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	5 (19.2)	3 (11.5)	2 (16.7)	1 (25.0)	11 (16.2)
Neutropenia	1 (3.8)	3 (11.5)	2 (16.7)	0 (0.0)	6 (8.8)
Neutrophil count decreased	4 (15.4)	0 (0.0)	0 (0.0)	1 (25.0)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (7.7)	3 (11.5)	0 (0.0)	0 (0.0)	5 (7.4)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.5:
TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	2 (7.7)	5 (19.2)	2 (16.7)	2 (50.0)	11 (16.2)
Thrombocytopenia	1 (3.8)	3 (11.5)	2 (16.7)	1 (25.0)	7 (10.3)
Platelet count decreased	1 (3.8)	2 (7.7)	0 (0.0)	1 (25.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-05-teae-si-eoipt-mzltype.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One TEAE of Special Interest	24 (72.7)	24 (85.7)	6 (85.7)	54 (79.4)
Anemia	2 (6.1)	1 (3.6)	1 (14.3)	4 (5.9)
Anaemia	2 (6.1)	1 (3.6)	1 (14.3)	4 (5.9)
Atrial Fibrillation and Flutter	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	14 (42.4)	12 (42.9)	2 (28.6)	28 (41.2)
Petechiae/Purpura/Contusion	10 (30.3)	8 (28.6)	2 (28.6)	20 (29.4)
Contusion	8 (24.2)	6 (21.4)	2 (28.6)	16 (23.5)
Epistaxis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Petechiae	2 (6.1)	1 (3.6)	0 (0.0)	3 (4.4)
Ecchymosis	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Haematuria	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Increased tendency to bruise	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Procedural haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pulmonary haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Major Hemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	1 (3.0)	3 (10.7)	0 (0.0)	4 (5.9)
Hypertension	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Prehypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infections	15 (45.5)	19 (67.9)	4 (57.1)	38 (55.9)
Upper respiratory tract infection	6 (18.2)	3 (10.7)	0 (0.0)	9 (13.2)
COVID-19	0 (0.0)	5 (17.9)	1 (14.3)	6 (8.8)
COVID-19 pneumonia	0 (0.0)	4 (14.3)	1 (14.3)	5 (7.4)
Pneumonia	2 (6.1)	2 (7.1)	1 (14.3)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Tonsillitis	1 (3.0)	3 (10.7)	0 (0.0)	4 (5.9)
Urinary tract infection	2 (6.1)	2 (7.1)	0 (0.0)	4 (5.9)
Lower respiratory tract infection	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Oral herpes	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Cellulitis	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Gastroenteritis viral	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Herpes zoster	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Nasopharyngitis	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Vulvovaginal candidiasis	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Cystitis escherichia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gastroenteritis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infected bite	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Onychomycosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Otitis media	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Parotitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Pneumonia fungal	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Pyelonephritis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory tract infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Skin infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Wound infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (3.0)	1 (3.6)	1 (14.3)	3 (4.4)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	6 (18.2)	5 (17.9)	0 (0.0)	11 (16.2)
Neutropenia	1 (3.0)	5 (17.9)	0 (0.0)	6 (8.8)
Neutrophil count decreased	5 (15.2)	0 (0.0)	0 (0.0)	5 (7.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (6.1)	3 (10.7)	0 (0.0)	5 (7.4)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Acute myeloid leukaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.1.6:
TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Thrombocytopenia	6 (18.2)	5 (17.9)	0 (0.0)	11 (16.2)
Thrombocytopenia	2 (6.1)	5 (17.9)	0 (0.0)	7 (10.3)
Platelet count decreased	4 (12.1)	0 (0.0)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-eoipt.sas 18NOV2022 01:09 t-14-03-01-02-07-01-06-teae-si-eoipt-region.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	26 (72.2)	22 (68.8)	48 (70.6)
Anemia	2 (5.6)	0 (0.0)	2 (2.9)
Anaemia	2 (5.6)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (3.1)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)
Hemorrhage	15 (41.7)	13 (40.6)	28 (41.2)
Petechiae/Purpura/Contusion	12 (33.3)	8 (25.0)	20 (29.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	11 (30.6)	5 (15.6)	16 (23.5)
Epistaxis	0 (0.0)	3 (9.4)	3 (4.4)
Petechiae	1 (2.8)	2 (6.3)	3 (4.4)
Ecchymosis	2 (5.6)	0 (0.0)	2 (2.9)
Haematuria	1 (2.8)	1 (3.1)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.8)	1 (3.1)	2 (2.9)
Purpura	0 (0.0)	2 (6.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.8)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.8)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (3.1)	1 (1.5)
Haemorrhage urinary tract	1 (2.8)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (2.8)	0 (0.0)	1 (1.5)
Melaena	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Mouth haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Procedural haemorrhage	1 (2.8)	0 (0.0)	1 (1.5)
Pulmonary haematoma	1 (2.8)	0 (0.0)	1 (1.5)
Hypertension	3 (8.3)	0 (0.0)	3 (4.4)
Hypertension	2 (5.6)	0 (0.0)	2 (2.9)
Prehypertension	1 (2.8)	0 (0.0)	1 (1.5)
Infections	18 (50.0)	16 (50.0)	34 (50.0)
Upper respiratory tract infection	6 (16.7)	3 (9.4)	9 (13.2)
COVID-19	4 (11.1)	2 (6.3)	6 (8.8)
Tonsillitis	3 (8.3)	1 (3.1)	4 (5.9)
Urinary tract infection	2 (5.6)	2 (6.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral herpes	1 (2.8)	2 (6.3)	3 (4.4)
Cellulitis	1 (2.8)	1 (3.1)	2 (2.9)
Gastroenteritis viral	1 (2.8)	1 (3.1)	2 (2.9)
Herpes zoster	1 (2.8)	1 (3.1)	2 (2.9)
Lower respiratory tract infection	1 (2.8)	1 (3.1)	2 (2.9)
Nasopharyngitis	1 (2.8)	1 (3.1)	2 (2.9)
Pneumonia	2 (5.6)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	0 (0.0)	2 (6.3)	2 (2.9)
Bacteraemia	1 (2.8)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.1)	1 (1.5)
Conjunctivitis	1 (2.8)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.1)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Gastroenteritis	1 (2.8)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	1 (3.1)	1 (1.5)
Lymph gland infection	1 (2.8)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.8)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.1)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.1)	1 (1.5)
Oral infection	0 (0.0)	1 (3.1)	1 (1.5)
Orchitis	1 (2.8)	0 (0.0)	1 (1.5)
Otitis media	1 (2.8)	0 (0.0)	1 (1.5)
Parotitis	1 (2.8)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.1)	1 (1.5)
Respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin infection	1 (2.8)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	1 (3.1)	1 (1.5)
Tinea versicolour	1 (2.8)	0 (0.0)	1 (1.5)
Tooth abscess	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Wound infection	1 (2.8)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (3.1)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Neutropenia	0 (0.0)	4 (12.5)	4 (5.9)
Neutrophil count decreased	0 (0.0)	3 (9.4)	3 (4.4)
Neutropenia	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.1:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.6)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.6)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.8)	0 (0.0)	1 (1.5)
Thrombocytopenia	6 (16.7)	3 (9.4)	9 (13.2)
Thrombocytopenia	4 (11.1)	1 (3.1)	5 (7.4)
Platelet count decreased	2 (5.6)	2 (6.3)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-01-teae-si-grd2-eoipt-sex.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	19 (70.4)	29 (70.7)	36 (73.5)	12 (63.2)	48 (70.6)
Anemia	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Anaemia	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hemorrhage	7 (25.9)	21 (51.2)	19 (38.8)	9 (47.4)	28 (41.2)
Petechiae/Purpura/Contusion	4 (14.8)	16 (39.0)	11 (22.4)	9 (47.4)	20 (29.4)
Contusion	3 (11.1)	13 (31.7)	9 (18.4)	7 (36.8)	16 (23.5)
Epistaxis	0 (0.0)	3 (7.3)	3 (6.1)	0 (0.0)	3 (4.4)
Petechiae	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Ecchymosis	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Haematuria	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	0 (0.0)	2 (4.9)	0 (0.0)	2 (10.5)	2 (2.9)
Diarrhoea haemorrhagic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Gingival bleeding	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Procedural haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category Preferred Term	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hypertension	1 (3.7)	2 (4.9)	1 (2.0)	2 (10.5)	3 (4.4)
Hypertension	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Prehypertension	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Infections	14 (51.9)	20 (48.8)	26 (53.1)	8 (42.1)	34 (50.0)
Upper respiratory tract infection	4 (14.8)	5 (12.2)	7 (14.3)	2 (10.5)	9 (13.2)
COVID-19	3 (11.1)	3 (7.3)	5 (10.2)	1 (5.3)	6 (8.8)
Tonsillitis	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Urinary tract infection	2 (7.4)	2 (4.9)	3 (6.1)	1 (5.3)	4 (5.9)
Oral herpes	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Cellulitis	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Herpes zoster	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Lower respiratory tract infection	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Nasopharyngitis	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Pneumonia	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Vulvovaginal candidiasis	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Cystitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Cystitis escherichia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Oral candidiasis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Rhinitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tinea cruris	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tooth abscess	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Wound infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category Preferred Term	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Opportunistic Infections	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	1 (3.7)	3 (7.3)	3 (6.1)	1 (5.3)	4 (5.9)
Neutrophil count decreased	1 (3.7)	2 (4.9)	3 (6.1)	0 (0.0)	3 (4.4)
Neutropenia	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Second Primary Malignancies	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.2:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Skin Cancers	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	0 (0.0)	2 (4.9)	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Thrombocytopenia	3 (11.1)	6 (14.6)	7 (14.3)	2 (10.5)	9 (13.2)
Thrombocytopenia	1 (3.7)	4 (9.8)	3 (6.1)	2 (10.5)	5 (7.4)
Platelet count decreased	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-02-teae-si-grd2-eoipt-age.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	29 (74.4)	19 (65.5)	48 (70.6)
Anemia	0 (0.0)	2 (6.9)	2 (2.9)
Anaemia	0 (0.0)	2 (6.9)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	19 (48.7)	9 (31.0)	28 (41.2)
Petechiae/Purpura/Contusion	12 (30.8)	8 (27.6)	20 (29.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	10 (25.6)	6 (20.7)	16 (23.5)
Epistaxis	2 (5.1)	1 (3.4)	3 (4.4)
Petechiae	3 (7.7)	0 (0.0)	3 (4.4)
Ecchymosis	1 (2.6)	1 (3.4)	2 (2.9)
Haematuria	2 (5.1)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.6)	1 (3.4)	2 (2.9)
Purpura	0 (0.0)	2 (6.9)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.6)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.6)	0 (0.0)	1 (1.5)
Haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (2.6)	0 (0.0)	1 (1.5)
Increased tendency to bruise	1 (2.6)	0 (0.0)	1 (1.5)
Melaena	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Mouth haemorrhage	0 (0.0)	1 (3.4)	1 (1.5)
Procedural haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Pulmonary haematoma	1 (2.6)	0 (0.0)	1 (1.5)
Hypertension	1 (2.6)	2 (6.9)	3 (4.4)
Hypertension	1 (2.6)	1 (3.4)	2 (2.9)
Prehypertension	0 (0.0)	1 (3.4)	1 (1.5)
Infections	20 (51.3)	14 (48.3)	34 (50.0)
Upper respiratory tract infection	3 (7.7)	6 (20.7)	9 (13.2)
COVID-19	4 (10.3)	2 (6.9)	6 (8.8)
Tonsillitis	1 (2.6)	3 (10.3)	4 (5.9)
Urinary tract infection	3 (7.7)	1 (3.4)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral herpes	2 (5.1)	1 (3.4)	3 (4.4)
Cellulitis	2 (5.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	2 (5.1)	0 (0.0)	2 (2.9)
Herpes zoster	1 (2.6)	1 (3.4)	2 (2.9)
Lower respiratory tract infection	0 (0.0)	2 (6.9)	2 (2.9)
Nasopharyngitis	2 (5.1)	0 (0.0)	2 (2.9)
Pneumonia	0 (0.0)	2 (6.9)	2 (2.9)
Vulvovaginal candidiasis	1 (2.6)	1 (3.4)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.4)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.4)	1 (1.5)
Conjunctivitis	1 (2.6)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.4)	1 (1.5)
Cystitis escherichia	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Gastroenteritis	1 (2.6)	0 (0.0)	1 (1.5)
Infected bite	1 (2.6)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.6)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.6)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.4)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.4)	1 (1.5)
Oral infection	0 (0.0)	1 (3.4)	1 (1.5)
Orchitis	1 (2.6)	0 (0.0)	1 (1.5)
Otitis media	1 (2.6)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.4)	1 (1.5)
Respiratory syncytial virus infection	1 (2.6)	0 (0.0)	1 (1.5)
Respiratory tract infection	1 (2.6)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin infection	1 (2.6)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.6)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.4)	1 (1.5)
Tooth abscess	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Wound infection	1 (2.6)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Neutropenia	1 (2.6)	3 (10.3)	4 (5.9)
Neutrophil count decreased	1 (2.6)	2 (6.9)	3 (4.4)
Neutropenia	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.3:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)
Skin Cancers	2 (5.1)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (5.1)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	6 (15.4)	3 (10.3)	9 (13.2)
Thrombocytopenia	3 (7.7)	2 (6.9)	5 (7.4)
Platelet count decreased	3 (7.7)	1 (3.4)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-03-teae-si-grd2-eoipt-ecog.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	31 (63.3)	17 (89.5)	48 (70.6)
Anemia	1 (2.0)	1 (5.3)	2 (2.9)
Anaemia	1 (2.0)	1 (5.3)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	19 (38.8)	9 (47.4)	28 (41.2)
Petechiae/Purpura/Contusion	14 (28.6)	6 (31.6)	20 (29.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	11 (22.4)	5 (26.3)	16 (23.5)
Epistaxis	1 (2.0)	2 (10.5)	3 (4.4)
Petechiae	2 (4.1)	1 (5.3)	3 (4.4)
Ecchymosis	1 (2.0)	1 (5.3)	2 (2.9)
Haematuria	1 (2.0)	1 (5.3)	2 (2.9)
Haemorrhoidal haemorrhage	1 (2.0)	1 (5.3)	2 (2.9)
Purpura	1 (2.0)	1 (5.3)	2 (2.9)
Diarrhoea haemorrhagic	1 (2.0)	0 (0.0)	1 (1.5)
Gingival bleeding	1 (2.0)	0 (0.0)	1 (1.5)
Haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	0 (0.0)	1 (5.3)	1 (1.5)
Increased tendency to bruise	1 (2.0)	0 (0.0)	1 (1.5)
Melaena	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Mouth haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)
Procedural haemorrhage	0 (0.0)	1 (5.3)	1 (1.5)
Pulmonary haematoma	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	3 (6.1)	0 (0.0)	3 (4.4)
Hypertension	2 (4.1)	0 (0.0)	2 (2.9)
Prehypertension	1 (2.0)	0 (0.0)	1 (1.5)
Infections	22 (44.9)	12 (63.2)	34 (50.0)
Upper respiratory tract infection	5 (10.2)	4 (21.1)	9 (13.2)
COVID-19	5 (10.2)	1 (5.3)	6 (8.8)
Tonsillitis	3 (6.1)	1 (5.3)	4 (5.9)
Urinary tract infection	4 (8.2)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral herpes	2 (4.1)	1 (5.3)	3 (4.4)
Cellulitis	2 (4.1)	0 (0.0)	2 (2.9)
Gastroenteritis viral	1 (2.0)	1 (5.3)	2 (2.9)
Herpes zoster	1 (2.0)	1 (5.3)	2 (2.9)
Lower respiratory tract infection	1 (2.0)	1 (5.3)	2 (2.9)
Nasopharyngitis	1 (2.0)	1 (5.3)	2 (2.9)
Pneumonia	2 (4.1)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	2 (4.1)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (5.3)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (5.3)	1 (1.5)
Conjunctivitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis	1 (2.0)	0 (0.0)	1 (1.5)
Cystitis escherichia	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Gastroenteritis	1 (2.0)	0 (0.0)	1 (1.5)
Infected bite	1 (2.0)	0 (0.0)	1 (1.5)
Lymph gland infection	1 (2.0)	0 (0.0)	1 (1.5)
Nasal herpes	1 (2.0)	0 (0.0)	1 (1.5)
Onychomycosis	1 (2.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (2.0)	0 (0.0)	1 (1.5)
Oral infection	1 (2.0)	0 (0.0)	1 (1.5)
Orchitis	1 (2.0)	0 (0.0)	1 (1.5)
Otitis media	1 (2.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (5.3)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Rhinitis	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin infection	1 (2.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (2.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (5.3)	1 (1.5)
Tooth abscess	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Wound infection	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Neutropenia	3 (6.1)	1 (5.3)	4 (5.9)
Neutrophil count decreased	3 (6.1)	0 (0.0)	3 (4.4)
Neutropenia	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.4:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)
Skin Cancers	1 (2.0)	1 (5.3)	2 (2.9)
Basal cell carcinoma	1 (2.0)	1 (5.3)	2 (2.9)
Squamous cell carcinoma of skin	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	4 (8.2)	5 (26.3)	9 (13.2)
Thrombocytopenia	2 (4.1)	3 (15.8)	5 (7.4)
Platelet count decreased	2 (4.1)	2 (10.5)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-04-teae-si-grd2-eoipt-pst.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	16 (61.5)	18 (69.2)	11 (91.7)	3 (75.0)	48 (70.6)
Anemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	2 (2.9)
Anaemia	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	10 (38.5)	12 (46.2)	5 (41.7)	1 (25.0)	28 (41.2)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Petechiae/Purpura/Contusion	6 (23.1)	9 (34.6)	5 (41.7)	0 (0.0)	20 (29.4)
Contusion	5 (19.2)	7 (26.9)	4 (33.3)	0 (0.0)	16 (23.5)
Epistaxis	2 (7.7)	1 (3.8)	0 (0.0)	0 (0.0)	3 (4.4)
Petechiae	1 (3.8)	1 (3.8)	1 (8.3)	0 (0.0)	3 (4.4)
Ecchymosis	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Haematuria	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)
Haemorrhoidal haemorrhage	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Haematoma	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Increased tendency to bruise	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Melaena	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Mouth haemorrhage	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Procedural haemorrhage	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pulmonary haematoma	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Hypertension	2 (7.7)	0 (0.0)	1 (8.3)	0 (0.0)	3 (4.4)
Hypertension	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Prehypertension	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Infections	11 (42.3)	13 (50.0)	8 (66.7)	2 (50.0)	34 (50.0)
Upper respiratory tract infection	1 (3.8)	5 (19.2)	2 (16.7)	1 (25.0)	9 (13.2)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
COVID-19	3 (11.5)	1 (3.8)	2 (16.7)	0 (0.0)	6 (8.8)
Tonsillitis	1 (3.8)	1 (3.8)	2 (16.7)	0 (0.0)	4 (5.9)
Urinary tract infection	2 (7.7)	2 (7.7)	0 (0.0)	0 (0.0)	4 (5.9)
Oral herpes	0 (0.0)	1 (3.8)	2 (16.7)	0 (0.0)	3 (4.4)
Cellulitis	0 (0.0)	0 (0.0)	1 (8.3)	1 (25.0)	2 (2.9)
Gastroenteritis viral	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Herpes zoster	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Lower respiratory tract infection	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Nasopharyngitis	1 (3.8)	0 (0.0)	1 (8.3)	0 (0.0)	2 (2.9)
Pneumonia	0 (0.0)	1 (3.8)	1 (8.3)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	1 (25.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
COVID-19 pneumonia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Conjunctivitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Gastroenteritis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Infected bite	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Onychomycosis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Otitis media	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Parotitis	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory tract infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Skin infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Wound infection	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Opportunistic Infections	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	3 (11.5)	0 (0.0)	1 (8.3)	0 (0.0)	4 (5.9)
Neutrophil count decreased	3 (11.5)	0 (0.0)	0 (0.0)	0 (0.0)	3 (4.4)
Neutropenia	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Second Primary Malignancies	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.5:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Skin Cancers	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	2 (7.7)	3 (11.5)	2 (16.7)	2 (50.0)	9 (13.2)
Thrombocytopenia	1 (3.8)	1 (3.8)	2 (16.7)	1 (25.0)	5 (7.4)
Platelet count decreased	1 (3.8)	2 (7.7)	0 (0.0)	1 (25.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.
Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.
Percentages are based on N for each MZL subtype or total.
TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).
Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.
Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.
AE terms with n=0 are not shown in the table.
/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-05-teae-si-grd2-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 2 or Lower TEAE of Special Interest	22 (66.7)	23 (82.1)	3 (42.9)	48 (70.6)
Anemia	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Anaemia	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	14 (42.4)	12 (42.9)	2 (28.6)	28 (41.2)
Petechiae/Purpura/Contusion	10 (30.3)	8 (28.6)	2 (28.6)	20 (29.4)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Contusion	8 (24.2)	6 (21.4)	2 (28.6)	16 (23.5)
Epistaxis	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Petechiae	2 (6.1)	1 (3.6)	0 (0.0)	3 (4.4)
Ecchymosis	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Haematuria	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Haemorrhoidal haemorrhage	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Purpura	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Diarrhoea haemorrhagic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Gingival bleeding	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Haemorrhage urinary tract	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Increased tendency to bruise	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Melaena	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Mouth haemorrhage	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Procedural haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Pulmonary haematoma	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	0 (0.0)	3 (10.7)	0 (0.0)	3 (4.4)
Hypertension	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Prehypertension	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infections	15 (45.5)	17 (60.7)	2 (28.6)	34 (50.0)
Upper respiratory tract infection	6 (18.2)	3 (10.7)	0 (0.0)	9 (13.2)
COVID-19	0 (0.0)	5 (17.9)	1 (14.3)	6 (8.8)
Tonsillitis	1 (3.0)	3 (10.7)	0 (0.0)	4 (5.9)
Urinary tract infection	2 (6.1)	2 (7.1)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Oral herpes	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Cellulitis	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Gastroenteritis viral	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Herpes zoster	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Lower respiratory tract infection	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Nasopharyngitis	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Pneumonia	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Vulvovaginal candidiasis	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Bacteraemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
COVID-19 pneumonia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Conjunctivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Cystitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cystitis escherichia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Gastroenteritis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Infected bite	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Lymph gland infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Nasal herpes	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Onychomycosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral candidiasis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Oral infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Orchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Otitis media	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Parotitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Respiratory tract infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Rhinitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Skin infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea cruris	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tinea versicolour	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tooth abscess	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Wound infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	3 (9.1)	1 (3.6)	0 (0.0)	4 (5.9)
Neutrophil count decreased	3 (9.1)	0 (0.0)	0 (0.0)	3 (4.4)
Neutropenia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.6:
TEAE of Special Interest of Grade 2 or Lower by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Skin Cancers	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Basal cell carcinoma	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Squamous cell carcinoma of skin	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	6 (18.2)	3 (10.7)	0 (0.0)	9 (13.2)
Thrombocytopenia	2 (6.1)	3 (10.7)	0 (0.0)	5 (7.4)
Platelet count decreased	4 (12.1)	0 (0.0)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd2-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-06-teae-si-grd2-eoipt-region.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	18 (50.0)	5 (15.6)	23 (33.8)
Anemia	1 (2.8)	1 (3.1)	2 (2.9)
Anaemia	1 (2.8)	1 (3.1)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.8)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Hemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Hypertension	2 (5.6)	0 (0.0)	2 (2.9)
Hypertension	2 (5.6)	0 (0.0)	2 (2.9)
Infections	12 (33.3)	3 (9.4)	15 (22.1)
COVID-19 pneumonia	3 (8.3)	1 (3.1)	4 (5.9)
Pneumonia	3 (8.3)	0 (0.0)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Cellulitis	0 (0.0)	1 (3.1)	1 (1.5)
Gingivitis	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.8)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	1 (3.1)	1 (1.5)
Respiratory syncytial virus infection	1 (2.8)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (2.8)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Tonsillitis	1 (2.8)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (5.6)	0 (0.0)	2 (2.9)
Herpes ophthalmic	1 (2.8)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.8)	0 (0.0)	1 (1.5)
Neutropenia	7 (19.4)	1 (3.1)	8 (11.8)
Neutropenia	5 (13.9)	1 (3.1)	6 (8.8)
Neutrophil count decreased	2 (5.6)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.7:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	3 (8.3)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	1 (2.8)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.8)	0 (0.0)	1 (1.5)
Thrombocytopenia	3 (8.3)	0 (0.0)	3 (4.4)
Thrombocytopenia	2 (5.6)	0 (0.0)	2 (2.9)
Platelet count decreased	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-07-teae-si-grd3-eoipt-sex.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	11 (40.7)	12 (29.3)	17 (34.7)	6 (31.6)	23 (33.8)
Anemia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Anaemia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Major Hemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Hypertension	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Infections	7 (25.9)	8 (19.5)	11 (22.4)	4 (21.1)	15 (22.1)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
COVID-19 pneumonia	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)
Pneumonia	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Septic encephalopathy	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Upper respiratory tract infection	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.7)	1 (2.4)	2 (4.1)	0 (0.0)	2 (2.9)
Herpes ophthalmic	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Neutropenia	5 (18.5)	3 (7.3)	6 (12.2)	2 (10.5)	8 (11.8)
Neutropenia	4 (14.8)	2 (4.9)	5 (10.2)	1 (5.3)	6 (8.8)
Neutrophil count decreased	1 (3.7)	1 (2.4)	1 (2.0)	1 (5.3)	2 (2.9)
Second Primary Malignancies	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.8:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Thrombocytopenia	2 (7.4)	1 (2.4)	3 (6.1)	0 (0.0)	3 (4.4)
Thrombocytopenia	2 (7.4)	0 (0.0)	2 (4.1)	0 (0.0)	2 (2.9)
Platelet count decreased	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-08-teae-si-grd3-eoipt-age.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	11 (28.2)	12 (41.4)	23 (33.8)
Anemia	0 (0.0)	2 (6.9)	2 (2.9)
Anaemia	0 (0.0)	2 (6.9)	2 (2.9)
Atrial Fibrillation and Flutter	1 (2.6)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Hypertension	1 (2.6)	1 (3.4)	2 (2.9)
Hypertension	1 (2.6)	1 (3.4)	2 (2.9)
Infections	6 (15.4)	9 (31.0)	15 (22.1)
COVID-19 pneumonia	2 (5.1)	2 (6.9)	4 (5.9)
Pneumonia	1 (2.6)	2 (6.9)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Cellulitis	1 (2.6)	0 (0.0)	1 (1.5)
Gingivitis	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.4)	1 (1.5)
Pyelonephritis	1 (2.6)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.4)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.4)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.4)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	1 (2.6)	1 (3.4)	2 (2.9)
Herpes ophthalmic	1 (2.6)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.4)	1 (1.5)
Neutropenia	4 (10.3)	4 (13.8)	8 (11.8)
Neutropenia	3 (7.7)	3 (10.3)	6 (8.8)
Neutrophil count decreased	1 (2.6)	1 (3.4)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.9:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	1 (2.6)	2 (6.9)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.4)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.4)	1 (1.5)
Thrombocytopenia	0 (0.0)	3 (10.3)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (6.9)	2 (2.9)
Platelet count decreased	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-09-teae-si-grd3-eoipt-ecog.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	16 (32.7)	7 (36.8)	23 (33.8)
Anemia	1 (2.0)	1 (5.3)	2 (2.9)
Anaemia	1 (2.0)	1 (5.3)	2 (2.9)
Atrial Fibrillation and Flutter	0 (0.0)	1 (5.3)	1 (1.5)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Hemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Hypertension	1 (2.0)	1 (5.3)	2 (2.9)
Hypertension	1 (2.0)	1 (5.3)	2 (2.9)
Infections	11 (22.4)	4 (21.1)	15 (22.1)
COVID-19 pneumonia	3 (6.1)	1 (5.3)	4 (5.9)
Pneumonia	1 (2.0)	2 (10.5)	3 (4.4)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	1 (2.0)	0 (0.0)	1 (1.5)
Gingivitis	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.0)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	1 (2.0)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	2 (4.1)	0 (0.0)	2 (2.9)
Herpes ophthalmic	1 (2.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	1 (2.0)	0 (0.0)	1 (1.5)
Neutropenia	3 (6.1)	5 (26.3)	8 (11.8)
Neutropenia	3 (6.1)	3 (15.8)	6 (8.8)
Neutrophil count decreased	0 (0.0)	2 (10.5)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.10:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (5.3)	1 (1.5)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (2.0)	2 (10.5)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (10.5)	2 (2.9)
Platelet count decreased	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-10-teae-si-grd3-eoipt-pst.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	5 (19.2)	10 (38.5)	5 (41.7)	3 (75.0)	23 (33.8)
Anemia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Anaemia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Major Hemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Hypertension	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Hypertension	1 (3.8)	1 (3.8)	0 (0.0)	0 (0.0)	2 (2.9)
Infections	3 (11.5)	7 (26.9)	3 (25.0)	2 (50.0)	15 (22.1)
COVID-19 pneumonia	0 (0.0)	3 (11.5)	1 (8.3)	0 (0.0)	4 (5.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Pneumonia	0 (0.0)	2 (7.7)	0 (0.0)	1 (25.0)	3 (4.4)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gingivitis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Tonsillitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Herpes ophthalmic	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Neutropenia	2 (7.7)	3 (11.5)	2 (16.7)	1 (25.0)	8 (11.8)
Neutropenia	1 (3.8)	3 (11.5)	2 (16.7)	0 (0.0)	6 (8.8)
Neutrophil count decreased	1 (3.8)	0 (0.0)	0 (0.0)	1 (25.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.11:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Second Primary Malignancies	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	0 (0.0)	2 (7.7)	0 (0.0)	1 (25.0)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	2 (2.9)
Platelet count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-11-teae-si-grd3-eoipt-mzltype.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Grade 3 or Higher TEAE of Special Interest	7 (21.2)	12 (42.9)	4 (57.1)	23 (33.8)
Anemia	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Anaemia	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Atrial Fibrillation and Flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hypertension	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Hypertension	1 (3.0)	1 (3.6)	0 (0.0)	2 (2.9)
Infections	3 (9.1)	9 (32.1)	3 (42.9)	15 (22.1)
COVID-19 pneumonia	0 (0.0)	3 (10.7)	1 (14.3)	4 (5.9)
Pneumonia	1 (3.0)	1 (3.6)	1 (14.3)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cellulitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gingivitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Pyelonephritis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Upper respiratory tract infection	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Opportunistic Infections	0 (0.0)	1 (3.6)	1 (14.3)	2 (2.9)
Herpes ophthalmic	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Pneumonia fungal	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Neutropenia	3 (9.1)	5 (17.9)	0 (0.0)	8 (11.8)
Neutropenia	1 (3.0)	5 (17.9)	0 (0.0)	6 (8.8)
Neutrophil count decreased	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.3.12:
TEAE of Special Interest of Grade 3 or Higher by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	0 (0.0)	3 (10.7)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (3.0)	2 (7.1)	0 (0.0)	3 (4.4)
Thrombocytopenia	0 (0.0)	2 (7.1)	0 (0.0)	2 (2.9)
Platelet count decreased	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Adverse event grades are evaluated based on NCI-CTCAE Version 4.03.

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si-grd3-eoipt.sas 18NOV2022 01:08 t-14-03-01-02-07-03-12-teae-si-grd3-eoipt-region.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	13 (36.1)	5 (15.6)	18 (26.5)
Anemia	1 (2.8)	0 (0.0)	1 (1.5)
Anaemia	1 (2.8)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	1 (2.8)	1 (3.1)	2 (2.9)
Atrial fibrillation	1 (2.8)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (3.1)	1 (1.5)
Hemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category Preferred Term	**Male (N = 36) n (%)**	**Female (N = 32) n (%)**	**Total (N = 68) n (%)**
Major Hemorrhage	0 (0.0)	1 (3.1)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	10 (27.8)	4 (12.5)	14 (20.6)
COVID-19 pneumonia	3 (8.3)	1 (3.1)	4 (5.9)
Pneumonia	3 (8.3)	0 (0.0)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.1)	1 (1.5)
Cellulitis	0 (0.0)	1 (3.1)	1 (1.5)
Influenza	1 (2.8)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	1 (3.1)	1 (1.5)
Respiratory syncytial virus infection	1 (2.8)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (2.8)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.1)	1 (1.5)
Tonsillitis	1 (2.8)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.1:
Serious TEAE of Special Interest by Category and Preferred Term and by Gender
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**Male** **(N = 36)** **n (%)**	**Female** **(N = 32)** **n (%)**	**Total** **(N = 68)** **n (%)**
Urinary tract infection	1 (2.8)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (3.1)	1 (1.5)
Tuberculosis	0 (0.0)	1 (3.1)	1 (1.5)
Second Primary Malignancies	3 (8.3)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	1 (2.8)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (2.8)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.8)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.8)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (2.8)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (2.8)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each gender group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-01-teae-si-eoipt-sae-sex.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Patients with at Least One Serious TEAE of Special Interest	7 (25.9)	11 (26.8)	13 (26.5)	5 (26.3)	18 (26.5)
Anemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Anaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	0 (0.0)	2 (4.9)	2 (4.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Atrial flutter	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Hemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Major Hemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Infections	6 (22.2)	8 (19.5)	9 (18.4)	5 (26.3)	14 (20.6)
COVID-19 pneumonia	2 (7.4)	2 (4.9)	4 (8.2)	0 (0.0)	4 (5.9)
Pneumonia	1 (3.7)	2 (4.9)	1 (2.0)	2 (10.5)	3 (4.4)
Bronchitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years (N = 27) n (%)**	**≥ 65 years (N = 41) n (%)**	**< 75 years (N = 49) n (%)**	**≥ 75 years (N = 19) n (%)**	**Total (N = 68) n (%)**
Influenza	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Pyelonephritis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Sinusitis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Urinary tract infection	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Opportunistic Infections	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.2:
Serious TEAE of Special Interest by Category and Preferred Term and by Age
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**< 65 years** **(N = 27)** **n (%)**	**≥ 65 years** **(N = 41)** **n (%)**	**< 75 years** **(N = 49)** **n (%)**	**≥ 75 years** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	2 (7.4)	1 (2.4)	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Papillary thyroid cancer	1 (3.7)	0 (0.0)	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (2.4)	0 (0.0)	1 (5.3)	1 (1.5)
Thrombocytopenia	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)
Platelet count decreased	0 (0.0)	1 (2.4)	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each age group or total.

The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and ≥ 65 years, which is equivalent to the total of the subgroups < 75 years and ≥ 75 years.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-02-teae-si-eoipt-sae-age.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	9 (23.1)	9 (31.0)	18 (26.5)
Anemia	0 (0.0)	1 (3.4)	1 (1.5)
Anaemia	0 (0.0)	1 (3.4)	1 (1.5)
Atrial Fibrillation and Flutter	2 (5.1)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (2.6)	0 (0.0)	1 (1.5)
Atrial flutter	1 (2.6)	0 (0.0)	1 (1.5)
Hemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (2.6)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	6 (15.4)	8 (27.6)	14 (20.6)
COVID-19 pneumonia	2 (5.1)	2 (6.9)	4 (5.9)
Pneumonia	1 (2.6)	2 (6.9)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.4)	1 (1.5)
Cellulitis	1 (2.6)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.4)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.4)	1 (1.5)
Pyelonephritis	1 (2.6)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.4)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.4)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.4)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.4)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.3:
Serious TEAE of Special Interest by Category and Preferred Term and by ECOG Performance Status
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**0** **(N = 39)** **n (%)**	**≥ 1** **(N = 29)** **n (%)**	**Total** **(N = 68)** **n (%)**
Urinary tract infection	1 (2.6)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (2.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (2.6)	0 (0.0)	1 (1.5)
Second Primary Malignancies	1 (2.6)	2 (6.9)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.4)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.4)	1 (1.5)
Papillary thyroid cancer	1 (2.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.4)	1 (1.5)
Thrombocytopenia	0 (0.0)	1 (3.4)	1 (1.5)
Platelet count decreased	0 (0.0)	1 (3.4)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each ECOG group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-03-teae-si-eoipt-sae-ecog.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	14 (28.6)	4 (21.1)	18 (26.5)
Anemia	0 (0.0)	1 (5.3)	1 (1.5)
Anaemia	0 (0.0)	1 (5.3)	1 (1.5)
Atrial Fibrillation and Flutter	1 (2.0)	1 (5.3)	2 (2.9)
Atrial fibrillation	0 (0.0)	1 (5.3)	1 (1.5)
Atrial flutter	1 (2.0)	0 (0.0)	1 (1.5)
Hemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (2.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	11 (22.4)	3 (15.8)	14 (20.6)
COVID-19 pneumonia	3 (6.1)	1 (5.3)	4 (5.9)
Pneumonia	2 (4.1)	1 (5.3)	3 (4.4)
Bronchitis	1 (2.0)	0 (0.0)	1 (1.5)
Cellulitis	1 (2.0)	0 (0.0)	1 (1.5)
Influenza	1 (2.0)	0 (0.0)	1 (1.5)
Lower respiratory tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (2.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	1 (2.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (2.0)	0 (0.0)	1 (1.5)
Sinusitis	1 (2.0)	0 (0.0)	1 (1.5)
Tonsillitis	1 (2.0)	0 (0.0)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.4:
Serious TEAE of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
Safety Analysis Set

	Zanubrutinib (N = 68)		
TEAE of Special Interest Category **Preferred Term**	**< 3** **(N = 49)** **n (%)**	**≥ 3** **(N = 19)** **n (%)**	**Total** **(N = 68)** **n (%)**
Urinary tract infection	1 (2.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	0 (0.0)	1 (5.3)	1 (1.5)
Tuberculosis	0 (0.0)	1 (5.3)	1 (1.5)
Second Primary Malignancies	2 (4.1)	1 (5.3)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (5.3)	1 (1.5)
Bladder cancer recurrent	1 (2.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	1 (2.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (2.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (2.0)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (2.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each prior line of therapy group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-04-teae-si-eoipt-sae-pst.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	6 (23.1)	7 (26.9)	3 (25.0)	2 (50.0)	18 (26.5)
Anemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Anaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	2 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Hemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Major Hemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Infections	4 (15.4)	6 (23.1)	3 (25.0)	1 (25.0)	14 (20.6)
COVID-19 pneumonia	0 (0.0)	3 (11.5)	1 (8.3)	0 (0.0)	4 (5.9)
Pneumonia	0 (0.0)	2 (7.7)	1 (8.3)	0 (0.0)	3 (4.4)
Bronchitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Cellulitis	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Influenza	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT (N = 26)** **n (%)**	**NMZL (N = 26)** **n (%)**	**SMZL (N = 12)** **n (%)**	**Unknown (N = 4)** **n (%)**	**Total (N = 68)** **n (%)**
Lower respiratory tract infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Pyelonephritis	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Respiratory syncytial virus infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Septic encephalopathy	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	0 (0.0)	1 (8.3)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Urinary tract infection	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.5:
Serious TEAE of Special Interest by Category and Preferred Term and by MZL Subtype
Safety Analysis Set

	Zanubrutinib (N = 68)				
TEAE of Special Interest Category **Preferred Term**	**MALT** **(N = 26)** **n (%)**	**NMZL** **(N = 26)** **n (%)**	**SMZL** **(N = 12)** **n (%)**	**Unknown** **(N = 4)** **n (%)**	**Total** **(N = 68)** **n (%)**
Second Primary Malignancies	1 (3.8)	2 (7.7)	0 (0.0)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	1 (1.5)
Prostate cancer	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)
Platelet count decreased	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event; MALT, Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue; NMZL, Nodal Marginal Zone Lymphoma; SMZL, Splenic Marginal Zone Lymphoma.

Percentages are based on N for each MZL subtype or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-05-teae-si-eoipt-sae-mzltype.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Patients with at Least One Serious TEAE of Special Interest	5 (15.2)	10 (35.7)	3 (42.9)	18 (26.5)
Anemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Anaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Atrial Fibrillation and Flutter	2 (6.1)	0 (0.0)	0 (0.0)	2 (2.9)
Atrial fibrillation	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Atrial flutter	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Hemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Major Hemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Gastrointestinal haemorrhage	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Infections	2 (6.1)	9 (32.1)	3 (42.9)	14 (20.6)
COVID-19 pneumonia	0 (0.0)	3 (10.7)	1 (14.3)	4 (5.9)
Pneumonia	0 (0.0)	2 (7.1)	1 (14.3)	3 (4.4)
Bronchitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Cellulitis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Influenza	0 (0.0)	0 (0.0)	1 (14.3)	1 (1.5)
Lower respiratory tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Pyelonephritis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Respiratory syncytial virus infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Septic encephalopathy	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Sinusitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tonsillitis	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.3.1.2.7.5.6:
Serious TEAE of Special Interest by Category and Preferred Term and by Geographic Region
Safety Analysis Set

	Zanubrutinib (N = 68)			
TEAE of Special Interest Category **Preferred Term**	**Asia Pacific** **(N = 33)** **n (%)**	**Europe** **(N = 28)** **n (%)**	**North America** **(N = 7)** **n (%)**	**Total** **(N = 68)** **n (%)**
Urinary tract infection	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Opportunistic Infections	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Tuberculosis	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Second Primary Malignancies	0 (0.0)	3 (10.7)	0 (0.0)	3 (4.4)
Acute myeloid leukaemia	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Bladder cancer recurrent	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Papillary thyroid cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Prostate cancer	0 (0.0)	1 (3.6)	0 (0.0)	1 (1.5)
Thrombocytopenia	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)
Platelet count decreased	1 (3.0)	0 (0.0)	0 (0.0)	1 (1.5)

Source: ADSL, ADAE. Data cutoff: 04MAY2022. Data extraction: 31MAY2022.

Abbreviation: TEAE, treatment-emergent adverse event.

Percentages are based on N for each geographic region group or total.

TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of a new anticancer therapy. Worsening of an event to Grade 5 beyond day 30 after last dose of study of a treatment-emergent adverse event is also considered a treatment-emergent adverse event (if it is prior to new anticancer therapy start).

Patients with multiple events for a given preferred term and TEAE of special interest category are counted only once for each preferred term and TEAE of special interest category, respectively.

AE terms with n=0 are not shown in the table.

/bgb_3111/filing_mzl_2021_new/rtq_20220504_214/dev/pgm/tlfs/t-teae-si.sas 18NOV2022 01:07 t-14-03-01-02-07-05-06-teae-si-eoipt-sae-region.rtf

Table 14.2.1.4.6
Observation Period
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)
ORR by Investigator (months)	
n	20
Mean (SD)	26.45 (14.587)
Median	28.63
Q1, Q3	15.33, 34.12
Min, Max	4.1, 55.7
PFS by Investigator (months)	
n	20
Mean (SD)	27.84 (13.249)
Median	28.63
Q1, Q3	20.40, 34.12
Min, Max	5.4, 55.7
OS (months)	
n	20
Mean (SD)	34.57 (12.682)
Median	34.12
Q1, Q3	26.55, 39.39
Min, Max	8.3, 58.3
AE (months)	
n	20
Mean (SD)	27.92 (16.117)
Median	32.07
Q1, Q3	11.10, 36.71
Min, Max	4.8, 58.6

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE, ADRS
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.

Programmer: xiaoli1.sun, Location:
/bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_op.sas
Output: t-14-2-1-4-6-op.rtf (Date Generated: 28SEP2022:18:27)

Table 14.2.1.4.5.1
Analysis of Overall Survival by Gender
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Overall Survival			
Death	1 (10.0)	2 (20.0)	3 (15.0)
Alive	9 (90.0)	8 (80.0)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	38.8 (8.3, 55.7)	34.1 (21.6, 39.4)	35.5 (32.1, 39.4)
(Min, Max)	(8.3, 58.3)	(20.3, 57.3)	(8.3, 58.3)
Overall Survival (months) [b]			
Median (95% CI)	NE (21.2, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (21.2, NE)	NE (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(8.3+, 58.3+)	(20.3, 57.3+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-1-os-gender.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.1
Analysis of Overall Survival by Gender
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	88.9 (43.3, 98.4)	78.8 (38.1, 94.3)	83.9 (57.9, 94.5)
30 months	88.9 (43.3, 98.4)	78.8 (38.1, 94.3)	83.9 (57.9, 94.5)
36 months	88.9 (43.3, 98.4)	78.8 (38.1, 94.3)	83.9 (57.9, 94.5)
48 months	88.9 (43.3, 98.4)	78.8 (38.1, 94.3)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-1-os-gender.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.2
Analysis of Overall Survival by Age
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Overall Survival					
Death	0 (0.0)	3 (18.8)	2 (12.5)	1 (25.0)	3 (15.0)
Alive	4 (100.0)	13 (81.3)	14 (87.5)	3 (75.0)	17 (85.0)
Follow-up Time (months)					
Median (95% CI) [a]	37.9 (34.1, 55.7)	34.2 (31.1, 39.4)	38.8 (31.2, 40.3)	32.1 (8.3, 36.8)	35.5 (32.1, 39.4)
(Min, Max)	(34.1, 55.7)	(8.3, 58.3)	(21.2, 58.3)	(8.3, 36.8)	(8.3, 58.3)
Overall Survival (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (21.2, NE)	20.3 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Range	(34.1+, 55.7+)	(8.3+, 58.3+)	(21.2, 58.3+)	(8.3+, 36.8+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-2-os-age.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.2
Analysis of Overall Survival by Age
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]					
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	79.4 (48.8, 92.9)	87.1 (57.3, 96.6)	66.7 (5.4, 94.5)	83.9 (57.9, 94.5)
30 months	100.0 (NE, NE)	79.4 (48.8, 92.9)	87.1 (57.3, 96.6)	66.7 (5.4, 94.5)	83.9 (57.9, 94.5)
36 months	100.0 (NE, NE)	79.4 (48.8, 92.9)	87.1 (57.3, 96.6)	66.7 (5.4, 94.5)	83.9 (57.9, 94.5)
48 months	100.0 (NE, NE)	79.4 (48.8, 92.9)	87.1 (57.3, 96.6)	NE (NE, NE)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-2-os-age.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.3
Analysis of Overall Survival by ECOG Performance Status
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Overall Survival			
Death	2 (28.6)	1 (7.7)	3 (15.0)
Alive	5 (71.4)	12 (92.3)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	34.1 (31.1, 58.3)	36.8 (21.6, 39.4)	35.5 (32.1, 39.4)
(Min, Max)	(21.2, 58.3)	(8.3, 55.7)	(8.3, 58.3)
Overall Survival (months)[b]			
Median (95% CI)	NE (21.2, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	22.0 (21.2, NE)	NE (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(21.2, 58.3+)	(8.3+, 55.7+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-3-os-ecog.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.3
Analysis of Overall Survival by ECOG Performance Status
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	83.9 (57.9, 94.5)
30 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	83.9 (57.9, 94.5)
36 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	83.9 (57.9, 94.5)
48 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-3-os-ecog.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.4
Analysis of Overall Survival by Prior Line of Therapy for MZL
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Overall Survival			
Death	1 (6.3)	2 (50.0)	3 (15.0)
Alive	15 (93.8)	2 (50.0)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	34.2 (31.2, 39.4)	37.8 (36.8, 38.8)	35.5 (32.1, 39.4)
(Min, Max)	(8.3, 58.3)	(20.3, 38.8)	(8.3, 58.3)
Overall Survival (months)[b]			
Median (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (21.2, NE)	21.1 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Range	(8.3+, 58.3+)	(20.3, 38.8+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-4-os-prior.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.4
Analysis of Overall Survival by Prior Line of Therapy for MZL
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	83.9 (57.9, 94.5)
30 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	83.9 (57.9, 94.5)
36 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	83.9 (57.9, 94.5)
48 months	93.3 (61.3, 99.0)	NE (NE, NE)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-4-os-prior.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.5
Analysis of Overall Survival by MZL Subtypes
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Overall Survival				
Death	0 (0.0)	1 (20.0)	2 (33.3)	3 (15.0)
Alive	9 (100.0)	4 (80.0)	4 (66.7)	17 (85.0)
Follow-up Time (months)				
Median (95% CI) [a]	38.8 (8.3, 57.3)	36.2 (34.2, 55.7)	33.1 (31.1, 39.4)	35.5 (32.1, 39.4)
(Min, Max)	(8.3, 58.3)	(22.0, 55.7)	(20.3, 39.4)	(8.3, 58.3)
Overall Survival (months)[b]				
Median (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	NE (22.0, NE)	21.2 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (21.2, NE)	NE (NE, NE)
Range	(8.3+, 58.3+)	(22.0, 55.7+)	(20.3, 39.4+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-5-os-subtype.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.5
Analysis of Overall Survival by MZL Subtypes
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	83.9 (57.9, 94.5)
30 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	83.9 (57.9, 94.5)
36 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	83.9 (57.9, 94.5)
48 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	NE (NE, NE)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-5-os-subtype.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.6
Analysis of Overall Survival by Geographic Region
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Overall Survival				
Death	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Alive	1 (100.0)	2 (66.7)	14 (87.5)	17 (85.0)
Follow-up Time (months)				
Median (95% CI) [a]	40.3 (NE, NE)	33.1 (32.1, 34.2)	36.8 (31.1, 39.4)	35.5 (32.1, 39.4)
(Min, Max)	(40.3, 40.3)	(20.3, 34.2)	(8.3, 58.3)	(8.3, 58.3)
Overall Survival (months) [b]				
Median (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	20.3 (20.3, NE)	NE (21.2, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)	NE (NE, NE)
Range	0 (0.0)	(20.3, 34.2+)	(8.3+, 58.3+)	(8.3+, 58.3+)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-6-os-reg.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.5.6
Analysis of Overall Survival by Geographic Region
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	66.7 (5.4, 94.5)	86.2 (55.0, 96.4)	83.9 (57.9, 94.5)
30 months	100.0 (NE, NE)	66.7 (5.4, 94.5)	86.2 (55.0, 96.4)	83.9 (57.9, 94.5)
36 months	100.0 (NE, NE)	NE (NE, NE)	86.2 (55.0, 96.4)	83.9 (57.9, 94.5)
48 months	NE (NE, NE)	NE (NE, NE)	86.2 (55.0, 96.4)	83.9 (57.9, 94.5)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-6-os-reg.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.1
Analysis of Progression Free Survival by Gender and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	2 (20.0)	5 (50.0)	7 (35.0)
Progressive disease	2 (20.0)	5 (50.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	8 (80.0)	5 (50.0)	13 (65.0)
No documented progressive disease/death	7 (70.0)	4 (40.0)	11 (55.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (10.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (10.0)	0 (0.0)	1 (5.0)
Follow-up Time (months)			
Median (95% CI) [a]	34.2 (5.5, 49.8)	28.9 (5.7, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 55.7)	(5.4, 39.4)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-1-pfs-inv-gender.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.1
Analysis of Progression Free Survival by Gender and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Progression Free Survival(months) [b]			
Median (95% CI)	NE (4.1, NE)	19.6 (5.4, NE)	NE (17.1, NE)
Q1 (95% CI)	NE (4.1, NE)	12.0 (5.4, 19.6)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (17.1, NE)	NE (NE, NE)
Range	(4.1, 55.7+)	(5.4, 39.4+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]			
6 months	90.0 (47.3, 98.5)	80.0 (40.9, 94.6)	84.7 (59.7, 94.8)
12 months	90.0 (47.3, 98.5)	68.6 (30.5, 88.7)	78.7 (52.4, 91.5)
18 months	90.0 (47.3, 98.5)	57.1 (21.7, 81.5)	72.6 (45.9, 87.7)
24 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
30 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
36 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
48 months	77.1 (34.5, 93.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-1-pfs-inv-gender.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.2
Analysis of Progression Free Survival by Age and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Progression Free Survival					
Events, n (%)	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Progressive disease	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	3 (75.0)	10 (62.5)	10 (62.5)	3 (75.0)	13 (65.0)
No documented progressive disease/death	3 (75.0)	8 (50.0)	9 (56.3)	2 (50.0)	11 (55.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Follow-up Time (months)					
Median (95% CI) [a]	33.7 (8.3, 55.7)	34.1 (28.4, 39.3)	34.2 (28.4, 39.4)	28.9 (5.5, 34.1)	33.7 (28.4, 39.3)
(Min, Max)	(8.3, 55.7)	(4.1, 49.8)	(4.1, 55.7)	(5.5, 34.1)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-2-pfs-inv-age.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.2
Analysis of Progression Free Survival by Age and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Progression Free Survival(months) [b]					
Median (95% CI)	NE (17.1, NE)	NE (12.0, NE)	NE (12.0, NE)	NE (19.6, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (17.1, NE)	12.0 (4.1, NE)	12.0 (4.1, NE)	19.6 (19.6, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (17.1, NE)	NE (NE, NE)	NE (NE, NE)	NE (19.6, NE)	NE (NE, NE)
Range	(8.3+, 55.7+)	(4.1, 49.8+)	(4.1, 55.7+)	(5.5+, 34.1+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]					
6 months	100.0 (NE, NE)	80.8 (51.4, 93.4)	81.3 (52.5, 93.5)	100.0 (NE, NE)	84.7 (59.7, 94.8)
12 months	100.0 (NE, NE)	73.4 (43.5, 89.2)	73.9 (44.2, 89.4)	100.0 (NE, NE)	78.7 (52.4, 91.5)
18 months	66.7 (5.4, 94.5)	73.4 (43.5, 89.2)	66.5 (36.9, 84.6)	100.0 (NE, NE)	72.6 (45.9, 87.7)
24 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	66.7 (5.4, 94.5)	60.5 (34.2, 79.0)
30 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	66.7 (5.4, 94.5)	60.5 (34.2, 79.0)
36 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	NE (NE, NE)	60.5 (34.2, 79.0)
48 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-2-pfs-inv-age.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.3
Analysis of Progression Free Survival by ECOG Performance Status and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	4 (57.1)	3 (23.1)	7 (35.0)
Progressive disease	4 (57.1)	3 (23.1)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	3 (42.9)	10 (76.9)	13 (65.0)
No documented progressive disease/death	3 (42.9)	8 (61.5)	11 (55.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (7.7)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	1 (7.7)	1 (5.0)
Follow-up Time (months)			
Median (95% CI) [a]	29.2 (28.4, 49.8)	34.1 (5.7, 39.3)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 49.8)	(5.5, 55.7)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-3-pfs-inv-ecog.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.3
Analysis of Progression Free Survival by ECOG Performance Status and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	>= 1 (N = 13)	Total (N = 20)
Progression Free Survival(months) [b]			
Median (95% CI)	17.1 (4.1, NE)	NE (18.7, NE)	NE (17.1, NE)
Q1 (95% CI)	5.4 (4.1, 17.1)	19.6 (5.6, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (12.0, NE)	NE (NE, NE)	NE (NE, NE)
Range	(4.1, 49.8+)	(5.5+, 55.7+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]			
6 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.7 (59.7, 94.8)
12 months	57.1 (17.2, 83.7)	91.7 (53.9, 98.8)	78.7 (52.4, 91.5)
18 months	42.9 (9.8, 73.4)	91.7 (53.9, 98.8)	72.6 (45.9, 87.7)
24 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
30 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
36 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
48 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-3-pfs-inv-ecog.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.4
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	4 (25.0)	3 (75.0)	7 (35.0)
Progressive disease	4 (25.0)	3 (75.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	12 (75.0)	1 (25.0)	13 (65.0)
No documented progressive disease/death	10 (62.5)	1 (25.0)	11 (55.0)
Progressive disease/death after >1 missed assessment	1 (6.3)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (6.3)	0 (0.0)	1 (5.0)
Follow-up Time (months)			
Median (95% CI) [a]	33.7 (8.3, 39.4)	34.1 (NE, NE)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 55.7)	(12.0, 34.1)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-4-pfs-inv-prior.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.4
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Progression Free Survival(months) [b]			
Median (95% CI)	NE (17.1, NE)	19.1 (12.0, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (4.1, NE)	15.3 (12.0, 19.6)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (12.0, NE)	NE (NE, NE)
Range	(4.1, 55.7+)	(12.0, 34.1+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]			
6 months	80.8 (51.4, 93.4)	100.0 (NE, NE)	84.7 (59.7, 94.8)
12 months	80.8 (51.4, 93.4)	75.0 (12.8, 96.1)	78.7 (52.4, 91.5)
18 months	72.7 (42.0, 88.9)	75.0 (12.8, 96.1)	72.6 (45.9, 87.7)
24 months	72.7 (42.0, 88.9)	25.0 (0.9, 66.5)	60.5 (34.2, 79.0)
30 months	72.7 (42.0, 88.9)	25.0 (0.9, 66.5)	60.5 (34.2, 79.0)
36 months	72.7 (42.0, 88.9)	NE (NE, NE)	60.5 (34.2, 79.0)
48 months	72.7 (42.0, 88.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-4-pfs-inv-prior.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.5
Analysis of Progression Free Survival by MZL Subtypes and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Progression Free Survival				
Events, n (%)	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Progressive disease	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	6 (66.7)	4 (80.0)	3 (50.0)	13 (65.0)
No documented progressive disease/death	4 (44.4)	4 (80.0)	3 (50.0)	11 (55.0)
Progressive disease/death after >1 missed assessment	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Follow-up Time (months)				
Median (95% CI) [a]	29.2 (5.5, 49.8)	34.1 (33.7, 55.7)	28.9 (28.4, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(5.4, 49.8)	(12.0, 55.7)	(4.1, 39.4)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-5-pfs-inv-subtype.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.5
Analysis of Progression Free Survival by MZL Subtypes and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Progression Free Survival(months) [b]				
Median (95% CI)	NE (5.4, NE)	NE (12.0, NE)	NE (4.1, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (5.4, NE)	NE (12.0, NE)	5.6 (4.1, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (17.1, NE)	NE (12.0, NE)	NE (5.6, NE)	NE (NE, NE)
Range	(5.4, 49.8+)	(12.0, 55.7+)	(4.1, 39.4+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]				
6 months	88.9 (43.3, 98.4)	100.0 (NE, NE)	66.7 (19.5, 90.4)	84.7 (59.7, 94.8)
12 months	88.9 (43.3, 98.4)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	78.7 (52.4, 91.5)
18 months	71.1 (23.3, 92.3)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	72.6 (45.9, 87.7)
24 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
30 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
36 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
48 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-5-pfs-inv-subtype.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.6
Analysis of Progression Free Survival by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	Europe (N = 3)	Asia Pacific (N = 16)	Total (N = 20)
Progression Free Survival				
Events, n (%)	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Progressive disease	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	1 (100.0)	2 (66.7)	10 (62.5)	13 (65.0)
No documented progressive disease/death	1 (100.0)	2 (66.7)	8 (50.0)	11 (55.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Follow-up Time (months)				
Median (95% CI) [a]	8.3 (NE, NE)	31.5 (28.9, 34.2)	34.1 (28.4, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(8.3, 8.3)	(19.6, 34.2)	(4.1, 55.7)	(4.1, 55.7)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-6-pfs-inv-reg.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.4.6
Analysis of Progression Free Survival by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Progression Free Survival(months) [b]				
Median (95% CI)	NE (NE, NE)	NE (19.6, NE)	NE (12.0, NE)	NE (17.1, NE)
Q1 (95% CI)	NE (NE, NE)	19.6 (19.6, NE)	12.0 (4.1, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (19.6, NE)	NE (NE, NE)	NE (NE, NE)
Range	(8.3+, 8.3+)	(19.6, 34.2+)	(4.1, 55.7+)	(4.1, 55.7+)
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	80.8 (51.4, 93.4)	84.7 (59.7, 94.8)
12 months	NE (NE, NE)	100.0 (NE, NE)	73.4 (43.5, 89.2)	78.7 (52.4, 91.5)
18 months	NE (NE, NE)	100.0 (NE, NE)	66.1 (36.4, 84.4)	72.6 (45.9, 87.7)
24 months	NE (NE, NE)	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
30 months	NE (NE, NE)	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
36 months	NE (NE, NE)	NE (NE, NE)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
48 months	NE (NE, NE)	NE (NE, NE)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-6-pfs-inv-reg.rtf (Date Generated: 27JUL2022:20:20)

Table 14.2.1.4.1.2
Analysis of Disease Response by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
Response Category	**North America (N = 1)**	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Best Overall Response, n (%)				
Complete Response	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Partial Response	1 (100.0)	3 (100.0)	10 (62.5)	14 (70.0)
Stable Disease	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Progressive Disease	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Overall Response Rate, n (%)	1 (100.0)	3 (100.0)	13 (81.3)	17 (85.0)
(95% CI) [a]	(2.5, 100.0)	(29.2, 100.0)	(54.4, 96.0)	(62.1, 96.8)
Complete Response Rate, n (%)	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
(95% CI) [a]	(0.0, 97.5)	(0.0, 70.8)	(4.0, 45.6)	(3.2, 37.9)
Time to Response (Months) [b]				
n	1	3	13	17
Mean (SD)	2.8 (NE)	13.7 (7.69)	8.5 (11.84)	9.1 (10.93)
Median	2.8	14.6	2.8	2.9
Q1, Q3	2.8, 2.8	5.7, 21.0	2.7, 5.6	2.7, 8.5
Min, Max	2.8, 2.8	5.7, 21.0	2.6, 39.6	2.6, 39.6

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not evaluable.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first) for patients discontinued from the study or the database cutoff date for ongoing patients.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-2-orr-inv-reg.rtf (Date Generated: 01DEC2022:08:06)

Table 14.2.1.4.1.2
Analysis of Disease Response by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
Response Category	**North America (N = 1)**	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Study Follow-up Time (months) [c]				
n	1	3	16	20
Mean (SD)	42.0 (NE)	29.4 (7.95)	35.8 (14.11)	35.2 (13.11)
Median	42.0	32.9	35.9	35.2
Q1, Q3	42.0, 42.0	20.3, 35.0	26.6, 40.2	26.6, 40.2
Min, Max	42.0, 42.0	20.3, 35.0	8.3, 59.2	8.3, 59.2

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not evaluable.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first) for patients discontinued from the study or the database cutoff date for ongoing patients.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-2-orr-inv-reg.rtf (Date Generated: 01DEC2022:08:06)

Table 14.2.1.4.1.1
Analysis of Disease Response by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
Response Category	**< 3 (N = 16)**	**>= 3 (N = 4)**	**Total (N = 20)**
Best Overall Response, n (%)			
Complete Response	2 (12.5)	1 (25.0)	3 (15.0)
Partial Response	12 (75.0)	2 (50.0)	14 (70.0)
Stable Disease	1 (6.3)	1 (25.0)	2 (10.0)
Progressive Disease	1 (6.3)	0 (0.0)	1 (5.0)
Overall Response Rate, n (%)	14 (87.5)	3 (75.0)	17 (85.0)
(95% CI) [a]	(61.7, 98.4)	(19.4, 99.4)	(62.1, 96.8)
Complete Response Rate, n (%)	2 (12.5)	1 (25.0)	3 (15.0)
(95% CI) [a]	(1.6, 38.3)	(0.6, 80.6)	(3.2, 37.9)
Time to Response (Months) [b]			
n	14	3	17
Mean (SD)	8.9 (11.98)	9.6 (4.62)	9.1 (10.93)
Median	2.8	8.5	2.9
Q1, Q3	2.7, 5.7	5.6, 14.6	2.7, 8.5
Min, Max	2.6, 39.6	5.6, 14.6	2.6, 39.6

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first) for patients discontinued from the study or the database cutoff date for ongoing patients.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-1-orr-inv-prior.rtf (Date Generated: 01DEC2022:08:06)

Table 14.2.1.4.1.1
Analysis of Disease Response by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
Response Category	**< 3 (N = 16)**	**>= 3 (N = 4)**	**Total (N = 20)**
Study Follow-up Time (months) [c]			
n	16	4	20
Mean (SD)	36.5 (13.70)	29.8 (10.05)	35.2 (13.11)
Median	35.2	29.6	35.2
Q1, Q3	31.2, 41.4	21.1, 38.4	26.6, 40.2
Min, Max	8.3, 59.2	20.3, 39.7	8.3, 59.2

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first) for patients discontinued from the study or the database cutoff date for ongoing patients.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-1-orr-inv-prior.rtf (Date Generated: 01DEC2022:08:06)

Table 14.3.1.2.1.3.1
Overall Summary of Treatment-Emergent Adverse Events by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	Male (N = 10) n (%)	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	10 (100.0)	10 (100.0)	20 (100.0)
Grade 3 or Higher [a]	4 (40.0)	7 (70.0)	11 (55.0)
Grade 2 or Lower [a]	10 (100.0)	10 (100.0)	20 (100.0)
Serious	4 (40.0)	5 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	1 (10.0)	1 (5.0)
Leading to Dose Modification	5 (50.0)	5 (50.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (20.0)	2 (10.0)
Leading to Dose Interruption	5 (50.0)	5 (50.0)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-1-teae-sum-gender.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.1.3.2
Overall Summary of Treatment-Emergent Adverse Events by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4) n (%)	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	4 (100.0)	16 (100.0)	16 (100.0)	4 (100.0)	20 (100.0)
Grade 3 or Higher [a]	2 (50.0)	9 (56.3)	9 (56.3)	2 (50.0)	11 (55.0)
Grade 2 or Lower [a]	4 (100.0)	16 (100.0)	16 (100.0)	4 (100.0)	20 (100.0)
Serious	1 (25.0)	8 (50.0)	7 (43.8)	2 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Leading to Dose Modification	1 (25.0)	9 (56.3)	7 (43.8)	3 (75.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Leading to Dose Interruption	1 (25.0)	9 (56.3)	7 (43.8)	3 (75.0)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-2-teae-sum-age.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.1.3.3
Overall Summary of Treatment-Emergent Adverse Events by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	0 (N = 7) n (%)	**>= 1 (N = 13) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	7 (100.0)	13 (100.0)	20 (100.0)
Grade 3 or Higher [a]	5 (71.4)	6 (46.2)	11 (55.0)
Grade 2 or Lower [a]	7 (100.0)	13 (100.0)	20 (100.0)
Serious	3 (42.9)	6 (46.2)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	1 (7.7)	1 (5.0)
Leading to Dose Modification	3 (42.9)	7 (53.8)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (15.4)	2 (10.0)
Leading to Dose Interruption	3 (42.9)	7 (53.8)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-3-teae-sum-ecog.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.1.3.4
Overall Summary of Treatment-Emergent Adverse Events by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16) n (%)	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	16 (100.0)	4 (100.0)	20 (100.0)
Grade 3 or Higher [a]	9 (56.3)	2 (50.0)	11 (55.0)
Grade 2 or Lower [a]	16 (100.0)	4 (100.0)	20 (100.0)
Serious	7 (43.8)	2 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	1 (6.3)	0 (0.0)	1 (5.0)
Leading to Dose Modification	7 (43.8)	3 (75.0)	10 (50.0)
Leading to Dose Reduction	2 (12.5)	0 (0.0)	2 (10.0)
Leading to Dose Interruption	7 (43.8)	3 (75.0)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-4-teae-sum-prior.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.1.3.5
Overall Summary of Treatment-Emergent Adverse Events by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9) n (%)	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	9 (100.0)	5 (100.0)	6 (100.0)	20 (100.0)
Grade 3 or Higher [a]	5 (55.6)	1 (20.0)	5 (83.3)	11 (55.0)
Grade 2 or Lower [a]	9 (100.0)	5 (100.0)	6 (100.0)	20 (100.0)
Serious	4 (44.4)	1 (20.0)	4 (66.7)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Leading to Dose Modification	4 (44.4)	2 (40.0)	4 (66.7)	10 (50.0)
Leading to Dose Reduction	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Leading to Dose Interruption	4 (44.4)	2 (40.0)	4 (66.7)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-5-teae-sum-subtype.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.1.3.6
Overall Summary of Treatment-Emergent Adverse Events by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
	North America (N = 1) n (%)	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	1 (100.0)	3 (100.0)	16 (100.0)	20 (100.0)
Grade 3 or Higher [a]	0 (0.0)	2 (66.7)	9 (56.3)	11 (55.0)
Grade 2 or Lower [a]	1 (100.0)	3 (100.0)	16 (100.0)	20 (100.0)
Serious	0 (0.0)	2 (66.7)	7 (43.8)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Leading to Dose Modification	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Leading to Dose Interruption	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-6-teae-sum-reg.rtf (Date Generated: 27JUL2022:20:20)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	9 (90.0)	10 (100.0)	19 (95.0)
Grade 1	3 (30.0)	0 (0.0)	3 (15.0)
Grade 2	3 (30.0)	3 (30.0)	6 (30.0)
Grade 3	2 (20.0)	5 (50.0)	7 (35.0)
Grade 4	1 (10.0)	2 (20.0)	3 (15.0)
Anemia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 3	1 (10.0)	2 (20.0)	3 (15.0)
Anaemia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 3	1 (10.0)	2 (20.0)	3 (15.0)
Hemorrhage	6 (60.0)	6 (60.0)	12 (60.0)
Grade 1	4 (40.0)	4 (40.0)	8 (40.0)
Grade 2	2 (20.0)	1 (10.0)	3 (15.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Contusion	3 (30.0)	4 (40.0)	7 (35.0)
Grade 1	2 (20.0)	3 (30.0)	5 (25.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Epistaxis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 1	1 (10.0)	1 (10.0)	2 (10.0)
Haemoptysis	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Blood blister	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Conjunctival haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Haematuria	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Petechiae	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Post procedural contusion	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Purpura	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)			
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Infections	5 (50.0)	10 (100.0)	15 (75.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	2 (20.0)	8 (80.0)	10 (50.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Grade 4	1 (10.0)	1 (10.0)	2 (10.0)
Upper respiratory tract infection	3 (30.0)	3 (30.0)	6 (30.0)
Grade 2	3 (30.0)	3 (30.0)	6 (30.0)
Nasopharyngitis	1 (10.0)	4 (40.0)	5 (25.0)
Grade 1	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	1 (10.0)	2 (20.0)	3 (15.0)
Sinusitis	2 (20.0)	2 (20.0)	4 (20.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	2 (20.0)	3 (15.0)
Escherichia urinary tract infection	1 (10.0)	2 (20.0)	3 (15.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Conjunctivitis	2 (20.0)	0 (0.0)	2 (10.0)
Grade 2	2 (20.0)	0 (0.0)	2 (10.0)
Cystitis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Herpes zoster	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Localised infection	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Oral herpes	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	2 (20.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Pneumonia	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Pyelonephritis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Ear infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Grade 4	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Parainfluenzae virus infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Soft tissue infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Neutropenia	2 (20.0)	4 (40.0)	6 (30.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Grade 4	0 (0.0)	2 (20.0)	2 (10.0)
Neutropenia	2 (20.0)	3 (30.0)	5 (25.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)			
Neutrophil count decreased	0 (0.0)	1 (10.0)	1 (5.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)
Second primary malignancies	2 (20.0)	1 (10.0)	3 (15.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Prostate cancer	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Skin cancers	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	2 (20.0)	2 (10.0)
Platelet count decreased	1 (10.0)	1 (10.0)	2 (10.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	4 (100.0)	15 (93.8)	16 (100.0)	3 (75.0)	19 (95.0)
Grade 1	1 (25.0)	2 (12.5)	3 (18.8)	0 (0.0)	3 (15.0)
Grade 2	1 (25.0)	5 (31.3)	5 (31.3)	1 (25.0)	6 (30.0)
Grade 3	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Grade 4	1 (25.0)	2 (12.5)	2 (12.5)	1 (25.0)	3 (15.0)
Anemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 3	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Anaemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 3	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Hemorrhage	1 (25.0)	11 (68.8)	9 (56.3)	3 (75.0)	12 (60.0)
Grade 1	1 (25.0)	7 (43.8)	6 (37.5)	2 (50.0)	8 (40.0)
Grade 2	0 (0.0)	3 (18.8)	3 (18.8)	0 (0.0)	3 (15.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Contusion	0 (0.0)	7 (43.8)	6 (37.5)	1 (25.0)	7 (35.0)
Grade 1	0 (0.0)	5 (31.3)	4 (25.0)	1 (25.0)	5 (25.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Epistaxis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Haemoptysis	0 (0.0)	2 (12.5)	0 (0.0)	2 (50.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Blood blister	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Petechiae	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Post procedural contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)					
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Infections	4 (100.0)	11 (68.8)	12 (75.0)	3 (75.0)	15 (75.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	3 (75.0)	7 (43.8)	9 (56.3)	1 (25.0)	10 (50.0)
Grade 3	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Grade 4	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Upper respiratory tract infection	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	1 (25.0)	4 (25.0)	5 (31.3)	0 (0.0)	5 (25.0)
Grade 1	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (25.0)	2 (12.5)	3 (18.8)	0 (0.0)	3 (15.0)
Sinusitis	3 (75.0)	1 (6.3)	4 (25.0)	0 (0.0)	4 (20.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	2 (50.0)	1 (6.3)	3 (18.8)	0 (0.0)	3 (15.0)
Escherichia urinary tract infection	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Conjunctivitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Cystitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Localised infection	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Oral herpes	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Pneumonia	0 (0.0)	2 (12.5)	0 (0.0)	2 (50.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Urinary tract infection	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category Preferred Term Maximum Severity	< 65 years (N = 4) n (%)	>= 65 years (N = 16) n (%)	< 75 years (N = 16) n (%)	>= 75 years (N = 4) n (%)	Total (N = 20) n (%)
Infections (continued)					
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 4	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Parainfluenzae virus infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Soft tissue infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)					
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	2 (50.0)	4 (25.0)	4 (25.0)	2 (50.0)	6 (30.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	1 (25.0)	1 (6.3)	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	1 (25.0)	4 (25.0)	3 (18.8)	2 (50.0)	5 (25.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)					
Neutrophil count decreased	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	0 (0.0)	3 (18.8)	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Prostate cancer	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	7 (100.0)	12 (92.3)	19 (95.0)
Grade 1	0 (0.0)	3 (23.1)	3 (15.0)
Grade 2	2 (28.6)	4 (30.8)	6 (30.0)
Grade 3	4 (57.1)	3 (23.1)	7 (35.0)
Grade 4	1 (14.3)	2 (15.4)	3 (15.0)
Anemia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	1 (14.3)	2 (15.4)	3 (15.0)
Anaemia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	1 (14.3)	2 (15.4)	3 (15.0)
Hemorrhage	3 (42.9)	9 (69.2)	12 (60.0)
Grade 1	2 (28.6)	6 (46.2)	8 (40.0)
Grade 2	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Contusion	3 (42.9)	4 (30.8)	7 (35.0)
Grade 1	2 (28.6)	3 (23.1)	5 (25.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Epistaxis	0 (0.0)	2 (15.4)	2 (10.0)
Grade 1	0 (0.0)	2 (15.4)	2 (10.0)
Haemoptysis	0 (0.0)	2 (15.4)	2 (10.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Blood blister	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Conjunctival haemorrhage	1 (14.3)	0 (0.0)	1 (5.0)
Grade 1	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Haematuria	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Petechiae	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Post procedural contusion	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Purpura	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (15.4)	2 (10.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Major hemorrhage (continued)			
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Infections	6 (85.7)	9 (69.2)	15 (75.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	4 (57.1)	6 (46.2)	10 (50.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Grade 4	1 (14.3)	1 (7.7)	2 (10.0)
Upper respiratory tract infection	3 (42.9)	3 (23.1)	6 (30.0)
Grade 2	3 (42.9)	3 (23.1)	6 (30.0)
Nasopharyngitis	3 (42.9)	2 (15.4)	5 (25.0)
Grade 1	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	2 (28.6)	1 (7.7)	3 (15.0)
Sinusitis	1 (14.3)	3 (23.1)	4 (20.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	1 (14.3)	2 (15.4)	3 (15.0)
Escherichia urinary tract infection	1 (14.3)	2 (15.4)	3 (15.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Conjunctivitis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Cystitis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Herpes zoster	2 (28.6)	0 (0.0)	2 (10.0)
Grade 2	2 (28.6)	0 (0.0)	2 (10.0)
Localised infection	2 (28.6)	0 (0.0)	2 (10.0)
Grade 1	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Oral herpes	1 (14.3)	1 (7.7)	2 (10.0)
Grade 1	1 (14.3)	1 (7.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	2 (15.4)	2 (10.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Urinary tract infection	2 (28.6)	0 (0.0)	2 (10.0)
Grade 2	2 (28.6)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Ear infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Grade 4	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Periodontitis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Soft tissue infection	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Neutropenia	3 (42.9)	3 (23.1)	6 (30.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	2 (28.6)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	2 (15.4)	2 (10.0)
Neutropenia	3 (42.9)	2 (15.4)	5 (25.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	2 (28.6)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia (continued)			
Neutrophil count decreased	0 (0.0)	1 (7.7)	1 (5.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)
Second primary malignancies	1 (14.3)	2 (15.4)	3 (15.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Prostate cancer	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Skin cancers	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)
Platelet count decreased	1 (14.3)	1 (7.7)	2 (10.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	15 (93.8)	4 (100.0)	19 (95.0)
Grade 1	3 (18.8)	0 (0.0)	3 (15.0)
Grade 2	3 (18.8)	3 (75.0)	6 (30.0)
Grade 3	6 (37.5)	1 (25.0)	7 (35.0)
Grade 4	3 (18.8)	0 (0.0)	3 (15.0)
Anemia	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	2 (12.5)	1 (25.0)	3 (15.0)
Anaemia	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	2 (12.5)	1 (25.0)	3 (15.0)
Hemorrhage	9 (56.3)	3 (75.0)	12 (60.0)
Grade 1	6 (37.5)	2 (50.0)	8 (40.0)
Grade 2	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Contusion	5 (31.3)	2 (50.0)	7 (35.0)
Grade 1	3 (18.8)	2 (50.0)	5 (25.0)
Grade 2	2 (12.5)	0 (0.0)	2 (10.0)
Epistaxis	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)
Haemoptysis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Blood blister	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Petechiae	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Post procedural contusion	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)			
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Infections	12 (75.0)	3 (75.0)	15 (75.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	8 (50.0)	2 (50.0)	10 (50.0)
Grade 3	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Grade 4	2 (12.5)	0 (0.0)	2 (10.0)
Upper respiratory tract infection	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	4 (25.0)	1 (25.0)	5 (25.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	2 (12.5)	1 (25.0)	3 (15.0)
Sinusitis	4 (25.0)	0 (0.0)	4 (20.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	3 (18.8)	0 (0.0)	3 (15.0)
Escherichia urinary tract infection	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category Preferred Term Maximum Severity	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Conjunctivitis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Cystitis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Localised infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Oral herpes	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	2 (50.0)	2 (10.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Urinary tract infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	2 (12.5)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)
Parainfluenzae virus infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Soft tissue infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	2 (12.5)	0 (0.0)	2 (10.0)
Neutropenia	4 (25.0)	1 (25.0)	5 (25.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia (continued)			
Neutrophil count decreased	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Prostate cancer	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	1 (6.3)	2 (50.0)	3 (15.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	8 (88.9)	5 (100.0)	6 (100.0)	19 (95.0)
Grade 1	2 (22.2)	1 (20.0)	0 (0.0)	3 (15.0)
Grade 2	2 (22.2)	3 (60.0)	1 (16.7)	6 (30.0)
Grade 3	3 (33.3)	0 (0.0)	4 (66.7)	7 (35.0)
Grade 4	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Anemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Anaemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Hemorrhage	4 (44.4)	3 (60.0)	5 (83.3)	12 (60.0)
Grade 1	2 (22.2)	3 (60.0)	3 (50.0)	8 (40.0)
Grade 2	2 (22.2)	0 (0.0)	1 (16.7)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Hemorrhage (continued)				
Contusion	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Grade 1	2 (22.2)	1 (20.0)	2 (33.3)	5 (25.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Epistaxis	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Haemoptysis	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Blood blister	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Conjunctival haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haematuria	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Petechiae	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Post procedural contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Purpura	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Infections	6 (66.7)	4 (80.0)	5 (83.3)	15 (75.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	3 (33.3)	4 (80.0)	3 (50.0)	10 (50.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Infections (continued)				
Grade 4	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Upper respiratory tract infection	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Grade 2	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Nasopharyngitis	2 (22.2)	2 (40.0)	1 (16.7)	5 (25.0)
Grade 1	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	2 (40.0)	0 (0.0)	3 (15.0)
Sinusitis	2 (22.2)	1 (20.0)	1 (16.7)	4 (20.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Escherichia urinary tract infection	1 (11.1)	0 (0.0)	2 (33.3)	3 (15.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Conjunctivitis	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Cystitis	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Herpes zoster	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Localised infection	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Oral herpes	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pyelonephritis	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Ear infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 4	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Soft tissue infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Opportunistic infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Neutropenia	2 (22.2)	1 (20.0)	3 (50.0)	6 (30.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 4	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Neutropenia	2 (22.2)	0 (0.0)	3 (50.0)	5 (25.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 4	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)				
Neutrophil count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Second primary malignancies	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Prostate cancer	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (20.0)	2 (33.3)	3 (15.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	1 (100.0)	3 (100.0)	15 (93.8)	19 (95.0)
Grade 1	1 (100.0)	1 (33.3)	1 (6.3)	3 (15.0)
Grade 2	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Grade 3	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Grade 4	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Anemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 3	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Anaemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 3	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Hemorrhage	0 (0.0)	3 (100.0)	9 (56.3)	12 (60.0)
Grade 1	0 (0.0)	2 (66.7)	6 (37.5)	8 (40.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	7 (43.8)	7 (35.0)
Grade 1	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Epistaxis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 1	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Haemoptysis	0 (0.0)	2 (66.7)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Blood blister	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haematuria	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Petechiae	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Post procedural contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Purpura	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Infections	1 (100.0)	2 (66.7)	12 (75.0)	15 (75.0)
Grade 1	1 (100.0)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	10 (62.5)	10 (50.0)
Grade 3	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Grade 4	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Grade 2	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Nasopharyngitis	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Grade 1	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Sinusitis	1 (100.0)	0 (0.0)	3 (18.8)	4 (20.0)
Grade 1	1 (100.0)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Escherichia urinary tract infection	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Conjunctivitis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Cystitis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Herpes zoster	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Localised infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Oral herpes	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Urinary tract infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Cellulitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Ear infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Periodontitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Soft tissue infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Neutropenia	0 (0.0)	2 (66.7)	4 (25.0)	6 (30.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 4	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Neutropenia	0 (0.0)	2 (66.7)	3 (18.8)	5 (25.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 4	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)				
Neutrophil count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Prostate cancer	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:35)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Patients with at least 1 Grade 2 or Lower TEAE of special interest	8 (80.0)	10 (100.0)	18 (90.0)
Anemia	0 (0.0)	1 (10.0)	1 (5.0)
Anaemia	0 (0.0)	1 (10.0)	1 (5.0)
Hemorrhage	6 (60.0)	5 (50.0)	11 (55.0)
Contusion	3 (30.0)	4 (40.0)	7 (35.0)
Epistaxis	1 (10.0)	1 (10.0)	2 (10.0)
Blood blister	0 (0.0)	1 (10.0)	1 (5.0)
Conjunctival haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Haematuria	1 (10.0)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Petechiae	1 (10.0)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (10.0)	1 (5.0)
Purpura	1 (10.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Infections	5 (50.0)	10 (100.0)	15 (75.0)
Upper respiratory tract infection	3 (30.0)	3 (30.0)	6 (30.0)
Nasopharyngitis	1 (10.0)	4 (40.0)	5 (25.0)
Sinusitis	2 (20.0)	2 (20.0)	4 (20.0)
Conjunctivitis	2 (20.0)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections (continued)			
Cystitis	1 (10.0)	1 (10.0)	2 (10.0)
Escherichia urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Herpes zoster	1 (10.0)	1 (10.0)	2 (10.0)
Localised infection	0 (0.0)	2 (20.0)	2 (10.0)
Oral herpes	0 (0.0)	2 (20.0)	2 (10.0)
Urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Ear infection	1 (10.0)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (10.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections (continued)			
Pneumonia	1 (10.0)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (10.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Soft tissue infection	1 (10.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (10.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (10.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia	1 (10.0)	1 (10.0)	2 (10.0)
Neutropenia	1 (10.0)	1 (10.0)	2 (10.0)
Second primary malignancies	1 (10.0)	0 (0.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Skin Cancers	1 (10.0)	0 (0.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (10.0)	1 (10.0)	2 (10.0)
Platelet count decreased	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	4 (100.0)	14 (87.5)	15 (93.8)	3 (75.0)	18 (90.0)
Anemia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Anaemia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hemorrhage	1 (25.0)	10 (62.5)	9 (56.3)	2 (50.0)	11 (55.0)
Contusion	0 (0.0)	7 (43.8)	6 (37.5)	1 (25.0)	7 (35.0)
Epistaxis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Blood blister	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Petechiae	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Infections	4 (100.0)	11 (68.8)	12 (75.0)	3 (75.0)	15 (75.0)
Upper respiratory tract infection	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	1 (25.0)	4 (25.0)	5 (31.3)	0 (0.0)	5 (25.0)
Sinusitis	3 (75.0)	1 (6.3)	4 (25.0)	0 (0.0)	4 (20.0)
Conjunctivitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Cystitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Escherichia urinary tract infection	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Localised infection	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Oral herpes	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Urinary tract infection	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Pneumonia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Neutropenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Second primary malignancies	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (12.5)	0 (0.0)	2 (50.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	6 (85.7)	12 (92.3)	18 (90.0)
Anemia	0 (0.0)	1 (7.7)	1 (5.0)
Anaemia	0 (0.0)	1 (7.7)	1 (5.0)
Hemorrhage	3 (42.9)	8 (61.5)	11 (55.0)
Contusion	3 (42.9)	4 (30.8)	7 (35.0)
Epistaxis	0 (0.0)	2 (15.4)	2 (10.0)
Blood blister	0 (0.0)	1 (7.7)	1 (5.0)
Conjunctival haemorrhage	1 (14.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Haematuria	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Petechiae	0 (0.0)	1 (7.7)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (7.7)	1 (5.0)
Purpura	0 (0.0)	1 (7.7)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Infections	6 (85.7)	9 (69.2)	15 (75.0)
Upper respiratory tract infection	3 (42.9)	3 (23.1)	6 (30.0)
Nasopharyngitis	3 (42.9)	2 (15.4)	5 (25.0)
Sinusitis	1 (14.3)	3 (23.1)	4 (20.0)
Conjunctivitis	1 (14.3)	1 (7.7)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Cystitis	1 (14.3)	1 (7.7)	2 (10.0)
Escherichia urinary tract infection	1 (14.3)	1 (7.7)	2 (10.0)
Herpes zoster	2 (28.6)	0 (0.0)	2 (10.0)
Localised infection	2 (28.6)	0 (0.0)	2 (10.0)
Oral herpes	1 (14.3)	1 (7.7)	2 (10.0)
Urinary tract infection	2 (28.6)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Ear infection	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (7.7)	1 (5.0)
Periodontitis	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (7.7)	1 (5.0)
Skin infection	1 (14.3)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (14.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (7.7)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (7.7)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia	1 (14.3)	1 (7.7)	2 (10.0)
Neutropenia	1 (14.3)	1 (7.7)	2 (10.0)
Second primary malignancies	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Skin Cancers	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (15.4)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	14 (87.5)	4 (100.0)	18 (90.0)
Anemia	0 (0.0)	1 (25.0)	1 (5.0)
Anaemia	0 (0.0)	1 (25.0)	1 (5.0)
Hemorrhage	8 (50.0)	3 (75.0)	11 (55.0)
Contusion	5 (31.3)	2 (50.0)	7 (35.0)
Epistaxis	2 (12.5)	0 (0.0)	2 (10.0)
Blood blister	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (25.0)	1 (5.0)
Haemorrhoidal haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Petechiae	1 (6.3)	0 (0.0)	1 (5.0)
Post procedural contusion	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Infections	12 (75.0)	3 (75.0)	15 (75.0)
Upper respiratory tract infection	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	4 (25.0)	1 (25.0)	5 (25.0)
Sinusitis	4 (25.0)	0 (0.0)	4 (20.0)
Conjunctivitis	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Cystitis	1 (6.3)	1 (25.0)	2 (10.0)
Escherichia urinary tract infection	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	1 (6.3)	1 (25.0)	2 (10.0)
Localised infection	2 (12.5)	0 (0.0)	2 (10.0)
Oral herpes	2 (12.5)	0 (0.0)	2 (10.0)
Urinary tract infection	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (25.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	1 (6.3)	1 (25.0)	2 (10.0)
Second primary malignancies	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (50.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	8 (88.9)	5 (100.0)	5 (83.3)	18 (90.0)
Anemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hemorrhage	4 (44.4)	3 (60.0)	4 (66.7)	11 (55.0)
Contusion	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Epistaxis	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Blood blister	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Conjunctival haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haematuria	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Petechiae	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Purpura	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Infections	6 (66.7)	4 (80.0)	5 (83.3)	15 (75.0)
Upper respiratory tract infection	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Nasopharyngitis	2 (22.2)	2 (40.0)	1 (16.7)	5 (25.0)
Sinusitis	2 (22.2)	1 (20.0)	1 (16.7)	4 (20.0)
Conjunctivitis	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Cystitis	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Escherichia urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Herpes zoster	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Localised infection	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Oral herpes	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Ear infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Opportunistic infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Neutropenia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Neutropenia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Second primary malignancies	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	1 (100.0)	3 (100.0)	14 (87.5)	18 (90.0)
Anemia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Anaemia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	2 (66.7)	9 (56.3)	11 (55.0)
Contusion	0 (0.0)	0 (0.0)	7 (43.8)	7 (35.0)
Epistaxis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Blood blister	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haematuria	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Petechiae	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Post procedural contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Purpura	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Infections	1 (100.0)	2 (66.7)	12 (75.0)	15 (75.0)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Nasopharyngitis	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Sinusitis	1 (100.0)	0 (0.0)	3 (18.8)	4 (20.0)
Conjunctivitis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1)** **n (%)**	**Europe (N = 3)** **n (%)**	**Asia Pacific (N = 16)** **n (%)**	**Total (N = 20)** **n (%)**
Infections (continued)				
Cystitis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Escherichia urinary tract infection	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Herpes zoster	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Localised infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Oral herpes	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Urinary tract infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Cellulitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Ear infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Periodontitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Soft tissue infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Neutropenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Neutropenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Second primary malignancies	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin Cancers	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Patients with at least 1 Grade 3 or Higher TEAE of special interest	3 (30.0)	7 (70.0)	10 (50.0)
Anemia	1 (10.0)	2 (20.0)	3 (15.0)
Anaemia	1 (10.0)	2 (20.0)	3 (15.0)
Hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections	2 (20.0)	2 (20.0)	4 (20.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (10.0)	1 (5.0)
Pyelonephritis	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Neutropenia	1 (10.0)	3 (30.0)	4 (20.0)
Neutropenia	1 (10.0)	2 (20.0)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Second primary malignancies	1 (10.0)	1 (10.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)
Prostate cancer	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (20.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (10.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	2 (50.0)	8 (50.0)	8 (50.0)	2 (50.0)	10 (50.0)
Anemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Anaemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Hemorrhage	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	4 (25.0)	2 (12.5)	2 (50.0)	4 (20.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	2 (50.0)	2 (12.5)	3 (18.8)	1 (25.0)	4 (20.0)
Neutropenia	1 (25.0)	2 (12.5)	2 (12.5)	1 (25.0)	3 (15.0)
Neutrophil count decreased	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Prostate cancer	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	5 (71.4)	5 (38.5)	10 (50.0)
Anemia	1 (14.3)	2 (15.4)	3 (15.0)
Anaemia	1 (14.3)	2 (15.4)	3 (15.0)
Hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (28.6)	2 (15.4)	4 (20.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Pneumonia	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (7.7)	1 (5.0)
Neutropenia	2 (28.6)	2 (15.4)	4 (20.0)
Neutropenia	2 (28.6)	1 (7.7)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Second primary malignancies	1 (14.3)	1 (7.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)
Prostate cancer	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (14.3)	1 (7.7)	2 (10.0)
Platelet count decreased	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	9 (56.3)	1 (25.0)	10 (50.0)
Anemia	2 (12.5)	1 (25.0)	3 (15.0)
Anaemia	2 (12.5)	1 (25.0)	3 (15.0)
Hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections	3 (18.8)	1 (25.0)	4 (20.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Escherichia urinary tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Neutropenia	4 (25.0)	0 (0.0)	4 (20.0)
Neutropenia	3 (18.8)	0 (0.0)	3 (15.0)
Neutrophil count decreased	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Second primary malignancies	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)
Prostate cancer	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	4 (44.4)	1 (20.0)	5 (83.3)	10 (50.0)
Anemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Anaemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections	2 (22.2)	0 (0.0)	2 (33.3)	4 (20.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pneumonia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Neutropenia	1 (11.1)	1 (20.0)	2 (33.3)	4 (20.0)
Neutropenia	1 (11.1)	0 (0.0)	2 (33.3)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Prostate cancer	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)
Anemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Anaemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Hemorrhage	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	2 (66.7)	2 (12.5)	4 (20.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Neutropenia	0 (0.0)	1 (33.3)	3 (18.8)	4 (20.0)
Neutropenia	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Neutrophil count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Prostate cancer	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.1
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (30.0)	4 (40.0)	7 (35.0)
Anemia	1 (10.0)	0 (0.0)	1 (5.0)
Anaemia	1 (10.0)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-1-aesi-ser-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.1
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (20.0)	2 (20.0)	4 (20.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (10.0)	1 (5.0)
Pyelonephritis	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (10.0)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-1-aesi-ser-gender.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.2
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	0 (0.0)	7 (43.8)	5 (31.3)	2 (50.0)	7 (35.0)
Anemia	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Anaemia	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-2-aesi-ser-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.2
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category Preferred Term	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	4 (25.0)	2 (12.5)	2 (50.0)	4 (20.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-2-aesi-ser-age.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.3
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (42.9)	4 (30.8)	7 (35.0)
Anemia	1 (14.3)	0 (0.0)	1 (5.0)
Anaemia	1 (14.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-3-aesi-ser-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.3
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (28.6)	2 (15.4)	4 (20.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Pneumonia	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (7.7)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (7.7)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-3-aesi-ser-ecog.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.4
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	6 (37.5)	1 (25.0)	7 (35.0)
Anemia	1 (6.3)	0 (0.0)	1 (5.0)
Anaemia	1 (6.3)	0 (0.0)	1 (5.0)
Hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-4-aesi-ser-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.4
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	3 (18.8)	1 (25.0)	4 (20.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	1 (6.3)	0 (0.0)	1 (5.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-4-aesi-ser-prior.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.5
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (33.3)	0 (0.0)	4 (66.7)	7 (35.0)
Anemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-5-aesi-ser-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.5
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections	2 (22.2)	0 (0.0)	2 (33.3)	4 (20.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pneumonia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-5-aesi-ser-subtype.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.6
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	0 (0.0)	2 (66.7)	5 (31.3)	7 (35.0)
Anemia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-6-aesi-ser-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.3.1.2.6.3.3.6
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	2 (66.7)	2 (12.5)	4 (20.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pneumonia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 02OCT2020; Data extraction: 09NOV2020; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20201002_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-6-aesi-ser-reg.rtf (Date Generated: 14OCT2022:01:36)

Table 14.2.1.4.6
Observation Period
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)
ORR by Investigator (months)	
n	20
Mean (SD)	27.09 (15.471)
Median	28.63
Q1, Q3	15.33, 34.12
Min, Max	4.1, 58.3
PFS by Investigator (months)	
n	20
Mean (SD)	28.48 (14.150)
Median	28.63
Q1, Q3	20.40, 34.12
Min, Max	5.4, 58.3
OS (months)	
n	20
Mean (SD)	39.05 (14.232)
Median	39.24
Q1, Q3	33.58, 43.78
Min, Max	8.3, 62.2
AE (months)	
n	20
Mean (SD)	29.41 (17.255)
Median	33.58
Q1, Q3	11.10, 39.93
Min, Max	4.8, 60.8

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE, ADRS
Observation period of ORR is defined as the time from the first dose to last disease assessment timepoint.
Observation period of PFS is defined as the time from the first dose to last disease assessment/death.
Observation period of OS is defined as the time from the first dose to death/last known alive date.
Observation period of AE is defined as the treatment-emergent period.

Programmer: xiaoli1.sun, Location:
/bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_op.sas
Output: t-14-2-1-4-6-op.rtf (Date Generated: 28SEP2022:18:27)

Table 14.2.1.4.5.1
Analysis of Overall Survival by Gender
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Overall Survival			
Death	1 (10.0)	2 (20.0)	3 (15.0)
Alive	9 (90.0)	8 (80.0)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	42.1 (8.3, 59.9)	38.4 (33.3, 58.1)	40.2 (36.0, 44.4)
(Min, Max)	(8.3, 60.8)	(20.3, 62.2)	(8.3, 62.2)
Overall Survival (months) [b]			
Median (95% CI)	NE (21.2, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (21.2, NE)	NE (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(8.3+, 60.8+)	(20.3, 62.2+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-1-os-gender.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.1
Analysis of Overall Survival by Gender
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	88.9 (43.3, 98.4)	80.0 (40.9, 94.6)	84.2 (58.7, 94.6)
30 months	88.9 (43.3, 98.4)	80.0 (40.9, 94.6)	84.2 (58.7, 94.6)
36 months	88.9 (43.3, 98.4)	80.0 (40.9, 94.6)	84.2 (58.7, 94.6)
48 months	88.9 (43.3, 98.4)	80.0 (40.9, 94.6)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-1-os-gender.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.2
Analysis of Overall Survival by Age
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Overall Survival					
Death	0 (0.0)	3 (18.8)	2 (12.5)	1 (25.0)	3 (15.0)
Alive	4 (100.0)	13 (81.3)	14 (87.5)	3 (75.0)	17 (85.0)
Follow-up Time (months)					
Median (95% CI) [a]	41.6 (38.0, 59.9)	40.2 (33.9, 43.2)	42.0 (36.8, 58.1)	36.0 (8.3, 39.6)	40.2 (36.0, 44.4)
(Min, Max)	(38.0, 59.9)	(8.3, 62.2)	(21.2, 62.2)	(8.3, 39.6)	(8.3, 62.2)
Overall Survival (months) [b]					
Median (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (21.2, NE)	20.3 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Range	(38.0+, 59.9+)	(8.3+, 62.2+)	(21.2, 62.2+)	(8.3+, 39.6+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-2-os-age.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.2
Analysis of Overall Survival by Age
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]					
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	80.0 (50.0, 93.1)	87.5 (58.6, 96.7)	66.7 (5.4, 94.5)	84.2 (58.7, 94.6)
30 months	100.0 (NE, NE)	80.0 (50.0, 93.1)	87.5 (58.6, 96.7)	66.7 (5.4, 94.5)	84.2 (58.7, 94.6)
36 months	100.0 (NE, NE)	80.0 (50.0, 93.1)	87.5 (58.6, 96.7)	66.7 (5.4, 94.5)	84.2 (58.7, 94.6)
48 months	100.0 (NE, NE)	80.0 (50.0, 93.1)	87.5 (58.6, 96.7)	NE (NE, NE)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-2-os-age.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.3
Analysis of Overall Survival by ECOG Performance Status
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Overall Survival			
Death	2 (28.6)	1 (7.7)	3 (15.0)
Alive	5 (71.4)	12 (92.3)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	38.9 (33.3, 62.2)	42.0 (36.0, 44.4)	40.2 (36.0, 44.4)
(Min, Max)	(21.2, 62.2)	(8.3, 59.9)	(8.3, 62.2)
Overall Survival (months)[b]			
Median (95% CI)	NE (21.2, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	22.0 (21.2, NE)	NE (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Range	(21.2, 62.2+)	(8.3+, 59.9+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-3-os-ecog.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.3
Analysis of Overall Survival by ECOG Performance Status
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.2 (58.7, 94.6)
30 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.2 (58.7, 94.6)
36 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.2 (58.7, 94.6)
48 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-3-os-ecog.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.4
Analysis of Overall Survival by Prior Line of Therapy for MZL
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Overall Survival			
Death	1 (6.3)	2 (50.0)	3 (15.0)
Alive	15 (93.8)	2 (50.0)	17 (85.0)
Follow-up Time (months)			
Median (95% CI) [a]	40.2 (36.0, 44.4)	40.8 (39.6, 42.1)	40.2 (36.0, 44.4)
(Min, Max)	(8.3, 62.2)	(20.3, 42.1)	(8.3, 62.2)
Overall Survival (months)[b]			
Median (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (21.2, NE)	21.1 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)
Range	(8.3+, 62.2+)	(20.3, 42.1+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-4-os-prior.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.4
Analysis of Overall Survival by Prior Line of Therapy for MZL
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]			
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	84.2 (58.7, 94.6)
30 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	84.2 (58.7, 94.6)
36 months	93.3 (61.3, 99.0)	50.0 (5.8, 84.5)	84.2 (58.7, 94.6)
48 months	93.3 (61.3, 99.0)	NE (NE, NE)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-4-os-prior.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.5
Analysis of Overall Survival by MZL Subtypes
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Overall Survival				
Death	0 (0.0)	1 (20.0)	2 (33.3)	3 (15.0)
Alive	9 (100.0)	4 (80.0)	4 (66.7)	17 (85.0)
Follow-up Time (months)				
Median (95% CI) [a]	43.2 (8.3, 60.8)	39.9 (38.0, 59.9)	36.4 (33.3, 42.0)	40.2 (36.0, 44.4)
(Min, Max)	(8.3, 62.2)	(22.0, 59.9)	(20.3, 42.0)	(8.3, 62.2)
Overall Survival (months)[b]				
Median (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (20.3, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	NE (22.0, NE)	21.2 (20.3, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (22.0, NE)	NE (21.2, NE)	NE (NE, NE)
Range	(8.3+, 62.2+)	(22.0, 59.9+)	(20.3, 42.0+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-5-os-subtype.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.5
Analysis of Overall Survival by MZL Subtypes
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	84.2 (58.7, 94.6)
30 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	84.2 (58.7, 94.6)
36 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	84.2 (58.7, 94.6)
48 months	100.0 (NE, NE)	80.0 (20.4, 96.9)	NE (NE, NE)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-5-os-subtype.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.6
Analysis of Overall Survival by Geographic Region
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Overall Survival				
Death	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Alive	1 (100.0)	2 (66.7)	14 (87.5)	17 (85.0)
Follow-up Time (months)				
Median (95% CI) [a]	44.4 (NE, NE)	38.1 (36.0, 40.2)	42.0 (33.9, 58.1)	40.2 (36.0, 44.4)
(Min, Max)	(44.4, 44.4)	(20.3, 40.2)	(8.3, 62.2)	(8.3, 62.2)
Overall Survival (months) [b]				
Median (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)	NE (NE, NE)
Q1 (95% CI)	NE (NE, NE)	20.3 (20.3, NE)	NE (21.2, NE)	NE (20.3, NE)
Q3 (95% CI)	NE (NE, NE)	NE (20.3, NE)	NE (NE, NE)	NE (NE, NE)
Range	0 (0.0)	(20.3, 40.2+)	(8.3+, 62.2+)	(8.3+, 62.2+)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-6-os-reg.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.5.6
Analysis of Overall Survival by Geographic Region
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
12 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
18 months	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
24 months	100.0 (NE, NE)	66.7 (5.4, 94.5)	86.7 (56.4, 96.5)	84.2 (58.7, 94.6)
30 months	100.0 (NE, NE)	66.7 (5.4, 94.5)	86.7 (56.4, 96.5)	84.2 (58.7, 94.6)
36 months	100.0 (NE, NE)	66.7 (5.4, 94.5)	86.7 (56.4, 96.5)	84.2 (58.7, 94.6)
48 months	NE (NE, NE)	NE (NE, NE)	86.7 (56.4, 96.5)	84.2 (58.7, 94.6)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_os.sas
Output: t-14-2-1-4-5-6-os-reg.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.1
Analysis of Progression Free Survival by Gender and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	2 (20.0)	5 (50.0)	7 (35.0)
Progressive disease	2 (20.0)	5 (50.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	8 (80.0)	5 (50.0)	13 (65.0)
No documented progressive disease/death	6 (60.0)	3 (30.0)	9 (45.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (10.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	2 (20.0)	1 (10.0)	3 (15.0)
Follow-up Time (months)			
Median (95% CI) [a]	34.2 (5.5, 55.7)	28.9 (5.7, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 58.3)	(5.4, 39.4)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-1-pfs-inv-gender.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.1
Analysis of Progression Free Survival by Gender and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	Male (N = 10)	**Female (N = 10)**	**Total (N = 20)**
Progression Free Survival(months) [b]			
Median (95% CI)	NE (4.1, NE)	19.6 (5.4, NE)	NE (17.1, NE)
Q1 (95% CI)	NE (4.1, NE)	12.0 (5.4, 19.6)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (17.1, NE)	NE (NE, NE)
Range	(4.1, 58.3+)	(5.4, 39.4+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]			
6 months	90.0 (47.3, 98.5)	80.0 (40.9, 94.6)	84.7 (59.7, 94.8)
12 months	90.0 (47.3, 98.5)	68.6 (30.5, 88.7)	78.7 (52.4, 91.5)
18 months	90.0 (47.3, 98.5)	57.1 (21.7, 81.5)	72.6 (45.9, 87.7)
24 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
30 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
36 months	77.1 (34.5, 93.9)	45.7 (14.3, 73.0)	60.5 (34.2, 79.0)
48 months	77.1 (34.5, 93.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-1-pfs-inv-gender.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.2
Analysis of Progression Free Survival by Age and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Progression Free Survival					
Events, n (%)	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Progressive disease	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	3 (75.0)	10 (62.5)	10 (62.5)	3 (75.0)	13 (65.0)
No documented progressive disease/death	2 (50.0)	7 (43.8)	8 (50.0)	1 (25.0)	9 (45.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (25.0)	2 (12.5)	1 (6.3)	2 (50.0)	3 (15.0)
Follow-up Time (months)					
Median (95% CI) [a]	33.7 (8.3, 55.7)	34.1 (28.4, 39.3)	34.2 (28.4, 39.4)	28.9 (5.5, 34.1)	33.7 (28.4, 39.3)
(Min, Max)	(8.3, 55.7)	(4.1, 58.3)	(4.1, 58.3)	(5.5, 34.1)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-2-pfs-inv-age.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.2
Analysis of Progression Free Survival by Age and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4)	**>= 65 years (N = 16)**	**< 75 years (N = 16)**	**>= 75 years (N = 4)**	**Total (N = 20)**
Progression Free Survival(months) [b]					
Median (95% CI)	NE (17.1, NE)	NE (12.0, NE)	NE (12.0, NE)	NE (19.6, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (17.1, NE)	12.0 (4.1, NE)	12.0 (4.1, NE)	19.6 (19.6, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (17.1, NE)	NE (NE, NE)	NE (NE, NE)	NE (19.6, NE)	NE (NE, NE)
Range	(8.3+, 55.7+)	(4.1, 58.3+)	(4.1, 58.3+)	(5.5+, 34.1+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]					
6 months	100.0 (NE, NE)	80.8 (51.4, 93.4)	81.3 (52.5, 93.5)	100.0 (NE, NE)	84.7 (59.7, 94.8)
12 months	100.0 (NE, NE)	73.4 (43.5, 89.2)	73.9 (44.2, 89.4)	100.0 (NE, NE)	78.7 (52.4, 91.5)
18 months	66.7 (5.4, 94.5)	73.4 (43.5, 89.2)	66.5 (36.9, 84.6)	100.0 (NE, NE)	72.6 (45.9, 87.7)
24 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	66.7 (5.4, 94.5)	60.5 (34.2, 79.0)
30 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	66.7 (5.4, 94.5)	60.5 (34.2, 79.0)
36 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	NE (NE, NE)	60.5 (34.2, 79.0)
48 months	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	59.1 (30.3, 79.3)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-2-pfs-inv-age.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.3
Analysis of Progression Free Survival by ECOG Performance Status and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	**>= 1 (N = 13)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	4 (57.1)	3 (23.1)	7 (35.0)
Progressive disease	4 (57.1)	3 (23.1)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	3 (42.9)	10 (76.9)	13 (65.0)
No documented progressive disease/death	3 (42.9)	6 (46.2)	9 (45.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	1 (7.7)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	0 (0.0)	3 (23.1)	3 (15.0)
Follow-up Time (months)			
Median (95% CI) [a]	33.6 (28.4, 58.3)	34.1 (5.7, 39.3)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 58.3)	(5.5, 55.7)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-3-pfs-inv-ecog.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.3
Analysis of Progression Free Survival by ECOG Performance Status and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	0 (N = 7)	>= 1 (N = 13)	Total (N = 20)
Progression Free Survival(months) [b]			
Median (95% CI)	17.1 (4.1, NE)	NE (18.7, NE)	NE (17.1, NE)
Q1 (95% CI)	5.4 (4.1, 17.1)	19.6 (5.6, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (12.0, NE)	NE (NE, NE)	NE (NE, NE)
Range	(4.1, 58.3+)	(5.5+, 55.7+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]			
6 months	71.4 (25.8, 92.0)	91.7 (53.9, 98.8)	84.7 (59.7, 94.8)
12 months	57.1 (17.2, 83.7)	91.7 (53.9, 98.8)	78.7 (52.4, 91.5)
18 months	42.9 (9.8, 73.4)	91.7 (53.9, 98.8)	72.6 (45.9, 87.7)
24 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
30 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
36 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)
48 months	42.9 (9.8, 73.4)	71.3 (34.4, 89.8)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-3-pfs-inv-ecog.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.4
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Progression Free Survival			
Events, n (%)	4 (25.0)	3 (75.0)	7 (35.0)
Progressive disease	4 (25.0)	3 (75.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	12 (75.0)	1 (25.0)	13 (65.0)
No documented progressive disease/death	8 (50.0)	1 (25.0)	9 (45.0)
Progressive disease/death after >1 missed assessment	1 (6.3)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	3 (18.8)	0 (0.0)	3 (15.0)
Follow-up Time (months)			
Median (95% CI) [a]	33.7 (8.3, 39.4)	34.1 (NE, NE)	33.7 (28.4, 39.3)
(Min, Max)	(4.1, 58.3)	(12.0, 34.1)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-4-pfs-inv-prior.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.4
Analysis of Progression Free Survival by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16)	**>= 3 (N = 4)**	**Total (N = 20)**
Progression Free Survival(months) [b]			
Median (95% CI)	NE (17.1, NE)	19.1 (12.0, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (4.1, NE)	15.3 (12.0, 19.6)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (12.0, NE)	NE (NE, NE)
Range	(4.1, 58.3+)	(12.0, 34.1+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]			
6 months	80.8 (51.4, 93.4)	100.0 (NE, NE)	84.7 (59.7, 94.8)
12 months	80.8 (51.4, 93.4)	75.0 (12.8, 96.1)	78.7 (52.4, 91.5)
18 months	72.7 (42.0, 88.9)	75.0 (12.8, 96.1)	72.6 (45.9, 87.7)
24 months	72.7 (42.0, 88.9)	25.0 (0.9, 66.5)	60.5 (34.2, 79.0)
30 months	72.7 (42.0, 88.9)	25.0 (0.9, 66.5)	60.5 (34.2, 79.0)
36 months	72.7 (42.0, 88.9)	NE (NE, NE)	60.5 (34.2, 79.0)
48 months	72.7 (42.0, 88.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-4-pfs-inv-prior.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.5
Analysis of Progression Free Survival by MZL Subtypes and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Progression Free Survival				
Events, n (%)	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Progressive disease	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	6 (66.7)	4 (80.0)	3 (50.0)	13 (65.0)
No documented progressive disease/death	3 (33.3)	4 (80.0)	2 (33.3)	9 (45.0)
Progressive disease/death after >1 missed assessment	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	2 (22.2)	0 (0.0)	1 (16.7)	3 (15.0)
Follow-up Time (months)				
Median (95% CI) [a]	33.6 (5.5, 58.3)	34.1 (33.7, 55.7)	28.9 (28.4, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(5.4, 58.3)	(12.0, 55.7)	(4.1, 39.4)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-5-pfs-inv-subtype.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.5
Analysis of Progression Free Survival by MZL Subtypes and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9)	**Nodal (N = 5)**	**Splenic (N = 6)**	**Total (N = 20)**
Progression Free Survival(months) [b]				
Median (95% CI)	NE (5.4, NE)	NE (12.0, NE)	NE (4.1, NE)	NE (17.1, NE)
Q1 (95% CI)	17.1 (5.4, NE)	NE (12.0, NE)	5.6 (4.1, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (17.1, NE)	NE (12.0, NE)	NE (5.6, NE)	NE (NE, NE)
Range	(5.4, 58.3+)	(12.0, 55.7+)	(4.1, 39.4+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]				
6 months	88.9 (43.3, 98.4)	100.0 (NE, NE)	66.7 (19.5, 90.4)	84.7 (59.7, 94.8)
12 months	88.9 (43.3, 98.4)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	78.7 (52.4, 91.5)
18 months	71.1 (23.3, 92.3)	80.0 (20.4, 96.9)	66.7 (19.5, 90.4)	72.6 (45.9, 87.7)
24 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
30 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
36 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	50.0 (11.1, 80.4)	60.5 (34.2, 79.0)
48 months	53.3 (12.5, 82.7)	80.0 (20.4, 96.9)	NE (NE, NE)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-5-pfs-inv-subtype.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.6
Analysis of Progression Free Survival by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Progression Free Survival				
Events, n (%)	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Progressive disease	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Censored, n (%)	1 (100.0)	2 (66.7)	10 (62.5)	13 (65.0)
No documented progressive disease/death	0 (0.0)	1 (33.3)	8 (50.0)	9 (45.0)
Progressive disease/death after >1 missed assessment	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
No documented progressive disease/death: Withdrew consent/lost to follow-up	1 (100.0)	1 (33.3)	1 (6.3)	3 (15.0)
Follow-up Time (months)				
Median (95% CI) [a]	8.3 (NE, NE)	31.5 (28.9, 34.2)	34.1 (28.4, 39.4)	33.7 (28.4, 39.3)
(Min, Max)	(8.3, 8.3)	(19.6, 34.2)	(4.1, 58.3)	(4.1, 58.3)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-6-pfs-inv-reg.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.4.6
Analysis of Progression Free Survival by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
	North America (N = 1)	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Progression Free Survival(months) [b]				
Median (95% CI)	NE (NE, NE)	NE (19.6, NE)	NE (12.0, NE)	NE (17.1, NE)
Q1 (95% CI)	NE (NE, NE)	19.6 (19.6, NE)	12.0 (4.1, NE)	17.1 (4.1, NE)
Q3 (95% CI)	NE (NE, NE)	NE (19.6, NE)	NE (NE, NE)	NE (NE, NE)
Range	(8.3+, 8.3+)	(19.6, 34.2+)	(4.1, 58.3+)	(4.1, 58.3+)
Event Free Rate at, % (95% CI) [c]				
6 months	100.0 (NE, NE)	100.0 (NE, NE)	80.8 (51.4, 93.4)	84.7 (59.7, 94.8)
12 months	NE (NE, NE)	100.0 (NE, NE)	73.4 (43.5, 89.2)	78.7 (52.4, 91.5)
18 months	NE (NE, NE)	100.0 (NE, NE)	66.1 (36.4, 84.4)	72.6 (45.9, 87.7)
24 months	NE (NE, NE)	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
30 months	NE (NE, NE)	66.7 (5.4, 94.5)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
36 months	NE (NE, NE)	NE (NE, NE)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)
48 months	NE (NE, NE)	NE (NE, NE)	58.7 (29.9, 79.1)	60.5 (34.2, 79.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not estimable; '+', censored.
Percentages are based on N, unless otherwise specified.

[a] Median follow-up time was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[b] Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

[c] Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_pfs.sas
Output: t-14-2-1-4-4-6-pfs-inv-reg.rtf (Date Generated: 14AUG2022:20:39)

Table 14.2.1.4.1.2
Analysis of Disease Response by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
Response Category	**North America (N = 1)**	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Best Overall Response, n (%)				
Complete Response	0 (0.0)	0 (0.0)	4 (25.0)	4 (20.0)
Partial Response	1 (100.0)	3 (100.0)	9 (56.3)	13 (65.0)
Stable Disease	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Progressive Disease	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Overall Response Rate, n (%)	1 (100.0)	3 (100.0)	13 (81.3)	17 (85.0)
(95% CI) [a]	(2.5, 100.0)	(29.2, 100.0)	(54.4, 96.0)	(62.1, 96.8)
Complete Response Rate, n (%)	0 (0.0)	0 (0.0)	4 (25.0)	4 (20.0)
(95% CI) [a]	(0.0, 97.5)	(0.0, 70.8)	(7.3, 52.4)	(5.7, 43.7)
Time to Response (Months) [b]				
n	1	3	13	17
Mean (SD)	2.8 (NE)	13.7 (7.69)	8.5 (11.84)	9.1 (10.93)
Median	2.8	14.6	2.8	2.9
Q1, Q3	2.8, 2.8	5.7, 21.0	2.7, 5.6	2.7, 8.5
Min, Max	2.8, 2.8	5.7, 21.0	2.6, 39.6	2.6, 39.6

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not evaluable.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-2-orr-inv-reg.rtf (Date Generated: 01DEC2022:01:05)

Table 14.2.1.4.1.2
Analysis of Disease Response by Geographic Region and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)			
Response Category	**North America (N = 1)**	**Europe (N = 3)**	**Asia Pacific (N = 16)**	**Total (N = 20)**
Study Follow-up Time (months) [c]				
n	1	3	16	20
Mean (SD)	44.4 (NE)	32.2 (10.51)	40.0 (15.15)	39.0 (14.23)
Median	44.4	36.0	39.2	39.2
Q1, Q3	44.4, 44.4	20.3, 40.2	33.6, 50.6	33.6, 43.8
Min, Max	44.4, 44.4	20.3, 40.2	8.3, 62.2	8.3, 62.2

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma; NE, not evaluable.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-2-orr-inv-reg.rtf (Date Generated: 01DEC2022:01:05)

Table 14.2.1.4.1.1
Analysis of Disease Response by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
Response Category	**< 3 (N = 16)**	**>= 3 (N = 4)**	**Total (N = 20)**
Best Overall Response, n (%)			
Complete Response	3 (18.8)	1 (25.0)	4 (20.0)
Partial Response	11 (68.8)	2 (50.0)	13 (65.0)
Stable Disease	1 (6.3)	1 (25.0)	2 (10.0)
Progressive Disease	1 (6.3)	0 (0.0)	1 (5.0)
Overall Response Rate, n (%)	14 (87.5)	3 (75.0)	17 (85.0)
(95% CI) [a]	(61.7, 98.4)	(19.4, 99.4)	(62.1, 96.8)
Complete Response Rate, n (%)	3 (18.8)	1 (25.0)	4 (20.0)
(95% CI) [a]	(4.0, 45.6)	(0.6, 80.6)	(5.7, 43.7)
Time to Response (Months) [b]			
n	14	3	17
Mean (SD)	8.9 (11.98)	9.6 (4.62)	9.1 (10.93)
Median	2.8	8.5	2.9
Q1, Q3	2.7, 5.7	5.6, 14.6	2.7, 8.5
Min, Max	2.6, 39.6	5.6, 14.6	2.6, 39.6

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-1-orr-inv-prior.rtf (Date Generated: 01DEC2022:01:05)

Table 14.2.1.4.1.1
Analysis of Disease Response by Prior Line of Therapy for MZL and by Investigator
(MZL Efficacy Evaluable Set)

	Zanubrutinib (N = 20)		
Response Category	**< 3 (N = 16)**	**>= 3 (N = 4)**	**Total (N = 20)**
Study Follow-up Time (months) [c]			
n	16	4	20
Mean (SD)	41.1 (14.45)	31.0 (11.44)	39.0 (14.23)
Median	39.6	30.8	39.2
Q1, Q3	34.9, 51.2	21.1, 40.8	33.6, 43.8
Min, Max	8.3, 62.2	20.3, 42.1	8.3, 62.2

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADRS, ADTTE
Abbreviations: CI, confidence interval; MZL, Marginal zone lymphoma.
Percentages are based on N, unless otherwise specified.

[a] The 95% CI was estimated using the Clopper-Pearson method.

[b] Time to response is defined as the time from the first dose date to the date of earliest qualifying response (partial response or better). Only responders were included in the analysis.

[c] Study follow-up time is defined as the time from the first dose date to the death date or end of study date (whichever occurs first).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_ef_disres.sas
Output: t-14-2-1-4-1-1-orr-inv-prior.rtf (Date Generated: 01DEC2022:01:05)

Table 14.3.1.2.1.3.1
Overall Summary of Treatment-Emergent Adverse Events by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	Male (N = 10) n (%)	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	10 (100.0)	10 (100.0)	20 (100.0)
Grade 3 or Higher [a]	4 (40.0)	7 (70.0)	11 (55.0)
Grade 2 or Lower [a]	10 (100.0)	10 (100.0)	20 (100.0)
Serious	4 (40.0)	5 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	2 (20.0)	2 (10.0)
Leading to Dose Modification	5 (50.0)	5 (50.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (20.0)	2 (10.0)
Leading to Dose Interruption	5 (50.0)	5 (50.0)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-1-teae-sum-gender.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.1.3.2
Overall Summary of Treatment-Emergent Adverse Events by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
	< 65 years (N = 4) n (%)	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	4 (100.0)	16 (100.0)	16 (100.0)	4 (100.0)	20 (100.0)
Grade 3 or Higher [a]	2 (50.0)	9 (56.3)	9 (56.3)	2 (50.0)	11 (55.0)
Grade 2 or Lower [a]	4 (100.0)	16 (100.0)	16 (100.0)	4 (100.0)	20 (100.0)
Serious	1 (25.0)	8 (50.0)	7 (43.8)	2 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Leading to Dose Modification	1 (25.0)	9 (56.3)	7 (43.8)	3 (75.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Leading to Dose Interruption	1 (25.0)	9 (56.3)	7 (43.8)	3 (75.0)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-2-teae-sum-age.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.1.3.3
Overall Summary of Treatment-Emergent Adverse Events by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	0 (N = 7) n (%)	**>= 1 (N = 13) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	7 (100.0)	13 (100.0)	20 (100.0)
Grade 3 or Higher [a]	5 (71.4)	6 (46.2)	11 (55.0)
Grade 2 or Lower [a]	7 (100.0)	13 (100.0)	20 (100.0)
Serious	3 (42.9)	6 (46.2)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	2 (15.4)	2 (10.0)
Leading to Dose Modification	3 (42.9)	7 (53.8)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	2 (15.4)	2 (10.0)
Leading to Dose Interruption	3 (42.9)	7 (53.8)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-3-teae-sum-ecog.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.1.3.4
Overall Summary of Treatment-Emergent Adverse Events by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
	< 3 (N = 16) n (%)	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	16 (100.0)	4 (100.0)	20 (100.0)
Grade 3 or Higher [a]	9 (56.3)	2 (50.0)	11 (55.0)
Grade 2 or Lower [a]	16 (100.0)	4 (100.0)	20 (100.0)
Serious	7 (43.8)	2 (50.0)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	2 (12.5)	0 (0.0)	2 (10.0)
Leading to Dose Modification	7 (43.8)	3 (75.0)	10 (50.0)
Leading to Dose Reduction	2 (12.5)	0 (0.0)	2 (10.0)
Leading to Dose Interruption	7 (43.8)	3 (75.0)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-4-teae-sum-prior.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.1.3.5
Overall Summary of Treatment-Emergent Adverse Events by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
	Extranodal (N = 9) n (%)	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	9 (100.0)	5 (100.0)	6 (100.0)	20 (100.0)
Grade 3 or Higher [a]	5 (55.6)	1 (20.0)	5 (83.3)	11 (55.0)
Grade 2 or Lower [a]	9 (100.0)	5 (100.0)	6 (100.0)	20 (100.0)
Serious	4 (44.4)	1 (20.0)	4 (66.7)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Leading to Dose Modification	4 (44.4)	2 (40.0)	4 (66.7)	10 (50.0)
Leading to Dose Reduction	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Leading to Dose Interruption	4 (44.4)	2 (40.0)	4 (66.7)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-5-teae-sum-subtype.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.1.3.6
Overall Summary of Treatment-Emergent Adverse Events by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
	North America (N = 1) n (%)	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients With at Least One TEAE	1 (100.0)	3 (100.0)	16 (100.0)	20 (100.0)
Grade 3 or Higher [a]	0 (0.0)	2 (66.7)	9 (56.3)	11 (55.0)
Grade 2 or Lower [a]	1 (100.0)	3 (100.0)	16 (100.0)	20 (100.0)
Serious	0 (0.0)	2 (66.7)	7 (43.8)	9 (45.0)
Leading to Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Leading to Treatment Discontinuation	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Leading to Dose Modification	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)
Leading to Dose Reduction	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Leading to Dose Interruption	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
TEAEs leading to death include all TEAEs with CTCAE grade 5.
TEAEs leading to treatment discontinuation include all TEAEs leading to study drug discontinuation for patients with AE as the primary reason for end of treatment.
[a] Adverse event grades are evaluated based on NCI-CTCAE (version 4.03).

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_sum.sas
Output: t-14-3-1-2-1-3-6-teae-sum-reg.rtf (Date Generated: 14AUG2022:20:37)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	9 (90.0)	10 (100.0)	19 (95.0)
Grade 1	3 (30.0)	0 (0.0)	3 (15.0)
Grade 2	3 (30.0)	3 (30.0)	6 (30.0)
Grade 3	2 (20.0)	5 (50.0)	7 (35.0)
Grade 4	1 (10.0)	2 (20.0)	3 (15.0)
Anemia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 3	1 (10.0)	2 (20.0)	3 (15.0)
Anaemia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 3	1 (10.0)	2 (20.0)	3 (15.0)
Hemorrhage	6 (60.0)	6 (60.0)	12 (60.0)
Grade 1	4 (40.0)	4 (40.0)	8 (40.0)
Grade 2	2 (20.0)	1 (10.0)	3 (15.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Contusion	3 (30.0)	4 (40.0)	7 (35.0)
Grade 1	2 (20.0)	3 (30.0)	5 (25.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Epistaxis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 1	1 (10.0)	1 (10.0)	2 (10.0)
Haemoptysis	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Blood blister	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Conjunctival haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Haematuria	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Petechiae	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Post procedural contusion	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Purpura	1 (10.0)	0 (0.0)	1 (5.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)			
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Infections	5 (50.0)	10 (100.0)	15 (75.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	2 (20.0)	8 (80.0)	10 (50.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Grade 4	1 (10.0)	1 (10.0)	2 (10.0)
Upper respiratory tract infection	3 (30.0)	3 (30.0)	6 (30.0)
Grade 2	3 (30.0)	3 (30.0)	6 (30.0)
Nasopharyngitis	1 (10.0)	4 (40.0)	5 (25.0)
Grade 1	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	1 (10.0)	2 (20.0)	3 (15.0)
Sinusitis	2 (20.0)	2 (20.0)	4 (20.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	2 (20.0)	3 (15.0)
Escherichia urinary tract infection	1 (10.0)	2 (20.0)	3 (15.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Pneumonia	2 (20.0)	1 (10.0)	3 (15.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Conjunctivitis	2 (20.0)	0 (0.0)	2 (10.0)
Grade 2	2 (20.0)	0 (0.0)	2 (10.0)
Cystitis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Herpes zoster	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Localised infection	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Oral herpes	0 (0.0)	2 (20.0)	2 (10.0)
Grade 1	0 (0.0)	2 (20.0)	2 (10.0)
Pyelonephritis	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	2 (20.0)	2 (10.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Ear infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Grade 4	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Parainfluenzae virus infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Soft tissue infection	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Grade 1	0 (0.0)	1 (10.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Wound infection	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Grade 2	0 (0.0)	1 (10.0)	1 (5.0)
Neutropenia	2 (20.0)	4 (40.0)	6 (30.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Grade 4	0 (0.0)	2 (20.0)	2 (10.0)
Neutropenia	2 (20.0)	3 (30.0)	5 (25.0)
Grade 2	1 (10.0)	1 (10.0)	2 (10.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)			
Neutrophil count decreased	0 (0.0)	1 (10.0)	1 (5.0)
Grade 4	0 (0.0)	1 (10.0)	1 (5.0)
Second primary malignancies	2 (20.0)	1 (10.0)	3 (15.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	1 (10.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Prostate cancer	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	1 (10.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.1
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Skin cancers	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Grade 2	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (10.0)	2 (20.0)	3 (15.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	2 (20.0)	2 (10.0)
Platelet count decreased	1 (10.0)	1 (10.0)	2 (10.0)
Grade 1	1 (10.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)
Grade 3	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-1-aesi-ptsev-gender.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	4 (100.0)	15 (93.8)	16 (100.0)	3 (75.0)	19 (95.0)
Grade 1	1 (25.0)	2 (12.5)	3 (18.8)	0 (0.0)	3 (15.0)
Grade 2	1 (25.0)	5 (31.3)	5 (31.3)	1 (25.0)	6 (30.0)
Grade 3	1 (25.0)	6 (37.5)	6 (37.5)	1 (25.0)	7 (35.0)
Grade 4	1 (25.0)	2 (12.5)	2 (12.5)	1 (25.0)	3 (15.0)
Anemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 3	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Anaemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 3	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Hemorrhage	1 (25.0)	11 (68.8)	9 (56.3)	3 (75.0)	12 (60.0)
Grade 1	1 (25.0)	7 (43.8)	6 (37.5)	2 (50.0)	8 (40.0)
Grade 2	0 (0.0)	3 (18.8)	3 (18.8)	0 (0.0)	3 (15.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Contusion	0 (0.0)	7 (43.8)	6 (37.5)	1 (25.0)	7 (35.0)
Grade 1	0 (0.0)	5 (31.3)	4 (25.0)	1 (25.0)	5 (25.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Epistaxis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Haemoptysis	0 (0.0)	2 (12.5)	0 (0.0)	2 (50.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Blood blister	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Petechiae	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Post procedural contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)					
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Infections	4 (100.0)	11 (68.8)	12 (75.0)	3 (75.0)	15 (75.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	3 (75.0)	7 (43.8)	9 (56.3)	1 (25.0)	10 (50.0)
Grade 3	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Grade 4	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Upper respiratory tract infection	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	1 (25.0)	4 (25.0)	5 (31.3)	0 (0.0)	5 (25.0)
Grade 1	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (25.0)	2 (12.5)	3 (18.8)	0 (0.0)	3 (15.0)
Sinusitis	3 (75.0)	1 (6.3)	4 (25.0)	0 (0.0)	4 (20.0)
Grade 1	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	2 (50.0)	1 (6.3)	3 (18.8)	0 (0.0)	3 (15.0)
Escherichia urinary tract infection	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Pneumonia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Conjunctivitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Cystitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Localised infection	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Oral herpes	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Pyelonephritis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Urinary tract infection	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 4	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Parainfluenzae virus infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Wound infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)					
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	2 (50.0)	4 (25.0)	4 (25.0)	2 (50.0)	6 (30.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	1 (25.0)	1 (6.3)	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	1 (25.0)	4 (25.0)	3 (18.8)	2 (50.0)	5 (25.0)
Grade 2	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)					
Neutrophil count decreased	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	0 (0.0)	3 (18.8)	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Prostate cancer	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.2
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term** **Maximum Severity**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-2-aesi-ptsev-age.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	7 (100.0)	12 (92.3)	19 (95.0)
Grade 1	0 (0.0)	3 (23.1)	3 (15.0)
Grade 2	2 (28.6)	4 (30.8)	6 (30.0)
Grade 3	4 (57.1)	3 (23.1)	7 (35.0)
Grade 4	1 (14.3)	2 (15.4)	3 (15.0)
Anemia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	1 (14.3)	2 (15.4)	3 (15.0)
Anaemia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	1 (14.3)	2 (15.4)	3 (15.0)
Hemorrhage	3 (42.9)	9 (69.2)	12 (60.0)
Grade 1	2 (28.6)	6 (46.2)	8 (40.0)
Grade 2	1 (14.3)	2 (15.4)	3 (15.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Contusion	3 (42.9)	4 (30.8)	7 (35.0)
Grade 1	2 (28.6)	3 (23.1)	5 (25.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Epistaxis	0 (0.0)	2 (15.4)	2 (10.0)
Grade 1	0 (0.0)	2 (15.4)	2 (10.0)
Haemoptysis	0 (0.0)	2 (15.4)	2 (10.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Blood blister	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Conjunctival haemorrhage	1 (14.3)	0 (0.0)	1 (5.0)
Grade 1	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Haematuria	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Petechiae	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Post procedural contusion	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Purpura	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	2 (15.4)	2 (10.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Major hemorrhage (continued)			
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Infections	6 (85.7)	9 (69.2)	15 (75.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	4 (57.1)	6 (46.2)	10 (50.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Grade 4	1 (14.3)	1 (7.7)	2 (10.0)
Upper respiratory tract infection	3 (42.9)	3 (23.1)	6 (30.0)
Grade 2	3 (42.9)	3 (23.1)	6 (30.0)
Nasopharyngitis	3 (42.9)	2 (15.4)	5 (25.0)
Grade 1	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	2 (28.6)	1 (7.7)	3 (15.0)
Sinusitis	1 (14.3)	3 (23.1)	4 (20.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	1 (14.3)	2 (15.4)	3 (15.0)
Escherichia urinary tract infection	1 (14.3)	2 (15.4)	3 (15.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)
Conjunctivitis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Cystitis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Herpes zoster	2 (28.6)	0 (0.0)	2 (10.0)
Grade 2	2 (28.6)	0 (0.0)	2 (10.0)
Localised infection	2 (28.6)	0 (0.0)	2 (10.0)
Grade 1	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Oral herpes	1 (14.3)	1 (7.7)	2 (10.0)
Grade 1	1 (14.3)	1 (7.7)	2 (10.0)
Pyelonephritis	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	1 (14.3)	1 (7.7)	2 (10.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Urinary tract infection	2 (28.6)	0 (0.0)	2 (10.0)
Grade 2	2 (28.6)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Ear infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Grade 4	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Periodontitis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Soft tissue infection	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Wound infection	1 (14.3)	0 (0.0)	1 (5.0)
Grade 2	1 (14.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Neutropenia	3 (42.9)	3 (23.1)	6 (30.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	2 (28.6)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	2 (15.4)	2 (10.0)
Neutropenia	3 (42.9)	2 (15.4)	5 (25.0)
Grade 2	1 (14.3)	1 (7.7)	2 (10.0)
Grade 3	2 (28.6)	0 (0.0)	2 (10.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia (continued)			
Neutrophil count decreased	0 (0.0)	1 (7.7)	1 (5.0)
Grade 4	0 (0.0)	1 (7.7)	1 (5.0)
Second primary malignancies	1 (14.3)	2 (15.4)	3 (15.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Prostate cancer	1 (14.3)	0 (0.0)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.3
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Skin cancers	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Grade 2	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	1 (14.3)	2 (15.4)	3 (15.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	1 (7.7)	2 (10.0)
Platelet count decreased	1 (14.3)	1 (7.7)	2 (10.0)
Grade 1	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)
Grade 3	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-3-aesi-ptsev-ecog.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 TEAE of special interest	15 (93.8)	4 (100.0)	19 (95.0)
Grade 1	3 (18.8)	0 (0.0)	3 (15.0)
Grade 2	3 (18.8)	3 (75.0)	6 (30.0)
Grade 3	6 (37.5)	1 (25.0)	7 (35.0)
Grade 4	3 (18.8)	0 (0.0)	3 (15.0)
Anemia	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	2 (12.5)	1 (25.0)	3 (15.0)
Anaemia	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	2 (12.5)	1 (25.0)	3 (15.0)
Hemorrhage	9 (56.3)	3 (75.0)	12 (60.0)
Grade 1	6 (37.5)	2 (50.0)	8 (40.0)
Grade 2	2 (12.5)	1 (25.0)	3 (15.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Contusion	5 (31.3)	2 (50.0)	7 (35.0)
Grade 1	3 (18.8)	2 (50.0)	5 (25.0)
Grade 2	2 (12.5)	0 (0.0)	2 (10.0)
Epistaxis	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)
Haemoptysis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Blood blister	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Petechiae	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Post procedural contusion	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Major hemorrhage (continued)			
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Infections	12 (75.0)	3 (75.0)	15 (75.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	8 (50.0)	2 (50.0)	10 (50.0)
Grade 3	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Grade 4	2 (12.5)	0 (0.0)	2 (10.0)
Upper respiratory tract infection	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	4 (25.0)	1 (25.0)	5 (25.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	2 (12.5)	1 (25.0)	3 (15.0)
Sinusitis	4 (25.0)	0 (0.0)	4 (20.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	3 (18.8)	0 (0.0)	3 (15.0)
Escherichia urinary tract infection	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	1 (6.3)	2 (50.0)	3 (15.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	1 (25.0)	2 (10.0)
Conjunctivitis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Cystitis	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	1 (6.3)	1 (25.0)	2 (10.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Localised infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Oral herpes	2 (12.5)	0 (0.0)	2 (10.0)
Grade 1	2 (12.5)	0 (0.0)	2 (10.0)
Pyelonephritis	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Urinary tract infection	2 (12.5)	0 (0.0)	2 (10.0)
Grade 2	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)
Parainfluenzae virus infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 1	1 (6.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Wound infection	1 (6.3)	0 (0.0)	1 (5.0)
Grade 2	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Opportunistic infection (continued)			
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	5 (31.3)	1 (25.0)	6 (30.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	2 (12.5)	0 (0.0)	2 (10.0)
Neutropenia	4 (25.0)	1 (25.0)	5 (25.0)
Grade 2	1 (6.3)	1 (25.0)	2 (10.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia (continued)			
Neutrophil count decreased	1 (6.3)	0 (0.0)	1 (5.0)
Grade 4	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	2 (12.5)	1 (25.0)	3 (15.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Prostate cancer	1 (6.3)	0 (0.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.4
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term** **Maximum Severity**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Skin cancers	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Grade 2	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	1 (6.3)	2 (50.0)	3 (15.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	1 (6.3)	1 (25.0)	2 (10.0)
Grade 1	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)
Grade 3	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-4-aesi-ptsev-prior.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	8 (88.9)	5 (100.0)	6 (100.0)	19 (95.0)
Grade 1	2 (22.2)	1 (20.0)	0 (0.0)	3 (15.0)
Grade 2	2 (22.2)	3 (60.0)	1 (16.7)	6 (30.0)
Grade 3	3 (33.3)	0 (0.0)	4 (66.7)	7 (35.0)
Grade 4	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Anemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Anaemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Hemorrhage	4 (44.4)	3 (60.0)	5 (83.3)	12 (60.0)
Grade 1	2 (22.2)	3 (60.0)	3 (50.0)	8 (40.0)
Grade 2	2 (22.2)	0 (0.0)	1 (16.7)	3 (15.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Contusion	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Grade 1	2 (22.2)	1 (20.0)	2 (33.3)	5 (25.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Epistaxis	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Haemoptysis	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Blood blister	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Conjunctival haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haematuria	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Petechiae	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Post procedural contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Purpura	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Infections	6 (66.7)	4 (80.0)	5 (83.3)	15 (75.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	3 (33.3)	4 (80.0)	3 (50.0)	10 (50.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Grade 4	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Upper respiratory tract infection	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Grade 2	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Nasopharyngitis	2 (22.2)	2 (40.0)	1 (16.7)	5 (25.0)
Grade 1	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	2 (40.0)	0 (0.0)	3 (15.0)
Sinusitis	2 (22.2)	1 (20.0)	1 (16.7)	4 (20.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Escherichia urinary tract infection	1 (11.1)	0 (0.0)	2 (33.3)	3 (15.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Conjunctivitis	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Cystitis	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Herpes zoster	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Localised infection	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Grade 1	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Oral herpes	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Pyelonephritis	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Infections (continued)				
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Ear infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Infections (continued)				
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 4	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Infections (continued)				
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Wound infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Neutropenia	2 (22.2)	1 (20.0)	3 (50.0)	6 (30.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 4	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Neutropenia	2 (22.2)	0 (0.0)	3 (50.0)	5 (25.0)
Grade 2	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Grade 4	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Neutropenia (continued)				
Neutrophil count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Second primary malignancies	1 (11.1)	1 (20.0)	1 (16.7)	3 (15.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Prostate cancer	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 3	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.5
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (20.0)	2 (33.3)	3 (15.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Grade 1	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-5-aesi-ptsev-subtype.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 TEAE of special interest	1 (100.0)	3 (100.0)	15 (93.8)	19 (95.0)
Grade 1	1 (100.0)	1 (33.3)	1 (6.3)	3 (15.0)
Grade 2	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Grade 3	0 (0.0)	1 (33.3)	6 (37.5)	7 (35.0)
Grade 4	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Anemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 3	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Anaemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 3	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Hemorrhage	0 (0.0)	3 (100.0)	9 (56.3)	12 (60.0)
Grade 1	0 (0.0)	2 (66.7)	6 (37.5)	8 (40.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	7 (43.8)	7 (35.0)
Grade 1	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Epistaxis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 1	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Haemoptysis	0 (0.0)	2 (66.7)	0 (0.0)	2 (10.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Blood blister	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haematuria	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Petechiae	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)				
Post procedural contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Purpura	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Major hemorrhage (continued)				
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Infections	1 (100.0)	2 (66.7)	12 (75.0)	15 (75.0)
Grade 1	1 (100.0)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	10 (62.5)	10 (50.0)
Grade 3	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Grade 4	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Grade 2	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Nasopharyngitis	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Grade 1	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Sinusitis	1 (100.0)	0 (0.0)	3 (18.8)	4 (20.0)
Grade 1	1 (100.0)	0 (0.0)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Escherichia urinary tract infection	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Conjunctivitis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Cystitis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Herpes zoster	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Localised infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Oral herpes	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Pyelonephritis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Urinary tract infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 2	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term Maximum Severity	North America (N = 1) n (%)	Europe (N = 3) n (%)	Asia Pacific (N = 16) n (%)	Total (N = 20) n (%)
Infections (continued)				
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Cellulitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Ear infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 4	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Periodontitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Soft tissue infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 1	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Wound infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Opportunistic infection (continued)				
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 2	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Neutropenia	0 (0.0)	2 (66.7)	4 (25.0)	6 (30.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 4	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Neutropenia	0 (0.0)	2 (66.7)	3 (18.8)	5 (25.0)
Grade 2	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 4	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Neutropenia (continued)				
Neutrophil count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 4	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	3 (18.8)	3 (15.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Prostate cancer	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.1.3.6
Treatment-Emergent Adverse Events of Special Interest by Category, Preferred Term, and Maximum Severity and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term** **Maximum Severity**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Skin cancers	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 2	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Grade 1	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Grade 3	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Grade 3	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once at the worst severity for the preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_aesi_sev.sas
Output: t-14-3-1-2-6-1-3-6-aesi-ptsev-reg.rtf (Date Generated: 14OCT2022:01:46)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	 Female (N = 10) n (%)	 Total (N = 20) n (%)
Patients with at least 1 Grade 2 or Lower TEAE of special interest	8 (80.0)	10 (100.0)	18 (90.0)
Anemia	0 (0.0)	1 (10.0)	1 (5.0)
Anaemia	0 (0.0)	1 (10.0)	1 (5.0)
Hemorrhage	6 (60.0)	5 (50.0)	11 (55.0)
Contusion	3 (30.0)	4 (40.0)	7 (35.0)
Epistaxis	1 (10.0)	1 (10.0)	2 (10.0)
Blood blister	0 (0.0)	1 (10.0)	1 (5.0)
Conjunctival haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Haematuria	1 (10.0)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male (N = 10) n (%)**	**Female (N = 10) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)			
Petechiae	1 (10.0)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (10.0)	1 (5.0)
Purpura	1 (10.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (10.0)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (10.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Infections	5 (50.0)	10 (100.0)	15 (75.0)
Upper respiratory tract infection	3 (30.0)	3 (30.0)	6 (30.0)
Nasopharyngitis	1 (10.0)	4 (40.0)	5 (25.0)
Sinusitis	2 (20.0)	2 (20.0)	4 (20.0)
Conjunctivitis	2 (20.0)	0 (0.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections (continued)			
Cystitis	1 (10.0)	1 (10.0)	2 (10.0)
Escherichia urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Herpes zoster	1 (10.0)	1 (10.0)	2 (10.0)
Localised infection	0 (0.0)	2 (20.0)	2 (10.0)
Oral herpes	0 (0.0)	2 (20.0)	2 (10.0)
Urinary tract infection	1 (10.0)	1 (10.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Ear infection	1 (10.0)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (10.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections (continued)			
Pneumonia	1 (10.0)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (10.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Soft tissue infection	1 (10.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (10.0)	1 (5.0)
Wound infection	0 (0.0)	1 (10.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (10.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (10.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.1
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Neutropenia	1 (10.0)	1 (10.0)	2 (10.0)
Neutropenia	1 (10.0)	1 (10.0)	2 (10.0)
Second primary malignancies	1 (10.0)	1 (10.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Skin Cancers	1 (10.0)	0 (0.0)	1 (5.0)
Lentigo maligna	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (10.0)	1 (10.0)	2 (10.0)
Platelet count decreased	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-1-aesi-g2-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	4 (100.0)	14 (87.5)	15 (93.8)	3 (75.0)	18 (90.0)
Anemia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Anaemia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hemorrhage	1 (25.0)	10 (62.5)	9 (56.3)	2 (50.0)	11 (55.0)
Contusion	0 (0.0)	7 (43.8)	6 (37.5)	1 (25.0)	7 (35.0)
Epistaxis	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Blood blister	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Hemorrhage (continued)					
Petechiae	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Infections	4 (100.0)	11 (68.8)	12 (75.0)	3 (75.0)	15 (75.0)
Upper respiratory tract infection	2 (50.0)	4 (25.0)	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	1 (25.0)	4 (25.0)	5 (31.3)	0 (0.0)	5 (25.0)
Sinusitis	3 (75.0)	1 (6.3)	4 (25.0)	0 (0.0)	4 (20.0)
Conjunctivitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Cystitis	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Escherichia urinary tract infection	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Localised infection	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Oral herpes	1 (25.0)	1 (6.3)	2 (12.5)	0 (0.0)	2 (10.0)
Urinary tract infection	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)					
Pneumonia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Wound infection	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.2
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category Preferred Term	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Neutropenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Second primary malignancies	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (12.5)	0 (0.0)	2 (50.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-2-aesi-g2-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	6 (85.7)	12 (92.3)	18 (90.0)
Anemia	0 (0.0)	1 (7.7)	1 (5.0)
Anaemia	0 (0.0)	1 (7.7)	1 (5.0)
Hemorrhage	3 (42.9)	8 (61.5)	11 (55.0)
Contusion	3 (42.9)	4 (30.8)	7 (35.0)
Epistaxis	0 (0.0)	2 (15.4)	2 (10.0)
Blood blister	0 (0.0)	1 (7.7)	1 (5.0)
Conjunctival haemorrhage	1 (14.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Haematuria	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Petechiae	0 (0.0)	1 (7.7)	1 (5.0)
Post procedural contusion	0 (0.0)	1 (7.7)	1 (5.0)
Purpura	0 (0.0)	1 (7.7)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (7.7)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Infections	6 (85.7)	9 (69.2)	15 (75.0)
Upper respiratory tract infection	3 (42.9)	3 (23.1)	6 (30.0)
Nasopharyngitis	3 (42.9)	2 (15.4)	5 (25.0)
Sinusitis	1 (14.3)	3 (23.1)	4 (20.0)
Conjunctivitis	1 (14.3)	1 (7.7)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Cystitis	1 (14.3)	1 (7.7)	2 (10.0)
Escherichia urinary tract infection	1 (14.3)	1 (7.7)	2 (10.0)
Herpes zoster	2 (28.6)	0 (0.0)	2 (10.0)
Localised infection	2 (28.6)	0 (0.0)	2 (10.0)
Oral herpes	1 (14.3)	1 (7.7)	2 (10.0)
Urinary tract infection	2 (28.6)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Ear infection	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (7.7)	1 (5.0)
Periodontitis	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (7.7)	1 (5.0)
Skin infection	1 (14.3)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (14.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	1 (7.7)	1 (5.0)
Wound infection	1 (14.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (7.7)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (7.7)	1 (5.0)
Tuberculosis	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.3
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia	1 (14.3)	1 (7.7)	2 (10.0)
Neutropenia	1 (14.3)	1 (7.7)	2 (10.0)
Second primary malignancies	0 (0.0)	2 (15.4)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Skin Cancers	0 (0.0)	1 (7.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (15.4)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (7.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-3-aesi-g2-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	14 (87.5)	4 (100.0)	18 (90.0)
Anemia	0 (0.0)	1 (25.0)	1 (5.0)
Anaemia	0 (0.0)	1 (25.0)	1 (5.0)
Hemorrhage	8 (50.0)	3 (75.0)	11 (55.0)
Contusion	5 (31.3)	2 (50.0)	7 (35.0)
Epistaxis	2 (12.5)	0 (0.0)	2 (10.0)
Blood blister	0 (0.0)	1 (25.0)	1 (5.0)
Conjunctival haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Haematuria	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (25.0)	1 (5.0)
Haemorrhoidal haemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Increased tendency to bruise	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Hemorrhage (continued)			
Petechiae	1 (6.3)	0 (0.0)	1 (5.0)
Post procedural contusion	1 (6.3)	0 (0.0)	1 (5.0)
Purpura	0 (0.0)	1 (25.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (25.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Infections	12 (75.0)	3 (75.0)	15 (75.0)
Upper respiratory tract infection	5 (31.3)	1 (25.0)	6 (30.0)
Nasopharyngitis	4 (25.0)	1 (25.0)	5 (25.0)
Sinusitis	4 (25.0)	0 (0.0)	4 (20.0)
Conjunctivitis	1 (6.3)	1 (25.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections (continued)			
Cystitis	1 (6.3)	1 (25.0)	2 (10.0)
Escherichia urinary tract infection	1 (6.3)	1 (25.0)	2 (10.0)
Herpes zoster	1 (6.3)	1 (25.0)	2 (10.0)
Localised infection	2 (12.5)	0 (0.0)	2 (10.0)
Oral herpes	2 (12.5)	0 (0.0)	2 (10.0)
Urinary tract infection	2 (12.5)	0 (0.0)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Cellulitis	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Ear infection	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	1 (6.3)	0 (0.0)	1 (5.0)
Periodontitis	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3 (N = 16) n (%)**	**>= 3 (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections (continued)			
Pneumonia	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (6.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)
Viral upper respiratory tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	1 (6.3)	0 (0.0)	1 (5.0)
Wound infection	1 (6.3)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (25.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (25.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.4
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Neutropenia	1 (6.3)	1 (25.0)	2 (10.0)
Neutropenia	1 (6.3)	1 (25.0)	2 (10.0)
Second primary malignancies	1 (6.3)	1 (25.0)	2 (10.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (25.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (50.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (25.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-4-aesi-g2-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	8 (88.9)	5 (100.0)	5 (83.3)	18 (90.0)
Anemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hemorrhage	4 (44.4)	3 (60.0)	4 (66.7)	11 (55.0)
Contusion	3 (33.3)	1 (20.0)	3 (50.0)	7 (35.0)
Epistaxis	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Blood blister	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Conjunctival haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haematuria	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Hemorrhage (continued)				
Petechiae	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Post procedural contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Purpura	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Upper gastrointestinal haemorrhage	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Infections	6 (66.7)	4 (80.0)	5 (83.3)	15 (75.0)
Upper respiratory tract infection	3 (33.3)	2 (40.0)	1 (16.7)	6 (30.0)
Nasopharyngitis	2 (22.2)	2 (40.0)	1 (16.7)	5 (25.0)
Sinusitis	2 (22.2)	1 (20.0)	1 (16.7)	4 (20.0)
Conjunctivitis	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Extranodal (N = 9) n (%)	Nodal (N = 5) n (%)	Splenic (N = 6) n (%)	Total (N = 20) n (%)
Infections (continued)				
Cystitis	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Escherichia urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Herpes zoster	1 (11.1)	1 (20.0)	0 (0.0)	2 (10.0)
Localised infection	2 (22.2)	0 (0.0)	0 (0.0)	2 (10.0)
Oral herpes	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Urinary tract infection	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Cellulitis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Ear infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Periodontitis	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Soft tissue infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Wound infection	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Opportunistic infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Tuberculosis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.5
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Neutropenia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Neutropenia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Second primary malignancies	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Skin Cancers	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Lentigo maligna	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (20.0)	1 (16.7)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-5-aesi-g2-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 2 or Lower TEAE of special interest	1 (100.0)	3 (100.0)	14 (87.5)	18 (90.0)
Anemia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Anaemia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	2 (66.7)	9 (56.3)	11 (55.0)
Contusion	0 (0.0)	0 (0.0)	7 (43.8)	7 (35.0)
Epistaxis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Blood blister	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Conjunctival haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haematuria	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemorrhoidal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Increased tendency to bruise	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1)** **n (%)**	**Europe (N = 3)** **n (%)**	**Asia Pacific (N = 16)** **n (%)**	**Total (N = 20)** **n (%)**
Hemorrhage (continued)				
Petechiae	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Post procedural contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Purpura	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Subcutaneous haematoma	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Upper gastrointestinal haemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Infections	1 (100.0)	2 (66.7)	12 (75.0)	15 (75.0)
Upper respiratory tract infection	0 (0.0)	0 (0.0)	6 (37.5)	6 (30.0)
Nasopharyngitis	0 (0.0)	0 (0.0)	5 (31.3)	5 (25.0)
Sinusitis	1 (100.0)	0 (0.0)	3 (18.8)	4 (20.0)
Conjunctivitis	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category Preferred Term	North America (N = 1) n (%)	Europe (N = 3) n (%)	Asia Pacific (N = 16) n (%)	Total (N = 20) n (%)
Infections (continued)				
Cystitis	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Escherichia urinary tract infection	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Herpes zoster	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Localised infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Oral herpes	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Urinary tract infection	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Cellulitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Ear infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Parainfluenzae virus infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Periodontitis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections (continued)				
Pneumonia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Soft tissue infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Viral upper respiratory tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Vulvovaginal candidiasis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Wound infection	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Opportunistic infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Bronchopulmonary aspergillosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Tuberculosis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.4.6
Grade 2 or Lower Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Neutropenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Neutropenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Second primary malignancies	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin Cancers	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Lentigo maligna	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-4-6-aesi-g2-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	3 (30.0)	7 (70.0)	10 (50.0)
Anemia	1 (10.0)	2 (20.0)	3 (15.0)
Anaemia	1 (10.0)	2 (20.0)	3 (15.0)
Hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Infections	2 (20.0)	2 (20.0)	4 (20.0)
Pneumonia	1 (10.0)	1 (10.0)	2 (10.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (10.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Pyelonephritis	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Neutropenia	1 (10.0)	3 (30.0)	4 (20.0)
Neutropenia	1 (10.0)	2 (20.0)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.1
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

Category Preferred Term	Zanubrutinib (N = 20) Male (N = 10) n (%)	Zanubrutinib (N = 20) Female (N = 10) n (%)	Zanubrutinib (N = 20) Total (N = 20) n (%)
Second primary malignancies	1 (10.0)	1 (10.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)
Prostate cancer	1 (10.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (20.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (10.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-1-aesi-g3-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	2 (50.0)	8 (50.0)	8 (50.0)	2 (50.0)	10 (50.0)
Anemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Anaemia	0 (0.0)	3 (18.8)	1 (6.3)	2 (50.0)	3 (15.0)
Hemorrhage	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	4 (25.0)	2 (12.5)	2 (50.0)	4 (20.0)
Pneumonia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Neutropenia	2 (50.0)	2 (12.5)	3 (18.8)	1 (25.0)	4 (20.0)
Neutropenia	1 (25.0)	2 (12.5)	2 (12.5)	1 (25.0)	3 (15.0)
Neutrophil count decreased	1 (25.0)	0 (0.0)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.2
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	0 (0.0)	2 (12.5)	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Prostate cancer	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-2-aesi-g3-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	5 (71.4)	5 (38.5)	10 (50.0)
Anemia	1 (14.3)	2 (15.4)	3 (15.0)
Anaemia	1 (14.3)	2 (15.4)	3 (15.0)
Hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Haemoptysis	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (28.6)	2 (15.4)	4 (20.0)
Pneumonia	1 (14.3)	1 (7.7)	2 (10.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (7.7)	1 (5.0)
Neutropenia	2 (28.6)	2 (15.4)	4 (20.0)
Neutropenia	2 (28.6)	1 (7.7)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.3
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Second primary malignancies	1 (14.3)	1 (7.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)
Prostate cancer	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (14.3)	1 (7.7)	2 (10.0)
Platelet count decreased	1 (14.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-3-aesi-g3-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	9 (56.3)	1 (25.0)	10 (50.0)
Anemia	2 (12.5)	1 (25.0)	3 (15.0)
Anaemia	2 (12.5)	1 (25.0)	3 (15.0)
Hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Haemoptysis	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	3 (18.8)	1 (25.0)	4 (20.0)
Pneumonia	1 (6.3)	1 (25.0)	2 (10.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Escherichia urinary tract infection	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Neutropenia	4 (25.0)	0 (0.0)	4 (20.0)
Neutropenia	3 (18.8)	0 (0.0)	3 (15.0)
Neutrophil count decreased	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.4
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Second primary malignancies	2 (12.5)	0 (0.0)	2 (10.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)
Prostate cancer	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	1 (6.3)	1 (25.0)	2 (10.0)
Platelet count decreased	1 (6.3)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (25.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-4-aesi-g3-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	4 (44.4)	1 (20.0)	5 (83.3)	10 (50.0)
Anemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Anaemia	0 (0.0)	0 (0.0)	3 (50.0)	3 (15.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Haemoptysis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections	2 (22.2)	0 (0.0)	2 (33.3)	4 (20.0)
Pneumonia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Neutropenia	1 (11.1)	1 (20.0)	2 (33.3)	4 (20.0)
Neutropenia	1 (11.1)	0 (0.0)	2 (33.3)	3 (15.0)
Neutrophil count decreased	0 (0.0)	1 (20.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.5
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Prostate cancer	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	2 (33.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-5-aesi-g3-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Grade 3 or Higher TEAE of special interest	0 (0.0)	2 (66.7)	8 (50.0)	10 (50.0)
Anemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Anaemia	0 (0.0)	2 (66.7)	1 (6.3)	3 (15.0)
Hemorrhage	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Haemoptysis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	2 (66.7)	2 (12.5)	4 (20.0)
Pneumonia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia urinary tract infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Neutropenia	0 (0.0)	1 (33.3)	3 (18.8)	4 (20.0)
Neutropenia	0 (0.0)	1 (33.3)	2 (12.5)	3 (15.0)
Neutrophil count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.4.3.6
Grade 3 or Higher Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Second primary malignancies	0 (0.0)	0 (0.0)	2 (12.5)	2 (10.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Prostate cancer	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Thrombocytopenia	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
Adverse event grades are evaluated based on NCI-CTCAE (version 4.03). MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_27.sas
Output: t-14-3-1-2-6-4-3-6-aesi-g3-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.1
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (30.0)	4 (40.0)	7 (35.0)
Anemia	1 (10.0)	0 (0.0)	1 (5.0)
Anaemia	1 (10.0)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (10.0)	1 (5.0)
Contusion	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)
Hypertension	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-1-aesi-ser-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.1
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Gender
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**Male** **(N = 10)** **n (%)**	**Female** **(N = 10)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (20.0)	2 (20.0)	4 (20.0)
Pneumonia	1 (10.0)	1 (10.0)	2 (10.0)
Carbuncle	1 (10.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (10.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (10.0)	1 (5.0)
Gastroenteritis	1 (10.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (10.0)	1 (5.0)
Pyelonephritis	1 (10.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (10.0)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (10.0)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (10.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-1-aesi-ser-gender.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.2
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category **Preferred Term**	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	0 (0.0)	7 (43.8)	5 (31.3)	2 (50.0)	7 (35.0)
Anemia	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Anaemia	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-2-aesi-ser-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.2
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Age
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)				
Category Preferred Term	**< 65 years (N = 4) n (%)**	**>= 65 years (N = 16) n (%)**	**< 75 years (N = 16) n (%)**	**>= 75 years (N = 4) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	4 (25.0)	2 (12.5)	2 (50.0)	4 (20.0)
Pneumonia	0 (0.0)	2 (12.5)	1 (6.3)	1 (25.0)	2 (10.0)
Carbuncle	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Gastroenteritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (6.3)	0 (0.0)	1 (25.0)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (6.3)	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
The total column is not the total of all four age subgroups; it is the total of the subgroups < 65 years and >= 65 years, which is equivalent to the total of the subgroups < 75 years and >= 75 years.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-2-aesi-ser-age.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.3
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (42.9)	4 (30.8)	7 (35.0)
Anemia	1 (14.3)	0 (0.0)	1 (5.0)
Anaemia	1 (14.3)	0 (0.0)	1 (5.0)
Hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Major hemorrhage	0 (0.0)	1 (7.7)	1 (5.0)
Contusion	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)
Hypertension	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-3-aesi-ser-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.3
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by ECOG Performance Status
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**0** **(N = 7)** **n (%)**	**>= 1** **(N = 13)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	2 (28.6)	2 (15.4)	4 (20.0)
Pneumonia	1 (14.3)	1 (7.7)	2 (10.0)
Carbuncle	1 (14.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (7.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (7.7)	1 (5.0)
Gastroenteritis	1 (14.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (7.7)	1 (5.0)
Pyelonephritis	1 (14.3)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	1 (7.7)	1 (5.0)
Second primary malignancies	0 (0.0)	1 (7.7)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	1 (7.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-3-aesi-ser-ecog.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.4
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Patients with at least 1 Serious TEAE of special interest	6 (37.5)	1 (25.0)	7 (35.0)
Anemia	1 (6.3)	0 (0.0)	1 (5.0)
Anaemia	1 (6.3)	0 (0.0)	1 (5.0)
Hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Major hemorrhage	1 (6.3)	0 (0.0)	1 (5.0)
Contusion	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)
Hypertension	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-4-aesi-ser-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.4
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Prior Line of Therapy for MZL
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)		
Category **Preferred Term**	**< 3** **(N = 16)** **n (%)**	**>= 3** **(N = 4)** **n (%)**	**Total** **(N = 20)** **n (%)**
Infections	3 (18.8)	1 (25.0)	4 (20.0)
Pneumonia	1 (6.3)	1 (25.0)	2 (10.0)
Carbuncle	1 (6.3)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (25.0)	1 (5.0)
Escherichia sepsis	1 (6.3)	0 (0.0)	1 (5.0)
Gastroenteritis	1 (6.3)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	1 (25.0)	1 (5.0)
Pyelonephritis	1 (6.3)	0 (0.0)	1 (5.0)
Skin infection	1 (6.3)	0 (0.0)	1 (5.0)
Second primary malignancies	1 (6.3)	0 (0.0)	1 (5.0)
Invasive ductal breast carcinoma	1 (6.3)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-4-aesi-ser-prior.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.5
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	3 (33.3)	0 (0.0)	4 (66.7)	7 (35.0)
Anemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Hypertension	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-5-aesi-ser-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.5
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by MZL Subtypes
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**Extranodal (N = 9) n (%)**	**Nodal (N = 5) n (%)**	**Splenic (N = 6) n (%)**	**Total (N = 20) n (%)**
Infections	2 (22.2)	0 (0.0)	2 (33.3)	4 (20.0)
Pneumonia	1 (11.1)	0 (0.0)	1 (16.7)	2 (10.0)
Carbuncle	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Escherichia sepsis	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Gastroenteritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Influenza	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Pyelonephritis	1 (11.1)	0 (0.0)	0 (0.0)	1 (5.0)
Skin infection	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (16.7)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-5-aesi-ser-subtype.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.6
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Patients with at least 1 Serious TEAE of special interest	0 (0.0)	2 (66.7)	5 (31.3)	7 (35.0)
Anemia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Anaemia	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Major hemorrhage	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Contusion	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Hypertension	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-6-aesi-ser-reg.rtf (Date Generated: 14OCT2022:01:47)

Table 14.3.1.2.6.3.3.6
Serious Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term and by Geographic Region
(MZL Safety Analysis Set)

	Zanubrutinib (N = 20)			
Category **Preferred Term**	**North America (N = 1) n (%)**	**Europe (N = 3) n (%)**	**Asia Pacific (N = 16) n (%)**	**Total (N = 20) n (%)**
Infections	0 (0.0)	2 (66.7)	2 (12.5)	4 (20.0)
Pneumonia	0 (0.0)	1 (33.3)	1 (6.3)	2 (10.0)
Carbuncle	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Clostridium difficile colitis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Escherichia sepsis	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Gastroenteritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Influenza	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Pyelonephritis	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Skin infection	0 (0.0)	1 (33.3)	0 (0.0)	1 (5.0)
Second primary malignancies	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)
Invasive ductal breast carcinoma	0 (0.0)	0 (0.0)	1 (6.3)	1 (5.0)

Data cut-off: 31MAR2021; Data extraction: 03MAY2021; Data Source: ADSL, ADAE
Abbreviations: MZL, Marginal zone lymphoma; TEAE, treatment emergent adverse event.
Patients with multiple events for a given preferred term and category are counted only once for each preferred term and category, respectively.
Events are first sorted by category alphabetically, then by decreasing frequency of preferred term in the last column.
MedDRA Version 23.0. AE terms with n=0 are not shown in the table.

Programmer: xiaoli1.sun, Location: /bgb_3111/filing_mzl_2021_new/rtq_20210331_au003/dev/pgm/tlfs/t_teae_aesi_28.sas
Output: t-14-3-1-2-6-3-3-6-aesi-ser-reg.rtf (Date Generated: 14OCT2022:01:47)